{"doc_id": "10084639_1", "wnd_id": "10084639_1_1", "text": "BACKGROUND : How to best treat psychotic patients who have had past clozapine - induced agranulocytosis or granulocytopenia remains a problem .", "tokens": ["BACKGROUND", ":", "How", "to", "best", "treat", "psychotic", "patients", "who", "have", "had", "past", "clozapine", "-", "induced", "agranulocytosis", "or", "granulocytopenia", "remains", "a", "problem", "."], "event_mentions": [{"id": "10084639_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "10084639_1_Ent4", "role": "Treatment_Disorder", "text": "psychotic", "start": 6, "end": 7}, {"entity_id": "10084639_1_Ent0", "role": "Subject", "text": "psychotic patients", "start": 6, "end": 8}, {"entity_id": "10084639_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent1", "role": "Effect", "text": "agranulocytosis or granulocytopenia", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10084639_1_Ent4", "text": "psychotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10084639_1_Ent0", "text": "psychotic patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10084639_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent1", "text": "agranulocytosis or granulocytopenia", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10225085_1", "wnd_id": "10225085_1_1", "text": "Although the two local anesthetics usually do not cause methemoglobinemia , we suspect that the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants , was the reason for the development of methemoglobinemia .", "tokens": ["Although", "the", "two", "local", "anesthetics", "usually", "do", "not", "cause", "methemoglobinemia", ",", "we", "suspect", "that", "the", "displacement", "of", "lidocaine", "from", "protein", "binding", "by", "bupivacaine", ",", "in", "combination", "with", "metabolic", "acidosis", "and", "treatment", "with", "other", "oxidants", ",", "was", "the", "reason", "for", "the", "development", "of", "methemoglobinemia", "."], "event_mentions": [{"id": "10225085_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reason", "start": 37, "end": 38}, "arguments": [{"entity_id": "10225085_1_Ent1", "role": "Treatment", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "start": 14, "end": 34}, {"entity_id": "10225085_1_Ent3", "role": "Treatment_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent9", "role": "Combination_Drug", "text": "lidocaine", "start": 17, "end": 18}, {"entity_id": "10225085_1_Ent2", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent8", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_1_Ent4", "role": "Treatment_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent6", "role": "Combination_Drug", "text": "metabolic acidosis", "start": 27, "end": 29}, {"entity_id": "10225085_1_Ent5", "role": "Treatment_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent7", "role": "Combination_Drug", "text": "oxidants", "start": 33, "end": 34}, {"entity_id": "10225085_1_Ent0", "role": "Effect", "text": "methemoglobinemia", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "10225085_1_Ent1", "text": "the displacement of lidocaine from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants", "entity_type": "Entity", "start": 14, "end": 34}, {"id": "10225085_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent9", "text": "lidocaine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10225085_1_Ent2", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent8", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_1_Ent4", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent6", "text": "metabolic acidosis", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10225085_1_Ent5", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent7", "text": "oxidants", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10225085_1_Ent0", "text": "methemoglobinemia", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "10225085_2", "wnd_id": "10225085_2_1", "text": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["Methemoglobinemia", "after", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "10225085_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "10225085_2_Ent1", "role": "Treatment", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 2, "end": 15}, {"entity_id": "10225085_2_Ent3", "role": "Treatment_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent6", "role": "Combination_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent2", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "10225085_2_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 10, "end": 11}, {"entity_id": "10225085_2_Ent5", "role": "Combination_Drug", "text": "lidocaine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10225085_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10225085_2_Ent1", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "10225085_2_Ent3", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent6", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent2", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10225085_2_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10225085_2_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10225085_3", "wnd_id": "10225085_3_1", "text": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["We", "report", "a", "patient", "with", "chronic", "renal", "failure", "and", "ischemic", "heart", "disease", "who", "developed", "clinically", "significant", "methemoglobinemia", "after", "an", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "10225085_3_Ent0", "role": "Subject", "text": "a patient with chronic renal failure and ischemic heart disease", "start": 2, "end": 12}, {"entity_id": "10225085_3_Ent3", "role": "Treatment_Disorder", "text": "chronic renal failure and ischemic heart disease", "start": 5, "end": 12}, {"entity_id": "10225085_3_Ent1", "role": "Effect", "text": "clinically significant methemoglobinemia", "start": 14, "end": 17}, {"entity_id": "10225085_3_Ent2", "role": "Treatment", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 18, "end": 32}, {"entity_id": "10225085_3_Ent4", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent7", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent6", "role": "Treatment_Route", "text": "injection", "start": 25, "end": 26}, {"entity_id": "10225085_3_Ent5", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "10225085_3_Ent8", "role": "Combination_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "10225085_3_Ent0", "text": "a patient with chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "10225085_3_Ent3", "text": "chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "10225085_3_Ent1", "text": "clinically significant methemoglobinemia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10225085_3_Ent2", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 18, "end": 32}, {"id": "10225085_3_Ent4", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent7", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent6", "text": "injection", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10225085_3_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10225085_3_Ent8", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "10327035_1", "wnd_id": "10327035_1_1", "text": "An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX ) is reported in a young adult with metastastic gastric cancer .", "tokens": ["An", "episode", "of", "subacute", "encephalopathy", "after", "the", "infusion", "of", "a", "moderate", "dose", "of", "methotrexate", "(", "1500", "mg", "/", "m2", ")", "(", "MTX", ")", "is", "reported", "in", "a", "young", "adult", "with", "metastastic", "gastric", "cancer", "."], "event_mentions": [{"id": "10327035_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "10327035_1_Ent2", "role": "Effect", "text": "subacute encephalopathy", "start": 3, "end": 5}, {"entity_id": "10327035_1_Ent3", "role": "Treatment", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "start": 9, "end": 23}, {"entity_id": "10327035_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "10327035_1_Ent4", "role": "Treatment_Dosage", "text": "1500 mg / m2", "start": 15, "end": 19}, {"entity_id": "10327035_1_Ent0", "role": "Subject", "text": "a young adult with metastastic gastric cancer", "start": 26, "end": 33}, {"entity_id": "10327035_1_Ent1", "role": "Subject_Age", "text": "young adult", "start": 27, "end": 29}, {"entity_id": "10327035_1_Ent6", "role": "Treatment_Disorder", "text": "metastastic gastric cancer", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "10327035_1_Ent2", "text": "subacute encephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10327035_1_Ent3", "text": "a moderate dose of methotrexate ( 1500 mg / m2 ) ( MTX )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10327035_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10327035_1_Ent4", "text": "1500 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "10327035_1_Ent0", "text": "a young adult with metastastic gastric cancer", "entity_type": "Entity", "start": 26, "end": 33}, {"id": "10327035_1_Ent1", "text": "young adult", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "10327035_1_Ent6", "text": "metastastic gastric cancer", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "10327035_2", "wnd_id": "10327035_2_1", "text": "We believe that this represents an unusual case of moderate - dose MTX - induced neurotoxicity in a patient with gastric cancer , which has not previously been reported .", "tokens": ["We", "believe", "that", "this", "represents", "an", "unusual", "case", "of", "moderate", "-", "dose", "MTX", "-", "induced", "neurotoxicity", "in", "a", "patient", "with", "gastric", "cancer", ",", "which", "has", "not", "previously", "been", "reported", "."], "event_mentions": [{"id": "10327035_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "10327035_2_Ent5", "role": "Treatment_Dosage", "text": "moderate - dose", "start": 9, "end": 12}, {"entity_id": "10327035_2_Ent2", "role": "Treatment", "text": "moderate - dose MTX", "start": 9, "end": 13}, {"entity_id": "10327035_2_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "10327035_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 15, "end": 16}, {"entity_id": "10327035_2_Ent0", "role": "Subject", "text": "patient with gastric cancer", "start": 18, "end": 22}, {"entity_id": "10327035_2_Ent3", "role": "Treatment_Disorder", "text": "gastric cancer", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "10327035_2_Ent5", "text": "moderate - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "10327035_2_Ent2", "text": "moderate - dose MTX", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10327035_2_Ent4", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10327035_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10327035_2_Ent0", "text": "patient with gastric cancer", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "10327035_2_Ent3", "text": "gastric cancer", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "10405480_3", "wnd_id": "10405480_3_1", "text": "We report a case of acute generalized exanthematous pustulosis ( AGEP ) induced by salazosulfapyridine in a patient with ulcerative colitis .", "tokens": ["We", "report", "a", "case", "of", "acute", "generalized", "exanthematous", "pustulosis", "(", "AGEP", ")", "induced", "by", "salazosulfapyridine", "in", "a", "patient", "with", "ulcerative", "colitis", "."], "event_mentions": [{"id": "10405480_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 12, "end": 14}, "arguments": [{"entity_id": "10405480_3_Ent1", "role": "Effect", "text": "acute generalized exanthematous pustulosis ( AGEP )", "start": 5, "end": 12}, {"entity_id": "10405480_3_Ent2", "role": "Treatment", "text": "salazosulfapyridine", "start": 14, "end": 15}, {"entity_id": "10405480_3_Ent4", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 14, "end": 15}, {"entity_id": "10405480_3_Ent0", "role": "Subject", "text": "a patient with ulcerative colitis", "start": 16, "end": 21}, {"entity_id": "10405480_3_Ent3", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "10405480_3_Ent1", "text": "acute generalized exanthematous pustulosis ( AGEP )", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "10405480_3_Ent2", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10405480_3_Ent4", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10405480_3_Ent0", "text": "a patient with ulcerative colitis", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "10405480_3_Ent3", "text": "ulcerative colitis", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "10452772_3", "wnd_id": "10452772_3_1", "text": "OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin , as well as standard insulin desensitization , could control allergic symptoms in a patient allergic to both NPH and regular insulin .", "tokens": ["OBJECTIVE", ":", "The", "purpose", "of", "this", "study", "was", "to", "determine", "whether", "desensitization", "to", "NPH", "insulin", ",", "as", "well", "as", "standard", "insulin", "desensitization", ",", "could", "control", "allergic", "symptoms", "in", "a", "patient", "allergic", "to", "both", "NPH", "and", "regular", "insulin", "."], "event_mentions": [{"id": "10452772_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "control", "start": 24, "end": 25}, "arguments": [{"entity_id": "10452772_3_Ent5", "role": "Treatment_Route", "text": "desensitization", "start": 11, "end": 12}, {"entity_id": "10452772_3_Ent1", "role": "Treatment", "text": "desensitization to NPH insulin , as well as standard insulin desensitization", "start": 11, "end": 22}, {"entity_id": "10452772_3_Ent3", "role": "Treatment_Drug", "text": "NPH insulin", "start": 13, "end": 15}, {"entity_id": "10452772_3_Ent7", "role": "Combination_Drug", "text": "NPH insulin", "start": 13, "end": 15}, {"entity_id": "10452772_3_Ent4", "role": "Treatment_Drug", "text": "standard insulin", "start": 19, "end": 21}, {"entity_id": "10452772_3_Ent8", "role": "Combination_Drug", "text": "standard insulin", "start": 19, "end": 21}, {"entity_id": "10452772_3_Ent6", "role": "Treatment_Route", "text": "desensitization", "start": 21, "end": 22}, {"entity_id": "10452772_3_Ent2", "role": "Treatment_Disorder", "text": "allergic symptoms in a patient allergic to both NPH and regular insulin", "start": 25, "end": 37}, {"entity_id": "10452772_3_Ent0", "role": "Subject", "text": "a patient allergic to both NPH and regular insulin", "start": 28, "end": 37}]}], "entity_mentions": [{"id": "10452772_3_Ent5", "text": "desensitization", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10452772_3_Ent1", "text": "desensitization to NPH insulin , as well as standard insulin desensitization", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "10452772_3_Ent3", "text": "NPH insulin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10452772_3_Ent7", "text": "NPH insulin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10452772_3_Ent4", "text": "standard insulin", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10452772_3_Ent8", "text": "standard insulin", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10452772_3_Ent6", "text": "desensitization", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10452772_3_Ent2", "text": "allergic symptoms in a patient allergic to both NPH and regular insulin", "entity_type": "Entity", "start": 25, "end": 37}, {"id": "10452772_3_Ent0", "text": "a patient allergic to both NPH and regular insulin", "entity_type": "Entity", "start": 28, "end": 37}], "lang": "en"}
{"doc_id": "10461415_2", "wnd_id": "10461415_2_1", "text": "Hepato - biliary abnormalities secondary to ceftriaxone use : a case report .", "tokens": ["Hepato", "-", "biliary", "abnormalities", "secondary", "to", "ceftriaxone", "use", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10461415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 4, "end": 6}, "arguments": [{"entity_id": "10461415_2_Ent0", "role": "Effect", "text": "Hepato - biliary abnormalities", "start": 0, "end": 4}, {"entity_id": "10461415_2_Ent2", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 6, "end": 7}, {"entity_id": "10461415_2_Ent1", "role": "Treatment", "text": "ceftriaxone use", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10461415_2_Ent0", "text": "Hepato - biliary abnormalities", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10461415_2_Ent2", "text": "ceftriaxone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10461415_2_Ent1", "text": "ceftriaxone use", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10467499_2", "wnd_id": "10467499_2_1", "text": "With the negative viral serologies , the clinical picture was most consistent with an infectious mononucleosis - like syndrome produced by the minocycline ingestion .", "tokens": ["With", "the", "negative", "viral", "serologies", ",", "the", "clinical", "picture", "was", "most", "consistent", "with", "an", "infectious", "mononucleosis", "-", "like", "syndrome", "produced", "by", "the", "minocycline", "ingestion", "."], "event_mentions": [{"id": "10467499_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 19, "end": 20}, "arguments": [{"entity_id": "10467499_2_Ent0", "role": "Effect", "text": "infectious mononucleosis - like syndrome", "start": 14, "end": 19}, {"entity_id": "10467499_2_Ent3", "role": "Treatment_Drug", "text": "minocycline", "start": 22, "end": 23}, {"entity_id": "10467499_2_Ent1", "role": "Treatment", "text": "minocycline ingestion", "start": 22, "end": 24}, {"entity_id": "10467499_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10467499_2_Ent0", "text": "infectious mononucleosis - like syndrome", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10467499_2_Ent3", "text": "minocycline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10467499_2_Ent1", "text": "minocycline ingestion", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10467499_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10475726_3", "wnd_id": "10475726_3_1", "text": "This is the first report of a possible association between an acute cardiovascular event and venlafaxine .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "possible", "association", "between", "an", "acute", "cardiovascular", "event", "and", "venlafaxine", "."], "event_mentions": [{"id": "10475726_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 8, "end": 9}, "arguments": [{"entity_id": "10475726_3_Ent0", "role": "Effect", "text": "an acute cardiovascular event", "start": 10, "end": 14}, {"entity_id": "10475726_3_Ent1", "role": "Treatment", "text": "venlafaxine", "start": 15, "end": 16}, {"entity_id": "10475726_3_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "10475726_3_Ent0", "text": "an acute cardiovascular event", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10475726_3_Ent1", "text": "venlafaxine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10475726_3_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "10487084_2", "wnd_id": "10487084_2_1", "text": "Paradoxical seizures in phenytoin toxicity .", "tokens": ["Paradoxical", "seizures", "in", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "10487084_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seizures", "start": 1, "end": 2}, "arguments": [{"entity_id": "10487084_2_Ent0", "role": "Effect", "text": "Paradoxical seizures", "start": 0, "end": 2}, {"entity_id": "10487084_2_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "10487084_2_Ent1", "role": "Treatment", "text": "phenytoin toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "10487084_2_Ent0", "text": "Paradoxical seizures", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10487084_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10487084_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "10492493_3", "wnd_id": "10492493_3_1", "text": "OBJECTIVE : To report a case of angioedema associated with losartan administration .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "angioedema", "associated", "with", "losartan", "administration", "."], "event_mentions": [{"id": "10492493_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_3_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "10492493_3_Ent1", "role": "Effect", "text": "angioedema", "start": 7, "end": 8}, {"entity_id": "10492493_3_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "10492493_3_Ent2", "role": "Treatment", "text": "losartan administration", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10492493_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10492493_3_Ent1", "text": "angioedema", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10492493_3_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10492493_3_Ent2", "text": "losartan administration", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10510017_3", "wnd_id": "10510017_3_1", "text": "There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin - induced thrombocytopenia , especially in children .", "tokens": ["There", "remains", "a", "paucity", "of", "information", "pertaining", "to", "alternative", "anticoagulation", "strategies", "for", "use", "during", "cardiopulmonary", "bypass", "concomitant", "with", "heparin", "-", "induced", "thrombocytopenia", ",", "especially", "in", "children", "."], "event_mentions": [{"id": "10510017_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "10510017_3_Ent3", "role": "Treatment", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 18, "end": 19}, {"entity_id": "10510017_3_Ent2", "role": "Effect", "text": "thrombocytopenia", "start": 21, "end": 22}, {"entity_id": "10510017_3_Ent0", "role": "Subject", "text": "children", "start": 25, "end": 26}, {"entity_id": "10510017_3_Ent1", "role": "Subject_Age", "text": "children", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10510017_3_Ent3", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent4", "text": "heparin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10510017_3_Ent2", "text": "thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10510017_3_Ent0", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10510017_3_Ent1", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10510017_4", "wnd_id": "10510017_4_1", "text": "We report the successful treatment of heparin - induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ) .", "tokens": ["We", "report", "the", "successful", "treatment", "of", "heparin", "-", "induced", "thrombocytopenia", "and", "subsequent", "hemorrhagic", "complications", "postoperatively", "in", "a", "2", "-", "year", "-", "old", "child", "with", "Danaparoid", "(", "orgaran", ")", "."], "event_mentions": [{"id": "10510017_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "10510017_4_Ent8", "role": "Treatment_Disorder", "text": "heparin - induced thrombocytopenia and subsequent hemorrhagic complications", "start": 6, "end": 14}, {"entity_id": "10510017_4_Ent5", "role": "Subject", "text": "a 2 - year - old child", "start": 16, "end": 23}, {"entity_id": "10510017_4_Ent6", "role": "Subject_Age", "text": "2 - year - old child", "start": 17, "end": 23}, {"entity_id": "10510017_4_Ent9", "role": "Treatment_Drug", "text": "Danaparoid", "start": 24, "end": 25}, {"entity_id": "10510017_4_Ent7", "role": "Treatment", "text": "Danaparoid ( orgaran )", "start": 24, "end": 28}]}, {"id": "10510017_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10510017_4_Ent3", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "10510017_4_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "10510017_4_Ent2", "role": "Effect", "text": "thrombocytopenia and subsequent hemorrhagic complications", "start": 9, "end": 14}, {"entity_id": "10510017_4_Ent0", "role": "Subject", "text": "a 2 - year - old child", "start": 16, "end": 23}, {"entity_id": "10510017_4_Ent1", "role": "Subject_Age", "text": "2 - year - old child", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "10510017_4_Ent3", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10510017_4_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10510017_4_Ent8", "text": "heparin - induced thrombocytopenia and subsequent hemorrhagic complications", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "10510017_4_Ent2", "text": "thrombocytopenia and subsequent hemorrhagic complications", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "10510017_4_Ent0", "text": "a 2 - year - old child", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10510017_4_Ent5", "text": "a 2 - year - old child", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "10510017_4_Ent1", "text": "2 - year - old child", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "10510017_4_Ent6", "text": "2 - year - old child", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "10510017_4_Ent9", "text": "Danaparoid", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10510017_4_Ent7", "text": "Danaparoid ( orgaran )", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10510156_2", "wnd_id": "10510156_2_1", "text": "AIMS : To identify the   human cytochrome P450 enzyme ( s ) involved in the in vitro metabolism of rosiglitazone , a potential oral antidiabetic agent for the treatment of type 2 diabetes - mellitus .", "tokens": ["AIMS", ":", "To", "identify", "the", " ", "human", "cytochrome", "P450", "enzyme", "(", "s", ")", "involved", "in", "the", "in", "vitro", "metabolism", "of", "rosiglitazone", ",", "a", "potential", "oral", "antidiabetic", "agent", "for", "the", "treatment", "of", "type", "2", "diabetes", "-", "mellitus", "."], "event_mentions": [{"id": "10510156_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "potential oral", "start": 23, "end": 25}, "arguments": [{"entity_id": "10510156_2_Ent0", "role": "Treatment", "text": "rosiglitazone", "start": 20, "end": 21}, {"entity_id": "10510156_2_Ent1", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 20, "end": 21}, {"entity_id": "10510156_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "10510156_2_Ent2", "role": "Treatment_Disorder", "text": "type 2 diabetes - mellitus .", "start": 31, "end": 37}]}], "entity_mentions": [{"id": "10510156_2_Ent0", "text": "rosiglitazone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10510156_2_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10510156_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10510156_2_Ent2", "text": "type 2 diabetes - mellitus .", "entity_type": "Entity", "start": 31, "end": 37}], "lang": "en"}
{"doc_id": "10524732_2", "wnd_id": "10524732_2_1", "text": "We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone .", "tokens": ["We", "report", "a", "case", "of", "recurrent", "torsades", "de", "pointes", "following", "treatment", "with", "pentavalent", "antimonial", "drugs", "and", "amiodarone", "."], "event_mentions": [{"id": "10524732_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment with", "start": 10, "end": 12}, "arguments": [{"entity_id": "10524732_2_Ent0", "role": "Effect", "text": "recurrent torsades de pointes", "start": 5, "end": 9}, {"entity_id": "10524732_2_Ent3", "role": "Treatment_Drug", "text": "pentavalent antimonial drugs", "start": 12, "end": 15}, {"entity_id": "10524732_2_Ent4", "role": "Combination_Drug", "text": "pentavalent antimonial drugs", "start": 12, "end": 15}, {"entity_id": "10524732_2_Ent1", "role": "Treatment", "text": "pentavalent antimonial drugs and amiodarone", "start": 12, "end": 17}, {"entity_id": "10524732_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 16, "end": 17}, {"entity_id": "10524732_2_Ent5", "role": "Combination_Drug", "text": "amiodarone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10524732_2_Ent0", "text": "recurrent torsades de pointes", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10524732_2_Ent3", "text": "pentavalent antimonial drugs", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10524732_2_Ent4", "text": "pentavalent antimonial drugs", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10524732_2_Ent1", "text": "pentavalent antimonial drugs and amiodarone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10524732_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10524732_2_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10573314_8", "wnd_id": "10573314_8_1", "text": "Thus , tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits .", "tokens": ["Thus", ",", "tolterodine", "was", "ineffective", "in", "both", "patients", "and", "was", "discontinued", "one", "to", "two", "days", "before", "the", "elevated", "INRs", "were", "determined", "during", "routine", "clinic", "visits", "."], "event_mentions": [{"id": "10573314_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ineffective", "start": 4, "end": 5}, "arguments": [{"entity_id": "10573314_8_Ent1", "role": "Treatment", "text": "tolterodine", "start": 2, "end": 3}, {"entity_id": "10573314_8_Ent2", "role": "Treatment_Drug", "text": "tolterodine", "start": 2, "end": 3}, {"entity_id": "10573314_8_Ent0", "role": "Subject", "text": "both patients", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10573314_8_Ent1", "text": "tolterodine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10573314_8_Ent2", "text": "tolterodine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10573314_8_Ent0", "text": "both patients", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10579985_2", "wnd_id": "10579985_2_1", "text": "The relationship between infliximab treatment and lymphoma in Crohn 's disease .", "tokens": ["The", "relationship", "between", "infliximab", "treatment", "and", "lymphoma", "in", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "10579985_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 2, "end": 3}, "arguments": [{"entity_id": "10579985_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "10579985_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "10579985_2_Ent0", "role": "Effect", "text": "lymphoma", "start": 6, "end": 7}, {"entity_id": "10579985_2_Ent2", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "10579985_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10579985_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10579985_2_Ent0", "text": "lymphoma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10579985_2_Ent2", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "10589077_1", "wnd_id": "10589077_1_1", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB ) have been shown to increase fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia .", "tokens": ["Hydroxyurea", "(", "HU", ")", "and", "sodium", "phenylbutyrate", "(", "SPB", ")", "have", "been", "shown", "to", "increase", "fetal", "hemoglobin", "(", "Hb", "F", ")", "levels", "in", "patients", "with", "thalassemia", "intermedia", "."], "event_mentions": [{"id": "10589077_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 14, "end": 15}, "arguments": [{"entity_id": "10589077_1_Ent3", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10589077_1_Ent6", "role": "Combination_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10589077_1_Ent2", "role": "Treatment", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB )", "start": 0, "end": 10}, {"entity_id": "10589077_1_Ent4", "role": "Treatment_Drug", "text": "sodium phenylbutyrate", "start": 5, "end": 7}, {"entity_id": "10589077_1_Ent7", "role": "Combination_Drug", "text": "sodium phenylbutyrate", "start": 5, "end": 7}, {"entity_id": "10589077_1_Ent1", "role": "Effect", "text": "hemoglobin ( Hb F ) levels", "start": 16, "end": 22}, {"entity_id": "10589077_1_Ent0", "role": "Subject", "text": "patients with thalassemia intermedia", "start": 23, "end": 27}, {"entity_id": "10589077_1_Ent5", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "10589077_1_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10589077_1_Ent6", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10589077_1_Ent2", "text": "Hydroxyurea ( HU ) and sodium phenylbutyrate ( SPB )", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10589077_1_Ent4", "text": "sodium phenylbutyrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10589077_1_Ent7", "text": "sodium phenylbutyrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10589077_1_Ent1", "text": "hemoglobin ( Hb F ) levels", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "10589077_1_Ent0", "text": "patients with thalassemia intermedia", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10589077_1_Ent5", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "10592946_1", "wnd_id": "10592946_1_1", "text": "A 36 - y - o patient with schizophrenia , who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day , became delirious and was admitted to a psychiatric hospital .", "tokens": ["A", "36", "-", "y", "-", "o", "patient", "with", "schizophrenia", ",", "who", "had", "consumed", "gradually", "increasing", "quantities", "of", "oolong", "tea", "that", "eventually", "reached", "15", "L", "each", "day", ",", "became", "delirious", "and", "was", "admitted", "to", "a", "psychiatric", "hospital", "."], "event_mentions": [{"id": "10592946_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 27, "end": 28}, "arguments": [{"entity_id": "10592946_1_Ent0", "role": "Subject", "text": "A 36 - y - o patient with schizophrenia", "start": 0, "end": 9}, {"entity_id": "10592946_1_Ent1", "role": "Subject_Age", "text": "36 - y - o", "start": 1, "end": 6}, {"entity_id": "10592946_1_Ent2", "role": "Subject_Disorder", "text": "schizophrenia", "start": 8, "end": 9}, {"entity_id": "10592946_1_Ent4", "role": "Treatment", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "start": 13, "end": 26}, {"entity_id": "10592946_1_Ent7", "role": "Treatment_Drug", "text": "oolong tea", "start": 17, "end": 19}, {"entity_id": "10592946_1_Ent5", "role": "Treatment_Dosage", "text": "15 L", "start": 22, "end": 24}, {"entity_id": "10592946_1_Ent6", "role": "Treatment_Freq", "text": "each day", "start": 24, "end": 26}, {"entity_id": "10592946_1_Ent3", "role": "Effect", "text": "delirious", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "10592946_1_Ent0", "text": "A 36 - y - o patient with schizophrenia", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "10592946_1_Ent1", "text": "36 - y - o", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10592946_1_Ent2", "text": "schizophrenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10592946_1_Ent4", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "10592946_1_Ent7", "text": "oolong tea", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10592946_1_Ent5", "text": "15 L", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10592946_1_Ent6", "text": "each day", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "10592946_1_Ent3", "text": "delirious", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "10614572_3", "wnd_id": "10614572_3_1", "text": "We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11 - year - old girl .", "tokens": ["We", "report", "a", "case", "of", "severe", "hypotension", "associated", "with", "intravenous", "valproate", "used", "to", "treat", "status", "epilepticus", "in", "an", "11", "-", "year", "-", "old", "girl", "."], "event_mentions": [{"id": "10614572_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "10614572_3_Ent3", "role": "Effect", "text": "hypotension", "start": 6, "end": 7}, {"entity_id": "10614572_3_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 9, "end": 10}, {"entity_id": "10614572_3_Ent4", "role": "Treatment", "text": "intravenous valproate", "start": 9, "end": 11}, {"entity_id": "10614572_3_Ent7", "role": "Treatment_Drug", "text": "valproate", "start": 10, "end": 11}, {"entity_id": "10614572_3_Ent5", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 14, "end": 16}, {"entity_id": "10614572_3_Ent0", "role": "Subject", "text": "an 11 - year - old girl", "start": 17, "end": 24}, {"entity_id": "10614572_3_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 18, "end": 23}, {"entity_id": "10614572_3_Ent2", "role": "Subject_Gender", "text": "girl", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10614572_3_Ent3", "text": "hypotension", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10614572_3_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10614572_3_Ent4", "text": "intravenous valproate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10614572_3_Ent7", "text": "valproate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10614572_3_Ent5", "text": "status epilepticus", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10614572_3_Ent0", "text": "an 11 - year - old girl", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "10614572_3_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "10614572_3_Ent2", "text": "girl", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10619721_1", "wnd_id": "10619721_1_1", "text": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine .", "tokens": ["In", "both", "patients", "the", "rippling", "phenomena", "worsened", "with", "pyridostigmine", "treatment", "but", "markedly", "improved", "after", "immunosuppression", "with", "azathioprine", "."], "event_mentions": [{"id": "10619721_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "worsened", "start": 6, "end": 7}, "arguments": [{"entity_id": "10619721_1_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "10619721_1_Ent0", "role": "Subject", "text": "both patients", "start": 1, "end": 3}, {"entity_id": "10619721_1_Ent2", "role": "Effect", "text": "rippling phenomena", "start": 4, "end": 6}, {"entity_id": "10619721_1_Ent3", "role": "Treatment", "text": "pyridostigmine", "start": 8, "end": 9}, {"entity_id": "10619721_1_Ent4", "role": "Treatment_Drug", "text": "pyridostigmine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10619721_1_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10619721_1_Ent0", "text": "both patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10619721_1_Ent2", "text": "rippling phenomena", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10619721_1_Ent3", "text": "pyridostigmine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10619721_1_Ent4", "text": "pyridostigmine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10633877_3", "wnd_id": "10633877_3_1", "text": "Theophylline intoxication mimicking diabetic ketoacidosis in a child .", "tokens": ["Theophylline", "intoxication", "mimicking", "diabetic", "ketoacidosis", "in", "a", "child", "."], "event_mentions": [{"id": "10633877_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "10633877_3_Ent3", "role": "Treatment", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "10633877_3_Ent4", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "10633877_3_Ent2", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "10633877_3_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "10633877_3_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10633877_3_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10633877_3_Ent4", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10633877_3_Ent2", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10633877_3_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10633877_3_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10650865_2", "wnd_id": "10650865_2_1", "text": "We report on a 14 - year - old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII .", "tokens": ["We", "report", "on", "a", "14", "-", "year", "-", "old", "boy", "with", "severe", "haemophilia", "A", "who", "developed", "a", "portal", "vein", "thrombosis", "during", "continuous", "infusion", "of", "F", "VIII", "."], "event_mentions": [{"id": "10650865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "10650865_2_Ent0", "role": "Subject", "text": "a 14 - year - old boy with severe haemophilia A", "start": 3, "end": 14}, {"entity_id": "10650865_2_Ent1", "role": "Subject_Age", "text": "14 - year - old", "start": 4, "end": 9}, {"entity_id": "10650865_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 9, "end": 10}, {"entity_id": "10650865_2_Ent8", "role": "Treatment_Disorder", "text": "haemophilia A", "start": 12, "end": 14}, {"entity_id": "10650865_2_Ent3", "role": "Effect", "text": "a portal vein thrombosis", "start": 16, "end": 20}, {"entity_id": "10650865_2_Ent5", "role": "Treatment_Freq", "text": "continuous", "start": 21, "end": 22}, {"entity_id": "10650865_2_Ent4", "role": "Treatment", "text": "continuous infusion of F VIII", "start": 21, "end": 26}, {"entity_id": "10650865_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}, {"entity_id": "10650865_2_Ent7", "role": "Treatment_Drug", "text": "F VIII", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "10650865_2_Ent0", "text": "a 14 - year - old boy with severe haemophilia A", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "10650865_2_Ent1", "text": "14 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10650865_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10650865_2_Ent8", "text": "haemophilia A", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10650865_2_Ent3", "text": "a portal vein thrombosis", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "10650865_2_Ent5", "text": "continuous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10650865_2_Ent4", "text": "continuous infusion of F VIII", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "10650865_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10650865_2_Ent7", "text": "F VIII", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "10656221_1", "wnd_id": "10656221_1_1", "text": "Gliclazide - induced acute hepatitis .", "tokens": ["Gliclazide", "-", "induced", "acute", "hepatitis", "."], "event_mentions": [{"id": "10656221_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10656221_1_Ent1", "role": "Treatment", "text": "Gliclazide", "start": 0, "end": 1}, {"entity_id": "10656221_1_Ent2", "role": "Treatment_Drug", "text": "Gliclazide", "start": 0, "end": 1}, {"entity_id": "10656221_1_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "10656221_1_Ent1", "text": "Gliclazide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10656221_1_Ent2", "text": "Gliclazide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10656221_1_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "10660641_2", "wnd_id": "10660641_2_1", "text": "A patient treated with itraconazole ( ITCZ ) under the diagnosis of Aspergillus flavus - induced chronic hypertrophic pachymeningitis is presented .", "tokens": ["A", "patient", "treated", "with", "itraconazole", "(", "ITCZ", ")", "under", "the", "diagnosis", "of", "Aspergillus", "flavus", "-", "induced", "chronic", "hypertrophic", "pachymeningitis", "is", "presented", "."], "event_mentions": [{"id": "10660641_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10660641_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "10660641_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "10660641_2_Ent1", "role": "Treatment", "text": "itraconazole ( ITCZ )", "start": 4, "end": 8}, {"entity_id": "10660641_2_Ent3", "role": "Treatment_Disorder", "text": "Aspergillus flavus - induced chronic hypertrophic pachymeningitis", "start": 12, "end": 19}]}], "entity_mentions": [{"id": "10660641_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10660641_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10660641_2_Ent1", "text": "itraconazole ( ITCZ )", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10660641_2_Ent3", "text": "Aspergillus flavus - induced chronic hypertrophic pachymeningitis", "entity_type": "Entity", "start": 12, "end": 19}], "lang": "en"}
{"doc_id": "10660641_7", "wnd_id": "10660641_7_1", "text": "The infection tended to subside with the AMPH administration .", "tokens": ["The", "infection", "tended", "to", "subside", "with", "the", "AMPH", "administration", "."], "event_mentions": [{"id": "10660641_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subside", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_7_Ent0", "role": "Effect", "text": "infection tended", "start": 1, "end": 3}, {"entity_id": "10660641_7_Ent2", "role": "Treatment_Drug", "text": "AMPH", "start": 7, "end": 8}, {"entity_id": "10660641_7_Ent1", "role": "Treatment", "text": "AMPH administration", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10660641_7_Ent0", "text": "infection tended", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_7_Ent2", "text": "AMPH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10660641_7_Ent1", "text": "AMPH administration", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10660641_8", "wnd_id": "10660641_8_1", "text": "Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective , daily administration of 200 mg of ITCZ was initiated , and the inflammatory signs and symptoms gradually subsided .", "tokens": ["Since", "renal", "insufficiency", "was", "induced", "by", "AMPH", "and", "the", "other", "antifungal", "drugs", "were", "ineffective", ",", "daily", "administration", "of", "200", "mg", "of", "ITCZ", "was", "initiated", ",", "and", "the", "inflammatory", "signs", "and", "symptoms", "gradually", "subsided", "."], "event_mentions": [{"id": "10660641_8_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_8_Ent6", "role": "Effect", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent7", "role": "Treatment", "text": "AMPH", "start": 6, "end": 7}, {"entity_id": "10660641_8_Ent8", "role": "Treatment_Drug", "text": "AMPH", "start": 6, "end": 7}]}, {"id": "10660641_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 23, "end": 24}, "arguments": [{"entity_id": "10660641_8_Ent2", "role": "Treatment_Disorder", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent4", "role": "Treatment_Freq", "text": "daily administration", "start": 15, "end": 17}, {"entity_id": "10660641_8_Ent1", "role": "Treatment", "text": "daily administration of 200 mg of ITCZ", "start": 15, "end": 22}, {"entity_id": "10660641_8_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 18, "end": 20}, {"entity_id": "10660641_8_Ent5", "role": "Treatment_Drug", "text": "ITCZ", "start": 21, "end": 22}, {"entity_id": "10660641_8_Ent0", "role": "Effect", "text": "the inflammatory signs and symptoms gradually subsided .", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "10660641_8_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent6", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent7", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent8", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent4", "text": "daily administration", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10660641_8_Ent1", "text": "daily administration of 200 mg of ITCZ", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10660641_8_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10660641_8_Ent5", "text": "ITCZ", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10660641_8_Ent0", "text": "the inflammatory signs and symptoms gradually subsided .", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "10667036_1", "wnd_id": "10667036_1_1", "text": "Caution is , therefore , needed to prevent undesired accumulation of TCA that may lead to protracted Cushing 's syndrome .", "tokens": ["Caution", "is", ",", "therefore", ",", "needed", "to", "prevent", "undesired", "accumulation", "of", "TCA", "that", "may", "lead", "to", "protracted", "Cushing", "'s", "syndrome", "."], "event_mentions": [{"id": "10667036_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead to", "start": 14, "end": 16}, "arguments": [{"entity_id": "10667036_1_Ent1", "role": "Treatment", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent2", "role": "Treatment_Drug", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent0", "role": "Effect", "text": "protracted Cushing 's syndrome", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "10667036_1_Ent1", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent2", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent0", "text": "protracted Cushing 's syndrome", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "10679548_4", "wnd_id": "10679548_4_1", "text": "The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP .", "tokens": ["The", "favourable", "outcome", "in", "these", "two", "patients", "contrasts", "with", "the", "fatal", "outcome", "of", "the", "two", "other", "reported", "cases", "of", "nitrofurantoin", "induced", "BOOP", "."], "event_mentions": [{"id": "10679548_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "10679548_4_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "10679548_4_Ent0", "role": "Subject", "text": "two patients", "start": 5, "end": 7}, {"entity_id": "10679548_4_Ent3", "role": "Treatment", "text": "nitrofurantoin", "start": 19, "end": 20}, {"entity_id": "10679548_4_Ent4", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 19, "end": 20}, {"entity_id": "10679548_4_Ent2", "role": "Effect", "text": "BOOP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10679548_4_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10679548_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10679548_4_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10679548_4_Ent4", "text": "nitrofurantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10679548_4_Ent2", "text": "BOOP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10682234_2", "wnd_id": "10682234_2_1", "text": "A 28 year - old man with chronic hepatitis B was administered interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days .", "tokens": ["A", "28", "year", "-", "old", "man", "with", "chronic", "hepatitis", "B", "was", "administered", "interferon", "-", "alpha", "(", "5", "x", "10(6", ")", "IU", ")", "intramuscularly", "once", "a", "day", "for", "28", "days", "."], "event_mentions": [{"id": "10682234_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 11, "end": 12}, "arguments": [{"entity_id": "10682234_2_Ent0", "role": "Subject", "text": "A 28 year - old man with chronic hepatitis B", "start": 0, "end": 10}, {"entity_id": "10682234_2_Ent1", "role": "Subject_Age", "text": "28 year - old", "start": 1, "end": 5}, {"entity_id": "10682234_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 5, "end": 6}, {"entity_id": "10682234_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis B", "start": 7, "end": 10}, {"entity_id": "10682234_2_Ent5", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "10682234_2_Ent3", "role": "Treatment", "text": "interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days", "start": 12, "end": 29}, {"entity_id": "10682234_2_Ent6", "role": "Treatment_Route", "text": "intramuscularly", "start": 22, "end": 23}, {"entity_id": "10682234_2_Ent7", "role": "Treatment_Freq", "text": "once a day", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "10682234_2_Ent0", "text": "A 28 year - old man with chronic hepatitis B", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10682234_2_Ent1", "text": "28 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10682234_2_Ent2", "text": "man", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10682234_2_Ent4", "text": "chronic hepatitis B", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10682234_2_Ent5", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10682234_2_Ent3", "text": "interferon - alpha ( 5 x 10(6 ) IU ) intramuscularly once a day for 28 days", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "10682234_2_Ent6", "text": "intramuscularly", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10682234_2_Ent7", "text": "once a day", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "10682234_3", "wnd_id": "10682234_3_1", "text": "Eight days after the end of interferon treatment , he showed signs of inability to sit still for ten seconds and walked around constantly .", "tokens": ["Eight", "days", "after", "the", "end", "of", "interferon", "treatment", ",", "he", "showed", "signs", "of", "inability", "to", "sit", "still", "for", "ten", "seconds", "and", "walked", "around", "constantly", "."], "event_mentions": [{"id": "10682234_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inability", "start": 13, "end": 14}, "arguments": [{"entity_id": "10682234_3_Ent4", "role": "Treatment_Time_elapsed", "text": "Eight days", "start": 0, "end": 2}, {"entity_id": "10682234_3_Ent3", "role": "Treatment", "text": "Eight days after the end of interferon treatment", "start": 0, "end": 8}, {"entity_id": "10682234_3_Ent5", "role": "Treatment_Drug", "text": "interferon", "start": 6, "end": 7}, {"entity_id": "10682234_3_Ent0", "role": "Subject", "text": "he", "start": 9, "end": 10}, {"entity_id": "10682234_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 9, "end": 10}, {"entity_id": "10682234_3_Ent2", "role": "Effect", "text": "signs of inability to sit still for ten seconds and walked around constantly", "start": 11, "end": 24}]}], "entity_mentions": [{"id": "10682234_3_Ent4", "text": "Eight days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10682234_3_Ent3", "text": "Eight days after the end of interferon treatment", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10682234_3_Ent5", "text": "interferon", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10682234_3_Ent0", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10682234_3_Ent1", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10682234_3_Ent2", "text": "signs of inability to sit still for ten seconds and walked around constantly", "entity_type": "Entity", "start": 11, "end": 24}], "lang": "en"}
{"doc_id": "10682234_6", "wnd_id": "10682234_6_1", "text": "Two days ' administration of levomepromazine 100 mg led him to a coma for 2 days .", "tokens": ["Two", "days", "'", "administration", "of", "levomepromazine", "100", "mg", "led", "him", "to", "a", "coma", "for", "2", "days", "."], "event_mentions": [{"id": "10682234_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 8, "end": 9}, "arguments": [{"entity_id": "10682234_6_Ent4", "role": "Treatment_Duration", "text": "Two days", "start": 0, "end": 2}, {"entity_id": "10682234_6_Ent1", "role": "Treatment", "text": "Two days ' administration of levomepromazine 100 mg", "start": 0, "end": 8}, {"entity_id": "10682234_6_Ent2", "role": "Treatment_Drug", "text": "levomepromazine", "start": 5, "end": 6}, {"entity_id": "10682234_6_Ent3", "role": "Treatment_Dosage", "text": "100 mg", "start": 6, "end": 8}, {"entity_id": "10682234_6_Ent0", "role": "Effect", "text": "a coma for 2 days", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10682234_6_Ent4", "text": "Two days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10682234_6_Ent1", "text": "Two days ' administration of levomepromazine 100 mg", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10682234_6_Ent2", "text": "levomepromazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10682234_6_Ent3", "text": "100 mg", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_6_Ent0", "text": "a coma for 2 days", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10682234_8", "wnd_id": "10682234_8_1", "text": "He became completely premorbid 2 weeks after administration of levodopa .", "tokens": ["He", "became", "completely", "premorbid", "2", "weeks", "after", "administration", "of", "levodopa", "."], "event_mentions": [{"id": "10682234_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "10682234_8_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "10682234_8_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "10682234_8_Ent2", "role": "Effect", "text": "premorbid", "start": 3, "end": 4}, {"entity_id": "10682234_8_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 4, "end": 6}, {"entity_id": "10682234_8_Ent3", "role": "Treatment", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "10682234_8_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "10682234_8_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_8_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_8_Ent2", "text": "premorbid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_8_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10682234_8_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10682234_8_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "10698143_4", "wnd_id": "10698143_4_1", "text": "We report the case of an 11 - month - old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone .", "tokens": ["We", "report", "the", "case", "of", "an", "11", "-", "month", "-", "old", "female", "infant", "with", "a", "depressed", "level", "of", "consciousness", "after", "ingestion", "of", "ibuprofen", "whose", "mental", "status", "markedly", "improved", "with", "administration", "of", "naloxone", "."], "event_mentions": [{"id": "10698143_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10698143_4_Ent0", "role": "Subject", "text": "an 11 - month - old female infant", "start": 5, "end": 13}, {"entity_id": "10698143_4_Ent1", "role": "Subject_Age", "text": "11 - month - old", "start": 6, "end": 11}, {"entity_id": "10698143_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "10698143_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "10698143_4_Ent4", "role": "Effect", "text": "a depressed level of consciousness", "start": 14, "end": 19}, {"entity_id": "10698143_4_Ent7", "role": "Treatment_Route", "text": "ingestion", "start": 20, "end": 21}, {"entity_id": "10698143_4_Ent5", "role": "Treatment", "text": "ingestion of ibuprofen", "start": 20, "end": 23}, {"entity_id": "10698143_4_Ent6", "role": "Treatment_Drug", "text": "ibuprofen", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "10698143_4_Ent0", "text": "an 11 - month - old female infant", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10698143_4_Ent1", "text": "11 - month - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10698143_4_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10698143_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10698143_4_Ent4", "text": "a depressed level of consciousness", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10698143_4_Ent7", "text": "ingestion", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10698143_4_Ent5", "text": "ingestion of ibuprofen", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10698143_4_Ent6", "text": "ibuprofen", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "10707759_1", "wnd_id": "10707759_1_1", "text": "Flecainide - associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome .", "tokens": ["Flecainide", "-", "associated", "pneumonitis", "with", "acute", "respiratory", "failure", "in", "a", "patient", "with", "the", "LEOPARD", "syndrome", "."], "event_mentions": [{"id": "10707759_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10707759_1_Ent2", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent3", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_1_Ent1", "role": "Effect", "text": "pneumonitis with acute respiratory failure", "start": 3, "end": 8}, {"entity_id": "10707759_1_Ent0", "role": "Subject", "text": "a patient with the LEOPARD syndrome", "start": 9, "end": 15}, {"entity_id": "10707759_1_Ent4", "role": "Treatment_Disorder", "text": "LEOPARD syndrome .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10707759_1_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent3", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_1_Ent1", "text": "pneumonitis with acute respiratory failure", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10707759_1_Ent0", "text": "a patient with the LEOPARD syndrome", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "10707759_1_Ent4", "text": "LEOPARD syndrome .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10715308_4", "wnd_id": "10715308_4_1", "text": "Patients with previously untreated NSCLC were randomized to receive either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles .", "tokens": ["Patients", "with", "previously", "untreated", "NSCLC", "were", "randomized", "to", "receive", "either", "tirapazamine", "(", "390", "mg", "/", "m(2", ")", "infused", "over", "2", "hours", ")", "followed", "1", "hour", "later", "by", "cisplatin", "(", "75", "mg", "/", "m(2", ")", "over", "1", "hour", ")", "or", "75", "mg", "/", "m(2", ")", "of", "cisplatin", "alone", ",", "every", "3", "weeks", "for", "a", "maximum", "of", "eight", "cycles", "."], "event_mentions": [{"id": "10715308_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 8, "end": 9}, "arguments": [{"entity_id": "10715308_4_Ent0", "role": "Subject", "text": "Patients with previously untreated NSCLC", "start": 0, "end": 5}, {"entity_id": "10715308_4_Ent12", "role": "Treatment_Disorder", "text": "NSCLC", "start": 4, "end": 5}, {"entity_id": "10715308_4_Ent1", "role": "Treatment", "text": "either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles", "start": 9, "end": 57}, {"entity_id": "10715308_4_Ent2", "role": "Treatment_Drug", "text": "tirapazamine", "start": 10, "end": 11}, {"entity_id": "10715308_4_Ent13", "role": "Combination_Drug", "text": "tirapazamine", "start": 10, "end": 11}, {"entity_id": "10715308_4_Ent5", "role": "Treatment_Dosage", "text": "390 mg / m(2 )", "start": 12, "end": 17}, {"entity_id": "10715308_4_Ent8", "role": "Treatment_Route", "text": "infused", "start": 17, "end": 18}, {"entity_id": "10715308_4_Ent9", "role": "Treatment_Time_elapsed", "text": "over 2 hours", "start": 18, "end": 21}, {"entity_id": "10715308_4_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "10715308_4_Ent14", "role": "Combination_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "10715308_4_Ent6", "role": "Treatment_Dosage", "text": "75 mg / m(2 )", "start": 29, "end": 34}, {"entity_id": "10715308_4_Ent10", "role": "Treatment_Time_elapsed", "text": "over 1 hour", "start": 34, "end": 37}, {"entity_id": "10715308_4_Ent7", "role": "Treatment_Dosage", "text": "75 mg / m(2 )", "start": 39, "end": 44}, {"entity_id": "10715308_4_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 45, "end": 46}, {"entity_id": "10715308_4_Ent11", "role": "Treatment_Freq", "text": "every 3 weeks for a maximum of eight cycles", "start": 48, "end": 57}]}], "entity_mentions": [{"id": "10715308_4_Ent0", "text": "Patients with previously untreated NSCLC", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10715308_4_Ent12", "text": "NSCLC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10715308_4_Ent1", "text": "either tirapazamine ( 390 mg / m(2 ) infused over 2 hours ) followed 1 hour later by cisplatin ( 75 mg / m(2 ) over 1 hour ) or 75 mg / m(2 ) of cisplatin alone , every 3 weeks for a maximum of eight cycles", "entity_type": "Entity", "start": 9, "end": 57}, {"id": "10715308_4_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10715308_4_Ent13", "text": "tirapazamine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10715308_4_Ent5", "text": "390 mg / m(2 )", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10715308_4_Ent8", "text": "infused", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10715308_4_Ent9", "text": "over 2 hours", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10715308_4_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10715308_4_Ent14", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10715308_4_Ent6", "text": "75 mg / m(2 )", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "10715308_4_Ent10", "text": "over 1 hour", "entity_type": "Entity", "start": 34, "end": 37}, {"id": "10715308_4_Ent7", "text": "75 mg / m(2 )", "entity_type": "Entity", "start": 39, "end": 44}, {"id": "10715308_4_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 45, "end": 46}, {"id": "10715308_4_Ent11", "text": "every 3 weeks for a maximum of eight cycles", "entity_type": "Entity", "start": 48, "end": 57}], "lang": "en"}
{"doc_id": "10717401_1", "wnd_id": "10717401_1_1", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L - asparaginase treatment : case report and review of the literature .", "tokens": ["Sagittal", "sinus", "thrombosis", "associated", "with", "transient", "free", "protein", "S", "deficiency", "after", "L", "-", "asparaginase", "treatment", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "10717401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "10717401_1_Ent0", "role": "Effect", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency", "start": 0, "end": 10}, {"entity_id": "10717401_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "10717401_1_Ent1", "role": "Treatment", "text": "L - asparaginase treatment", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10717401_1_Ent0", "text": "Sagittal sinus thrombosis associated with transient free protein S deficiency", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10717401_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10717401_1_Ent1", "text": "L - asparaginase treatment", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10728450_1", "wnd_id": "10728450_1_1", "text": "We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.", "tokens": ["We", "report", "2", "patients", "who", "developed", "polyarteritis", "nodosa", "following", "vaccination", "against", "hepatitis", "B."], "event_mentions": [{"id": "10728450_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10728450_1_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "10728450_1_Ent0", "role": "Subject", "text": "2 patients", "start": 2, "end": 4}, {"entity_id": "10728450_1_Ent2", "role": "Effect", "text": "polyarteritis nodosa", "start": 6, "end": 8}, {"entity_id": "10728450_1_Ent3", "role": "Treatment", "text": "vaccination against hepatitis B.", "start": 9, "end": 13}, {"entity_id": "10728450_1_Ent4", "role": "Treatment_Drug", "text": "vaccination against hepatitis B.", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "10728450_1_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10728450_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10728450_1_Ent2", "text": "polyarteritis nodosa", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10728450_1_Ent3", "text": "vaccination against hepatitis B.", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10728450_1_Ent4", "text": "vaccination against hepatitis B.", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "10745478_1", "wnd_id": "10745478_1_1", "text": "This case report illustrates the use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine - induced refractory coronary vasospasm .", "tokens": ["This", "case", "report", "illustrates", "the", "use", "of", "continuous", "high", "-", "dose", "intracoronary", "nitroglycerin", "infusion", "through", "a", "6", "French", "coronary", "guiding", "catheter", "in", "the", "treatment", "of", "a", "patient", "with", "cocaine", "-", "induced", "refractory", "coronary", "vasospasm", "."], "event_mentions": [{"id": "10745478_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "10745478_1_Ent3", "role": "Treatment", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "start": 5, "end": 21}, {"entity_id": "10745478_1_Ent7", "role": "Treatment_Dosage", "text": "high - dose", "start": 8, "end": 11}, {"entity_id": "10745478_1_Ent5", "role": "Treatment_Drug", "text": "intracoronary nitroglycerin", "start": 11, "end": 13}, {"entity_id": "10745478_1_Ent6", "role": "Treatment_Route", "text": "infusion through a 6 French coronary guiding catheter", "start": 13, "end": 21}, {"entity_id": "10745478_1_Ent4", "role": "Treatment_Disorder", "text": "cocaine - induced refractory coronary vasospasm", "start": 28, "end": 34}]}, {"id": "10745478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "10745478_1_Ent1", "role": "Treatment", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent2", "role": "Treatment_Drug", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent0", "role": "Effect", "text": "refractory coronary vasospasm", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "10745478_1_Ent3", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "10745478_1_Ent7", "text": "high - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10745478_1_Ent5", "text": "intracoronary nitroglycerin", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10745478_1_Ent6", "text": "infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "10745478_1_Ent1", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent2", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent4", "text": "cocaine - induced refractory coronary vasospasm", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "10745478_1_Ent0", "text": "refractory coronary vasospasm", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "10755579_2", "wnd_id": "10755579_2_1", "text": "The medical examiner 's report indicated death caused by fluoxetine toxicity .", "tokens": ["The", "medical", "examiner", "'s", "report", "indicated", "death", "caused", "by", "fluoxetine", "toxicity", "."], "event_mentions": [{"id": "10755579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "10755579_2_Ent0", "role": "Effect", "text": "death", "start": 6, "end": 7}, {"entity_id": "10755579_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "10755579_2_Ent1", "role": "Treatment", "text": "fluoxetine toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10755579_2_Ent0", "text": "death", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10755579_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10755579_2_Ent1", "text": "fluoxetine toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10755579_3", "wnd_id": "10755579_3_1", "text": "This is the first report of a fluoxetine - related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "fluoxetine", "-", "related", "death", "in", "a", "child", "with", "a", "confirmed", "genetic", "polymorphism", "of", "the", "CYP2D6", "gene", "that", "results", "in", "impaired", "drug", "metabolism", "."], "event_mentions": [{"id": "10755579_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10755579_3_Ent4", "role": "Treatment", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "10755579_3_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "10755579_3_Ent3", "role": "Effect", "text": "death", "start": 10, "end": 11}, {"entity_id": "10755579_3_Ent0", "role": "Subject", "text": "a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "start": 12, "end": 29}, {"entity_id": "10755579_3_Ent1", "role": "Subject_Age", "text": "child", "start": 13, "end": 14}, {"entity_id": "10755579_3_Ent2", "role": "Subject_Disorder", "text": "genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "start": 17, "end": 29}]}], "entity_mentions": [{"id": "10755579_3_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10755579_3_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10755579_3_Ent3", "text": "death", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10755579_3_Ent0", "text": "a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "10755579_3_Ent1", "text": "child", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10755579_3_Ent2", "text": "genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "entity_type": "Entity", "start": 17, "end": 29}], "lang": "en"}
{"doc_id": "10774758_2", "wnd_id": "10774758_2_1", "text": "This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide .", "tokens": ["This", "is", "the", "first", "report", "of", "an", "adverse", "effect", "of", "fetal", "renal", "circulation", "by", "maternal", "ingestion", "of", "nimesulide", "."], "event_mentions": [{"id": "10774758_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "10774758_2_Ent0", "role": "Subject", "text": "first report of an adverse effect of fetal renal circulation", "start": 3, "end": 13}, {"entity_id": "10774758_2_Ent1", "role": "Effect", "text": "fetal renal circulation", "start": 10, "end": 13}, {"entity_id": "10774758_2_Ent5", "role": "Treatment_Route", "text": "maternal ingestion", "start": 14, "end": 16}, {"entity_id": "10774758_2_Ent2", "role": "Treatment", "text": "maternal ingestion of nimesulide", "start": 14, "end": 18}, {"entity_id": "10774758_2_Ent3", "role": "Treatment", "text": "nimesulide", "start": 17, "end": 18}, {"entity_id": "10774758_2_Ent4", "role": "Treatment_Drug", "text": "nimesulide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10774758_2_Ent0", "text": "first report of an adverse effect of fetal renal circulation", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "10774758_2_Ent1", "text": "fetal renal circulation", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10774758_2_Ent5", "text": "maternal ingestion", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10774758_2_Ent2", "text": "maternal ingestion of nimesulide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10774758_2_Ent3", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10774758_2_Ent4", "text": "nimesulide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10779995_3", "wnd_id": "10779995_3_1", "text": "The authors present a case of t - AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide , given for palliation purpose .", "tokens": ["The", "authors", "present", "a", "case", "of", "t", "-", "AML", "that", "developed", "in", "a", "child", "with", "metastatic", "neuroblastoma", "18", "months", "after", "he", "received", "oral", "etoposide", ",", "given", "for", "palliation", "purpose", "."], "event_mentions": [{"id": "10779995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10779995_3_Ent2", "role": "Effect", "text": "t - AML", "start": 6, "end": 9}, {"entity_id": "10779995_3_Ent0", "role": "Subject", "text": "a child with metastatic neuroblastoma", "start": 12, "end": 17}, {"entity_id": "10779995_3_Ent1", "role": "Subject_Age", "text": "child", "start": 13, "end": 14}, {"entity_id": "10779995_3_Ent7", "role": "Treatment_Disorder", "text": "metastatic neuroblastoma", "start": 15, "end": 17}, {"entity_id": "10779995_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 17, "end": 19}, {"entity_id": "10779995_3_Ent5", "role": "Treatment_Route", "text": "oral", "start": 22, "end": 23}, {"entity_id": "10779995_3_Ent3", "role": "Treatment", "text": "oral etoposide", "start": 22, "end": 24}, {"entity_id": "10779995_3_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10779995_3_Ent2", "text": "t - AML", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10779995_3_Ent0", "text": "a child with metastatic neuroblastoma", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10779995_3_Ent1", "text": "child", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10779995_3_Ent7", "text": "metastatic neuroblastoma", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10779995_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10779995_3_Ent5", "text": "oral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10779995_3_Ent3", "text": "oral etoposide", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10779995_3_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10803790_4", "wnd_id": "10803790_4_1", "text": "Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases .", "tokens": ["Case", "4", ":", "A", "61", "-", "year", "-", "old", "male", "alcoholic", "who", "remained", "completely", "abstinent", "while", "taking", "cyanamide", "for", "3", "years", "showed", "slight", "elevation", "of", "serum", "transaminases", "."], "event_mentions": [{"id": "10803790_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 16, "end": 17}, "arguments": [{"entity_id": "10803790_4_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_4_Ent0", "role": "Subject", "text": "61 - year - old male alcoholic who remained completely abstinent", "start": 4, "end": 15}, {"entity_id": "10803790_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "10803790_4_Ent7", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_4_Ent5", "role": "Treatment_Drug", "text": "cyanamide", "start": 17, "end": 18}, {"entity_id": "10803790_4_Ent4", "role": "Treatment", "text": "cyanamide for 3 years", "start": 17, "end": 21}, {"entity_id": "10803790_4_Ent6", "role": "Treatment_Duration", "text": "3 years", "start": 19, "end": 21}, {"entity_id": "10803790_4_Ent3", "role": "Effect", "text": "elevation of serum transaminases", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "10803790_4_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_4_Ent0", "text": "61 - year - old male alcoholic who remained completely abstinent", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10803790_4_Ent2", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_4_Ent7", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_4_Ent5", "text": "cyanamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10803790_4_Ent4", "text": "cyanamide for 3 years", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10803790_4_Ent6", "text": "3 years", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10803790_4_Ent3", "text": "elevation of serum transaminases", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "10812579_1", "wnd_id": "10812579_1_1", "text": "A 77 - year - old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma .", "tokens": ["A", "77", "-", "year", "-", "old", "woman", "with", "no", "history", "of", "epilepsy", "presented", "a", "probable", "nonconvulsive", "status", "epilepticus", "while", "receiving", "continuous", "intravenous", "morphine", "for", "back", "pain", "relating", "to", "vertebral", "metastasis", "of", "a", "malignant", "lymphoma", "."], "event_mentions": [{"id": "10812579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 19, "end": 20}, "arguments": [{"entity_id": "10812579_1_Ent0", "role": "Subject", "text": "A 77 - year - old woman with no history of epilepsy", "start": 0, "end": 12}, {"entity_id": "10812579_1_Ent1", "role": "Subject_Age", "text": "77 - year - old", "start": 1, "end": 6}, {"entity_id": "10812579_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10812579_1_Ent3", "role": "Subject_Disorder", "text": "no history of epilepsy", "start": 8, "end": 12}, {"entity_id": "10812579_1_Ent4", "role": "Effect", "text": "a probable nonconvulsive status epilepticus", "start": 13, "end": 18}, {"entity_id": "10812579_1_Ent8", "role": "Treatment_Freq", "text": "continuous", "start": 20, "end": 21}, {"entity_id": "10812579_1_Ent5", "role": "Treatment", "text": "continuous intravenous morphine", "start": 20, "end": 23}, {"entity_id": "10812579_1_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "10812579_1_Ent6", "role": "Treatment_Drug", "text": "morphine", "start": 22, "end": 23}, {"entity_id": "10812579_1_Ent9", "role": "Treatment_Disorder", "text": "back pain relating to vertebral metastasis of a malignant lymphoma", "start": 24, "end": 34}]}], "entity_mentions": [{"id": "10812579_1_Ent0", "text": "A 77 - year - old woman with no history of epilepsy", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "10812579_1_Ent1", "text": "77 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10812579_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10812579_1_Ent3", "text": "no history of epilepsy", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10812579_1_Ent4", "text": "a probable nonconvulsive status epilepticus", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "10812579_1_Ent8", "text": "continuous", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10812579_1_Ent5", "text": "continuous intravenous morphine", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10812579_1_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10812579_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10812579_1_Ent9", "text": "back pain relating to vertebral metastasis of a malignant lymphoma", "entity_type": "Entity", "start": 24, "end": 34}], "lang": "en"}
{"doc_id": "10840527_1", "wnd_id": "10840527_1_1", "text": "Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials , case reports , and chart reviews , it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( EPS ) .", "tokens": ["Although", "the", "literature", "on", "the", "use", "of", "risperidone", "in", "elderly", "patients", "with", "dementia", "consists", "largely", "of", "uncontrolled", "trials", ",", "case", "reports", ",", "and", "chart", "reviews", ",", "it", "appears", "that", "this", "agent", "is", "effective", "for", "managing", "agitation", "in", "this", "population", "and", "does", "so", "with", "a", "low", "frequency", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "."], "event_mentions": [{"id": "10840527_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "is", "start": 31, "end": 32}, "arguments": [{"entity_id": "10840527_1_Ent2", "role": "Treatment", "text": "use of risperidone", "start": 5, "end": 8}, {"entity_id": "10840527_1_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10840527_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 9, "end": 10}, {"entity_id": "10840527_1_Ent0", "role": "Subject", "text": "elderly patients with dementia", "start": 9, "end": 13}, {"entity_id": "10840527_1_Ent4", "role": "Treatment_Disorder", "text": "dementia", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10840527_1_Ent2", "text": "use of risperidone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10840527_1_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10840527_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10840527_1_Ent0", "text": "elderly patients with dementia", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10840527_1_Ent4", "text": "dementia", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10891991_1", "wnd_id": "10891991_1_1", "text": "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy , especially if they develop menstrual cycle disturbances during treatment .", "tokens": ["An", "evaluation", "of", "ovarian", "structure", "and", "function", "should", "be", "considered", "in", "women", "of", "reproductive", "age", "being", "treated", "with", "valproate", "for", "epilepsy", ",", "especially", "if", "they", "develop", "menstrual", "cycle", "disturbances", "during", "treatment", "."], "event_mentions": [{"id": "10891991_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "10891991_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}, {"entity_id": "10891991_1_Ent0", "role": "Subject", "text": "women of reproductive age", "start": 11, "end": 15}, {"entity_id": "10891991_1_Ent2", "role": "Subject_Age", "text": "reproductive age", "start": 13, "end": 15}, {"entity_id": "10891991_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 18, "end": 19}, {"entity_id": "10891991_1_Ent4", "role": "Treatment", "text": "valproate for epilepsy", "start": 18, "end": 21}, {"entity_id": "10891991_1_Ent6", "role": "Treatment_Disorder", "text": "epilepsy", "start": 20, "end": 21}, {"entity_id": "10891991_1_Ent3", "role": "Effect", "text": "menstrual cycle disturbances", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "10891991_1_Ent1", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10891991_1_Ent0", "text": "women of reproductive age", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "10891991_1_Ent2", "text": "reproductive age", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10891991_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10891991_1_Ent4", "text": "valproate for epilepsy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10891991_1_Ent6", "text": "epilepsy", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_1_Ent3", "text": "menstrual cycle disturbances", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "10891991_5", "wnd_id": "10891991_5_1", "text": "PATIENTS : Three patients developed a reproductive endocrine disorder during treatment with valproate .", "tokens": ["PATIENTS", ":", "Three", "patients", "developed", "a", "reproductive", "endocrine", "disorder", "during", "treatment", "with", "valproate", "."], "event_mentions": [{"id": "10891991_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "10891991_5_Ent1", "role": "Subject_Population", "text": "Three", "start": 2, "end": 3}, {"entity_id": "10891991_5_Ent0", "role": "Subject", "text": "Three patients", "start": 2, "end": 4}, {"entity_id": "10891991_5_Ent2", "role": "Effect", "text": "reproductive endocrine disorder", "start": 6, "end": 9}, {"entity_id": "10891991_5_Ent3", "role": "Treatment", "text": "valproate", "start": 12, "end": 13}, {"entity_id": "10891991_5_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10891991_5_Ent1", "text": "Three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10891991_5_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10891991_5_Ent2", "text": "reproductive endocrine disorder", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10891991_5_Ent3", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10891991_5_Ent4", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10891991_7", "wnd_id": "10891991_7_1", "text": "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued , and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication .", "tokens": ["The", "polycystic", "changes", "disappeared", "from", "the", "ovaries", "in", "2", "of", "the", "women", "after", "valproate", "therapy", "was", "discontinued", ",", "and", "the", "2", "women", "who", "had", "gained", "weight", "and", "developed", "amenorrhea", "while", "being", "treated", "with", "valproate", "lost", "weight", "and", "resumed", "menstruating", "after", "the", "change", "in", "medication", "."], "event_mentions": [{"id": "10891991_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 3, "end": 4}, "arguments": [{"entity_id": "10891991_7_Ent3", "role": "Effect", "text": "polycystic changes disappeared from the ovaries", "start": 1, "end": 7}, {"entity_id": "10891991_7_Ent1", "role": "Subject_Population", "text": "2", "start": 8, "end": 9}, {"entity_id": "10891991_7_Ent0", "role": "Subject", "text": "2 of the women", "start": 8, "end": 12}, {"entity_id": "10891991_7_Ent2", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}, {"entity_id": "10891991_7_Ent5", "role": "Treatment", "text": "after valproate therapy was discontinued", "start": 12, "end": 17}, {"entity_id": "10891991_7_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 13, "end": 14}, {"entity_id": "10891991_7_Ent4", "role": "Effect", "text": "lost weight and resumed menstruating", "start": 34, "end": 39}]}, {"id": "10891991_7_Evt1", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 29, "end": 30}, "arguments": [{"entity_id": "10891991_7_Ent8", "role": "Subject_Population", "text": "2", "start": 20, "end": 21}, {"entity_id": "10891991_7_Ent7", "role": "Subject", "text": "2 women", "start": 20, "end": 22}, {"entity_id": "10891991_7_Ent9", "role": "Subject_Gender", "text": "women", "start": 21, "end": 22}, {"entity_id": "10891991_7_Ent10", "role": "Effect", "text": "gained weight and developed amenorrhea", "start": 24, "end": 29}, {"entity_id": "10891991_7_Ent11", "role": "Treatment", "text": "valproate", "start": 33, "end": 34}, {"entity_id": "10891991_7_Ent12", "role": "Treatment_Drug", "text": "valproate", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "10891991_7_Ent3", "text": "polycystic changes disappeared from the ovaries", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "10891991_7_Ent1", "text": "2", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10891991_7_Ent0", "text": "2 of the women", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10891991_7_Ent2", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10891991_7_Ent5", "text": "after valproate therapy was discontinued", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10891991_7_Ent6", "text": "valproate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10891991_7_Ent8", "text": "2", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_7_Ent7", "text": "2 women", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10891991_7_Ent9", "text": "women", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10891991_7_Ent10", "text": "gained weight and developed amenorrhea", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "10891991_7_Ent11", "text": "valproate", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10891991_7_Ent12", "text": "valproate", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10891991_7_Ent4", "text": "lost weight and resumed menstruating", "entity_type": "Entity", "start": 34, "end": 39}], "lang": "en"}
{"doc_id": "10904571_1", "wnd_id": "10904571_1_1", "text": "A 60 year - old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine .", "tokens": ["A", "60", "year", "-", "old", "woman", "with", "chronic", "renal", "failure", "developed", "acute", "proximal", "muscle", "weakness", "after", "receiving", "a", "regular", "dosage", "of", "colchicine", "."], "event_mentions": [{"id": "10904571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "10904571_1_Ent0", "role": "Subject", "text": "A 60 year - old woman with chronic renal failure", "start": 0, "end": 10}, {"entity_id": "10904571_1_Ent1", "role": "Subject_Age", "text": "60 year - old", "start": 1, "end": 5}, {"entity_id": "10904571_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "10904571_1_Ent5", "role": "Treatment_Disorder", "text": "chronic renal failure", "start": 7, "end": 10}, {"entity_id": "10904571_1_Ent3", "role": "Effect", "text": "acute proximal muscle weakness", "start": 11, "end": 15}, {"entity_id": "10904571_1_Ent7", "role": "Treatment_Dosage", "text": "regular dosage", "start": 18, "end": 20}, {"entity_id": "10904571_1_Ent4", "role": "Treatment", "text": "regular dosage of colchicine", "start": 18, "end": 22}, {"entity_id": "10904571_1_Ent6", "role": "Treatment_Drug", "text": "colchicine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10904571_1_Ent0", "text": "A 60 year - old woman with chronic renal failure", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "10904571_1_Ent1", "text": "60 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10904571_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10904571_1_Ent5", "text": "chronic renal failure", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10904571_1_Ent3", "text": "acute proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "10904571_1_Ent7", "text": "regular dosage", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10904571_1_Ent4", "text": "regular dosage of colchicine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "10904571_1_Ent6", "text": "colchicine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10904571_3", "wnd_id": "10904571_3_1", "text": "Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine - induced myopathy .", "tokens": ["Muscle", "biopsy", "revealed", "variation", "in", "muscle", "fiber", "size", "and", "few", "vacuolated", "fibers", "which", "were", "features", "of", "colchicine", "-", "induced", "myopathy", "."], "event_mentions": [{"id": "10904571_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "10904571_3_Ent0", "role": "Effect", "text": "variation in muscle fiber size and few vacuolated fibers", "start": 3, "end": 12}, {"entity_id": "10904571_3_Ent2", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "10904571_3_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "10904571_3_Ent1", "role": "Effect", "text": "myopathy", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "10904571_3_Ent0", "text": "variation in muscle fiber size and few vacuolated fibers", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "10904571_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10904571_3_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10904571_3_Ent1", "text": "myopathy", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "10907391_2", "wnd_id": "10907391_2_1", "text": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity .", "tokens": ["Phantom", "limb", "pain", "as", "a", "manifestation", "of", "paclitaxel", "neurotoxicity", "."], "event_mentions": [{"id": "10907391_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestation", "start": 5, "end": 6}, "arguments": [{"entity_id": "10907391_2_Ent0", "role": "Effect", "text": "Phantom limb pain", "start": 0, "end": 3}, {"entity_id": "10907391_2_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "10907391_2_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10907391_2_Ent0", "text": "Phantom limb pain", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10907391_2_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10907391_2_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10981493_3", "wnd_id": "10981493_3_1", "text": "Propafenone - induced ataxia : report of three cases .", "tokens": ["Propafenone", "-", "induced", "ataxia", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "10981493_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10981493_3_Ent3", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "10981493_3_Ent4", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "10981493_3_Ent2", "role": "Effect", "text": "ataxia", "start": 3, "end": 4}, {"entity_id": "10981493_3_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "10981493_3_Ent0", "role": "Subject", "text": "three cases", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10981493_3_Ent3", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_3_Ent4", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_3_Ent2", "text": "ataxia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10981493_3_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10981493_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11001600_1", "wnd_id": "11001600_1_1", "text": "The cases are important in documenting that drug - induced dystonias do occur in patients with dementia , that risperidone appears to have contributed to dystonia among elderly patients , and that the categorization of dystonic reactions needs further clarification .", "tokens": ["The", "cases", "are", "important", "in", "documenting", "that", "drug", "-", "induced", "dystonias", "do", "occur", "in", "patients", "with", "dementia", ",", "that", "risperidone", "appears", "to", "have", "contributed", "to", "dystonia", "among", "elderly", "patients", ",", "and", "that", "the", "categorization", "of", "dystonic", "reactions", "needs", "further", "clarification", "."], "event_mentions": [{"id": "11001600_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 23, "end": 24}, "arguments": [{"entity_id": "11001600_1_Ent0", "role": "Subject", "text": "patients with dementia", "start": 14, "end": 17}, {"entity_id": "11001600_1_Ent2", "role": "Subject_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "11001600_1_Ent5", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "11001600_1_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "11001600_1_Ent4", "role": "Effect", "text": "dystonia", "start": 25, "end": 26}, {"entity_id": "11001600_1_Ent3", "role": "Subject_Age", "text": "elderly", "start": 27, "end": 28}, {"entity_id": "11001600_1_Ent1", "role": "Subject", "text": "elderly patients", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "11001600_1_Ent0", "text": "patients with dementia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11001600_1_Ent2", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11001600_1_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11001600_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11001600_1_Ent4", "text": "dystonia", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11001600_1_Ent3", "text": "elderly", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11001600_1_Ent1", "text": "elderly patients", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "11008259_3", "wnd_id": "11008259_3_1", "text": "This is the first report of non - convulsive status epilepticus provoked by tiagabine in adolescent patients .", "tokens": ["This", "is", "the", "first", "report", "of", "non", "-", "convulsive", "status", "epilepticus", "provoked", "by", "tiagabine", "in", "adolescent", "patients", "."], "event_mentions": [{"id": "11008259_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 11, "end": 12}, "arguments": [{"entity_id": "11008259_3_Ent2", "role": "Effect", "text": "non - convulsive status epilepticus", "start": 6, "end": 11}, {"entity_id": "11008259_3_Ent3", "role": "Treatment", "text": "tiagabine", "start": 13, "end": 14}, {"entity_id": "11008259_3_Ent4", "role": "Treatment_Drug", "text": "tiagabine", "start": 13, "end": 14}, {"entity_id": "11008259_3_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 15, "end": 16}, {"entity_id": "11008259_3_Ent0", "role": "Subject", "text": "adolescent patients", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11008259_3_Ent2", "text": "non - convulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11008259_3_Ent3", "text": "tiagabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11008259_3_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11008259_3_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11008259_3_Ent0", "text": "adolescent patients", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "110153_1", "wnd_id": "110153_1_1", "text": "There have been many reports of probable lithium - induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range .", "tokens": ["There", "have", "been", "many", "reports", "of", "probable", "lithium", "-", "induced", "organic", "brain", "syndromes", "occurring", "when", "serum", "lithium", "levels", "are", "within", "or", "close", "to", "the", "therapeutic", "range", "."], "event_mentions": [{"id": "110153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "110153_1_Ent1", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent0", "role": "Effect", "text": "organic brain syndromes", "start": 10, "end": 13}, {"entity_id": "110153_1_Ent2", "role": "Treatment", "text": "when serum lithium levels are within or close to the therapeutic range", "start": 14, "end": 26}]}], "entity_mentions": [{"id": "110153_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent0", "text": "organic brain syndromes", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "110153_1_Ent2", "text": "when serum lithium levels are within or close to the therapeutic range", "entity_type": "Entity", "start": 14, "end": 26}], "lang": "en"}
{"doc_id": "11020127_3", "wnd_id": "11020127_3_1", "text": "Ritonavir acted as a CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity .", "tokens": ["Ritonavir", "acted", "as", "a", "CYP3A4", "inhibitor", ",", "diminishing", "carbamazepine", "metabolism", "and", "provoking", "an", "increase", "in", "serum", "levels", "and", "clinical", "toxicity", "."], "event_mentions": [{"id": "11020127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "acted", "start": 1, "end": 2}, "arguments": [{"entity_id": "11020127_3_Ent1", "role": "Treatment", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent2", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent0", "role": "Effect", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "start": 4, "end": 20}]}], "entity_mentions": [{"id": "11020127_3_Ent1", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent2", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent0", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "entity_type": "Entity", "start": 4, "end": 20}], "lang": "en"}
{"doc_id": "11022272_1", "wnd_id": "11022272_1_1", "text": "Anaphylaxis to calcitonin .", "tokens": ["Anaphylaxis", "to", "calcitonin", "."], "event_mentions": [{"id": "11022272_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "11022272_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "11022272_1_Ent1", "role": "Treatment", "text": "calcitonin", "start": 2, "end": 3}, {"entity_id": "11022272_1_Ent2", "role": "Treatment_Drug", "text": "calcitonin", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "11022272_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11022272_1_Ent1", "text": "calcitonin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11022272_1_Ent2", "text": "calcitonin", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "11022272_2", "wnd_id": "11022272_2_1", "text": "CONCLUSION : We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction .", "tokens": ["CONCLUSION", ":", "We", "have", "introduced", "a", "case", "of", "anaphylaxis", "by", "calcitonin", "that", "suggest", "an", "IgE", "mediated", "hypersensitivity", "reaction", "."], "event_mentions": [{"id": "11022272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 9, "end": 10}, "arguments": [{"entity_id": "11022272_2_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}, {"entity_id": "11022272_2_Ent1", "role": "Effect", "text": "anaphylaxis", "start": 8, "end": 9}, {"entity_id": "11022272_2_Ent2", "role": "Treatment", "text": "calcitonin", "start": 10, "end": 11}, {"entity_id": "11022272_2_Ent3", "role": "Treatment_Drug", "text": "calcitonin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11022272_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11022272_2_Ent1", "text": "anaphylaxis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11022272_2_Ent2", "text": "calcitonin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11022272_2_Ent3", "text": "calcitonin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11026106_2", "wnd_id": "11026106_2_1", "text": "Minocycline - induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis .", "tokens": ["Minocycline", "-", "induced", "autoimmune", "hepatitis", "is", "usually", "identical", "to", "sporadic", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11026106_2_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent3", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 3, "end": 5}, {"entity_id": "11026106_2_Ent2", "role": "Treatment_Disorder", "text": "sporadic autoimmune hepatitis", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "11026106_2_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent3", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11026106_2_Ent2", "text": "sporadic autoimmune hepatitis", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "11026106_3", "wnd_id": "11026106_3_1", "text": "We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline - induced autoimmune hepatitis ( group 1 ) .", "tokens": ["We", "describe", "the", "clinical", "and", "liver", "biopsy", "morphologic", "features", "for", "4", "patients", "with", "minocycline", "-", "induced", "autoimmune", "hepatitis", "(", "group", "1", ")", "."], "event_mentions": [{"id": "11026106_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "11026106_3_Ent1", "role": "Subject_Population", "text": "4", "start": 10, "end": 11}, {"entity_id": "11026106_3_Ent0", "role": "Subject", "text": "4 patients", "start": 10, "end": 12}, {"entity_id": "11026106_3_Ent3", "role": "Treatment", "text": "minocycline", "start": 13, "end": 14}, {"entity_id": "11026106_3_Ent4", "role": "Treatment_Drug", "text": "minocycline", "start": 13, "end": 14}, {"entity_id": "11026106_3_Ent2", "role": "Effect", "text": "autoimmune hepatitis", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "11026106_3_Ent1", "text": "4", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11026106_3_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11026106_3_Ent3", "text": "minocycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11026106_3_Ent4", "text": "minocycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11026106_3_Ent2", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "11030530_1", "wnd_id": "11030530_1_1", "text": "L - asparaginase - provoked seizures as singular expression of central nervous toxicity .", "tokens": ["L", "-", "asparaginase", "-", "provoked", "seizures", "as", "singular", "expression", "of", "central", "nervous", "toxicity", "."], "event_mentions": [{"id": "11030530_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "11030530_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent0", "role": "Effect", "text": "seizures as singular expression of central nervous toxicity", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "11030530_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent0", "text": "seizures as singular expression of central nervous toxicity", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "11030530_2", "wnd_id": "11030530_2_1", "text": "Patients treated with L - asparaginase may present with hemorrhagic and thrombotic cerebrovascular events .", "tokens": ["Patients", "treated", "with", "L", "-", "asparaginase", "may", "present", "with", "hemorrhagic", "and", "thrombotic", "cerebrovascular", "events", "."], "event_mentions": [{"id": "11030530_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 7, "end": 8}, "arguments": [{"entity_id": "11030530_2_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "11030530_2_Ent2", "role": "Treatment", "text": "L - asparaginase", "start": 3, "end": 6}, {"entity_id": "11030530_2_Ent3", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 3, "end": 6}, {"entity_id": "11030530_2_Ent1", "role": "Effect", "text": "hemorrhagic and thrombotic cerebrovascular events", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "11030530_2_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11030530_2_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11030530_2_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11030530_2_Ent1", "text": "hemorrhagic and thrombotic cerebrovascular events", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "11033734_1", "wnd_id": "11033734_1_1", "text": "Eighty - two patients with various malignancies who received imipenem / cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology , Gazi University , were identified .", "tokens": ["Eighty", "-", "two", "patients", "with", "various", "malignancies", "who", "received", "imipenem", "/", "cilastatin", "143", "times", "for", "neutropenic", "fever", "between", "March", "1994", "and", "October", "1999", "in", "Department", "of", "Pediatric", "Oncology", ",", "Gazi", "University", ",", "were", "identified", "."], "event_mentions": [{"id": "11033734_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 8, "end": 9}, "arguments": [{"entity_id": "11033734_1_Ent1", "role": "Subject_Population", "text": "Eighty - two", "start": 0, "end": 3}, {"entity_id": "11033734_1_Ent0", "role": "Subject", "text": "Eighty - two patients with various malignancies", "start": 0, "end": 7}, {"entity_id": "11033734_1_Ent2", "role": "Subject_Disorder", "text": "various malignancies", "start": 5, "end": 7}, {"entity_id": "11033734_1_Ent4", "role": "Treatment_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_1_Ent7", "role": "Combination_Drug", "text": "imipenem", "start": 9, "end": 10}, {"entity_id": "11033734_1_Ent3", "role": "Treatment", "text": "imipenem / cilastatin 143 times for neutropenic fever", "start": 9, "end": 17}, {"entity_id": "11033734_1_Ent5", "role": "Treatment_Drug", "text": "cilastatin", "start": 11, "end": 12}, {"entity_id": "11033734_1_Ent8", "role": "Combination_Drug", "text": "cilastatin", "start": 11, "end": 12}, {"entity_id": "11033734_1_Ent6", "role": "Treatment_Disorder", "text": "neutropenic fever", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11033734_1_Ent1", "text": "Eighty - two", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11033734_1_Ent0", "text": "Eighty - two patients with various malignancies", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11033734_1_Ent2", "text": "various malignancies", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11033734_1_Ent4", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_1_Ent7", "text": "imipenem", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11033734_1_Ent3", "text": "imipenem / cilastatin 143 times for neutropenic fever", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "11033734_1_Ent5", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11033734_1_Ent8", "text": "cilastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11033734_1_Ent6", "text": "neutropenic fever", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11033734_3", "wnd_id": "11033734_3_1", "text": "Proconvulsive tendency of imipenem / cilastatin is one of its well - known side effects .", "tokens": ["Proconvulsive", "tendency", "of", "imipenem", "/", "cilastatin", "is", "one", "of", "its", "well", "-", "known", "side", "effects", "."], "event_mentions": [{"id": "11033734_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 13, "end": 15}, "arguments": [{"entity_id": "11033734_3_Ent0", "role": "Effect", "text": "Proconvulsive tendency", "start": 0, "end": 2}, {"entity_id": "11033734_3_Ent3", "role": "Treatment_Drug", "text": "imipenem", "start": 3, "end": 4}, {"entity_id": "11033734_3_Ent4", "role": "Combination_Drug", "text": "imipenem", "start": 3, "end": 4}, {"entity_id": "11033734_3_Ent1", "role": "Treatment", "text": "imipenem / cilastatin", "start": 3, "end": 6}, {"entity_id": "11033734_3_Ent2", "role": "Treatment_Drug", "text": "cilastatin", "start": 5, "end": 6}, {"entity_id": "11033734_3_Ent5", "role": "Combination_Drug", "text": "cilastatin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11033734_3_Ent0", "text": "Proconvulsive tendency", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11033734_3_Ent3", "text": "imipenem", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11033734_3_Ent4", "text": "imipenem", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11033734_3_Ent1", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11033734_3_Ent2", "text": "cilastatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_3_Ent5", "text": "cilastatin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11033734_4", "wnd_id": "11033734_4_1", "text": "Three of these patients had convulsions attributed to imipenem / cilastatin ; 3.6 % of the patients had seizure , or 2 % of imipenem / cilastatin administrations was followed by a seizure attack .", "tokens": ["Three", "of", "these", "patients", "had", "convulsions", "attributed", "to", "imipenem", "/", "cilastatin", ";", "3.6", "%", "of", "the", "patients", "had", "seizure", ",", "or", "2", "%", "of", "imipenem", "/", "cilastatin", "administrations", "was", "followed", "by", "a", "seizure", "attack", "."], "event_mentions": [{"id": "11033734_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 6, "end": 7}, "arguments": [{"entity_id": "11033734_4_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "11033734_4_Ent0", "role": "Subject", "text": "Three of these patients", "start": 0, "end": 4}, {"entity_id": "11033734_4_Ent2", "role": "Effect", "text": "convulsions", "start": 5, "end": 6}, {"entity_id": "11033734_4_Ent4", "role": "Treatment_Drug", "text": "imipenem", "start": 8, "end": 9}, {"entity_id": "11033734_4_Ent6", "role": "Combination_Drug", "text": "imipenem", "start": 8, "end": 9}, {"entity_id": "11033734_4_Ent3", "role": "Treatment", "text": "imipenem / cilastatin", "start": 8, "end": 11}, {"entity_id": "11033734_4_Ent5", "role": "Treatment_Drug", "text": "cilastatin", "start": 10, "end": 11}, {"entity_id": "11033734_4_Ent7", "role": "Combination_Drug", "text": "cilastatin", "start": 10, "end": 11}]}, {"id": "11033734_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11033734_4_Ent8", "role": "Subject", "text": "2 %", "start": 21, "end": 23}, {"entity_id": "11033734_4_Ent9", "role": "Subject_Population", "text": "2 %", "start": 21, "end": 23}, {"entity_id": "11033734_4_Ent12", "role": "Treatment_Drug", "text": "imipenem", "start": 24, "end": 25}, {"entity_id": "11033734_4_Ent14", "role": "Combination_Drug", "text": "imipenem", "start": 24, "end": 25}, {"entity_id": "11033734_4_Ent11", "role": "Treatment", "text": "imipenem / cilastatin", "start": 24, "end": 27}, {"entity_id": "11033734_4_Ent13", "role": "Treatment_Drug", "text": "cilastatin", "start": 26, "end": 27}, {"entity_id": "11033734_4_Ent15", "role": "Combination_Drug", "text": "cilastatin", "start": 26, "end": 27}, {"entity_id": "11033734_4_Ent10", "role": "Effect", "text": "seizure", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11033734_4_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11033734_4_Ent0", "text": "Three of these patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11033734_4_Ent2", "text": "convulsions", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_4_Ent4", "text": "imipenem", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11033734_4_Ent6", "text": "imipenem", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11033734_4_Ent3", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11033734_4_Ent5", "text": "cilastatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11033734_4_Ent7", "text": "cilastatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11033734_4_Ent8", "text": "2 %", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11033734_4_Ent9", "text": "2 %", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11033734_4_Ent12", "text": "imipenem", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11033734_4_Ent14", "text": "imipenem", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11033734_4_Ent11", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11033734_4_Ent13", "text": "cilastatin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "11033734_4_Ent15", "text": "cilastatin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "11033734_4_Ent10", "text": "seizure", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11034877_1", "wnd_id": "11034877_1_1", "text": "Gabapentin - induced mood changes with hypomanic features in adults .", "tokens": ["Gabapentin", "-", "induced", "mood", "changes", "with", "hypomanic", "features", "in", "adults", "."], "event_mentions": [{"id": "11034877_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11034877_1_Ent3", "role": "Treatment", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "11034877_1_Ent4", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "11034877_1_Ent2", "role": "Effect", "text": "mood changes with hypomanic features", "start": 3, "end": 8}, {"entity_id": "11034877_1_Ent0", "role": "Subject", "text": "adults", "start": 9, "end": 10}, {"entity_id": "11034877_1_Ent1", "role": "Subject_Age", "text": "adults", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11034877_1_Ent3", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11034877_1_Ent4", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11034877_1_Ent2", "text": "mood changes with hypomanic features", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11034877_1_Ent0", "text": "adults", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11034877_1_Ent1", "text": "adults", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11077455_2", "wnd_id": "11077455_2_1", "text": "Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .", "tokens": ["Electro", "-", "oculography", ",", "electroretinography", ",", "visual", "evoked", "potentials", ",", "and", "multifocal", "electroretinography", "in", "patients", "with", "vigabatrin", "-", "attributed", "visual", "field", "constriction", "."], "event_mentions": [{"id": "11077455_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 18, "end": 19}, "arguments": [{"entity_id": "11077455_2_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "11077455_2_Ent2", "role": "Treatment", "text": "vigabatrin", "start": 16, "end": 17}, {"entity_id": "11077455_2_Ent3", "role": "Treatment_Drug", "text": "vigabatrin", "start": 16, "end": 17}, {"entity_id": "11077455_2_Ent1", "role": "Effect", "text": "visual field constriction", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11077455_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11077455_2_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11077455_2_Ent3", "text": "vigabatrin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11077455_2_Ent1", "text": "visual field constriction", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11111942_2", "wnd_id": "11111942_2_1", "text": "We present a case of significant over - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy .", "tokens": ["We", "present", "a", "case", "of", "significant", "over", "-", "anticoagulation", "temporally", "associated", "with", "a", "bout", "of", "protracted", "diarrhea", "in", "a", "patient", "on", "warfarin", "therapy", "."], "event_mentions": [{"id": "11111942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - anticoagulation", "start": 6, "end": 9}, "arguments": [{"entity_id": "11111942_2_Ent0", "role": "Effect", "text": "protracted diarrhea", "start": 15, "end": 17}, {"entity_id": "11111942_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 21, "end": 22}, {"entity_id": "11111942_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11111942_2_Ent0", "text": "protracted diarrhea", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11111942_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11111942_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11122162_1", "wnd_id": "11122162_1_1", "text": "MI related to the use of activated and non - activated PCCs predominantly affects young patients who often have no preceding history of , or risk factors for , MI and tends to be associated with large cumulative doses of concentrate .", "tokens": ["MI", "related", "to", "the", "use", "of", "activated", "and", "non", "-", "activated", "PCCs", "predominantly", "affects", "young", "patients", "who", "often", "have", "no", "preceding", "history", "of", ",", "or", "risk", "factors", "for", ",", "MI", "and", "tends", "to", "be", "associated", "with", "large", "cumulative", "doses", "of", "concentrate", "."], "event_mentions": [{"id": "11122162_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "11122162_1_Ent2", "role": "Effect", "text": "MI", "start": 0, "end": 1}, {"entity_id": "11122162_1_Ent6", "role": "Treatment_Drug", "text": "activated", "start": 6, "end": 7}, {"entity_id": "11122162_1_Ent3", "role": "Treatment", "text": "activated and non - activated PCCs", "start": 6, "end": 12}, {"entity_id": "11122162_1_Ent5", "role": "Treatment_Drug", "text": "non - activated PCCs", "start": 8, "end": 12}, {"entity_id": "11122162_1_Ent7", "role": "Treatment_Drug", "text": "PCCs", "start": 11, "end": 12}, {"entity_id": "11122162_1_Ent1", "role": "Subject_Age", "text": "young", "start": 14, "end": 15}, {"entity_id": "11122162_1_Ent0", "role": "Subject", "text": "young patients who often have no preceding history of , or risk factors for , MI", "start": 14, "end": 30}, {"entity_id": "11122162_1_Ent8", "role": "Treatment_Dosage", "text": "large cumulative doses", "start": 36, "end": 39}, {"entity_id": "11122162_1_Ent4", "role": "Treatment", "text": "large cumulative doses of concentrate", "start": 36, "end": 41}]}], "entity_mentions": [{"id": "11122162_1_Ent2", "text": "MI", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11122162_1_Ent6", "text": "activated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11122162_1_Ent3", "text": "activated and non - activated PCCs", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11122162_1_Ent5", "text": "non - activated PCCs", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "11122162_1_Ent7", "text": "PCCs", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11122162_1_Ent1", "text": "young", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11122162_1_Ent0", "text": "young patients who often have no preceding history of , or risk factors for , MI", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "11122162_1_Ent8", "text": "large cumulative doses", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "11122162_1_Ent4", "text": "large cumulative doses of concentrate", "entity_type": "Entity", "start": 36, "end": 41}], "lang": "en"}
{"doc_id": "11122162_3", "wnd_id": "11122162_3_1", "text": "We have safely used recombinant factor VIIa to treat bleeding in the immediate and long - term period following PCC - related MI .", "tokens": ["We", "have", "safely", "used", "recombinant", "factor", "VIIa", "to", "treat", "bleeding", "in", "the", "immediate", "and", "long", "-", "term", "period", "following", "PCC", "-", "related", "MI", "."], "event_mentions": [{"id": "11122162_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 8, "end": 9}, "arguments": [{"entity_id": "11122162_3_Ent2", "role": "Treatment", "text": "recombinant factor VIIa", "start": 4, "end": 7}, {"entity_id": "11122162_3_Ent5", "role": "Treatment_Drug", "text": "recombinant factor VIIa", "start": 4, "end": 7}, {"entity_id": "11122162_3_Ent3", "role": "Treatment_Disorder", "text": "bleeding", "start": 9, "end": 10}, {"entity_id": "11122162_3_Ent4", "role": "Treatment_Time_elapsed", "text": "immediate and long - term period", "start": 12, "end": 18}, {"entity_id": "11122162_3_Ent0", "role": "Subject", "text": "PCC - related MI", "start": 19, "end": 23}, {"entity_id": "11122162_3_Ent1", "role": "Subject_Disorder", "text": "PCC - related MI", "start": 19, "end": 23}]}, {"id": "11122162_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 21, "end": 22}, "arguments": [{"entity_id": "11122162_3_Ent7", "role": "Treatment", "text": "PCC", "start": 19, "end": 20}, {"entity_id": "11122162_3_Ent8", "role": "Treatment_Drug", "text": "PCC", "start": 19, "end": 20}, {"entity_id": "11122162_3_Ent6", "role": "Effect", "text": "MI", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11122162_3_Ent2", "text": "recombinant factor VIIa", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11122162_3_Ent5", "text": "recombinant factor VIIa", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11122162_3_Ent3", "text": "bleeding", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11122162_3_Ent4", "text": "immediate and long - term period", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "11122162_3_Ent7", "text": "PCC", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11122162_3_Ent8", "text": "PCC", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11122162_3_Ent0", "text": "PCC - related MI", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11122162_3_Ent1", "text": "PCC - related MI", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11122162_3_Ent6", "text": "MI", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11144696_11", "wnd_id": "11144696_11_1", "text": "We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures .", "tokens": ["We", "hypothesize", "that", "a", "pharmacodynamic", "or", "pharmacokinetic", "drug", "interaction", "between", "venlafaxine", "and", "trimipramine", "involving", "the", "CYP2D6", "isoenzyme", "may", "have", "played", "a", "role", "in", "inducing", "the", "seizures", "."], "event_mentions": [{"id": "11144696_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 23, "end": 24}, "arguments": [{"entity_id": "11144696_11_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent4", "role": "Combination_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent1", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 10, "end": 13}, {"entity_id": "11144696_11_Ent3", "role": "Treatment_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent5", "role": "Combination_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent0", "role": "Effect", "text": "seizures", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "11144696_11_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent1", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11144696_11_Ent3", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent5", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent0", "text": "seizures", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "11160777_1", "wnd_id": "11160777_1_1", "text": "New oral therapies for type 2 diabetes mellitus :", "tokens": ["New", "oral", "therapies", "for", "type", "2", "diabetes", "mellitus", ":"], "event_mentions": [{"id": "11160777_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "11160777_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 1, "end": 2}, {"entity_id": "11160777_1_Ent0", "role": "Treatment", "text": "oral therapies", "start": 1, "end": 3}, {"entity_id": "11160777_1_Ent1", "role": "Treatment_Disorder", "text": "type 2 diabetes mellitus", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "11160777_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11160777_1_Ent0", "text": "oral therapies", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11160777_1_Ent1", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "11181395_1", "wnd_id": "11181395_1_1", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer .", "tokens": ["Restoration", "of", "vancomycin", "susceptibility", "in", "Enterococcus", "faecalis", "by", "antiresistance", "determinant", "gene", "transfer", "."], "event_mentions": [{"id": "11181395_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "by", "start": 7, "end": 8}, "arguments": [{"entity_id": "11181395_1_Ent0", "role": "Effect", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis", "start": 0, "end": 7}, {"entity_id": "11181395_1_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 2, "end": 3}, {"entity_id": "11181395_1_Ent1", "role": "Treatment", "text": "antiresistance determinant gene transfer", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "11181395_1_Ent0", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11181395_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11181395_1_Ent1", "text": "antiresistance determinant gene transfer", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "11197767_2", "wnd_id": "11197767_2_1", "text": "The toxicity of cadmium , zinc and cadmium / zinc mixtures at concentrations ranging from 1000 to 50000 microg / l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus .", "tokens": ["The", "toxicity", "of", "cadmium", ",", "zinc", "and", "cadmium", "/", "zinc", "mixtures", "at", "concentrations", "ranging", "from", "1000", "to", "50000", "microg", "/", "l", "were", "investigated", "against", "cercariae", "and", "metacercariae", "of", "Parorchis", "acanthus", "obtained", "from", "the", "dog", "whelk", "Nucella", "lapillus", "."], "event_mentions": [{"id": "11197767_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "against", "start": 23, "end": 24}, "arguments": [{"entity_id": "11197767_2_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "11197767_2_Ent2", "role": "Treatment_Drug", "text": "cadmium", "start": 3, "end": 4}, {"entity_id": "11197767_2_Ent1", "role": "Treatment", "text": "cadmium , zinc and cadmium / zinc mixtures at concentrations ranging from 1000 to 50000 microg / l", "start": 3, "end": 21}, {"entity_id": "11197767_2_Ent3", "role": "Treatment_Drug", "text": "zinc", "start": 5, "end": 6}, {"entity_id": "11197767_2_Ent4", "role": "Treatment_Drug", "text": "cadmium", "start": 7, "end": 8}, {"entity_id": "11197767_2_Ent7", "role": "Combination_Drug", "text": "cadmium", "start": 7, "end": 8}, {"entity_id": "11197767_2_Ent5", "role": "Treatment_Drug", "text": "zinc", "start": 9, "end": 10}, {"entity_id": "11197767_2_Ent8", "role": "Combination_Drug", "text": "zinc", "start": 9, "end": 10}, {"entity_id": "11197767_2_Ent6", "role": "Treatment_Dosage", "text": "1000 to 50000 microg / l", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "11197767_2_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11197767_2_Ent2", "text": "cadmium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11197767_2_Ent1", "text": "cadmium , zinc and cadmium / zinc mixtures at concentrations ranging from 1000 to 50000 microg / l", "entity_type": "Entity", "start": 3, "end": 21}, {"id": "11197767_2_Ent3", "text": "zinc", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11197767_2_Ent4", "text": "cadmium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11197767_2_Ent7", "text": "cadmium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11197767_2_Ent5", "text": "zinc", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11197767_2_Ent8", "text": "zinc", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11197767_2_Ent6", "text": "1000 to 50000 microg / l", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "11202801_1", "wnd_id": "11202801_1_1", "text": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long - term cyclophosphamide treatment .", "tokens": ["A", "review", "of", "the", "literature", "revealed", "two", "other", "cases", "of", "hepatic", "angiosarcoma", "in", "patients", "after", "long", "-", "term", "cyclophosphamide", "treatment", "."], "event_mentions": [{"id": "11202801_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "11202801_1_Ent1", "role": "Effect", "text": "hepatic angiosarcoma", "start": 10, "end": 12}, {"entity_id": "11202801_1_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}, {"entity_id": "11202801_1_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 15, "end": 18}, {"entity_id": "11202801_1_Ent2", "role": "Treatment", "text": "long - term cyclophosphamide treatment", "start": 15, "end": 20}, {"entity_id": "11202801_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "11202801_1_Ent1", "text": "hepatic angiosarcoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11202801_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11202801_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11202801_1_Ent2", "text": "long - term cyclophosphamide treatment", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11202801_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "11207969_3", "wnd_id": "11207969_3_1", "text": "Toxic epidermal necrolysis after the use of high - dose cytosine arabinoside .", "tokens": ["Toxic", "epidermal", "necrolysis", "after", "the", "use", "of", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "11207969_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "11207969_3_Ent0", "role": "Effect", "text": "Toxic epidermal necrolysis", "start": 0, "end": 3}, {"entity_id": "11207969_3_Ent1", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 7, "end": 12}, {"entity_id": "11207969_3_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "11207969_3_Ent0", "text": "Toxic epidermal necrolysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11207969_3_Ent1", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "11207969_3_Ent2", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "11212595_1", "wnd_id": "11212595_1_1", "text": "Quetiapine and obsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced OCS .", "tokens": ["Quetiapine", "and", "obsessive", "-", "compulsive", "symptoms", "(", "OCS", ")", ":", "case", "report", "and", "review", "of", "atypical", "antipsychotic", "-", "induced", "OCS", "."], "event_mentions": [{"id": "11212595_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "11212595_1_Ent0", "role": "Effect", "text": "obsessive - compulsive symptoms ( OCS )", "start": 2, "end": 9}, {"entity_id": "11212595_1_Ent2", "role": "Treatment", "text": "antipsychotic", "start": 16, "end": 17}, {"entity_id": "11212595_1_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 16, "end": 17}, {"entity_id": "11212595_1_Ent1", "role": "Effect", "text": "OCS", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "11212595_1_Ent0", "text": "obsessive - compulsive symptoms ( OCS )", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "11212595_1_Ent2", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11212595_1_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11212595_1_Ent1", "text": "OCS", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "11243427_3", "wnd_id": "11243427_3_1", "text": "DISCUSSION : Patients with 5 - FU - induced ectropion experience tender , red , scaled lids , making contact lens wear difficult .", "tokens": ["DISCUSSION", ":", "Patients", "with", "5", "-", "FU", "-", "induced", "ectropion", "experience", "tender", ",", "red", ",", "scaled", "lids", ",", "making", "contact", "lens", "wear", "difficult", "."], "event_mentions": [{"id": "11243427_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "11243427_3_Ent0", "role": "Subject", "text": "Patients with 5 - FU - induced ectropion", "start": 2, "end": 10}, {"entity_id": "11243427_3_Ent3", "role": "Treatment", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 4, "end": 7}, {"entity_id": "11243427_3_Ent1", "role": "Effect", "text": "ectropion", "start": 9, "end": 10}, {"entity_id": "11243427_3_Ent2", "role": "Effect", "text": "tender , red , scaled lids", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "11243427_3_Ent0", "text": "Patients with 5 - FU - induced ectropion", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "11243427_3_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11243427_3_Ent1", "text": "ectropion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11243427_3_Ent2", "text": "tender , red , scaled lids", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "11247558_1", "wnd_id": "11247558_1_1", "text": "Ischaemic colitis in a patient taking meloxicam .", "tokens": ["Ischaemic", "colitis", "in", "a", "patient", "taking", "meloxicam", "."], "event_mentions": [{"id": "11247558_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_1_Ent1", "role": "Effect", "text": "Ischaemic colitis", "start": 0, "end": 2}, {"entity_id": "11247558_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "11247558_1_Ent2", "role": "Treatment", "text": "meloxicam", "start": 6, "end": 7}, {"entity_id": "11247558_1_Ent3", "role": "Treatment_Drug", "text": "meloxicam", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11247558_1_Ent1", "text": "Ischaemic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11247558_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11247558_1_Ent2", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11247558_1_Ent3", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11283125_2", "wnd_id": "11283125_2_1", "text": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX ) to reduce the incidence of CNS and systemic relapses in children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma treated with a Berlin - Frankfurt - Munster ( BFM) - based regimen .", "tokens": ["The", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "study", "was", "designed", "to", "test", "in", "a", "prospective", "multicentric", "randomized", "trial", "the", "value", "of", "high", "-", "dose", "(", "HD", ")", "intravenous", "(", "IV", ")", "cytarabine", "(", "Ara", "-", "C", ")", "added", "to", "HD", "IV", "methotrexate", "(", "MTX", ")", "to", "reduce", "the", "incidence", "of", "CNS", "and", "systemic", "relapses", "in", "children", "with", "increased", "-", "risk", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "or", "stage", "III", "and", "IV", "lymphoblastic", "lymphoma", "treated", "with", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "(", "BFM)", "-", "based", "regimen", "."], "event_mentions": [{"id": "11283125_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 48, "end": 49}, "arguments": [{"entity_id": "11283125_2_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 24, "end": 27}, {"entity_id": "11283125_2_Ent3", "role": "Treatment", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "start": 24, "end": 48}, {"entity_id": "11283125_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 30, "end": 31}, {"entity_id": "11283125_2_Ent6", "role": "Treatment_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent10", "role": "Combination_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent11", "role": "Combination_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent2", "role": "Effect", "text": "reduce the incidence of CNS and systemic relapses", "start": 49, "end": 57}, {"entity_id": "11283125_2_Ent1", "role": "Subject_Age", "text": "children", "start": 58, "end": 59}, {"entity_id": "11283125_2_Ent0", "role": "Subject", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "start": 58, "end": 76}, {"entity_id": "11283125_2_Ent8", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 63, "end": 66}, {"entity_id": "11283125_2_Ent9", "role": "Treatment_Disorder", "text": "stage III and IV lymphoblastic lymphoma", "start": 70, "end": 76}]}], "entity_mentions": [{"id": "11283125_2_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11283125_2_Ent3", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "entity_type": "Entity", "start": 24, "end": 48}, {"id": "11283125_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11283125_2_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent10", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent11", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent2", "text": "reduce the incidence of CNS and systemic relapses", "entity_type": "Entity", "start": 49, "end": 57}, {"id": "11283125_2_Ent1", "text": "children", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_2_Ent0", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 58, "end": 76}, {"id": "11283125_2_Ent8", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 63, "end": 66}, {"id": "11283125_2_Ent9", "text": "stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 70, "end": 76}], "lang": "en"}
{"doc_id": "11283125_9", "wnd_id": "11283125_9_1", "text": "Disappointingly , with the dose schedule used in this protocol , HD Ara - C added to HD MTX , although well tolerated , failed to further decrease the incidence of CNS relapse or to improve the overall DFS .", "tokens": ["Disappointingly", ",", "with", "the", "dose", "schedule", "used", "in", "this", "protocol", ",", "HD", "Ara", "-", "C", "added", "to", "HD", "MTX", ",", "although", "well", "tolerated", ",", "failed", "to", "further", "decrease", "the", "incidence", "of", "CNS", "relapse", "or", "to", "improve", "the", "overall", "DFS", "."], "event_mentions": [{"id": "11283125_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "failed", "start": 24, "end": 25}, "arguments": [{"entity_id": "11283125_9_Ent1", "role": "Treatment", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent3", "role": "Treatment_Drug", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent5", "role": "Combination_Drug", "text": "HD Ara - C", "start": 11, "end": 15}, {"entity_id": "11283125_9_Ent2", "role": "Treatment", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent4", "role": "Treatment_Drug", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent6", "role": "Combination_Drug", "text": "HD MTX", "start": 17, "end": 19}, {"entity_id": "11283125_9_Ent0", "role": "Effect", "text": "further decrease the incidence of CNS relapse or to improve the overall DFS", "start": 26, "end": 39}]}], "entity_mentions": [{"id": "11283125_9_Ent1", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent3", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent5", "text": "HD Ara - C", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11283125_9_Ent2", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent4", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent6", "text": "HD MTX", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11283125_9_Ent0", "text": "further decrease the incidence of CNS relapse or to improve the overall DFS", "entity_type": "Entity", "start": 26, "end": 39}], "lang": "en"}
{"doc_id": "11295724_3", "wnd_id": "11295724_3_1", "text": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient .", "tokens": ["Clofazimine", "enteropathy", "in", "a", "pediatric", "bone", "marrow", "transplant", "recipient", "."], "event_mentions": [{"id": "11295724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "11295724_3_Ent2", "role": "Treatment", "text": "Clofazimine", "start": 0, "end": 1}, {"entity_id": "11295724_3_Ent3", "role": "Treatment_Drug", "text": "Clofazimine", "start": 0, "end": 1}, {"entity_id": "11295724_3_Ent1", "role": "Effect", "text": "enteropathy", "start": 1, "end": 2}, {"entity_id": "11295724_3_Ent0", "role": "Subject", "text": "a pediatric bone marrow transplant recipient", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "11295724_3_Ent2", "text": "Clofazimine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11295724_3_Ent3", "text": "Clofazimine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11295724_3_Ent1", "text": "enteropathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11295724_3_Ent0", "text": "a pediatric bone marrow transplant recipient", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "11328247_3", "wnd_id": "11328247_3_1", "text": "OBJECTIVE : The aim of this paper is to describe a case of increased libido during fluvoxamine therapy .", "tokens": ["OBJECTIVE", ":", "The", "aim", "of", "this", "paper", "is", "to", "describe", "a", "case", "of", "increased", "libido", "during", "fluvoxamine", "therapy", "."], "event_mentions": [{"id": "11328247_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "11328247_3_Ent0", "role": "Subject", "text": "a case", "start": 10, "end": 12}, {"entity_id": "11328247_3_Ent1", "role": "Effect", "text": "increased libido", "start": 13, "end": 15}, {"entity_id": "11328247_3_Ent3", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 16, "end": 17}, {"entity_id": "11328247_3_Ent2", "role": "Treatment", "text": "fluvoxamine therapy .", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "11328247_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11328247_3_Ent1", "text": "increased libido", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11328247_3_Ent3", "text": "fluvoxamine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11328247_3_Ent2", "text": "fluvoxamine therapy .", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "11328247_4", "wnd_id": "11328247_4_1", "text": "RESULTS : The patient , a 27 - year - old married Japanese woman with borderline personality disorder , developed an increased libido with the administration of fluvoxamine .", "tokens": ["RESULTS", ":", "The", "patient", ",", "a", "27", "-", "year", "-", "old", "married", "Japanese", "woman", "with", "borderline", "personality", "disorder", ",", "developed", "an", "increased", "libido", "with", "the", "administration", "of", "fluvoxamine", "."], "event_mentions": [{"id": "11328247_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "11328247_4_Ent0", "role": "Subject", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "start": 2, "end": 18}, {"entity_id": "11328247_4_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "11328247_4_Ent2", "role": "Subject_Race", "text": "Japanese", "start": 12, "end": 13}, {"entity_id": "11328247_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "11328247_4_Ent6", "role": "Treatment_Disorder", "text": "borderline personality disorder", "start": 15, "end": 18}, {"entity_id": "11328247_4_Ent4", "role": "Effect", "text": "increased libido", "start": 21, "end": 23}, {"entity_id": "11328247_4_Ent5", "role": "Treatment", "text": "administration of fluvoxamine", "start": 25, "end": 28}, {"entity_id": "11328247_4_Ent7", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "11328247_4_Ent0", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "entity_type": "Entity", "start": 2, "end": 18}, {"id": "11328247_4_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11328247_4_Ent2", "text": "Japanese", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11328247_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11328247_4_Ent6", "text": "borderline personality disorder", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11328247_4_Ent4", "text": "increased libido", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11328247_4_Ent5", "text": "administration of fluvoxamine", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11328247_4_Ent7", "text": "fluvoxamine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "11332679_1", "wnd_id": "11332679_1_1", "text": "An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported .", "tokens": ["An", "infant", "who", "developed", "pancreatitis", "during", "meglumine", "antimoniate", "treatment", "for", "visceral", "leishmaniasis", "and", "who", "was", "successfully", "treated", "with", "a", "combination", "of", "allopurinol", "and", "ketoconazole", "is", "reported", "."], "event_mentions": [{"id": "11332679_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 16, "end": 17}, "arguments": [{"entity_id": "11332679_1_Ent0", "role": "Subject", "text": "An infant", "start": 0, "end": 2}, {"entity_id": "11332679_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 1, "end": 2}, {"entity_id": "11332679_1_Ent2", "role": "Effect", "text": "pancreatitis", "start": 4, "end": 5}, {"entity_id": "11332679_1_Ent3", "role": "Treatment", "text": "a combination of allopurinol and ketoconazole", "start": 18, "end": 24}, {"entity_id": "11332679_1_Ent4", "role": "Treatment_Drug", "text": "allopurinol", "start": 21, "end": 22}, {"entity_id": "11332679_1_Ent6", "role": "Combination_Drug", "text": "allopurinol", "start": 21, "end": 22}, {"entity_id": "11332679_1_Ent5", "role": "Treatment_Drug", "text": "ketoconazole", "start": 23, "end": 24}, {"entity_id": "11332679_1_Ent7", "role": "Combination_Drug", "text": "ketoconazole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11332679_1_Ent0", "text": "An infant", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11332679_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11332679_1_Ent2", "text": "pancreatitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11332679_1_Ent3", "text": "a combination of allopurinol and ketoconazole", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "11332679_1_Ent4", "text": "allopurinol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11332679_1_Ent6", "text": "allopurinol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11332679_1_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11332679_1_Ent7", "text": "ketoconazole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11332679_2", "wnd_id": "11332679_2_1", "text": "Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate .", "tokens": ["Successful", "treatment", "of", "visceral", "leishmaniasis", "with", "allopurinol", "plus", "ketoconazole", "in", "an", "infant", "who", "developed", "pancreatitis", "caused", "by", "meglumine", "antimoniate", "."], "event_mentions": [{"id": "11332679_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "11332679_2_Ent4", "role": "Treatment_Disorder", "text": "visceral leishmaniasis", "start": 3, "end": 5}, {"entity_id": "11332679_2_Ent3", "role": "Treatment", "text": "visceral leishmaniasis with allopurinol plus ketoconazole", "start": 3, "end": 9}, {"entity_id": "11332679_2_Ent5", "role": "Treatment_Drug", "text": "allopurinol", "start": 6, "end": 7}, {"entity_id": "11332679_2_Ent8", "role": "Combination_Drug", "text": "allopurinol", "start": 6, "end": 7}, {"entity_id": "11332679_2_Ent6", "role": "Treatment_Drug", "text": "ketoconazole", "start": 8, "end": 9}, {"entity_id": "11332679_2_Ent7", "role": "Combination_Drug", "text": "ketoconazole", "start": 8, "end": 9}, {"entity_id": "11332679_2_Ent0", "role": "Subject", "text": "an infant who developed pancreatitis caused by meglumine antimoniate", "start": 10, "end": 19}, {"entity_id": "11332679_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "11332679_2_Ent1", "role": "Subject_Disorder", "text": "pancreatitis caused by meglumine antimoniate", "start": 14, "end": 19}]}, {"id": "11332679_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "11332679_2_Ent9", "role": "Effect", "text": "pancreatitis", "start": 14, "end": 15}, {"entity_id": "11332679_2_Ent10", "role": "Treatment", "text": "meglumine antimoniate", "start": 17, "end": 19}, {"entity_id": "11332679_2_Ent11", "role": "Treatment_Drug", "text": "meglumine antimoniate", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11332679_2_Ent4", "text": "visceral leishmaniasis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11332679_2_Ent3", "text": "visceral leishmaniasis with allopurinol plus ketoconazole", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11332679_2_Ent5", "text": "allopurinol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11332679_2_Ent8", "text": "allopurinol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11332679_2_Ent6", "text": "ketoconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11332679_2_Ent7", "text": "ketoconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11332679_2_Ent0", "text": "an infant who developed pancreatitis caused by meglumine antimoniate", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "11332679_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11332679_2_Ent9", "text": "pancreatitis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11332679_2_Ent1", "text": "pancreatitis caused by meglumine antimoniate", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11332679_2_Ent10", "text": "meglumine antimoniate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11332679_2_Ent11", "text": "meglumine antimoniate", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11359026_2", "wnd_id": "11359026_2_1", "text": "Neurotoxicity of valacyclovir in peritoneal dialysis : a pharmacokinetic study .", "tokens": ["Neurotoxicity", "of", "valacyclovir", "in", "peritoneal", "dialysis", ":", "a", "pharmacokinetic", "study", "."], "event_mentions": [{"id": "11359026_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Neurotoxicity", "start": 0, "end": 1}, "arguments": [{"entity_id": "11359026_2_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "11359026_2_Ent2", "role": "Treatment_Drug", "text": "valacyclovir", "start": 2, "end": 3}, {"entity_id": "11359026_2_Ent1", "role": "Treatment", "text": "valacyclovir in peritoneal dialysis", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "11359026_2_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11359026_2_Ent2", "text": "valacyclovir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11359026_2_Ent1", "text": "valacyclovir in peritoneal dialysis", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "11373877_2", "wnd_id": "11373877_2_1", "text": "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation , and who subsequently developed femoral head avascular necrosis .", "tokens": ["We", "report", "the", "case", "histories", "of", "two", "patients", "with", "histologically", "confirmed", "adenocarcinoma", "of", "the", "prostate", ",", "both", "of", "whom", "had", "been", "treated", "with", "steroidal", "anti", "-", "androgen", "therapy", "in", "the", "form", "of", "cyproterone", "acetate", "prior", "to", "radical", "or", "palliative", "pelvic", "irradiation", ",", "and", "who", "subsequently", "developed", "femoral", "head", "avascular", "necrosis", "."], "event_mentions": [{"id": "11373877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11373877_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "11373877_2_Ent0", "role": "Subject", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "start": 6, "end": 15}, {"entity_id": "11373877_2_Ent4", "role": "Treatment_Disorder", "text": "adenocarcinoma of the prostate", "start": 11, "end": 15}, {"entity_id": "11373877_2_Ent3", "role": "Treatment", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "start": 23, "end": 41}, {"entity_id": "11373877_2_Ent5", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 32, "end": 34}, {"entity_id": "11373877_2_Ent2", "role": "Effect", "text": "femoral head avascular necrosis .", "start": 46, "end": 51}]}], "entity_mentions": [{"id": "11373877_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11373877_2_Ent0", "text": "two patients with histologically confirmed adenocarcinoma of the prostate", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "11373877_2_Ent4", "text": "adenocarcinoma of the prostate", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "11373877_2_Ent3", "text": "steroidal anti - androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation", "entity_type": "Entity", "start": 23, "end": 41}, {"id": "11373877_2_Ent5", "text": "cyproterone acetate", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "11373877_2_Ent2", "text": "femoral head avascular necrosis .", "entity_type": "Entity", "start": 46, "end": 51}], "lang": "en"}
{"doc_id": "11388112_2", "wnd_id": "11388112_2_1", "text": "We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias .", "tokens": ["We", "report", "the", "first", "case", "of", "polymorphic", "ventricular", "tachycardia", "with", "normal", "QT", "interval", "associated", "with", "the", "oral", "use", "of", "levofloxacin", "in", "the", "absence", "of", "other", "etiologies", "known", "to", "cause", "these", "arrhythmias", "."], "event_mentions": [{"id": "11388112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "11388112_2_Ent0", "role": "Subject", "text": "the first case", "start": 2, "end": 5}, {"entity_id": "11388112_2_Ent1", "role": "Effect", "text": "polymorphic ventricular tachycardia with normal QT interval", "start": 6, "end": 13}, {"entity_id": "11388112_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 16, "end": 17}, {"entity_id": "11388112_2_Ent3", "role": "Treatment", "text": "oral use of levofloxacin", "start": 16, "end": 20}, {"entity_id": "11388112_2_Ent5", "role": "Treatment_Drug", "text": "levofloxacin", "start": 19, "end": 20}, {"entity_id": "11388112_2_Ent2", "role": "Effect", "text": "arrhythmias", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "11388112_2_Ent0", "text": "the first case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11388112_2_Ent1", "text": "polymorphic ventricular tachycardia with normal QT interval", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "11388112_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11388112_2_Ent3", "text": "oral use of levofloxacin", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "11388112_2_Ent5", "text": "levofloxacin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11388112_2_Ent2", "text": "arrhythmias", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "11399735_3", "wnd_id": "11399735_3_1", "text": "Ticlopidine - induced interstitial pulmonary disease : a case report .", "tokens": ["Ticlopidine", "-", "induced", "interstitial", "pulmonary", "disease", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11399735_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11399735_3_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent0", "role": "Effect", "text": "interstitial pulmonary disease", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "11399735_3_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent0", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "11406880_2", "wnd_id": "11406880_2_1", "text": "Methadone is recommended as being free of some of the neuropsychological side effects noticed with morphine , which are attributed to active metabolites .", "tokens": ["Methadone", "is", "recommended", "as", "being", "free", "of", "some", "of", "the", "neuropsychological", "side", "effects", "noticed", "with", "morphine", ",", "which", "are", "attributed", "to", "active", "metabolites", "."], "event_mentions": [{"id": "11406880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noticed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11406880_2_Ent0", "role": "Effect", "text": "neuropsychological side effects", "start": 10, "end": 13}, {"entity_id": "11406880_2_Ent1", "role": "Treatment", "text": "morphine", "start": 15, "end": 16}, {"entity_id": "11406880_2_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11406880_2_Ent0", "text": "neuropsychological side effects", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11406880_2_Ent1", "text": "morphine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11406880_2_Ent2", "text": "morphine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11414270_13", "wnd_id": "11414270_13_1", "text": "CONCLUSION : Oral mucositis is a frequent and potentially severe complication of cancer chemotherapy .", "tokens": ["CONCLUSION", ":", "Oral", "mucositis", "is", "a", "frequent", "and", "potentially", "severe", "complication", "of", "cancer", "chemotherapy", "."], "event_mentions": [{"id": "11414270_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 10, "end": 11}, "arguments": [{"entity_id": "11414270_13_Ent0", "role": "Effect", "text": "Oral mucositis", "start": 2, "end": 4}, {"entity_id": "11414270_13_Ent3", "role": "Treatment_Disorder", "text": "cancer", "start": 12, "end": 13}, {"entity_id": "11414270_13_Ent1", "role": "Treatment", "text": "cancer chemotherapy", "start": 12, "end": 14}, {"entity_id": "11414270_13_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11414270_13_Ent0", "text": "Oral mucositis", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11414270_13_Ent3", "text": "cancer", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11414270_13_Ent1", "text": "cancer chemotherapy", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11414270_13_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11414270_15", "wnd_id": "11414270_15_1", "text": "Only nondepolarizing muscle relaxants should be used in patients who are at risk for mucositis .", "tokens": ["Only", "nondepolarizing", "muscle", "relaxants", "should", "be", "used", "in", "patients", "who", "are", "at", "risk", "for", "mucositis", "."], "event_mentions": [{"id": "11414270_15_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 6, "end": 7}, "arguments": [{"entity_id": "11414270_15_Ent2", "role": "Treatment", "text": "nondepolarizing muscle relaxants", "start": 1, "end": 4}, {"entity_id": "11414270_15_Ent3", "role": "Treatment_Drug", "text": "nondepolarizing muscle relaxants", "start": 1, "end": 4}, {"entity_id": "11414270_15_Ent0", "role": "Subject", "text": "patients who are at risk for mucositis", "start": 8, "end": 15}, {"entity_id": "11414270_15_Ent1", "role": "Subject_Disorder", "text": "mucositis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11414270_15_Ent2", "text": "nondepolarizing muscle relaxants", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11414270_15_Ent3", "text": "nondepolarizing muscle relaxants", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11414270_15_Ent0", "text": "patients who are at risk for mucositis", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "11414270_15_Ent1", "text": "mucositis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11414270_5", "wnd_id": "11414270_5_1", "text": "PATIENTS : One patient with mucositis secondary to chemotherapy .", "tokens": ["PATIENTS", ":", "One", "patient", "with", "mucositis", "secondary", "to", "chemotherapy", "."], "event_mentions": [{"id": "11414270_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "11414270_5_Ent1", "role": "Subject_Population", "text": "One", "start": 2, "end": 3}, {"entity_id": "11414270_5_Ent0", "role": "Subject", "text": "One patient", "start": 2, "end": 4}, {"entity_id": "11414270_5_Ent2", "role": "Effect", "text": "mucositis", "start": 5, "end": 6}, {"entity_id": "11414270_5_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 8, "end": 9}, {"entity_id": "11414270_5_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11414270_5_Ent1", "text": "One", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11414270_5_Ent0", "text": "One patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11414270_5_Ent2", "text": "mucositis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11414270_5_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11414270_5_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11428480_3", "wnd_id": "11428480_3_1", "text": "We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre - excited atrial fibrillation and were given 12 mg of adenosine .", "tokens": ["We", "observed", "ventricular", "fibrillation", "in", "2", "patients", "who", "presented", "to", "the", "emergency", "department", "with", "pre", "-", "excited", "atrial", "fibrillation", "and", "were", "given", "12", "mg", "of", "adenosine", "."], "event_mentions": [{"id": "11428480_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 21, "end": 22}, "arguments": [{"entity_id": "11428480_3_Ent2", "role": "Effect", "text": "ventricular fibrillation", "start": 2, "end": 4}, {"entity_id": "11428480_3_Ent1", "role": "Subject_Population", "text": "2", "start": 5, "end": 6}, {"entity_id": "11428480_3_Ent0", "role": "Subject", "text": "2 patients who presented to the emergency department with pre - excited atrial fibrillation", "start": 5, "end": 19}, {"entity_id": "11428480_3_Ent4", "role": "Treatment_Disorder", "text": "pre - excited atrial fibrillation", "start": 14, "end": 19}, {"entity_id": "11428480_3_Ent5", "role": "Treatment_Dosage", "text": "12 mg", "start": 22, "end": 24}, {"entity_id": "11428480_3_Ent3", "role": "Treatment", "text": "12 mg of adenosine", "start": 22, "end": 26}, {"entity_id": "11428480_3_Ent6", "role": "Treatment_Drug", "text": "adenosine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "11428480_3_Ent2", "text": "ventricular fibrillation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11428480_3_Ent1", "text": "2", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11428480_3_Ent0", "text": "2 patients who presented to the emergency department with pre - excited atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11428480_3_Ent4", "text": "pre - excited atrial fibrillation", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11428480_3_Ent5", "text": "12 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11428480_3_Ent3", "text": "12 mg of adenosine", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "11428480_3_Ent6", "text": "adenosine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "11450788_1", "wnd_id": "11450788_1_1", "text": "Antiretroviral - induced hepatic steatosis and lactic acidosis : case report and review of the literature .", "tokens": ["Antiretroviral", "-", "induced", "hepatic", "steatosis", "and", "lactic", "acidosis", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "11450788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11450788_1_Ent2", "role": "Treatment", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent3", "role": "Treatment_Drug", "text": "Antiretroviral", "start": 0, "end": 1}, {"entity_id": "11450788_1_Ent1", "role": "Effect", "text": "hepatic steatosis and lactic acidosis", "start": 3, "end": 8}, {"entity_id": "11450788_1_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11450788_1_Ent2", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent3", "text": "Antiretroviral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11450788_1_Ent1", "text": "hepatic steatosis and lactic acidosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11450788_1_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11450788_4", "wnd_id": "11450788_4_1", "text": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical , biologic , histologic , and ultrastructural findings with reports described previously .", "tokens": ["We", "report", "a", "case", "of", "fulminant", "hepatic", "failure", "associated", "with", "didanosine", "and", "masquerading", "as", "a", "surgical", "abdomen", "and", "compare", "the", "clinical", ",", "biologic", ",", "histologic", ",", "and", "ultrastructural", "findings", "with", "reports", "described", "previously", "."], "event_mentions": [{"id": "11450788_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "11450788_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11450788_4_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 5, "end": 8}, {"entity_id": "11450788_4_Ent2", "role": "Treatment", "text": "didanosine", "start": 10, "end": 11}, {"entity_id": "11450788_4_Ent3", "role": "Treatment_Drug", "text": "didanosine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11450788_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11450788_4_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11450788_4_Ent2", "text": "didanosine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11450788_4_Ent3", "text": "didanosine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11483161_2", "wnd_id": "11483161_2_1", "text": "The bleeding resolved on discontinuation of APV .", "tokens": ["The", "bleeding", "resolved", "on", "discontinuation", "of", "APV", "."], "event_mentions": [{"id": "11483161_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 2, "end": 3}, "arguments": [{"entity_id": "11483161_2_Ent1", "role": "Treatment_Disorder", "text": "The bleeding", "start": 0, "end": 2}, {"entity_id": "11483161_2_Ent0", "role": "Treatment", "text": "discontinuation of APV", "start": 4, "end": 7}, {"entity_id": "11483161_2_Ent2", "role": "Treatment_Drug", "text": "APV", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11483161_2_Ent1", "text": "The bleeding", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11483161_2_Ent0", "text": "discontinuation of APV", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11483161_2_Ent2", "text": "APV", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11485141_4", "wnd_id": "11485141_4_1", "text": "OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by gemcitabine .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "linear", "immunoglobulin", "(", "Ig", ")", "A", "bullous", "dermatosis", "(", "LABD", ")", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "11485141_4_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "11485141_4_Ent1", "role": "Effect", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "start": 7, "end": 18}, {"entity_id": "11485141_4_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 20, "end": 21}, {"entity_id": "11485141_4_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11485141_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11485141_4_Ent1", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "11485141_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11485141_4_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11506739_1", "wnd_id": "11506739_1_1", "text": "Myasthenia gravis during low - dose IFN - alpha therapy for chronic hepatitis C.", "tokens": ["Myasthenia", "gravis", "during", "low", "-", "dose", "IFN", "-", "alpha", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "11506739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "11506739_1_Ent0", "role": "Effect", "text": "Myasthenia gravis", "start": 0, "end": 2}, {"entity_id": "11506739_1_Ent2", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "11506739_1_Ent1", "role": "Treatment", "text": "low - dose IFN - alpha therapy", "start": 3, "end": 10}, {"entity_id": "11506739_1_Ent3", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 6, "end": 9}, {"entity_id": "11506739_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11506739_1_Ent0", "text": "Myasthenia gravis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11506739_1_Ent2", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11506739_1_Ent1", "text": "low - dose IFN - alpha therapy", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11506739_1_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11506739_1_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11510798_4", "wnd_id": "11510798_4_1", "text": "Once extensive microbiological studies proved negative , corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved .", "tokens": ["Once", "extensive", "microbiological", "studies", "proved", "negative", ",", "corticosteroids", "were", "given", "and", "a", "complete", "remission", "of", "clinical", "and", "radiological", "abnormalities", "was", "achieved", "."], "event_mentions": [{"id": "11510798_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "achieved", "start": 20, "end": 21}, "arguments": [{"entity_id": "11510798_4_Ent1", "role": "Treatment", "text": "corticosteroids", "start": 7, "end": 8}, {"entity_id": "11510798_4_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 7, "end": 8}, {"entity_id": "11510798_4_Ent0", "role": "Effect", "text": "a complete remission of clinical and radiological abnormalities was achieved", "start": 11, "end": 21}, {"entity_id": "11510798_4_Ent3", "role": "Treatment_Disorder", "text": "clinical and radiological abnormalities", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "11510798_4_Ent1", "text": "corticosteroids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11510798_4_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11510798_4_Ent0", "text": "a complete remission of clinical and radiological abnormalities was achieved", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "11510798_4_Ent3", "text": "clinical and radiological abnormalities", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "11545487_3", "wnd_id": "11545487_3_1", "text": "Papillary necrosis associated with the HIV protease inhibitor indinavir .", "tokens": ["Papillary", "necrosis", "associated", "with", "the", "HIV", "protease", "inhibitor", "indinavir", "."], "event_mentions": [{"id": "11545487_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_3_Ent0", "role": "Effect", "text": "Papillary necrosis", "start": 0, "end": 2}, {"entity_id": "11545487_3_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 5, "end": 6}, {"entity_id": "11545487_3_Ent1", "role": "Treatment", "text": "indinavir", "start": 8, "end": 9}, {"entity_id": "11545487_3_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11545487_3_Ent0", "text": "Papillary necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11545487_3_Ent3", "text": "HIV", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_3_Ent1", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11545487_3_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11545487_4", "wnd_id": "11545487_4_1", "text": "Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis .", "tokens": ["Physicians", "should", "be", "aware", "that", "indinavir", "nephrolithiasis", "may", "cause", "papillary", "necrosis", "."], "event_mentions": [{"id": "11545487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "11545487_4_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 5, "end": 6}, {"entity_id": "11545487_4_Ent1", "role": "Treatment", "text": "indinavir nephrolithiasis", "start": 5, "end": 7}, {"entity_id": "11545487_4_Ent0", "role": "Effect", "text": "papillary necrosis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "11545487_4_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_4_Ent1", "text": "indinavir nephrolithiasis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11545487_4_Ent0", "text": "papillary necrosis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "11545487_5", "wnd_id": "11545487_5_1", "text": "The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis .", "tokens": ["The", "HIV", "protease", "inhibitor", "indinavir", "may", "cause", "nephrolithiasis", "and", "interstitial", "nephritis", "."], "event_mentions": [{"id": "11545487_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "11545487_5_Ent1", "role": "Treatment", "text": "HIV protease inhibitor indinavir", "start": 1, "end": 5}, {"entity_id": "11545487_5_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "11545487_5_Ent0", "role": "Effect", "text": "nephrolithiasis and interstitial nephritis", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "11545487_5_Ent1", "text": "HIV protease inhibitor indinavir", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "11545487_5_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11545487_5_Ent0", "text": "nephrolithiasis and interstitial nephritis", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "11590881_2", "wnd_id": "11590881_2_1", "text": "A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively .", "tokens": ["A", "53", "year", "old", "Greenlandic", "male", "was", "admitted", "twice", "over", "a", "period", "of", "4", "years", "with", "a", "new", "complete", "right", "bundle", "branch", "block", "after", "ingestion", "of", "10", "g", "and", "4", "g", "of", "carbamazepine", "respectively", "."], "event_mentions": [{"id": "11590881_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "11590881_2_Ent0", "role": "Subject", "text": "A 53 year old Greenlandic male", "start": 0, "end": 6}, {"entity_id": "11590881_2_Ent1", "role": "Subject_Age", "text": "53 year old", "start": 1, "end": 4}, {"entity_id": "11590881_2_Ent2", "role": "Subject_Race", "text": "Greenlandic", "start": 4, "end": 5}, {"entity_id": "11590881_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "11590881_2_Ent4", "role": "Effect", "text": "was admitted twice over a period of 4 years with a new complete right bundle branch block", "start": 6, "end": 23}, {"entity_id": "11590881_2_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 24, "end": 25}, {"entity_id": "11590881_2_Ent5", "role": "Treatment", "text": "ingestion of 10 g and 4 g of carbamazepine", "start": 24, "end": 33}, {"entity_id": "11590881_2_Ent7", "role": "Treatment_Dosage", "text": "10 g and 4 g", "start": 26, "end": 31}, {"entity_id": "11590881_2_Ent8", "role": "Treatment_Drug", "text": "carbamazepine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11590881_2_Ent0", "text": "A 53 year old Greenlandic male", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11590881_2_Ent1", "text": "53 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11590881_2_Ent2", "text": "Greenlandic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11590881_2_Ent3", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11590881_2_Ent4", "text": "was admitted twice over a period of 4 years with a new complete right bundle branch block", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "11590881_2_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11590881_2_Ent5", "text": "ingestion of 10 g and 4 g of carbamazepine", "entity_type": "Entity", "start": 24, "end": 33}, {"id": "11590881_2_Ent7", "text": "10 g and 4 g", "entity_type": "Entity", "start": 26, "end": 31}, {"id": "11590881_2_Ent8", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11597289_14", "wnd_id": "11597289_14_1", "text": "In patients receiving antithrombin III and concomitant heparin , a significantly increased bleeding incidence was observed ( 23.8 % for antithrombin III group vs 13.5 % for placebo group ; P<.001 ) .", "tokens": ["In", "patients", "receiving", "antithrombin", "III", "and", "concomitant", "heparin", ",", "a", "significantly", "increased", "bleeding", "incidence", "was", "observed", "(", "23.8", "%", "for", "antithrombin", "III", "group", "vs", "13.5", "%", "for", "placebo", "group", ";", "P<.001", ")", "."], "event_mentions": [{"id": "11597289_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 11, "end": 12}, "arguments": [{"entity_id": "11597289_14_Ent0", "role": "Subject", "text": "patients", "start": 1, "end": 2}, {"entity_id": "11597289_14_Ent4", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent5", "role": "Combination_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent2", "role": "Treatment", "text": "antithrombin III and concomitant heparin", "start": 3, "end": 8}, {"entity_id": "11597289_14_Ent3", "role": "Treatment_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent6", "role": "Combination_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent1", "role": "Effect", "text": "bleeding incidence", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11597289_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11597289_14_Ent4", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent5", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent2", "text": "antithrombin III and concomitant heparin", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11597289_14_Ent3", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent6", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent1", "text": "bleeding incidence", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11675845_4", "wnd_id": "11675845_4_1", "text": "Ropinirole was added to his current therapy for Parkinson disease , with a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing .", "tokens": ["Ropinirole", "was", "added", "to", "his", "current", "therapy", "for", "Parkinson", "disease", ",", "with", "a", "corresponding", "decrease", "in", "the", "dose", "of", "levodopa", "/", "carbidopa", "to", "allow", "levodopa", "sparing", "."], "event_mentions": [{"id": "11675845_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "added", "start": 2, "end": 3}, "arguments": [{"entity_id": "11675845_4_Ent0", "role": "Treatment", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent2", "role": "Treatment_Drug", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent6", "role": "Combination_Drug", "text": "Ropinirole", "start": 0, "end": 1}, {"entity_id": "11675845_4_Ent5", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 8, "end": 10}, {"entity_id": "11675845_4_Ent1", "role": "Treatment", "text": "a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing", "start": 12, "end": 26}, {"entity_id": "11675845_4_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 19, "end": 20}, {"entity_id": "11675845_4_Ent7", "role": "Combination_Drug", "text": "levodopa", "start": 19, "end": 20}, {"entity_id": "11675845_4_Ent4", "role": "Treatment_Drug", "text": "carbidopa", "start": 21, "end": 22}, {"entity_id": "11675845_4_Ent8", "role": "Combination_Drug", "text": "carbidopa", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11675845_4_Ent0", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent2", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent6", "text": "Ropinirole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11675845_4_Ent5", "text": "Parkinson disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11675845_4_Ent1", "text": "a corresponding decrease in the dose of levodopa / carbidopa to allow levodopa sparing", "entity_type": "Entity", "start": 12, "end": 26}, {"id": "11675845_4_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11675845_4_Ent7", "text": "levodopa", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11675845_4_Ent4", "text": "carbidopa", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11675845_4_Ent8", "text": "carbidopa", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11675845_9", "wnd_id": "11675845_9_1", "text": "Furthermore , the warfarin dose was again increased after discontinuation of ropinirole due to common gastrointestinal adverse effects .", "tokens": ["Furthermore", ",", "the", "warfarin", "dose", "was", "again", "increased", "after", "discontinuation", "of", "ropinirole", "due", "to", "common", "gastrointestinal", "adverse", "effects", "."], "event_mentions": [{"id": "11675845_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "11675845_9_Ent0", "role": "Treatment", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "start": 2, "end": 12}, {"entity_id": "11675845_9_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "11675845_9_Ent1", "role": "Treatment_Disorder", "text": "gastrointestinal adverse effects", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "11675845_9_Ent0", "text": "the warfarin dose was again increased after discontinuation of ropinirole", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11675845_9_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11675845_9_Ent1", "text": "gastrointestinal adverse effects", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "11700998_2", "wnd_id": "11700998_2_1", "text": "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam .", "tokens": ["The", "aim", "of", "this", "report", "is", "to", "describe", "the", "clinical", "and", "electroencephalographic", "findings", "seen", "in", "an", "elderly", "woman", "without", "previous", "history", "of", "seizures", "who", "developed", "a", "nonconvulsive", "generalized", "status", "epilepticus", "following", "acute", "withdrawal", "of", "lorazepam", "."], "event_mentions": [{"id": "11700998_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 30, "end": 31}, "arguments": [{"entity_id": "11700998_2_Ent0", "role": "Subject", "text": "an elderly woman", "start": 15, "end": 18}, {"entity_id": "11700998_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 16, "end": 17}, {"entity_id": "11700998_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 17, "end": 18}, {"entity_id": "11700998_2_Ent3", "role": "Effect", "text": "nonconvulsive generalized status epilepticus", "start": 26, "end": 30}, {"entity_id": "11700998_2_Ent4", "role": "Treatment", "text": "acute withdrawal of lorazepam", "start": 31, "end": 35}, {"entity_id": "11700998_2_Ent5", "role": "Treatment_Drug", "text": "lorazepam", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "11700998_2_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11700998_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11700998_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11700998_2_Ent3", "text": "nonconvulsive generalized status epilepticus", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "11700998_2_Ent4", "text": "acute withdrawal of lorazepam", "entity_type": "Entity", "start": 31, "end": 35}, {"id": "11700998_2_Ent5", "text": "lorazepam", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "11703329_1", "wnd_id": "11703329_1_1", "text": "Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening vincristine neurotoxicity .", "tokens": ["Early", "recognition", "of", "hereditary", "motor", "and", "sensory", "neuropathy", "type", "1", "can", "avoid", "life", "-", "threatening", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "11703329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "can", "start": 10, "end": 11}, "arguments": [{"entity_id": "11703329_1_Ent0", "role": "Treatment", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "start": 0, "end": 10}]}], "entity_mentions": [{"id": "11703329_1_Ent0", "text": "Early recognition of hereditary motor and sensory neuropathy type 1", "entity_type": "Entity", "start": 0, "end": 10}], "lang": "en"}
{"doc_id": "11720625_1", "wnd_id": "11720625_1_1", "text": "Torsades de pointes due to drug interaction between disopyramide and clarithromycin .", "tokens": ["Torsades", "de", "pointes", "due", "to", "drug", "interaction", "between", "disopyramide", "and", "clarithromycin", "."], "event_mentions": [{"id": "11720625_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 3, "end": 5}, "arguments": [{"entity_id": "11720625_1_Ent0", "role": "Effect", "text": "Torsades de pointes", "start": 0, "end": 3}, {"entity_id": "11720625_1_Ent1", "role": "Treatment", "text": "drug interaction between disopyramide and clarithromycin", "start": 5, "end": 11}, {"entity_id": "11720625_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent4", "role": "Combination_Drug", "text": "disopyramide", "start": 8, "end": 9}, {"entity_id": "11720625_1_Ent3", "role": "Treatment_Drug", "text": "clarithromycin", "start": 10, "end": 11}, {"entity_id": "11720625_1_Ent5", "role": "Combination_Drug", "text": "clarithromycin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11720625_1_Ent0", "text": "Torsades de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11720625_1_Ent1", "text": "drug interaction between disopyramide and clarithromycin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11720625_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent4", "text": "disopyramide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11720625_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11720625_1_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11724089_6", "wnd_id": "11724089_6_1", "text": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug - induced toxic epidermal necrolysis .", "tokens": ["This", "report", "rules", "out", "other", "causes", "of", "toxic", "epidermal", "necrolysis", "and", "implicates", "ofloxacin", "in", "what", "appears", "to", "be", "an", "atypical", "presentation", "of", "drug", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "11724089_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "drug - induced", "start": 22, "end": 25}, "arguments": [{"entity_id": "11724089_6_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 12, "end": 13}, {"entity_id": "11724089_6_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 12, "end": 13}, {"entity_id": "11724089_6_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "11724089_6_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11724089_6_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11724089_6_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "11737689_2", "wnd_id": "11737689_2_1", "text": "A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G - CSF .", "tokens": ["A", "girl", "with", "cystic", "fibrosis", "and", "cyclic", "neutropenia", "developed", "an", "erythematous", "papular", "eruption", "without", "fever", "or", "neutrophilia", "7", "months", "after", "commencing", "therapy", "with", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11737689_2_Ent0", "role": "Subject", "text": "A girl with cystic fibrosis and cyclic neutropenia", "start": 0, "end": 8}, {"entity_id": "11737689_2_Ent1", "role": "Subject_Gender", "text": "girl", "start": 1, "end": 2}, {"entity_id": "11737689_2_Ent2", "role": "Subject_Disorder", "text": "cystic fibrosis", "start": 3, "end": 5}, {"entity_id": "11737689_2_Ent5", "role": "Treatment_Disorder", "text": "cyclic neutropenia", "start": 6, "end": 8}, {"entity_id": "11737689_2_Ent3", "role": "Effect", "text": "erythematous papular eruption without fever or neutrophilia", "start": 10, "end": 17}, {"entity_id": "11737689_2_Ent7", "role": "Treatment_Time_elapsed", "text": "7 months", "start": 17, "end": 19}, {"entity_id": "11737689_2_Ent4", "role": "Treatment", "text": "7 months after commencing therapy with G - CSF .", "start": 17, "end": 27}, {"entity_id": "11737689_2_Ent6", "role": "Treatment_Drug", "text": "G - CSF", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "11737689_2_Ent0", "text": "A girl with cystic fibrosis and cyclic neutropenia", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11737689_2_Ent1", "text": "girl", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_2_Ent2", "text": "cystic fibrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11737689_2_Ent5", "text": "cyclic neutropenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11737689_2_Ent3", "text": "erythematous papular eruption without fever or neutrophilia", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "11737689_2_Ent7", "text": "7 months", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11737689_2_Ent4", "text": "7 months after commencing therapy with G - CSF .", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "11737689_2_Ent6", "text": "G - CSF", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "1174301_1", "wnd_id": "1174301_1_1", "text": "There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism .", "tokens": ["There", "is", "a", "putative", "role", "of", "liothyronine", "administration", "in", "precipitating", "or", "activating", "hyperthyroidism", "."], "event_mentions": [{"id": "1174301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitating or activating", "start": 9, "end": 12}, "arguments": [{"entity_id": "1174301_1_Ent1", "role": "Treatment", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent2", "role": "Treatment_Drug", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1174301_1_Ent1", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent2", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11749112_2", "wnd_id": "11749112_2_1", "text": "This case report describes the development of asymptomatic visual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment .", "tokens": ["This", "case", "report", "describes", "the", "development", "of", "asymptomatic", "visual", "field", "defects", "(", "VFDs", ")", "in", "a", "psychiatric", "patient", "with", "bipolar", "disorder", "receiving", "adjunctive", "tiagabine", "treatment", "."], "event_mentions": [{"id": "11749112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "11749112_2_Ent1", "role": "Effect", "text": "asymptomatic visual field defects", "start": 7, "end": 11}, {"entity_id": "11749112_2_Ent0", "role": "Subject", "text": "patient", "start": 17, "end": 18}, {"entity_id": "11749112_2_Ent3", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 19, "end": 21}, {"entity_id": "11749112_2_Ent2", "role": "Treatment", "text": "tiagabine", "start": 23, "end": 24}, {"entity_id": "11749112_2_Ent4", "role": "Treatment_Drug", "text": "tiagabine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11749112_2_Ent1", "text": "asymptomatic visual field defects", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11749112_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11749112_2_Ent3", "text": "bipolar disorder", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11749112_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11749112_2_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11804071_2", "wnd_id": "11804071_2_1", "text": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption .", "tokens": ["Isonicotinic", "acid", "hydrazide", "induced", "anagen", "effluvium", "and", "associated", "lichenoid", "eruption", "."], "event_mentions": [{"id": "11804071_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11804071_2_Ent1", "role": "Treatment", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent2", "role": "Treatment_Drug", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent0", "role": "Effect", "text": "anagen effluvium and associated lichenoid eruption", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "11804071_2_Ent1", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent2", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent0", "text": "anagen effluvium and associated lichenoid eruption", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "11804071_3", "wnd_id": "11804071_3_1", "text": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously .", "tokens": ["Such", "anagen", "effluvium", "with", "lichenoid", "eruption", "following", "INH", "therapy", "has", "not", "been", "observed", "previously", "."], "event_mentions": [{"id": "11804071_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "11804071_3_Ent0", "role": "Effect", "text": "anagen effluvium with lichenoid eruption", "start": 1, "end": 6}, {"entity_id": "11804071_3_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "11804071_3_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11804071_3_Ent0", "text": "anagen effluvium with lichenoid eruption", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11804071_3_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11804071_3_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11816261_4", "wnd_id": "11816261_4_1", "text": "Serotonin syndrome caused by selective serotonin reuptake - inhibitors - metoclopramide interaction .", "tokens": ["Serotonin", "syndrome", "caused", "by", "selective", "serotonin", "reuptake", "-", "inhibitors", "-", "metoclopramide", "interaction", "."], "event_mentions": [{"id": "11816261_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "11816261_4_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "11816261_4_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent5", "role": "Combination_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent1", "role": "Treatment", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "start": 4, "end": 12}, {"entity_id": "11816261_4_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 10, "end": 11}, {"entity_id": "11816261_4_Ent4", "role": "Combination_Drug", "text": "metoclopramide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11816261_4_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11816261_4_Ent3", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent5", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent1", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "11816261_4_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11816261_4_Ent4", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11868077_2", "wnd_id": "11868077_2_1", "text": "We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection ( PEI ) for treatment of hepatocellular carcinoma .", "tokens": ["We", "describe", "a", "case", "of", "subcutaneous", "metastasis", "along", "the", "needle", "track", "after", "percutaneous", "ethanol", "injection", "(", "PEI", ")", "for", "treatment", "of", "hepatocellular", "carcinoma", "."], "event_mentions": [{"id": "11868077_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "11868077_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11868077_2_Ent1", "role": "Effect", "text": "subcutaneous metastasis", "start": 5, "end": 7}, {"entity_id": "11868077_2_Ent2", "role": "Treatment", "text": "percutaneous ethanol injection ( PEI )", "start": 12, "end": 18}, {"entity_id": "11868077_2_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 13, "end": 14}, {"entity_id": "11868077_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 14, "end": 15}, {"entity_id": "11868077_2_Ent5", "role": "Treatment_Disorder", "text": "hepatocellular carcinoma", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11868077_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11868077_2_Ent1", "text": "subcutaneous metastasis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11868077_2_Ent2", "text": "percutaneous ethanol injection ( PEI )", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "11868077_2_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11868077_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11868077_2_Ent5", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "11881322_6", "wnd_id": "11881322_6_1", "text": "We report on three patients who developed acute liver damage during therapy with itraconazole , and in whom liver biopsy specimens were obtained .", "tokens": ["We", "report", "on", "three", "patients", "who", "developed", "acute", "liver", "damage", "during", "therapy", "with", "itraconazole", ",", "and", "in", "whom", "liver", "biopsy", "specimens", "were", "obtained", "."], "event_mentions": [{"id": "11881322_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "11881322_6_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "11881322_6_Ent0", "role": "Subject", "text": "three patients", "start": 3, "end": 5}, {"entity_id": "11881322_6_Ent2", "role": "Effect", "text": "acute liver damage", "start": 7, "end": 10}, {"entity_id": "11881322_6_Ent3", "role": "Treatment", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "11881322_6_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11881322_6_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_6_Ent0", "text": "three patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11881322_6_Ent2", "text": "acute liver damage", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11881322_6_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11881322_6_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11886466_3", "wnd_id": "11886466_3_1", "text": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII .", "tokens": ["We", "have", "recently", "encountered", "a", "patient", "with", "acquired", "haemophilia", "who", "developed", "a", "thrombotic", "left", "middle", "cerebral", "artery", "distribution", "stroke", "while", "being", "treated", "with", "pFVIII", "."], "event_mentions": [{"id": "11886466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11886466_3_Ent0", "role": "Subject", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "start": 5, "end": 19}, {"entity_id": "11886466_3_Ent3", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 7, "end": 9}, {"entity_id": "11886466_3_Ent1", "role": "Effect", "text": "thrombotic left middle cerebral artery distribution stroke", "start": 12, "end": 19}, {"entity_id": "11886466_3_Ent2", "role": "Treatment", "text": "pFVIII", "start": 23, "end": 24}, {"entity_id": "11886466_3_Ent4", "role": "Treatment_Drug", "text": "pFVIII", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11886466_3_Ent0", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11886466_3_Ent3", "text": "acquired haemophilia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11886466_3_Ent1", "text": "thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "11886466_3_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11886466_3_Ent4", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11918514_4", "wnd_id": "11918514_4_1", "text": "Severe serotonin syndrome induced by mirtazapine monotherapy .", "tokens": ["Severe", "serotonin", "syndrome", "induced", "by", "mirtazapine", "monotherapy", "."], "event_mentions": [{"id": "11918514_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "11918514_4_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "11918514_4_Ent2", "role": "Treatment_Drug", "text": "mirtazapine", "start": 5, "end": 6}, {"entity_id": "11918514_4_Ent1", "role": "Treatment", "text": "mirtazapine monotherapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11918514_4_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11918514_4_Ent2", "text": "mirtazapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11918514_4_Ent1", "text": "mirtazapine monotherapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11972105_1", "wnd_id": "11972105_1_1", "text": "The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin , with severe toxicity .", "tokens": ["The", "authors", "report", "two", "cases", "of", "delayed", "elimination", "of", "methotrexate", "in", "patients", "receiving", "ciprofloxacin", ",", "with", "severe", "toxicity", "."], "event_mentions": [{"id": "11972105_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "11972105_1_Ent1", "role": "Effect", "text": "delayed elimination", "start": 6, "end": 8}, {"entity_id": "11972105_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11972105_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "11972105_1_Ent0", "role": "Subject", "text": "patients receiving ciprofloxacin", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11972105_1_Ent1", "text": "delayed elimination", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11972105_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11972105_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11972105_1_Ent0", "text": "patients receiving ciprofloxacin", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11999915_3", "wnd_id": "11999915_3_1", "text": "The female patient received clozapine in a daily dose of 400 mg , which induced agranulocytosis after 2 months .", "tokens": ["The", "female", "patient", "received", "clozapine", "in", "a", "daily", "dose", "of", "400", "mg", ",", "which", "induced", "agranulocytosis", "after", "2", "months", "."], "event_mentions": [{"id": "11999915_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "11999915_3_Ent0", "role": "Subject", "text": "The female patient", "start": 0, "end": 3}, {"entity_id": "11999915_3_Ent1", "role": "Subject_Gender", "text": "female", "start": 1, "end": 2}, {"entity_id": "11999915_3_Ent8", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "11999915_3_Ent3", "role": "Treatment", "text": "clozapine in a daily dose of 400 mg", "start": 4, "end": 12}, {"entity_id": "11999915_3_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 7, "end": 8}, {"entity_id": "11999915_3_Ent6", "role": "Treatment_Dosage", "text": "400 mg", "start": 10, "end": 12}, {"entity_id": "11999915_3_Ent2", "role": "Effect", "text": "agranulocytosis", "start": 15, "end": 16}, {"entity_id": "11999915_3_Ent4", "role": "Treatment", "text": "after 2 months", "start": 16, "end": 19}, {"entity_id": "11999915_3_Ent5", "role": "Treatment_Duration", "text": "2 months", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11999915_3_Ent0", "text": "The female patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_3_Ent1", "text": "female", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11999915_3_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11999915_3_Ent3", "text": "clozapine in a daily dose of 400 mg", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "11999915_3_Ent7", "text": "daily", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11999915_3_Ent6", "text": "400 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11999915_3_Ent2", "text": "agranulocytosis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11999915_3_Ent4", "text": "after 2 months", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "11999915_3_Ent5", "text": "2 months", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "12022905_3", "wnd_id": "12022905_3_1", "text": "DISCUSSION : The occurrence of priapism in our patient was related to zuclopenthixol .", "tokens": ["DISCUSSION", ":", "The", "occurrence", "of", "priapism", "in", "our", "patient", "was", "related", "to", "zuclopenthixol", "."], "event_mentions": [{"id": "12022905_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "12022905_3_Ent1", "role": "Effect", "text": "priapism", "start": 5, "end": 6}, {"entity_id": "12022905_3_Ent0", "role": "Subject", "text": "our patient", "start": 7, "end": 9}, {"entity_id": "12022905_3_Ent2", "role": "Treatment", "text": "zuclopenthixol", "start": 12, "end": 13}, {"entity_id": "12022905_3_Ent3", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12022905_3_Ent1", "text": "priapism", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12022905_3_Ent0", "text": "our patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12022905_3_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12022905_3_Ent3", "text": "zuclopenthixol", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12022905_5", "wnd_id": "12022905_5_1", "text": "Priapism associated with zuclopenthixol .", "tokens": ["Priapism", "associated", "with", "zuclopenthixol", "."], "event_mentions": [{"id": "12022905_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12022905_5_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "12022905_5_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 3, "end": 4}, {"entity_id": "12022905_5_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12022905_5_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12022905_5_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12022905_5_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12042592_2", "wnd_id": "12042592_2_1", "text": "Metamizole , a nonsteroidal antiinflammatory agent , is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries .", "tokens": ["Metamizole", ",", "a", "nonsteroidal", "antiinflammatory", "agent", ",", "is", "prohibited", "in", "the", "United", "States", "because", "of", "the", "risk", "of", "agranulocytosis", "but", "is", "widely", "used", "in", "Mexico", "and", "other", "countries", "."], "event_mentions": [{"id": "12042592_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 16, "end": 17}, "arguments": [{"entity_id": "12042592_2_Ent1", "role": "Treatment", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent2", "role": "Treatment_Drug", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12042592_2_Ent1", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent2", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12053072_1", "wnd_id": "12053072_1_1", "text": "Erythropoietin is beneficial in mitomycin - induced hemolytic - uremic syndrome .", "tokens": ["Erythropoietin", "is", "beneficial", "in", "mitomycin", "-", "induced", "hemolytic", "-", "uremic", "syndrome", "."], "event_mentions": [{"id": "12053072_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "beneficial", "start": 2, "end": 3}, "arguments": [{"entity_id": "12053072_1_Ent0", "role": "Treatment", "text": "Erythropoietin", "start": 0, "end": 1}, {"entity_id": "12053072_1_Ent2", "role": "Treatment_Drug", "text": "Erythropoietin", "start": 0, "end": 1}, {"entity_id": "12053072_1_Ent1", "role": "Treatment_Disorder", "text": "mitomycin - induced hemolytic - uremic syndrome", "start": 4, "end": 11}]}, {"id": "12053072_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "12053072_1_Ent4", "role": "Treatment", "text": "mitomycin", "start": 4, "end": 5}, {"entity_id": "12053072_1_Ent5", "role": "Treatment_Drug", "text": "mitomycin", "start": 4, "end": 5}, {"entity_id": "12053072_1_Ent3", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "12053072_1_Ent0", "text": "Erythropoietin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12053072_1_Ent2", "text": "Erythropoietin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12053072_1_Ent4", "text": "mitomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12053072_1_Ent5", "text": "mitomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12053072_1_Ent1", "text": "mitomycin - induced hemolytic - uremic syndrome", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "12053072_1_Ent3", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "12066972_2", "wnd_id": "12066972_2_1", "text": "To our knowledge , this case is the first published report of levofloxacin - induced TEN .", "tokens": ["To", "our", "knowledge", ",", "this", "case", "is", "the", "first", "published", "report", "of", "levofloxacin", "-", "induced", "TEN", "."], "event_mentions": [{"id": "12066972_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "12066972_2_Ent1", "role": "Treatment", "text": "levofloxacin", "start": 12, "end": 13}, {"entity_id": "12066972_2_Ent2", "role": "Treatment_Drug", "text": "levofloxacin", "start": 12, "end": 13}, {"entity_id": "12066972_2_Ent0", "role": "Effect", "text": "TEN", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12066972_2_Ent1", "text": "levofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12066972_2_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12066972_2_Ent0", "text": "TEN", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12086549_1", "wnd_id": "12086549_1_1", "text": "After 5 days of treatment with IL - 2 , the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis , as well as grade 4 pancytopenia .", "tokens": ["After", "5", "days", "of", "treatment", "with", "IL", "-", "2", ",", "the", "patient", "developed", "a", "hemorrhagic", "lesion", "that", "progressed", "to", "toxic", "epidermal", "necrolysis", ",", "as", "well", "as", "grade", "4", "pancytopenia", "."], "event_mentions": [{"id": "12086549_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "12086549_1_Ent4", "role": "Treatment_Time_elapsed", "text": "After 5 days", "start": 0, "end": 3}, {"entity_id": "12086549_1_Ent2", "role": "Treatment", "text": "5 days of treatment with IL - 2", "start": 1, "end": 9}, {"entity_id": "12086549_1_Ent3", "role": "Treatment_Drug", "text": "IL - 2", "start": 6, "end": 9}, {"entity_id": "12086549_1_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "12086549_1_Ent1", "role": "Effect", "text": "a hemorrhagic lesion that progressed to toxic epidermal necrolysis , as well as grade 4 pancytopenia", "start": 13, "end": 29}]}], "entity_mentions": [{"id": "12086549_1_Ent4", "text": "After 5 days", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12086549_1_Ent2", "text": "5 days of treatment with IL - 2", "entity_type": "Entity", "start": 1, "end": 9}, {"id": "12086549_1_Ent3", "text": "IL - 2", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12086549_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12086549_1_Ent1", "text": "a hemorrhagic lesion that progressed to toxic epidermal necrolysis , as well as grade 4 pancytopenia", "entity_type": "Entity", "start": 13, "end": 29}], "lang": "en"}
{"doc_id": "12086549_2", "wnd_id": "12086549_2_1", "text": "OBJECTIVE : To report a case of cutaneous and hematologic toxicity in a patient treated with IL - 2 .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "cutaneous", "and", "hematologic", "toxicity", "in", "a", "patient", "treated", "with", "IL", "-", "2", "."], "event_mentions": [{"id": "12086549_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 5, "end": 6}, "arguments": [{"entity_id": "12086549_2_Ent1", "role": "Effect", "text": "cutaneous and hematologic toxicity", "start": 7, "end": 11}, {"entity_id": "12086549_2_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "12086549_2_Ent2", "role": "Treatment", "text": "IL - 2", "start": 16, "end": 19}, {"entity_id": "12086549_2_Ent3", "role": "Treatment_Drug", "text": "IL - 2", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "12086549_2_Ent1", "text": "cutaneous and hematologic toxicity", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "12086549_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12086549_2_Ent2", "text": "IL - 2", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "12086549_2_Ent3", "text": "IL - 2", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "12086549_4", "wnd_id": "12086549_4_1", "text": "Toxic epidermal necrolysis associated with interleukin - 2 .", "tokens": ["Toxic", "epidermal", "necrolysis", "associated", "with", "interleukin", "-", "2", "."], "event_mentions": [{"id": "12086549_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12086549_4_Ent0", "role": "Effect", "text": "Toxic epidermal necrolysis", "start": 0, "end": 3}, {"entity_id": "12086549_4_Ent1", "role": "Treatment", "text": "interleukin - 2", "start": 5, "end": 8}, {"entity_id": "12086549_4_Ent2", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "12086549_4_Ent0", "text": "Toxic epidermal necrolysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12086549_4_Ent1", "text": "interleukin - 2", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12086549_4_Ent2", "text": "interleukin - 2", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "12107858_1", "wnd_id": "12107858_1_1", "text": "The epivodes of NMS occured under treatment with clozapine , risperidone , and amisulpride .", "tokens": ["The", "epivodes", "of", "NMS", "occured", "under", "treatment", "with", "clozapine", ",", "risperidone", ",", "and", "amisulpride", "."], "event_mentions": [{"id": "12107858_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occured", "start": 4, "end": 5}, "arguments": [{"entity_id": "12107858_1_Ent0", "role": "Effect", "text": "NMS", "start": 3, "end": 4}, {"entity_id": "12107858_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "12107858_1_Ent5", "role": "Combination_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "12107858_1_Ent1", "role": "Treatment", "text": "clozapine , risperidone , and amisulpride", "start": 8, "end": 14}, {"entity_id": "12107858_1_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12107858_1_Ent6", "role": "Combination_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "12107858_1_Ent4", "role": "Treatment_Drug", "text": "amisulpride", "start": 13, "end": 14}, {"entity_id": "12107858_1_Ent7", "role": "Combination_Drug", "text": "amisulpride", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12107858_1_Ent0", "text": "NMS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12107858_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12107858_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12107858_1_Ent1", "text": "clozapine , risperidone , and amisulpride", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12107858_1_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12107858_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12107858_1_Ent4", "text": "amisulpride", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12107858_1_Ent7", "text": "amisulpride", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12121061_1", "wnd_id": "12121061_1_1", "text": "Ticlopidine - induced marrow aplasia treated with cyclosporine .", "tokens": ["Ticlopidine", "-", "induced", "marrow", "aplasia", "treated", "with", "cyclosporine", "."], "event_mentions": [{"id": "12121061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12121061_1_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12121061_1_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12121061_1_Ent0", "role": "Effect", "text": "marrow aplasia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "12121061_1_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12121061_1_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12121061_1_Ent0", "text": "marrow aplasia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "12121061_2", "wnd_id": "12121061_2_1", "text": "A 50 - year - old diabetic and hypertensive male patient is reported who had ticlopidine - induced marrow aplasia partially responsive to colony - stimulating factors and corticosteroids , but experienced complete recovery with cyclosporine .", "tokens": ["A", "50", "-", "year", "-", "old", "diabetic", "and", "hypertensive", "male", "patient", "is", "reported", "who", "had", "ticlopidine", "-", "induced", "marrow", "aplasia", "partially", "responsive", "to", "colony", "-", "stimulating", "factors", "and", "corticosteroids", ",", "but", "experienced", "complete", "recovery", "with", "cyclosporine", "."], "event_mentions": [{"id": "12121061_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "12121061_2_Ent2", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent0", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent1", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent5", "role": "Treatment", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent4", "role": "Effect", "text": "marrow aplasia", "start": 18, "end": 20}]}, {"id": "12121061_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 34, "end": 35}, "arguments": [{"entity_id": "12121061_2_Ent9", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent7", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent8", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent10", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent13", "role": "Treatment_Disorder", "text": "ticlopidine - induced marrow aplasia", "start": 15, "end": 20}, {"entity_id": "12121061_2_Ent11", "role": "Effect", "text": "experienced complete recovery", "start": 31, "end": 34}, {"entity_id": "12121061_2_Ent12", "role": "Treatment", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "12121061_2_Ent14", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "12121061_2_Ent2", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent9", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent0", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent7", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent1", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent8", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent3", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent10", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent5", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent13", "text": "ticlopidine - induced marrow aplasia", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "12121061_2_Ent4", "text": "marrow aplasia", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "12121061_2_Ent11", "text": "experienced complete recovery", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "12121061_2_Ent12", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "12121061_2_Ent14", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "12126225_1", "wnd_id": "12126225_1_1", "text": "A 53 - year - old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day .", "tokens": ["A", "53", "-", "year", "-", "old", "man", "developed", "lower", "leg", "edema", "4", "weeks", "after", "rosiglitazone", "was", "increased", "from", "4", "mg", "once", "/", "day", "to", "4", "mg", "twice", "/", "day", "."], "event_mentions": [{"id": "12126225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "12126225_1_Ent0", "role": "Subject", "text": "A 53 - year - old man", "start": 0, "end": 7}, {"entity_id": "12126225_1_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "12126225_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12126225_1_Ent3", "role": "Effect", "text": "lower leg edema", "start": 8, "end": 11}, {"entity_id": "12126225_1_Ent5", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 11, "end": 13}, {"entity_id": "12126225_1_Ent4", "role": "Treatment", "text": "4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day", "start": 11, "end": 29}, {"entity_id": "12126225_1_Ent6", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 14, "end": 15}, {"entity_id": "12126225_1_Ent7", "role": "Treatment_Dosage", "text": "4 mg", "start": 24, "end": 26}, {"entity_id": "12126225_1_Ent8", "role": "Treatment_Freq", "text": "twice / day", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "12126225_1_Ent0", "text": "A 53 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12126225_1_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12126225_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12126225_1_Ent3", "text": "lower leg edema", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12126225_1_Ent5", "text": "4 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12126225_1_Ent4", "text": "4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day", "entity_type": "Entity", "start": 11, "end": 29}, {"id": "12126225_1_Ent6", "text": "rosiglitazone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12126225_1_Ent7", "text": "4 mg", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "12126225_1_Ent8", "text": "twice / day", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "12126225_2", "wnd_id": "12126225_2_1", "text": "A 75 - year - old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone .", "tokens": ["A", "75", "-", "year", "-", "old", "man", "developed", "bilateral", "lower", "leg", "edema", "6", "months", "after", "switching", "from", "troglitazone", "to", "pioglitazone", "."], "event_mentions": [{"id": "12126225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12126225_2_Ent0", "role": "Subject", "text": "A 75 - year - old man", "start": 0, "end": 7}, {"entity_id": "12126225_2_Ent1", "role": "Subject_Age", "text": "75 - year - old", "start": 1, "end": 6}, {"entity_id": "12126225_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12126225_2_Ent3", "role": "Effect", "text": "bilateral lower leg edema", "start": 8, "end": 12}, {"entity_id": "12126225_2_Ent6", "role": "Treatment_Drug", "text": "6 months", "start": 12, "end": 14}, {"entity_id": "12126225_2_Ent4", "role": "Treatment", "text": "6 months after switching from troglitazone to pioglitazone", "start": 12, "end": 20}, {"entity_id": "12126225_2_Ent7", "role": "Treatment_Drug", "text": "troglitazone", "start": 17, "end": 18}, {"entity_id": "12126225_2_Ent5", "role": "Treatment_Drug", "text": "pioglitazone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "12126225_2_Ent0", "text": "A 75 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12126225_2_Ent1", "text": "75 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12126225_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12126225_2_Ent3", "text": "bilateral lower leg edema", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12126225_2_Ent6", "text": "6 months", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12126225_2_Ent4", "text": "6 months after switching from troglitazone to pioglitazone", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "12126225_2_Ent7", "text": "troglitazone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12126225_2_Ent5", "text": "pioglitazone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "12149193_1", "wnd_id": "12149193_1_1", "text": "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide : implications for therapy .", "tokens": ["Thrombogenic", "activity", "of", "doxorubicin", "in", "myeloma", "patients", "receiving", "thalidomide", ":", "implications", "for", "therapy", "."], "event_mentions": [{"id": "12149193_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_1_Ent1", "role": "Effect", "text": "Thrombogenic activity", "start": 0, "end": 2}, {"entity_id": "12149193_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 3, "end": 4}, {"entity_id": "12149193_1_Ent4", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_1_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_1_Ent3", "role": "Treatment", "text": "thalidomide", "start": 8, "end": 9}, {"entity_id": "12149193_1_Ent6", "role": "Treatment_Drug", "text": "thalidomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12149193_1_Ent1", "text": "Thrombogenic activity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12149193_1_Ent4", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_1_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_1_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_1_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12149193_3", "wnd_id": "12149193_3_1", "text": "Thalidomide has proven activity in refractory multiple myeloma ( MM ) , and although single - agent thalidomide has minimal prothrombogenic activity , its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT .", "tokens": ["Thalidomide", "has", "proven", "activity", "in", "refractory", "multiple", "myeloma", "(", "MM", ")", ",", "and", "although", "single", "-", "agent", "thalidomide", "has", "minimal", "prothrombogenic", "activity", ",", "its", "combination", "with", "cytotoxic", "chemotherapy", "is", "associated", "with", "a", "significantly", "increased", "risk", "of", "DVT", "."], "event_mentions": [{"id": "12149193_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 29, "end": 30}, "arguments": [{"entity_id": "12149193_3_Ent3", "role": "Treatment_Disorder", "text": "refractory multiple myeloma ( MM )", "start": 5, "end": 11}, {"entity_id": "12149193_3_Ent1", "role": "Treatment", "text": "single - agent thalidomide", "start": 14, "end": 18}, {"entity_id": "12149193_3_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent7", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent2", "role": "Treatment", "text": "combination with cytotoxic chemotherapy", "start": 24, "end": 28}, {"entity_id": "12149193_3_Ent5", "role": "Treatment_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent8", "role": "Combination_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 27, "end": 28}, {"entity_id": "12149193_3_Ent0", "role": "Effect", "text": "significantly increased risk of DVT", "start": 32, "end": 37}]}], "entity_mentions": [{"id": "12149193_3_Ent3", "text": "refractory multiple myeloma ( MM )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12149193_3_Ent1", "text": "single - agent thalidomide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "12149193_3_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent2", "text": "combination with cytotoxic chemotherapy", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "12149193_3_Ent5", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent8", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12149193_3_Ent0", "text": "significantly increased risk of DVT", "entity_type": "Entity", "start": 32, "end": 37}], "lang": "en"}
{"doc_id": "12149193_4", "wnd_id": "12149193_4_1", "text": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one .", "tokens": ["We", "analyzed", "the", "incidence", "of", "DVT", "in", "232", "MM", "patients", "who", "received", "a", "combination", "of", "chemotherapy", "and", "thalidomide", "on", "2", "protocols", "that", "differed", "only", "by", "the", "inclusion", "of", "doxorubicin", "in", "one", "."], "event_mentions": [{"id": "12149193_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 3, "end": 4}, "arguments": [{"entity_id": "12149193_4_Ent2", "role": "Effect", "text": "DVT", "start": 5, "end": 6}, {"entity_id": "12149193_4_Ent1", "role": "Subject_Population", "text": "232", "start": 7, "end": 8}, {"entity_id": "12149193_4_Ent0", "role": "Subject", "text": "232 MM patients", "start": 7, "end": 10}, {"entity_id": "12149193_4_Ent5", "role": "Treatment_Disorder", "text": "MM", "start": 8, "end": 9}, {"entity_id": "12149193_4_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent6", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent8", "role": "Combination_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent4", "role": "Treatment", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent7", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent9", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "12149193_4_Ent2", "text": "DVT", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_4_Ent1", "text": "232", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_4_Ent0", "text": "232 MM patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12149193_4_Ent5", "text": "MM", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent9", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "12149193_9", "wnd_id": "12149193_9_1", "text": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT .", "tokens": ["MM", "patients", "treated", "with", "thalidomide", "and", "doxorubicin", "have", "a", "high", "risk", "of", "developing", "DVT", "."], "event_mentions": [{"id": "12149193_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_9_Ent3", "role": "Treatment_Disorder", "text": "MM", "start": 0, "end": 1}, {"entity_id": "12149193_9_Ent0", "role": "Subject", "text": "MM patients", "start": 0, "end": 2}, {"entity_id": "12149193_9_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent6", "role": "Combination_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent2", "role": "Treatment", "text": "thalidomide and doxorubicin", "start": 4, "end": 7}, {"entity_id": "12149193_9_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent7", "role": "Combination_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent1", "role": "Effect", "text": "a high risk of developing DVT", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "12149193_9_Ent3", "text": "MM", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12149193_9_Ent0", "text": "MM patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_9_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent2", "text": "thalidomide and doxorubicin", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12149193_9_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent7", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent1", "text": "a high risk of developing DVT", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "12150593_3", "wnd_id": "12150593_3_1", "text": "We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine .", "tokens": ["We", "suggest", "adding", "this", "side", "effect", "to", "the", "list", "of", "untoward", "effects", "of", "lidocaine", "and", "to", "the", "differential", "diagnosis", "of", "fixed", "dilated", "pupils", "in", "neonates", "treated", "with", "lidocaine", "."], "event_mentions": [{"id": "12150593_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 25, "end": 26}, "arguments": [{"entity_id": "12150593_3_Ent2", "role": "Effect", "text": "side effect", "start": 4, "end": 6}, {"entity_id": "12150593_3_Ent0", "role": "Subject", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent1", "role": "Subject_Age", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent3", "role": "Treatment", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "12150593_3_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12150593_3_Ent2", "text": "side effect", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12150593_3_Ent0", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent1", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12150593_3_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12163813_1", "wnd_id": "12163813_1_1", "text": "CONCLUSIONS : Peripheral administration of low - dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications .", "tokens": ["CONCLUSIONS", ":", "Peripheral", "administration", "of", "low", "-", "dose", "vasopressin", "for", "septic", "shock", "should", "be", "discouraged", "because", "of", "the", "risk", "of", "ischemic", "skin", "complications", "."], "event_mentions": [{"id": "12163813_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 18, "end": 19}, "arguments": [{"entity_id": "12163813_1_Ent5", "role": "Treatment_Route", "text": "Peripheral administration", "start": 2, "end": 4}, {"entity_id": "12163813_1_Ent1", "role": "Treatment", "text": "Peripheral administration of low - dose vasopressin", "start": 2, "end": 9}, {"entity_id": "12163813_1_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 5, "end": 8}, {"entity_id": "12163813_1_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_1_Ent2", "role": "Treatment_Disorder", "text": "septic shock", "start": 10, "end": 12}, {"entity_id": "12163813_1_Ent0", "role": "Effect", "text": "ischemic skin complications", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "12163813_1_Ent5", "text": "Peripheral administration", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12163813_1_Ent1", "text": "Peripheral administration of low - dose vasopressin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "12163813_1_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12163813_1_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_1_Ent2", "text": "septic shock", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12163813_1_Ent0", "text": "ischemic skin complications", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "12166705_2", "wnd_id": "12166705_2_1", "text": "Mitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome .", "tokens": ["Mitomycin", "-", "C", "is", "used", "widely", "in", "the", "treatment", "of", "malignancies", "and", "is", "associated", "with", "serious", "dose", "related", "adverse", "effects", "including", "the", "occurrence", "of", "hemolytic", "uremic", "syndrome", "."], "event_mentions": [{"id": "12166705_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "12166705_2_Ent1", "role": "Treatment", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent2", "role": "Treatment_Disorder", "text": "malignancies", "start": 10, "end": 11}, {"entity_id": "12166705_2_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "12166705_2_Ent1", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent3", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent2", "text": "malignancies", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12166705_2_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "12187348_1", "wnd_id": "12187348_1_1", "text": "Gigantomastia induced by bucillamine .", "tokens": ["Gigantomastia", "induced", "by", "bucillamine", "."], "event_mentions": [{"id": "12187348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "12187348_1_Ent0", "role": "Effect", "text": "Gigantomastia", "start": 0, "end": 1}, {"entity_id": "12187348_1_Ent1", "role": "Treatment", "text": "bucillamine", "start": 3, "end": 4}, {"entity_id": "12187348_1_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12187348_1_Ent0", "text": "Gigantomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_1_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12187348_1_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12187348_2", "wnd_id": "12187348_2_1", "text": "Drug - induced mammary hyperplasias have been reported as rare complications of D - penicillamine and Neothetazone .", "tokens": ["Drug", "-", "induced", "mammary", "hyperplasias", "have", "been", "reported", "as", "rare", "complications", "of", "D", "-", "penicillamine", "and", "Neothetazone", "."], "event_mentions": [{"id": "12187348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12187348_2_Ent1", "role": "Treatment", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent3", "role": "Treatment_Drug", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent0", "role": "Effect", "text": "mammary hyperplasias", "start": 3, "end": 5}, {"entity_id": "12187348_2_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent6", "role": "Combination_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent2", "role": "Treatment", "text": "D - penicillamine and Neothetazone", "start": 12, "end": 17}, {"entity_id": "12187348_2_Ent4", "role": "Treatment_Drug", "text": "Neothetazone", "start": 16, "end": 17}, {"entity_id": "12187348_2_Ent7", "role": "Combination_Drug", "text": "Neothetazone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12187348_2_Ent1", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent3", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent0", "text": "mammary hyperplasias", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12187348_2_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent6", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent2", "text": "D - penicillamine and Neothetazone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12187348_2_Ent4", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12187348_2_Ent7", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12187348_3", "wnd_id": "12187348_3_1", "text": "The authors report the first case of bucillamine - induced giant mammary hyperplasia .", "tokens": ["The", "authors", "report", "the", "first", "case", "of", "bucillamine", "-", "induced", "giant", "mammary", "hyperplasia", "."], "event_mentions": [{"id": "12187348_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "12187348_3_Ent1", "role": "Treatment", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 7, "end": 8}, {"entity_id": "12187348_3_Ent0", "role": "Effect", "text": "giant mammary hyperplasia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12187348_3_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12187348_3_Ent0", "text": "giant mammary hyperplasia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "12218252_2", "wnd_id": "12218252_2_1", "text": "We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis , in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition .", "tokens": ["We", "report", "a", "50", "-", "year", "-", "old", "male", "patient", "with", "a", "15", "-", "year", "history", "of", "psoriasis", "including", "mutilating", "psoriatic", "arthritis", ",", "in", "whom", "the", "withdrawal", "of", "cyclosporin", "A", "induced", "a", "generalised", "pustular", "exacerbation", "and", "a", "aggravation", "of", "the", "joint", "condition", "."], "event_mentions": [{"id": "12218252_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "12218252_2_Ent0", "role": "Subject", "text": "a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis", "start": 2, "end": 22}, {"entity_id": "12218252_2_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 3, "end": 8}, {"entity_id": "12218252_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "12218252_2_Ent3", "role": "Subject_Disorder", "text": "psoriasis including mutilating psoriatic arthritis", "start": 17, "end": 22}, {"entity_id": "12218252_2_Ent5", "role": "Treatment", "text": "the withdrawal of cyclosporin A", "start": 25, "end": 30}, {"entity_id": "12218252_2_Ent6", "role": "Treatment_Drug", "text": "cyclosporin A", "start": 28, "end": 30}, {"entity_id": "12218252_2_Ent4", "role": "Effect", "text": "a generalised pustular exacerbation and a aggravation of the joint condition", "start": 31, "end": 42}]}], "entity_mentions": [{"id": "12218252_2_Ent0", "text": "a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis", "entity_type": "Entity", "start": 2, "end": 22}, {"id": "12218252_2_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12218252_2_Ent2", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12218252_2_Ent3", "text": "psoriasis including mutilating psoriatic arthritis", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "12218252_2_Ent5", "text": "the withdrawal of cyclosporin A", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "12218252_2_Ent6", "text": "cyclosporin A", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "12218252_2_Ent4", "text": "a generalised pustular exacerbation and a aggravation of the joint condition", "entity_type": "Entity", "start": 31, "end": 42}], "lang": "en"}
{"doc_id": "12221670_2", "wnd_id": "12221670_2_1", "text": "The second was an 82 - year - old man receiving ticlopidine for 2 years when , during a febrile episode , he was found neutropenic with marrow aplasia .", "tokens": ["The", "second", "was", "an", "82", "-", "year", "-", "old", "man", "receiving", "ticlopidine", "for", "2", "years", "when", ",", "during", "a", "febrile", "episode", ",", "he", "was", "found", "neutropenic", "with", "marrow", "aplasia", "."], "event_mentions": [{"id": "12221670_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 24, "end": 25}, "arguments": [{"entity_id": "12221670_2_Ent1", "role": "Subject_Age", "text": "82 - year - old", "start": 4, "end": 9}, {"entity_id": "12221670_2_Ent0", "role": "Subject", "text": "82 - year - old man", "start": 4, "end": 10}, {"entity_id": "12221670_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "12221670_2_Ent4", "role": "Treatment", "text": "receiving ticlopidine for 2 years", "start": 10, "end": 15}, {"entity_id": "12221670_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 11, "end": 12}, {"entity_id": "12221670_2_Ent5", "role": "Treatment_Duration", "text": "2 years", "start": 13, "end": 15}, {"entity_id": "12221670_2_Ent3", "role": "Effect", "text": "neutropenic with marrow aplasia .", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "12221670_2_Ent1", "text": "82 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "12221670_2_Ent0", "text": "82 - year - old man", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "12221670_2_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12221670_2_Ent4", "text": "receiving ticlopidine for 2 years", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "12221670_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12221670_2_Ent5", "text": "2 years", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12221670_2_Ent3", "text": "neutropenic with marrow aplasia .", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "12243603_2", "wnd_id": "12243603_2_1", "text": "To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem .", "tokens": ["To", "report", "a", "case", "of", "rhabdomyolysis", "and", "acute", "hepatitis", "associated", "with", "the", "coadministration", "of", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12243603_2_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute hepatitis", "start": 5, "end": 9}, {"entity_id": "12243603_2_Ent1", "role": "Treatment", "text": "coadministration of atorvastatin and diltiazem", "start": 12, "end": 17}, {"entity_id": "12243603_2_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent3", "role": "Treatment_Drug", "text": "diltiazem", "start": 16, "end": 17}, {"entity_id": "12243603_2_Ent5", "role": "Combination_Drug", "text": "diltiazem", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12243603_2_Ent0", "text": "rhabdomyolysis and acute hepatitis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12243603_2_Ent1", "text": "coadministration of atorvastatin and diltiazem", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12243603_2_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12243603_2_Ent5", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12243603_6", "wnd_id": "12243603_6_1", "text": "Rhabdomyolysis has been reported in patients receiving hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism .", "tokens": ["Rhabdomyolysis", "has", "been", "reported", "in", "patients", "receiving", "hydroxymethylglutaryl", "coenzyme", "A", "(", "HMG", "-", "CoA", ")", "reductase", "inhibitors", "when", "coadministered", "with", "agents", "that", "may", "inhibit", "their", "metabolism", "."], "event_mentions": [{"id": "12243603_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12243603_6_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_6_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "12243603_6_Ent3", "role": "Treatment_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent5", "role": "Combination_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent2", "role": "Treatment", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "start": 7, "end": 26}, {"entity_id": "12243603_6_Ent4", "role": "Treatment_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}, {"entity_id": "12243603_6_Ent6", "role": "Combination_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "12243603_6_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_6_Ent3", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent5", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent2", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "entity_type": "Entity", "start": 7, "end": 26}, {"id": "12243603_6_Ent4", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "12243603_6_Ent6", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "12324937_5", "wnd_id": "12324937_5_1", "text": "METHODS : A case is presented of a 45 - year - old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation .", "tokens": ["METHODS", ":", "A", "case", "is", "presented", "of", "a", "45", "-", "year", "-", "old", "woman", "on", "prolonged", "gemcitabine", "treatment", "for", "ovarian", "cancer", "who", "developed", "HUS", "and", "recovered", "after", "drug", "discontinuation", "."], "event_mentions": [{"id": "12324937_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "12324937_5_Ent0", "role": "Subject", "text": "a 45 - year - old woman", "start": 7, "end": 14}, {"entity_id": "12324937_5_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 8, "end": 13}, {"entity_id": "12324937_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "12324937_5_Ent6", "role": "Treatment_Duration", "text": "prolonged", "start": 15, "end": 16}, {"entity_id": "12324937_5_Ent4", "role": "Treatment", "text": "prolonged gemcitabine treatment", "start": 15, "end": 18}, {"entity_id": "12324937_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 16, "end": 17}, {"entity_id": "12324937_5_Ent7", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 19, "end": 21}, {"entity_id": "12324937_5_Ent3", "role": "Effect", "text": "HUS", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12324937_5_Ent0", "text": "a 45 - year - old woman", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "12324937_5_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "12324937_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12324937_5_Ent6", "text": "prolonged", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12324937_5_Ent4", "text": "prolonged gemcitabine treatment", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12324937_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12324937_5_Ent7", "text": "ovarian cancer", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12324937_5_Ent3", "text": "HUS", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12365708_2", "wnd_id": "12365708_2_1", "text": "Biomicroscopy revealed amiodarone corneal deposits .", "tokens": ["Biomicroscopy", "revealed", "amiodarone", "corneal", "deposits", "."], "event_mentions": [{"id": "12365708_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revealed", "start": 1, "end": 2}, "arguments": [{"entity_id": "12365708_2_Ent1", "role": "Treatment", "text": "Biomicroscopy", "start": 0, "end": 1}, {"entity_id": "12365708_2_Ent2", "role": "Treatment_Drug", "text": "Biomicroscopy", "start": 0, "end": 1}, {"entity_id": "12365708_2_Ent0", "role": "Effect", "text": "amiodarone corneal deposits", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "12365708_2_Ent1", "text": "Biomicroscopy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12365708_2_Ent2", "text": "Biomicroscopy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12365708_2_Ent0", "text": "amiodarone corneal deposits", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "12365708_3", "wnd_id": "12365708_3_1", "text": "CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ) , a 76 - year - old man came to us with symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision .", "tokens": ["CASE", "REPORT", ":", "Soon", "after", "initiation", "of", "amiodarone", "HCl", "(", "200", "mg", "/", "day", ")", ",", "a", "76", "-", "year", "-", "old", "man", "came", "to", "us", "with", "symptoms", "of", "visual", "\"", "shining", ",", "\"", "glare", ",", "color", "vision", "anomalies", ",", "and", "gradually", "decreased", "vision", "."], "event_mentions": [{"id": "12365708_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after initiation", "start": 4, "end": 6}, "arguments": [{"entity_id": "12365708_3_Ent4", "role": "Treatment", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent5", "role": "Treatment_Drug", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent6", "role": "Treatment_Dosage", "text": "( 200 mg", "start": 9, "end": 12}, {"entity_id": "12365708_3_Ent7", "role": "Treatment_Freq", "text": "day", "start": 13, "end": 14}, {"entity_id": "12365708_3_Ent0", "role": "Subject", "text": "a 76 - year - old man", "start": 16, "end": 23}, {"entity_id": "12365708_3_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 17, "end": 22}, {"entity_id": "12365708_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 22, "end": 23}, {"entity_id": "12365708_3_Ent3", "role": "Effect", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "start": 27, "end": 44}]}], "entity_mentions": [{"id": "12365708_3_Ent4", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent5", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent6", "text": "( 200 mg", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12365708_3_Ent7", "text": "day", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12365708_3_Ent0", "text": "a 76 - year - old man", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "12365708_3_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "12365708_3_Ent2", "text": "man", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12365708_3_Ent3", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "entity_type": "Entity", "start": 27, "end": 44}], "lang": "en"}
{"doc_id": "12365708_4", "wnd_id": "12365708_4_1", "text": "Visual changes secondary to initiation of amiodarone : a case report and review involving ocular management in cardiac polypharmacy .", "tokens": ["Visual", "changes", "secondary", "to", "initiation", "of", "amiodarone", ":", "a", "case", "report", "and", "review", "involving", "ocular", "management", "in", "cardiac", "polypharmacy", "."], "event_mentions": [{"id": "12365708_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "12365708_4_Ent1", "role": "Effect", "text": "Visual changes", "start": 0, "end": 2}, {"entity_id": "12365708_4_Ent2", "role": "Treatment", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "12365708_4_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 6, "end": 7}, {"entity_id": "12365708_4_Ent0", "role": "Subject", "text": "a case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "12365708_4_Ent1", "text": "Visual changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12365708_4_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12365708_4_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12365708_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "12365708_5", "wnd_id": "12365708_5_1", "text": "While both amiodarone and digoxin can cause permanent visual changes , the ocular effects are often reversible .", "tokens": ["While", "both", "amiodarone", "and", "digoxin", "can", "cause", "permanent", "visual", "changes", ",", "the", "ocular", "effects", "are", "often", "reversible", "."], "event_mentions": [{"id": "12365708_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "12365708_5_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "12365708_5_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "12365708_5_Ent1", "role": "Treatment", "text": "amiodarone and digoxin", "start": 2, "end": 5}, {"entity_id": "12365708_5_Ent3", "role": "Treatment_Drug", "text": "digoxin", "start": 4, "end": 5}, {"entity_id": "12365708_5_Ent5", "role": "Combination_Drug", "text": "digoxin", "start": 4, "end": 5}, {"entity_id": "12365708_5_Ent0", "role": "Effect", "text": "permanent visual changes", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "12365708_5_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12365708_5_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12365708_5_Ent1", "text": "amiodarone and digoxin", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12365708_5_Ent3", "text": "digoxin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12365708_5_Ent5", "text": "digoxin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12365708_5_Ent0", "text": "permanent visual changes", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "12390172_2", "wnd_id": "12390172_2_1", "text": "PURPOSE : To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to retinal damage by rifabutin .", "tokens": ["PURPOSE", ":", "To", "describe", "the", "clinical", "and", "electrophysiological", "findings", "in", "a", "young", "boy", "with", "decreased", "vision", "possibly", "due", "to", "retinal", "damage", "by", "rifabutin", "."], "event_mentions": [{"id": "12390172_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 17, "end": 18}, "arguments": [{"entity_id": "12390172_2_Ent0", "role": "Subject", "text": "a young boy", "start": 10, "end": 13}, {"entity_id": "12390172_2_Ent1", "role": "Subject_Age", "text": "young", "start": 11, "end": 12}, {"entity_id": "12390172_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 12, "end": 13}, {"entity_id": "12390172_2_Ent3", "role": "Effect", "text": "decreased vision", "start": 14, "end": 16}, {"entity_id": "12390172_2_Ent4", "role": "Effect", "text": "retinal damage", "start": 19, "end": 21}, {"entity_id": "12390172_2_Ent5", "role": "Treatment", "text": "rifabutin", "start": 22, "end": 23}, {"entity_id": "12390172_2_Ent6", "role": "Treatment_Drug", "text": "rifabutin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12390172_2_Ent0", "text": "a young boy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "12390172_2_Ent1", "text": "young", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12390172_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12390172_2_Ent3", "text": "decreased vision", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12390172_2_Ent4", "text": "retinal damage", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12390172_2_Ent5", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12390172_2_Ent6", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12390172_4", "wnd_id": "12390172_4_1", "text": "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with visual disturbance during treatment with rifabutin .", "tokens": ["We", "suggest", "that", "objective", "evaluation", "of", "retinal", "function", "with", "electrophysiological", "methods", "should", "be", "performed", "in", "patients", "with", "visual", "disturbance", "during", "treatment", "with", "rifabutin", "."], "event_mentions": [{"id": "12390172_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 19, "end": 20}, "arguments": [{"entity_id": "12390172_4_Ent0", "role": "Effect", "text": "visual disturbance", "start": 17, "end": 19}, {"entity_id": "12390172_4_Ent1", "role": "Treatment", "text": "rifabutin", "start": 22, "end": 23}, {"entity_id": "12390172_4_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12390172_4_Ent0", "text": "visual disturbance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "12390172_4_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12390172_4_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12410494_1", "wnd_id": "12410494_1_1", "text": "Simvastatin - nelfinavir interaction implicated in rhabdomyolysis and death .", "tokens": ["Simvastatin", "-", "nelfinavir", "interaction", "implicated", "in", "rhabdomyolysis", "and", "death", "."], "event_mentions": [{"id": "12410494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12410494_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent1", "role": "Treatment", "text": "Simvastatin - nelfinavir interaction", "start": 0, "end": 4}, {"entity_id": "12410494_1_Ent2", "role": "Treatment_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent4", "role": "Combination_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent0", "role": "Effect", "text": "rhabdomyolysis and death", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12410494_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent1", "text": "Simvastatin - nelfinavir interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12410494_1_Ent2", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent4", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent0", "text": "rhabdomyolysis and death", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12439602_3", "wnd_id": "12439602_3_1", "text": "Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy .", "tokens": ["Hypersensitivity", "to", "carboplatin", "is", "a", "rare", "but", "real", "complication", "of", "therapy", "and", "should", "be", "considered", "in", "patients", "presenting", "with", "hyperacute", "changes", "on", "ECG", "whilst", "receiving", "carboplatin", "therapy", "."], "event_mentions": [{"id": "12439602_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 8, "end": 9}, "arguments": [{"entity_id": "12439602_3_Ent2", "role": "Effect", "text": "Hypersensitivity to carboplatin", "start": 0, "end": 3}, {"entity_id": "12439602_3_Ent0", "role": "Subject", "text": "patients presenting with hyperacute changes on ECG", "start": 16, "end": 23}, {"entity_id": "12439602_3_Ent1", "role": "Subject_Disorder", "text": "hyperacute changes on ECG", "start": 19, "end": 23}, {"entity_id": "12439602_3_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 25, "end": 26}, {"entity_id": "12439602_3_Ent3", "role": "Treatment", "text": "carboplatin therapy", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "12439602_3_Ent2", "text": "Hypersensitivity to carboplatin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12439602_3_Ent0", "text": "patients presenting with hyperacute changes on ECG", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "12439602_3_Ent1", "text": "hyperacute changes on ECG", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "12439602_3_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "12439602_3_Ent3", "text": "carboplatin therapy", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "12452753_3", "wnd_id": "12452753_3_1", "text": "Fluorouracil for allergic reactions to capecitabine .", "tokens": ["Fluorouracil", "for", "allergic", "reactions", "to", "capecitabine", "."], "event_mentions": [{"id": "12452753_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 1, "end": 2}, "arguments": [{"entity_id": "12452753_3_Ent3", "role": "Treatment", "text": "Fluorouracil", "start": 0, "end": 1}, {"entity_id": "12452753_3_Ent5", "role": "Treatment_Drug", "text": "Fluorouracil", "start": 0, "end": 1}, {"entity_id": "12452753_3_Ent4", "role": "Treatment_Disorder", "text": "allergic reactions to capecitabine", "start": 2, "end": 6}]}, {"id": "12452753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "12452753_3_Ent0", "role": "Effect", "text": "allergic reactions", "start": 2, "end": 4}, {"entity_id": "12452753_3_Ent1", "role": "Treatment", "text": "capecitabine", "start": 5, "end": 6}, {"entity_id": "12452753_3_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12452753_3_Ent3", "text": "Fluorouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12452753_3_Ent5", "text": "Fluorouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12452753_3_Ent0", "text": "allergic reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12452753_3_Ent4", "text": "allergic reactions to capecitabine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12452753_3_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12452753_3_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12452753_6", "wnd_id": "12452753_6_1", "text": "She developed a generalized rash and itching , sore throat , and dizziness approximately 4 hours after the first dose of capecitabine .", "tokens": ["She", "developed", "a", "generalized", "rash", "and", "itching", ",", "sore", "throat", ",", "and", "dizziness", "approximately", "4", "hours", "after", "the", "first", "dose", "of", "capecitabine", "."], "event_mentions": [{"id": "12452753_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "12452753_6_Ent0", "role": "Effect", "text": "a generalized rash and itching , sore throat , and dizziness", "start": 2, "end": 13}, {"entity_id": "12452753_6_Ent1", "role": "Treatment", "text": "approximately 4 hours after the first dose of capecitabine", "start": 13, "end": 22}, {"entity_id": "12452753_6_Ent2", "role": "Treatment_Time_elapsed", "text": "4 hours", "start": 14, "end": 16}, {"entity_id": "12452753_6_Ent3", "role": "Treatment_Drug", "text": "capecitabine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12452753_6_Ent0", "text": "a generalized rash and itching , sore throat , and dizziness", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "12452753_6_Ent1", "text": "approximately 4 hours after the first dose of capecitabine", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "12452753_6_Ent2", "text": "4 hours", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12452753_6_Ent3", "text": "capecitabine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12460237_1", "wnd_id": "12460237_1_1", "text": "Recurrent palmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia .", "tokens": ["Recurrent", "palmar", "-", "plantar", "erythrodysaesthesia", "following", "high", "-", "dose", "cytarabine", "treatment", "for", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "12460237_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 10, "end": 11}, "arguments": [{"entity_id": "12460237_1_Ent0", "role": "Effect", "text": "palmar - plantar erythrodysaesthesia", "start": 1, "end": 5}, {"entity_id": "12460237_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "12460237_1_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 6, "end": 10}, {"entity_id": "12460237_1_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 9, "end": 10}, {"entity_id": "12460237_1_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "12460237_1_Ent0", "text": "palmar - plantar erythrodysaesthesia", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12460237_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12460237_1_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12460237_1_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12460237_1_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "12488741_2", "wnd_id": "12488741_2_1", "text": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment .", "tokens": ["Proton", "MRS", "examination", "demonstrated", "a", "persistent", "lactate", "elevation", "during", "metronidazole", "treatment", "."], "event_mentions": [{"id": "12488741_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "12488741_2_Ent0", "role": "Effect", "text": "persistent lactate elevation", "start": 5, "end": 8}, {"entity_id": "12488741_2_Ent1", "role": "Treatment", "text": "metronidazole", "start": 9, "end": 10}, {"entity_id": "12488741_2_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12488741_2_Ent0", "text": "persistent lactate elevation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12488741_2_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12488741_2_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12494253_1", "wnd_id": "12494253_1_1", "text": "After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin .", "tokens": ["After", "nine", "previous", "uncomplicated", "cycles", "she", "developed", "severe", "anaphylaxis", "to", "cisplatin", "."], "event_mentions": [{"id": "12494253_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12494253_1_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "12494253_1_Ent1", "role": "Subject_Gender", "text": "she", "start": 5, "end": 6}, {"entity_id": "12494253_1_Ent2", "role": "Effect", "text": "severe anaphylaxis", "start": 7, "end": 9}, {"entity_id": "12494253_1_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "12494253_1_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12494253_1_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12494253_1_Ent1", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12494253_1_Ent2", "text": "severe anaphylaxis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12494253_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12494253_1_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12503933_2", "wnd_id": "12503933_2_1", "text": "A second possibility is an interaction between clarithromycin and isradipine , potentially increasing the hepatic toxicity of isradipine .", "tokens": ["A", "second", "possibility", "is", "an", "interaction", "between", "clarithromycin", "and", "isradipine", ",", "potentially", "increasing", "the", "hepatic", "toxicity", "of", "isradipine", "."], "event_mentions": [{"id": "12503933_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increasing", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_2_Ent1", "role": "Treatment", "text": "interaction between clarithromycin and isradipine", "start": 5, "end": 10}, {"entity_id": "12503933_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent4", "role": "Combination_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent3", "role": "Treatment_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent5", "role": "Combination_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent0", "role": "Effect", "text": "hepatic toxicity", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12503933_2_Ent1", "text": "interaction between clarithromycin and isradipine", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12503933_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent3", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent5", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent0", "text": "hepatic toxicity", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12503933_5", "wnd_id": "12503933_5_1", "text": "Fulminant liver failure associated with clarithromycin .", "tokens": ["Fulminant", "liver", "failure", "associated", "with", "clarithromycin", "."], "event_mentions": [{"id": "12503933_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_5_Ent0", "role": "Effect", "text": "Fulminant liver failure", "start": 0, "end": 3}, {"entity_id": "12503933_5_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 5, "end": 6}, {"entity_id": "12503933_5_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12503933_5_Ent0", "text": "Fulminant liver failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12503933_5_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12503933_5_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12503933_7", "wnd_id": "12503933_7_1", "text": "The most likely cause of liver failure in this patient was , therefore , clarithromycin , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure .", "tokens": ["The", "most", "likely", "cause", "of", "liver", "failure", "in", "this", "patient", "was", ",", "therefore", ",", "clarithromycin", ",", "which", "undergoes", "hepatic", "metabolism", "and", "has", "been", "reported", "to", "cause", "fulminant", "hepatic", "failure", "."], "event_mentions": [{"id": "12503933_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_7_Ent0", "role": "Effect", "text": "liver failure", "start": 5, "end": 7}, {"entity_id": "12503933_7_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_7_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12503933_7_Ent0", "text": "liver failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12503933_7_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_7_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12546343_5", "wnd_id": "12546343_5_1", "text": "The successful development and implementation of this protocol will have impact on patients who have anaphylactic reactions to MTX but require this medication for specific diseases .", "tokens": ["The", "successful", "development", "and", "implementation", "of", "this", "protocol", "will", "have", "impact", "on", "patients", "who", "have", "anaphylactic", "reactions", "to", "MTX", "but", "require", "this", "medication", "for", "specific", "diseases", "."], "event_mentions": [{"id": "12546343_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 14, "end": 15}, "arguments": [{"entity_id": "12546343_5_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "12546343_5_Ent1", "role": "Effect", "text": "anaphylactic reactions", "start": 15, "end": 17}, {"entity_id": "12546343_5_Ent2", "role": "Treatment", "text": "MTX", "start": 18, "end": 19}, {"entity_id": "12546343_5_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12546343_5_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12546343_5_Ent1", "text": "anaphylactic reactions", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12546343_5_Ent2", "text": "MTX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12546343_5_Ent3", "text": "MTX", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12561997_1", "wnd_id": "12561997_1_1", "text": "Gelatinous transformation of bone marrow following chemotherapy for myeloma .", "tokens": ["Gelatinous", "transformation", "of", "bone", "marrow", "following", "chemotherapy", "for", "myeloma", "."], "event_mentions": [{"id": "12561997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "12561997_1_Ent0", "role": "Effect", "text": "Gelatinous transformation of bone marrow", "start": 0, "end": 5}, {"entity_id": "12561997_1_Ent1", "role": "Treatment", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12561997_1_Ent0", "text": "Gelatinous transformation of bone marrow", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12561997_1_Ent1", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12587815_3", "wnd_id": "12587815_3_1", "text": "Neuroleptic malignant syndrome in an adolescent receiving olanzapine - lithium combination therapy .", "tokens": ["Neuroleptic", "malignant", "syndrome", "in", "an", "adolescent", "receiving", "olanzapine", "-", "lithium", "combination", "therapy", "."], "event_mentions": [{"id": "12587815_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12587815_3_Ent1", "role": "Effect", "text": "Neuroleptic malignant syndrome", "start": 0, "end": 3}, {"entity_id": "12587815_3_Ent0", "role": "Subject", "text": "adolescent", "start": 5, "end": 6}, {"entity_id": "12587815_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "12587815_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "12587815_3_Ent2", "role": "Treatment", "text": "olanzapine - lithium combination therapy", "start": 7, "end": 12}, {"entity_id": "12587815_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "12587815_3_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12587815_3_Ent1", "text": "Neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12587815_3_Ent0", "text": "adolescent", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12587815_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12587815_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12587815_3_Ent2", "text": "olanzapine - lithium combination therapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12587815_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12587815_3_Ent5", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12590235_3", "wnd_id": "12590235_3_1", "text": "This case highlights the need to monitor liver enzymes in patients treated with 6 - TG and identifies the need for additional research focused on the mechanism of thiopurine - induced hepatic injury .", "tokens": ["This", "case", "highlights", "the", "need", "to", "monitor", "liver", "enzymes", "in", "patients", "treated", "with", "6", "-", "TG", "and", "identifies", "the", "need", "for", "additional", "research", "focused", "on", "the", "mechanism", "of", "thiopurine", "-", "induced", "hepatic", "injury", "."], "event_mentions": [{"id": "12590235_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "12590235_3_Ent0", "role": "Subject", "text": "patients treated with 6 - TG", "start": 10, "end": 16}, {"entity_id": "12590235_3_Ent2", "role": "Treatment", "text": "thiopurine", "start": 28, "end": 29}, {"entity_id": "12590235_3_Ent3", "role": "Treatment_Drug", "text": "thiopurine", "start": 28, "end": 29}, {"entity_id": "12590235_3_Ent1", "role": "Effect", "text": "hepatic injury", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "12590235_3_Ent0", "text": "patients treated with 6 - TG", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "12590235_3_Ent2", "text": "thiopurine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12590235_3_Ent3", "text": "thiopurine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12590235_3_Ent1", "text": "hepatic injury", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "12598508_4", "wnd_id": "12598508_4_1", "text": "Early peritoneal dialysis has not previously been reported for lisinopril induced multiorgan failure .", "tokens": ["Early", "peritoneal", "dialysis", "has", "not", "previously", "been", "reported", "for", "lisinopril", "induced", "multiorgan", "failure", "."], "event_mentions": [{"id": "12598508_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "12598508_4_Ent1", "role": "Treatment", "text": "lisinopril", "start": 9, "end": 10}, {"entity_id": "12598508_4_Ent2", "role": "Treatment_Drug", "text": "lisinopril", "start": 9, "end": 10}, {"entity_id": "12598508_4_Ent0", "role": "Effect", "text": "multiorgan failure", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "12598508_4_Ent1", "text": "lisinopril", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12598508_4_Ent2", "text": "lisinopril", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12598508_4_Ent0", "text": "multiorgan failure", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "12625995_1", "wnd_id": "12625995_1_1", "text": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents , particularly clozapine , and is easily misdiagnosed in children .", "tokens": ["Akathisia", "is", "a", "relatively", "rare", "side", "effect", "with", "the", "newer", "atypical", "antipsychotic", "agents", ",", "particularly", "clozapine", ",", "and", "is", "easily", "misdiagnosed", "in", "children", "."], "event_mentions": [{"id": "12625995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_1_Ent1", "role": "Effect", "text": "Akathisia", "start": 0, "end": 1}, {"entity_id": "12625995_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent0", "role": "Subject", "text": "children", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12625995_1_Ent1", "text": "Akathisia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent0", "text": "children", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12656748_2", "wnd_id": "12656748_2_1", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia .", "tokens": ["Emergence", "of", "Philadelphia", "positive", "chronic", "myeloid", "leukaemia", "during", "treatment", "with", "hydroxyurea", "for", "Philadelphia", "negative", "essential", "thrombocythaemia", "."], "event_mentions": [{"id": "12656748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "12656748_2_Ent0", "role": "Effect", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "start": 0, "end": 7}, {"entity_id": "12656748_2_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent3", "role": "Treatment_Disorder", "text": "Philadelphia negative essential thrombocythaemia", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "12656748_2_Ent0", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12656748_2_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent3", "text": "Philadelphia negative essential thrombocythaemia", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "12656748_3", "wnd_id": "12656748_3_1", "text": "There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea .", "tokens": ["There", "are", "no", "previous", "reports", "in", "the", "literature", "about", "the", "emergence", "of", "CML", "during", "treatment", "with", "hydroxyurea", "."], "event_mentions": [{"id": "12656748_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "12656748_3_Ent0", "role": "Effect", "text": "CML", "start": 12, "end": 13}, {"entity_id": "12656748_3_Ent1", "role": "Treatment", "text": "treatment with hydroxyurea", "start": 14, "end": 17}, {"entity_id": "12656748_3_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12656748_3_Ent0", "text": "CML", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12656748_3_Ent1", "text": "treatment with hydroxyurea", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "12656748_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12661801_3", "wnd_id": "12661801_3_1", "text": "We present the management of agranulocytosis and neutropenic sepsis secondary to carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF ) .", "tokens": ["We", "present", "the", "management", "of", "agranulocytosis", "and", "neutropenic", "sepsis", "secondary", "to", "carbimazole", "with", "recombinant", "human", "granulocyte", "colony", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "12661801_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "12661801_3_Ent0", "role": "Effect", "text": "agranulocytosis and neutropenic sepsis", "start": 5, "end": 9}, {"entity_id": "12661801_3_Ent2", "role": "Treatment_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent5", "role": "Combination_Drug", "text": "carbimazole", "start": 11, "end": 12}, {"entity_id": "12661801_3_Ent1", "role": "Treatment", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "start": 11, "end": 24}, {"entity_id": "12661801_3_Ent3", "role": "Treatment_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}, {"entity_id": "12661801_3_Ent4", "role": "Combination_Drug", "text": "recombinant human granulocyte colony stimulating factor", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "12661801_3_Ent0", "text": "agranulocytosis and neutropenic sepsis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12661801_3_Ent2", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent5", "text": "carbimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12661801_3_Ent1", "text": "carbimazole with recombinant human granulocyte colony stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "12661801_3_Ent3", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "12661801_3_Ent4", "text": "recombinant human granulocyte colony stimulating factor", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "12663440_12", "wnd_id": "12663440_12_1", "text": "We conclude that quinine does not improve the survival of adult patients with de novo AML , even though it improves CR rate in a small subgroup of patients defined by rhodamine 123 efflux .", "tokens": ["We", "conclude", "that", "quinine", "does", "not", "improve", "the", "survival", "of", "adult", "patients", "with", "de", "novo", "AML", ",", "even", "though", "it", "improves", "CR", "rate", "in", "a", "small", "subgroup", "of", "patients", "defined", "by", "rhodamine", "123", "efflux", "."], "event_mentions": [{"id": "12663440_12_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improve", "start": 6, "end": 7}, "arguments": [{"entity_id": "12663440_12_Ent9", "role": "Treatment", "text": "quinine", "start": 3, "end": 4}, {"entity_id": "12663440_12_Ent11", "role": "Treatment_Drug", "text": "quinine", "start": 3, "end": 4}, {"entity_id": "12663440_12_Ent8", "role": "Subject_Age", "text": "adult", "start": 10, "end": 11}, {"entity_id": "12663440_12_Ent7", "role": "Subject", "text": "adult patients", "start": 10, "end": 12}, {"entity_id": "12663440_12_Ent10", "role": "Treatment_Disorder", "text": "de novo AML", "start": 13, "end": 16}]}, {"id": "12663440_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improves", "start": 20, "end": 21}, "arguments": [{"entity_id": "12663440_12_Ent4", "role": "Treatment", "text": "quinine", "start": 3, "end": 4}, {"entity_id": "12663440_12_Ent6", "role": "Treatment_Drug", "text": "quinine", "start": 3, "end": 4}, {"entity_id": "12663440_12_Ent5", "role": "Treatment_Disorder", "text": "de novo AML", "start": 13, "end": 16}, {"entity_id": "12663440_12_Ent3", "role": "Effect", "text": "improves CR rate", "start": 20, "end": 23}, {"entity_id": "12663440_12_Ent2", "role": "Subject_Population", "text": "a small subgroup", "start": 24, "end": 27}, {"entity_id": "12663440_12_Ent0", "role": "Subject", "text": "a small subgroup of patients defined by rhodamine 123 efflux", "start": 24, "end": 34}, {"entity_id": "12663440_12_Ent1", "role": "Subject_Disorder", "text": "rhodamine 123 efflux", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "12663440_12_Ent4", "text": "quinine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12663440_12_Ent6", "text": "quinine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12663440_12_Ent9", "text": "quinine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12663440_12_Ent11", "text": "quinine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12663440_12_Ent8", "text": "adult", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12663440_12_Ent7", "text": "adult patients", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12663440_12_Ent5", "text": "de novo AML", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12663440_12_Ent10", "text": "de novo AML", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12663440_12_Ent3", "text": "improves CR rate", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "12663440_12_Ent2", "text": "a small subgroup", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "12663440_12_Ent0", "text": "a small subgroup of patients defined by rhodamine 123 efflux", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "12663440_12_Ent1", "text": "rhodamine 123 efflux", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "12663440_2", "wnd_id": "12663440_2_1", "text": "Based on our previous demonstration that quinine could be used clinically to reverse P - glycoprotein - mediated resistance , we designed a multicenter , randomized trial aiming to determine whether quinine would improve the survival of adult patients ( 15 - 60 years old ) with de novo acute myelogenous leukemia ( AML ) .", "tokens": ["Based", "on", "our", "previous", "demonstration", "that", "quinine", "could", "be", "used", "clinically", "to", "reverse", "P", "-", "glycoprotein", "-", "mediated", "resistance", ",", "we", "designed", "a", "multicenter", ",", "randomized", "trial", "aiming", "to", "determine", "whether", "quinine", "would", "improve", "the", "survival", "of", "adult", "patients", "(", "15", "-", "60", "years", "old", ")", "with", "de", "novo", "acute", "myelogenous", "leukemia", "(", "AML", ")", "."], "event_mentions": [{"id": "12663440_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improve", "start": 33, "end": 34}, "arguments": [{"entity_id": "12663440_2_Ent4", "role": "Treatment", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "12663440_2_Ent5", "role": "Treatment_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "12663440_2_Ent3", "role": "Effect", "text": "reverse P - glycoprotein - mediated resistance", "start": 12, "end": 19}, {"entity_id": "12663440_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 37, "end": 38}, {"entity_id": "12663440_2_Ent0", "role": "Subject", "text": "adult patients ( 15 - 60 years old )", "start": 37, "end": 46}, {"entity_id": "12663440_2_Ent2", "role": "Subject_Age", "text": "15 - 60 years old", "start": 40, "end": 45}, {"entity_id": "12663440_2_Ent6", "role": "Treatment_Disorder", "text": "de novo acute myelogenous leukemia ( AML )", "start": 47, "end": 55}]}], "entity_mentions": [{"id": "12663440_2_Ent4", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12663440_2_Ent5", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12663440_2_Ent3", "text": "reverse P - glycoprotein - mediated resistance", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12663440_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "12663440_2_Ent0", "text": "adult patients ( 15 - 60 years old )", "entity_type": "Entity", "start": 37, "end": 46}, {"id": "12663440_2_Ent2", "text": "15 - 60 years old", "entity_type": "Entity", "start": 40, "end": 45}, {"id": "12663440_2_Ent6", "text": "de novo acute myelogenous leukemia ( AML )", "entity_type": "Entity", "start": 47, "end": 55}], "lang": "en"}
{"doc_id": "12680486_1", "wnd_id": "12680486_1_1", "text": "Based on these findings , the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride .", "tokens": ["Based", "on", "these", "findings", ",", "the", "patient", "was", "diagnosed", "with", "diabetes", "insipidus", "secondary", "to", "lithium", "therapy", "and", "was", "treated", "successfully", "with", "amiloride", "."], "event_mentions": [{"id": "12680486_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12680486_1_Ent0", "role": "Effect", "text": "diabetes insipidus", "start": 10, "end": 12}, {"entity_id": "12680486_1_Ent1", "role": "Treatment", "text": "lithium", "start": 14, "end": 15}, {"entity_id": "12680486_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 14, "end": 15}]}, {"id": "12680486_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 18, "end": 19}, "arguments": [{"entity_id": "12680486_1_Ent5", "role": "Treatment_Disorder", "text": "diabetes insipidus secondary to lithium therapy", "start": 10, "end": 16}, {"entity_id": "12680486_1_Ent3", "role": "Effect", "text": "successfully", "start": 19, "end": 20}, {"entity_id": "12680486_1_Ent4", "role": "Treatment", "text": "amiloride", "start": 21, "end": 22}, {"entity_id": "12680486_1_Ent6", "role": "Treatment_Drug", "text": "amiloride", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12680486_1_Ent0", "text": "diabetes insipidus", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12680486_1_Ent5", "text": "diabetes insipidus secondary to lithium therapy", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "12680486_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12680486_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12680486_1_Ent3", "text": "successfully", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12680486_1_Ent4", "text": "amiloride", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12680486_1_Ent6", "text": "amiloride", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12702914_2", "wnd_id": "12702914_2_1", "text": "Soon after introduction of insulin therapy , she developed severe anasarca , including marked peripheral oedema , ascites and pleural effusion .", "tokens": ["Soon", "after", "introduction", "of", "insulin", "therapy", ",", "she", "developed", "severe", "anasarca", ",", "including", "marked", "peripheral", "oedema", ",", "ascites", "and", "pleural", "effusion", "."], "event_mentions": [{"id": "12702914_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12702914_2_Ent3", "role": "Treatment", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent2", "role": "Effect", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "start": 10, "end": 21}]}], "entity_mentions": [{"id": "12702914_2_Ent3", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent4", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent2", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "entity_type": "Entity", "start": 10, "end": 21}], "lang": "en"}
{"doc_id": "12776809_1", "wnd_id": "12776809_1_1", "text": "Safety aspects of a coumarin - troxerutin combination regarding liver function in a double - blind placebo - controlled study .", "tokens": ["Safety", "aspects", "of", "a", "coumarin", "-", "troxerutin", "combination", "regarding", "liver", "function", "in", "a", "double", "-", "blind", "placebo", "-", "controlled", "study", "."], "event_mentions": [{"id": "12776809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Safety aspects", "start": 0, "end": 2}, "arguments": [{"entity_id": "12776809_1_Ent2", "role": "Treatment_Drug", "text": "coumarin", "start": 4, "end": 5}, {"entity_id": "12776809_1_Ent5", "role": "Combination_Drug", "text": "coumarin", "start": 4, "end": 5}, {"entity_id": "12776809_1_Ent1", "role": "Treatment", "text": "coumarin - troxerutin combination", "start": 4, "end": 8}, {"entity_id": "12776809_1_Ent3", "role": "Treatment_Drug", "text": "troxerutin", "start": 6, "end": 7}, {"entity_id": "12776809_1_Ent4", "role": "Combination_Drug", "text": "troxerutin", "start": 6, "end": 7}, {"entity_id": "12776809_1_Ent0", "role": "Effect", "text": "liver function", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "12776809_1_Ent2", "text": "coumarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12776809_1_Ent5", "text": "coumarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12776809_1_Ent1", "text": "coumarin - troxerutin combination", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "12776809_1_Ent3", "text": "troxerutin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12776809_1_Ent4", "text": "troxerutin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12776809_1_Ent0", "text": "liver function", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "12776809_2", "wnd_id": "12776809_2_1", "text": "Coumarin is reported to elevate liver function tests ( LFT ) values .", "tokens": ["Coumarin", "is", "reported", "to", "elevate", "liver", "function", "tests", "(", "LFT", ")", "values", "."], "event_mentions": [{"id": "12776809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 2, "end": 3}, "arguments": [{"entity_id": "12776809_2_Ent1", "role": "Treatment", "text": "Coumarin", "start": 0, "end": 1}, {"entity_id": "12776809_2_Ent2", "role": "Treatment_Drug", "text": "Coumarin", "start": 0, "end": 1}, {"entity_id": "12776809_2_Ent0", "role": "Effect", "text": "elevate liver function tests ( LFT ) values", "start": 4, "end": 12}]}], "entity_mentions": [{"id": "12776809_2_Ent1", "text": "Coumarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12776809_2_Ent2", "text": "Coumarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12776809_2_Ent0", "text": "elevate liver function tests ( LFT ) values", "entity_type": "Entity", "start": 4, "end": 12}], "lang": "en"}
{"doc_id": "12796597_2", "wnd_id": "12796597_2_1", "text": "Despite the underlying hepatitis C , this case represents renal abnormalities consistent with IFNalpha therapy for CML .", "tokens": ["Despite", "the", "underlying", "hepatitis", "C", ",", "this", "case", "represents", "renal", "abnormalities", "consistent", "with", "IFNalpha", "therapy", "for", "CML", "."], "event_mentions": [{"id": "12796597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent", "start": 11, "end": 12}, "arguments": [{"entity_id": "12796597_2_Ent0", "role": "Subject", "text": "this case", "start": 6, "end": 8}, {"entity_id": "12796597_2_Ent1", "role": "Effect", "text": "renal abnormalities", "start": 9, "end": 11}, {"entity_id": "12796597_2_Ent3", "role": "Treatment_Drug", "text": "IFNalpha", "start": 13, "end": 14}, {"entity_id": "12796597_2_Ent2", "role": "Treatment", "text": "IFNalpha therapy", "start": 13, "end": 15}, {"entity_id": "12796597_2_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12796597_2_Ent0", "text": "this case", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12796597_2_Ent1", "text": "renal abnormalities", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12796597_2_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12796597_2_Ent2", "text": "IFNalpha therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12796597_2_Ent4", "text": "CML", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12796597_4", "wnd_id": "12796597_4_1", "text": "The renal biopsy showed focal segmental glomerulosclerosis , which has only been previously reported in two cases of CML treated with IFNalpha .", "tokens": ["The", "renal", "biopsy", "showed", "focal", "segmental", "glomerulosclerosis", ",", "which", "has", "only", "been", "previously", "reported", "in", "two", "cases", "of", "CML", "treated", "with", "IFNalpha", "."], "event_mentions": [{"id": "12796597_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 13, "end": 14}, "arguments": [{"entity_id": "12796597_4_Ent2", "role": "Effect", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "start": 0, "end": 7}, {"entity_id": "12796597_4_Ent1", "role": "Subject_Population", "text": "two", "start": 15, "end": 16}, {"entity_id": "12796597_4_Ent0", "role": "Subject", "text": "two cases", "start": 15, "end": 17}, {"entity_id": "12796597_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 18, "end": 19}, {"entity_id": "12796597_4_Ent3", "role": "Treatment", "text": "IFNalpha", "start": 21, "end": 22}, {"entity_id": "12796597_4_Ent5", "role": "Treatment_Drug", "text": "IFNalpha", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12796597_4_Ent2", "text": "The renal biopsy showed focal segmental glomerulosclerosis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12796597_4_Ent1", "text": "two", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12796597_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "12796597_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12796597_4_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12796597_4_Ent5", "text": "IFNalpha", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12806509_1", "wnd_id": "12806509_1_1", "text": "Early - onset acute transverse myelitis following hepatitis B vaccination and respiratory infection : case report .", "tokens": ["Early", "-", "onset", "acute", "transverse", "myelitis", "following", "hepatitis", "B", "vaccination", "and", "respiratory", "infection", ":", "case", "report", "."], "event_mentions": [{"id": "12806509_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "12806509_1_Ent1", "role": "Effect", "text": "Early - onset acute transverse myelitis", "start": 0, "end": 6}, {"entity_id": "12806509_1_Ent2", "role": "Treatment", "text": "hepatitis B vaccination", "start": 7, "end": 10}, {"entity_id": "12806509_1_Ent3", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 7, "end": 10}, {"entity_id": "12806509_1_Ent0", "role": "Subject", "text": "case", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12806509_1_Ent1", "text": "Early - onset acute transverse myelitis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12806509_1_Ent2", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12806509_1_Ent3", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12806509_1_Ent0", "text": "case", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12836099_1", "wnd_id": "12836099_1_1", "text": "Stevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "in", "a", "boy", "with", "nephrotic", "syndrome", "during", "prednisolone", "therapy", "."], "event_mentions": [{"id": "12836099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "12836099_1_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "12836099_1_Ent0", "role": "Subject", "text": "a boy with nephrotic syndrome", "start": 5, "end": 10}, {"entity_id": "12836099_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12836099_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "12836099_1_Ent3", "role": "Treatment", "text": "prednisolone", "start": 11, "end": 12}, {"entity_id": "12836099_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12836099_1_Ent2", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12836099_1_Ent0", "text": "a boy with nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12836099_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12836099_1_Ent5", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12836099_1_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12836099_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12851279_15", "wnd_id": "12851279_15_1", "text": "Tifacogin administration was associated with an increase in risk of bleeding , irrespective of baseline INR .", "tokens": ["Tifacogin", "administration", "was", "associated", "with", "an", "increase", "in", "risk", "of", "bleeding", ",", "irrespective", "of", "baseline", "INR", "."], "event_mentions": [{"id": "12851279_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12851279_15_Ent1", "role": "Treatment", "text": "Tifacogin", "start": 0, "end": 1}, {"entity_id": "12851279_15_Ent2", "role": "Treatment_Drug", "text": "Tifacogin", "start": 0, "end": 1}, {"entity_id": "12851279_15_Ent0", "role": "Effect", "text": "an increase in risk of bleeding", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "12851279_15_Ent1", "text": "Tifacogin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12851279_15_Ent2", "text": "Tifacogin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12851279_15_Ent0", "text": "an increase in risk of bleeding", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "12860350_1", "wnd_id": "12860350_1_1", "text": "Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen .", "tokens": ["Acute", "abdomen", "due", "to", "endometriosis", "in", "a", "premenopausal", "woman", "taking", "tamoxifen", "."], "event_mentions": [{"id": "12860350_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 9, "end": 10}, "arguments": [{"entity_id": "12860350_1_Ent0", "role": "Effect", "text": "Acute abdomen due to endometriosis", "start": 0, "end": 5}, {"entity_id": "12860350_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "12860350_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12860350_1_Ent0", "text": "Acute abdomen due to endometriosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12860350_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12860350_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12862258_3", "wnd_id": "12862258_3_1", "text": "Various case reports concerning dapsone - induced agranulocytosis are reviewed .", "tokens": ["Various", "case", "reports", "concerning", "dapsone", "-", "induced", "agranulocytosis", "are", "reviewed", "."], "event_mentions": [{"id": "12862258_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "12862258_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12862258_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12908837_1", "wnd_id": "12908837_1_1", "text": "Behavioral side effects associated with clonazepam may include agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums .", "tokens": ["Behavioral", "side", "effects", "associated", "with", "clonazepam", "may", "include", "agitation", ",", "aggression", ",", "hyperactivity", ",", "irritability", ",", "property", "destruction", ",", "and", "temper", "tantrums", "."], "event_mentions": [{"id": "12908837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12908837_1_Ent1", "role": "Treatment", "text": "clonazepam", "start": 5, "end": 6}, {"entity_id": "12908837_1_Ent2", "role": "Treatment_Drug", "text": "clonazepam", "start": 5, "end": 6}, {"entity_id": "12908837_1_Ent0", "role": "Effect", "text": "agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums", "start": 8, "end": 22}]}], "entity_mentions": [{"id": "12908837_1_Ent1", "text": "clonazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12908837_1_Ent2", "text": "clonazepam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12908837_1_Ent0", "text": "agitation , aggression , hyperactivity , irritability , property destruction , and temper tantrums", "entity_type": "Entity", "start": 8, "end": 22}], "lang": "en"}
{"doc_id": "12915840_2", "wnd_id": "12915840_2_1", "text": "We report the first case of IHA associated with cefuroxime administration .", "tokens": ["We", "report", "the", "first", "case", "of", "IHA", "associated", "with", "cefuroxime", "administration", "."], "event_mentions": [{"id": "12915840_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "12915840_2_Ent0", "role": "Subject", "text": "the first case", "start": 2, "end": 5}, {"entity_id": "12915840_2_Ent1", "role": "Effect", "text": "IHA", "start": 6, "end": 7}, {"entity_id": "12915840_2_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 9, "end": 10}, {"entity_id": "12915840_2_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12915840_2_Ent0", "text": "the first case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12915840_2_Ent1", "text": "IHA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12915840_2_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12915840_2_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12921505_1", "wnd_id": "12921505_1_1", "text": "After 39 hours on argatroban , the infusion was stopped when minor bleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds .", "tokens": ["After", "39", "hours", "on", "argatroban", ",", "the", "infusion", "was", "stopped", "when", "minor", "bleeding", "was", "observed", "with", "a", "concurrent", "activated", "partial", "thromboplastin", "time", "(", "aPTT", ")", "of", "100", "seconds", "."], "event_mentions": [{"id": "12921505_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "12921505_1_Ent2", "role": "Treatment_Time_elapsed", "text": "39 hours", "start": 1, "end": 3}, {"entity_id": "12921505_1_Ent1", "role": "Treatment", "text": "argatroban", "start": 4, "end": 5}, {"entity_id": "12921505_1_Ent3", "role": "Treatment_Drug", "text": "argatroban", "start": 4, "end": 5}, {"entity_id": "12921505_1_Ent0", "role": "Effect", "text": "minor bleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds", "start": 11, "end": 28}]}], "entity_mentions": [{"id": "12921505_1_Ent2", "text": "39 hours", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12921505_1_Ent1", "text": "argatroban", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12921505_1_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12921505_1_Ent0", "text": "minor bleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds", "entity_type": "Entity", "start": 11, "end": 28}], "lang": "en"}
{"doc_id": "12932249_1", "wnd_id": "12932249_1_1", "text": "Hyperpigmentation during interferon - alpha therapy for chronic hepatitis C virus infection .", "tokens": ["Hyperpigmentation", "during", "interferon", "-", "alpha", "therapy", "for", "chronic", "hepatitis", "C", "virus", "infection", "."], "event_mentions": [{"id": "12932249_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "12932249_1_Ent0", "role": "Effect", "text": "Hyperpigmentation", "start": 0, "end": 1}, {"entity_id": "12932249_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 2, "end": 5}, {"entity_id": "12932249_1_Ent1", "role": "Treatment", "text": "interferon - alpha therapy", "start": 2, "end": 6}, {"entity_id": "12932249_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C virus infection", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "12932249_1_Ent0", "text": "Hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12932249_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12932249_1_Ent1", "text": "interferon - alpha therapy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12932249_1_Ent3", "text": "chronic hepatitis C virus infection", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "1295628_2", "wnd_id": "1295628_2_1", "text": "A 14 - year - old female developed systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy .", "tokens": ["A", "14", "-", "year", "-", "old", "female", "developed", "systemic", "lupus", "erythematosus", "(", "SLE)", "-", "like", "symptoms", ",", "rash", ",", "fever", ",", "leukopenia", "and", "positive", "anti", "-", "nuclear", "antibody", "(", "ANA", ")", "two", "weeks", "after", "administration", "of", "carbamazepine", "(", "CBZ", ";", "Tegretol", ")", "used", "against", "benign", "Rolandic", "epilepsy", "."], "event_mentions": [{"id": "1295628_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "1295628_2_Ent0", "role": "Subject", "text": "A 14 - year - old female", "start": 0, "end": 7}, {"entity_id": "1295628_2_Ent1", "role": "Subject_Age", "text": "14 - year - old", "start": 1, "end": 6}, {"entity_id": "1295628_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "1295628_2_Ent3", "role": "Effect", "text": "systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA )", "start": 8, "end": 31}, {"entity_id": "1295628_2_Ent4", "role": "Treatment", "text": "administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy", "start": 34, "end": 47}, {"entity_id": "1295628_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 36, "end": 37}, {"entity_id": "1295628_2_Ent6", "role": "Treatment_Disorder", "text": "benign Rolandic epilepsy", "start": 44, "end": 47}]}], "entity_mentions": [{"id": "1295628_2_Ent0", "text": "A 14 - year - old female", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1295628_2_Ent1", "text": "14 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1295628_2_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1295628_2_Ent3", "text": "systemic lupus erythematosus ( SLE) - like symptoms , rash , fever , leukopenia and positive anti - nuclear antibody ( ANA )", "entity_type": "Entity", "start": 8, "end": 31}, {"id": "1295628_2_Ent4", "text": "administration of carbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy", "entity_type": "Entity", "start": 34, "end": 47}, {"id": "1295628_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "1295628_2_Ent6", "text": "benign Rolandic epilepsy", "entity_type": "Entity", "start": 44, "end": 47}], "lang": "en"}
{"doc_id": "1310879_3", "wnd_id": "1310879_3_1", "text": "Heparin - associated thrombocytopenia : successful therapy with the heparinoid Org 10172 in a patient showing cross - reaction to LMW heparins .", "tokens": ["Heparin", "-", "associated", "thrombocytopenia", ":", "successful", "therapy", "with", "the", "heparinoid", "Org", "10172", "in", "a", "patient", "showing", "cross", "-", "reaction", "to", "LMW", "heparins", "."], "event_mentions": [{"id": "1310879_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1310879_3_Ent2", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent3", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1310879_3_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}, {"entity_id": "1310879_3_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "1310879_3_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent3", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1310879_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1310879_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "1359782_2", "wnd_id": "1359782_2_1", "text": "Pulmonary infiltrates and skin pigmentation associated with sulfasalazine .", "tokens": ["Pulmonary", "infiltrates", "and", "skin", "pigmentation", "associated", "with", "sulfasalazine", "."], "event_mentions": [{"id": "1359782_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "1359782_2_Ent0", "role": "Effect", "text": "Pulmonary infiltrates and skin pigmentation", "start": 0, "end": 5}, {"entity_id": "1359782_2_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "1359782_2_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1359782_2_Ent0", "text": "Pulmonary infiltrates and skin pigmentation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1359782_2_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1359782_2_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1388041_2", "wnd_id": "1388041_2_1", "text": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti - depressant activity .", "tokens": ["Paroxetine", "is", "a", "selective", "serotonin", "reuptake", "inhibitor", "possessing", "anti", "-", "depressant", "activity", "."], "event_mentions": [{"id": "1388041_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "possessing", "start": 7, "end": 8}, "arguments": [{"entity_id": "1388041_2_Ent0", "role": "Treatment", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent2", "role": "Treatment_Drug", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent1", "role": "Treatment_Disorder", "text": "anti - depressant activity", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "1388041_2_Ent0", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent2", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent1", "text": "anti - depressant activity", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "1393348_2", "wnd_id": "1393348_2_1", "text": "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE can not be excluded , SLE could be considered as an adverse effect of carbamazepine .", "tokens": ["Although", "both", "the", "spontaneous", "occurrence", "of", "SLE", "and", "the", "psychosis", "as", "a", "sign", "of", "CNS", "involvement", "of", "SLE", "can", "not", "be", "excluded", ",", "SLE", "could", "be", "considered", "as", "an", "adverse", "effect", "of", "carbamazepine", "."], "event_mentions": [{"id": "1393348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 26, "end": 27}, "arguments": [{"entity_id": "1393348_2_Ent0", "role": "Effect", "text": "SLE", "start": 23, "end": 24}, {"entity_id": "1393348_2_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 32, "end": 33}, {"entity_id": "1393348_2_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "1393348_2_Ent0", "text": "SLE", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1393348_2_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "1393348_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "1414247_1", "wnd_id": "1414247_1_1", "text": "Carbamyl phosphate synthetase - 1 deficiency discovered after valproic acid - induced coma .", "tokens": ["Carbamyl", "phosphate", "synthetase", "-", "1", "deficiency", "discovered", "after", "valproic", "acid", "-", "induced", "coma", "."], "event_mentions": [{"id": "1414247_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "1414247_1_Ent1", "role": "Effect", "text": "Carbamyl phosphate synthetase - 1 deficiency", "start": 0, "end": 6}, {"entity_id": "1414247_1_Ent2", "role": "Treatment", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "1414247_1_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "1414247_1_Ent0", "role": "Effect", "text": "coma", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1414247_1_Ent1", "text": "Carbamyl phosphate synthetase - 1 deficiency", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1414247_1_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1414247_1_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1414247_1_Ent0", "text": "coma", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1422497_1", "wnd_id": "1422497_1_1", "text": "Encephalopathy and seizures induced by intravesical alum irrigations .", "tokens": ["Encephalopathy", "and", "seizures", "induced", "by", "intravesical", "alum", "irrigations", "."], "event_mentions": [{"id": "1422497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1422497_1_Ent0", "role": "Effect", "text": "Encephalopathy and seizures", "start": 0, "end": 3}, {"entity_id": "1422497_1_Ent3", "role": "Treatment_Route", "text": "intravesical", "start": 5, "end": 6}, {"entity_id": "1422497_1_Ent1", "role": "Treatment", "text": "intravesical alum irrigations", "start": 5, "end": 8}, {"entity_id": "1422497_1_Ent2", "role": "Treatment_Drug", "text": "alum", "start": 6, "end": 7}, {"entity_id": "1422497_1_Ent4", "role": "Treatment_Route", "text": "irrigations", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1422497_1_Ent0", "text": "Encephalopathy and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1422497_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1422497_1_Ent1", "text": "intravesical alum irrigations", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1422497_1_Ent2", "text": "alum", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1422497_1_Ent4", "text": "irrigations", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1445134_2", "wnd_id": "1445134_2_1", "text": "However , follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance .", "tokens": ["However", ",", "follow", "-", "up", "revealed", "that", "gestational", "diabetes", "when", "associated", "with", "norethisterone", "had", "a", "lesser", "risk", "of", "emerging", "diabetes", "mellitus", "and", "impaired", "glucose", "tolerance", "."], "event_mentions": [{"id": "1445134_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerging", "start": 18, "end": 19}, "arguments": [{"entity_id": "1445134_2_Ent1", "role": "Treatment", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent0", "role": "Effect", "text": "diabetes mellitus and impaired glucose tolerance", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "1445134_2_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent0", "text": "diabetes mellitus and impaired glucose tolerance", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "1450506_1", "wnd_id": "1450506_1_1", "text": "An adverse reaction to IFN was strongly suspected as the cause of CHF .", "tokens": ["An", "adverse", "reaction", "to", "IFN", "was", "strongly", "suspected", "as", "the", "cause", "of", "CHF", "."], "event_mentions": [{"id": "1450506_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "1450506_1_Ent1", "role": "Treatment", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 4, "end": 5}, {"entity_id": "1450506_1_Ent0", "role": "Effect", "text": "CHF", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1450506_1_Ent1", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent2", "text": "IFN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1450506_1_Ent0", "text": "CHF", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1450506_2", "wnd_id": "1450506_2_1", "text": "Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha - interferon .", "tokens": ["Multiple", "myeloma", "complicated", "by", "congestive", "heart", "failure", "following", "first", "administration", "of", "recombinant", "alpha", "-", "interferon", "."], "event_mentions": [{"id": "1450506_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "1450506_2_Ent0", "role": "Effect", "text": "Multiple myeloma complicated by congestive heart failure", "start": 0, "end": 7}, {"entity_id": "1450506_2_Ent1", "role": "Treatment", "text": "first administration of recombinant alpha - interferon", "start": 8, "end": 15}, {"entity_id": "1450506_2_Ent2", "role": "Treatment_Drug", "text": "recombinant alpha - interferon", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "1450506_2_Ent0", "text": "Multiple myeloma complicated by congestive heart failure", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1450506_2_Ent1", "text": "first administration of recombinant alpha - interferon", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "1450506_2_Ent2", "text": "recombinant alpha - interferon", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "1450506_3", "wnd_id": "1450506_3_1", "text": "Sixteen hours after the first administration of IFN , IFN was suspended by the symptoms of congestive heart failure ( CHF ) .", "tokens": ["Sixteen", "hours", "after", "the", "first", "administration", "of", "IFN", ",", "IFN", "was", "suspended", "by", "the", "symptoms", "of", "congestive", "heart", "failure", "(", "CHF", ")", "."], "event_mentions": [{"id": "1450506_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspended", "start": 11, "end": 12}, "arguments": [{"entity_id": "1450506_3_Ent1", "role": "Treatment", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent0", "role": "Effect", "text": "congestive heart failure ( CHF )", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "1450506_3_Ent1", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent2", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent0", "text": "congestive heart failure ( CHF )", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "14526130_1", "wnd_id": "14526130_1_1", "text": "Can roxithromycin and betamethasone induce acute pancreatitis ? A case report .", "tokens": ["Can", "roxithromycin", "and", "betamethasone", "induce", "acute", "pancreatitis", "?", "A", "case", "report", "."], "event_mentions": [{"id": "14526130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 4, "end": 5}, "arguments": [{"entity_id": "14526130_1_Ent2", "role": "Treatment_Drug", "text": "roxithromycin", "start": 1, "end": 2}, {"entity_id": "14526130_1_Ent4", "role": "Combination_Drug", "text": "roxithromycin", "start": 1, "end": 2}, {"entity_id": "14526130_1_Ent1", "role": "Treatment", "text": "roxithromycin and betamethasone", "start": 1, "end": 4}, {"entity_id": "14526130_1_Ent3", "role": "Treatment_Drug", "text": "betamethasone", "start": 3, "end": 4}, {"entity_id": "14526130_1_Ent5", "role": "Combination_Drug", "text": "betamethasone", "start": 3, "end": 4}, {"entity_id": "14526130_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "14526130_1_Ent2", "text": "roxithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14526130_1_Ent4", "text": "roxithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14526130_1_Ent1", "text": "roxithromycin and betamethasone", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "14526130_1_Ent3", "text": "betamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14526130_1_Ent5", "text": "betamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14526130_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "14530108_1", "wnd_id": "14530108_1_1", "text": "Renal tubular acidosis secondary to FK506 in living donor liver transplantation : a case report .", "tokens": ["Renal", "tubular", "acidosis", "secondary", "to", "FK506", "in", "living", "donor", "liver", "transplantation", ":", "a", "case", "report", "."], "event_mentions": [{"id": "14530108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 3, "end": 4}, "arguments": [{"entity_id": "14530108_1_Ent1", "role": "Effect", "text": "Renal tubular acidosis", "start": 0, "end": 3}, {"entity_id": "14530108_1_Ent2", "role": "Treatment", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent3", "role": "Treatment_Drug", "text": "FK506", "start": 5, "end": 6}, {"entity_id": "14530108_1_Ent0", "role": "Subject", "text": "a case", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14530108_1_Ent1", "text": "Renal tubular acidosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14530108_1_Ent2", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent3", "text": "FK506", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14530108_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "14530108_4", "wnd_id": "14530108_4_1", "text": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated .", "tokens": ["The", "mechanism", "of", "RTA", "induced", "by", "FK506", "has", "not", "yet", "been", "clearly", "elucidated", "."], "event_mentions": [{"id": "14530108_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14530108_4_Ent0", "role": "Effect", "text": "RTA", "start": 3, "end": 4}, {"entity_id": "14530108_4_Ent1", "role": "Treatment", "text": "FK506", "start": 6, "end": 7}, {"entity_id": "14530108_4_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14530108_4_Ent0", "text": "RTA", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14530108_4_Ent1", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14530108_4_Ent2", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14585456_1", "wnd_id": "14585456_1_1", "text": "We present a case of a 20 - year - old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose , glucagon , and diazoxide .", "tokens": ["We", "present", "a", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "who", "ingested", "900", "mg", "of", "glyburide", "causing", "refractory", "hypoglycemia", "resistant", "to", "treatment", "with", "intravenous", "dextrose", ",", "glucagon", ",", "and", "diazoxide", "."], "event_mentions": [{"id": "14585456_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "ingested", "start": 13, "end": 14}, "arguments": [{"entity_id": "14585456_1_Ent0", "role": "Subject", "text": "a 20 - year - old woman", "start": 5, "end": 12}, {"entity_id": "14585456_1_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "14585456_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "14585456_1_Ent5", "role": "Treatment_Dosage", "text": "900 mg", "start": 14, "end": 16}, {"entity_id": "14585456_1_Ent4", "role": "Treatment", "text": "900 mg of glyburide", "start": 14, "end": 18}, {"entity_id": "14585456_1_Ent6", "role": "Treatment_Drug", "text": "glyburide", "start": 17, "end": 18}, {"entity_id": "14585456_1_Ent3", "role": "Effect", "text": "refractory hypoglycemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "14585456_1_Ent0", "text": "a 20 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "14585456_1_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "14585456_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14585456_1_Ent5", "text": "900 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "14585456_1_Ent4", "text": "900 mg of glyburide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14585456_1_Ent6", "text": "glyburide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14585456_1_Ent3", "text": "refractory hypoglycemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "14601701_1", "wnd_id": "14601701_1_1", "text": "Ocular ethambutol toxicity .", "tokens": ["Ocular", "ethambutol", "toxicity", "."], "event_mentions": [{"id": "14601701_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 2, "end": 3}, "arguments": [{"entity_id": "14601701_1_Ent2", "role": "Treatment_Route", "text": "Ocular", "start": 0, "end": 1}, {"entity_id": "14601701_1_Ent1", "role": "Treatment", "text": "Ocular ethambutol", "start": 0, "end": 2}, {"entity_id": "14601701_1_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 1, "end": 2}, {"entity_id": "14601701_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "14601701_1_Ent2", "text": "Ocular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_1_Ent1", "text": "Ocular ethambutol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14601701_1_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14601701_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "14632592_4", "wnd_id": "14632592_4_1", "text": "In our patient , an objective causality scale showed that therapeutic doses of colchicine for FMF were the definite cause of myopathy , even though his renal and hepatic function were normal .", "tokens": ["In", "our", "patient", ",", "an", "objective", "causality", "scale", "showed", "that", "therapeutic", "doses", "of", "colchicine", "for", "FMF", "were", "the", "definite", "cause", "of", "myopathy", ",", "even", "though", "his", "renal", "and", "hepatic", "function", "were", "normal", "."], "event_mentions": [{"id": "14632592_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 19, "end": 20}, "arguments": [{"entity_id": "14632592_4_Ent0", "role": "Subject", "text": "our patient", "start": 1, "end": 3}, {"entity_id": "14632592_4_Ent7", "role": "Treatment_Dosage", "text": "therapeutic doses", "start": 10, "end": 12}, {"entity_id": "14632592_4_Ent4", "role": "Treatment", "text": "therapeutic doses of colchicine for FMF", "start": 10, "end": 16}, {"entity_id": "14632592_4_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 13, "end": 14}, {"entity_id": "14632592_4_Ent6", "role": "Treatment_Disorder", "text": "FMF", "start": 15, "end": 16}, {"entity_id": "14632592_4_Ent3", "role": "Effect", "text": "myopathy", "start": 21, "end": 22}, {"entity_id": "14632592_4_Ent2", "role": "Subject_Gender", "text": "his", "start": 25, "end": 26}, {"entity_id": "14632592_4_Ent1", "role": "Subject", "text": "his renal and hepatic function were normal", "start": 25, "end": 32}]}], "entity_mentions": [{"id": "14632592_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14632592_4_Ent7", "text": "therapeutic doses", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14632592_4_Ent4", "text": "therapeutic doses of colchicine for FMF", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14632592_4_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14632592_4_Ent6", "text": "FMF", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14632592_4_Ent3", "text": "myopathy", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14632592_4_Ent2", "text": "his", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "14632592_4_Ent1", "text": "his renal and hepatic function were normal", "entity_type": "Entity", "start": 25, "end": 32}], "lang": "en"}
{"doc_id": "14632592_5", "wnd_id": "14632592_5_1", "text": "OBJECTIVE : To report a case of colchicine - induced myopathy in a teenager with familial Mediterranean fever ( FMF ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "colchicine", "-", "induced", "myopathy", "in", "a", "teenager", "with", "familial", "Mediterranean", "fever", "(", "FMF", ")", "."], "event_mentions": [{"id": "14632592_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "14632592_5_Ent3", "role": "Treatment", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "14632592_5_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "14632592_5_Ent2", "role": "Effect", "text": "myopathy", "start": 10, "end": 11}, {"entity_id": "14632592_5_Ent0", "role": "Subject", "text": "a teenager with familial Mediterranean fever ( FMF )", "start": 12, "end": 21}, {"entity_id": "14632592_5_Ent1", "role": "Subject_Age", "text": "teenager", "start": 13, "end": 14}, {"entity_id": "14632592_5_Ent4", "role": "Treatment_Disorder", "text": "familial Mediterranean fever", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "14632592_5_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14632592_5_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14632592_5_Ent2", "text": "myopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "14632592_5_Ent0", "text": "a teenager with familial Mediterranean fever ( FMF )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "14632592_5_Ent1", "text": "teenager", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14632592_5_Ent4", "text": "familial Mediterranean fever", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "14641354_1", "wnd_id": "14641354_1_1", "text": "Angioedema and dysphagia caused by contact allergy to inhaled budesonide .", "tokens": ["Angioedema", "and", "dysphagia", "caused", "by", "contact", "allergy", "to", "inhaled", "budesonide", "."], "event_mentions": [{"id": "14641354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inhaled", "start": 8, "end": 9}, "arguments": [{"entity_id": "14641354_1_Ent1", "role": "Effect", "text": "Angioedema and dysphagia", "start": 0, "end": 3}, {"entity_id": "14641354_1_Ent0", "role": "Effect", "text": "contact allergy", "start": 5, "end": 7}, {"entity_id": "14641354_1_Ent2", "role": "Treatment", "text": "budesonide", "start": 9, "end": 10}, {"entity_id": "14641354_1_Ent3", "role": "Treatment_Drug", "text": "budesonide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14641354_1_Ent1", "text": "Angioedema and dysphagia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14641354_1_Ent0", "text": "contact allergy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14641354_1_Ent2", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14641354_1_Ent3", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14660304_1", "wnd_id": "14660304_1_1", "text": "Infectious toxicity of dexamethasone during all remission - induction chemotherapy : report of two cases and literature review .", "tokens": ["Infectious", "toxicity", "of", "dexamethasone", "during", "all", "remission", "-", "induction", "chemotherapy", ":", "report", "of", "two", "cases", "and", "literature", "review", "."], "event_mentions": [{"id": "14660304_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "14660304_1_Ent2", "role": "Effect", "text": "Infectious toxicity", "start": 0, "end": 2}, {"entity_id": "14660304_1_Ent3", "role": "Treatment", "text": "dexamethasone", "start": 3, "end": 4}, {"entity_id": "14660304_1_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 3, "end": 4}, {"entity_id": "14660304_1_Ent4", "role": "Treatment", "text": "all remission - induction chemotherapy", "start": 5, "end": 10}, {"entity_id": "14660304_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 9, "end": 10}, {"entity_id": "14660304_1_Ent1", "role": "Subject_Population", "text": "two", "start": 13, "end": 14}, {"entity_id": "14660304_1_Ent0", "role": "Subject", "text": "two cases", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "14660304_1_Ent2", "text": "Infectious toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14660304_1_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14660304_1_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14660304_1_Ent4", "text": "all remission - induction chemotherapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "14660304_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14660304_1_Ent1", "text": "two", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14660304_1_Ent0", "text": "two cases", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "14674674_4", "wnd_id": "14674674_4_1", "text": "Treatment with infliximab is known to produce an increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease .", "tokens": ["Treatment", "with", "infliximab", "is", "known", "to", "produce", "an", "increase", "of", "autoantibodies", "(", "antinuclear", "antibodies", ",", "anti", "-", "double", "-", "stranded", "DNA", ")", ",", "but", "not", "clinical", "disease", "."], "event_mentions": [{"id": "14674674_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 6, "end": 7}, "arguments": [{"entity_id": "14674674_4_Ent1", "role": "Treatment", "text": "Treatment with infliximab", "start": 0, "end": 3}, {"entity_id": "14674674_4_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 2, "end": 3}, {"entity_id": "14674674_4_Ent0", "role": "Effect", "text": "increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease", "start": 8, "end": 27}]}], "entity_mentions": [{"id": "14674674_4_Ent1", "text": "Treatment with infliximab", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14674674_4_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14674674_4_Ent0", "text": "increase of autoantibodies ( antinuclear antibodies , anti - double - stranded DNA ) , but not clinical disease", "entity_type": "Entity", "start": 8, "end": 27}], "lang": "en"}
{"doc_id": "14677199_1", "wnd_id": "14677199_1_1", "text": "Severe Raynaud 's phenomenon with yohimbine therapy for erectile dysfunction .", "tokens": ["Severe", "Raynaud", "'s", "phenomenon", "with", "yohimbine", "therapy", "for", "erectile", "dysfunction", "."], "event_mentions": [{"id": "14677199_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "14677199_1_Ent0", "role": "Effect", "text": "Raynaud 's phenomenon", "start": 1, "end": 4}, {"entity_id": "14677199_1_Ent1", "role": "Treatment", "text": "yohimbine", "start": 5, "end": 6}, {"entity_id": "14677199_1_Ent2", "role": "Treatment_Drug", "text": "yohimbine", "start": 5, "end": 6}, {"entity_id": "14677199_1_Ent3", "role": "Treatment_Disorder", "text": "erectile dysfunction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "14677199_1_Ent0", "text": "Raynaud 's phenomenon", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "14677199_1_Ent1", "text": "yohimbine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14677199_1_Ent2", "text": "yohimbine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14677199_1_Ent3", "text": "erectile dysfunction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "14677199_2", "wnd_id": "14677199_2_1", "text": "We describe a patient with CREST syndrome ( calcinosis , Raynaud 's phenomenon , esophageal dysfunction , sclerodactyly , and telangiectasia ) who paradoxically experienced worsening of Raynaud 's phenomenon when using yohimbine for ED .", "tokens": ["We", "describe", "a", "patient", "with", "CREST", "syndrome", "(", "calcinosis", ",", "Raynaud", "'s", "phenomenon", ",", "esophageal", "dysfunction", ",", "sclerodactyly", ",", "and", "telangiectasia", ")", "who", "paradoxically", "experienced", "worsening", "of", "Raynaud", "'s", "phenomenon", "when", "using", "yohimbine", "for", "ED", "."], "event_mentions": [{"id": "14677199_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 24, "end": 25}, "arguments": [{"entity_id": "14677199_2_Ent0", "role": "Subject", "text": "a patient with CREST syndrome ( calcinosis , Raynaud 's phenomenon , esophageal dysfunction , sclerodactyly , and telangiectasia )", "start": 2, "end": 22}, {"entity_id": "14677199_2_Ent1", "role": "Subject_Disorder", "text": "CREST syndrome ( calcinosis , Raynaud 's phenomenon , esophageal dysfunction , sclerodactyly , and telangiectasia )", "start": 5, "end": 22}, {"entity_id": "14677199_2_Ent2", "role": "Effect", "text": "worsening of Raynaud 's phenomenon", "start": 25, "end": 30}, {"entity_id": "14677199_2_Ent3", "role": "Treatment", "text": "yohimbine", "start": 32, "end": 33}, {"entity_id": "14677199_2_Ent5", "role": "Treatment_Drug", "text": "yohimbine", "start": 32, "end": 33}, {"entity_id": "14677199_2_Ent4", "role": "Treatment_Disorder", "text": "ED", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "14677199_2_Ent0", "text": "a patient with CREST syndrome ( calcinosis , Raynaud 's phenomenon , esophageal dysfunction , sclerodactyly , and telangiectasia )", "entity_type": "Entity", "start": 2, "end": 22}, {"id": "14677199_2_Ent1", "text": "CREST syndrome ( calcinosis , Raynaud 's phenomenon , esophageal dysfunction , sclerodactyly , and telangiectasia )", "entity_type": "Entity", "start": 5, "end": 22}, {"id": "14677199_2_Ent2", "text": "worsening of Raynaud 's phenomenon", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "14677199_2_Ent3", "text": "yohimbine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "14677199_2_Ent5", "text": "yohimbine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "14677199_2_Ent4", "text": "ED", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "14693027_1", "wnd_id": "14693027_1_1", "text": "All patients had taken phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the skin lesions first appeared .", "tokens": ["All", "patients", "had", "taken", "phenytoin", "for", "variable", "time", "periods", "(", "range", "16", "-", "80", "days", ";", "mean", ":", "40", ")", "and", "were", "on", "the", "medication", "when", "the", "skin", "lesions", "first", "appeared", "."], "event_mentions": [{"id": "14693027_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 30, "end": 31}, "arguments": [{"entity_id": "14693027_1_Ent0", "role": "Subject", "text": "All patients", "start": 0, "end": 2}, {"entity_id": "14693027_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "14693027_1_Ent2", "role": "Treatment", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "start": 4, "end": 20}, {"entity_id": "14693027_1_Ent4", "role": "Treatment_Duration", "text": "16 - 80 days ;", "start": 11, "end": 16}, {"entity_id": "14693027_1_Ent5", "role": "Treatment_Duration", "text": "40", "start": 18, "end": 19}, {"entity_id": "14693027_1_Ent1", "role": "Effect", "text": "skin lesions", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "14693027_1_Ent0", "text": "All patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14693027_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14693027_1_Ent2", "text": "phenytoin for variable time periods ( range 16 - 80 days ; mean : 40 )", "entity_type": "Entity", "start": 4, "end": 20}, {"id": "14693027_1_Ent4", "text": "16 - 80 days ;", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "14693027_1_Ent5", "text": "40", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "14693027_1_Ent1", "text": "skin lesions", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "14700673_1", "wnd_id": "14700673_1_1", "text": "CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing , resulting in acute myopia and angle - closure glaucoma .", "tokens": ["CONCLUSIONS", ":", "Topiramate", "may", "be", "associated", "with", "ciliochoroidal", "effusion", "with", "forward", "displacement", "of", "the", "lens", "-", "iris", "diaphragm", "and", "anterior", "chamber", "shallowing", ",", "resulting", "in", "acute", "myopia", "and", "angle", "-", "closure", "glaucoma", "."], "event_mentions": [{"id": "14700673_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 23, "end": 24}, "arguments": [{"entity_id": "14700673_1_Ent1", "role": "Treatment", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_1_Ent2", "role": "Treatment_Drug", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_1_Ent0", "role": "Effect", "text": "acute myopia and angle - closure glaucoma", "start": 25, "end": 32}]}], "entity_mentions": [{"id": "14700673_1_Ent1", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_1_Ent2", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_1_Ent0", "text": "acute myopia and angle - closure glaucoma", "entity_type": "Entity", "start": 25, "end": 32}], "lang": "en"}
{"doc_id": "14711147_4", "wnd_id": "14711147_4_1", "text": "We present a case of photo - onycholysis in a patient treated with doxycycline for acne vulgaris .", "tokens": ["We", "present", "a", "case", "of", "photo", "-", "onycholysis", "in", "a", "patient", "treated", "with", "doxycycline", "for", "acne", "vulgaris", "."], "event_mentions": [{"id": "14711147_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "14711147_4_Ent1", "role": "Effect", "text": "photo - onycholysis", "start": 5, "end": 8}, {"entity_id": "14711147_4_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "14711147_4_Ent2", "role": "Treatment", "text": "doxycycline", "start": 13, "end": 14}, {"entity_id": "14711147_4_Ent3", "role": "Treatment_Drug", "text": "doxycycline", "start": 13, "end": 14}, {"entity_id": "14711147_4_Ent4", "role": "Treatment_Disorder", "text": "acne vulgaris", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14711147_4_Ent1", "text": "photo - onycholysis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14711147_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "14711147_4_Ent2", "text": "doxycycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14711147_4_Ent3", "text": "doxycycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14711147_4_Ent4", "text": "acne vulgaris", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "14723711_6", "wnd_id": "14723711_6_1", "text": "This fourth type of cutaneous minocycline hyperpigmentation may be a variant of Type I , but based on clinical , pathological and microanalytical differences , appears to be a new entity .", "tokens": ["This", "fourth", "type", "of", "cutaneous", "minocycline", "hyperpigmentation", "may", "be", "a", "variant", "of", "Type", "I", ",", "but", "based", "on", "clinical", ",", "pathological", "and", "microanalytical", "differences", ",", "appears", "to", "be", "a", "new", "entity", "."], "event_mentions": [{"id": "14723711_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 8, "end": 9}, "arguments": [{"entity_id": "14723711_6_Ent1", "role": "Treatment", "text": "minocycline", "start": 5, "end": 6}, {"entity_id": "14723711_6_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 5, "end": 6}, {"entity_id": "14723711_6_Ent0", "role": "Effect", "text": "hyperpigmentation", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14723711_6_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14723711_6_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14723711_6_Ent0", "text": "hyperpigmentation", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14740795_2", "wnd_id": "14740795_2_1", "text": "Amifostine - induced fever : case report and review of the literature .", "tokens": ["Amifostine", "-", "induced", "fever", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "14740795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14740795_2_Ent1", "role": "Treatment", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent2", "role": "Treatment_Drug", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14740795_2_Ent1", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent2", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14740795_4", "wnd_id": "14740795_4_1", "text": "To our knowledge , this is the first case report that demonstrates the occurrence of fever with low - dose amifostine therapy without the manifestation of accompanying rash or hypotension .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "report", "that", "demonstrates", "the", "occurrence", "of", "fever", "with", "low", "-", "dose", "amifostine", "therapy", "without", "the", "manifestation", "of", "accompanying", "rash", "or", "hypotension", "."], "event_mentions": [{"id": "14740795_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 13, "end": 14}, "arguments": [{"entity_id": "14740795_4_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "14740795_4_Ent1", "role": "Effect", "text": "fever", "start": 15, "end": 16}, {"entity_id": "14740795_4_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 17, "end": 20}, {"entity_id": "14740795_4_Ent2", "role": "Treatment", "text": "low - dose amifostine", "start": 17, "end": 21}, {"entity_id": "14740795_4_Ent4", "role": "Treatment_Drug", "text": "amifostine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14740795_4_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "14740795_4_Ent1", "text": "fever", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14740795_4_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "14740795_4_Ent2", "text": "low - dose amifostine", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "14740795_4_Ent4", "text": "amifostine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "1495728_4", "wnd_id": "1495728_4_1", "text": "We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy , but suggest that it be used with caution in view of possible systemic toxicity .", "tokens": ["We", "believe", "that", "methotrexate", "represents", "a", "relatively", "effective", "alternative", "to", "surgery", "in", "patients", "with", "early", "unruptured", "tubal", "pregnancy", ",", "but", "suggest", "that", "it", "be", "used", "with", "caution", "in", "view", "of", "possible", "systemic", "toxicity", "."], "event_mentions": [{"id": "1495728_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 26, "end": 27}, "arguments": [{"entity_id": "1495728_4_Ent2", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "1495728_4_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "1495728_4_Ent0", "role": "Subject", "text": "patients with early unruptured tubal pregnancy", "start": 12, "end": 18}, {"entity_id": "1495728_4_Ent4", "role": "Treatment_Disorder", "text": "early unruptured tubal pregnancy", "start": 14, "end": 18}, {"entity_id": "1495728_4_Ent1", "role": "Effect", "text": "systemic toxicity", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "1495728_4_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1495728_4_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1495728_4_Ent0", "text": "patients with early unruptured tubal pregnancy", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "1495728_4_Ent4", "text": "early unruptured tubal pregnancy", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1495728_4_Ent1", "text": "systemic toxicity", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "14960440_3", "wnd_id": "14960440_3_1", "text": "Warfarin - associated thoracic aortic dissection in an elderly woman .", "tokens": ["Warfarin", "-", "associated", "thoracic", "aortic", "dissection", "in", "an", "elderly", "woman", "."], "event_mentions": [{"id": "14960440_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "14960440_3_Ent4", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "14960440_3_Ent5", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "14960440_3_Ent3", "role": "Effect", "text": "thoracic aortic dissection", "start": 3, "end": 6}, {"entity_id": "14960440_3_Ent0", "role": "Subject", "text": "an elderly woman", "start": 7, "end": 10}, {"entity_id": "14960440_3_Ent1", "role": "Subject_Age", "text": "elderly", "start": 8, "end": 9}, {"entity_id": "14960440_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14960440_3_Ent4", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14960440_3_Ent5", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14960440_3_Ent3", "text": "thoracic aortic dissection", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "14960440_3_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "14960440_3_Ent1", "text": "elderly", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14960440_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14964753_7", "wnd_id": "14964753_7_1", "text": "Ramipril - induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before .", "tokens": ["Ramipril", "-", "induced", "cutaneous", "vasculitis", "is", "particularly", "rare", "and", "our", "case", "was", "atypical", "because", "the", "patient", "had", "tolerated", "lisinopril", "before", "."], "event_mentions": [{"id": "14964753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14964753_7_Ent3", "role": "Treatment", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent4", "role": "Treatment_Drug", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}, {"entity_id": "14964753_7_Ent0", "role": "Subject", "text": "the patient had tolerated lisinopril before", "start": 14, "end": 20}, {"entity_id": "14964753_7_Ent1", "role": "Subject_Disorder", "text": "tolerated lisinopril", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14964753_7_Ent3", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent4", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14964753_7_Ent0", "text": "the patient had tolerated lisinopril before", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "14964753_7_Ent1", "text": "tolerated lisinopril", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "14964753_8", "wnd_id": "14964753_8_1", "text": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group .", "tokens": ["Previous", "successful", "treatment", "with", "one", "ACE", "inhibitor", "does", "not", "rule", "out", "the", "vasculitis", "caused", "by", "the", "drug", "from", "the", "same", "group", "."], "event_mentions": [{"id": "14964753_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "14964753_8_Ent1", "role": "Treatment", "text": "ACE inhibitor", "start": 5, "end": 7}, {"entity_id": "14964753_8_Ent2", "role": "Treatment_Drug", "text": "ACE inhibitor", "start": 5, "end": 7}, {"entity_id": "14964753_8_Ent0", "role": "Effect", "text": "vasculitis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "14964753_8_Ent1", "text": "ACE inhibitor", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14964753_8_Ent2", "text": "ACE inhibitor", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14964753_8_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "14998226_10", "wnd_id": "14998226_10_1", "text": "Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione .", "tokens": ["Pravastatin", "does", "not", "appear", "to", "interact", "with", "warfarin", "but", "has", "caused", "an", "increased", "INR", "when", "combined", "with", "the", "anticoagulant", "fluindione", "."], "event_mentions": [{"id": "14998226_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "14998226_10_Ent1", "role": "Treatment", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent3", "role": "Treatment_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent5", "role": "Combination_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent0", "role": "Effect", "text": "increased INR", "start": 12, "end": 14}, {"entity_id": "14998226_10_Ent2", "role": "Treatment", "text": "combined with the anticoagulant fluindione", "start": 15, "end": 20}, {"entity_id": "14998226_10_Ent4", "role": "Treatment_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}, {"entity_id": "14998226_10_Ent6", "role": "Combination_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "14998226_10_Ent1", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent3", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent5", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent0", "text": "increased INR", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14998226_10_Ent2", "text": "combined with the anticoagulant fluindione", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "14998226_10_Ent4", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "14998226_10_Ent6", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "14998226_9", "wnd_id": "14998226_9_1", "text": "One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol , which resulted in an elevated INR .", "tokens": ["One", "case", "report", "describes", "an", "interaction", "between", "simvastatin", "and", "the", "anticoagulant", "acenocoumarol", ",", "which", "resulted", "in", "an", "elevated", "INR", "."], "event_mentions": [{"id": "14998226_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_9_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "14998226_9_Ent0", "role": "Subject", "text": "One case", "start": 0, "end": 2}, {"entity_id": "14998226_9_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent6", "role": "Combination_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent3", "role": "Treatment", "text": "simvastatin and the anticoagulant acenocoumarol", "start": 7, "end": 12}, {"entity_id": "14998226_9_Ent5", "role": "Treatment_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent7", "role": "Combination_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent2", "role": "Effect", "text": "elevated INR", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14998226_9_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_9_Ent0", "text": "One case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14998226_9_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent3", "text": "simvastatin and the anticoagulant acenocoumarol", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "14998226_9_Ent5", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent7", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent2", "text": "elevated INR", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15034704_3", "wnd_id": "15034704_3_1", "text": "Male volunteers ( n=12 ) participated in a randomised , two - period , crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism .", "tokens": ["Male", "volunteers", "(", "n=12", ")", "participated", "in", "a", "randomised", ",", "two", "-", "period", ",", "crossover", "trial", "evaluating", "the", "effect", "of", "multiple", "doses", "of", "600", "mg", "rifampicin", "once", "daily", "for", "7", "days", "on", "repaglinide", "metabolism", "."], "event_mentions": [{"id": "15034704_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 31, "end": 32}, "arguments": [{"entity_id": "15034704_3_Ent1", "role": "Subject_Gender", "text": "Male", "start": 0, "end": 1}, {"entity_id": "15034704_3_Ent0", "role": "Subject", "text": "Male volunteers ( n=12 )", "start": 0, "end": 5}, {"entity_id": "15034704_3_Ent2", "role": "Subject_Population", "text": "n=12", "start": 3, "end": 4}, {"entity_id": "15034704_3_Ent5", "role": "Treatment_Dosage", "text": "multiple doses of 600 mg", "start": 20, "end": 25}, {"entity_id": "15034704_3_Ent4", "role": "Treatment", "text": "multiple doses of 600 mg rifampicin once daily for 7 days", "start": 20, "end": 31}, {"entity_id": "15034704_3_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 25, "end": 26}, {"entity_id": "15034704_3_Ent7", "role": "Treatment_Freq", "text": "once daily", "start": 26, "end": 28}, {"entity_id": "15034704_3_Ent8", "role": "Treatment_Duration", "text": "7 days", "start": 29, "end": 31}, {"entity_id": "15034704_3_Ent3", "role": "Effect", "text": "repaglinide metabolism", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15034704_3_Ent1", "text": "Male", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15034704_3_Ent0", "text": "Male volunteers ( n=12 )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15034704_3_Ent2", "text": "n=12", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15034704_3_Ent5", "text": "multiple doses of 600 mg", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "15034704_3_Ent4", "text": "multiple doses of 600 mg rifampicin once daily for 7 days", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "15034704_3_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15034704_3_Ent7", "text": "once daily", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15034704_3_Ent8", "text": "7 days", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15034704_3_Ent3", "text": "repaglinide metabolism", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "1504404_3", "wnd_id": "1504404_3_1", "text": "DATA SYNTHESIS : A 49 - year - old man developed symptoms of severe psychosis concomitant with ciprofloxacin ( 250 mg bid ) treatment .", "tokens": ["DATA", "SYNTHESIS", ":", "A", "49", "-", "year", "-", "old", "man", "developed", "symptoms", "of", "severe", "psychosis", "concomitant", "with", "ciprofloxacin", "(", "250", "mg", "bid", ")", "treatment", "."], "event_mentions": [{"id": "1504404_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "1504404_3_Ent0", "role": "Subject", "text": "A 49 - year - old man", "start": 3, "end": 10}, {"entity_id": "1504404_3_Ent1", "role": "Subject_Age", "text": "49 - year - old", "start": 4, "end": 9}, {"entity_id": "1504404_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "1504404_3_Ent3", "role": "Effect", "text": "psychosis", "start": 14, "end": 15}, {"entity_id": "1504404_3_Ent4", "role": "Treatment", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent5", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent6", "role": "Treatment_Dosage", "text": "250 mg bid", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "1504404_3_Ent0", "text": "A 49 - year - old man", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "1504404_3_Ent1", "text": "49 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1504404_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1504404_3_Ent3", "text": "psychosis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1504404_3_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent6", "text": "250 mg bid", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "15093850_2", "wnd_id": "15093850_2_1", "text": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia , mild hypotension , and muscarinic symptoms in a patient with Sjogren 's syndrome .", "tokens": ["We", "report", "a", "case", "of", "unintentional", "overdose", "of", "oral", "pilocarpine", "tablets", "that", "resulted", "in", "bradycardia", ",", "mild", "hypotension", ",", "and", "muscarinic", "symptoms", "in", "a", "patient", "with", "Sjogren", "'s", "syndrome", "."], "event_mentions": [{"id": "15093850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 12, "end": 13}, "arguments": [{"entity_id": "15093850_2_Ent2", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "15093850_2_Ent1", "role": "Treatment", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent3", "role": "Treatment_Drug", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent0", "role": "Effect", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "15093850_2_Ent2", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15093850_2_Ent1", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent3", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent0", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "15097937_3", "wnd_id": "15097937_3_1", "text": "We report a case of a previously healthy , postmenopausal woman who developed anticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes .", "tokens": ["We", "report", "a", "case", "of", "a", "previously", "healthy", ",", "postmenopausal", "woman", "who", "developed", "anticonvulsant", "hypersensitivity", "syndrome", "while", "taking", "Bellamine", "S", "(", "belladonna", "alkaloids", ";", "ergotamine", ";", "phenobarbital", ")", "for", "hot", "flashes", "."], "event_mentions": [{"id": "15097937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "15097937_3_Ent0", "role": "Subject", "text": "a previously healthy , postmenopausal woman", "start": 5, "end": 11}, {"entity_id": "15097937_3_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "15097937_3_Ent2", "role": "Effect", "text": "anticonvulsant hypersensitivity syndrome", "start": 13, "end": 16}, {"entity_id": "15097937_3_Ent5", "role": "Treatment_Drug", "text": "Bellamine S", "start": 18, "end": 20}, {"entity_id": "15097937_3_Ent3", "role": "Treatment", "text": "Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital )", "start": 18, "end": 28}, {"entity_id": "15097937_3_Ent6", "role": "Treatment_Drug", "text": "belladonna alkaloids", "start": 21, "end": 23}, {"entity_id": "15097937_3_Ent7", "role": "Treatment_Drug", "text": "ergotamine", "start": 24, "end": 25}, {"entity_id": "15097937_3_Ent8", "role": "Treatment_Drug", "text": "phenobarbital", "start": 26, "end": 27}, {"entity_id": "15097937_3_Ent4", "role": "Treatment_Disorder", "text": "hot flashes", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "15097937_3_Ent0", "text": "a previously healthy , postmenopausal woman", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "15097937_3_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15097937_3_Ent2", "text": "anticonvulsant hypersensitivity syndrome", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15097937_3_Ent5", "text": "Bellamine S", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15097937_3_Ent3", "text": "Bellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital )", "entity_type": "Entity", "start": 18, "end": 28}, {"id": "15097937_3_Ent6", "text": "belladonna alkaloids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15097937_3_Ent7", "text": "ergotamine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15097937_3_Ent8", "text": "phenobarbital", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15097937_3_Ent4", "text": "hot flashes", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "15133245_3", "wnd_id": "15133245_3_1", "text": "Recently , it has been reported that terfenadine and astemizole , which have antiallergic actions similar to those of oxatomide , show side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest .", "tokens": ["Recently", ",", "it", "has", "been", "reported", "that", "terfenadine", "and", "astemizole", ",", "which", "have", "antiallergic", "actions", "similar", "to", "those", "of", "oxatomide", ",", "show", "side", "effects", "on", "the", "cardiovascular", "system", ",", "such", "as", "QT", "prolongation", ",", "ventricular", "arrhythmia", "and", "cardiac", "arrest", "."], "event_mentions": [{"id": "15133245_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "show", "start": 21, "end": 22}, "arguments": [{"entity_id": "15133245_3_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent4", "role": "Combination_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "15133245_3_Ent1", "role": "Treatment", "text": "terfenadine and astemizole", "start": 7, "end": 10}, {"entity_id": "15133245_3_Ent3", "role": "Treatment_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent5", "role": "Combination_Drug", "text": "astemizole", "start": 9, "end": 10}, {"entity_id": "15133245_3_Ent0", "role": "Effect", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "start": 22, "end": 39}]}], "entity_mentions": [{"id": "15133245_3_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent4", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15133245_3_Ent1", "text": "terfenadine and astemizole", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15133245_3_Ent3", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent5", "text": "astemizole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15133245_3_Ent0", "text": "side effects on the cardiovascular system , such as QT prolongation , ventricular arrhythmia and cardiac arrest", "entity_type": "Entity", "start": 22, "end": 39}], "lang": "en"}
{"doc_id": "15157248_1", "wnd_id": "15157248_1_1", "text": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin .", "tokens": ["An", "immediate", "hemolytic", "reaction", "induced", "by", "repeated", "administration", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15157248_1_Ent0", "role": "Effect", "text": "immediate hemolytic reaction", "start": 1, "end": 4}, {"entity_id": "15157248_1_Ent2", "role": "Treatment_Freq", "text": "repeated", "start": 6, "end": 7}, {"entity_id": "15157248_1_Ent1", "role": "Treatment", "text": "repeated administration of oxaliplatin", "start": 6, "end": 10}, {"entity_id": "15157248_1_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15157248_1_Ent0", "text": "immediate hemolytic reaction", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15157248_1_Ent2", "text": "repeated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15157248_1_Ent1", "text": "repeated administration of oxaliplatin", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15157248_1_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15224368_1", "wnd_id": "15224368_1_1", "text": "Sweet 's syndrome associated with sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment .", "tokens": ["Sweet", "'s", "syndrome", "associated", "with", "sargramostim", "(", "granulocyte", "-", "macrophage", "colony", "stimulating", "factor", ")", "treatment", "."], "event_mentions": [{"id": "15224368_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15224368_1_Ent0", "role": "Effect", "text": "Sweet 's syndrome", "start": 0, "end": 3}, {"entity_id": "15224368_1_Ent2", "role": "Treatment_Drug", "text": "sargramostim", "start": 5, "end": 6}, {"entity_id": "15224368_1_Ent1", "role": "Treatment", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "start": 5, "end": 15}]}], "entity_mentions": [{"id": "15224368_1_Ent0", "text": "Sweet 's syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15224368_1_Ent2", "text": "sargramostim", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15224368_1_Ent1", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "entity_type": "Entity", "start": 5, "end": 15}], "lang": "en"}
{"doc_id": "15235919_3", "wnd_id": "15235919_3_1", "text": "The case concerns the sudden death of a 29 - year - old male during clozapine therapy started 2 weeks before .", "tokens": ["The", "case", "concerns", "the", "sudden", "death", "of", "a", "29", "-", "year", "-", "old", "male", "during", "clozapine", "therapy", "started", "2", "weeks", "before", "."], "event_mentions": [{"id": "15235919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_3_Ent3", "role": "Effect", "text": "sudden death", "start": 4, "end": 6}, {"entity_id": "15235919_3_Ent0", "role": "Subject", "text": "a 29 - year - old male", "start": 7, "end": 14}, {"entity_id": "15235919_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 8, "end": 13}, {"entity_id": "15235919_3_Ent2", "role": "Subject_Population", "text": "male", "start": 13, "end": 14}, {"entity_id": "15235919_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks before", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "15235919_3_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15235919_3_Ent0", "text": "a 29 - year - old male", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15235919_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15235919_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15235919_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent6", "text": "2 weeks before", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "15286697_5", "wnd_id": "15286697_5_1", "text": "We report here a 26 - year - old female with diffuse large B - cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high - dose BCNU ( 600 mg / m2 ) .", "tokens": ["We", "report", "here", "a", "26", "-", "year", "-", "old", "female", "with", "diffuse", "large", "B", "-", "cell", "lymphoma", "who", "died", "of", "severe", "pulmonary", "fibrosis", "81", "days", "after", "the", "administration", "of", "high", "-", "dose", "BCNU", "(", "600", "mg", "/", "m2", ")", "."], "event_mentions": [{"id": "15286697_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 27, "end": 28}, "arguments": [{"entity_id": "15286697_5_Ent1", "role": "Subject_Age", "text": "26 - year - old", "start": 4, "end": 9}, {"entity_id": "15286697_5_Ent0", "role": "Subject", "text": "26 - year - old female with diffuse large B - cell lymphoma", "start": 4, "end": 17}, {"entity_id": "15286697_5_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "15286697_5_Ent8", "role": "Treatment_Disorder", "text": "diffuse large B - cell lymphoma", "start": 11, "end": 17}, {"entity_id": "15286697_5_Ent3", "role": "Effect", "text": "died of severe pulmonary fibrosis", "start": 18, "end": 23}, {"entity_id": "15286697_5_Ent7", "role": "Treatment_Time_elapsed", "text": "81 days after", "start": 23, "end": 26}, {"entity_id": "15286697_5_Ent4", "role": "Treatment", "text": "high - dose BCNU ( 600 mg / m2 )", "start": 29, "end": 39}, {"entity_id": "15286697_5_Ent5", "role": "Treatment_Drug", "text": "BCNU", "start": 32, "end": 33}, {"entity_id": "15286697_5_Ent6", "role": "Treatment_Dosage", "text": "600 mg / m2", "start": 34, "end": 38}]}], "entity_mentions": [{"id": "15286697_5_Ent1", "text": "26 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15286697_5_Ent0", "text": "26 - year - old female with diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 4, "end": 17}, {"id": "15286697_5_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15286697_5_Ent8", "text": "diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "15286697_5_Ent3", "text": "died of severe pulmonary fibrosis", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "15286697_5_Ent7", "text": "81 days after", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15286697_5_Ent4", "text": "high - dose BCNU ( 600 mg / m2 )", "entity_type": "Entity", "start": 29, "end": 39}, {"id": "15286697_5_Ent5", "text": "BCNU", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "15286697_5_Ent6", "text": "600 mg / m2", "entity_type": "Entity", "start": 34, "end": 38}], "lang": "en"}
{"doc_id": "15307435_1", "wnd_id": "15307435_1_1", "text": "Case report : life - threatening hypoglycaemia associated with sulfadoxine - pyrimethamine , a commonly used antimalarial drug .", "tokens": ["Case", "report", ":", "life", "-", "threatening", "hypoglycaemia", "associated", "with", "sulfadoxine", "-", "pyrimethamine", ",", "a", "commonly", "used", "antimalarial", "drug", "."], "event_mentions": [{"id": "15307435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "15307435_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "15307435_1_Ent1", "role": "Effect", "text": "life - threatening hypoglycaemia", "start": 3, "end": 7}, {"entity_id": "15307435_1_Ent2", "role": "Treatment", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}, {"entity_id": "15307435_1_Ent3", "role": "Treatment_Drug", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15307435_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15307435_1_Ent1", "text": "life - threatening hypoglycaemia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15307435_1_Ent2", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15307435_1_Ent3", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15311565_1", "wnd_id": "15311565_1_1", "text": "Initial treatment with heparin was substituted with thrombolysis , which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage .", "tokens": ["Initial", "treatment", "with", "heparin", "was", "substituted", "with", "thrombolysis", ",", "which", "resulted", "in", "clinical", "improvement", "and", "dissolution", "of", "right", "heart", "thrombus", "but", "was", "followed", "by", "fatal", "intracerebral", "haemorrhage", "."], "event_mentions": [{"id": "15311565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 10, "end": 11}, "arguments": [{"entity_id": "15311565_1_Ent1", "role": "Treatment", "text": "thrombolysis", "start": 7, "end": 8}, {"entity_id": "15311565_1_Ent2", "role": "Treatment_Drug", "text": "thrombolysis", "start": 7, "end": 8}, {"entity_id": "15311565_1_Ent0", "role": "Effect", "text": "fatal intracerebral haemorrhage", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "15311565_1_Ent1", "text": "thrombolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15311565_1_Ent2", "text": "thrombolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15311565_1_Ent0", "text": "fatal intracerebral haemorrhage", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "15331204_6", "wnd_id": "15331204_6_1", "text": "CONCLUSION : Therapy with indapamide may induce diabetes in essential hypertension patients .", "tokens": ["CONCLUSION", ":", "Therapy", "with", "indapamide", "may", "induce", "diabetes", "in", "essential", "hypertension", "patients", "."], "event_mentions": [{"id": "15331204_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "15331204_6_Ent2", "role": "Treatment", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent3", "role": "Treatment_Drug", "text": "indapamide", "start": 4, "end": 5}, {"entity_id": "15331204_6_Ent1", "role": "Effect", "text": "diabetes", "start": 7, "end": 8}, {"entity_id": "15331204_6_Ent4", "role": "Treatment_Disorder", "text": "essential hypertension", "start": 9, "end": 11}, {"entity_id": "15331204_6_Ent0", "role": "Subject", "text": "essential hypertension patients", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15331204_6_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent3", "text": "indapamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15331204_6_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15331204_6_Ent4", "text": "essential hypertension", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15331204_6_Ent0", "text": "essential hypertension patients", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15338554_4", "wnd_id": "15338554_4_1", "text": "OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature .", "tokens": ["OBJECTIVES", ":", "To", "describe", "the", "clinicopathologic", "features", "of", "3", "patients", "with", "CML", "who", "rapidly", "progressed", "from", "chronic", "phase", "to", "blast", "crisis", "while", "taking", "imatinib", "and", "to", "perform", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15338554_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "progressed", "start": 14, "end": 15}, "arguments": [{"entity_id": "15338554_4_Ent1", "role": "Subject_Population", "text": "3", "start": 8, "end": 9}, {"entity_id": "15338554_4_Ent0", "role": "Subject", "text": "3 patients with CML", "start": 8, "end": 12}, {"entity_id": "15338554_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 11, "end": 12}, {"entity_id": "15338554_4_Ent2", "role": "Effect", "text": "from chronic phase to blast crisis", "start": 15, "end": 21}, {"entity_id": "15338554_4_Ent3", "role": "Treatment", "text": "imatinib", "start": 23, "end": 24}, {"entity_id": "15338554_4_Ent5", "role": "Treatment_Drug", "text": "imatinib", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15338554_4_Ent1", "text": "3", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15338554_4_Ent0", "text": "3 patients with CML", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15338554_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15338554_4_Ent2", "text": "from chronic phase to blast crisis", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "15338554_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15338554_4_Ent5", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15362597_1", "wnd_id": "15362597_1_1", "text": "Refractory hypoglycemia from ciprofloxacin and glyburide interaction .", "tokens": ["Refractory", "hypoglycemia", "from", "ciprofloxacin", "and", "glyburide", "interaction", "."], "event_mentions": [{"id": "15362597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "15362597_1_Ent0", "role": "Effect", "text": "Refractory hypoglycemia", "start": 0, "end": 2}, {"entity_id": "15362597_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15362597_1_Ent1", "role": "Treatment", "text": "ciprofloxacin and glyburide interaction", "start": 3, "end": 7}, {"entity_id": "15362597_1_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 5, "end": 6}, {"entity_id": "15362597_1_Ent4", "role": "Combination_Drug", "text": "glyburide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15362597_1_Ent0", "text": "Refractory hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15362597_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15362597_1_Ent1", "text": "ciprofloxacin and glyburide interaction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15362597_1_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15362597_1_Ent4", "text": "glyburide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15368548_1", "wnd_id": "15368548_1_1", "text": "L - asparaginase - induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "is", "an", "uncommon", "but", "potential", "lethal", "complication", "of", "the", "treatment", "of", "leukemia", "."], "event_mentions": [{"id": "15368548_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_1_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}, {"entity_id": "15368548_1_Ent3", "role": "Treatment_Disorder", "text": "leukemia", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15368548_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_1_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15368548_1_Ent3", "text": "leukemia", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15368548_3", "wnd_id": "15368548_3_1", "text": "Most cases of pancreatitis associated with L - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation .", "tokens": ["Most", "cases", "of", "pancreatitis", "associated", "with", "L", "-", "asparaginase", "toxicity", "are", "self", "-", "limiting", "and", "respond", "favorably", "to", "nasogastric", "decompression", "and", "intravenous", "hyperalimentation", "."], "event_mentions": [{"id": "15368548_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_3_Ent0", "role": "Subject", "text": "Most cases", "start": 0, "end": 2}, {"entity_id": "15368548_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 3, "end": 4}, {"entity_id": "15368548_3_Ent2", "role": "Treatment", "text": "L - asparaginase", "start": 6, "end": 9}, {"entity_id": "15368548_3_Ent3", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "15368548_3_Ent0", "text": "Most cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15368548_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15368548_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15368548_3_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "15379082_1", "wnd_id": "15379082_1_1", "text": "Disulfiram - induced fulminant hepatic failure in an active duty soldier .", "tokens": ["Disulfiram", "-", "induced", "fulminant", "hepatic", "failure", "in", "an", "active", "duty", "soldier", "."], "event_mentions": [{"id": "15379082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15379082_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}, {"entity_id": "15379082_1_Ent0", "role": "Subject", "text": "an active duty soldier", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "15379082_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15379082_1_Ent0", "text": "an active duty soldier", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "15379082_3", "wnd_id": "15379082_3_1", "text": "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence .", "tokens": ["This", "case", "describes", "fulminant", "hepatic", "failure", "in", "a", "patient", "taking", "disulfiram", "with", "no", "previous", "liver", "disease", "and", "report", "of", "being", "compliant", "with", "alcohol", "abstinence", "."], "event_mentions": [{"id": "15379082_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_3_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}, {"entity_id": "15379082_3_Ent0", "role": "Subject", "text": "a patient", "start": 7, "end": 9}, {"entity_id": "15379082_3_Ent2", "role": "Treatment", "text": "disulfiram", "start": 10, "end": 11}, {"entity_id": "15379082_3_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "15379082_3_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15379082_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15379082_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15379082_3_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "15383642_1", "wnd_id": "15383642_1_1", "text": "Hypotension due to interaction between lisinopril and tizanidine .", "tokens": ["Hypotension", "due", "to", "interaction", "between", "lisinopril", "and", "tizanidine", "."], "event_mentions": [{"id": "15383642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 1, "end": 3}, "arguments": [{"entity_id": "15383642_1_Ent0", "role": "Effect", "text": "Hypotension", "start": 0, "end": 1}, {"entity_id": "15383642_1_Ent1", "role": "Treatment", "text": "interaction between lisinopril and tizanidine", "start": 3, "end": 8}, {"entity_id": "15383642_1_Ent3", "role": "Treatment_Drug", "text": "lisinopril", "start": 5, "end": 6}, {"entity_id": "15383642_1_Ent4", "role": "Combination_Drug", "text": "lisinopril", "start": 5, "end": 6}, {"entity_id": "15383642_1_Ent2", "role": "Treatment_Drug", "text": "tizanidine", "start": 7, "end": 8}, {"entity_id": "15383642_1_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15383642_1_Ent0", "text": "Hypotension", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15383642_1_Ent1", "text": "interaction between lisinopril and tizanidine", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15383642_1_Ent3", "text": "lisinopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15383642_1_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15383642_1_Ent2", "text": "tizanidine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15383642_1_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15383642_2", "wnd_id": "15383642_2_1", "text": "To report a case in which significant hypotension occurred after initiation of tizanidine in a patient using the antihypertensive agent lisinopril .", "tokens": ["To", "report", "a", "case", "in", "which", "significant", "hypotension", "occurred", "after", "initiation", "of", "tizanidine", "in", "a", "patient", "using", "the", "antihypertensive", "agent", "lisinopril", "."], "event_mentions": [{"id": "15383642_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "15383642_2_Ent1", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15383642_2_Ent2", "role": "Effect", "text": "hypotension", "start": 7, "end": 8}, {"entity_id": "15383642_2_Ent3", "role": "Treatment", "text": "initiation of tizanidine", "start": 10, "end": 13}, {"entity_id": "15383642_2_Ent6", "role": "Treatment_Drug", "text": "tizanidine", "start": 12, "end": 13}, {"entity_id": "15383642_2_Ent0", "role": "Subject", "text": "a patient", "start": 14, "end": 16}, {"entity_id": "15383642_2_Ent4", "role": "Treatment", "text": "lisinopril", "start": 20, "end": 21}, {"entity_id": "15383642_2_Ent5", "role": "Treatment_Drug", "text": "lisinopril", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15383642_2_Ent1", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15383642_2_Ent2", "text": "hypotension", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15383642_2_Ent3", "text": "initiation of tizanidine", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15383642_2_Ent6", "text": "tizanidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15383642_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15383642_2_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15383642_2_Ent5", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15454180_1", "wnd_id": "15454180_1_1", "text": "A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive - line infection who was receiving linezolid , an antibiotic used for serious infections with gram - positive organisms .", "tokens": ["A", "case", "of", "sideroblastic", "anemia", "is", "presented", "in", "a", "patient", "with", "a", "left", "ventricular", "assist", "device", "drive", "-", "line", "infection", "who", "was", "receiving", "linezolid", ",", "an", "antibiotic", "used", "for", "serious", "infections", "with", "gram", "-", "positive", "organisms", "."], "event_mentions": [{"id": "15454180_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 6, "end": 7}, "arguments": [{"entity_id": "15454180_1_Ent2", "role": "Effect", "text": "sideroblastic anemia", "start": 3, "end": 5}, {"entity_id": "15454180_1_Ent0", "role": "Subject", "text": "a patient with a left ventricular assist device drive - line infection", "start": 8, "end": 20}, {"entity_id": "15454180_1_Ent1", "role": "Subject_Disorder", "text": "left ventricular assist device drive - line infection", "start": 12, "end": 20}, {"entity_id": "15454180_1_Ent3", "role": "Treatment", "text": "receiving linezolid", "start": 22, "end": 24}, {"entity_id": "15454180_1_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 23, "end": 24}, {"entity_id": "15454180_1_Ent5", "role": "Treatment_Disorder", "text": "serious infections with gram - positive organisms", "start": 29, "end": 36}]}], "entity_mentions": [{"id": "15454180_1_Ent2", "text": "sideroblastic anemia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15454180_1_Ent0", "text": "a patient with a left ventricular assist device drive - line infection", "entity_type": "Entity", "start": 8, "end": 20}, {"id": "15454180_1_Ent1", "text": "left ventricular assist device drive - line infection", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15454180_1_Ent3", "text": "receiving linezolid", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15454180_1_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15454180_1_Ent5", "text": "serious infections with gram - positive organisms", "entity_type": "Entity", "start": 29, "end": 36}], "lang": "en"}
{"doc_id": "15454180_3", "wnd_id": "15454180_3_1", "text": "Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device .", "tokens": ["Sideroblastic", "anemia", "due", "to", "linezolid", "in", "a", "patient", "with", "a", "left", "ventricular", "assist", "device", "."], "event_mentions": [{"id": "15454180_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "15454180_3_Ent1", "role": "Effect", "text": "Sideroblastic anemia", "start": 0, "end": 2}, {"entity_id": "15454180_3_Ent2", "role": "Treatment", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent0", "role": "Subject", "text": "patient with a left ventricular assist device", "start": 7, "end": 14}, {"entity_id": "15454180_3_Ent4", "role": "Treatment_Disorder", "text": "left ventricular assist device", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "15454180_3_Ent1", "text": "Sideroblastic anemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15454180_3_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent0", "text": "patient with a left ventricular assist device", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15454180_3_Ent4", "text": "left ventricular assist device", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "15463865_3", "wnd_id": "15463865_3_1", "text": "We report two young patients with cystic fibrosis who presented with acute renal insufficiency after 2 - 3 weeks of oral ciprofloxacin therapy .", "tokens": ["We", "report", "two", "young", "patients", "with", "cystic", "fibrosis", "who", "presented", "with", "acute", "renal", "insufficiency", "after", "2", "-", "3", "weeks", "of", "oral", "ciprofloxacin", "therapy", "."], "event_mentions": [{"id": "15463865_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "15463865_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "15463865_3_Ent0", "role": "Subject", "text": "two young patients with cystic fibrosis", "start": 2, "end": 8}, {"entity_id": "15463865_3_Ent2", "role": "Subject_Age", "text": "young", "start": 3, "end": 4}, {"entity_id": "15463865_3_Ent5", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 6, "end": 8}, {"entity_id": "15463865_3_Ent3", "role": "Effect", "text": "acute renal insufficiency", "start": 11, "end": 14}, {"entity_id": "15463865_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 - 3 weeks", "start": 15, "end": 19}, {"entity_id": "15463865_3_Ent4", "role": "Treatment", "text": "2 - 3 weeks of oral ciprofloxacin therapy", "start": 15, "end": 23}, {"entity_id": "15463865_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "15463865_3_Ent7", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15463865_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15463865_3_Ent0", "text": "two young patients with cystic fibrosis", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "15463865_3_Ent2", "text": "young", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_3_Ent5", "text": "cystic fibrosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15463865_3_Ent3", "text": "acute renal insufficiency", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15463865_3_Ent6", "text": "2 - 3 weeks", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15463865_3_Ent4", "text": "2 - 3 weeks of oral ciprofloxacin therapy", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "15463865_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15463865_3_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15463865_5", "wnd_id": "15463865_5_1", "text": "Multiple mechanisms for ciprofloxacin - induced nephrotoxicity have been proposed .", "tokens": ["Multiple", "mechanisms", "for", "ciprofloxacin", "-", "induced", "nephrotoxicity", "have", "been", "proposed", "."], "event_mentions": [{"id": "15463865_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15463865_5_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15463865_5_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "15463865_5_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15463865_5_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_5_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15463865_5_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15482394_3", "wnd_id": "15482394_3_1", "text": "Despite the low dosage of warfarin , international normalized ratio ( INR ) was markedly elevated from 1.15 to 11.28 for only 4 days , and bleeding symptoms concurrently developed .", "tokens": ["Despite", "the", "low", "dosage", "of", "warfarin", ",", "international", "normalized", "ratio", "(", "INR", ")", "was", "markedly", "elevated", "from", "1.15", "to", "11.28", "for", "only", "4", "days", ",", "and", "bleeding", "symptoms", "concurrently", "developed", "."], "event_mentions": [{"id": "15482394_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "15482394_3_Ent4", "role": "Treatment_Dosage", "text": "low dosage", "start": 2, "end": 4}, {"entity_id": "15482394_3_Ent2", "role": "Treatment", "text": "low dosage of warfarin", "start": 2, "end": 6}, {"entity_id": "15482394_3_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "15482394_3_Ent0", "role": "Effect", "text": "international normalized ratio ( INR ) was markedly elevated", "start": 7, "end": 16}, {"entity_id": "15482394_3_Ent5", "role": "Treatment_Dosage", "text": "1.15", "start": 17, "end": 18}, {"entity_id": "15482394_3_Ent6", "role": "Treatment_Dosage", "text": "11.28", "start": 19, "end": 20}, {"entity_id": "15482394_3_Ent7", "role": "Treatment_Duration", "text": "4 days", "start": 22, "end": 24}, {"entity_id": "15482394_3_Ent1", "role": "Effect", "text": "bleeding symptoms", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "15482394_3_Ent4", "text": "low dosage", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15482394_3_Ent2", "text": "low dosage of warfarin", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "15482394_3_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15482394_3_Ent0", "text": "international normalized ratio ( INR ) was markedly elevated", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15482394_3_Ent5", "text": "1.15", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15482394_3_Ent6", "text": "11.28", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15482394_3_Ent7", "text": "4 days", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15482394_3_Ent1", "text": "bleeding symptoms", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "15482394_5", "wnd_id": "15482394_5_1", "text": "Unusual hypersensitivity to warfarin in a critically ill patient .", "tokens": ["Unusual", "hypersensitivity", "to", "warfarin", "in", "a", "critically", "ill", "patient", "."], "event_mentions": [{"id": "15482394_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 2, "end": 3}, "arguments": [{"entity_id": "15482394_5_Ent2", "role": "Effect", "text": "Unusual hypersensitivity", "start": 0, "end": 2}, {"entity_id": "15482394_5_Ent3", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "15482394_5_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "15482394_5_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 5, "end": 9}, {"entity_id": "15482394_5_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15482394_5_Ent2", "text": "Unusual hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15482394_5_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15482394_5_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15482394_5_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "15482394_5_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15494638_2", "wnd_id": "15494638_2_1", "text": "5 - fluorouracil ( 5 - FU) - associated peripheral neuropathy is an uncommon event .", "tokens": ["5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "associated", "peripheral", "neuropathy", "is", "an", "uncommon", "event", "."], "event_mentions": [{"id": "15494638_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "15494638_2_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent0", "role": "Effect", "text": "peripheral neuropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15494638_2_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent0", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15494638_20", "wnd_id": "15494638_20_1", "text": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A , with no recurrence after reinitiating CAP alone at 2000 mg / m2 .", "tokens": ["Neurologic", "symptoms", "resolved", "after", "stopping", "CAP", "for", "4", "weeks", "in", "Patient", "A", ",", "with", "no", "recurrence", "after", "reinitiating", "CAP", "alone", "at", "2000", "mg", "/", "m2", "."], "event_mentions": [{"id": "15494638_20_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15494638_20_Ent0", "role": "Effect", "text": "Neurologic symptoms resolved", "start": 0, "end": 3}, {"entity_id": "15494638_20_Ent1", "role": "Treatment", "text": "stopping CAP for 4 weeks", "start": 4, "end": 9}, {"entity_id": "15494638_20_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 5, "end": 6}, {"entity_id": "15494638_20_Ent3", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15494638_20_Ent0", "text": "Neurologic symptoms resolved", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_20_Ent1", "text": "stopping CAP for 4 weeks", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15494638_20_Ent2", "text": "CAP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15494638_20_Ent3", "text": "4 weeks", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15507779_1", "wnd_id": "15507779_1_1", "text": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine .", "tokens": ["Severe", "leukopenia", "associated", "with", "mild", "hepatotoxicity", "in", "an", "HIV", "carrier", "treated", "with", "nevirapine", "."], "event_mentions": [{"id": "15507779_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 11, "end": 12}, "arguments": [{"entity_id": "15507779_1_Ent1", "role": "Effect", "text": "leukopenia", "start": 1, "end": 2}, {"entity_id": "15507779_1_Ent0", "role": "Subject", "text": "an HIV carrier", "start": 7, "end": 10}, {"entity_id": "15507779_1_Ent4", "role": "Treatment_Disorder", "text": "HIV carrier", "start": 8, "end": 10}, {"entity_id": "15507779_1_Ent2", "role": "Treatment", "text": "nevirapine", "start": 12, "end": 13}, {"entity_id": "15507779_1_Ent3", "role": "Treatment_Drug", "text": "nevirapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15507779_1_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15507779_1_Ent0", "text": "an HIV carrier", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15507779_1_Ent4", "text": "HIV carrier", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15507779_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15507779_1_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15522120_10", "wnd_id": "15522120_10_1", "text": "The symptoms disappeared with clemastine and betametasone treatment .", "tokens": ["The", "symptoms", "disappeared", "with", "clemastine", "and", "betametasone", "treatment", "."], "event_mentions": [{"id": "15522120_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 2, "end": 3}, "arguments": [{"entity_id": "15522120_10_Ent0", "role": "Effect", "text": "The symptoms disappeared", "start": 0, "end": 3}, {"entity_id": "15522120_10_Ent2", "role": "Treatment_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent5", "role": "Combination_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent1", "role": "Treatment", "text": "clemastine and betametasone", "start": 4, "end": 7}, {"entity_id": "15522120_10_Ent3", "role": "Treatment_Drug", "text": "betametasone", "start": 6, "end": 7}, {"entity_id": "15522120_10_Ent4", "role": "Combination_Drug", "text": "betametasone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15522120_10_Ent0", "text": "The symptoms disappeared", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15522120_10_Ent2", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent1", "text": "clemastine and betametasone", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15522120_10_Ent3", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15522120_10_Ent4", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15533031_2", "wnd_id": "15533031_2_1", "text": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine , a centrally acting analgesic and antispastic drug .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "increased", "cerebral", "cortical", "excitability", "following", "intoxication", "with", "flupirtine", ",", "a", "centrally", "acting", "analgesic", "and", "antispastic", "drug", "."], "event_mentions": [{"id": "15533031_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 12, "end": 13}, "arguments": [{"entity_id": "15533031_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15533031_2_Ent1", "role": "Effect", "text": "increased cerebral cortical excitability", "start": 8, "end": 12}, {"entity_id": "15533031_2_Ent2", "role": "Treatment", "text": "flupirtine", "start": 15, "end": 16}, {"entity_id": "15533031_2_Ent3", "role": "Treatment_Drug", "text": "flupirtine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15533031_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_2_Ent1", "text": "increased cerebral cortical excitability", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15533031_2_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15533031_2_Ent3", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15543388_2", "wnd_id": "15543388_2_1", "text": "Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.", "tokens": ["Celiac", "disease", "onset", "after", "pegylated", "interferon", "and", "ribavirin", "treatment", "of", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15543388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 2, "end": 3}, "arguments": [{"entity_id": "15543388_2_Ent0", "role": "Effect", "text": "Celiac disease", "start": 0, "end": 2}, {"entity_id": "15543388_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent5", "role": "Combination_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent1", "role": "Treatment", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "start": 4, "end": 13}, {"entity_id": "15543388_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent6", "role": "Combination_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "15543388_2_Ent0", "text": "Celiac disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15543388_2_Ent2", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent5", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent1", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15543388_2_Ent3", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent6", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15549981_1", "wnd_id": "15549981_1_1", "text": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine , but occurred following the administration of the alpha - agonist metaraminol .", "tokens": ["We", "present", "two", "cases", "of", "anaphylaxis", "under", "anaesthesia", "where", "return", "of", "spontaneous", "circulation", "was", "refractory", "to", "epinephrine", ",", "but", "occurred", "following", "the", "administration", "of", "the", "alpha", "-", "agonist", "metaraminol", "."], "event_mentions": [{"id": "15549981_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "occurred", "start": 19, "end": 20}, "arguments": [{"entity_id": "15549981_1_Ent3", "role": "Treatment_Disorder", "text": "anaphylaxis under anaesthesia", "start": 5, "end": 8}, {"entity_id": "15549981_1_Ent0", "role": "Effect", "text": "return of spontaneous circulation", "start": 9, "end": 13}, {"entity_id": "15549981_1_Ent1", "role": "Treatment", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent5", "role": "Treatment_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent6", "role": "Combination_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent2", "role": "Treatment", "text": "administration of the alpha - agonist metaraminol", "start": 22, "end": 29}, {"entity_id": "15549981_1_Ent4", "role": "Treatment_Drug", "text": "metaraminol", "start": 28, "end": 29}, {"entity_id": "15549981_1_Ent7", "role": "Combination_Drug", "text": "metaraminol", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "15549981_1_Ent3", "text": "anaphylaxis under anaesthesia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15549981_1_Ent0", "text": "return of spontaneous circulation", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15549981_1_Ent1", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent5", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent6", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent2", "text": "administration of the alpha - agonist metaraminol", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "15549981_1_Ent4", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "15549981_1_Ent7", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "15588385_3", "wnd_id": "15588385_3_1", "text": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil - induced acute hepatic failure .", "tokens": ["Successful", "treatment", "of", "hyperthyroidism", "with", "amiodarone", "in", "a", "patient", "with", "propylthiouracil", "-", "induced", "acute", "hepatic", "failure", "."], "event_mentions": [{"id": "15588385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "15588385_3_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 3, "end": 4}, {"entity_id": "15588385_3_Ent2", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent0", "role": "Subject", "text": "a patient with propylthiouracil - induced acute hepatic failure", "start": 7, "end": 16}, {"entity_id": "15588385_3_Ent1", "role": "Subject_Disorder", "text": "propylthiouracil - induced acute hepatic failure", "start": 10, "end": 16}]}, {"id": "15588385_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "15588385_3_Ent6", "role": "Treatment", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent7", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent5", "role": "Effect", "text": "acute hepatic failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15588385_3_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15588385_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent0", "text": "a patient with propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15588385_3_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent7", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent1", "text": "propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "15588385_3_Ent5", "text": "acute hepatic failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15592331_12", "wnd_id": "15592331_12_1", "text": "Ciprofloxacin greatly elevates plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects , mainly by inhibiting its CYP1A2 - mediated metabolism , at least when administered 1 hour before tizanidine .", "tokens": ["Ciprofloxacin", "greatly", "elevates", "plasma", "concentrations", "of", "tizanidine", "and", "dangerously", "potentiates", "its", "hypotensive", "and", "sedative", "effects", ",", "mainly", "by", "inhibiting", "its", "CYP1A2", "-", "mediated", "metabolism", ",", "at", "least", "when", "administered", "1", "hour", "before", "tizanidine", "."], "event_mentions": [{"id": "15592331_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "elevates", "start": 2, "end": 3}, "arguments": [{"entity_id": "15592331_12_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15592331_12_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15592331_12_Ent0", "role": "Effect", "text": "plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects", "start": 3, "end": 15}, {"entity_id": "15592331_12_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 6, "end": 7}, {"entity_id": "15592331_12_Ent4", "role": "Treatment_Drug", "text": "tizanidine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "15592331_12_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15592331_12_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15592331_12_Ent0", "text": "plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "15592331_12_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15592331_12_Ent4", "text": "tizanidine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "15595320_1", "wnd_id": "15595320_1_1", "text": "Epstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib : idiosyncratic reaction or pharmacogenetics ?", "tokens": ["Epstein", "-", "Barr", "virus", "-", "associated", "lymphoproliferative", "disorder", "in", "a", "patient", "with", "rheumatoid", "arthritis", "on", "methotrexate", "and", "rofecoxib", ":", "idiosyncratic", "reaction", "or", "pharmacogenetics", "?"], "event_mentions": [{"id": "15595320_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "15595320_1_Ent1", "role": "Effect", "text": "Epstein - Barr virus - associated lymphoproliferative disorder", "start": 0, "end": 8}, {"entity_id": "15595320_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 9, "end": 14}, {"entity_id": "15595320_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "15595320_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "15595320_1_Ent2", "role": "Treatment", "text": "methotrexate and rofecoxib", "start": 15, "end": 18}, {"entity_id": "15595320_1_Ent5", "role": "Treatment_Drug", "text": "rofecoxib", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15595320_1_Ent1", "text": "Epstein - Barr virus - associated lymphoproliferative disorder", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15595320_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15595320_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "15595320_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15595320_1_Ent2", "text": "methotrexate and rofecoxib", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15595320_1_Ent5", "text": "rofecoxib", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15628319_1", "wnd_id": "15628319_1_1", "text": "Allergic side effects of AZA are rare , and reported allergic skin eruptions from AZA are very limited in Japan .", "tokens": ["Allergic", "side", "effects", "of", "AZA", "are", "rare", ",", "and", "reported", "allergic", "skin", "eruptions", "from", "AZA", "are", "very", "limited", "in", "Japan", "."], "event_mentions": [{"id": "15628319_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "15628319_1_Ent0", "role": "Effect", "text": "allergic skin eruptions", "start": 10, "end": 13}, {"entity_id": "15628319_1_Ent1", "role": "Treatment", "text": "AZA", "start": 14, "end": 15}, {"entity_id": "15628319_1_Ent2", "role": "Treatment_Drug", "text": "AZA", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15628319_1_Ent0", "text": "allergic skin eruptions", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15628319_1_Ent1", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15628319_1_Ent2", "text": "AZA", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15671134_1", "wnd_id": "15671134_1_1", "text": "A case of clozapine - induced tonic - clonic seizures managed with valproate : implications for clinical care .", "tokens": ["A", "case", "of", "clozapine", "-", "induced", "tonic", "-", "clonic", "seizures", "managed", "with", "valproate", ":", "implications", "for", "clinical", "care", "."], "event_mentions": [{"id": "15671134_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15671134_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "15671134_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "15671134_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "15671134_1_Ent1", "role": "Effect", "text": "tonic - clonic seizures", "start": 6, "end": 10}]}, {"id": "15671134_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "managed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15671134_1_Ent4", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "15671134_1_Ent7", "role": "Treatment_Disorder", "text": "clozapine - induced tonic - clonic seizures", "start": 3, "end": 10}, {"entity_id": "15671134_1_Ent5", "role": "Treatment", "text": "valproate", "start": 12, "end": 13}, {"entity_id": "15671134_1_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15671134_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15671134_1_Ent4", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15671134_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15671134_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15671134_1_Ent7", "text": "clozapine - induced tonic - clonic seizures", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "15671134_1_Ent1", "text": "tonic - clonic seizures", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15671134_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15671134_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1569260_1", "wnd_id": "1569260_1_1", "text": "To the best of our knowledge , this is the first reported patient with captopril - induced pemphigus in whom no new lesions developed after subsequent treatment with enalapril .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "patient", "with", "captopril", "-", "induced", "pemphigus", "in", "whom", "no", "new", "lesions", "developed", "after", "subsequent", "treatment", "with", "enalapril", "."], "event_mentions": [{"id": "1569260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "1569260_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "1569260_1_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "1569260_1_Ent1", "role": "Effect", "text": "pemphigus", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "1569260_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1569260_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1569260_1_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15719254_1", "wnd_id": "15719254_1_1", "text": "Cis - retinoic acid ( RA ) may further increase the risk of developing BMTN .", "tokens": ["Cis", "-", "retinoic", "acid", "(", "RA", ")", "may", "further", "increase", "the", "risk", "of", "developing", "BMTN", "."], "event_mentions": [{"id": "15719254_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 13, "end": 14}, "arguments": [{"entity_id": "15719254_1_Ent2", "role": "Treatment_Drug", "text": "Cis - retinoic acid", "start": 0, "end": 4}, {"entity_id": "15719254_1_Ent1", "role": "Treatment", "text": "Cis - retinoic acid ( RA )", "start": 0, "end": 7}, {"entity_id": "15719254_1_Ent0", "role": "Effect", "text": "BMTN", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15719254_1_Ent2", "text": "Cis - retinoic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15719254_1_Ent1", "text": "Cis - retinoic acid ( RA )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15719254_1_Ent0", "text": "BMTN", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15729090_3", "wnd_id": "15729090_3_1", "text": "A 64 - year - old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine .", "tokens": ["A", "64", "-", "year", "-", "old", "man", "with", "schizophrenia", "developed", "myoclonic", "jerks", "when", "given", "higher", "doses", "of", "quetiapine", "."], "event_mentions": [{"id": "15729090_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "15729090_3_Ent0", "role": "Subject", "text": "A 64 - year - old man with schizophrenia", "start": 0, "end": 9}, {"entity_id": "15729090_3_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 1, "end": 6}, {"entity_id": "15729090_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "15729090_3_Ent5", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 8, "end": 9}, {"entity_id": "15729090_3_Ent3", "role": "Effect", "text": "myoclonic jerks", "start": 10, "end": 12}, {"entity_id": "15729090_3_Ent7", "role": "Treatment_Dosage", "text": "higher doses", "start": 14, "end": 16}, {"entity_id": "15729090_3_Ent4", "role": "Treatment", "text": "higher doses of quetiapine", "start": 14, "end": 18}, {"entity_id": "15729090_3_Ent6", "role": "Treatment_Drug", "text": "quetiapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15729090_3_Ent0", "text": "A 64 - year - old man with schizophrenia", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15729090_3_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15729090_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15729090_3_Ent5", "text": "schizophrenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15729090_3_Ent3", "text": "myoclonic jerks", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15729090_3_Ent7", "text": "higher doses", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15729090_3_Ent4", "text": "higher doses of quetiapine", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15729090_3_Ent6", "text": "quetiapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15752306_2", "wnd_id": "15752306_2_1", "text": "We report two patients who developed intense livedo reticularis clearly related to the administration of interferon alpha 2b as an adjuvant therapy for melanoma .", "tokens": ["We", "report", "two", "patients", "who", "developed", "intense", "livedo", "reticularis", "clearly", "related", "to", "the", "administration", "of", "interferon", "alpha", "2b", "as", "an", "adjuvant", "therapy", "for", "melanoma", "."], "event_mentions": [{"id": "15752306_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "15752306_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "15752306_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "15752306_2_Ent2", "role": "Effect", "text": "intense livedo reticularis", "start": 6, "end": 9}, {"entity_id": "15752306_2_Ent4", "role": "Treatment_Drug", "text": "interferon alpha 2b", "start": 15, "end": 18}, {"entity_id": "15752306_2_Ent3", "role": "Treatment", "text": "interferon alpha 2b as an adjuvant therapy for melanoma", "start": 15, "end": 24}, {"entity_id": "15752306_2_Ent5", "role": "Treatment_Disorder", "text": "melanoma", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15752306_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15752306_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15752306_2_Ent2", "text": "intense livedo reticularis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15752306_2_Ent4", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15752306_2_Ent3", "text": "interferon alpha 2b as an adjuvant therapy for melanoma", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "15752306_2_Ent5", "text": "melanoma", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15752306_6", "wnd_id": "15752306_6_1", "text": "These cases highlight the occurrence of livedo reticularis as an uncommon side - effect of interferon alpha treatment .", "tokens": ["These", "cases", "highlight", "the", "occurrence", "of", "livedo", "reticularis", "as", "an", "uncommon", "side", "-", "effect", "of", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "15752306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effect", "start": 11, "end": 14}, "arguments": [{"entity_id": "15752306_6_Ent0", "role": "Subject", "text": "These cases", "start": 0, "end": 2}, {"entity_id": "15752306_6_Ent1", "role": "Effect", "text": "livedo reticularis", "start": 6, "end": 8}, {"entity_id": "15752306_6_Ent2", "role": "Treatment", "text": "interferon alpha", "start": 15, "end": 17}, {"entity_id": "15752306_6_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15752306_6_Ent0", "text": "These cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15752306_6_Ent1", "text": "livedo reticularis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15752306_6_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15752306_6_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15773973_1", "wnd_id": "15773973_1_1", "text": "Flucloxacillin - induced aplastic anaemia and liver failure .", "tokens": ["Flucloxacillin", "-", "induced", "aplastic", "anaemia", "and", "liver", "failure", "."], "event_mentions": [{"id": "15773973_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15773973_1_Ent1", "role": "Treatment", "text": "Flucloxacillin", "start": 0, "end": 1}, {"entity_id": "15773973_1_Ent2", "role": "Treatment_Drug", "text": "Flucloxacillin", "start": 0, "end": 1}, {"entity_id": "15773973_1_Ent0", "role": "Effect", "text": "aplastic anaemia and liver failure", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "15773973_1_Ent1", "text": "Flucloxacillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15773973_1_Ent2", "text": "Flucloxacillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15773973_1_Ent0", "text": "aplastic anaemia and liver failure", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "15773973_2", "wnd_id": "15773973_2_1", "text": "It is well - recognized that flucloxacillin may occasionally result in fatal hepatic injury .", "tokens": ["It", "is", "well", "-", "recognized", "that", "flucloxacillin", "may", "occasionally", "result", "in", "fatal", "hepatic", "injury", "."], "event_mentions": [{"id": "15773973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 9, "end": 10}, "arguments": [{"entity_id": "15773973_2_Ent1", "role": "Treatment", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent2", "role": "Treatment_Drug", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent0", "role": "Effect", "text": "hepatic injury", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15773973_2_Ent1", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent2", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent0", "text": "hepatic injury", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15790469_4", "wnd_id": "15790469_4_1", "text": "Recently , some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( MTX ) and malignant lymphoma developing .", "tokens": ["Recently", ",", "some", "studies", "have", "also", "reported", "association", "between", "patients", "with", "juvenile", "rheumatoid", "arthritis", "(", "JRA", ")", "treated", "with", "Methotrexate", "(", "MTX", ")", "and", "malignant", "lymphoma", "developing", "."], "event_mentions": [{"id": "15790469_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 7, "end": 8}, "arguments": [{"entity_id": "15790469_4_Ent0", "role": "Subject", "text": "patients with juvenile rheumatoid arthritis ( JRA", "start": 9, "end": 16}, {"entity_id": "15790469_4_Ent4", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 11, "end": 14}, {"entity_id": "15790469_4_Ent3", "role": "Treatment_Drug", "text": "Methotrexate", "start": 19, "end": 20}, {"entity_id": "15790469_4_Ent2", "role": "Treatment", "text": "Methotrexate ( MTX )", "start": 19, "end": 23}, {"entity_id": "15790469_4_Ent1", "role": "Effect", "text": "malignant lymphoma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "15790469_4_Ent0", "text": "patients with juvenile rheumatoid arthritis ( JRA", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "15790469_4_Ent4", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15790469_4_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15790469_4_Ent2", "text": "Methotrexate ( MTX )", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "15790469_4_Ent1", "text": "malignant lymphoma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "15811174_3", "wnd_id": "15811174_3_1", "text": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "acute", "rhabdomyolysis", "after", "taking", "cerivastatin", "."], "event_mentions": [{"id": "15811174_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "15811174_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "15811174_3_Ent1", "role": "Effect", "text": "acute rhabdomyolysis", "start": 7, "end": 9}, {"entity_id": "15811174_3_Ent2", "role": "Treatment", "text": "cerivastatin", "start": 11, "end": 12}, {"entity_id": "15811174_3_Ent3", "role": "Treatment_Drug", "text": "cerivastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15811174_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15811174_3_Ent1", "text": "acute rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15811174_3_Ent2", "text": "cerivastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15811174_3_Ent3", "text": "cerivastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15823103_1", "wnd_id": "15823103_1_1", "text": "Carboplatin hypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer .", "tokens": ["Carboplatin", "hypersensitivity", "induced", "by", "low", "-", "dose", "paclitaxel", "/", "carboplatin", "in", "multiple", "platinum", "-", "treated", "patients", "with", "recurrent", "ovarian", "cancer", "."], "event_mentions": [{"id": "15823103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15823103_1_Ent1", "role": "Effect", "text": "Carboplatin hypersensitivity", "start": 0, "end": 2}, {"entity_id": "15823103_1_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 4, "end": 7}, {"entity_id": "15823103_1_Ent2", "role": "Treatment", "text": "low - dose paclitaxel / carboplatin", "start": 4, "end": 10}, {"entity_id": "15823103_1_Ent3", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent8", "role": "Combination_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent9", "role": "Combination_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent0", "role": "Subject", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "start": 11, "end": 20}, {"entity_id": "15823103_1_Ent5", "role": "Treatment_Drug", "text": "platinum", "start": 12, "end": 13}, {"entity_id": "15823103_1_Ent7", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "15823103_1_Ent1", "text": "Carboplatin hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15823103_1_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15823103_1_Ent2", "text": "low - dose paclitaxel / carboplatin", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15823103_1_Ent3", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent8", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent9", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent0", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15823103_1_Ent5", "text": "platinum", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15823103_1_Ent7", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "15827071_5", "wnd_id": "15827071_5_1", "text": "She displayed symptoms of ST 8 days after the introduction of linezolid .", "tokens": ["She", "displayed", "symptoms", "of", "ST", "8", "days", "after", "the", "introduction", "of", "linezolid", "."], "event_mentions": [{"id": "15827071_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "displayed", "start": 1, "end": 2}, "arguments": [{"entity_id": "15827071_5_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "15827071_5_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "15827071_5_Ent2", "role": "Effect", "text": "symptoms of ST", "start": 2, "end": 5}, {"entity_id": "15827071_5_Ent4", "role": "Treatment_Time_elapsed", "text": "8 days", "start": 5, "end": 7}, {"entity_id": "15827071_5_Ent3", "role": "Treatment", "text": "8 days after the introduction of linezolid", "start": 5, "end": 12}, {"entity_id": "15827071_5_Ent5", "role": "Treatment_Route", "text": "introduction", "start": 9, "end": 10}, {"entity_id": "15827071_5_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15827071_5_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15827071_5_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15827071_5_Ent2", "text": "symptoms of ST", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15827071_5_Ent4", "text": "8 days", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15827071_5_Ent3", "text": "8 days after the introduction of linezolid", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15827071_5_Ent5", "text": "introduction", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15827071_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15827071_8", "wnd_id": "15827071_8_1", "text": "A 37 - year - old male with multiple myeloma received citalopram 40 mg / day and trazodone 150 mg / day for anxiety - related disorders .", "tokens": ["A", "37", "-", "year", "-", "old", "male", "with", "multiple", "myeloma", "received", "citalopram", "40", "mg", "/", "day", "and", "trazodone", "150", "mg", "/", "day", "for", "anxiety", "-", "related", "disorders", "."], "event_mentions": [{"id": "15827071_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 22, "end": 23}, "arguments": [{"entity_id": "15827071_8_Ent0", "role": "Subject", "text": "A 37 - year - old male with multiple myeloma", "start": 0, "end": 10}, {"entity_id": "15827071_8_Ent1", "role": "Subject_Age", "text": "37 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_8_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "15827071_8_Ent3", "role": "Subject_Disorder", "text": "multiple myeloma", "start": 8, "end": 10}, {"entity_id": "15827071_8_Ent6", "role": "Treatment_Drug", "text": "citalopram", "start": 11, "end": 12}, {"entity_id": "15827071_8_Ent10", "role": "Combination_Drug", "text": "citalopram", "start": 11, "end": 12}, {"entity_id": "15827071_8_Ent4", "role": "Treatment", "text": "citalopram 40 mg / day and trazodone 150 mg / day", "start": 11, "end": 22}, {"entity_id": "15827071_8_Ent8", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 12, "end": 16}, {"entity_id": "15827071_8_Ent7", "role": "Treatment_Drug", "text": "trazodone", "start": 17, "end": 18}, {"entity_id": "15827071_8_Ent11", "role": "Combination_Drug", "text": "trazodone", "start": 17, "end": 18}, {"entity_id": "15827071_8_Ent9", "role": "Treatment_Dosage", "text": "150 mg / day", "start": 18, "end": 22}, {"entity_id": "15827071_8_Ent5", "role": "Treatment_Disorder", "text": "anxiety - related disorders", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "15827071_8_Ent0", "text": "A 37 - year - old male with multiple myeloma", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "15827071_8_Ent1", "text": "37 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_8_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_8_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15827071_8_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15827071_8_Ent10", "text": "citalopram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15827071_8_Ent4", "text": "citalopram 40 mg / day and trazodone 150 mg / day", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "15827071_8_Ent8", "text": "40 mg / day", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15827071_8_Ent7", "text": "trazodone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15827071_8_Ent11", "text": "trazodone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15827071_8_Ent9", "text": "150 mg / day", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "15827071_8_Ent5", "text": "anxiety - related disorders", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "15836666_2", "wnd_id": "15836666_2_1", "text": "We report a case of a 64 - year - old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome .", "tokens": ["We", "report", "a", "case", "of", "a", "64", "-", "year", "-", "old", "man", "with", "secondary", "adrenocortical", "insufficiency", "who", "has", "been", "on", "a", "chronic", "transdermal", "fentanyl", "treatment", "because", "of", "sciatic", "pain", "syndrome", "."], "event_mentions": [{"id": "15836666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 12, "end": 13}, "arguments": [{"entity_id": "15836666_2_Ent0", "role": "Subject", "text": "a 64 - year - old man", "start": 5, "end": 12}, {"entity_id": "15836666_2_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 6, "end": 11}, {"entity_id": "15836666_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "15836666_2_Ent3", "role": "Effect", "text": "secondary adrenocortical insufficiency", "start": 13, "end": 16}, {"entity_id": "15836666_2_Ent4", "role": "Treatment", "text": "a chronic transdermal fentanyl treatment", "start": 20, "end": 25}, {"entity_id": "15836666_2_Ent8", "role": "Treatment_Freq", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "15836666_2_Ent7", "role": "Treatment_Route", "text": "transdermal", "start": 22, "end": 23}, {"entity_id": "15836666_2_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 23, "end": 24}, {"entity_id": "15836666_2_Ent6", "role": "Treatment_Disorder", "text": "sciatic pain syndrome", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "15836666_2_Ent0", "text": "a 64 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15836666_2_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15836666_2_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15836666_2_Ent3", "text": "secondary adrenocortical insufficiency", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15836666_2_Ent4", "text": "a chronic transdermal fentanyl treatment", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "15836666_2_Ent8", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15836666_2_Ent7", "text": "transdermal", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15836666_2_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15836666_2_Ent6", "text": "sciatic pain syndrome", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "15840734_1", "wnd_id": "15840734_1_1", "text": "Fluphenazine - induced neuroleptic malignant syndrome in a schizophrenic patient .", "tokens": ["Fluphenazine", "-", "induced", "neuroleptic", "malignant", "syndrome", "in", "a", "schizophrenic", "patient", "."], "event_mentions": [{"id": "15840734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15840734_1_Ent2", "role": "Treatment", "text": "Fluphenazine", "start": 0, "end": 1}, {"entity_id": "15840734_1_Ent3", "role": "Treatment_Drug", "text": "Fluphenazine", "start": 0, "end": 1}, {"entity_id": "15840734_1_Ent1", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 3, "end": 6}, {"entity_id": "15840734_1_Ent0", "role": "Subject", "text": "a schizophrenic patient", "start": 7, "end": 10}, {"entity_id": "15840734_1_Ent4", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15840734_1_Ent2", "text": "Fluphenazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15840734_1_Ent3", "text": "Fluphenazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15840734_1_Ent1", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15840734_1_Ent0", "text": "a schizophrenic patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15840734_1_Ent4", "text": "schizophrenic", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15852680_1", "wnd_id": "15852680_1_1", "text": "Successful recovery from interstitial pneumonitis , induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer .", "tokens": ["Successful", "recovery", "from", "interstitial", "pneumonitis", ",", "induced", "by", "bicalutamide", "and", "leuprorelin", "acetate", "given", "as", "treatment", "for", "prostate", "cancer", "."], "event_mentions": [{"id": "15852680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15852680_1_Ent0", "role": "Effect", "text": "interstitial pneumonitis", "start": 3, "end": 5}, {"entity_id": "15852680_1_Ent2", "role": "Treatment_Drug", "text": "bicalutamide", "start": 8, "end": 9}, {"entity_id": "15852680_1_Ent5", "role": "Combination_Drug", "text": "bicalutamide", "start": 8, "end": 9}, {"entity_id": "15852680_1_Ent1", "role": "Treatment", "text": "bicalutamide and leuprorelin acetate", "start": 8, "end": 12}, {"entity_id": "15852680_1_Ent3", "role": "Treatment_Drug", "text": "leuprorelin acetate", "start": 10, "end": 12}, {"entity_id": "15852680_1_Ent6", "role": "Combination_Drug", "text": "leuprorelin acetate", "start": 10, "end": 12}, {"entity_id": "15852680_1_Ent4", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "15852680_1_Ent0", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15852680_1_Ent2", "text": "bicalutamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15852680_1_Ent5", "text": "bicalutamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15852680_1_Ent1", "text": "bicalutamide and leuprorelin acetate", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15852680_1_Ent3", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15852680_1_Ent6", "text": "leuprorelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15852680_1_Ent4", "text": "prostate cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "15866658_3", "wnd_id": "15866658_3_1", "text": "The mean time from starting MMF to the development of neutropenia was 4 months .", "tokens": ["The", "mean", "time", "from", "starting", "MMF", "to", "the", "development", "of", "neutropenia", "was", "4", "months", "."], "event_mentions": [{"id": "15866658_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 8, "end": 9}, "arguments": [{"entity_id": "15866658_3_Ent1", "role": "Treatment", "text": "MMF", "start": 5, "end": 6}, {"entity_id": "15866658_3_Ent2", "role": "Treatment_Drug", "text": "MMF", "start": 5, "end": 6}, {"entity_id": "15866658_3_Ent0", "role": "Effect", "text": "neutropenia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "15866658_3_Ent1", "text": "MMF", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15866658_3_Ent2", "text": "MMF", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15866658_3_Ent0", "text": "neutropenia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "15895899_1", "wnd_id": "15895899_1_1", "text": "After the second infliximab infusion , he was found to have a severe transient neutropenia ( 0.5 x 10(9)/L ) .", "tokens": ["After", "the", "second", "infliximab", "infusion", ",", "he", "was", "found", "to", "have", "a", "severe", "transient", "neutropenia", "(", "0.5", "x", "10(9)/L", ")", "."], "event_mentions": [{"id": "15895899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 8, "end": 9}, "arguments": [{"entity_id": "15895899_1_Ent3", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 4, "end": 5}, {"entity_id": "15895899_1_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent2", "role": "Effect", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "start": 12, "end": 20}]}], "entity_mentions": [{"id": "15895899_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent5", "text": "infusion", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_1_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent2", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "entity_type": "Entity", "start": 12, "end": 20}], "lang": "en"}
{"doc_id": "15895899_2", "wnd_id": "15895899_2_1", "text": "Drug - induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy .", "tokens": ["Drug", "-", "induced", "agranulocytosis", "during", "treatment", "with", "infliximab", "in", "enteropathic", "spondyloarthropathy", "."], "event_mentions": [{"id": "15895899_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15895899_2_Ent0", "role": "Effect", "text": "Drug - induced agranulocytosis", "start": 0, "end": 4}, {"entity_id": "15895899_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent3", "role": "Treatment_Disorder", "text": "enteropathic spondyloarthropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15895899_2_Ent0", "text": "Drug - induced agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15895899_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent3", "text": "enteropathic spondyloarthropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15941649_3", "wnd_id": "15941649_3_1", "text": "Vigabatrin - induced visual field defects are at present the most important safety issue in the use of the drug .", "tokens": ["Vigabatrin", "-", "induced", "visual", "field", "defects", "are", "at", "present", "the", "most", "important", "safety", "issue", "in", "the", "use", "of", "the", "drug", "."], "event_mentions": [{"id": "15941649_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15941649_3_Ent1", "role": "Treatment", "text": "Vigabatrin", "start": 0, "end": 1}, {"entity_id": "15941649_3_Ent2", "role": "Treatment_Drug", "text": "Vigabatrin", "start": 0, "end": 1}, {"entity_id": "15941649_3_Ent0", "role": "Effect", "text": "visual field defects", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "15941649_3_Ent1", "text": "Vigabatrin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15941649_3_Ent2", "text": "Vigabatrin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15941649_3_Ent0", "text": "visual field defects", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "15944830_5", "wnd_id": "15944830_5_1", "text": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy , and the latter patient complained twice during IFN therapy that his visual acuity had decreased .", "tokens": ["The", "former", "patient", "had", "complained", "once", "that", "his", "visual", "acuity", "had", "decreased", "after", "the", "termination", "of", "IFN", "therapy", ",", "and", "the", "latter", "patient", "complained", "twice", "during", "IFN", "therapy", "that", "his", "visual", "acuity", "had", "decreased", "."], "event_mentions": [{"id": "15944830_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "15944830_5_Ent0", "role": "Subject", "text": "The former patient", "start": 0, "end": 3}, {"entity_id": "15944830_5_Ent1", "role": "Effect", "text": "visual acuity had decreased", "start": 8, "end": 12}, {"entity_id": "15944830_5_Ent2", "role": "Treatment", "text": "IFN", "start": 16, "end": 17}, {"entity_id": "15944830_5_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 16, "end": 17}]}, {"id": "15944830_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 25, "end": 26}, "arguments": [{"entity_id": "15944830_5_Ent4", "role": "Subject", "text": "patient", "start": 22, "end": 23}, {"entity_id": "15944830_5_Ent7", "role": "Treatment_Drug", "text": "IFN", "start": 26, "end": 27}, {"entity_id": "15944830_5_Ent6", "role": "Treatment", "text": "IFN therapy", "start": 26, "end": 28}, {"entity_id": "15944830_5_Ent5", "role": "Effect", "text": "visual acuity had decreased", "start": 30, "end": 34}]}], "entity_mentions": [{"id": "15944830_5_Ent0", "text": "The former patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15944830_5_Ent1", "text": "visual acuity had decreased", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15944830_5_Ent2", "text": "IFN", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15944830_5_Ent3", "text": "IFN", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15944830_5_Ent4", "text": "patient", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15944830_5_Ent7", "text": "IFN", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15944830_5_Ent6", "text": "IFN therapy", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15944830_5_Ent5", "text": "visual acuity had decreased", "entity_type": "Entity", "start": 30, "end": 34}], "lang": "en"}
{"doc_id": "16005413_2", "wnd_id": "16005413_2_1", "text": "To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome ( SS ) , mechanism of the interaction , and the spectrum of SS in elderly residents of a long - term care facility .", "tokens": ["To", "describe", "the", "potential", "for", "interaction", "between", "opioids", "and", "serotonergic", "antidepressants", "leading", "to", "the", "development", "of", "serotonin", "syndrome", "(", "SS", ")", ",", "mechanism", "of", "the", "interaction", ",", "and", "the", "spectrum", "of", "SS", "in", "elderly", "residents", "of", "a", "long", "-", "term", "care", "facility", "."], "event_mentions": [{"id": "16005413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 11, "end": 12}, "arguments": [{"entity_id": "16005413_2_Ent3", "role": "Treatment", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent5", "role": "Treatment_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent7", "role": "Combination_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent4", "role": "Treatment", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent6", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent8", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 16, "end": 18}, {"entity_id": "16005413_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 33, "end": 34}, {"entity_id": "16005413_2_Ent0", "role": "Subject", "text": "elderly residents", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "16005413_2_Ent3", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent5", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent7", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent4", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent8", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16005413_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "16005413_2_Ent0", "text": "elderly residents", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "16005413_9", "wnd_id": "16005413_9_1", "text": "While many can benefit from coadministration of serotonergic antidepressants and opioids , it appears that some individuals are at increased risk for SS .", "tokens": ["While", "many", "can", "benefit", "from", "coadministration", "of", "serotonergic", "antidepressants", "and", "opioids", ",", "it", "appears", "that", "some", "individuals", "are", "at", "increased", "risk", "for", "SS", "."], "event_mentions": [{"id": "16005413_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 20, "end": 21}, "arguments": [{"entity_id": "16005413_9_Ent2", "role": "Treatment", "text": "coadministration of serotonergic antidepressants and opioids", "start": 5, "end": 11}, {"entity_id": "16005413_9_Ent3", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent6", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent4", "role": "Treatment_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent5", "role": "Combination_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent0", "role": "Subject", "text": "some individuals", "start": 15, "end": 17}, {"entity_id": "16005413_9_Ent1", "role": "Effect", "text": "SS", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16005413_9_Ent2", "text": "coadministration of serotonergic antidepressants and opioids", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16005413_9_Ent3", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent4", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent5", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent0", "text": "some individuals", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16005413_9_Ent1", "text": "SS", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16008658_2", "wnd_id": "16008658_2_1", "text": "Abdominal wall ulceration and mucinosis secondary to recombinant human interferon - beta - 1b .", "tokens": ["Abdominal", "wall", "ulceration", "and", "mucinosis", "secondary", "to", "recombinant", "human", "interferon", "-", "beta", "-", "1b", "."], "event_mentions": [{"id": "16008658_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 5, "end": 6}, "arguments": [{"entity_id": "16008658_2_Ent0", "role": "Effect", "text": "Abdominal wall ulceration and mucinosis", "start": 0, "end": 5}, {"entity_id": "16008658_2_Ent1", "role": "Treatment", "text": "recombinant human interferon - beta - 1b", "start": 7, "end": 14}, {"entity_id": "16008658_2_Ent2", "role": "Treatment_Drug", "text": "recombinant human interferon - beta - 1b", "start": 7, "end": 14}]}], "entity_mentions": [{"id": "16008658_2_Ent0", "text": "Abdominal wall ulceration and mucinosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16008658_2_Ent1", "text": "recombinant human interferon - beta - 1b", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "16008658_2_Ent2", "text": "recombinant human interferon - beta - 1b", "entity_type": "Entity", "start": 7, "end": 14}], "lang": "en"}
{"doc_id": "16018164_5", "wnd_id": "16018164_5_1", "text": "This is a case of pseudoephedrine - induced intracerebral hemorrhage in a patient with an underlying vascular malformation .", "tokens": ["This", "is", "a", "case", "of", "pseudoephedrine", "-", "induced", "intracerebral", "hemorrhage", "in", "a", "patient", "with", "an", "underlying", "vascular", "malformation", "."], "event_mentions": [{"id": "16018164_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16018164_5_Ent3", "role": "Treatment", "text": "pseudoephedrine", "start": 5, "end": 6}, {"entity_id": "16018164_5_Ent4", "role": "Treatment_Drug", "text": "pseudoephedrine", "start": 5, "end": 6}, {"entity_id": "16018164_5_Ent2", "role": "Effect", "text": "intracerebral hemorrhage", "start": 8, "end": 10}, {"entity_id": "16018164_5_Ent0", "role": "Subject", "text": "a patient with an underlying vascular malformation", "start": 11, "end": 18}, {"entity_id": "16018164_5_Ent1", "role": "Subject_Disorder", "text": "vascular malformation", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16018164_5_Ent3", "text": "pseudoephedrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16018164_5_Ent4", "text": "pseudoephedrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16018164_5_Ent2", "text": "intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16018164_5_Ent0", "text": "a patient with an underlying vascular malformation", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "16018164_5_Ent1", "text": "vascular malformation", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16025424_1", "wnd_id": "16025424_1_1", "text": "Rapid onset of quetiapine - induced diabetic ketoacidosis in an elderly patient : a case report .", "tokens": ["Rapid", "onset", "of", "quetiapine", "-", "induced", "diabetic", "ketoacidosis", "in", "an", "elderly", "patient", ":", "a", "case", "report", "."], "event_mentions": [{"id": "16025424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16025424_1_Ent3", "role": "Treatment", "text": "quetiapine", "start": 3, "end": 4}, {"entity_id": "16025424_1_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 3, "end": 4}, {"entity_id": "16025424_1_Ent2", "role": "Effect", "text": "diabetic ketoacidosis", "start": 6, "end": 8}, {"entity_id": "16025424_1_Ent0", "role": "Subject", "text": "an elderly patient", "start": 9, "end": 12}, {"entity_id": "16025424_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16025424_1_Ent3", "text": "quetiapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16025424_1_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16025424_1_Ent2", "text": "diabetic ketoacidosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16025424_1_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16025424_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "160443_2", "wnd_id": "160443_2_1", "text": "The clinical aspect closely resembled classical transient global amnesia but the episode after clioquinol lasted longer ( 24 hours to three days ) and a more or less extensive retrograde amnesia persisted permanently .", "tokens": ["The", "clinical", "aspect", "closely", "resembled", "classical", "transient", "global", "amnesia", "but", "the", "episode", "after", "clioquinol", "lasted", "longer", "(", "24", "hours", "to", "three", "days", ")", "and", "a", "more", "or", "less", "extensive", "retrograde", "amnesia", "persisted", "permanently", "."], "event_mentions": [{"id": "160443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "160443_2_Ent0", "role": "Effect", "text": "classical transient global amnesia", "start": 5, "end": 9}, {"entity_id": "160443_2_Ent2", "role": "Treatment", "text": "clioquinol", "start": 13, "end": 14}, {"entity_id": "160443_2_Ent3", "role": "Treatment_Drug", "text": "clioquinol", "start": 13, "end": 14}, {"entity_id": "160443_2_Ent1", "role": "Effect", "text": "a more or less extensive retrograde amnesia", "start": 24, "end": 31}]}], "entity_mentions": [{"id": "160443_2_Ent0", "text": "classical transient global amnesia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "160443_2_Ent2", "text": "clioquinol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "160443_2_Ent3", "text": "clioquinol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "160443_2_Ent1", "text": "a more or less extensive retrograde amnesia", "entity_type": "Entity", "start": 24, "end": 31}], "lang": "en"}
{"doc_id": "16046172_2", "wnd_id": "16046172_2_1", "text": "One patient was an 80 - year - old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids .", "tokens": ["One", "patient", "was", "an", "80", "-", "year", "-", "old", "woman", "who", "was", "admitted", "for", "Staphylococcus", "aureus", "knee", "arthritis", "after", "several", "intraarticular", "injections", "of", "sodium", "hyaluronate", "and", "corticosteroids", "."], "event_mentions": [{"id": "16046172_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "16046172_2_Ent0", "role": "Subject", "text": "an 80 - year - old woman", "start": 3, "end": 10}, {"entity_id": "16046172_2_Ent1", "role": "Subject_Age", "text": "80 - year - old", "start": 4, "end": 9}, {"entity_id": "16046172_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "16046172_2_Ent3", "role": "Effect", "text": "Staphylococcus aureus knee arthritis", "start": 14, "end": 18}, {"entity_id": "16046172_2_Ent8", "role": "Treatment_Freq", "text": "several", "start": 19, "end": 20}, {"entity_id": "16046172_2_Ent7", "role": "Treatment_Route", "text": "injections", "start": 21, "end": 22}, {"entity_id": "16046172_2_Ent5", "role": "Treatment_Drug", "text": "sodium hyaluronate", "start": 23, "end": 25}, {"entity_id": "16046172_2_Ent9", "role": "Combination_Drug", "text": "sodium hyaluronate", "start": 23, "end": 25}, {"entity_id": "16046172_2_Ent4", "role": "Treatment", "text": "sodium hyaluronate and corticosteroids", "start": 23, "end": 27}, {"entity_id": "16046172_2_Ent6", "role": "Treatment_Drug", "text": "corticosteroids", "start": 26, "end": 27}, {"entity_id": "16046172_2_Ent10", "role": "Combination_Drug", "text": "corticosteroids", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16046172_2_Ent0", "text": "an 80 - year - old woman", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "16046172_2_Ent1", "text": "80 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16046172_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16046172_2_Ent3", "text": "Staphylococcus aureus knee arthritis", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16046172_2_Ent8", "text": "several", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16046172_2_Ent7", "text": "injections", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16046172_2_Ent5", "text": "sodium hyaluronate", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16046172_2_Ent9", "text": "sodium hyaluronate", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16046172_2_Ent4", "text": "sodium hyaluronate and corticosteroids", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "16046172_2_Ent6", "text": "corticosteroids", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16046172_2_Ent10", "text": "corticosteroids", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16087771_1", "wnd_id": "16087771_1_1", "text": "Pleuropulmonary fibrosis after long - term treatment with the dopamine agonist pergolide for Parkinson Disease .", "tokens": ["Pleuropulmonary", "fibrosis", "after", "long", "-", "term", "treatment", "with", "the", "dopamine", "agonist", "pergolide", "for", "Parkinson", "Disease", "."], "event_mentions": [{"id": "16087771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16087771_1_Ent0", "role": "Effect", "text": "Pleuropulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "16087771_1_Ent1", "role": "Treatment", "text": "long - term treatment with the dopamine agonist pergolide", "start": 3, "end": 12}, {"entity_id": "16087771_1_Ent2", "role": "Treatment_Drug", "text": "pergolide", "start": 11, "end": 12}, {"entity_id": "16087771_1_Ent3", "role": "Treatment_Disorder", "text": "Parkinson Disease", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16087771_1_Ent0", "text": "Pleuropulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16087771_1_Ent1", "text": "long - term treatment with the dopamine agonist pergolide", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "16087771_1_Ent2", "text": "pergolide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16087771_1_Ent3", "text": "Parkinson Disease", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16099004_1", "wnd_id": "16099004_1_1", "text": "Recrudescence of imported falciparum malaria after quinine therapy : potential drug interaction with phenytoin .", "tokens": ["Recrudescence", "of", "imported", "falciparum", "malaria", "after", "quinine", "therapy", ":", "potential", "drug", "interaction", "with", "phenytoin", "."], "event_mentions": [{"id": "16099004_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16099004_1_Ent0", "role": "Effect", "text": "Recrudescence of imported falciparum malaria", "start": 0, "end": 5}, {"entity_id": "16099004_1_Ent1", "role": "Treatment", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent6", "role": "Combination_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent2", "role": "Treatment", "text": "phenytoin", "start": 13, "end": 14}, {"entity_id": "16099004_1_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 13, "end": 14}, {"entity_id": "16099004_1_Ent5", "role": "Combination_Drug", "text": "phenytoin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16099004_1_Ent0", "text": "Recrudescence of imported falciparum malaria", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16099004_1_Ent1", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent3", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent6", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16099004_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16099004_1_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16099004_2", "wnd_id": "16099004_2_1", "text": "Quinine remains a reliable treatment for falciparum malaria in most parts of the world .", "tokens": ["Quinine", "remains", "a", "reliable", "treatment", "for", "falciparum", "malaria", "in", "most", "parts", "of", "the", "world", "."], "event_mentions": [{"id": "16099004_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "16099004_2_Ent0", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "16099004_2_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "16099004_2_Ent1", "role": "Treatment_Disorder", "text": "falciparum malaria", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16099004_2_Ent0", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16099004_2_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16099004_2_Ent1", "text": "falciparum malaria", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16109609_3", "wnd_id": "16109609_3_1", "text": "Physicians should be aware of the potential for developing a gemcitabine - induced radiation recall reaction resulting in hemodynamically significant pericardial effusion .", "tokens": ["Physicians", "should", "be", "aware", "of", "the", "potential", "for", "developing", "a", "gemcitabine", "-", "induced", "radiation", "recall", "reaction", "resulting", "in", "hemodynamically", "significant", "pericardial", "effusion", "."], "event_mentions": [{"id": "16109609_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16109609_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16109609_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16109609_3_Ent0", "role": "Effect", "text": "radiation recall reaction resulting in hemodynamically significant pericardial effusion", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "16109609_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16109609_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16109609_3_Ent0", "text": "radiation recall reaction resulting in hemodynamically significant pericardial effusion", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "16119501_3", "wnd_id": "16119501_3_1", "text": "The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen .", "tokens": ["The", "patient", "continued", "to", "have", "fever", "and", "autonomic", "instability", "without", "evidence", "of", "infection", "which", "entirely", "resolved", "within", "24", "hours", "of", "reinstitution", "of", "full", "preadmission", "dosing", "of", "oral", "baclofen", "."], "event_mentions": [{"id": "16119501_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 4, "end": 5}, "arguments": [{"entity_id": "16119501_3_Ent0", "role": "Effect", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "start": 5, "end": 16}, {"entity_id": "16119501_3_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 17, "end": 19}, {"entity_id": "16119501_3_Ent1", "role": "Treatment", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "start": 17, "end": 28}, {"entity_id": "16119501_3_Ent2", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "16119501_3_Ent3", "role": "Treatment_Drug", "text": "baclofen", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16119501_3_Ent0", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "16119501_3_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16119501_3_Ent1", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "16119501_3_Ent2", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16119501_3_Ent3", "text": "baclofen", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16122280_19", "wnd_id": "16122280_19_1", "text": "In phase III clinical trials , the telithromycin 800 mg once - daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae , Haemophilus influenzae and Staphylococcus aureus in patients with community - acquired pneumonia .", "tokens": ["In", "phase", "III", "clinical", "trials", ",", "the", "telithromycin", "800", "mg", "once", "-", "daily", "dose", "has", "been", "shown", "to", "provide", "close", "to", "the", "maximum", "antimicrobial", "activity", "against", "S.", "pneumoniae", ",", "Haemophilus", "influenzae", "and", "Staphylococcus", "aureus", "in", "patients", "with", "community", "-", "acquired", "pneumonia", "."], "event_mentions": [{"id": "16122280_19_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "provide", "start": 18, "end": 19}, "arguments": [{"entity_id": "16122280_19_Ent6", "role": "Treatment_Drug", "text": "telithromycin", "start": 7, "end": 8}, {"entity_id": "16122280_19_Ent1", "role": "Treatment", "text": "telithromycin 800 mg once - daily dose", "start": 7, "end": 14}, {"entity_id": "16122280_19_Ent7", "role": "Treatment_Dosage", "text": "800 mg", "start": 8, "end": 10}, {"entity_id": "16122280_19_Ent8", "role": "Treatment_Freq", "text": "once - daily", "start": 10, "end": 13}, {"entity_id": "16122280_19_Ent2", "role": "Treatment_Disorder", "text": "S. pneumoniae", "start": 26, "end": 28}, {"entity_id": "16122280_19_Ent3", "role": "Treatment_Disorder", "text": "Haemophilus influenzae", "start": 29, "end": 31}, {"entity_id": "16122280_19_Ent4", "role": "Treatment_Disorder", "text": "Staphylococcus aureus", "start": 32, "end": 34}, {"entity_id": "16122280_19_Ent0", "role": "Subject", "text": "patients with community - acquired pneumonia", "start": 35, "end": 41}, {"entity_id": "16122280_19_Ent5", "role": "Treatment_Disorder", "text": "pneumonia", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "16122280_19_Ent6", "text": "telithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16122280_19_Ent1", "text": "telithromycin 800 mg once - daily dose", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "16122280_19_Ent7", "text": "800 mg", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16122280_19_Ent8", "text": "once - daily", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16122280_19_Ent2", "text": "S. pneumoniae", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "16122280_19_Ent3", "text": "Haemophilus influenzae", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16122280_19_Ent4", "text": "Staphylococcus aureus", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "16122280_19_Ent0", "text": "patients with community - acquired pneumonia", "entity_type": "Entity", "start": 35, "end": 41}, {"id": "16122280_19_Ent5", "text": "pneumonia", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "16122280_3", "wnd_id": "16122280_3_1", "text": "Clinical experience in infectious patients has shown that oral telithromycin 800 mg once daily for 5 - 10 days is effective for the treatment of community - acquired upper and lower respiratory tract infections .", "tokens": ["Clinical", "experience", "in", "infectious", "patients", "has", "shown", "that", "oral", "telithromycin", "800", "mg", "once", "daily", "for", "5", "-", "10", "days", "is", "effective", "for", "the", "treatment", "of", "community", "-", "acquired", "upper", "and", "lower", "respiratory", "tract", "infections", "."], "event_mentions": [{"id": "16122280_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "16122280_3_Ent1", "role": "Subject_Disorder", "text": "infectious", "start": 3, "end": 4}, {"entity_id": "16122280_3_Ent0", "role": "Subject", "text": "infectious patients", "start": 3, "end": 5}, {"entity_id": "16122280_3_Ent8", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "16122280_3_Ent2", "role": "Treatment", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "start": 8, "end": 19}, {"entity_id": "16122280_3_Ent3", "role": "Treatment_Drug", "text": "telithromycin", "start": 9, "end": 10}, {"entity_id": "16122280_3_Ent4", "role": "Treatment_Dosage", "text": "800 mg", "start": 10, "end": 12}, {"entity_id": "16122280_3_Ent5", "role": "Treatment_Freq", "text": "once daily", "start": 12, "end": 14}, {"entity_id": "16122280_3_Ent6", "role": "Treatment_Duration", "text": "5 - 10 days", "start": 15, "end": 19}, {"entity_id": "16122280_3_Ent7", "role": "Treatment_Disorder", "text": "community - acquired upper and lower respiratory tract infections", "start": 25, "end": 34}]}], "entity_mentions": [{"id": "16122280_3_Ent1", "text": "infectious", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16122280_3_Ent0", "text": "infectious patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16122280_3_Ent8", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16122280_3_Ent2", "text": "oral telithromycin 800 mg once daily for 5 - 10 days", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "16122280_3_Ent3", "text": "telithromycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16122280_3_Ent4", "text": "800 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16122280_3_Ent5", "text": "once daily", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16122280_3_Ent6", "text": "5 - 10 days", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16122280_3_Ent7", "text": "community - acquired upper and lower respiratory tract infections", "entity_type": "Entity", "start": 25, "end": 34}], "lang": "en"}
{"doc_id": "16181292_2", "wnd_id": "16181292_2_1", "text": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration .", "tokens": ["Severe", "loss", "of", "vision", "after", "removal", "of", "cataract", "caused", "by", "intravitreal", "triamcinolone", "in", "combination", "with", "photodynamic", "therapy", "for", "exudative", "age", "-", "related", "macular", "degeneration", "."], "event_mentions": [{"id": "16181292_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "16181292_2_Ent0", "role": "Effect", "text": "Severe loss of vision", "start": 0, "end": 4}, {"entity_id": "16181292_2_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone", "start": 10, "end": 12}, {"entity_id": "16181292_2_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent6", "role": "Combination_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent2", "role": "Treatment", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent4", "role": "Treatment_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent7", "role": "Combination_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent5", "role": "Treatment_Disorder", "text": "exudative age - related macular degeneration", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "16181292_2_Ent0", "text": "Severe loss of vision", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16181292_2_Ent1", "text": "intravitreal triamcinolone", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16181292_2_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent6", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent2", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent4", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent7", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent5", "text": "exudative age - related macular degeneration", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "16192734_1", "wnd_id": "16192734_1_1", "text": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy .", "tokens": ["Rhabdomyolysis", "caused", "by", "tocolysis", "with", "oral", "ritodrine", "hydrochloride", "in", "a", "pregnant", "patient", "with", "myotonic", "dystrophy", "."], "event_mentions": [{"id": "16192734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "16192734_1_Ent2", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "16192734_1_Ent3", "role": "Treatment", "text": "tocolysis with oral ritodrine hydrochloride", "start": 3, "end": 8}, {"entity_id": "16192734_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 5, "end": 6}, {"entity_id": "16192734_1_Ent5", "role": "Treatment_Drug", "text": "ritodrine hydrochloride", "start": 6, "end": 8}, {"entity_id": "16192734_1_Ent0", "role": "Subject", "text": "a pregnant patient with myotonic dystrophy", "start": 9, "end": 15}, {"entity_id": "16192734_1_Ent1", "role": "Subject_Disorder", "text": "myotonic dystrophy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16192734_1_Ent2", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16192734_1_Ent3", "text": "tocolysis with oral ritodrine hydrochloride", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16192734_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16192734_1_Ent5", "text": "ritodrine hydrochloride", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16192734_1_Ent0", "text": "a pregnant patient with myotonic dystrophy", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "16192734_1_Ent1", "text": "myotonic dystrophy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16200540_1", "wnd_id": "16200540_1_1", "text": "Polysomnographic and pharmacokinetic findings in levodopa - induced augmentation of restless legs syndrome .", "tokens": ["Polysomnographic", "and", "pharmacokinetic", "findings", "in", "levodopa", "-", "induced", "augmentation", "of", "restless", "legs", "syndrome", "."], "event_mentions": [{"id": "16200540_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16200540_1_Ent1", "role": "Treatment", "text": "levodopa", "start": 5, "end": 6}, {"entity_id": "16200540_1_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 5, "end": 6}, {"entity_id": "16200540_1_Ent0", "role": "Effect", "text": "augmentation of restless legs syndrome", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "16200540_1_Ent1", "text": "levodopa", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16200540_1_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16200540_1_Ent0", "text": "augmentation of restless legs syndrome", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "16207263_1", "wnd_id": "16207263_1_1", "text": "Linezolid - induced dyserythropoiesis : chloramphenicol toxicity revisited .", "tokens": ["Linezolid", "-", "induced", "dyserythropoiesis", ":", "chloramphenicol", "toxicity", "revisited", "."], "event_mentions": [{"id": "16207263_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16207263_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "16207263_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "16207263_1_Ent0", "role": "Effect", "text": "dyserythropoiesis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16207263_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16207263_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16207263_1_Ent0", "text": "dyserythropoiesis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "1621023_2", "wnd_id": "1621023_2_1", "text": "In addition , a 31 - year - old man with obsessive - compulsive disorder developed RBD soon after starting fluoxetine therapy , which persisted at PSG study 19 months after fluoxetine discontinuation .", "tokens": ["In", "addition", ",", "a", "31", "-", "year", "-", "old", "man", "with", "obsessive", "-", "compulsive", "disorder", "developed", "RBD", "soon", "after", "starting", "fluoxetine", "therapy", ",", "which", "persisted", "at", "PSG", "study", "19", "months", "after", "fluoxetine", "discontinuation", "."], "event_mentions": [{"id": "1621023_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "1621023_2_Ent0", "role": "Subject", "text": "a 31 - year - old man with obsessive - compulsive disorder", "start": 3, "end": 15}, {"entity_id": "1621023_2_Ent1", "role": "Subject_Age", "text": "31 - year - old", "start": 4, "end": 9}, {"entity_id": "1621023_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "1621023_2_Ent8", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder", "start": 11, "end": 15}, {"entity_id": "1621023_2_Ent3", "role": "Effect", "text": "RBD", "start": 16, "end": 17}, {"entity_id": "1621023_2_Ent7", "role": "Treatment_Time_elapsed", "text": "soon after starting", "start": 17, "end": 20}, {"entity_id": "1621023_2_Ent5", "role": "Treatment", "text": "starting fluoxetine therapy", "start": 19, "end": 22}, {"entity_id": "1621023_2_Ent6", "role": "Treatment_Drug", "text": "fluoxetine", "start": 20, "end": 21}, {"entity_id": "1621023_2_Ent4", "role": "Effect", "text": "which persisted at PSG study 19 months after fluoxetine discontinuation", "start": 23, "end": 33}]}], "entity_mentions": [{"id": "1621023_2_Ent0", "text": "a 31 - year - old man with obsessive - compulsive disorder", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "1621023_2_Ent1", "text": "31 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1621023_2_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1621023_2_Ent8", "text": "obsessive - compulsive disorder", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "1621023_2_Ent3", "text": "RBD", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1621023_2_Ent7", "text": "soon after starting", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "1621023_2_Ent5", "text": "starting fluoxetine therapy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "1621023_2_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1621023_2_Ent4", "text": "which persisted at PSG study 19 months after fluoxetine discontinuation", "entity_type": "Entity", "start": 23, "end": 33}], "lang": "en"}
{"doc_id": "16211208_1", "wnd_id": "16211208_1_1", "text": "Because of serious side effects of an increase in the QT interval causing torsades de pointes , dofetilide must be initiated with close monitoring of the QT interval in an inpatient setting .", "tokens": ["Because", "of", "serious", "side", "effects", "of", "an", "increase", "in", "the", "QT", "interval", "causing", "torsades", "de", "pointes", ",", "dofetilide", "must", "be", "initiated", "with", "close", "monitoring", "of", "the", "QT", "interval", "in", "an", "inpatient", "setting", "."], "event_mentions": [{"id": "16211208_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 7, "end": 8}, "arguments": [{"entity_id": "16211208_1_Ent0", "role": "Effect", "text": "QT interval causing torsades de pointes", "start": 10, "end": 16}, {"entity_id": "16211208_1_Ent1", "role": "Treatment", "text": "dofetilide", "start": 17, "end": 18}, {"entity_id": "16211208_1_Ent2", "role": "Treatment_Drug", "text": "dofetilide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16211208_1_Ent0", "text": "QT interval causing torsades de pointes", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "16211208_1_Ent1", "text": "dofetilide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16211208_1_Ent2", "text": "dofetilide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16216617_1", "wnd_id": "16216617_1_1", "text": "Prominent positive U waves appearing with high - dose intravenous phenylephrine .", "tokens": ["Prominent", "positive", "U", "waves", "appearing", "with", "high", "-", "dose", "intravenous", "phenylephrine", "."], "event_mentions": [{"id": "16216617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appearing", "start": 4, "end": 5}, "arguments": [{"entity_id": "16216617_1_Ent0", "role": "Effect", "text": "Prominent positive U waves", "start": 0, "end": 4}, {"entity_id": "16216617_1_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "16216617_1_Ent1", "role": "Treatment", "text": "high - dose intravenous phenylephrine", "start": 6, "end": 11}, {"entity_id": "16216617_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 9, "end": 10}, {"entity_id": "16216617_1_Ent2", "role": "Treatment_Drug", "text": "phenylephrine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "16216617_1_Ent0", "text": "Prominent positive U waves", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16216617_1_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16216617_1_Ent1", "text": "high - dose intravenous phenylephrine", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16216617_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16216617_1_Ent2", "text": "phenylephrine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "16225183_10", "wnd_id": "16225183_10_1", "text": "This latest ( third ) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.", "tokens": ["This", "latest", "(", "third", ")", "report", "suggests", "that", "the", "safety", "profile", "should", "be", "reexamined", "and", "at", "least", "raises", "the", "question", "of", "potential", "renal", "toxicity", "of", "interferons", "in", "MS."], "event_mentions": [{"id": "16225183_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "raises", "start": 17, "end": 18}, "arguments": [{"entity_id": "16225183_10_Ent0", "role": "Effect", "text": "potential renal toxicity", "start": 21, "end": 24}, {"entity_id": "16225183_10_Ent1", "role": "Treatment", "text": "interferons", "start": 25, "end": 26}, {"entity_id": "16225183_10_Ent2", "role": "Treatment_Drug", "text": "interferons", "start": 25, "end": 26}, {"entity_id": "16225183_10_Ent3", "role": "Treatment_Disorder", "text": "MS.", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16225183_10_Ent0", "text": "potential renal toxicity", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "16225183_10_Ent1", "text": "interferons", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16225183_10_Ent2", "text": "interferons", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16225183_10_Ent3", "text": "MS.", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16298824_6", "wnd_id": "16298824_6_1", "text": "We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( ARDS ) after a single infusion of rituximab .", "tokens": ["We", "report", "the", "case", "of", "a", "43", "-", "year", "-", "old", "man", "with", "ITP", "refractory", "to", "steroids", "and", "intravenous", "immunoglobulin", "who", "developed", "acute", "respiratory", "distress", "syndrome", "(", "ARDS", ")", "after", "a", "single", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "16298824_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "16298824_6_Ent0", "role": "Subject", "text": "the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin", "start": 2, "end": 20}, {"entity_id": "16298824_6_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 6, "end": 11}, {"entity_id": "16298824_6_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "16298824_6_Ent8", "role": "Treatment_Disorder", "text": "ITP", "start": 13, "end": 14}, {"entity_id": "16298824_6_Ent3", "role": "Subject_Disorder", "text": "refractory to steroids and intravenous immunoglobulin", "start": 14, "end": 20}, {"entity_id": "16298824_6_Ent4", "role": "Effect", "text": "acute respiratory distress syndrome ( ARDS )", "start": 22, "end": 29}, {"entity_id": "16298824_6_Ent5", "role": "Treatment", "text": "single infusion of rituximab", "start": 31, "end": 35}, {"entity_id": "16298824_6_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 32, "end": 33}, {"entity_id": "16298824_6_Ent7", "role": "Treatment_Drug", "text": "rituximab", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16298824_6_Ent0", "text": "the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin", "entity_type": "Entity", "start": 2, "end": 20}, {"id": "16298824_6_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16298824_6_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16298824_6_Ent8", "text": "ITP", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16298824_6_Ent3", "text": "refractory to steroids and intravenous immunoglobulin", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "16298824_6_Ent4", "text": "acute respiratory distress syndrome ( ARDS )", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "16298824_6_Ent5", "text": "single infusion of rituximab", "entity_type": "Entity", "start": 31, "end": 35}, {"id": "16298824_6_Ent6", "text": "infusion", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16298824_6_Ent7", "text": "rituximab", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16317298_5", "wnd_id": "16317298_5_1", "text": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation - recall related to gemcitabine and review literature .", "tokens": ["We", "report", "a", "patient", "with", "inoperable", "pancreatic", "cancer", "who", "developed", "gastrointestinal", "bleeding", "secondary", "to", "radiation", "-", "recall", "related", "to", "gemcitabine", "and", "review", "literature", "."], "event_mentions": [{"id": "16317298_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "16317298_5_Ent0", "role": "Subject", "text": "a patient with inoperable pancreatic cancer", "start": 2, "end": 8}, {"entity_id": "16317298_5_Ent4", "role": "Treatment_Disorder", "text": "inoperable pancreatic cancer", "start": 5, "end": 8}, {"entity_id": "16317298_5_Ent1", "role": "Effect", "text": "gastrointestinal bleeding", "start": 10, "end": 12}, {"entity_id": "16317298_5_Ent2", "role": "Effect", "text": "radiation - recall", "start": 14, "end": 17}, {"entity_id": "16317298_5_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 19, "end": 20}, {"entity_id": "16317298_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16317298_5_Ent0", "text": "a patient with inoperable pancreatic cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16317298_5_Ent4", "text": "inoperable pancreatic cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16317298_5_Ent1", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16317298_5_Ent2", "text": "radiation - recall", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16317298_5_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16317298_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16355099_4", "wnd_id": "16355099_4_1", "text": "When thrombosis develops during heparin treatment , it is important to suspect HITTs and to assay for the associated antibodies , regardless of the actual platelet count .", "tokens": ["When", "thrombosis", "develops", "during", "heparin", "treatment", ",", "it", "is", "important", "to", "suspect", "HITTs", "and", "to", "assay", "for", "the", "associated", "antibodies", ",", "regardless", "of", "the", "actual", "platelet", "count", "."], "event_mentions": [{"id": "16355099_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develops", "start": 2, "end": 3}, "arguments": [{"entity_id": "16355099_4_Ent0", "role": "Effect", "text": "thrombosis", "start": 1, "end": 2}, {"entity_id": "16355099_4_Ent2", "role": "Treatment", "text": "heparin", "start": 4, "end": 5}, {"entity_id": "16355099_4_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 4, "end": 5}, {"entity_id": "16355099_4_Ent1", "role": "Effect", "text": "HITTs", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16355099_4_Ent0", "text": "thrombosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16355099_4_Ent2", "text": "heparin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16355099_4_Ent3", "text": "heparin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16355099_4_Ent1", "text": "HITTs", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1635565_2", "wnd_id": "1635565_2_1", "text": "CONCLUSIONS : The administration of prostaglandin E1 to neonates can cause gastric - outlet obstruction due to antral hyperplasia .", "tokens": ["CONCLUSIONS", ":", "The", "administration", "of", "prostaglandin", "E1", "to", "neonates", "can", "cause", "gastric", "-", "outlet", "obstruction", "due", "to", "antral", "hyperplasia", "."], "event_mentions": [{"id": "1635565_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "1635565_2_Ent3", "role": "Treatment", "text": "prostaglandin E1", "start": 5, "end": 7}, {"entity_id": "1635565_2_Ent4", "role": "Treatment_Drug", "text": "prostaglandin E1", "start": 5, "end": 7}, {"entity_id": "1635565_2_Ent0", "role": "Subject", "text": "neonates", "start": 8, "end": 9}, {"entity_id": "1635565_2_Ent1", "role": "Subject_Age", "text": "neonates", "start": 8, "end": 9}, {"entity_id": "1635565_2_Ent2", "role": "Effect", "text": "gastric - outlet obstruction due to antral hyperplasia", "start": 11, "end": 19}]}], "entity_mentions": [{"id": "1635565_2_Ent3", "text": "prostaglandin E1", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1635565_2_Ent4", "text": "prostaglandin E1", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1635565_2_Ent0", "text": "neonates", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1635565_2_Ent1", "text": "neonates", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1635565_2_Ent2", "text": "gastric - outlet obstruction due to antral hyperplasia", "entity_type": "Entity", "start": 11, "end": 19}], "lang": "en"}
{"doc_id": "16411025_3", "wnd_id": "16411025_3_1", "text": "OBJECTIVES : A delayed stroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( MTX ) for childhood leukemia .", "tokens": ["OBJECTIVES", ":", "A", "delayed", "stroke", "-", "like", "leukoencephalopathy", "has", "been", "observed", "in", "patients", "receiving", "methotrexate", "(", "MTX", ")", "for", "childhood", "leukemia", "."], "event_mentions": [{"id": "16411025_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "has been observed", "start": 8, "end": 11}, "arguments": [{"entity_id": "16411025_3_Ent3", "role": "Effect", "text": "delayed stroke - like leukoencephalopathy", "start": 3, "end": 8}, {"entity_id": "16411025_3_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "16411025_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "16411025_3_Ent4", "role": "Treatment", "text": "methotrexate ( MTX )", "start": 14, "end": 18}, {"entity_id": "16411025_3_Ent2", "role": "Subject_Age", "text": "childhood", "start": 19, "end": 20}, {"entity_id": "16411025_3_Ent1", "role": "Subject", "text": "childhood leukemia", "start": 19, "end": 21}, {"entity_id": "16411025_3_Ent6", "role": "Treatment_Disorder", "text": "childhood leukemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "16411025_3_Ent3", "text": "delayed stroke - like leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16411025_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16411025_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16411025_3_Ent4", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16411025_3_Ent2", "text": "childhood", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16411025_3_Ent1", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16411025_3_Ent6", "text": "childhood leukemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "16411025_4", "wnd_id": "16411025_4_1", "text": "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered subacute neurotoxicity after intrathecal MTX .", "tokens": ["Our", "objective", "is", "to", "present", "a", "retrospective", "analysis", "of", "the", "DWI", "findings", "in", "four", "patients", "who", "suffered", "subacute", "neurotoxicity", "after", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "16411025_4_Ent1", "role": "Subject_Population", "text": "four", "start": 13, "end": 14}, {"entity_id": "16411025_4_Ent0", "role": "Subject", "text": "four patients", "start": 13, "end": 15}, {"entity_id": "16411025_4_Ent2", "role": "Effect", "text": "subacute neurotoxicity", "start": 17, "end": 19}, {"entity_id": "16411025_4_Ent3", "role": "Treatment", "text": "intrathecal MTX", "start": 20, "end": 22}, {"entity_id": "16411025_4_Ent4", "role": "Treatment_Drug", "text": "intrathecal MTX", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16411025_4_Ent1", "text": "four", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16411025_4_Ent0", "text": "four patients", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16411025_4_Ent2", "text": "subacute neurotoxicity", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16411025_4_Ent3", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "16411025_4_Ent4", "text": "intrathecal MTX", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "1642627_1", "wnd_id": "1642627_1_1", "text": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam - induced eating disorder .", "tokens": ["A", "combination", "of", "behavioural", "and", "cognitive", "adverse", "effects", "is", "illustrated", "in", "this", "case", "report", "of", "a", "recurrent", "triazolam", "-", "induced", "eating", "disorder", "."], "event_mentions": [{"id": "1642627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "1642627_1_Ent1", "role": "Treatment", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent2", "role": "Treatment_Drug", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent0", "role": "Effect", "text": "eating disorder", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1642627_1_Ent1", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent2", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent0", "text": "eating disorder", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16436462_1", "wnd_id": "16436462_1_1", "text": "Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer .", "tokens": ["Neutropenic", "colitis", "during", "standard", "dose", "combination", "chemotherapy", "with", "nedaplatin", "and", "irinotecan", "for", "testicular", "cancer", "."], "event_mentions": [{"id": "16436462_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "16436462_1_Ent0", "role": "Effect", "text": "Neutropenic colitis", "start": 0, "end": 2}, {"entity_id": "16436462_1_Ent3", "role": "Treatment_Dosage", "text": "standard dose", "start": 3, "end": 5}, {"entity_id": "16436462_1_Ent1", "role": "Treatment", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "start": 3, "end": 14}, {"entity_id": "16436462_1_Ent4", "role": "Treatment_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent6", "role": "Combination_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent5", "role": "Treatment_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent7", "role": "Combination_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent2", "role": "Treatment_Disorder", "text": "testicular cancer", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16436462_1_Ent0", "text": "Neutropenic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16436462_1_Ent3", "text": "standard dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16436462_1_Ent1", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "16436462_1_Ent4", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent6", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent7", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent2", "text": "testicular cancer", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16446228_1", "wnd_id": "16446228_1_1", "text": "Here , we present a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids .", "tokens": ["Here", ",", "we", "present", "a", "case", "of", "sirolimus", "-", "associated", "interstitial", "pneumonitis", "in", "a", "cardiac", "transplant", "recipient", "that", "resolved", "completely", "with", "withdrawal", "of", "the", "drug", "and", "treatment", "with", "corticosteroids", "."], "event_mentions": [{"id": "16446228_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "16446228_1_Ent4", "role": "Treatment", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent5", "role": "Treatment_Drug", "text": "sirolimus", "start": 7, "end": 8}, {"entity_id": "16446228_1_Ent6", "role": "Treatment_Disorder", "text": "sirolimus - associated interstitial pneumonitis", "start": 7, "end": 12}, {"entity_id": "16446228_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis", "start": 10, "end": 12}]}, {"id": "16446228_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 18, "end": 19}, "arguments": [{"entity_id": "16446228_1_Ent0", "role": "Subject", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "start": 4, "end": 17}, {"entity_id": "16446228_1_Ent1", "role": "Treatment", "text": "withdrawal of the drug and treatment with corticosteroids", "start": 21, "end": 29}, {"entity_id": "16446228_1_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "16446228_1_Ent0", "text": "a case of sirolimus - associated interstitial pneumonitis in a cardiac transplant recipient", "entity_type": "Entity", "start": 4, "end": 17}, {"id": "16446228_1_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent5", "text": "sirolimus", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16446228_1_Ent6", "text": "sirolimus - associated interstitial pneumonitis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16446228_1_Ent3", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16446228_1_Ent1", "text": "withdrawal of the drug and treatment with corticosteroids", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "16446228_1_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "16449538_1", "wnd_id": "16449538_1_1", "text": "An objective causality assessment by use of the Naranjo probability scale revealed that NCSE due to ifosfamide was probable .", "tokens": ["An", "objective", "causality", "assessment", "by", "use", "of", "the", "Naranjo", "probability", "scale", "revealed", "that", "NCSE", "due", "to", "ifosfamide", "was", "probable", "."], "event_mentions": [{"id": "16449538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 14, "end": 15}, "arguments": [{"entity_id": "16449538_1_Ent0", "role": "Effect", "text": "NCSE", "start": 13, "end": 14}, {"entity_id": "16449538_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 16, "end": 17}, {"entity_id": "16449538_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16449538_1_Ent0", "text": "NCSE", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16449538_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16449538_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16449538_2", "wnd_id": "16449538_2_1", "text": "CASE SUMMARIES : Two patients who received ifosfamide - containing chemotherapy developed NCSE .", "tokens": ["CASE", "SUMMARIES", ":", "Two", "patients", "who", "received", "ifosfamide", "-", "containing", "chemotherapy", "developed", "NCSE", "."], "event_mentions": [{"id": "16449538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16449538_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "16449538_2_Ent0", "role": "Subject", "text": "Two patients", "start": 3, "end": 5}, {"entity_id": "16449538_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "16449538_2_Ent3", "role": "Treatment", "text": "ifosfamide - containing chemotherapy", "start": 7, "end": 11}, {"entity_id": "16449538_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "16449538_2_Ent2", "role": "Effect", "text": "NCSE", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16449538_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16449538_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16449538_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16449538_2_Ent3", "text": "ifosfamide - containing chemotherapy", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "16449538_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16449538_2_Ent2", "text": "NCSE", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16449538_5", "wnd_id": "16449538_5_1", "text": "Nonconvulsive status epilepticus due to ifosfamide .", "tokens": ["Nonconvulsive", "status", "epilepticus", "due", "to", "ifosfamide", "."], "event_mentions": [{"id": "16449538_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "16449538_5_Ent0", "role": "Effect", "text": "Nonconvulsive status epilepticus", "start": 0, "end": 3}, {"entity_id": "16449538_5_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 5, "end": 6}, {"entity_id": "16449538_5_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16449538_5_Ent0", "text": "Nonconvulsive status epilepticus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16449538_5_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16449538_5_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16459502_1", "wnd_id": "16459502_1_1", "text": "Cutaneous mycobacterial infection post intravesical BCG installation .", "tokens": ["Cutaneous", "mycobacterial", "infection", "post", "intravesical", "BCG", "installation", "."], "event_mentions": [{"id": "16459502_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "post", "start": 3, "end": 4}, "arguments": [{"entity_id": "16459502_1_Ent0", "role": "Effect", "text": "Cutaneous mycobacterial infection", "start": 0, "end": 3}, {"entity_id": "16459502_1_Ent2", "role": "Treatment_Route", "text": "intravesical", "start": 4, "end": 5}, {"entity_id": "16459502_1_Ent1", "role": "Treatment", "text": "intravesical BCG installation", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "16459502_1_Ent0", "text": "Cutaneous mycobacterial infection", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16459502_1_Ent2", "text": "intravesical", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16459502_1_Ent1", "text": "intravesical BCG installation", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "16498048_2", "wnd_id": "16498048_2_1", "text": "Destructive thyrotoxicosis appeared 4 - 6 months after starting IFN - alpha , followed by Graves ' hyperthyroidism within 8 to 11 months .", "tokens": ["Destructive", "thyrotoxicosis", "appeared", "4", "-", "6", "months", "after", "starting", "IFN", "-", "alpha", ",", "followed", "by", "Graves", "'", "hyperthyroidism", "within", "8", "to", "11", "months", "."], "event_mentions": [{"id": "16498048_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "16498048_2_Ent0", "role": "Effect", "text": "Destructive thyrotoxicosis", "start": 0, "end": 2}, {"entity_id": "16498048_2_Ent4", "role": "Treatment_Time_elapsed", "text": "4 - 6 months", "start": 3, "end": 7}, {"entity_id": "16498048_2_Ent2", "role": "Treatment", "text": "IFN - alpha", "start": 9, "end": 12}, {"entity_id": "16498048_2_Ent3", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 9, "end": 12}, {"entity_id": "16498048_2_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "16498048_2_Ent0", "text": "Destructive thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16498048_2_Ent4", "text": "4 - 6 months", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16498048_2_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16498048_2_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16498048_2_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "16507211_1", "wnd_id": "16507211_1_1", "text": "Herein , we describe 2 patients who developed unusual CD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab .", "tokens": ["Herein", ",", "we", "describe", "2", "patients", "who", "developed", "unusual", "CD8", "+", "cutaneous", "lymphoproliferative", "disorders", "after", "treatment", "with", "efalizumab", "and", "infliximab", "."], "event_mentions": [{"id": "16507211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16507211_1_Ent1", "role": "Subject_Population", "text": "2", "start": 4, "end": 5}, {"entity_id": "16507211_1_Ent0", "role": "Subject", "text": "2 patients", "start": 4, "end": 6}, {"entity_id": "16507211_1_Ent2", "role": "Effect", "text": "CD8 + cutaneous lymphoproliferative", "start": 9, "end": 13}, {"entity_id": "16507211_1_Ent4", "role": "Treatment_Drug", "text": "efalizumab", "start": 17, "end": 18}, {"entity_id": "16507211_1_Ent6", "role": "Combination_Drug", "text": "efalizumab", "start": 17, "end": 18}, {"entity_id": "16507211_1_Ent3", "role": "Treatment", "text": "efalizumab and infliximab", "start": 17, "end": 20}, {"entity_id": "16507211_1_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 19, "end": 20}, {"entity_id": "16507211_1_Ent7", "role": "Combination_Drug", "text": "infliximab", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16507211_1_Ent1", "text": "2", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16507211_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16507211_1_Ent2", "text": "CD8 + cutaneous lymphoproliferative", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16507211_1_Ent4", "text": "efalizumab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16507211_1_Ent6", "text": "efalizumab", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16507211_1_Ent3", "text": "efalizumab and infliximab", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "16507211_1_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16507211_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16515630_1", "wnd_id": "16515630_1_1", "text": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer .", "tokens": ["Fatal", "lung", "fibrosis", "caused", "by", "paclitaxel", "toxicity", "has", "not", "been", "reported", "In", "this", "report", ",", "we", "describe", "the", "case", "of", "a", "62", "-", "year", "-", "old", "woman", "who", "received", "six", "cycles", "of", "paclitaxel", "and", "carboplatin", "as", "combination", "chemotherapy", "for", "advanced", "ovarian", "cancer", "."], "event_mentions": [{"id": "16515630_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 28, "end": 29}, "arguments": [{"entity_id": "16515630_1_Ent4", "role": "Effect", "text": "Fatal lung fibrosis", "start": 0, "end": 3}, {"entity_id": "16515630_1_Ent2", "role": "Subject_Age", "text": "62 - year - old", "start": 21, "end": 26}, {"entity_id": "16515630_1_Ent0", "role": "Subject", "text": "62 - year - old woman", "start": 21, "end": 27}, {"entity_id": "16515630_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 26, "end": 27}, {"entity_id": "16515630_1_Ent6", "role": "Treatment_Dosage", "text": "six cycles", "start": 29, "end": 31}, {"entity_id": "16515630_1_Ent5", "role": "Treatment", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "start": 29, "end": 38}, {"entity_id": "16515630_1_Ent7", "role": "Treatment_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent11", "role": "Combination_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent8", "role": "Treatment_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent12", "role": "Combination_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent10", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}, {"entity_id": "16515630_1_Ent1", "role": "Subject", "text": "advanced ovarian cancer", "start": 39, "end": 42}, {"entity_id": "16515630_1_Ent9", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16515630_1_Ent4", "text": "Fatal lung fibrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16515630_1_Ent2", "text": "62 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "16515630_1_Ent0", "text": "62 - year - old woman", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "16515630_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16515630_1_Ent6", "text": "six cycles", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16515630_1_Ent5", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "16515630_1_Ent7", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent11", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent8", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent12", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16515630_1_Ent1", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "16515630_1_Ent9", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16531969_2", "wnd_id": "16531969_2_1", "text": "Grade 3 hepatotoxicity ( AST and ALT > 5 to 20 upper limit normal ) or higher has been observed in as many as 1.4 % of MS patients on IFN beta .", "tokens": ["Grade", "3", "hepatotoxicity", "(", "AST", "and", "ALT", ">", "5", "to", "20", "upper", "limit", "normal", ")", "or", "higher", "has", "been", "observed", "in", "as", "many", "as", "1.4", "%", "of", "MS", "patients", "on", "IFN", "beta", "."], "event_mentions": [{"id": "16531969_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16531969_2_Ent2", "role": "Effect", "text": "Grade 3 hepatotoxicity", "start": 0, "end": 3}, {"entity_id": "16531969_2_Ent1", "role": "Subject_Population", "text": "1.4 %", "start": 24, "end": 26}, {"entity_id": "16531969_2_Ent0", "role": "Subject", "text": "1.4 % of MS patients", "start": 24, "end": 29}, {"entity_id": "16531969_2_Ent5", "role": "Treatment_Disorder", "text": "MS", "start": 27, "end": 28}, {"entity_id": "16531969_2_Ent3", "role": "Treatment", "text": "IFN beta", "start": 30, "end": 32}, {"entity_id": "16531969_2_Ent4", "role": "Treatment_Drug", "text": "IFN beta", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "16531969_2_Ent2", "text": "Grade 3 hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16531969_2_Ent1", "text": "1.4 %", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "16531969_2_Ent0", "text": "1.4 % of MS patients", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "16531969_2_Ent5", "text": "MS", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "16531969_2_Ent3", "text": "IFN beta", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "16531969_2_Ent4", "text": "IFN beta", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "1655228_3", "wnd_id": "1655228_3_1", "text": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion .", "tokens": ["Three", "patients", "are", "reported", "without", "a", "history", "of", "angina", "pectoris", "who", "had", "clinical", "and", "electrocardiographic", "evidence", "of", "myocardial", "ischemia", "during", "and", "immediately", "after", "BCNU", "infusion", "."], "event_mentions": [{"id": "1655228_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 11, "end": 12}, "arguments": [{"entity_id": "1655228_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "1655228_3_Ent0", "role": "Subject", "text": "Three patients are reported without a history of angina pectoris", "start": 0, "end": 10}, {"entity_id": "1655228_3_Ent2", "role": "Effect", "text": "myocardial ischemia", "start": 17, "end": 19}, {"entity_id": "1655228_3_Ent3", "role": "Treatment", "text": "during and immediately after BCNU infusion", "start": 19, "end": 25}, {"entity_id": "1655228_3_Ent5", "role": "Treatment_Time_elapsed", "text": "immediately after", "start": 21, "end": 23}, {"entity_id": "1655228_3_Ent4", "role": "Treatment_Drug", "text": "BCNU", "start": 23, "end": 24}, {"entity_id": "1655228_3_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1655228_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1655228_3_Ent0", "text": "Three patients are reported without a history of angina pectoris", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "1655228_3_Ent2", "text": "myocardial ischemia", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "1655228_3_Ent3", "text": "during and immediately after BCNU infusion", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "1655228_3_Ent5", "text": "immediately after", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1655228_3_Ent4", "text": "BCNU", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1655228_3_Ent6", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16580907_9", "wnd_id": "16580907_9_1", "text": "Although cetirizine has less potential for causing arrhythmias than other histamine 1 blockers , such an interaction should be considered , especially in patients with renal insufficiency who are receiving pilsicainide .", "tokens": ["Although", "cetirizine", "has", "less", "potential", "for", "causing", "arrhythmias", "than", "other", "histamine", "1", "blockers", ",", "such", "an", "interaction", "should", "be", "considered", ",", "especially", "in", "patients", "with", "renal", "insufficiency", "who", "are", "receiving", "pilsicainide", "."], "event_mentions": [{"id": "16580907_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 6, "end": 7}, "arguments": [{"entity_id": "16580907_9_Ent3", "role": "Treatment", "text": "cetirizine", "start": 1, "end": 2}, {"entity_id": "16580907_9_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 1, "end": 2}, {"entity_id": "16580907_9_Ent2", "role": "Effect", "text": "arrhythmias", "start": 7, "end": 8}, {"entity_id": "16580907_9_Ent0", "role": "Subject", "text": "patients with renal insufficiency", "start": 23, "end": 27}, {"entity_id": "16580907_9_Ent1", "role": "Subject_Disorder", "text": "renal insufficiency", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "16580907_9_Ent3", "text": "cetirizine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16580907_9_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16580907_9_Ent2", "text": "arrhythmias", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16580907_9_Ent0", "text": "patients with renal insufficiency", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "16580907_9_Ent1", "text": "renal insufficiency", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "16599252_1", "wnd_id": "16599252_1_1", "text": "Adverse reaction in a patient with aspirin - induced asthma treated with zafirlukast .", "tokens": ["Adverse", "reaction", "in", "a", "patient", "with", "aspirin", "-", "induced", "asthma", "treated", "with", "zafirlukast", "."], "event_mentions": [{"id": "16599252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16599252_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "16599252_1_Ent2", "role": "Treatment", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent6", "role": "Combination_Drug", "text": "aspirin", "start": 6, "end": 7}, {"entity_id": "16599252_1_Ent1", "role": "Effect", "text": "asthma", "start": 9, "end": 10}, {"entity_id": "16599252_1_Ent4", "role": "Treatment_Drug", "text": "zafirlukast", "start": 12, "end": 13}, {"entity_id": "16599252_1_Ent5", "role": "Combination_Drug", "text": "zafirlukast", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16599252_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16599252_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16599252_1_Ent1", "text": "asthma", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16599252_1_Ent4", "text": "zafirlukast", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16599252_1_Ent5", "text": "zafirlukast", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16609346_2", "wnd_id": "16609346_2_1", "text": "Statin - associated myasthenia gravis : report of 4 cases and review of the literature .", "tokens": ["Statin", "-", "associated", "myasthenia", "gravis", ":", "report", "of", "4", "cases", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "16609346_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16609346_2_Ent3", "role": "Treatment", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent4", "role": "Treatment_Drug", "text": "Statin", "start": 0, "end": 1}, {"entity_id": "16609346_2_Ent2", "role": "Effect", "text": "myasthenia gravis", "start": 3, "end": 5}, {"entity_id": "16609346_2_Ent1", "role": "Subject_Population", "text": "4", "start": 8, "end": 9}, {"entity_id": "16609346_2_Ent0", "role": "Subject", "text": "4 cases", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16609346_2_Ent3", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent4", "text": "Statin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16609346_2_Ent2", "text": "myasthenia gravis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16609346_2_Ent1", "text": "4", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16609346_2_Ent0", "text": "4 cases", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16615675_3", "wnd_id": "16615675_3_1", "text": "CONCLUSION : The chronic use of HCQ for rheumatic diseases , or as an anti - malarial drug , should be balanced against the risk of developing potentially lethal cardiac arrhythmias .", "tokens": ["CONCLUSION", ":", "The", "chronic", "use", "of", "HCQ", "for", "rheumatic", "diseases", ",", "or", "as", "an", "anti", "-", "malarial", "drug", ",", "should", "be", "balanced", "against", "the", "risk", "of", "developing", "potentially", "lethal", "cardiac", "arrhythmias", "."], "event_mentions": [{"id": "16615675_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "against", "start": 22, "end": 23}, "arguments": [{"entity_id": "16615675_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 3, "end": 4}, {"entity_id": "16615675_3_Ent1", "role": "Treatment", "text": "chronic use of HCQ", "start": 3, "end": 7}, {"entity_id": "16615675_3_Ent3", "role": "Treatment_Drug", "text": "HCQ", "start": 6, "end": 7}, {"entity_id": "16615675_3_Ent2", "role": "Treatment_Disorder", "text": "rheumatic diseases", "start": 8, "end": 10}, {"entity_id": "16615675_3_Ent0", "role": "Effect", "text": "lethal cardiac arrhythmias", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "16615675_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16615675_3_Ent1", "text": "chronic use of HCQ", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16615675_3_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16615675_3_Ent2", "text": "rheumatic diseases", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16615675_3_Ent0", "text": "lethal cardiac arrhythmias", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "16623611_3", "wnd_id": "16623611_3_1", "text": "The patient was enrolled in a weight - loss clinic , and his diabetes medications were adjusted . Subsequently , olanzapine was discontinued because of weight gain and uncontrolled diabetes .", "tokens": ["The", "patient", "was", "enrolled", "in", "a", "weight", "-", "loss", "clinic", ",", "and", "his", "diabetes", "medications", "were", "adjusted", ".", "Subsequently", ",", "olanzapine", "was", "discontinued", "because", "of", "weight", "gain", "and", "uncontrolled", "diabetes", "."], "event_mentions": [{"id": "16623611_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 23, "end": 24}, "arguments": [{"entity_id": "16623611_3_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "16623611_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 20, "end": 21}, {"entity_id": "16623611_3_Ent2", "role": "Treatment", "text": "olanzapine was discontinued", "start": 20, "end": 23}, {"entity_id": "16623611_3_Ent1", "role": "Effect", "text": "weight gain and uncontrolled diabetes", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "16623611_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16623611_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16623611_3_Ent2", "text": "olanzapine was discontinued", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "16623611_3_Ent1", "text": "weight gain and uncontrolled diabetes", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "16641839_3", "wnd_id": "16641839_3_1", "text": "Cutaneous eruptions occur in 3 % of individuals administered carbamazepine .", "tokens": ["Cutaneous", "eruptions", "occur", "in", "3", "%", "of", "individuals", "administered", "carbamazepine", "."], "event_mentions": [{"id": "16641839_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "16641839_3_Ent0", "role": "Effect", "text": "Cutaneous eruptions", "start": 0, "end": 2}, {"entity_id": "16641839_3_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "16641839_3_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16641839_3_Ent0", "text": "Cutaneous eruptions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16641839_3_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16641839_3_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16641839_4", "wnd_id": "16641839_4_1", "text": "Cutaneous rashes and eruptions can be caused by many medications , including carbamazepine .", "tokens": ["Cutaneous", "rashes", "and", "eruptions", "can", "be", "caused", "by", "many", "medications", ",", "including", "carbamazepine", "."], "event_mentions": [{"id": "16641839_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "16641839_4_Ent0", "role": "Effect", "text": "Cutaneous rashes and eruptions", "start": 0, "end": 4}, {"entity_id": "16641839_4_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 12, "end": 13}, {"entity_id": "16641839_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16641839_4_Ent0", "text": "Cutaneous rashes and eruptions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16641839_4_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16685007_1", "wnd_id": "16685007_1_1", "text": "Ciclesonide reduces the need for oral steroid use in adult patients with severe , persistent asthma .", "tokens": ["Ciclesonide", "reduces", "the", "need", "for", "oral", "steroid", "use", "in", "adult", "patients", "with", "severe", ",", "persistent", "asthma", "."], "event_mentions": [{"id": "16685007_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduces", "start": 1, "end": 2}, "arguments": [{"entity_id": "16685007_1_Ent2", "role": "Treatment", "text": "Ciclesonide", "start": 0, "end": 1}, {"entity_id": "16685007_1_Ent4", "role": "Treatment_Drug", "text": "Ciclesonide", "start": 0, "end": 1}, {"entity_id": "16685007_1_Ent6", "role": "Treatment_Route", "text": "oral", "start": 5, "end": 6}, {"entity_id": "16685007_1_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 6, "end": 7}, {"entity_id": "16685007_1_Ent1", "role": "Subject_Age", "text": "adult", "start": 9, "end": 10}, {"entity_id": "16685007_1_Ent0", "role": "Subject", "text": "adult patients", "start": 9, "end": 11}, {"entity_id": "16685007_1_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16685007_1_Ent2", "text": "Ciclesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16685007_1_Ent4", "text": "Ciclesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16685007_1_Ent6", "text": "oral", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16685007_1_Ent5", "text": "steroid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16685007_1_Ent1", "text": "adult", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16685007_1_Ent0", "text": "adult patients", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16685007_1_Ent3", "text": "asthma", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16685007_5", "wnd_id": "16685007_5_1", "text": "Adult and adolescent patients ( > or = 12 years old ; n = 141 ) with severe , persistent , oral steroid ( prednisone) - dependent asthma .", "tokens": ["Adult", "and", "adolescent", "patients", "(", ">", "or", "=", "12", "years", "old", ";", "n", "=", "141", ")", "with", "severe", ",", "persistent", ",", "oral", "steroid", "(", "prednisone)", "-", "dependent", "asthma", "."], "event_mentions": [{"id": "16685007_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "dependent", "start": 26, "end": 27}, "arguments": [{"entity_id": "16685007_5_Ent1", "role": "Subject_Age", "text": "Adult and adolescent", "start": 0, "end": 3}, {"entity_id": "16685007_5_Ent0", "role": "Subject", "text": "Adult and adolescent patients", "start": 0, "end": 4}, {"entity_id": "16685007_5_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "16685007_5_Ent3", "role": "Treatment", "text": "oral steroid ( prednisone)", "start": 21, "end": 25}, {"entity_id": "16685007_5_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 22, "end": 23}, {"entity_id": "16685007_5_Ent6", "role": "Treatment_Drug", "text": "prednisone)", "start": 24, "end": 25}, {"entity_id": "16685007_5_Ent2", "role": "Effect", "text": "asthma", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16685007_5_Ent1", "text": "Adult and adolescent", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16685007_5_Ent0", "text": "Adult and adolescent patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16685007_5_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16685007_5_Ent3", "text": "oral steroid ( prednisone)", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16685007_5_Ent5", "text": "steroid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16685007_5_Ent6", "text": "prednisone)", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16685007_5_Ent2", "text": "asthma", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16685112_3", "wnd_id": "16685112_3_1", "text": "Gemcitabine - induced rectus abdominus radiation recall .", "tokens": ["Gemcitabine", "-", "induced", "rectus", "abdominus", "radiation", "recall", "."], "event_mentions": [{"id": "16685112_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16685112_3_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16685112_3_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16685112_3_Ent0", "role": "Effect", "text": "rectus abdominus radiation recall", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "16685112_3_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16685112_3_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16685112_3_Ent0", "text": "rectus abdominus radiation recall", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "16697705_2", "wnd_id": "16697705_2_1", "text": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy .", "tokens": ["This", "case", "highlights", "the", "possible", "development", "of", "acute", "coronary", "syndrome", "as", "a", "side", "effect", "of", "Capecitabine", "therapy", "."], "event_mentions": [{"id": "16697705_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "16697705_2_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "16697705_2_Ent1", "role": "Effect", "text": "acute coronary syndrome", "start": 7, "end": 10}, {"entity_id": "16697705_2_Ent2", "role": "Treatment", "text": "Capecitabine", "start": 15, "end": 16}, {"entity_id": "16697705_2_Ent3", "role": "Treatment_Drug", "text": "Capecitabine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16697705_2_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16697705_2_Ent1", "text": "acute coronary syndrome", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16697705_2_Ent2", "text": "Capecitabine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16697705_2_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16728538_1", "wnd_id": "16728538_1_1", "text": "After rechallenge with monotherapy pegvisomant , however , the hepatic enzyme disturbances reappeared within a few weeks , indicating that most likely pegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis .", "tokens": ["After", "rechallenge", "with", "monotherapy", "pegvisomant", ",", "however", ",", "the", "hepatic", "enzyme", "disturbances", "reappeared", "within", "a", "few", "weeks", ",", "indicating", "that", "most", "likely", "pegvisomant", "alone", "and", "not", "the", "long", "-", "acting", "somatostatin", "analog", "or", "the", "combination", "of", "these", "two", "drugs", "was", "responsible", "for", "this", "case", "of", "drug", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "16728538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 40, "end": 41}, "arguments": [{"entity_id": "16728538_1_Ent0", "role": "Effect", "text": "hepatic enzyme disturbances reappeared", "start": 9, "end": 13}, {"entity_id": "16728538_1_Ent3", "role": "Treatment_Time_elapsed", "text": "within a few weeks", "start": 13, "end": 17}, {"entity_id": "16728538_1_Ent2", "role": "Treatment", "text": "pegvisomant", "start": 22, "end": 23}, {"entity_id": "16728538_1_Ent4", "role": "Treatment_Drug", "text": "pegvisomant", "start": 22, "end": 23}, {"entity_id": "16728538_1_Ent1", "role": "Effect", "text": "hepatitis", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "16728538_1_Ent0", "text": "hepatic enzyme disturbances reappeared", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16728538_1_Ent3", "text": "within a few weeks", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16728538_1_Ent2", "text": "pegvisomant", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16728538_1_Ent4", "text": "pegvisomant", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16728538_1_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "16757971_2", "wnd_id": "16757971_2_1", "text": "Listeria brain abscess , Pneumocystis pneumonia and Kaposi 's sarcoma after temozolomide .", "tokens": ["Listeria", "brain", "abscess", ",", "Pneumocystis", "pneumonia", "and", "Kaposi", "'s", "sarcoma", "after", "temozolomide", "."], "event_mentions": [{"id": "16757971_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "16757971_2_Ent0", "role": "Effect", "text": "Listeria brain abscess , Pneumocystis pneumonia and Kaposi 's sarcoma", "start": 0, "end": 10}, {"entity_id": "16757971_2_Ent1", "role": "Treatment", "text": "temozolomide", "start": 11, "end": 12}, {"entity_id": "16757971_2_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16757971_2_Ent0", "text": "Listeria brain abscess , Pneumocystis pneumonia and Kaposi 's sarcoma", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "16757971_2_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16757971_2_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16791713_1", "wnd_id": "16791713_1_1", "text": "Acute myocardial infarction during high - dose methylprednisolone therapy for Graves ' ophthalmopathy .", "tokens": ["Acute", "myocardial", "infarction", "during", "high", "-", "dose", "methylprednisolone", "therapy", "for", "Graves", "'", "ophthalmopathy", "."], "event_mentions": [{"id": "16791713_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "16791713_1_Ent0", "role": "Effect", "text": "Acute myocardial infarction", "start": 0, "end": 3}, {"entity_id": "16791713_1_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "16791713_1_Ent1", "role": "Treatment", "text": "high - dose methylprednisolone therapy", "start": 4, "end": 9}, {"entity_id": "16791713_1_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 7, "end": 8}, {"entity_id": "16791713_1_Ent3", "role": "Treatment_Disorder", "text": "Graves ' ophthalmopathy", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "16791713_1_Ent0", "text": "Acute myocardial infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16791713_1_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16791713_1_Ent1", "text": "high - dose methylprednisolone therapy", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16791713_1_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16791713_1_Ent3", "text": "Graves ' ophthalmopathy", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "16791713_2", "wnd_id": "16791713_2_1", "text": "Except hypothyroidism after radioiodine treatment ( euthyroid under substitutional therapy ) , she suffered from no other diseases .", "tokens": ["Except", "hypothyroidism", "after", "radioiodine", "treatment", "(", "euthyroid", "under", "substitutional", "therapy", ")", ",", "she", "suffered", "from", "no", "other", "diseases", "."], "event_mentions": [{"id": "16791713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "16791713_2_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 1, "end": 2}, {"entity_id": "16791713_2_Ent4", "role": "Treatment_Drug", "text": "radioiodine", "start": 3, "end": 4}, {"entity_id": "16791713_2_Ent3", "role": "Treatment", "text": "radioiodine treatment ( euthyroid under substitutional therapy )", "start": 3, "end": 11}, {"entity_id": "16791713_2_Ent0", "role": "Subject", "text": "she", "start": 12, "end": 13}, {"entity_id": "16791713_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16791713_2_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16791713_2_Ent4", "text": "radioiodine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16791713_2_Ent3", "text": "radioiodine treatment ( euthyroid under substitutional therapy )", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "16791713_2_Ent0", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16791713_2_Ent1", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16791713_4", "wnd_id": "16791713_4_1", "text": "We conclude that myocardial infarction may develop in patients treated with high - dose glucocorticoids for Graves ' ophthalmopathy , and increased blood pressure may herald this complication .", "tokens": ["We", "conclude", "that", "myocardial", "infarction", "may", "develop", "in", "patients", "treated", "with", "high", "-", "dose", "glucocorticoids", "for", "Graves", "'", "ophthalmopathy", ",", "and", "increased", "blood", "pressure", "may", "herald", "this", "complication", "."], "event_mentions": [{"id": "16791713_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 6, "end": 7}, "arguments": [{"entity_id": "16791713_4_Ent1", "role": "Effect", "text": "myocardial infarction", "start": 3, "end": 5}, {"entity_id": "16791713_4_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "16791713_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "16791713_4_Ent3", "role": "Treatment", "text": "high - dose glucocorticoids", "start": 11, "end": 15}, {"entity_id": "16791713_4_Ent4", "role": "Treatment_Drug", "text": "glucocorticoids", "start": 14, "end": 15}, {"entity_id": "16791713_4_Ent6", "role": "Treatment_Disorder", "text": "Graves ' ophthalmopathy", "start": 16, "end": 19}, {"entity_id": "16791713_4_Ent2", "role": "Effect", "text": "increased blood pressure", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "16791713_4_Ent1", "text": "myocardial infarction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16791713_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16791713_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16791713_4_Ent3", "text": "high - dose glucocorticoids", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16791713_4_Ent4", "text": "glucocorticoids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16791713_4_Ent6", "text": "Graves ' ophthalmopathy", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16791713_4_Ent2", "text": "increased blood pressure", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "1680596_2", "wnd_id": "1680596_2_1", "text": "Psoriasis - like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy .", "tokens": ["Psoriasis", "-", "like", "skin", "reaction", "in", "a", "patient", "with", "rheumatoid", "arthritis", "after", "sulphasalazine", "therapy", "."], "event_mentions": [{"id": "1680596_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "1680596_2_Ent1", "role": "Effect", "text": "Psoriasis - like skin reaction", "start": 0, "end": 5}, {"entity_id": "1680596_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 6, "end": 11}, {"entity_id": "1680596_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}, {"entity_id": "1680596_2_Ent4", "role": "Treatment_Dosage", "text": "sulphasalazine", "start": 12, "end": 13}, {"entity_id": "1680596_2_Ent2", "role": "Treatment", "text": "sulphasalazine therapy", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1680596_2_Ent1", "text": "Psoriasis - like skin reaction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1680596_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "1680596_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1680596_2_Ent4", "text": "sulphasalazine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1680596_2_Ent2", "text": "sulphasalazine therapy", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16816519_2", "wnd_id": "16816519_2_1", "text": "We describe a 5 - year - old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment .", "tokens": ["We", "describe", "a", "5", "-", "year", "-", "old", "girl", "showed", "recovery", "of", "vincristine", "induced", "cranial", "polyneuropathy", "with", "pyridoxine", "and", "pyridostigmine", "treatment", "."], "event_mentions": [{"id": "16816519_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 16, "end": 17}, "arguments": [{"entity_id": "16816519_2_Ent0", "role": "Subject", "text": "a 5 - year - old girl", "start": 2, "end": 9}, {"entity_id": "16816519_2_Ent1", "role": "Subject_Age", "text": "5 - year - old", "start": 3, "end": 8}, {"entity_id": "16816519_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 8, "end": 9}, {"entity_id": "16816519_2_Ent3", "role": "Effect", "text": "recovery of vincristine induced cranial polyneuropathy", "start": 10, "end": 16}, {"entity_id": "16816519_2_Ent5", "role": "Treatment_Drug", "text": "pyridoxine", "start": 17, "end": 18}, {"entity_id": "16816519_2_Ent8", "role": "Combination_Drug", "text": "pyridoxine", "start": 17, "end": 18}, {"entity_id": "16816519_2_Ent4", "role": "Treatment", "text": "pyridoxine and pyridostigmine treatment", "start": 17, "end": 21}, {"entity_id": "16816519_2_Ent6", "role": "Treatment_Drug", "text": "pyridostigmine", "start": 19, "end": 20}, {"entity_id": "16816519_2_Ent7", "role": "Combination_Drug", "text": "pyridostigmine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16816519_2_Ent0", "text": "a 5 - year - old girl", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "16816519_2_Ent1", "text": "5 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16816519_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16816519_2_Ent3", "text": "recovery of vincristine induced cranial polyneuropathy", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "16816519_2_Ent5", "text": "pyridoxine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16816519_2_Ent8", "text": "pyridoxine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16816519_2_Ent4", "text": "pyridoxine and pyridostigmine treatment", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "16816519_2_Ent6", "text": "pyridostigmine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16816519_2_Ent7", "text": "pyridostigmine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "1688693_3", "wnd_id": "1688693_3_1", "text": "She manifested all the clinical symptoms and signs of caffeine toxicity .", "tokens": ["She", "manifested", "all", "the", "clinical", "symptoms", "and", "signs", "of", "caffeine", "toxicity", "."], "event_mentions": [{"id": "1688693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 1, "end": 2}, "arguments": [{"entity_id": "1688693_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent2", "role": "Effect", "text": "all the clinical symptoms and signs of caffeine toxicity .", "start": 2, "end": 12}, {"entity_id": "1688693_3_Ent3", "role": "Treatment", "text": "caffeine", "start": 9, "end": 10}, {"entity_id": "1688693_3_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "1688693_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent2", "text": "all the clinical symptoms and signs of caffeine toxicity .", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "1688693_3_Ent3", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1688693_3_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16901609_1", "wnd_id": "16901609_1_1", "text": "Anaphylaxis to intrathecal diamorphine .", "tokens": ["Anaphylaxis", "to", "intrathecal", "diamorphine", "."], "event_mentions": [{"id": "16901609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16901609_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "16901609_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "16901609_1_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 2, "end": 4}, {"entity_id": "16901609_1_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16901609_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16901609_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16901609_1_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16901609_1_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16923659_6", "wnd_id": "16923659_6_1", "text": "METHOD : Case analysis of a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine ) presenting with mixed SS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings .", "tokens": ["METHOD", ":", "Case", "analysis", "of", "a", "poly", "-", "drug", "overdose", "(", "venlafaxine", ",", "topiramate", ",", "divalproex", "sodium", ",", "risperidone", ",", "and", "carbamazepine", ")", "presenting", "with", "mixed", "SS", "/", "NMS", "features", "and", "whose", "clinical", "management", "suggests", "a", "practical", "algorithm", "for", "treatment", "of", "undifferentiated", "SS", "/", "NMS", "in", "critical", "care", "settings", "."], "event_mentions": [{"id": "16923659_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 23, "end": 24}, "arguments": [{"entity_id": "16923659_6_Ent1", "role": "Treatment", "text": "a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine )", "start": 5, "end": 23}, {"entity_id": "16923659_6_Ent7", "role": "Treatment_Dosage", "text": "overdose", "start": 9, "end": 10}, {"entity_id": "16923659_6_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 11, "end": 12}, {"entity_id": "16923659_6_Ent3", "role": "Treatment_Drug", "text": "topiramate", "start": 13, "end": 14}, {"entity_id": "16923659_6_Ent4", "role": "Treatment_Drug", "text": "divalproex sodium", "start": 15, "end": 17}, {"entity_id": "16923659_6_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 18, "end": 19}, {"entity_id": "16923659_6_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 21, "end": 22}, {"entity_id": "16923659_6_Ent0", "role": "Effect", "text": "mixed SS / NMS features", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "16923659_6_Ent1", "text": "a poly - drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and carbamazepine )", "entity_type": "Entity", "start": 5, "end": 23}, {"id": "16923659_6_Ent7", "text": "overdose", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16923659_6_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16923659_6_Ent3", "text": "topiramate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16923659_6_Ent4", "text": "divalproex sodium", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16923659_6_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16923659_6_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16923659_6_Ent0", "text": "mixed SS / NMS features", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "16948177_3", "wnd_id": "16948177_3_1", "text": "This is the first reported case of BOOP associated with single - agent rituximab , and along with two other patients we describe , as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations , strengthens the possibility of a causal relationship .", "tokens": ["This", "is", "the", "first", "reported", "case", "of", "BOOP", "associated", "with", "single", "-", "agent", "rituximab", ",", "and", "along", "with", "two", "other", "patients", "we", "describe", ",", "as", "well", "as", "two", "prior", "reports", "of", "BOOP", "in", "NHL", "patients", "receiving", "rituximab", "-", "based", "combinations", ",", "strengthens", "the", "possibility", "of", "a", "causal", "relationship", "."], "event_mentions": [{"id": "16948177_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "16948177_3_Ent0", "role": "Effect", "text": "BOOP", "start": 7, "end": 8}, {"entity_id": "16948177_3_Ent1", "role": "Treatment", "text": "single - agent rituximab", "start": 10, "end": 14}, {"entity_id": "16948177_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16948177_3_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16948177_3_Ent1", "text": "single - agent rituximab", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16948177_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16960880_1", "wnd_id": "16960880_1_1", "text": "Despite a very low complication rate , several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms .", "tokens": ["Despite", "a", "very", "low", "complication", "rate", ",", "several", "severe", "arterial", "thrombotic", "events", "have", "been", "reported", "following", "thrombin", "injection", "of", "pseudoaneurysms", "."], "event_mentions": [{"id": "16960880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "16960880_1_Ent0", "role": "Effect", "text": "arterial thrombotic", "start": 9, "end": 11}, {"entity_id": "16960880_1_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 16, "end": 17}, {"entity_id": "16960880_1_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 16, "end": 18}, {"entity_id": "16960880_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 17, "end": 18}, {"entity_id": "16960880_1_Ent4", "role": "Treatment_Disorder", "text": "pseudoaneurysms", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16960880_1_Ent0", "text": "arterial thrombotic", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16960880_1_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16960880_1_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16960880_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16960880_1_Ent4", "text": "pseudoaneurysms", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16960880_2", "wnd_id": "16960880_2_1", "text": "Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm .", "tokens": ["Lower", "extremity", "arterial", "thrombosis", "following", "sonographically", "guided", "thrombin", "injection", "of", "a", "femoral", "pseudoaneurysm", "."], "event_mentions": [{"id": "16960880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "16960880_2_Ent0", "role": "Effect", "text": "Lower extremity arterial thrombosis", "start": 0, "end": 4}, {"entity_id": "16960880_2_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 7, "end": 8}, {"entity_id": "16960880_2_Ent1", "role": "Treatment", "text": "thrombin injection of a femoral pseudoaneurysm", "start": 7, "end": 13}, {"entity_id": "16960880_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "16960880_2_Ent4", "role": "Treatment_Disorder", "text": "femoral pseudoaneurysm", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "16960880_2_Ent0", "text": "Lower extremity arterial thrombosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16960880_2_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16960880_2_Ent1", "text": "thrombin injection of a femoral pseudoaneurysm", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "16960880_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16960880_2_Ent4", "text": "femoral pseudoaneurysm", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "16968538_1", "wnd_id": "16968538_1_1", "text": "Hemolytic uremic syndrome following the infusion of oxaliplatin : case report .", "tokens": ["Hemolytic", "uremic", "syndrome", "following", "the", "infusion", "of", "oxaliplatin", ":", "case", "report", "."], "event_mentions": [{"id": "16968538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "16968538_1_Ent0", "role": "Effect", "text": "Hemolytic uremic syndrome", "start": 0, "end": 3}, {"entity_id": "16968538_1_Ent1", "role": "Treatment", "text": "oxaliplatin", "start": 7, "end": 8}, {"entity_id": "16968538_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16968538_1_Ent0", "text": "Hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16968538_1_Ent1", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16968538_1_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16978752_3", "wnd_id": "16978752_3_1", "text": "Second , we report a case of neutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide .", "tokens": ["Second", ",", "we", "report", "a", "case", "of", "neutropenia", ",", "which", "proved", "to", "be", "fatal", "in", "a", "schizophrenia", "patient", "receiving", "olanzapine", "and", "thiazide", "."], "event_mentions": [{"id": "16978752_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "16978752_3_Ent1", "role": "Effect", "text": "neutropenia", "start": 7, "end": 8}, {"entity_id": "16978752_3_Ent0", "role": "Subject", "text": "a schizophrenia patient", "start": 15, "end": 18}, {"entity_id": "16978752_3_Ent3", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "16978752_3_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent2", "role": "Treatment", "text": "olanzapine and thiazide", "start": 19, "end": 22}, {"entity_id": "16978752_3_Ent5", "role": "Treatment_Drug", "text": "thiazide", "start": 21, "end": 22}, {"entity_id": "16978752_3_Ent7", "role": "Combination_Drug", "text": "thiazide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16978752_3_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16978752_3_Ent0", "text": "a schizophrenia patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16978752_3_Ent3", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16978752_3_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent2", "text": "olanzapine and thiazide", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16978752_3_Ent5", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16978752_3_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17034541_1", "wnd_id": "17034541_1_1", "text": "Late lethal hepatitis B virus reactivation after rituximab treatment of low - grade cutaneous B - cell lymphoma .", "tokens": ["Late", "lethal", "hepatitis", "B", "virus", "reactivation", "after", "rituximab", "treatment", "of", "low", "-", "grade", "cutaneous", "B", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "17034541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "17034541_1_Ent0", "role": "Effect", "text": "Late lethal hepatitis B virus reactivation", "start": 0, "end": 6}, {"entity_id": "17034541_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent2", "role": "Treatment_Disorder", "text": "low - grade cutaneous B - cell lymphoma", "start": 10, "end": 18}]}], "entity_mentions": [{"id": "17034541_1_Ent0", "text": "Late lethal hepatitis B virus reactivation", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17034541_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent2", "text": "low - grade cutaneous B - cell lymphoma", "entity_type": "Entity", "start": 10, "end": 18}], "lang": "en"}
{"doc_id": "17060191_3", "wnd_id": "17060191_3_1", "text": "Hypoxia is a predisposing factor for premature ductal closure and often occurs after maternal indomethacin therapy .", "tokens": ["Hypoxia", "is", "a", "predisposing", "factor", "for", "premature", "ductal", "closure", "and", "often", "occurs", "after", "maternal", "indomethacin", "therapy", "."], "event_mentions": [{"id": "17060191_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17060191_3_Ent0", "role": "Effect", "text": "premature ductal closure", "start": 6, "end": 9}, {"entity_id": "17060191_3_Ent3", "role": "Treatment_Route", "text": "maternal", "start": 13, "end": 14}, {"entity_id": "17060191_3_Ent1", "role": "Treatment", "text": "maternal indomethacin therapy", "start": 13, "end": 16}, {"entity_id": "17060191_3_Ent2", "role": "Treatment_Drug", "text": "indomethacin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "17060191_3_Ent0", "text": "premature ductal closure", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17060191_3_Ent3", "text": "maternal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17060191_3_Ent1", "text": "maternal indomethacin therapy", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17060191_3_Ent2", "text": "indomethacin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "17068466_1", "wnd_id": "17068466_1_1", "text": "CONCLUSION : These cases suggest that moxifloxacin may interfere with the healing of corneal ulcers .", "tokens": ["CONCLUSION", ":", "These", "cases", "suggest", "that", "moxifloxacin", "may", "interfere", "with", "the", "healing", "of", "corneal", "ulcers", "."], "event_mentions": [{"id": "17068466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interfere", "start": 8, "end": 9}, "arguments": [{"entity_id": "17068466_1_Ent0", "role": "Subject", "text": "These cases", "start": 2, "end": 4}, {"entity_id": "17068466_1_Ent2", "role": "Treatment", "text": "moxifloxacin", "start": 6, "end": 7}, {"entity_id": "17068466_1_Ent3", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 6, "end": 7}, {"entity_id": "17068466_1_Ent1", "role": "Effect", "text": "interfere with the healing of corneal ulcers", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "17068466_1_Ent0", "text": "These cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17068466_1_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17068466_1_Ent3", "text": "moxifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17068466_1_Ent1", "text": "interfere with the healing of corneal ulcers", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "17083890_4", "wnd_id": "17083890_4_1", "text": "We describe a 52 - year - old male diagnosed with stage III multiple myeloma , who was treated with 5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone ) .", "tokens": ["We", "describe", "a", "52", "-", "year", "-", "old", "male", "diagnosed", "with", "stage", "III", "multiple", "myeloma", ",", "who", "was", "treated", "with", "5", "-", "monthly", "cycles", "of", "VAD", "(", "vincristine", ",", "adriamycin", "and", "dexamathasone", ")", "."], "event_mentions": [{"id": "17083890_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 18, "end": 19}, "arguments": [{"entity_id": "17083890_4_Ent0", "role": "Subject", "text": "a 52 - year - old male", "start": 2, "end": 9}, {"entity_id": "17083890_4_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 3, "end": 8}, {"entity_id": "17083890_4_Ent2", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "17083890_4_Ent4", "role": "Treatment_Disorder", "text": "stage III multiple myeloma", "start": 11, "end": 15}, {"entity_id": "17083890_4_Ent5", "role": "Treatment_Duration", "text": "5 - monthly", "start": 20, "end": 23}, {"entity_id": "17083890_4_Ent3", "role": "Treatment", "text": "5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone )", "start": 20, "end": 33}, {"entity_id": "17083890_4_Ent6", "role": "Treatment_Drug", "text": "vincristine", "start": 27, "end": 28}, {"entity_id": "17083890_4_Ent9", "role": "Combination_Drug", "text": "vincristine", "start": 27, "end": 28}, {"entity_id": "17083890_4_Ent7", "role": "Treatment_Drug", "text": "adriamycin", "start": 29, "end": 30}, {"entity_id": "17083890_4_Ent10", "role": "Combination_Drug", "text": "adriamycin", "start": 29, "end": 30}, {"entity_id": "17083890_4_Ent8", "role": "Treatment_Drug", "text": "dexamathasone", "start": 31, "end": 32}, {"entity_id": "17083890_4_Ent11", "role": "Combination_Drug", "text": "dexamathasone", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "17083890_4_Ent0", "text": "a 52 - year - old male", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "17083890_4_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17083890_4_Ent2", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17083890_4_Ent4", "text": "stage III multiple myeloma", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "17083890_4_Ent5", "text": "5 - monthly", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "17083890_4_Ent3", "text": "5 - monthly cycles of VAD ( vincristine , adriamycin and dexamathasone )", "entity_type": "Entity", "start": 20, "end": 33}, {"id": "17083890_4_Ent6", "text": "vincristine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17083890_4_Ent9", "text": "vincristine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17083890_4_Ent7", "text": "adriamycin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17083890_4_Ent10", "text": "adriamycin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17083890_4_Ent8", "text": "dexamathasone", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "17083890_4_Ent11", "text": "dexamathasone", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "17083890_8", "wnd_id": "17083890_8_1", "text": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy , which further pointed out towards adriamycin and vincristine as possible etiologic agents .", "tokens": ["All", "changes", "disappeared", "4", "months", "after", "the", "discontinuation", "of", "VAD", "chemotherapy", ",", "which", "further", "pointed", "out", "towards", "adriamycin", "and", "vincristine", "as", "possible", "etiologic", "agents", "."], "event_mentions": [{"id": "17083890_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "etiologic agents", "start": 22, "end": 24}, "arguments": [{"entity_id": "17083890_8_Ent0", "role": "Effect", "text": "All changes", "start": 0, "end": 2}, {"entity_id": "17083890_8_Ent2", "role": "Treatment_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent4", "role": "Combination_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent1", "role": "Treatment", "text": "adriamycin and vincristine", "start": 17, "end": 20}, {"entity_id": "17083890_8_Ent3", "role": "Treatment_Drug", "text": "vincristine", "start": 19, "end": 20}, {"entity_id": "17083890_8_Ent5", "role": "Combination_Drug", "text": "vincristine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17083890_8_Ent0", "text": "All changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17083890_8_Ent2", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent4", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent1", "text": "adriamycin and vincristine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17083890_8_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17083890_8_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17090724_3", "wnd_id": "17090724_3_1", "text": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient .", "tokens": ["Use", "of", "the", "Naranjo", "probability", "scale", "indicated", "a", "highly", "probable", "relationship", "between", "the", "observed", "cardiac", "toxicity", "and", "amphotericin", "B", "deoxycholate", "therapy", "in", "this", "patient", "."], "event_mentions": [{"id": "17090724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 10, "end": 11}, "arguments": [{"entity_id": "17090724_3_Ent1", "role": "Effect", "text": "cardiac toxicity", "start": 14, "end": 16}, {"entity_id": "17090724_3_Ent2", "role": "Treatment", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent3", "role": "Treatment_Drug", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17090724_3_Ent1", "text": "cardiac toxicity", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17090724_3_Ent2", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent3", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "1711090_6", "wnd_id": "1711090_6_1", "text": "The main side - effects of Lp - TAE combined with HT were low - grade fever , localized pain , myelo - suppression and liver dysfunction , but these were transient and eventually disappeared .", "tokens": ["The", "main", "side", "-", "effects", "of", "Lp", "-", "TAE", "combined", "with", "HT", "were", "low", "-", "grade", "fever", ",", "localized", "pain", ",", "myelo", "-", "suppression", "and", "liver", "dysfunction", ",", "but", "these", "were", "transient", "and", "eventually", "disappeared", "."], "event_mentions": [{"id": "1711090_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effects", "start": 2, "end": 5}, "arguments": [{"entity_id": "1711090_6_Ent2", "role": "Treatment_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_6_Ent4", "role": "Combination_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_6_Ent1", "role": "Treatment", "text": "Lp - TAE combined with HT", "start": 6, "end": 12}, {"entity_id": "1711090_6_Ent3", "role": "Treatment_Drug", "text": "HT", "start": 11, "end": 12}, {"entity_id": "1711090_6_Ent5", "role": "Combination_Drug", "text": "HT", "start": 11, "end": 12}, {"entity_id": "1711090_6_Ent0", "role": "Effect", "text": "low - grade fever , localized pain , myelo - suppression and liver dysfunction", "start": 13, "end": 27}]}], "entity_mentions": [{"id": "1711090_6_Ent2", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_6_Ent4", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_6_Ent1", "text": "Lp - TAE combined with HT", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "1711090_6_Ent3", "text": "HT", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1711090_6_Ent5", "text": "HT", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1711090_6_Ent0", "text": "low - grade fever , localized pain , myelo - suppression and liver dysfunction", "entity_type": "Entity", "start": 13, "end": 27}], "lang": "en"}
{"doc_id": "17122225_2", "wnd_id": "17122225_2_1", "text": "Serotonin syndrome is a potentially lethal adverse drug reaction that may occur in patients taking proserotoninergic medications .", "tokens": ["Serotonin", "syndrome", "is", "a", "potentially", "lethal", "adverse", "drug", "reaction", "that", "may", "occur", "in", "patients", "taking", "proserotoninergic", "medications", "."], "event_mentions": [{"id": "17122225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 11, "end": 12}, "arguments": [{"entity_id": "17122225_2_Ent1", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_2_Ent4", "role": "Treatment_Disorder", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}, {"entity_id": "17122225_2_Ent3", "role": "Treatment_Drug", "text": "proserotoninergic", "start": 15, "end": 16}, {"entity_id": "17122225_2_Ent2", "role": "Treatment", "text": "proserotoninergic medications", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17122225_2_Ent1", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_2_Ent4", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_2_Ent3", "text": "proserotoninergic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_2_Ent2", "text": "proserotoninergic medications", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17123120_1", "wnd_id": "17123120_1_1", "text": "Tacrolimus - induced HUS : an unusual cause of acute renal failure in nephrotic syndrome .", "tokens": ["Tacrolimus", "-", "induced", "HUS", ":", "an", "unusual", "cause", "of", "acute", "renal", "failure", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17123120_1_Ent1", "role": "Treatment", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent0", "role": "Effect", "text": "HUS", "start": 3, "end": 4}, {"entity_id": "17123120_1_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_1_Ent1", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent0", "text": "HUS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17123120_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17123120_2", "wnd_id": "17123120_2_1", "text": "Thus , tacrolimus - induced HUS is a rare cause of ARF in nephrotic syndrome .", "tokens": ["Thus", ",", "tacrolimus", "-", "induced", "HUS", "is", "a", "rare", "cause", "of", "ARF", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17123120_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent0", "role": "Effect", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "17123120_2_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17123120_2_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17133571_1", "wnd_id": "17133571_1_1", "text": "Liver transplantation for fulminant hepatitis related to nevirapine therapy .", "tokens": ["Liver", "transplantation", "for", "fulminant", "hepatitis", "related", "to", "nevirapine", "therapy", "."], "event_mentions": [{"id": "17133571_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "17133571_1_Ent0", "role": "Effect", "text": "Liver transplantation for fulminant hepatitis", "start": 0, "end": 5}, {"entity_id": "17133571_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 7, "end": 8}, {"entity_id": "17133571_1_Ent1", "role": "Treatment", "text": "nevirapine therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17133571_1_Ent0", "text": "Liver transplantation for fulminant hepatitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17133571_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17133571_1_Ent1", "text": "nevirapine therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17163271_3", "wnd_id": "17163271_3_1", "text": "The use of cyclosporin has been associated with the development of cholelithiasis in transplant recipients .", "tokens": ["The", "use", "of", "cyclosporin", "has", "been", "associated", "with", "the", "development", "of", "cholelithiasis", "in", "transplant", "recipients", "."], "event_mentions": [{"id": "17163271_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "17163271_3_Ent3", "role": "Treatment", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "17163271_3_Ent4", "role": "Treatment_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "17163271_3_Ent2", "role": "Effect", "text": "cholelithiasis", "start": 11, "end": 12}, {"entity_id": "17163271_3_Ent1", "role": "Subject_Disorder", "text": "transplant", "start": 13, "end": 14}, {"entity_id": "17163271_3_Ent0", "role": "Subject", "text": "transplant recipients", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17163271_3_Ent3", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17163271_3_Ent4", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17163271_3_Ent2", "text": "cholelithiasis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17163271_3_Ent1", "text": "transplant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17163271_3_Ent0", "text": "transplant recipients", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17182354_2", "wnd_id": "17182354_2_1", "text": "Large dose of methylphenidate may cause cataract and glaucoma .", "tokens": ["Large", "dose", "of", "methylphenidate", "may", "cause", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "17182354_2_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 3, "end": 4}, {"entity_id": "17182354_2_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "17182354_2_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17182354_2_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "17182354_4", "wnd_id": "17182354_4_1", "text": "We report a case of Ritalin - associated cataract and glaucoma .", "tokens": ["We", "report", "a", "case", "of", "Ritalin", "-", "associated", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17182354_4_Ent1", "role": "Treatment", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_4_Ent2", "role": "Treatment_Drug", "text": "Ritalin", "start": 5, "end": 6}, {"entity_id": "17182354_4_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "17182354_4_Ent1", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_4_Ent2", "text": "Ritalin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17182354_4_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "17188061_1", "wnd_id": "17188061_1_1", "text": "CONCLUSIONS : We report a typical symptoms of Charles - Bonnet syndrome ( CBS ) in patients with severe AMD after intravitreal Avastin - injections .", "tokens": ["CONCLUSIONS", ":", "We", "report", "a", "typical", "symptoms", "of", "Charles", "-", "Bonnet", "syndrome", "(", "CBS", ")", "in", "patients", "with", "severe", "AMD", "after", "intravitreal", "Avastin", "-", "injections", "."], "event_mentions": [{"id": "17188061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17188061_1_Ent1", "role": "Effect", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "start": 5, "end": 15}, {"entity_id": "17188061_1_Ent0", "role": "Subject", "text": "patients with severe AMD", "start": 16, "end": 20}, {"entity_id": "17188061_1_Ent6", "role": "Treatment_Disorder", "text": "AMD", "start": 19, "end": 20}, {"entity_id": "17188061_1_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 21, "end": 22}, {"entity_id": "17188061_1_Ent2", "role": "Treatment", "text": "intravitreal Avastin - injections", "start": 21, "end": 25}, {"entity_id": "17188061_1_Ent3", "role": "Treatment_Drug", "text": "Avastin", "start": 22, "end": 23}, {"entity_id": "17188061_1_Ent5", "role": "Treatment_Route", "text": "injections", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17188061_1_Ent1", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "17188061_1_Ent0", "text": "patients with severe AMD", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17188061_1_Ent6", "text": "AMD", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17188061_1_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17188061_1_Ent2", "text": "intravitreal Avastin - injections", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17188061_1_Ent3", "text": "Avastin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17188061_1_Ent5", "text": "injections", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17189581_16", "wnd_id": "17189581_16_1", "text": "Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine .", "tokens": ["Serotonin", "syndrome", "developed", "in", "a", "patient", "taking", "concurrent", "linezolid", "and", "fluoxetine", "."], "event_mentions": [{"id": "17189581_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "17189581_16_Ent1", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17189581_16_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "17189581_16_Ent2", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 7, "end": 11}, {"entity_id": "17189581_16_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent5", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 10, "end": 11}, {"entity_id": "17189581_16_Ent6", "role": "Combination_Drug", "text": "fluoxetine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17189581_16_Ent1", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17189581_16_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17189581_16_Ent2", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "17189581_16_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent5", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17189581_16_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17189581_3", "wnd_id": "17189581_3_1", "text": "A 23 - year - old white male patient was originally admitted to receive intravenous chemotherapy for acute myelogenous leukemia .", "tokens": ["A", "23", "-", "year", "-", "old", "white", "male", "patient", "was", "originally", "admitted", "to", "receive", "intravenous", "chemotherapy", "for", "acute", "myelogenous", "leukemia", "."], "event_mentions": [{"id": "17189581_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 13, "end": 14}, "arguments": [{"entity_id": "17189581_3_Ent0", "role": "Subject", "text": "A 23 - year - old white male patient", "start": 0, "end": 9}, {"entity_id": "17189581_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 1, "end": 6}, {"entity_id": "17189581_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "17189581_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "17189581_3_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "17189581_3_Ent4", "role": "Treatment", "text": "intravenous chemotherapy", "start": 14, "end": 16}, {"entity_id": "17189581_3_Ent5", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "17189581_3_Ent6", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "17189581_3_Ent0", "text": "A 23 - year - old white male patient", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17189581_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17189581_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17189581_3_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17189581_3_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17189581_3_Ent4", "text": "intravenous chemotherapy", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17189581_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17189581_3_Ent6", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "17189581_7", "wnd_id": "17189581_7_1", "text": "Despite treatment with levofloxacin , acyclovir , and voriconazole , the patient developed high fevers .", "tokens": ["Despite", "treatment", "with", "levofloxacin", ",", "acyclovir", ",", "and", "voriconazole", ",", "the", "patient", "developed", "high", "fevers", "."], "event_mentions": [{"id": "17189581_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "17189581_7_Ent3", "role": "Treatment_Drug", "text": "levofloxacin", "start": 3, "end": 4}, {"entity_id": "17189581_7_Ent2", "role": "Treatment", "text": "levofloxacin , acyclovir , and voriconazole", "start": 3, "end": 9}, {"entity_id": "17189581_7_Ent4", "role": "Treatment_Drug", "text": "acyclovir", "start": 5, "end": 6}, {"entity_id": "17189581_7_Ent5", "role": "Treatment_Drug", "text": "voriconazole", "start": 8, "end": 9}, {"entity_id": "17189581_7_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "17189581_7_Ent1", "role": "Effect", "text": "high fevers", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17189581_7_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17189581_7_Ent2", "text": "levofloxacin , acyclovir , and voriconazole", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "17189581_7_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17189581_7_Ent5", "text": "voriconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_7_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17189581_7_Ent1", "text": "high fevers", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17195428_1", "wnd_id": "17195428_1_1", "text": "A case of metoclopramide - induced oculogyric crisis in a 16 - year - old girl with cystic fibrosis .", "tokens": ["A", "case", "of", "metoclopramide", "-", "induced", "oculogyric", "crisis", "in", "a", "16", "-", "year", "-", "old", "girl", "with", "cystic", "fibrosis", "."], "event_mentions": [{"id": "17195428_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17195428_1_Ent5", "role": "Treatment", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "17195428_1_Ent6", "role": "Treatment_Drug", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "17195428_1_Ent4", "role": "Effect", "text": "oculogyric crisis", "start": 6, "end": 8}, {"entity_id": "17195428_1_Ent0", "role": "Subject", "text": "a 16 - year - old girl with cystic fibrosis", "start": 9, "end": 19}, {"entity_id": "17195428_1_Ent2", "role": "Subject_Age", "text": "16 - year - old", "start": 10, "end": 15}, {"entity_id": "17195428_1_Ent3", "role": "Subject_Gender", "text": "girl", "start": 15, "end": 16}, {"entity_id": "17195428_1_Ent1", "role": "Subject_Disorder", "text": "cystic fibrosis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "17195428_1_Ent5", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17195428_1_Ent6", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17195428_1_Ent4", "text": "oculogyric crisis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17195428_1_Ent0", "text": "a 16 - year - old girl with cystic fibrosis", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "17195428_1_Ent2", "text": "16 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "17195428_1_Ent3", "text": "girl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17195428_1_Ent1", "text": "cystic fibrosis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "172214_1", "wnd_id": "172214_1_1", "text": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin - D and mithramycin .", "tokens": ["Cardiomyopathy", "after", "widely", "separated", "courses", "of", "adriamycin", "exacerbated", "by", "actinomycin", "-", "D", "and", "mithramycin", "."], "event_mentions": [{"id": "172214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 7, "end": 8}, "arguments": [{"entity_id": "172214_1_Ent0", "role": "Effect", "text": "Cardiomyopathy", "start": 0, "end": 1}, {"entity_id": "172214_1_Ent2", "role": "Treatment", "text": "widely separated courses of adriamycin", "start": 2, "end": 7}, {"entity_id": "172214_1_Ent4", "role": "Treatment_Drug", "text": "adriamycin", "start": 6, "end": 7}, {"entity_id": "172214_1_Ent7", "role": "Combination_Drug", "text": "adriamycin", "start": 6, "end": 7}, {"entity_id": "172214_1_Ent1", "role": "Effect", "text": "exacerbated", "start": 7, "end": 8}, {"entity_id": "172214_1_Ent5", "role": "Treatment_Drug", "text": "actinomycin - D", "start": 9, "end": 12}, {"entity_id": "172214_1_Ent8", "role": "Combination_Drug", "text": "actinomycin - D", "start": 9, "end": 12}, {"entity_id": "172214_1_Ent3", "role": "Treatment", "text": "actinomycin - D and mithramycin", "start": 9, "end": 14}, {"entity_id": "172214_1_Ent6", "role": "Treatment_Drug", "text": "mithramycin", "start": 13, "end": 14}, {"entity_id": "172214_1_Ent9", "role": "Combination_Drug", "text": "mithramycin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "172214_1_Ent0", "text": "Cardiomyopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "172214_1_Ent2", "text": "widely separated courses of adriamycin", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "172214_1_Ent4", "text": "adriamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "172214_1_Ent7", "text": "adriamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "172214_1_Ent1", "text": "exacerbated", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "172214_1_Ent5", "text": "actinomycin - D", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "172214_1_Ent8", "text": "actinomycin - D", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "172214_1_Ent3", "text": "actinomycin - D and mithramycin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "172214_1_Ent6", "text": "mithramycin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "172214_1_Ent9", "text": "mithramycin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17224428_1", "wnd_id": "17224428_1_1", "text": "Cardiac hypersensitivity and myopericarditis have been reported during long - term treatment with mesalazine .", "tokens": ["Cardiac", "hypersensitivity", "and", "myopericarditis", "have", "been", "reported", "during", "long", "-", "term", "treatment", "with", "mesalazine", "."], "event_mentions": [{"id": "17224428_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "17224428_1_Ent0", "role": "Effect", "text": "Cardiac hypersensitivity and myopericarditis", "start": 0, "end": 4}, {"entity_id": "17224428_1_Ent2", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "17224428_1_Ent1", "role": "Treatment", "text": "long - term treatment with mesalazine", "start": 8, "end": 14}, {"entity_id": "17224428_1_Ent3", "role": "Treatment_Drug", "text": "mesalazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17224428_1_Ent0", "text": "Cardiac hypersensitivity and myopericarditis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17224428_1_Ent2", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17224428_1_Ent1", "text": "long - term treatment with mesalazine", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17224428_1_Ent3", "text": "mesalazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17228132_1", "wnd_id": "17228132_1_1", "text": "Acute drug induced hepatitis due to erlotinib .", "tokens": ["Acute", "drug", "induced", "hepatitis", "due", "to", "erlotinib", "."], "event_mentions": [{"id": "17228132_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 4, "end": 5}, "arguments": [{"entity_id": "17228132_1_Ent0", "role": "Effect", "text": "Acute drug induced hepatitis", "start": 0, "end": 4}, {"entity_id": "17228132_1_Ent1", "role": "Treatment", "text": "erlotinib", "start": 6, "end": 7}, {"entity_id": "17228132_1_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17228132_1_Ent0", "text": "Acute drug induced hepatitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17228132_1_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17228132_1_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1722991_2", "wnd_id": "1722991_2_1", "text": "Heparin - associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy .", "tokens": ["Heparin", "-", "associated", "thrombocytopenia", "and", "thrombosis", "is", "a", "severe", "complication", "of", "systemic", "heparin", "therapy", "."], "event_mentions": [{"id": "1722991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1722991_2_Ent1", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1722991_2_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "1722991_2_Ent0", "role": "Effect", "text": "thrombocytopenia and thrombosis", "start": 3, "end": 6}, {"entity_id": "1722991_2_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1722991_2_Ent1", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1722991_2_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1722991_2_Ent0", "text": "thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1722991_2_Ent3", "text": "heparin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17260498_2", "wnd_id": "17260498_2_1", "text": "Taxanes are widely used chemotherapeutic agents with the potential to induce pulmonary injury through a variety of mechanisms .", "tokens": ["Taxanes", "are", "widely", "used", "chemotherapeutic", "agents", "with", "the", "potential", "to", "induce", "pulmonary", "injury", "through", "a", "variety", "of", "mechanisms", "."], "event_mentions": [{"id": "17260498_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 10, "end": 11}, "arguments": [{"entity_id": "17260498_2_Ent1", "role": "Treatment", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent2", "role": "Treatment_Drug", "text": "Taxanes", "start": 0, "end": 1}, {"entity_id": "17260498_2_Ent0", "role": "Effect", "text": "pulmonary injury", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "17260498_2_Ent1", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent2", "text": "Taxanes", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17260498_2_Ent0", "text": "pulmonary injury", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "17266059_2", "wnd_id": "17266059_2_1", "text": "Thrombotic thrombocytopenic purpura induced by trimethoprim - sulfamethoxazole in a Jehovah 's Witness .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "induced", "by", "trimethoprim", "-", "sulfamethoxazole", "in", "a", "Jehovah", "'s", "Witness", "."], "event_mentions": [{"id": "17266059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17266059_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura", "start": 0, "end": 3}, {"entity_id": "17266059_2_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent0", "role": "Subject", "text": "a Jehovah 's Witness", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "17266059_2_Ent1", "text": "Thrombotic thrombocytopenic purpura", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17266059_2_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent3", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent0", "text": "a Jehovah 's Witness", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "17329303_10", "wnd_id": "17329303_10_1", "text": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate .", "tokens": ["Functional", "regulation", "of", "certain", "neuroreceptors", "during", "risperidone", "treatment", "may", "lead", "to", "altered", "behavioural", "responses", "upon", "switching", "to", "methylphenidate", "."], "event_mentions": [{"id": "17329303_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 9, "end": 10}, "arguments": [{"entity_id": "17329303_10_Ent1", "role": "Treatment", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent0", "role": "Effect", "text": "altered behavioural responses", "start": 11, "end": 14}, {"entity_id": "17329303_10_Ent2", "role": "Treatment", "text": "switching to methylphenidate", "start": 15, "end": 18}, {"entity_id": "17329303_10_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17329303_10_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent0", "text": "altered behavioural responses", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17329303_10_Ent2", "text": "switching to methylphenidate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17329303_10_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17329303_5", "wnd_id": "17329303_5_1", "text": "He developed severe hyperactivity and agitation on taking methylphenidate after the discontinuation of risperidone treatment .", "tokens": ["He", "developed", "severe", "hyperactivity", "and", "agitation", "on", "taking", "methylphenidate", "after", "the", "discontinuation", "of", "risperidone", "treatment", "."], "event_mentions": [{"id": "17329303_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "17329303_5_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "17329303_5_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "17329303_5_Ent2", "role": "Effect", "text": "hyperactivity and agitation", "start": 3, "end": 6}, {"entity_id": "17329303_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "17329303_5_Ent3", "role": "Treatment", "text": "methylphenidate after the discontinuation of risperidone", "start": 8, "end": 14}, {"entity_id": "17329303_5_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17329303_5_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17329303_5_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17329303_5_Ent2", "text": "hyperactivity and agitation", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17329303_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17329303_5_Ent3", "text": "methylphenidate after the discontinuation of risperidone", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17329303_5_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17329303_6", "wnd_id": "17329303_6_1", "text": "The second patient was a girl of 6 , already on risperidone for ADHD and borderline intellectual functioning when referred .", "tokens": ["The", "second", "patient", "was", "a", "girl", "of", "6", ",", "already", "on", "risperidone", "for", "ADHD", "and", "borderline", "intellectual", "functioning", "when", "referred", "."], "event_mentions": [{"id": "17329303_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "on", "start": 10, "end": 11}, "arguments": [{"entity_id": "17329303_6_Ent0", "role": "Subject", "text": "a girl of 6", "start": 4, "end": 8}, {"entity_id": "17329303_6_Ent1", "role": "Subject_Gender", "text": "girl", "start": 5, "end": 6}, {"entity_id": "17329303_6_Ent2", "role": "Subject_Age", "text": "6", "start": 7, "end": 8}, {"entity_id": "17329303_6_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent5", "role": "Treatment_Disorder", "text": "ADHD", "start": 13, "end": 14}, {"entity_id": "17329303_6_Ent6", "role": "Treatment_Disorder", "text": "borderline intellectual functioning", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "17329303_6_Ent0", "text": "a girl of 6", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_6_Ent1", "text": "girl", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17329303_6_Ent2", "text": "6", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent5", "text": "ADHD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17329303_6_Ent6", "text": "borderline intellectual functioning", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "17329303_9", "wnd_id": "17329303_9_1", "text": "In all the cases described here , it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug - free interval .", "tokens": ["In", "all", "the", "cases", "described", "here", ",", "it", "is", "only", "with", "the", "discontinuation", "of", "methylphenidate", "that", "the", "adverse", "reactions", "resolved", "and", "readministration", "of", "methylphenidate", "in", "two", "patients", "did", "not", "produce", "any", "adverse", "effect", "after", "a", "drug", "-", "free", "interval", "."], "event_mentions": [{"id": "17329303_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 19, "end": 20}, "arguments": [{"entity_id": "17329303_9_Ent1", "role": "Treatment", "text": "discontinuation of methylphenidate", "start": 12, "end": 15}, {"entity_id": "17329303_9_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 14, "end": 15}, {"entity_id": "17329303_9_Ent0", "role": "Effect", "text": "adverse reactions", "start": 17, "end": 19}]}, {"id": "17329303_9_Evt1", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 29, "end": 30}, "arguments": [{"entity_id": "17329303_9_Ent6", "role": "Treatment", "text": "methylphenidate", "start": 23, "end": 24}, {"entity_id": "17329303_9_Ent7", "role": "Treatment_Drug", "text": "methylphenidate", "start": 23, "end": 24}, {"entity_id": "17329303_9_Ent4", "role": "Subject_Population", "text": "two", "start": 25, "end": 26}, {"entity_id": "17329303_9_Ent3", "role": "Subject", "text": "two patients", "start": 25, "end": 27}, {"entity_id": "17329303_9_Ent5", "role": "Effect", "text": "adverse effect after a drug - free interval", "start": 31, "end": 39}]}], "entity_mentions": [{"id": "17329303_9_Ent1", "text": "discontinuation of methylphenidate", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17329303_9_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17329303_9_Ent0", "text": "adverse reactions", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17329303_9_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17329303_9_Ent7", "text": "methylphenidate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17329303_9_Ent4", "text": "two", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17329303_9_Ent3", "text": "two patients", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17329303_9_Ent5", "text": "adverse effect after a drug - free interval", "entity_type": "Entity", "start": 31, "end": 39}], "lang": "en"}
{"doc_id": "17352036_3", "wnd_id": "17352036_3_1", "text": "Under the suspicion of amiodarone - induced acute pancreatitis , amiodarone was substituted by propafenone .", "tokens": ["Under", "the", "suspicion", "of", "amiodarone", "-", "induced", "acute", "pancreatitis", ",", "amiodarone", "was", "substituted", "by", "propafenone", "."], "event_mentions": [{"id": "17352036_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "17352036_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17352036_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17387702_2", "wnd_id": "17387702_2_1", "text": "We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented renal failure following the second cycle of high - dose methotrexate ( HDMTX ) .", "tokens": ["We", "report", "the", "case", "of", "an", "11", "-", "year", "-", "old", "female", "treated", "for", "mediastinal", "T", "-", "cell", "lymphoma", "who", "presented", "renal", "failure", "following", "the", "second", "cycle", "of", "high", "-", "dose", "methotrexate", "(", "HDMTX", ")", "."], "event_mentions": [{"id": "17387702_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 20, "end": 21}, "arguments": [{"entity_id": "17387702_2_Ent0", "role": "Subject", "text": "an 11 - year - old female treated for mediastinal T - cell lymphoma", "start": 5, "end": 19}, {"entity_id": "17387702_2_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 6, "end": 11}, {"entity_id": "17387702_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "17387702_2_Ent8", "role": "Treatment_Disorder", "text": "mediastinal T - cell lymphoma", "start": 14, "end": 19}, {"entity_id": "17387702_2_Ent3", "role": "Effect", "text": "renal failure", "start": 21, "end": 23}, {"entity_id": "17387702_2_Ent4", "role": "Treatment", "text": "following the second cycle of high - dose methotrexate ( HDMTX )", "start": 23, "end": 35}, {"entity_id": "17387702_2_Ent6", "role": "Treatment_Freq", "text": "second cycle", "start": 25, "end": 27}, {"entity_id": "17387702_2_Ent7", "role": "Treatment_Dosage", "text": "high - dose", "start": 28, "end": 31}, {"entity_id": "17387702_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate ( HDMTX )", "start": 31, "end": 35}]}], "entity_mentions": [{"id": "17387702_2_Ent0", "text": "an 11 - year - old female treated for mediastinal T - cell lymphoma", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "17387702_2_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17387702_2_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17387702_2_Ent8", "text": "mediastinal T - cell lymphoma", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "17387702_2_Ent3", "text": "renal failure", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17387702_2_Ent4", "text": "following the second cycle of high - dose methotrexate ( HDMTX )", "entity_type": "Entity", "start": 23, "end": 35}, {"id": "17387702_2_Ent6", "text": "second cycle", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17387702_2_Ent7", "text": "high - dose", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "17387702_2_Ent5", "text": "methotrexate ( HDMTX )", "entity_type": "Entity", "start": 31, "end": 35}], "lang": "en"}
{"doc_id": "17404582_1", "wnd_id": "17404582_1_1", "text": "Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past .", "tokens": ["Docetaxel", "induced", "Meibomian", "duct", "inflammation", "and", "blockage", "is", "the", "likely", "cause", "of", "this", "presentation", "in", "a", "patient", "with", "no", "history", "of", "eyelid", "masses", "in", "the", "past", "."], "event_mentions": [{"id": "17404582_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "17404582_1_Ent2", "role": "Treatment", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent3", "role": "Treatment_Drug", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_1_Ent1", "role": "Effect", "text": "Meibomian duct inflammation and blockage", "start": 2, "end": 7}, {"entity_id": "17404582_1_Ent0", "role": "Subject", "text": "a patient with no history of eyelid masses in the past", "start": 15, "end": 26}]}], "entity_mentions": [{"id": "17404582_1_Ent2", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent3", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_1_Ent1", "text": "Meibomian duct inflammation and blockage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "17404582_1_Ent0", "text": "a patient with no history of eyelid masses in the past", "entity_type": "Entity", "start": 15, "end": 26}], "lang": "en"}
{"doc_id": "17406804_2", "wnd_id": "17406804_2_1", "text": "After having received gemcitabine on day 1 of the second course , the patient developed dry cough , subfebrile temperatures and dyspnea within 48 h.", "tokens": ["After", "having", "received", "gemcitabine", "on", "day", "1", "of", "the", "second", "course", ",", "the", "patient", "developed", "dry", "cough", ",", "subfebrile", "temperatures", "and", "dyspnea", "within", "48", "h."], "event_mentions": [{"id": "17406804_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "17406804_2_Ent2", "role": "Treatment", "text": "received gemcitabine on day 1 of the second course", "start": 2, "end": 11}, {"entity_id": "17406804_2_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 3, "end": 4}, {"entity_id": "17406804_2_Ent0", "role": "Subject", "text": "the patient", "start": 12, "end": 14}, {"entity_id": "17406804_2_Ent1", "role": "Effect", "text": "dry cough , subfebrile temperatures and dyspnea within 48 h.", "start": 15, "end": 25}, {"entity_id": "17406804_2_Ent4", "role": "Treatment_Time_elapsed", "text": "within 48 h.", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "17406804_2_Ent2", "text": "received gemcitabine on day 1 of the second course", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "17406804_2_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17406804_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "17406804_2_Ent1", "text": "dry cough , subfebrile temperatures and dyspnea within 48 h.", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "17406804_2_Ent4", "text": "within 48 h.", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "17406804_4", "wnd_id": "17406804_4_1", "text": "Radiation recall pneumonitis induced by gemcitabine .", "tokens": ["Radiation", "recall", "pneumonitis", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "17406804_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17406804_4_Ent0", "role": "Effect", "text": "Radiation recall pneumonitis", "start": 0, "end": 3}, {"entity_id": "17406804_4_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 5, "end": 6}, {"entity_id": "17406804_4_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17406804_4_Ent0", "text": "Radiation recall pneumonitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17406804_4_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17406804_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17420198_10", "wnd_id": "17420198_10_1", "text": "Facial , tongue , and arm movements were first reported approximately five weeks after the initiation of aripiprazole .", "tokens": ["Facial", ",", "tongue", ",", "and", "arm", "movements", "were", "first", "reported", "approximately", "five", "weeks", "after", "the", "initiation", "of", "aripiprazole", "."], "event_mentions": [{"id": "17420198_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "17420198_10_Ent0", "role": "Effect", "text": "Facial , tongue , and arm movements", "start": 0, "end": 7}, {"entity_id": "17420198_10_Ent2", "role": "Treatment_Time_elapsed", "text": "five weeks", "start": 11, "end": 13}, {"entity_id": "17420198_10_Ent1", "role": "Treatment", "text": "initiation of aripiprazole", "start": 15, "end": 18}, {"entity_id": "17420198_10_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17420198_10_Ent0", "text": "Facial , tongue , and arm movements", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17420198_10_Ent2", "text": "five weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17420198_10_Ent1", "text": "initiation of aripiprazole", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17420198_10_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17420198_18", "wnd_id": "17420198_18_1", "text": "Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder .", "tokens": ["Aripiprazole", "was", "subsequently", "discontinued", "secondary", "to", "its", "lack", "of", "efficacy", "for", "OCD", "and", "the", "development", "of", "a", "movement", "disorder", "."], "event_mentions": [{"id": "17420198_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 14, "end": 15}, "arguments": [{"entity_id": "17420198_18_Ent1", "role": "Treatment", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent3", "role": "Treatment_Drug", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent2", "role": "Treatment_Disorder", "text": "OCD", "start": 11, "end": 12}, {"entity_id": "17420198_18_Ent0", "role": "Effect", "text": "a movement disorder", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "17420198_18_Ent1", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent3", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent2", "text": "OCD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_18_Ent0", "text": "a movement disorder", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "17420198_8", "wnd_id": "17420198_8_1", "text": "Baclofen and oxazepam were prescribed secondary to right - sided hemiparesis contractures .", "tokens": ["Baclofen", "and", "oxazepam", "were", "prescribed", "secondary", "to", "right", "-", "sided", "hemiparesis", "contractures", "."], "event_mentions": [{"id": "17420198_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 4, "end": 5}, "arguments": [{"entity_id": "17420198_8_Ent1", "role": "Treatment", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent3", "role": "Treatment_Drug", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent6", "role": "Combination_Drug", "text": "Baclofen", "start": 0, "end": 1}, {"entity_id": "17420198_8_Ent0", "role": "Treatment", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent4", "role": "Treatment_Drug", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent5", "role": "Combination_Drug", "text": "oxazepam", "start": 2, "end": 3}, {"entity_id": "17420198_8_Ent2", "role": "Treatment_Disorder", "text": "right - sided hemiparesis contractures", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17420198_8_Ent1", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent3", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent6", "text": "Baclofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_8_Ent0", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent4", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent5", "text": "oxazepam", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17420198_8_Ent2", "text": "right - sided hemiparesis contractures", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17448102_4", "wnd_id": "17448102_4_1", "text": "Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias .", "tokens": ["Hypertonic", "sodium", "bicarbonate", "is", "recognized", "as", "effective", "therapy", "for", "hypotension", "and", "arrhythmias", "."], "event_mentions": [{"id": "17448102_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 6, "end": 7}, "arguments": [{"entity_id": "17448102_4_Ent0", "role": "Treatment", "text": "Hypertonic sodium bicarbonate", "start": 0, "end": 3}, {"entity_id": "17448102_4_Ent2", "role": "Treatment_Drug", "text": "sodium bicarbonate", "start": 1, "end": 3}, {"entity_id": "17448102_4_Ent1", "role": "Treatment_Disorder", "text": "hypotension and arrhythmias", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17448102_4_Ent0", "text": "Hypertonic sodium bicarbonate", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17448102_4_Ent2", "text": "sodium bicarbonate", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17448102_4_Ent1", "text": "hypotension and arrhythmias", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17473920_1", "wnd_id": "17473920_1_1", "text": "Pharmacokinetics of methadone in human - immunodeficiency - virus - infected patients receiving nevirapine once daily .", "tokens": ["Pharmacokinetics", "of", "methadone", "in", "human", "-", "immunodeficiency", "-", "virus", "-", "infected", "patients", "receiving", "nevirapine", "once", "daily", "."], "event_mentions": [{"id": "17473920_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 12, "end": 13}, "arguments": [{"entity_id": "17473920_1_Ent1", "role": "Treatment", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent6", "role": "Treatment_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent8", "role": "Combination_Drug", "text": "methadone", "start": 2, "end": 3}, {"entity_id": "17473920_1_Ent3", "role": "Treatment_Disorder", "text": "human - immunodeficiency - virus", "start": 4, "end": 9}, {"entity_id": "17473920_1_Ent0", "role": "Subject", "text": "human - immunodeficiency - virus - infected patients", "start": 4, "end": 12}, {"entity_id": "17473920_1_Ent5", "role": "Treatment_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent7", "role": "Combination_Drug", "text": "nevirapine", "start": 13, "end": 14}, {"entity_id": "17473920_1_Ent2", "role": "Treatment", "text": "nevirapine once daily", "start": 13, "end": 16}, {"entity_id": "17473920_1_Ent4", "role": "Treatment_Freq", "text": "once daily", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "17473920_1_Ent1", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent6", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent8", "text": "methadone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_1_Ent3", "text": "human - immunodeficiency - virus", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17473920_1_Ent0", "text": "human - immunodeficiency - virus - infected patients", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "17473920_1_Ent5", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent7", "text": "nevirapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17473920_1_Ent2", "text": "nevirapine once daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17473920_1_Ent4", "text": "once daily", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "17504225_3", "wnd_id": "17504225_3_1", "text": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae .", "tokens": ["In", "this", "paper", "it", "is", "reported", "an", "evidence", "of", "pharmacokinetic", "interaction", "between", "clarithromycin", "and", "sirolimus", "in", "a", "kidney", "transplanted", "woman", ",", "suffering", "from", "pulmonary", "infection", "sustained", "by", "a", "bacterial", "pathogen", ",", "in", "particular", "Hemophilus", "Influenzae", "."], "event_mentions": [{"id": "17504225_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 11, "end": 12}, "arguments": [{"entity_id": "17504225_3_Ent3", "role": "Effect", "text": "pharmacokinetic interaction", "start": 9, "end": 11}, {"entity_id": "17504225_3_Ent5", "role": "Treatment_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent8", "role": "Combination_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent4", "role": "Treatment", "text": "clarithromycin and sirolimus", "start": 12, "end": 15}, {"entity_id": "17504225_3_Ent6", "role": "Treatment_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent9", "role": "Combination_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent0", "role": "Subject", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "start": 16, "end": 35}, {"entity_id": "17504225_3_Ent1", "role": "Subject_Disorder", "text": "kidney transplanted", "start": 17, "end": 19}, {"entity_id": "17504225_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "17504225_3_Ent7", "role": "Treatment_Disorder", "text": "pulmonary infection", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "17504225_3_Ent3", "text": "pharmacokinetic interaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17504225_3_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent4", "text": "clarithromycin and sirolimus", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17504225_3_Ent6", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent9", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent0", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "entity_type": "Entity", "start": 16, "end": 35}, {"id": "17504225_3_Ent1", "text": "kidney transplanted", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17504225_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17504225_3_Ent7", "text": "pulmonary infection", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "17505739_1", "wnd_id": "17505739_1_1", "text": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient .", "tokens": ["Intravitreal", "triamcinolone", "may", "have", "had", "an", "influence", "on", "the", "exacerbation", "of", "retinochoroiditis", "in", "the", "posterior", "pole", "of", "the", "patient", "."], "event_mentions": [{"id": "17505739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "influence", "start": 6, "end": 7}, "arguments": [{"entity_id": "17505739_1_Ent4", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "17505739_1_Ent2", "role": "Treatment", "text": "Intravitreal triamcinolone", "start": 0, "end": 2}, {"entity_id": "17505739_1_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 1, "end": 2}, {"entity_id": "17505739_1_Ent1", "role": "Effect", "text": "exacerbation of retinochoroiditis in the posterior pole", "start": 9, "end": 16}, {"entity_id": "17505739_1_Ent0", "role": "Subject", "text": "the patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "17505739_1_Ent4", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17505739_1_Ent2", "text": "Intravitreal triamcinolone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17505739_1_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17505739_1_Ent1", "text": "exacerbation of retinochoroiditis in the posterior pole", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17505739_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "1751354_1", "wnd_id": "1751354_1_1", "text": "Psoriasis induced by interferon - alpha .", "tokens": ["Psoriasis", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "1751354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "1751354_1_Ent0", "role": "Effect", "text": "Psoriasis", "start": 0, "end": 1}, {"entity_id": "1751354_1_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 3, "end": 6}, {"entity_id": "1751354_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "1751354_1_Ent0", "text": "Psoriasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1751354_1_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1751354_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "1751354_2", "wnd_id": "1751354_2_1", "text": "Recombinant human interferon - alpha has been used in the treatment of several cancers , but there have been several reports that it may exacerbate psoriasis or trigger off its onset .", "tokens": ["Recombinant", "human", "interferon", "-", "alpha", "has", "been", "used", "in", "the", "treatment", "of", "several", "cancers", ",", "but", "there", "have", "been", "several", "reports", "that", "it", "may", "exacerbate", "psoriasis", "or", "trigger", "off", "its", "onset", "."], "event_mentions": [{"id": "1751354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 27, "end": 28}, "arguments": [{"entity_id": "1751354_2_Ent1", "role": "Treatment", "text": "Recombinant human interferon - alpha", "start": 0, "end": 5}, {"entity_id": "1751354_2_Ent2", "role": "Treatment_Drug", "text": "Recombinant human interferon - alpha", "start": 0, "end": 5}, {"entity_id": "1751354_2_Ent3", "role": "Treatment_Disorder", "text": "cancers", "start": 13, "end": 14}, {"entity_id": "1751354_2_Ent0", "role": "Effect", "text": "exacerbate psoriasis", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "1751354_2_Ent1", "text": "Recombinant human interferon - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1751354_2_Ent2", "text": "Recombinant human interferon - alpha", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1751354_2_Ent3", "text": "cancers", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1751354_2_Ent0", "text": "exacerbate psoriasis", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "17522786_1", "wnd_id": "17522786_1_1", "text": "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( VPA ) intoxication .", "tokens": ["INTRODUCTION", ":", "We", "describe", "the", "neurointensive", "care", "(", "NIC", ")", "management", "of", "a", "patient", "with", "severe", "cerebral", "swelling", "and", "raised", "intracranial", "pressure", "(", "ICP", ")", "after", "severe", "sodium", "valproic", "acid", "(", "VPA", ")", "intoxication", "."], "event_mentions": [{"id": "17522786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "17522786_1_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "17522786_1_Ent1", "role": "Effect", "text": "severe cerebral swelling and raised intracranial pressure ( ICP )", "start": 15, "end": 25}, {"entity_id": "17522786_1_Ent4", "role": "Treatment_Drug", "text": "sodium valproic acid", "start": 27, "end": 30}, {"entity_id": "17522786_1_Ent3", "role": "Treatment", "text": "sodium valproic acid ( VPA )", "start": 27, "end": 33}, {"entity_id": "17522786_1_Ent2", "role": "Effect", "text": "intoxication", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "17522786_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17522786_1_Ent1", "text": "severe cerebral swelling and raised intracranial pressure ( ICP )", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "17522786_1_Ent4", "text": "sodium valproic acid", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "17522786_1_Ent3", "text": "sodium valproic acid ( VPA )", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "17522786_1_Ent2", "text": "intoxication", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "17526968_3", "wnd_id": "17526968_3_1", "text": "We report a child with yolk sac tumor who developed localized pigmentation after the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin .", "tokens": ["We", "report", "a", "child", "with", "yolk", "sac", "tumor", "who", "developed", "localized", "pigmentation", "after", "the", "first", "course", "of", "chemotherapy", "regimen", "that", "included", "cisplatin", ",", "etoposide", "and", "bleomycin", "."], "event_mentions": [{"id": "17526968_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17526968_3_Ent0", "role": "Subject", "text": "a child with yolk sac tumor", "start": 2, "end": 8}, {"entity_id": "17526968_3_Ent1", "role": "Subject_Age", "text": "child", "start": 3, "end": 4}, {"entity_id": "17526968_3_Ent8", "role": "Treatment_Disorder", "text": "yolk sac tumor", "start": 5, "end": 8}, {"entity_id": "17526968_3_Ent2", "role": "Effect", "text": "localized pigmentation", "start": 10, "end": 12}, {"entity_id": "17526968_3_Ent4", "role": "Treatment_Duration", "text": "the first course", "start": 13, "end": 16}, {"entity_id": "17526968_3_Ent3", "role": "Treatment", "text": "the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin", "start": 13, "end": 26}, {"entity_id": "17526968_3_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "17526968_3_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "17526968_3_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 23, "end": 24}, {"entity_id": "17526968_3_Ent10", "role": "Combination_Drug", "text": "etoposide", "start": 23, "end": 24}, {"entity_id": "17526968_3_Ent7", "role": "Treatment_Drug", "text": "bleomycin", "start": 25, "end": 26}, {"entity_id": "17526968_3_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17526968_3_Ent0", "text": "a child with yolk sac tumor", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17526968_3_Ent1", "text": "child", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17526968_3_Ent8", "text": "yolk sac tumor", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17526968_3_Ent2", "text": "localized pigmentation", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17526968_3_Ent4", "text": "the first course", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17526968_3_Ent3", "text": "the first course of chemotherapy regimen that included cisplatin , etoposide and bleomycin", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "17526968_3_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17526968_3_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17526968_3_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_3_Ent10", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_3_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17526968_3_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "17526968_4", "wnd_id": "17526968_4_1", "text": "The hyperpigmentation was diffuse scattered , flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin .", "tokens": ["The", "hyperpigmentation", "was", "diffuse", "scattered", ",", "flagellate", "like", "and", "linear", "streaking", "which", "was", "thought", "to", "be", "mainly", "related", "to", "the", "skin", "toxicity", "of", "bleomycin", "."], "event_mentions": [{"id": "17526968_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 21, "end": 22}, "arguments": [{"entity_id": "17526968_4_Ent0", "role": "Effect", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "start": 1, "end": 11}, {"entity_id": "17526968_4_Ent1", "role": "Treatment", "text": "bleomycin", "start": 23, "end": 24}, {"entity_id": "17526968_4_Ent2", "role": "Treatment_Drug", "text": "bleomycin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17526968_4_Ent0", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "17526968_4_Ent1", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_4_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17536204_1", "wnd_id": "17536204_1_1", "text": "A cause - effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge .", "tokens": ["A", "cause", "-", "effect", "relationship", "to", "capecitabine", "was", "suggested", "due", "to", "resolution", "of", "headache", "with", "capecitabine", "withdrawal", "and", "reappearance", "with", "capecitabine", "rechallenge", "."], "event_mentions": [{"id": "17536204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship to", "start": 4, "end": 6}, "arguments": [{"entity_id": "17536204_1_Ent1", "role": "Treatment", "text": "capecitabine", "start": 6, "end": 7}, {"entity_id": "17536204_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 6, "end": 7}, {"entity_id": "17536204_1_Ent0", "role": "Effect", "text": "headache", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17536204_1_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17536204_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17536204_1_Ent0", "text": "headache", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17536204_2", "wnd_id": "17536204_2_1", "text": "BACKGROUND : Headaches have been reported as a potential side effect of capecitabine therapy .", "tokens": ["BACKGROUND", ":", "Headaches", "have", "been", "reported", "as", "a", "potential", "side", "effect", "of", "capecitabine", "therapy", "."], "event_mentions": [{"id": "17536204_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 11, "end": 12}, "arguments": [{"entity_id": "17536204_2_Ent0", "role": "Effect", "text": "Headaches", "start": 2, "end": 3}, {"entity_id": "17536204_2_Ent1", "role": "Treatment", "text": "capecitabine", "start": 12, "end": 13}, {"entity_id": "17536204_2_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17536204_2_Ent0", "text": "Headaches", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17536204_2_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17536204_2_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17547624_2", "wnd_id": "17547624_2_1", "text": "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels .", "tokens": ["We", "report", "a", "case", "of", "ST", "elevation", "in", "right", "precordial", "leads", "compatible", "with", "type", "1", "Brugada", "syndrome", "following", "administration", "of", "propafenone", "in", "a", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "who", "was", "receiving", "lithium", "at", "concentrations", "within", "therapeutic", "levels", "."], "event_mentions": [{"id": "17547624_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 17, "end": 18}, "arguments": [{"entity_id": "17547624_2_Ent1", "role": "Effect", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "start": 5, "end": 17}, {"entity_id": "17547624_2_Ent2", "role": "Treatment", "text": "administration of propafenone", "start": 18, "end": 21}, {"entity_id": "17547624_2_Ent4", "role": "Treatment_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent0", "role": "Subject", "text": "a patient with Wolff - Parkinson - White syndrome", "start": 22, "end": 31}, {"entity_id": "17547624_2_Ent6", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 25, "end": 31}, {"entity_id": "17547624_2_Ent3", "role": "Treatment", "text": "receiving lithium at concentrations within therapeutic levels", "start": 33, "end": 40}, {"entity_id": "17547624_2_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 34, "end": 35}, {"entity_id": "17547624_2_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "17547624_2_Ent1", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "17547624_2_Ent2", "text": "administration of propafenone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17547624_2_Ent4", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent0", "text": "a patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "17547624_2_Ent6", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17547624_2_Ent3", "text": "receiving lithium at concentrations within therapeutic levels", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "17547624_2_Ent5", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17547624_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "17556909_1", "wnd_id": "17556909_1_1", "text": "Bortezomib - induced paralytic ileus is a potential gastrointestinal side effect of this first - in - class anticancer proteasome inhibitor .", "tokens": ["Bortezomib", "-", "induced", "paralytic", "ileus", "is", "a", "potential", "gastrointestinal", "side", "effect", "of", "this", "first", "-", "in", "-", "class", "anticancer", "proteasome", "inhibitor", "."], "event_mentions": [{"id": "17556909_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17556909_1_Ent1", "role": "Treatment", "text": "Bortezomib", "start": 0, "end": 1}, {"entity_id": "17556909_1_Ent2", "role": "Treatment_Drug", "text": "Bortezomib", "start": 0, "end": 1}, {"entity_id": "17556909_1_Ent0", "role": "Effect", "text": "paralytic ileus", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17556909_1_Ent1", "text": "Bortezomib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17556909_1_Ent2", "text": "Bortezomib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17556909_1_Ent0", "text": "paralytic ileus", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1756352_1", "wnd_id": "1756352_1_1", "text": "A woman developed delusional parasitosis when taking phenelzine .", "tokens": ["A", "woman", "developed", "delusional", "parasitosis", "when", "taking", "phenelzine", "."], "event_mentions": [{"id": "1756352_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_1_Ent0", "role": "Subject", "text": "A woman", "start": 0, "end": 2}, {"entity_id": "1756352_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "1756352_1_Ent2", "role": "Effect", "text": "delusional parasitosis", "start": 3, "end": 5}, {"entity_id": "1756352_1_Ent3", "role": "Treatment", "text": "phenelzine", "start": 7, "end": 8}, {"entity_id": "1756352_1_Ent4", "role": "Treatment_Drug", "text": "phenelzine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1756352_1_Ent0", "text": "A woman", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1756352_1_Ent2", "text": "delusional parasitosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1756352_1_Ent3", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1756352_1_Ent4", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1759924_2", "wnd_id": "1759924_2_1", "text": "We report a case of fulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous metoclopramide .", "tokens": ["We", "report", "a", "case", "of", "fulminant", "neuroleptic", "malignant", "syndrome", "in", "a", "man", "aged", "70", "developing", "within", "12", "hours", "of", "starting", "six", "-", "hourly", "intravenous", "metoclopramide", "."], "event_mentions": [{"id": "1759924_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 14, "end": 15}, "arguments": [{"entity_id": "1759924_2_Ent3", "role": "Effect", "text": "fulminant neuroleptic malignant syndrome", "start": 5, "end": 9}, {"entity_id": "1759924_2_Ent0", "role": "Subject", "text": "a man aged 70", "start": 10, "end": 14}, {"entity_id": "1759924_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "1759924_2_Ent2", "role": "Subject_Age", "text": "aged 70", "start": 12, "end": 14}, {"entity_id": "1759924_2_Ent5", "role": "Treatment_Time_elapsed", "text": "within 12 hours", "start": 15, "end": 18}, {"entity_id": "1759924_2_Ent8", "role": "Treatment_Freq", "text": "six - hourly", "start": 20, "end": 23}, {"entity_id": "1759924_2_Ent4", "role": "Treatment", "text": "six - hourly intravenous metoclopramide", "start": 20, "end": 25}, {"entity_id": "1759924_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 23, "end": 24}, {"entity_id": "1759924_2_Ent7", "role": "Treatment_Drug", "text": "metoclopramide", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1759924_2_Ent3", "text": "fulminant neuroleptic malignant syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "1759924_2_Ent0", "text": "a man aged 70", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "1759924_2_Ent1", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1759924_2_Ent2", "text": "aged 70", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1759924_2_Ent5", "text": "within 12 hours", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "1759924_2_Ent8", "text": "six - hourly", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "1759924_2_Ent4", "text": "six - hourly intravenous metoclopramide", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "1759924_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1759924_2_Ent7", "text": "metoclopramide", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17619811_2", "wnd_id": "17619811_2_1", "text": "A case of colchicine - induced rhabdomyolysis is reported .", "tokens": ["A", "case", "of", "colchicine", "-", "induced", "rhabdomyolysis", "is", "reported", "."], "event_mentions": [{"id": "17619811_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17619811_2_Ent1", "role": "Treatment", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17619811_2_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17619811_4", "wnd_id": "17619811_4_1", "text": "Colchicine - induced rhabdomyolysis .", "tokens": ["Colchicine", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "17619811_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17619811_4_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17619811_4_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "17619811_5", "wnd_id": "17619811_5_1", "text": "Investigation confirmed the diagnosis of rhabdomyolysis , and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis .", "tokens": ["Investigation", "confirmed", "the", "diagnosis", "of", "rhabdomyolysis", ",", "and", "discontinuation", "of", "colchicine", "resulted", "in", "resolution", "of", "clinical", "and", "biochemical", "features", "of", "rhabdomylysis", "."], "event_mentions": [{"id": "17619811_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 11, "end": 12}, "arguments": [{"entity_id": "17619811_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "17619811_5_Ent0", "role": "Effect", "text": "rhabdomylysis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17619811_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17619811_5_Ent0", "text": "rhabdomylysis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "1765991_2", "wnd_id": "1765991_2_1", "text": "The development of systemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis .", "tokens": ["The", "development", "of", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "after", "38", "months", "of", "therapy", "with", "recombinant", "human", "interferon", "gamma", "(", "rIFN", "-", "gamma", ")", "was", "observed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "1765991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "1765991_2_Ent1", "role": "Effect", "text": "systemic lupus erythematosus", "start": 3, "end": 6}, {"entity_id": "1765991_2_Ent2", "role": "Treatment", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent4", "role": "Treatment_Time_elapsed", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent3", "role": "Treatment", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent5", "role": "Treatment_Drug", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis .", "start": 27, "end": 33}, {"entity_id": "1765991_2_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "1765991_2_Ent1", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_2_Ent2", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent4", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent3", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent5", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent0", "text": "a patient with rheumatoid arthritis .", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "1765991_2_Ent6", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "17675030_4", "wnd_id": "17675030_4_1", "text": "We describe in detail the first U.S. case report , of a 4(1/2) - year - old boy who experienced angioedema during treatment with oxcarbazepine .", "tokens": ["We", "describe", "in", "detail", "the", "first", "U.S.", "case", "report", ",", "of", "a", "4(1/2)", "-", "year", "-", "old", "boy", "who", "experienced", "angioedema", "during", "treatment", "with", "oxcarbazepine", "."], "event_mentions": [{"id": "17675030_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 22, "end": 23}, "arguments": [{"entity_id": "17675030_4_Ent0", "role": "Subject", "text": "a 4(1/2) - year - old boy", "start": 11, "end": 18}, {"entity_id": "17675030_4_Ent1", "role": "Subject_Age", "text": "4(1/2) - year - old", "start": 12, "end": 17}, {"entity_id": "17675030_4_Ent2", "role": "Subject_Gender", "text": "boy", "start": 17, "end": 18}, {"entity_id": "17675030_4_Ent3", "role": "Effect", "text": "angioedema", "start": 20, "end": 21}, {"entity_id": "17675030_4_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 24, "end": 25}, {"entity_id": "17675030_4_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17675030_4_Ent0", "text": "a 4(1/2) - year - old boy", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "17675030_4_Ent1", "text": "4(1/2) - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "17675030_4_Ent2", "text": "boy", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17675030_4_Ent3", "text": "angioedema", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17675030_4_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17675030_4_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17705565_1", "wnd_id": "17705565_1_1", "text": "Carbamazepine hypersensitivity syndrome is a rare , life - threatening condition .", "tokens": ["Carbamazepine", "hypersensitivity", "syndrome", "is", "a", "rare", ",", "life", "-", "threatening", "condition", "."], "event_mentions": [{"id": "17705565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 3, "end": 4}, "arguments": [{"entity_id": "17705565_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "17705565_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "17705565_1_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 1, "end": 3}]}], "entity_mentions": [{"id": "17705565_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17705565_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17705565_1_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 1, "end": 3}], "lang": "en"}
{"doc_id": "17710018_1", "wnd_id": "17710018_1_1", "text": "A patient with chronic myelomonocytic leukemia developed drug - induced pulmonary toxicity after using low dose oral etoposide .", "tokens": ["A", "patient", "with", "chronic", "myelomonocytic", "leukemia", "developed", "drug", "-", "induced", "pulmonary", "toxicity", "after", "using", "low", "dose", "oral", "etoposide", "."], "event_mentions": [{"id": "17710018_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17710018_1_Ent0", "role": "Subject", "text": "A patient with chronic myelomonocytic leukemia", "start": 0, "end": 6}, {"entity_id": "17710018_1_Ent1", "role": "Subject_Disorder", "text": "chronic myelomonocytic leukemia", "start": 3, "end": 6}, {"entity_id": "17710018_1_Ent2", "role": "Effect", "text": "pulmonary toxicity", "start": 10, "end": 12}, {"entity_id": "17710018_1_Ent3", "role": "Treatment", "text": "using low dose oral etoposide", "start": 13, "end": 18}, {"entity_id": "17710018_1_Ent6", "role": "Treatment_Dosage", "text": "low dose", "start": 14, "end": 16}, {"entity_id": "17710018_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 16, "end": 17}, {"entity_id": "17710018_1_Ent5", "role": "Treatment_Drug", "text": "etoposide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17710018_1_Ent0", "text": "A patient with chronic myelomonocytic leukemia", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17710018_1_Ent1", "text": "chronic myelomonocytic leukemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17710018_1_Ent2", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17710018_1_Ent3", "text": "using low dose oral etoposide", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17710018_1_Ent6", "text": "low dose", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17710018_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17710018_1_Ent5", "text": "etoposide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17710018_3", "wnd_id": "17710018_3_1", "text": "PET scintigraphy of etoposide - induced pulmonary toxicity .", "tokens": ["PET", "scintigraphy", "of", "etoposide", "-", "induced", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17710018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17710018_3_Ent1", "role": "Treatment", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "17710018_3_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "17827338_2", "wnd_id": "17827338_2_1", "text": "Vicriviroc ( SCH 417690 ) , a CCR5 receptor antagonist , is currently under investigation for the treatment of human immunodeficiency virus infection .", "tokens": ["Vicriviroc", "(", "SCH", "417690", ")", ",", "a", "CCR5", "receptor", "antagonist", ",", "is", "currently", "under", "investigation", "for", "the", "treatment", "of", "human", "immunodeficiency", "virus", "infection", "."], "event_mentions": [{"id": "17827338_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 17, "end": 18}, "arguments": [{"entity_id": "17827338_2_Ent2", "role": "Treatment_Drug", "text": "Vicriviroc", "start": 0, "end": 1}, {"entity_id": "17827338_2_Ent0", "role": "Treatment", "text": "Vicriviroc ( SCH 417690 ) , a CCR5 receptor antagonist", "start": 0, "end": 10}, {"entity_id": "17827338_2_Ent1", "role": "Treatment_Disorder", "text": "human immunodeficiency virus infection", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "17827338_2_Ent2", "text": "Vicriviroc", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17827338_2_Ent0", "text": "Vicriviroc ( SCH 417690 ) , a CCR5 receptor antagonist", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "17827338_2_Ent1", "text": "human immunodeficiency virus infection", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "17852449_1", "wnd_id": "17852449_1_1", "text": "Outcome of pregnancy in women treated with all - trans retinoic acid ; a case report and review of literature .", "tokens": ["Outcome", "of", "pregnancy", "in", "women", "treated", "with", "all", "-", "trans", "retinoic", "acid", ";", "a", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "17852449_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17852449_1_Ent4", "role": "Treatment_Disorder", "text": "pregnancy", "start": 2, "end": 3}, {"entity_id": "17852449_1_Ent0", "role": "Subject", "text": "pregnancy in women", "start": 2, "end": 5}, {"entity_id": "17852449_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 4, "end": 5}, {"entity_id": "17852449_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 7, "end": 12}, {"entity_id": "17852449_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17852449_1_Ent4", "text": "pregnancy", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17852449_1_Ent0", "text": "pregnancy in women", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17852449_1_Ent1", "text": "women", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17852449_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17852449_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17852449_2", "wnd_id": "17852449_2_1", "text": "All - trans - retinoic acid ( ATRA ) has been proved to be an effective treatment for acute promyelocytic leukemia ( APL ) , inducing remission in more than 90 % of cases .", "tokens": ["All", "-", "trans", "-", "retinoic", "acid", "(", "ATRA", ")", "has", "been", "proved", "to", "be", "an", "effective", "treatment", "for", "acute", "promyelocytic", "leukemia", "(", "APL", ")", ",", "inducing", "remission", "in", "more", "than", "90", "%", "of", "cases", "."], "event_mentions": [{"id": "17852449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "proved", "start": 11, "end": 12}, "arguments": [{"entity_id": "17852449_2_Ent4", "role": "Treatment_Drug", "text": "All - trans - retinoic acid", "start": 0, "end": 6}, {"entity_id": "17852449_2_Ent2", "role": "Treatment", "text": "All - trans - retinoic acid ( ATRA )", "start": 0, "end": 9}, {"entity_id": "17852449_2_Ent3", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia ( APL )", "start": 18, "end": 24}, {"entity_id": "17852449_2_Ent1", "role": "Subject_Population", "text": "more than 90 %", "start": 28, "end": 32}, {"entity_id": "17852449_2_Ent0", "role": "Subject", "text": "more than 90 % of cases", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "17852449_2_Ent4", "text": "All - trans - retinoic acid", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17852449_2_Ent2", "text": "All - trans - retinoic acid ( ATRA )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17852449_2_Ent3", "text": "acute promyelocytic leukemia ( APL )", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "17852449_2_Ent1", "text": "more than 90 %", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "17852449_2_Ent0", "text": "more than 90 % of cases", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "17852449_6", "wnd_id": "17852449_6_1", "text": "Review of all reported cases of the use of ATRA in pregnancy revealed no serious adverse outcomes or congenital anomalies although only very few cases had exposure in the first trimester .", "tokens": ["Review", "of", "all", "reported", "cases", "of", "the", "use", "of", "ATRA", "in", "pregnancy", "revealed", "no", "serious", "adverse", "outcomes", "or", "congenital", "anomalies", "although", "only", "very", "few", "cases", "had", "exposure", "in", "the", "first", "trimester", "."], "event_mentions": [{"id": "17852449_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revealed", "start": 12, "end": 13}, "arguments": [{"entity_id": "17852449_6_Ent3", "role": "Treatment", "text": "ATRA", "start": 9, "end": 10}, {"entity_id": "17852449_6_Ent4", "role": "Treatment_Drug", "text": "ATRA", "start": 9, "end": 10}, {"entity_id": "17852449_6_Ent0", "role": "Subject", "text": "in pregnancy", "start": 10, "end": 12}, {"entity_id": "17852449_6_Ent1", "role": "Subject_Disorder", "text": "pregnancy", "start": 11, "end": 12}, {"entity_id": "17852449_6_Ent2", "role": "Effect", "text": "adverse outcomes or congenital anomalies", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "17852449_6_Ent3", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17852449_6_Ent4", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17852449_6_Ent0", "text": "in pregnancy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17852449_6_Ent1", "text": "pregnancy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17852449_6_Ent2", "text": "adverse outcomes or congenital anomalies", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "17873198_4", "wnd_id": "17873198_4_1", "text": "This case and other published evidence should alert physicians to the possibility of fatal erlotinib - induced ILD .", "tokens": ["This", "case", "and", "other", "published", "evidence", "should", "alert", "physicians", "to", "the", "possibility", "of", "fatal", "erlotinib", "-", "induced", "ILD", "."], "event_mentions": [{"id": "17873198_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "17873198_4_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "17873198_4_Ent2", "role": "Treatment", "text": "erlotinib", "start": 14, "end": 15}, {"entity_id": "17873198_4_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 14, "end": 15}, {"entity_id": "17873198_4_Ent1", "role": "Effect", "text": "ILD", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17873198_4_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17873198_4_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17873198_4_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17873198_4_Ent1", "text": "ILD", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17876386_1", "wnd_id": "17876386_1_1", "text": "It has been reported that fluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause torsade de pointes .", "tokens": ["It", "has", "been", "reported", "that", "fluoroquinolone", "antimicrobials", "prolong", "the", "corrected", "QT", "interval", "but", "rarely", "cause", "torsade", "de", "pointes", "."], "event_mentions": [{"id": "17876386_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "prolong", "start": 7, "end": 8}, "arguments": [{"entity_id": "17876386_1_Ent2", "role": "Treatment_Drug", "text": "fluoroquinolone", "start": 5, "end": 6}, {"entity_id": "17876386_1_Ent1", "role": "Treatment", "text": "fluoroquinolone antimicrobials", "start": 5, "end": 7}, {"entity_id": "17876386_1_Ent0", "role": "Effect", "text": "corrected QT interval but rarely cause torsade de pointes", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "17876386_1_Ent2", "text": "fluoroquinolone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17876386_1_Ent1", "text": "fluoroquinolone antimicrobials", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17876386_1_Ent0", "text": "corrected QT interval but rarely cause torsade de pointes", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "17876386_2", "wnd_id": "17876386_2_1", "text": "Torsade de pointes associated with moxifloxacin : a rare but potentially fatal adverse event .", "tokens": ["Torsade", "de", "pointes", "associated", "with", "moxifloxacin", ":", "a", "rare", "but", "potentially", "fatal", "adverse", "event", "."], "event_mentions": [{"id": "17876386_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17876386_2_Ent0", "role": "Effect", "text": "Torsade de pointes", "start": 0, "end": 3}, {"entity_id": "17876386_2_Ent1", "role": "Treatment", "text": "moxifloxacin", "start": 5, "end": 6}, {"entity_id": "17876386_2_Ent2", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17876386_2_Ent0", "text": "Torsade de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17876386_2_Ent1", "text": "moxifloxacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17876386_2_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17921794_1", "wnd_id": "17921794_1_1", "text": "Both colchicine and statin therapy may be associated with myopathy , which usually occurs after several months of therapy .", "tokens": ["Both", "colchicine", "and", "statin", "therapy", "may", "be", "associated", "with", "myopathy", ",", "which", "usually", "occurs", "after", "several", "months", "of", "therapy", "."], "event_mentions": [{"id": "17921794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17921794_1_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent4", "role": "Combination_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent1", "role": "Treatment", "text": "colchicine and statin therapy", "start": 1, "end": 5}, {"entity_id": "17921794_1_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent5", "role": "Combination_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent0", "role": "Effect", "text": "myopathy", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17921794_1_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent1", "text": "colchicine and statin therapy", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "17921794_1_Ent3", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent5", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17931455_1", "wnd_id": "17931455_1_1", "text": "CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy .", "tokens": ["CASE", "REPORT", ":", "A", "six", "-", "year", "-", "old", "boy", "with", "transfusion", "-", "dependent", "beta", "-", "thalassaemia", "developed", "a", "unilateral", "hearing", "loss", "shortly", "after", "commencing", "desferrioxamine", "therapy", "."], "event_mentions": [{"id": "17931455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "17931455_1_Ent0", "role": "Subject", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "start": 3, "end": 17}, {"entity_id": "17931455_1_Ent1", "role": "Subject_Age", "text": "six - year - old", "start": 4, "end": 9}, {"entity_id": "17931455_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 9, "end": 10}, {"entity_id": "17931455_1_Ent5", "role": "Treatment_Disorder", "text": "transfusion - dependent beta - thalassaemia", "start": 11, "end": 17}, {"entity_id": "17931455_1_Ent3", "role": "Effect", "text": "a unilateral hearing loss", "start": 18, "end": 22}, {"entity_id": "17931455_1_Ent6", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 22, "end": 24}, {"entity_id": "17931455_1_Ent4", "role": "Treatment", "text": "commencing desferrioxamine therapy", "start": 24, "end": 27}, {"entity_id": "17931455_1_Ent7", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "17931455_1_Ent0", "text": "A six - year - old boy with transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 3, "end": 17}, {"id": "17931455_1_Ent1", "text": "six - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17931455_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17931455_1_Ent5", "text": "transfusion - dependent beta - thalassaemia", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "17931455_1_Ent3", "text": "a unilateral hearing loss", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "17931455_1_Ent6", "text": "shortly after", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17931455_1_Ent4", "text": "commencing desferrioxamine therapy", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17931455_1_Ent7", "text": "desferrioxamine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "17952482_2", "wnd_id": "17952482_2_1", "text": "Sulfasalazine - induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein - Barr virus .", "tokens": ["Sulfasalazine", "-", "induced", "hypersensitivity", "syndrome", "and", "hemophagocytic", "syndrome", "associated", "with", "reactivation", "of", "Epstein", "-", "Barr", "virus", "."], "event_mentions": [{"id": "17952482_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17952482_2_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "17952482_2_Ent2", "role": "Treatment_Drug", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "17952482_2_Ent0", "role": "Effect", "text": "hypersensitivity syndrome and hemophagocytic syndrome", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "17952482_2_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17952482_2_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17952482_2_Ent0", "text": "hypersensitivity syndrome and hemophagocytic syndrome", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "17965530_2", "wnd_id": "17965530_2_1", "text": "We concluded that the colonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and sorbitol .", "tokens": ["We", "concluded", "that", "the", "colonic", "ulcer", "and", "the", "sigmoidovesical", "fistula", "had", "been", "caused", "by", "the", "administration", "of", "calcium", "polystyrene", "sulfonate", "and", "sorbitol", "."], "event_mentions": [{"id": "17965530_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "17965530_2_Ent0", "role": "Effect", "text": "colonic ulcer and the sigmoidovesical fistula", "start": 4, "end": 10}, {"entity_id": "17965530_2_Ent2", "role": "Treatment_Drug", "text": "calcium polystyrene sulfonate", "start": 17, "end": 20}, {"entity_id": "17965530_2_Ent5", "role": "Combination_Drug", "text": "calcium polystyrene sulfonate", "start": 17, "end": 20}, {"entity_id": "17965530_2_Ent1", "role": "Treatment", "text": "calcium polystyrene sulfonate and sorbitol", "start": 17, "end": 22}, {"entity_id": "17965530_2_Ent3", "role": "Treatment_Drug", "text": "sorbitol", "start": 21, "end": 22}, {"entity_id": "17965530_2_Ent4", "role": "Combination_Drug", "text": "sorbitol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17965530_2_Ent0", "text": "colonic ulcer and the sigmoidovesical fistula", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17965530_2_Ent2", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17965530_2_Ent5", "text": "calcium polystyrene sulfonate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17965530_2_Ent1", "text": "calcium polystyrene sulfonate and sorbitol", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "17965530_2_Ent3", "text": "sorbitol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17965530_2_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17987285_12", "wnd_id": "17987285_12_1", "text": "Caution should be exercised , especially in patients who are given voriconazole or fluconazole during long - lasting fentanyl treatment , because insidiously elevated fentanyl concentration may lead to respiratory depression .", "tokens": ["Caution", "should", "be", "exercised", ",", "especially", "in", "patients", "who", "are", "given", "voriconazole", "or", "fluconazole", "during", "long", "-", "lasting", "fentanyl", "treatment", ",", "because", "insidiously", "elevated", "fentanyl", "concentration", "may", "lead", "to", "respiratory", "depression", "."], "event_mentions": [{"id": "17987285_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 27, "end": 28}, "arguments": [{"entity_id": "17987285_12_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "17987285_12_Ent3", "role": "Treatment_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "17987285_12_Ent6", "role": "Combination_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "17987285_12_Ent4", "role": "Treatment_Drug", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "17987285_12_Ent7", "role": "Combination_Drug", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "17987285_12_Ent2", "role": "Treatment", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17987285_12_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 24, "end": 25}, {"entity_id": "17987285_12_Ent1", "role": "Effect", "text": "respiratory depression", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17987285_12_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17987285_12_Ent3", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17987285_12_Ent6", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17987285_12_Ent4", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17987285_12_Ent7", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17987285_12_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17987285_12_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17987285_12_Ent1", "text": "respiratory depression", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "18025525_11", "wnd_id": "18025525_11_1", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics .", "tokens": ["Coadministration", "of", "200", "mg", "bid", "voriconazole", "with", "400", "mg", "(", "or", "higher", ")", "qd", "efavirenz", "is", "contraindicated", "due", "to", "the", "clinically", "significant", "effect", "of", "efavirenz", "on", "voriconazole", "pharmacokinetics", "."], "event_mentions": [{"id": "18025525_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contraindicated", "start": 16, "end": 17}, "arguments": [{"entity_id": "18025525_11_Ent1", "role": "Treatment", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz", "start": 0, "end": 15}, {"entity_id": "18025525_11_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 2, "end": 4}, {"entity_id": "18025525_11_Ent5", "role": "Treatment_Drug", "text": "voriconazole", "start": 5, "end": 6}, {"entity_id": "18025525_11_Ent9", "role": "Combination_Drug", "text": "voriconazole", "start": 5, "end": 6}, {"entity_id": "18025525_11_Ent4", "role": "Treatment_Dosage", "text": "400 mg", "start": 7, "end": 9}, {"entity_id": "18025525_11_Ent6", "role": "Treatment_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "18025525_11_Ent10", "role": "Combination_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "18025525_11_Ent0", "role": "Effect", "text": "clinically significant effect", "start": 20, "end": 23}, {"entity_id": "18025525_11_Ent7", "role": "Treatment_Drug", "text": "efavirenz", "start": 24, "end": 25}, {"entity_id": "18025525_11_Ent2", "role": "Treatment", "text": "efavirenz on voriconazole", "start": 24, "end": 27}, {"entity_id": "18025525_11_Ent8", "role": "Treatment_Drug", "text": "voriconazole", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18025525_11_Ent1", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "18025525_11_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18025525_11_Ent5", "text": "voriconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18025525_11_Ent9", "text": "voriconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18025525_11_Ent4", "text": "400 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18025525_11_Ent6", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18025525_11_Ent10", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18025525_11_Ent0", "text": "clinically significant effect", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "18025525_11_Ent7", "text": "efavirenz", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18025525_11_Ent2", "text": "efavirenz on voriconazole", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18025525_11_Ent8", "text": "voriconazole", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18037876_1", "wnd_id": "18037876_1_1", "text": "DIAGNOSIS : Sustained ventricular tachycardia possibly owing to thalidomide treatment .", "tokens": ["DIAGNOSIS", ":", "Sustained", "ventricular", "tachycardia", "possibly", "owing", "to", "thalidomide", "treatment", "."], "event_mentions": [{"id": "18037876_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "owing to", "start": 6, "end": 8}, "arguments": [{"entity_id": "18037876_1_Ent0", "role": "Effect", "text": "Sustained ventricular tachycardia", "start": 2, "end": 5}, {"entity_id": "18037876_1_Ent1", "role": "Treatment", "text": "thalidomide", "start": 8, "end": 9}, {"entity_id": "18037876_1_Ent2", "role": "Treatment_Drug", "text": "thalidomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18037876_1_Ent0", "text": "Sustained ventricular tachycardia", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18037876_1_Ent1", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18037876_1_Ent2", "text": "thalidomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18037876_3", "wnd_id": "18037876_3_1", "text": "Sustained ventricular tachycardia in a thalidomide - treated patient with primary plasma - cell leukemia .", "tokens": ["Sustained", "ventricular", "tachycardia", "in", "a", "thalidomide", "-", "treated", "patient", "with", "primary", "plasma", "-", "cell", "leukemia", "."], "event_mentions": [{"id": "18037876_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "18037876_3_Ent1", "role": "Effect", "text": "Sustained ventricular tachycardia", "start": 0, "end": 3}, {"entity_id": "18037876_3_Ent2", "role": "Treatment", "text": "thalidomide", "start": 5, "end": 6}, {"entity_id": "18037876_3_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 5, "end": 6}, {"entity_id": "18037876_3_Ent0", "role": "Subject", "text": "patient with primary plasma - cell leukemia", "start": 8, "end": 15}, {"entity_id": "18037876_3_Ent3", "role": "Treatment_Disorder", "text": "primary plasma - cell leukemia", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "18037876_3_Ent1", "text": "Sustained ventricular tachycardia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18037876_3_Ent2", "text": "thalidomide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18037876_3_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18037876_3_Ent0", "text": "patient with primary plasma - cell leukemia", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "18037876_3_Ent3", "text": "primary plasma - cell leukemia", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "18094347_6", "wnd_id": "18094347_6_1", "text": "OBJECTIVE : To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "a", "diffuse", "papular", "eruption", "following", "treatment", "of", "psoriasis", "with", "methotrexate", "injections", "."], "event_mentions": [{"id": "18094347_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "18094347_6_Ent0", "role": "Effect", "text": "diffuse papular eruption", "start": 8, "end": 11}, {"entity_id": "18094347_6_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 14, "end": 15}, {"entity_id": "18094347_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "18094347_6_Ent1", "role": "Treatment", "text": "methotrexate injections", "start": 16, "end": 18}, {"entity_id": "18094347_6_Ent3", "role": "Treatment_Route", "text": "injections", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "18094347_6_Ent0", "text": "diffuse papular eruption", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18094347_6_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18094347_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18094347_6_Ent1", "text": "methotrexate injections", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "18094347_6_Ent3", "text": "injections", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "1814986_1", "wnd_id": "1814986_1_1", "text": "Metabolic acidosis induced by acetazolamide .", "tokens": ["Metabolic", "acidosis", "induced", "by", "acetazolamide", "."], "event_mentions": [{"id": "1814986_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1814986_1_Ent0", "role": "Effect", "text": "Metabolic acidosis", "start": 0, "end": 2}, {"entity_id": "1814986_1_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1814986_1_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1814986_1_Ent0", "text": "Metabolic acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1814986_1_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1814986_1_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18166746_3", "wnd_id": "18166746_3_1", "text": "Methylene blue was administered to a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia .", "tokens": ["Methylene", "blue", "was", "administered", "to", "a", "58", "-", "yr", "-", "old", "woman", "undergoing", "a", "parathyroidectomy", "under", "general", "anesthesia", "."], "event_mentions": [{"id": "18166746_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered to", "start": 3, "end": 5}, "arguments": [{"entity_id": "18166746_3_Ent3", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "18166746_3_Ent4", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "18166746_3_Ent0", "role": "Subject", "text": "a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia", "start": 5, "end": 18}, {"entity_id": "18166746_3_Ent1", "role": "Subject_Age", "text": "58 - yr - old", "start": 6, "end": 11}, {"entity_id": "18166746_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18166746_3_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18166746_3_Ent4", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18166746_3_Ent0", "text": "a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "18166746_3_Ent1", "text": "58 - yr - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18166746_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18203308_3", "wnd_id": "18203308_3_1", "text": "Typical symptoms of active CD occurred 11 , 12 , and 26 months after start of etanercept therapy , respectively .", "tokens": ["Typical", "symptoms", "of", "active", "CD", "occurred", "11", ",", "12", ",", "and", "26", "months", "after", "start", "of", "etanercept", "therapy", ",", "respectively", "."], "event_mentions": [{"id": "18203308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "18203308_3_Ent0", "role": "Effect", "text": "Typical symptoms of active CD", "start": 0, "end": 5}, {"entity_id": "18203308_3_Ent3", "role": "Treatment_Time_elapsed", "text": "11 , 12 , and 26 months after start", "start": 6, "end": 15}, {"entity_id": "18203308_3_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 16, "end": 17}, {"entity_id": "18203308_3_Ent1", "role": "Treatment", "text": "etanercept therapy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "18203308_3_Ent0", "text": "Typical symptoms of active CD", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18203308_3_Ent3", "text": "11 , 12 , and 26 months after start", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "18203308_3_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18203308_3_Ent1", "text": "etanercept therapy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "18262450_1", "wnd_id": "18262450_1_1", "text": "Prolonged - release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients .", "tokens": ["Prolonged", "-", "release", "oxycodone", "enhances", "the", "effects", "of", "existing", "gabapentin", "therapy", "in", "painful", "diabetic", "neuropathy", "patients", "."], "event_mentions": [{"id": "18262450_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhances", "start": 4, "end": 5}, "arguments": [{"entity_id": "18262450_1_Ent1", "role": "Treatment", "text": "Prolonged - release oxycodone", "start": 0, "end": 4}, {"entity_id": "18262450_1_Ent3", "role": "Treatment_Drug", "text": "Prolonged - release oxycodone", "start": 0, "end": 4}, {"entity_id": "18262450_1_Ent2", "role": "Treatment", "text": "gabapentin therapy", "start": 9, "end": 11}, {"entity_id": "18262450_1_Ent0", "role": "Subject", "text": "painful diabetic neuropathy patients", "start": 12, "end": 16}, {"entity_id": "18262450_1_Ent4", "role": "Treatment_Disorder", "text": "diabetic neuropathy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "18262450_1_Ent1", "text": "Prolonged - release oxycodone", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18262450_1_Ent3", "text": "Prolonged - release oxycodone", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18262450_1_Ent2", "text": "gabapentin therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18262450_1_Ent0", "text": "painful diabetic neuropathy patients", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18262450_1_Ent4", "text": "diabetic neuropathy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "18343993_2", "wnd_id": "18343993_2_1", "text": "A female patient with HER2 positive , metastatic breast cancer presented with pulmonary infiltrates , and a plural effusion dyspnoea after several months of trastuzumab treatment .", "tokens": ["A", "female", "patient", "with", "HER2", "positive", ",", "metastatic", "breast", "cancer", "presented", "with", "pulmonary", "infiltrates", ",", "and", "a", "plural", "effusion", "dyspnoea", "after", "several", "months", "of", "trastuzumab", "treatment", "."], "event_mentions": [{"id": "18343993_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 10, "end": 11}, "arguments": [{"entity_id": "18343993_2_Ent0", "role": "Subject", "text": "A female patient with HER2 positive , metastatic breast cancer", "start": 0, "end": 10}, {"entity_id": "18343993_2_Ent1", "role": "Subject_Gender", "text": "female", "start": 1, "end": 2}, {"entity_id": "18343993_2_Ent4", "role": "Treatment_Disorder", "text": "HER2 positive , metastatic breast cancer", "start": 4, "end": 10}, {"entity_id": "18343993_2_Ent2", "role": "Effect", "text": "pulmonary infiltrates , and a plural effusion dyspnoea", "start": 12, "end": 20}, {"entity_id": "18343993_2_Ent6", "role": "Treatment_Time_elapsed", "text": "several months", "start": 21, "end": 23}, {"entity_id": "18343993_2_Ent3", "role": "Treatment", "text": "trastuzumab", "start": 24, "end": 25}, {"entity_id": "18343993_2_Ent5", "role": "Treatment_Drug", "text": "trastuzumab", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18343993_2_Ent0", "text": "A female patient with HER2 positive , metastatic breast cancer", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "18343993_2_Ent1", "text": "female", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18343993_2_Ent4", "text": "HER2 positive , metastatic breast cancer", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "18343993_2_Ent2", "text": "pulmonary infiltrates , and a plural effusion dyspnoea", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "18343993_2_Ent6", "text": "several months", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "18343993_2_Ent3", "text": "trastuzumab", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18343993_2_Ent5", "text": "trastuzumab", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18344734_2", "wnd_id": "18344734_2_1", "text": "We report the case of a woman who developed photo - onycholysis on multiple nails after uptake of olanzapine .", "tokens": ["We", "report", "the", "case", "of", "a", "woman", "who", "developed", "photo", "-", "onycholysis", "on", "multiple", "nails", "after", "uptake", "of", "olanzapine", "."], "event_mentions": [{"id": "18344734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "18344734_2_Ent0", "role": "Subject", "text": "a woman", "start": 5, "end": 7}, {"entity_id": "18344734_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "18344734_2_Ent2", "role": "Effect", "text": "photo - onycholysis on multiple nails", "start": 9, "end": 15}, {"entity_id": "18344734_2_Ent5", "role": "Treatment_Time_elapsed", "text": "after uptake", "start": 15, "end": 17}, {"entity_id": "18344734_2_Ent3", "role": "Treatment", "text": "uptake of olanzapine", "start": 16, "end": 19}, {"entity_id": "18344734_2_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18344734_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18344734_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18344734_2_Ent2", "text": "photo - onycholysis on multiple nails", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "18344734_2_Ent5", "text": "after uptake", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18344734_2_Ent3", "text": "uptake of olanzapine", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18344734_2_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "18354950_1", "wnd_id": "18354950_1_1", "text": "Hyponatraemia developed after rechallenge with controlled release carbamazepine .", "tokens": ["Hyponatraemia", "developed", "after", "rechallenge", "with", "controlled", "release", "carbamazepine", "."], "event_mentions": [{"id": "18354950_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "18354950_1_Ent0", "role": "Effect", "text": "Hyponatraemia", "start": 0, "end": 1}, {"entity_id": "18354950_1_Ent1", "role": "Treatment", "text": "rechallenge with controlled release carbamazepine", "start": 3, "end": 8}, {"entity_id": "18354950_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18354950_1_Ent0", "text": "Hyponatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18354950_1_Ent1", "text": "rechallenge with controlled release carbamazepine", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18354950_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18359591_1", "wnd_id": "18359591_1_1", "text": "In the present paper , we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine .", "tokens": ["In", "the", "present", "paper", ",", "we", "describe", "two", "patients", "with", "active", "UC", "who", "developed", "a", "severe", "systemic", "CMV", "infection", "during", "a", "treatment", "with", "an", "oral", "microemulsion", "form", "of", "cyclosporine", "."], "event_mentions": [{"id": "18359591_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 21, "end": 22}, "arguments": [{"entity_id": "18359591_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "18359591_1_Ent0", "role": "Subject", "text": "two patients with active UC", "start": 7, "end": 12}, {"entity_id": "18359591_1_Ent6", "role": "Treatment_Disorder", "text": "active UC", "start": 10, "end": 12}, {"entity_id": "18359591_1_Ent2", "role": "Effect", "text": "severe systemic CMV infection", "start": 15, "end": 19}, {"entity_id": "18359591_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "18359591_1_Ent3", "role": "Treatment", "text": "oral microemulsion form of cyclosporine", "start": 24, "end": 29}, {"entity_id": "18359591_1_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18359591_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18359591_1_Ent0", "text": "two patients with active UC", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18359591_1_Ent6", "text": "active UC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18359591_1_Ent2", "text": "severe systemic CMV infection", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "18359591_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18359591_1_Ent3", "text": "oral microemulsion form of cyclosporine", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "18359591_1_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18362995_4", "wnd_id": "18362995_4_1", "text": "We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection , on imatinib treatment , presenting with herpetic rash and acute liver failure .", "tokens": ["We", "report", "a", "45", "-", "year", "-", "old", "Chinese", "man", "with", "CML", "and", "chronic", "hepatitis", "B", "virus", "infection", ",", "on", "imatinib", "treatment", ",", "presenting", "with", "herpetic", "rash", "and", "acute", "liver", "failure", "."], "event_mentions": [{"id": "18362995_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 23, "end": 24}, "arguments": [{"entity_id": "18362995_4_Ent0", "role": "Subject", "text": "a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection", "start": 2, "end": 18}, {"entity_id": "18362995_4_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 3, "end": 8}, {"entity_id": "18362995_4_Ent2", "role": "Subject_Race", "text": "Chinese", "start": 8, "end": 9}, {"entity_id": "18362995_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "18362995_4_Ent7", "role": "Treatment_Disorder", "text": "CML and chronic hepatitis B", "start": 11, "end": 16}, {"entity_id": "18362995_4_Ent5", "role": "Treatment", "text": "on imatinib treatment", "start": 19, "end": 22}, {"entity_id": "18362995_4_Ent6", "role": "Treatment_Drug", "text": "imatinib", "start": 20, "end": 21}, {"entity_id": "18362995_4_Ent4", "role": "Effect", "text": "herpetic rash and acute liver failure", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "18362995_4_Ent0", "text": "a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection", "entity_type": "Entity", "start": 2, "end": 18}, {"id": "18362995_4_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18362995_4_Ent2", "text": "Chinese", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_4_Ent3", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18362995_4_Ent7", "text": "CML and chronic hepatitis B", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "18362995_4_Ent5", "text": "on imatinib treatment", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "18362995_4_Ent6", "text": "imatinib", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18362995_4_Ent4", "text": "herpetic rash and acute liver failure", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "18364401_5", "wnd_id": "18364401_5_1", "text": "There have been numerous case reports of hyperglycemia with olanzapine in the literature , but none reported hyperglycemia within days of initiation of the medication .", "tokens": ["There", "have", "been", "numerous", "case", "reports", "of", "hyperglycemia", "with", "olanzapine", "in", "the", "literature", ",", "but", "none", "reported", "hyperglycemia", "within", "days", "of", "initiation", "of", "the", "medication", "."], "event_mentions": [{"id": "18364401_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "18364401_5_Ent0", "role": "Effect", "text": "hyperglycemia", "start": 7, "end": 8}, {"entity_id": "18364401_5_Ent1", "role": "Treatment", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent3", "role": "Treatment_Time_elapsed", "text": "within days of initiation", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "18364401_5_Ent0", "text": "hyperglycemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18364401_5_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent3", "text": "within days of initiation", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "18371508_2", "wnd_id": "18371508_2_1", "text": "We report the first case of fulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure .", "tokens": ["We", "report", "the", "first", "case", "of", "fulminant", "adult", "respiratory", "distress", "syndrome", "(", "ARDS", ")", "associated", "with", "pegylated", "interferon", "alpha", "-", "2a", "(", "pegIFNalpha", "-", "2a", ")", "and", "ribavirin", "use", "for", "hepatitis", "C", ",", "complicated", "by", "subsequent", "and", "ultimately", "fatal", "sepsis", "and", "multiorgan", "failure", "."], "event_mentions": [{"id": "18371508_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "18371508_2_Ent0", "role": "Effect", "text": "adult respiratory distress syndrome ( ARDS )", "start": 7, "end": 14}, {"entity_id": "18371508_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon alpha - 2a", "start": 16, "end": 21}, {"entity_id": "18371508_2_Ent1", "role": "Treatment", "text": "pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin", "start": 16, "end": 28}, {"entity_id": "18371508_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 27, "end": 28}, {"entity_id": "18371508_2_Ent4", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "18371508_2_Ent0", "text": "adult respiratory distress syndrome ( ARDS )", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "18371508_2_Ent2", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "18371508_2_Ent1", "text": "pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin", "entity_type": "Entity", "start": 16, "end": 28}, {"id": "18371508_2_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18371508_2_Ent4", "text": "hepatitis C", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "18379937_1", "wnd_id": "18379937_1_1", "text": "Bilateral anterior uveitis associated with clomiphene citrate .", "tokens": ["Bilateral", "anterior", "uveitis", "associated", "with", "clomiphene", "citrate", "."], "event_mentions": [{"id": "18379937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "18379937_1_Ent0", "role": "Effect", "text": "Bilateral anterior uveitis", "start": 0, "end": 3}, {"entity_id": "18379937_1_Ent1", "role": "Treatment", "text": "clomiphene citrate", "start": 5, "end": 7}, {"entity_id": "18379937_1_Ent2", "role": "Treatment_Drug", "text": "clomiphene citrate", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18379937_1_Ent0", "text": "Bilateral anterior uveitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18379937_1_Ent1", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18379937_1_Ent2", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18421192_2", "wnd_id": "18421192_2_1", "text": "The clinical course suggested that recombinant alpha - 2b peginterferon plus ribavirin provoked type 1 diabetes mellitus , therefore , in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment .", "tokens": ["The", "clinical", "course", "suggested", "that", "recombinant", "alpha", "-", "2b", "peginterferon", "plus", "ribavirin", "provoked", "type", "1", "diabetes", "mellitus", ",", "therefore", ",", "in", "patients", "who", "are", "candidates", "for", "interferon", "therapy", "the", "presence", "of", "pancreatic", "autoantibodies", "and", "the", "fasting", "plasma", "glucose", "level", "should", "be", "investigated", "before", "and", "during", "treatment", "."], "event_mentions": [{"id": "18421192_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 12, "end": 13}, "arguments": [{"entity_id": "18421192_2_Ent2", "role": "Treatment_Drug", "text": "recombinant alpha - 2b peginterferon", "start": 5, "end": 10}, {"entity_id": "18421192_2_Ent5", "role": "Combination_Drug", "text": "recombinant alpha - 2b peginterferon", "start": 5, "end": 10}, {"entity_id": "18421192_2_Ent1", "role": "Treatment", "text": "recombinant alpha - 2b peginterferon plus ribavirin", "start": 5, "end": 12}, {"entity_id": "18421192_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_2_Ent4", "role": "Combination_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_2_Ent0", "role": "Effect", "text": "type 1 diabetes mellitus", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "18421192_2_Ent2", "text": "recombinant alpha - 2b peginterferon", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18421192_2_Ent5", "text": "recombinant alpha - 2b peginterferon", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18421192_2_Ent1", "text": "recombinant alpha - 2b peginterferon plus ribavirin", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "18421192_2_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_2_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_2_Ent0", "text": "type 1 diabetes mellitus", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "18431096_1", "wnd_id": "18431096_1_1", "text": "Methylphenidate and dextroamphetamine - induced peripheral vasculopathy .", "tokens": ["Methylphenidate", "and", "dextroamphetamine", "-", "induced", "peripheral", "vasculopathy", "."], "event_mentions": [{"id": "18431096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18431096_1_Ent3", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "18431096_1_Ent1", "role": "Treatment", "text": "Methylphenidate and dextroamphetamine", "start": 0, "end": 3}, {"entity_id": "18431096_1_Ent2", "role": "Treatment_Drug", "text": "dextroamphetamine", "start": 2, "end": 3}, {"entity_id": "18431096_1_Ent0", "role": "Effect", "text": "peripheral vasculopathy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18431096_1_Ent3", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18431096_1_Ent1", "text": "Methylphenidate and dextroamphetamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18431096_1_Ent2", "text": "dextroamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18431096_1_Ent0", "text": "peripheral vasculopathy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18431096_2", "wnd_id": "18431096_2_1", "text": "We report 4 patients , 2 on methylphenidate and 2 on dextroamphetamine who presented with acral cyanosis , livedo reticularis , or Raynaud phenomenon .", "tokens": ["We", "report", "4", "patients", ",", "2", "on", "methylphenidate", "and", "2", "on", "dextroamphetamine", "who", "presented", "with", "acral", "cyanosis", ",", "livedo", "reticularis", ",", "or", "Raynaud", "phenomenon", "."], "event_mentions": [{"id": "18431096_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 13, "end": 14}, "arguments": [{"entity_id": "18431096_2_Ent0", "role": "Subject", "text": "2", "start": 9, "end": 10}, {"entity_id": "18431096_2_Ent2", "role": "Treatment", "text": "dextroamphetamine", "start": 11, "end": 12}, {"entity_id": "18431096_2_Ent3", "role": "Treatment_Drug", "text": "dextroamphetamine", "start": 11, "end": 12}, {"entity_id": "18431096_2_Ent1", "role": "Effect", "text": "acral cyanosis , livedo reticularis , or Raynaud phenomenon", "start": 15, "end": 24}]}, {"id": "18431096_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 13, "end": 14}, "arguments": [{"entity_id": "18431096_2_Ent4", "role": "Subject", "text": "4 patients , 2 on", "start": 2, "end": 7}, {"entity_id": "18431096_2_Ent6", "role": "Treatment", "text": "methylphenidate", "start": 7, "end": 8}, {"entity_id": "18431096_2_Ent7", "role": "Treatment_Drug", "text": "methylphenidate", "start": 7, "end": 8}, {"entity_id": "18431096_2_Ent5", "role": "Effect", "text": "acral cyanosis , livedo reticularis , or Raynaud phenomenon", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "18431096_2_Ent4", "text": "4 patients , 2 on", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18431096_2_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18431096_2_Ent7", "text": "methylphenidate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18431096_2_Ent0", "text": "2", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18431096_2_Ent2", "text": "dextroamphetamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18431096_2_Ent3", "text": "dextroamphetamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18431096_2_Ent1", "text": "acral cyanosis , livedo reticularis , or Raynaud phenomenon", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "18431096_2_Ent5", "text": "acral cyanosis , livedo reticularis , or Raynaud phenomenon", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "18453852_10", "wnd_id": "18453852_10_1", "text": "After addition of lopinavir / ritonavir , eight volunteers suffered from both nausea and vomiting , one from nausea only , and one from vomiting only .", "tokens": ["After", "addition", "of", "lopinavir", "/", "ritonavir", ",", "eight", "volunteers", "suffered", "from", "both", "nausea", "and", "vomiting", ",", "one", "from", "nausea", "only", ",", "and", "one", "from", "vomiting", "only", "."], "event_mentions": [{"id": "18453852_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent4", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent6", "role": "Combination_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent3", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent5", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent7", "role": "Combination_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent1", "role": "Subject_Population", "text": "eight", "start": 7, "end": 8}, {"entity_id": "18453852_10_Ent0", "role": "Subject", "text": "eight volunteers", "start": 7, "end": 9}, {"entity_id": "18453852_10_Ent2", "role": "Effect", "text": "nausea and vomiting", "start": 12, "end": 15}]}, {"id": "18453852_10_Evt1", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent12", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent11", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent13", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent8", "role": "Subject", "text": "one", "start": 22, "end": 23}, {"entity_id": "18453852_10_Ent9", "role": "Subject_Population", "text": "one", "start": 22, "end": 23}, {"entity_id": "18453852_10_Ent10", "role": "Effect", "text": "vomiting", "start": 24, "end": 25}]}, {"id": "18453852_10_Evt2", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent18", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent17", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent19", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent14", "role": "Subject", "text": "one", "start": 16, "end": 17}, {"entity_id": "18453852_10_Ent15", "role": "Subject_Population", "text": "one", "start": 16, "end": 17}, {"entity_id": "18453852_10_Ent16", "role": "Effect", "text": "nausea", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18453852_10_Ent4", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent6", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent12", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent18", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent3", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent11", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent17", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent5", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent7", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent13", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent19", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent1", "text": "eight", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18453852_10_Ent0", "text": "eight volunteers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18453852_10_Ent2", "text": "nausea and vomiting", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18453852_10_Ent14", "text": "one", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_10_Ent15", "text": "one", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_10_Ent16", "text": "nausea", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18453852_10_Ent8", "text": "one", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18453852_10_Ent9", "text": "one", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18453852_10_Ent10", "text": "vomiting", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18492617_3", "wnd_id": "18492617_3_1", "text": "We describe a patient who , after receiving his first dose of pregabalin to relieve neuropathic pain , presented with a negative myoclonus .", "tokens": ["We", "describe", "a", "patient", "who", ",", "after", "receiving", "his", "first", "dose", "of", "pregabalin", "to", "relieve", "neuropathic", "pain", ",", "presented", "with", "a", "negative", "myoclonus", "."], "event_mentions": [{"id": "18492617_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 18, "end": 19}, "arguments": [{"entity_id": "18492617_3_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "18492617_3_Ent2", "role": "Treatment", "text": "pregabalin", "start": 12, "end": 13}, {"entity_id": "18492617_3_Ent4", "role": "Treatment_Drug", "text": "pregabalin", "start": 12, "end": 13}, {"entity_id": "18492617_3_Ent3", "role": "Treatment_Disorder", "text": "neuropathic pain", "start": 15, "end": 17}, {"entity_id": "18492617_3_Ent1", "role": "Effect", "text": "negative myoclonus", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "18492617_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18492617_3_Ent2", "text": "pregabalin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18492617_3_Ent4", "text": "pregabalin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18492617_3_Ent3", "text": "neuropathic pain", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18492617_3_Ent1", "text": "negative myoclonus", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "18504683_1", "wnd_id": "18504683_1_1", "text": "L - asparaginase - induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children .", "tokens": ["L", "-", "asparaginase", "-", "induced", "posterior", "reversible", "encephalopathy", "syndrome", "during", "acute", "lymphoblastic", "leukemia", "treatment", "in", "children", "."], "event_mentions": [{"id": "18504683_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18504683_1_Ent3", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent4", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent2", "role": "Effect", "text": "posterior reversible encephalopathy syndrome", "start": 5, "end": 9}, {"entity_id": "18504683_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 10, "end": 13}, {"entity_id": "18504683_1_Ent0", "role": "Subject", "text": "children", "start": 15, "end": 16}, {"entity_id": "18504683_1_Ent1", "role": "Subject_Age", "text": "children", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18504683_1_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent2", "text": "posterior reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18504683_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18504683_1_Ent0", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18504683_1_Ent1", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18505911_13", "wnd_id": "18505911_13_1", "text": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance .", "tokens": ["This", "case", "report", "and", "several", "others", "point", "toward", "azathioprine", "as", "a", "clinically", "significant", "inducer", "of", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducer", "start": 13, "end": 14}, "arguments": [{"entity_id": "18505911_13_Ent1", "role": "Treatment", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent3", "role": "Treatment_Drug", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 15, "end": 16}, {"entity_id": "18505911_13_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18505911_13_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18505911_13_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18515982_4", "wnd_id": "18515982_4_1", "text": "Renal injury due to anastrozole has not been published in the English literature .", "tokens": ["Renal", "injury", "due", "to", "anastrozole", "has", "not", "been", "published", "in", "the", "English", "literature", "."], "event_mentions": [{"id": "18515982_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "18515982_4_Ent0", "role": "Effect", "text": "Renal injury", "start": 0, "end": 2}, {"entity_id": "18515982_4_Ent1", "role": "Treatment", "text": "anastrozole", "start": 4, "end": 5}, {"entity_id": "18515982_4_Ent2", "role": "Treatment_Drug", "text": "anastrozole", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18515982_4_Ent0", "text": "Renal injury", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18515982_4_Ent1", "text": "anastrozole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18515982_4_Ent2", "text": "anastrozole", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18523232_4", "wnd_id": "18523232_4_1", "text": "OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced hepatitis .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "occurrence", "of", "acute", "cytolytic", "hepatitis", "in", "a", "patient", "exposed", "to", "pulse", "itraconazole", "therapy", "for", "24", "weeks", "and", "provide", "a", "concise", "review", "of", "the", "literature", "on", "cases", "of", "itraconazole", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "18523232_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed to", "start": 13, "end": 15}, "arguments": [{"entity_id": "18523232_4_Ent1", "role": "Effect", "text": "acute cytolytic hepatitis", "start": 7, "end": 10}, {"entity_id": "18523232_4_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "18523232_4_Ent2", "role": "Treatment", "text": "pulse itraconazole therapy for 24 weeks", "start": 15, "end": 21}, {"entity_id": "18523232_4_Ent3", "role": "Treatment_Drug", "text": "itraconazole", "start": 16, "end": 17}, {"entity_id": "18523232_4_Ent4", "role": "Treatment_Time_elapsed", "text": "24 weeks", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "18523232_4_Ent1", "text": "acute cytolytic hepatitis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18523232_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18523232_4_Ent2", "text": "pulse itraconazole therapy for 24 weeks", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "18523232_4_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18523232_4_Ent4", "text": "24 weeks", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "18562412_5", "wnd_id": "18562412_5_1", "text": "The second patient exhibited sudden PLMS following olanzapine injection .", "tokens": ["The", "second", "patient", "exhibited", "sudden", "PLMS", "following", "olanzapine", "injection", "."], "event_mentions": [{"id": "18562412_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "18562412_5_Ent0", "role": "Subject", "text": "The second patient", "start": 0, "end": 3}, {"entity_id": "18562412_5_Ent1", "role": "Effect", "text": "sudden PLMS", "start": 4, "end": 6}, {"entity_id": "18562412_5_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "18562412_5_Ent2", "role": "Treatment", "text": "olanzapine injection", "start": 7, "end": 9}, {"entity_id": "18562412_5_Ent4", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18562412_5_Ent0", "text": "The second patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_5_Ent1", "text": "sudden PLMS", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18562412_5_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18562412_5_Ent2", "text": "olanzapine injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18562412_5_Ent4", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18562412_6", "wnd_id": "18562412_6_1", "text": "The third patient had been suffering from serious akathisia while on risperidone , and was cured after switching to olanzapine , but thereafter the patient suffered from RLS at nighttime .", "tokens": ["The", "third", "patient", "had", "been", "suffering", "from", "serious", "akathisia", "while", "on", "risperidone", ",", "and", "was", "cured", "after", "switching", "to", "olanzapine", ",", "but", "thereafter", "the", "patient", "suffered", "from", "RLS", "at", "nighttime", "."], "event_mentions": [{"id": "18562412_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 5, "end": 6}, "arguments": [{"entity_id": "18562412_6_Ent0", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent1", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent2", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "18562412_6_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}]}, {"id": "18562412_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 25, "end": 26}, "arguments": [{"entity_id": "18562412_6_Ent4", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent7", "role": "Treatment_Disorder", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent6", "role": "Treatment", "text": "switching to olanzapine", "start": 17, "end": 20}, {"entity_id": "18562412_6_Ent8", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "18562412_6_Ent5", "role": "Effect", "text": "RLS at nighttime", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "18562412_6_Ent0", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent4", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent7", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent6", "text": "switching to olanzapine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18562412_6_Ent8", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18562412_6_Ent5", "text": "RLS at nighttime", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "18607107_2", "wnd_id": "18607107_2_1", "text": "Development of Crohn 's disease in a patient with multiple sclerosis treated with copaxone .", "tokens": ["Development", "of", "Crohn", "'s", "disease", "in", "a", "patient", "with", "multiple", "sclerosis", "treated", "with", "copaxone", "."], "event_mentions": [{"id": "18607107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "18607107_2_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 2, "end": 5}, {"entity_id": "18607107_2_Ent0", "role": "Subject", "text": "a patient with multiple sclerosis", "start": 6, "end": 11}, {"entity_id": "18607107_2_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 9, "end": 11}, {"entity_id": "18607107_2_Ent2", "role": "Treatment", "text": "copaxone", "start": 13, "end": 14}, {"entity_id": "18607107_2_Ent4", "role": "Treatment_Drug", "text": "copaxone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18607107_2_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18607107_2_Ent0", "text": "a patient with multiple sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18607107_2_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18607107_2_Ent2", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18607107_2_Ent4", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18607107_3", "wnd_id": "18607107_3_1", "text": "RESULTS : Our patient developed Crohn 's disease while on Copaxone treatment as a consequence of long - term immunosuppression .", "tokens": ["RESULTS", ":", "Our", "patient", "developed", "Crohn", "'s", "disease", "while", "on", "Copaxone", "treatment", "as", "a", "consequence", "of", "long", "-", "term", "immunosuppression", "."], "event_mentions": [{"id": "18607107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "18607107_3_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "18607107_3_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 5, "end": 8}, {"entity_id": "18607107_3_Ent3", "role": "Treatment", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent2", "role": "Effect", "text": "long - term immunosuppression", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18607107_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18607107_3_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18607107_3_Ent3", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent2", "text": "long - term immunosuppression", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "18607107_4", "wnd_id": "18607107_4_1", "text": "She had been on Copaxone 20 mg / day treatment for 2 years when she first exhibited gastrointestinal symptoms .", "tokens": ["She", "had", "been", "on", "Copaxone", "20", "mg", "/", "day", "treatment", "for", "2", "years", "when", "she", "first", "exhibited", "gastrointestinal", "symptoms", "."], "event_mentions": [{"id": "18607107_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 16, "end": 17}, "arguments": [{"entity_id": "18607107_4_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 4, "end": 5}, {"entity_id": "18607107_4_Ent3", "role": "Treatment", "text": "Copaxone 20 mg / day treatment for 2 years", "start": 4, "end": 13}, {"entity_id": "18607107_4_Ent5", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 5, "end": 9}, {"entity_id": "18607107_4_Ent6", "role": "Treatment_Duration", "text": "2 years", "start": 11, "end": 13}, {"entity_id": "18607107_4_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent2", "role": "Effect", "text": "gastrointestinal symptoms", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18607107_4_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18607107_4_Ent3", "text": "Copaxone 20 mg / day treatment for 2 years", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "18607107_4_Ent5", "text": "20 mg / day", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18607107_4_Ent6", "text": "2 years", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18607107_4_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent2", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18609153_1", "wnd_id": "18609153_1_1", "text": "Terlipressin - induced ventricular arrhythmia .", "tokens": ["Terlipressin", "-", "induced", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "18609153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18609153_1_Ent1", "role": "Treatment", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent2", "role": "Treatment_Drug", "text": "Terlipressin", "start": 0, "end": 1}, {"entity_id": "18609153_1_Ent0", "role": "Effect", "text": "ventricular arrhythmia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18609153_1_Ent1", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent2", "text": "Terlipressin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18609153_1_Ent0", "text": "ventricular arrhythmia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18622319_4", "wnd_id": "18622319_4_1", "text": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis .", "tokens": ["Bevacizumab", "is", "a", "recently", "developed", "monoclonal", "antibody", "against", "vascular", "endothelial", "growth", "factor", "receptor", "used", "to", "inhibit", "angiogenesis", "."], "event_mentions": [{"id": "18622319_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit", "start": 15, "end": 16}, "arguments": [{"entity_id": "18622319_4_Ent2", "role": "Treatment_Drug", "text": "Bevacizumab", "start": 0, "end": 1}, {"entity_id": "18622319_4_Ent0", "role": "Treatment", "text": "Bevacizumab is a recently developed monoclonal antibody", "start": 0, "end": 7}, {"entity_id": "18622319_4_Ent1", "role": "Treatment_Disorder", "text": "angiogenesis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18622319_4_Ent2", "text": "Bevacizumab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18622319_4_Ent0", "text": "Bevacizumab is a recently developed monoclonal antibody", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18622319_4_Ent1", "text": "angiogenesis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18648015_3", "wnd_id": "18648015_3_1", "text": "OBJECTIVE : To describe a case of cefazolin - induced leukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "cefazolin", "-", "induced", "leukopenia", "in", "a", "critically", "ill", "patient", "who", "developed", "this", "adverse", "reaction", "upon", "rechallenge", "with", "cefoxitin", "."], "event_mentions": [{"id": "18648015_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18648015_3_Ent3", "role": "Treatment", "text": "cefazolin", "start": 7, "end": 8}, {"entity_id": "18648015_3_Ent4", "role": "Treatment_Drug", "text": "cefazolin", "start": 7, "end": 8}, {"entity_id": "18648015_3_Ent2", "role": "Effect", "text": "leukopenia", "start": 10, "end": 11}, {"entity_id": "18648015_3_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 12, "end": 16}, {"entity_id": "18648015_3_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "18648015_3_Ent3", "text": "cefazolin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18648015_3_Ent4", "text": "cefazolin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18648015_3_Ent2", "text": "leukopenia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18648015_3_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18648015_3_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "18675768_13", "wnd_id": "18675768_13_1", "text": "This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "18675768_13_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent1", "role": "Treatment", "text": "propafenone and citalopram", "start": 10, "end": 13}, {"entity_id": "18675768_13_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent2", "role": "Treatment", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent0", "role": "Effect", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 16, "end": 31}]}], "entity_mentions": [{"id": "18675768_13_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent1", "text": "propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18675768_13_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent0", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 16, "end": 31}], "lang": "en"}
{"doc_id": "18675768_5", "wnd_id": "18675768_5_1", "text": "An 80 - year - old white female , followed up at the Memory Clinic for mild cognitive impairment , had been taking propafenone 900 mg / d for > 10 years for paroxysmal atrial fibrillation without adverse effects .", "tokens": ["An", "80", "-", "year", "-", "old", "white", "female", ",", "followed", "up", "at", "the", "Memory", "Clinic", "for", "mild", "cognitive", "impairment", ",", "had", "been", "taking", "propafenone", "900", "mg", "/", "d", "for", ">", "10", "years", "for", "paroxysmal", "atrial", "fibrillation", "without", "adverse", "effects", "."], "event_mentions": [{"id": "18675768_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 32, "end": 33}, "arguments": [{"entity_id": "18675768_5_Ent0", "role": "Subject", "text": "An 80 - year - old white female", "start": 0, "end": 8}, {"entity_id": "18675768_5_Ent1", "role": "Subject_Age", "text": "80 - year - old", "start": 1, "end": 6}, {"entity_id": "18675768_5_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "18675768_5_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "18675768_5_Ent4", "role": "Subject_Disorder", "text": "mild cognitive impairment", "start": 16, "end": 19}, {"entity_id": "18675768_5_Ent7", "role": "Treatment_Drug", "text": "propafenone", "start": 23, "end": 24}, {"entity_id": "18675768_5_Ent5", "role": "Treatment", "text": "propafenone 900 mg / d for > 10 years", "start": 23, "end": 32}, {"entity_id": "18675768_5_Ent8", "role": "Treatment_Dosage", "text": "900 mg / d", "start": 24, "end": 28}, {"entity_id": "18675768_5_Ent9", "role": "Treatment_Duration", "text": "> 10 years", "start": 29, "end": 32}, {"entity_id": "18675768_5_Ent6", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "18675768_5_Ent0", "text": "An 80 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18675768_5_Ent1", "text": "80 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18675768_5_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_5_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18675768_5_Ent4", "text": "mild cognitive impairment", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18675768_5_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18675768_5_Ent5", "text": "propafenone 900 mg / d for > 10 years", "entity_type": "Entity", "start": 23, "end": 32}, {"id": "18675768_5_Ent8", "text": "900 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "18675768_5_Ent9", "text": "> 10 years", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "18675768_5_Ent6", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "18676387_4", "wnd_id": "18676387_4_1", "text": "A 60 - yr - old woman , established on paroxetine for depression , underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction .", "tokens": ["A", "60", "-", "yr", "-", "old", "woman", ",", "established", "on", "paroxetine", "for", "depression", ",", "underwent", "excision", "of", "a", "chest", "wall", "myxofibrosarcoma", "and", "chest", "wall", "reconstruction", "."], "event_mentions": [{"id": "18676387_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "established", "start": 8, "end": 9}, "arguments": [{"entity_id": "18676387_4_Ent0", "role": "Subject", "text": "A 60 - yr - old woman", "start": 0, "end": 7}, {"entity_id": "18676387_4_Ent2", "role": "Subject_Age", "text": "60 - yr - old", "start": 1, "end": 6}, {"entity_id": "18676387_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "18676387_4_Ent4", "role": "Treatment", "text": "paroxetine", "start": 10, "end": 11}, {"entity_id": "18676387_4_Ent6", "role": "Treatment_Drug", "text": "paroxetine", "start": 10, "end": 11}, {"entity_id": "18676387_4_Ent1", "role": "Subject", "text": "depression", "start": 12, "end": 13}, {"entity_id": "18676387_4_Ent7", "role": "Treatment_Disorder", "text": "depression", "start": 12, "end": 13}, {"entity_id": "18676387_4_Ent5", "role": "Treatment", "text": "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction", "start": 14, "end": 25}, {"entity_id": "18676387_4_Ent8", "role": "Treatment_Disorder", "text": "myxofibrosarcoma", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18676387_4_Ent0", "text": "A 60 - yr - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18676387_4_Ent2", "text": "60 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18676387_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18676387_4_Ent4", "text": "paroxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18676387_4_Ent6", "text": "paroxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18676387_4_Ent1", "text": "depression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18676387_4_Ent7", "text": "depression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18676387_4_Ent5", "text": "underwent excision of a chest wall myxofibrosarcoma and chest wall reconstruction", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "18676387_4_Ent8", "text": "myxofibrosarcoma", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18676387_8", "wnd_id": "18676387_8_1", "text": "The co - administration of SSRIs and fentanyl may precipitate serotonin toxicity .", "tokens": ["The", "co", "-", "administration", "of", "SSRIs", "and", "fentanyl", "may", "precipitate", "serotonin", "toxicity", "."], "event_mentions": [{"id": "18676387_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 9, "end": 10}, "arguments": [{"entity_id": "18676387_8_Ent1", "role": "Treatment", "text": "co - administration of SSRIs and fentanyl", "start": 1, "end": 8}, {"entity_id": "18676387_8_Ent2", "role": "Treatment_Drug", "text": "SSRIs", "start": 5, "end": 6}, {"entity_id": "18676387_8_Ent4", "role": "Combination_Drug", "text": "SSRIs", "start": 5, "end": 6}, {"entity_id": "18676387_8_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 7, "end": 8}, {"entity_id": "18676387_8_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 7, "end": 8}, {"entity_id": "18676387_8_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18676387_8_Ent1", "text": "co - administration of SSRIs and fentanyl", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "18676387_8_Ent2", "text": "SSRIs", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18676387_8_Ent4", "text": "SSRIs", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18676387_8_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18676387_8_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18676387_8_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "1868481_2", "wnd_id": "1868481_2_1", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis , presented an episode of seizures and transient blindness at different times after i.v . pulse methylprednisolone ( IVPMP ) treatment .", "tokens": ["Two", "children", ",", "1", "with", "idiopathic", "nephrotic", "syndrome", "and", "1", "with", "endo", "-", "extracapillary", "glomerulonephritis", ",", "presented", "an", "episode", "of", "seizures", "and", "transient", "blindness", "at", "different", "times", "after", "i.v", ".", "pulse", "methylprednisolone", "(", "IVPMP", ")", "treatment", "."], "event_mentions": [{"id": "1868481_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 27, "end": 28}, "arguments": [{"entity_id": "1868481_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "1868481_2_Ent0", "role": "Subject", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis", "start": 0, "end": 15}, {"entity_id": "1868481_2_Ent4", "role": "Treatment_Disorder", "text": "idiopathic nephrotic syndrome", "start": 5, "end": 8}, {"entity_id": "1868481_2_Ent5", "role": "Treatment_Disorder", "text": "endo - extracapillary glomerulonephritis ,", "start": 11, "end": 16}, {"entity_id": "1868481_2_Ent2", "role": "Effect", "text": "seizures and transient blindness", "start": 20, "end": 24}, {"entity_id": "1868481_2_Ent7", "role": "Treatment_Route", "text": "i.v . pulse", "start": 28, "end": 31}, {"entity_id": "1868481_2_Ent3", "role": "Treatment", "text": "i.v . pulse methylprednisolone ( IVPMP ) treatment", "start": 28, "end": 36}, {"entity_id": "1868481_2_Ent6", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "1868481_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1868481_2_Ent0", "text": "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "1868481_2_Ent4", "text": "idiopathic nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1868481_2_Ent5", "text": "endo - extracapillary glomerulonephritis ,", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "1868481_2_Ent2", "text": "seizures and transient blindness", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "1868481_2_Ent7", "text": "i.v . pulse", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "1868481_2_Ent3", "text": "i.v . pulse methylprednisolone ( IVPMP ) treatment", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "1868481_2_Ent6", "text": "methylprednisolone", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18691992_4", "wnd_id": "18691992_4_1", "text": "CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use .", "tokens": ["CONCLUSIONS", ":", "We", "report", "this", "case", "of", "the", "concomitant", "appearance", "of", "multiple", "skin", "cancers", "and", "nail", "changes", "associated", "with", "hydroxyurea", "use", "."], "event_mentions": [{"id": "18691992_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "18691992_4_Ent0", "role": "Subject", "text": "case", "start": 5, "end": 6}, {"entity_id": "18691992_4_Ent1", "role": "Effect", "text": "multiple skin cancers and nail changes", "start": 11, "end": 17}, {"entity_id": "18691992_4_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 19, "end": 20}, {"entity_id": "18691992_4_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18691992_4_Ent0", "text": "case", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18691992_4_Ent1", "text": "multiple skin cancers and nail changes", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "18691992_4_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18691992_4_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18698687_2", "wnd_id": "18698687_2_1", "text": "Vanishing bile duct and Stevens - Johnson syndrome associated with ciprofloxacin treated with tacrolimus .", "tokens": ["Vanishing", "bile", "duct", "and", "Stevens", "-", "Johnson", "syndrome", "associated", "with", "ciprofloxacin", "treated", "with", "tacrolimus", "."], "event_mentions": [{"id": "18698687_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "18698687_2_Ent0", "role": "Effect", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "start": 0, "end": 8}, {"entity_id": "18698687_2_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 10, "end": 11}, {"entity_id": "18698687_2_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18698687_2_Ent0", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18698687_2_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18698687_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18707772_1", "wnd_id": "18707772_1_1", "text": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel .", "tokens": ["A", "64", "year", "old", "woman", "with", "previous", "history", "of", "coronary", "stenting", "five", "days", "before", "was", "admitted", "in", "our", "institution", "for", "intracranial", "bleeding", "while", "receiving", "aspirin", "and", "clopidogrel", "."], "event_mentions": [{"id": "18707772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "18707772_1_Ent0", "role": "Subject", "text": "A 64 year old woman with previous history of coronary stenting", "start": 0, "end": 11}, {"entity_id": "18707772_1_Ent1", "role": "Subject_Age", "text": "64 year old", "start": 1, "end": 4}, {"entity_id": "18707772_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "18707772_1_Ent8", "role": "Treatment_Disorder", "text": "coronary stenting", "start": 9, "end": 11}, {"entity_id": "18707772_1_Ent9", "role": "Treatment_Time_elapsed", "text": "five days", "start": 11, "end": 13}, {"entity_id": "18707772_1_Ent4", "role": "Treatment", "text": "five days before", "start": 11, "end": 14}, {"entity_id": "18707772_1_Ent3", "role": "Effect", "text": "intracranial bleeding", "start": 20, "end": 22}, {"entity_id": "18707772_1_Ent7", "role": "Treatment_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent10", "role": "Combination_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent5", "role": "Treatment", "text": "aspirin and clopidogrel", "start": 24, "end": 27}, {"entity_id": "18707772_1_Ent6", "role": "Treatment_Drug", "text": "clopidogrel", "start": 26, "end": 27}, {"entity_id": "18707772_1_Ent11", "role": "Combination_Drug", "text": "clopidogrel", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18707772_1_Ent0", "text": "A 64 year old woman with previous history of coronary stenting", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18707772_1_Ent1", "text": "64 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18707772_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18707772_1_Ent8", "text": "coronary stenting", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18707772_1_Ent9", "text": "five days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18707772_1_Ent4", "text": "five days before", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18707772_1_Ent3", "text": "intracranial bleeding", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "18707772_1_Ent7", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent10", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent5", "text": "aspirin and clopidogrel", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18707772_1_Ent6", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18707772_1_Ent11", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18717612_2", "wnd_id": "18717612_2_1", "text": "FDE from cephalosporins has been rarely reported , and to the best of our knowledge there is no published report of ceftriaxone - induced FDE in the literature .", "tokens": ["FDE", "from", "cephalosporins", "has", "been", "rarely", "reported", ",", "and", "to", "the", "best", "of", "our", "knowledge", "there", "is", "no", "published", "report", "of", "ceftriaxone", "-", "induced", "FDE", "in", "the", "literature", "."], "event_mentions": [{"id": "18717612_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "18717612_2_Ent0", "role": "Effect", "text": "FDE", "start": 0, "end": 1}, {"entity_id": "18717612_2_Ent1", "role": "Treatment", "text": "cephalosporins", "start": 2, "end": 3}, {"entity_id": "18717612_2_Ent2", "role": "Treatment_Drug", "text": "cephalosporins", "start": 2, "end": 3}]}, {"id": "18717612_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "18717612_2_Ent4", "role": "Treatment", "text": "ceftriaxone", "start": 21, "end": 22}, {"entity_id": "18717612_2_Ent5", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 21, "end": 22}, {"entity_id": "18717612_2_Ent3", "role": "Effect", "text": "FDE", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18717612_2_Ent0", "text": "FDE", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18717612_2_Ent1", "text": "cephalosporins", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18717612_2_Ent2", "text": "cephalosporins", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18717612_2_Ent4", "text": "ceftriaxone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18717612_2_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18717612_2_Ent3", "text": "FDE", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18717612_3", "wnd_id": "18717612_3_1", "text": "We report the first case of a 54 - year - old Turkish woman who presented with ceftriaxone - induced FDE .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "54", "-", "year", "-", "old", "Turkish", "woman", "who", "presented", "with", "ceftriaxone", "-", "induced", "FDE", "."], "event_mentions": [{"id": "18717612_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18717612_3_Ent0", "role": "Subject", "text": "a 54 - year - old Turkish woman", "start": 6, "end": 14}, {"entity_id": "18717612_3_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 7, "end": 12}, {"entity_id": "18717612_3_Ent2", "role": "Subject_Race", "text": "Turkish", "start": 12, "end": 13}, {"entity_id": "18717612_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "18717612_3_Ent5", "role": "Treatment", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent6", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent4", "role": "Effect", "text": "FDE", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18717612_3_Ent0", "text": "a 54 - year - old Turkish woman", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "18717612_3_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18717612_3_Ent2", "text": "Turkish", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18717612_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18717612_3_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent6", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent4", "text": "FDE", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18721173_2", "wnd_id": "18721173_2_1", "text": "Gabapentin toxicity in renal failure : the importance of dose adjustment .", "tokens": ["Gabapentin", "toxicity", "in", "renal", "failure", ":", "the", "importance", "of", "dose", "adjustment", "."], "event_mentions": [{"id": "18721173_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 1, "end": 2}, "arguments": [{"entity_id": "18721173_2_Ent1", "role": "Treatment", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "18721173_2_Ent2", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "18721173_2_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18721173_2_Ent1", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18721173_2_Ent2", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18721173_2_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18765315_4", "wnd_id": "18765315_4_1", "text": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively .", "tokens": ["The", "occurrence", "of", "symptoms", "that", "could", "be", "ascribed", "to", "an", "acute", "coronary", "syndrome", "should", "always", "be", "taken", "seriously", "during", "the", "first", "rituximab", "infusion", "and", "investigated", "aggressively", "."], "event_mentions": [{"id": "18765315_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "18765315_4_Ent0", "role": "Effect", "text": "acute coronary syndrome", "start": 10, "end": 13}, {"entity_id": "18765315_4_Ent2", "role": "Treatment_Duration", "text": "first", "start": 20, "end": 21}, {"entity_id": "18765315_4_Ent1", "role": "Treatment", "text": "first rituximab infusion", "start": 20, "end": 23}, {"entity_id": "18765315_4_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "18765315_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18765315_4_Ent0", "text": "acute coronary syndrome", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18765315_4_Ent2", "text": "first", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18765315_4_Ent1", "text": "first rituximab infusion", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "18765315_4_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18765315_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18765315_5", "wnd_id": "18765315_5_1", "text": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab .", "tokens": ["We", "reviewed", "the", "records", "of", "3", "patients", "with", "lymphoproliferative", "disorders", "who", "experienced", "acute", "coronary", "syndromes", "associated", "with", "their", "initial", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "18765315_5_Ent1", "role": "Subject_Population", "text": "3", "start": 5, "end": 6}, {"entity_id": "18765315_5_Ent0", "role": "Subject", "text": "3 patients with lymphoproliferative disorders", "start": 5, "end": 10}, {"entity_id": "18765315_5_Ent4", "role": "Treatment_Disorder", "text": "lymphoproliferative disorders", "start": 8, "end": 10}, {"entity_id": "18765315_5_Ent2", "role": "Effect", "text": "acute coronary syndromes", "start": 12, "end": 15}, {"entity_id": "18765315_5_Ent3", "role": "Treatment", "text": "their initial infusion of rituximab", "start": 17, "end": 22}, {"entity_id": "18765315_5_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "18765315_5_Ent5", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18765315_5_Ent1", "text": "3", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18765315_5_Ent0", "text": "3 patients with lymphoproliferative disorders", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18765315_5_Ent4", "text": "lymphoproliferative disorders", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18765315_5_Ent2", "text": "acute coronary syndromes", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18765315_5_Ent3", "text": "their initial infusion of rituximab", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "18765315_5_Ent6", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18765315_5_Ent5", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18775393_1", "wnd_id": "18775393_1_1", "text": "CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life - threatening laryngeal hematoma in this elderly patient .", "tokens": ["CONCLUSION", ":", "This", "report", "describes", "a", "case", "of", "a", "probable", "interaction", "between", "topical", "econazole", "lotion", "1", "%", "and", "acenocoumarol", "that", "resulted", "in", "overanticoagulation", "and", "a", "life", "-", "threatening", "laryngeal", "hematoma", "in", "this", "elderly", "patient", "."], "event_mentions": [{"id": "18775393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 20, "end": 21}, "arguments": [{"entity_id": "18775393_1_Ent3", "role": "Treatment", "text": "a probable interaction between topical econazole lotion 1 % and acenocoumarol", "start": 8, "end": 19}, {"entity_id": "18775393_1_Ent6", "role": "Treatment_Route", "text": "topical", "start": 12, "end": 13}, {"entity_id": "18775393_1_Ent4", "role": "Treatment_Drug", "text": "econazole", "start": 13, "end": 14}, {"entity_id": "18775393_1_Ent8", "role": "Combination_Drug", "text": "econazole", "start": 13, "end": 14}, {"entity_id": "18775393_1_Ent7", "role": "Treatment_Route", "text": "lotion", "start": 14, "end": 15}, {"entity_id": "18775393_1_Ent5", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 18, "end": 19}, {"entity_id": "18775393_1_Ent9", "role": "Combination_Drug", "text": "acenocoumarol", "start": 18, "end": 19}, {"entity_id": "18775393_1_Ent2", "role": "Effect", "text": "overanticoagulation and a life - threatening laryngeal hematoma", "start": 22, "end": 30}, {"entity_id": "18775393_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 32, "end": 33}, {"entity_id": "18775393_1_Ent0", "role": "Subject", "text": "elderly patient", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "18775393_1_Ent3", "text": "a probable interaction between topical econazole lotion 1 % and acenocoumarol", "entity_type": "Entity", "start": 8, "end": 19}, {"id": "18775393_1_Ent6", "text": "topical", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18775393_1_Ent4", "text": "econazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18775393_1_Ent8", "text": "econazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18775393_1_Ent7", "text": "lotion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18775393_1_Ent5", "text": "acenocoumarol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18775393_1_Ent9", "text": "acenocoumarol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18775393_1_Ent2", "text": "overanticoagulation and a life - threatening laryngeal hematoma", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "18775393_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18775393_1_Ent0", "text": "elderly patient", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "18795_1", "wnd_id": "18795_1_1", "text": "A 10 - year - old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks ' treatment with disodium cromoglycate .", "tokens": ["A", "10", "-", "year", "-", "old", "asthmatic", "boy", "began", "to", "suffer", "from", "urticarial", "rash", "and", "moderately", "severe", "bronchospasm", "after", "8", "weeks", "'", "treatment", "with", "disodium", "cromoglycate", "."], "event_mentions": [{"id": "18795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "18795_1_Ent0", "role": "Subject", "text": "A 10 - year - old asthmatic boy", "start": 0, "end": 8}, {"entity_id": "18795_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 1, "end": 6}, {"entity_id": "18795_1_Ent7", "role": "Treatment_Disorder", "text": "asthmatic", "start": 6, "end": 7}, {"entity_id": "18795_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 7, "end": 8}, {"entity_id": "18795_1_Ent3", "role": "Effect", "text": "urticarial rash and moderately severe bronchospasm", "start": 12, "end": 18}, {"entity_id": "18795_1_Ent5", "role": "Treatment_Time_elapsed", "text": "8 weeks '", "start": 19, "end": 22}, {"entity_id": "18795_1_Ent4", "role": "Treatment", "text": "8 weeks ' treatment with disodium cromoglycate", "start": 19, "end": 26}, {"entity_id": "18795_1_Ent6", "role": "Treatment_Drug", "text": "disodium cromoglycate", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "18795_1_Ent0", "text": "A 10 - year - old asthmatic boy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18795_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18795_1_Ent7", "text": "asthmatic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18795_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18795_1_Ent3", "text": "urticarial rash and moderately severe bronchospasm", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18795_1_Ent5", "text": "8 weeks '", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "18795_1_Ent4", "text": "8 weeks ' treatment with disodium cromoglycate", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "18795_1_Ent6", "text": "disodium cromoglycate", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "18795_2", "wnd_id": "18795_2_1", "text": "Asthma and urticaria during disodium cromoglycate treatment .", "tokens": ["Asthma", "and", "urticaria", "during", "disodium", "cromoglycate", "treatment", "."], "event_mentions": [{"id": "18795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "18795_2_Ent0", "role": "Effect", "text": "Asthma and urticaria", "start": 0, "end": 3}, {"entity_id": "18795_2_Ent2", "role": "Treatment_Drug", "text": "disodium cromoglycate", "start": 4, "end": 6}, {"entity_id": "18795_2_Ent1", "role": "Treatment", "text": "disodium cromoglycate treatment", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "18795_2_Ent0", "text": "Asthma and urticaria", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18795_2_Ent2", "text": "disodium cromoglycate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18795_2_Ent1", "text": "disodium cromoglycate treatment", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "18795_3", "wnd_id": "18795_3_1", "text": "When DSCG was withdrawn , urticaria vanished and the child remained symptom - free .", "tokens": ["When", "DSCG", "was", "withdrawn", ",", "urticaria", "vanished", "and", "the", "child", "remained", "symptom", "-", "free", "."], "event_mentions": [{"id": "18795_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "remained", "start": 10, "end": 11}, "arguments": [{"entity_id": "18795_3_Ent5", "role": "Treatment_Drug", "text": "DSCG", "start": 1, "end": 2}, {"entity_id": "18795_3_Ent4", "role": "Treatment", "text": "DSCG was withdrawn", "start": 1, "end": 4}, {"entity_id": "18795_3_Ent2", "role": "Effect", "text": "urticaria vanished", "start": 5, "end": 7}, {"entity_id": "18795_3_Ent0", "role": "Subject", "text": "the child", "start": 8, "end": 10}, {"entity_id": "18795_3_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "18795_3_Ent3", "role": "Effect", "text": "symptom - free", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "18795_3_Ent5", "text": "DSCG", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18795_3_Ent4", "text": "DSCG was withdrawn", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18795_3_Ent2", "text": "urticaria vanished", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18795_3_Ent0", "text": "the child", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18795_3_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18795_3_Ent3", "text": "symptom - free", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "1879988_3", "wnd_id": "1879988_3_1", "text": "After the first oral dose of propranolol , syncope developed together with atrioventricular block .", "tokens": ["After", "the", "first", "oral", "dose", "of", "propranolol", ",", "syncope", "developed", "together", "with", "atrioventricular", "block", "."], "event_mentions": [{"id": "1879988_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "1879988_3_Ent3", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "1879988_3_Ent2", "role": "Treatment", "text": "oral dose of propranolol", "start": 3, "end": 7}, {"entity_id": "1879988_3_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "1879988_3_Ent0", "role": "Effect", "text": "syncope", "start": 8, "end": 9}, {"entity_id": "1879988_3_Ent1", "role": "Effect", "text": "atrioventricular block", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1879988_3_Ent3", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1879988_3_Ent2", "text": "oral dose of propranolol", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "1879988_3_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1879988_3_Ent0", "text": "syncope", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1879988_3_Ent1", "text": "atrioventricular block", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "18805724_2", "wnd_id": "18805724_2_1", "text": "Leflunomide - induced toxic epidermal necrolysis in a patient with rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18805724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18805724_2_Ent2", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent4", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent1", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "18805724_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18805724_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18805724_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent4", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent1", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18805724_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18805724_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18810448_1", "wnd_id": "18810448_1_1", "text": "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ) , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment .", "tokens": ["In", "this", "report", "we", "described", "a", "case", "of", "juvenile", "idiopathic", "arthritis", "patient", "who", "developed", "thymic", "enlargement", "(", "true", "thymic", "hyperplasia", ")", ",", "mediastinal", "lymphadenopathy", "and", "pleurisy", "associated", "with", "systemic", "symptoms", "under", "Etanercept", "treatment", "."], "event_mentions": [{"id": "18810448_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "18810448_1_Ent0", "role": "Subject", "text": "a case of juvenile idiopathic arthritis patient", "start": 5, "end": 12}, {"entity_id": "18810448_1_Ent1", "role": "Subject_Age", "text": "juvenile", "start": 8, "end": 9}, {"entity_id": "18810448_1_Ent4", "role": "Treatment_Disorder", "text": "idiopathic arthritis", "start": 9, "end": 11}, {"entity_id": "18810448_1_Ent2", "role": "Effect", "text": "thymic enlargement ( true thymic hyperplasia ) , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms", "start": 14, "end": 30}, {"entity_id": "18810448_1_Ent3", "role": "Treatment", "text": "Etanercept", "start": 31, "end": 32}, {"entity_id": "18810448_1_Ent5", "role": "Treatment_Drug", "text": "Etanercept", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "18810448_1_Ent0", "text": "a case of juvenile idiopathic arthritis patient", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "18810448_1_Ent1", "text": "juvenile", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18810448_1_Ent4", "text": "idiopathic arthritis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18810448_1_Ent2", "text": "thymic enlargement ( true thymic hyperplasia ) , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "18810448_1_Ent3", "text": "Etanercept", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "18810448_1_Ent5", "text": "Etanercept", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "18812562_5", "wnd_id": "18812562_5_1", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours according to impaired renal function , was immediately started ; to avoid further nephrotoxicity , immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours .", "tokens": ["Intravenous", "fluconazole", "400", "mg", ",", "followed", "by", "100", "mg", "every", "24", "hours", "according", "to", "impaired", "renal", "function", ",", "was", "immediately", "started", ";", "to", "avoid", "further", "nephrotoxicity", ",", "immunosuppressant", "therapy", "was", "switched", "from", "cyclosporine", "plus", "mycophenolate", "mofetil", "to", "oral", "everolimus", "0.75", "mg", "every", "12", "hours", "."], "event_mentions": [{"id": "18812562_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "avoid", "start": 23, "end": 24}, "arguments": [{"entity_id": "18812562_5_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "18812562_5_Ent0", "role": "Treatment", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "start": 0, "end": 12}, {"entity_id": "18812562_5_Ent8", "role": "Treatment_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent13", "role": "Combination_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent10", "role": "Treatment_Dosage", "text": "400 mg , followed by 100 mg every 24 hours", "start": 2, "end": 12}, {"entity_id": "18812562_5_Ent2", "role": "Treatment_Disorder", "text": "nephrotoxicity", "start": 25, "end": 26}, {"entity_id": "18812562_5_Ent1", "role": "Treatment", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "start": 27, "end": 44}, {"entity_id": "18812562_5_Ent7", "role": "Treatment_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent6", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent12", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent3", "role": "Treatment_Route", "text": "oral", "start": 37, "end": 38}, {"entity_id": "18812562_5_Ent5", "role": "Treatment_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent14", "role": "Combination_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent9", "role": "Treatment_Dosage", "text": "0.75 mg every 12 hours", "start": 39, "end": 44}]}], "entity_mentions": [{"id": "18812562_5_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18812562_5_Ent0", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "18812562_5_Ent8", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent13", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent10", "text": "400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18812562_5_Ent2", "text": "nephrotoxicity", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18812562_5_Ent1", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "entity_type": "Entity", "start": 27, "end": 44}, {"id": "18812562_5_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent6", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent12", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent3", "text": "oral", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18812562_5_Ent5", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent14", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent9", "text": "0.75 mg every 12 hours", "entity_type": "Entity", "start": 39, "end": 44}], "lang": "en"}
{"doc_id": "18821094_1", "wnd_id": "18821094_1_1", "text": "Oxcarbazepine - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ) .", "tokens": ["Oxcarbazepine", "-", "induced", "Drug", "Reaction", "with", "Eosinophilia", "and", "Systemic", "Symptoms", "(", "DRESS", ")", "."], "event_mentions": [{"id": "18821094_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18821094_1_Ent1", "role": "Treatment", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "18821094_1_Ent2", "role": "Treatment_Drug", "text": "Oxcarbazepine", "start": 0, "end": 1}, {"entity_id": "18821094_1_Ent0", "role": "Effect", "text": "Eosinophilia and Systemic Symptoms ( DRESS )", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "18821094_1_Ent1", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18821094_1_Ent2", "text": "Oxcarbazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18821094_1_Ent0", "text": "Eosinophilia and Systemic Symptoms ( DRESS )", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "18821094_2", "wnd_id": "18821094_2_1", "text": "This is an image and brief case report of a 13 - year - old boy who presented with severe rash and systemic symptoms after starting oxcarbazepine .", "tokens": ["This", "is", "an", "image", "and", "brief", "case", "report", "of", "a", "13", "-", "year", "-", "old", "boy", "who", "presented", "with", "severe", "rash", "and", "systemic", "symptoms", "after", "starting", "oxcarbazepine", "."], "event_mentions": [{"id": "18821094_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "18821094_2_Ent0", "role": "Subject", "text": "a 13 - year - old boy", "start": 9, "end": 16}, {"entity_id": "18821094_2_Ent1", "role": "Subject_Age", "text": "13 - year - old", "start": 10, "end": 15}, {"entity_id": "18821094_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 15, "end": 16}, {"entity_id": "18821094_2_Ent3", "role": "Effect", "text": "severe rash and systemic symptoms", "start": 19, "end": 24}, {"entity_id": "18821094_2_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 26, "end": 27}, {"entity_id": "18821094_2_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18821094_2_Ent0", "text": "a 13 - year - old boy", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "18821094_2_Ent1", "text": "13 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "18821094_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18821094_2_Ent3", "text": "severe rash and systemic symptoms", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "18821094_2_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18821094_2_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18837734_2", "wnd_id": "18837734_2_1", "text": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81 - year - old - man and to discuss the pathogenetic role of Demodex folliculorum mites , found in the present patient , using skin scraping .", "tokens": ["The", "aim", "of", "this", "paper", "is", "to", "report", "the", "case", "of", "rosaceiform", "eruption", "induced", "by", "erlotinib", "in", "an", "81", "-", "year", "-", "old", "-", "man", "and", "to", "discuss", "the", "pathogenetic", "role", "of", "Demodex", "folliculorum", "mites", ",", "found", "in", "the", "present", "patient", ",", "using", "skin", "scraping", "."], "event_mentions": [{"id": "18837734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "18837734_2_Ent3", "role": "Effect", "text": "rosaceiform eruption", "start": 11, "end": 13}, {"entity_id": "18837734_2_Ent5", "role": "Treatment", "text": "erlotinib", "start": 15, "end": 16}, {"entity_id": "18837734_2_Ent7", "role": "Treatment_Drug", "text": "erlotinib", "start": 15, "end": 16}, {"entity_id": "18837734_2_Ent0", "role": "Subject", "text": "an 81 - year - old - man", "start": 17, "end": 25}, {"entity_id": "18837734_2_Ent2", "role": "Subject_Age", "text": "81 - year - old", "start": 18, "end": 23}, {"entity_id": "18837734_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 24, "end": 25}, {"entity_id": "18837734_2_Ent4", "role": "Effect", "text": "Demodex folliculorum mites", "start": 32, "end": 35}, {"entity_id": "18837734_2_Ent6", "role": "Treatment", "text": "skin scraping", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "18837734_2_Ent3", "text": "rosaceiform eruption", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18837734_2_Ent5", "text": "erlotinib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18837734_2_Ent7", "text": "erlotinib", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18837734_2_Ent0", "text": "an 81 - year - old - man", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "18837734_2_Ent2", "text": "81 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18837734_2_Ent1", "text": "man", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18837734_2_Ent4", "text": "Demodex folliculorum mites", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "18837734_2_Ent6", "text": "skin scraping", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "18855892_2", "wnd_id": "18855892_2_1", "text": "Anaphylactic / anaphylactoid reactions to methotrexate are rare .", "tokens": ["Anaphylactic", "/", "anaphylactoid", "reactions", "to", "methotrexate", "are", "rare", "."], "event_mentions": [{"id": "18855892_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "18855892_2_Ent0", "role": "Effect", "text": "Anaphylactic / anaphylactoid reactions", "start": 0, "end": 4}, {"entity_id": "18855892_2_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18855892_2_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "18855892_2_Ent0", "text": "Anaphylactic / anaphylactoid reactions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18855892_2_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18855892_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "1888256_3", "wnd_id": "1888256_3_1", "text": "To our knowledge , drug - induced fever has not been reported with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker .", "tokens": ["To", "our", "knowledge", ",", "drug", "-", "induced", "fever", "has", "not", "been", "reported", "with", "the", "use", "of", "diltiazem", "hydrochloride", ",", "a", "commonly", "prescribed", "calcium", "channel", "blocker", "."], "event_mentions": [{"id": "1888256_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "1888256_3_Ent1", "role": "Treatment", "text": "drug", "start": 4, "end": 5}, {"entity_id": "1888256_3_Ent0", "role": "Effect", "text": "fever", "start": 7, "end": 8}, {"entity_id": "1888256_3_Ent2", "role": "Treatment", "text": "with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker", "start": 12, "end": 25}, {"entity_id": "1888256_3_Ent3", "role": "Treatment_Drug", "text": "diltiazem hydrochloride", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1888256_3_Ent1", "text": "drug", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1888256_3_Ent0", "text": "fever", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1888256_3_Ent2", "text": "with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "1888256_3_Ent3", "text": "diltiazem hydrochloride", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "189279_1", "wnd_id": "189279_1_1", "text": "A case of congestive heart failure in a child with Wilms ' tumor treated Adriamycin is presented and discussed .", "tokens": ["A", "case", "of", "congestive", "heart", "failure", "in", "a", "child", "with", "Wilms", "'", "tumor", "treated", "Adriamycin", "is", "presented", "and", "discussed", "."], "event_mentions": [{"id": "189279_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "189279_1_Ent2", "role": "Effect", "text": "congestive heart failure", "start": 3, "end": 6}, {"entity_id": "189279_1_Ent0", "role": "Subject", "text": "a child with Wilms ' tumor", "start": 7, "end": 13}, {"entity_id": "189279_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "189279_1_Ent5", "role": "Treatment_Disorder", "text": "Wilms ' tumor", "start": 10, "end": 13}, {"entity_id": "189279_1_Ent3", "role": "Treatment", "text": "Adriamycin", "start": 14, "end": 15}, {"entity_id": "189279_1_Ent4", "role": "Treatment_Drug", "text": "Adriamycin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "189279_1_Ent2", "text": "congestive heart failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "189279_1_Ent0", "text": "a child with Wilms ' tumor", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "189279_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "189279_1_Ent5", "text": "Wilms ' tumor", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "189279_1_Ent3", "text": "Adriamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "189279_1_Ent4", "text": "Adriamycin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1893404_2", "wnd_id": "1893404_2_1", "text": "Diabetes Mellitus was observed in a patient given carbamazepine .", "tokens": ["Diabetes", "Mellitus", "was", "observed", "in", "a", "patient", "given", "carbamazepine", "."], "event_mentions": [{"id": "1893404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 7, "end": 8}, "arguments": [{"entity_id": "1893404_2_Ent1", "role": "Effect", "text": "Diabetes Mellitus", "start": 0, "end": 2}, {"entity_id": "1893404_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "1893404_2_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 8, "end": 9}, {"entity_id": "1893404_2_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1893404_2_Ent1", "text": "Diabetes Mellitus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1893404_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1893404_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1893404_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18957000_3", "wnd_id": "18957000_3_1", "text": "Heparin - dependent antibodies and thrombosis without heparin - induced thrombocytopenia .", "tokens": ["Heparin", "-", "dependent", "antibodies", "and", "thrombosis", "without", "heparin", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "18957000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_3_Ent1", "role": "Treatment", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18957000_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18991509_2", "wnd_id": "18991509_2_1", "text": "We report the first case of a human immunodeficiency virus type 1 ( HIV - 1) - infected individual receiving combination antiretroviral therapy , which included ritonavir , who developed Cushing syndrome with profound complications after epidural triamcinolone injections .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "human", "immunodeficiency", "virus", "type", "1", "(", "HIV", "-", "1)", "-", "infected", "individual", "receiving", "combination", "antiretroviral", "therapy", ",", "which", "included", "ritonavir", ",", "who", "developed", "Cushing", "syndrome", "with", "profound", "complications", "after", "epidural", "triamcinolone", "injections", "."], "event_mentions": [{"id": "18991509_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "18991509_2_Ent0", "role": "Subject", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "start": 6, "end": 19}, {"entity_id": "18991509_2_Ent4", "role": "Treatment_Disorder", "text": "human immunodeficiency virus type 1", "start": 7, "end": 12}, {"entity_id": "18991509_2_Ent2", "role": "Treatment", "text": "combination antiretroviral therapy , which included ritonavir", "start": 20, "end": 27}, {"entity_id": "18991509_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent1", "role": "Effect", "text": "Cushing syndrome", "start": 30, "end": 32}, {"entity_id": "18991509_2_Ent7", "role": "Treatment_Route", "text": "epidural", "start": 36, "end": 37}, {"entity_id": "18991509_2_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 36, "end": 39}, {"entity_id": "18991509_2_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent10", "role": "Combination_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent8", "role": "Treatment_Route", "text": "injections", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18991509_2_Ent0", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "18991509_2_Ent4", "text": "human immunodeficiency virus type 1", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18991509_2_Ent2", "text": "combination antiretroviral therapy , which included ritonavir", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "18991509_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent1", "text": "Cushing syndrome", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "18991509_2_Ent7", "text": "epidural", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "18991509_2_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "18991509_2_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent10", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent8", "text": "injections", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "19017039_2", "wnd_id": "19017039_2_1", "text": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis .", "tokens": ["Syringotropic", "hypersensitivity", "reaction", "associated", "with", "infliximab", "and", "leflunomide", "combination", "therapy", "in", "a", "child", "with", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "19017039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19017039_2_Ent2", "role": "Effect", "text": "Syringotropic hypersensitivity reaction", "start": 0, "end": 3}, {"entity_id": "19017039_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent8", "role": "Combination_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent3", "role": "Treatment", "text": "infliximab and leflunomide combination therapy", "start": 5, "end": 10}, {"entity_id": "19017039_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent7", "role": "Combination_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent0", "role": "Subject", "text": "a child with psoriatic arthritis", "start": 11, "end": 16}, {"entity_id": "19017039_2_Ent1", "role": "Subject_Age", "text": "child", "start": 12, "end": 13}, {"entity_id": "19017039_2_Ent6", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19017039_2_Ent2", "text": "Syringotropic hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19017039_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent3", "text": "infliximab and leflunomide combination therapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19017039_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent7", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent0", "text": "a child with psoriatic arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19017039_2_Ent1", "text": "child", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19017039_2_Ent6", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19018868_3", "wnd_id": "19018868_3_1", "text": "We describe a case of severe aplastic anemia ( AA ) that was probably induced by lenalidomide .", "tokens": ["We", "describe", "a", "case", "of", "severe", "aplastic", "anemia", "(", "AA", ")", "that", "was", "probably", "induced", "by", "lenalidomide", "."], "event_mentions": [{"id": "19018868_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "19018868_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19018868_3_Ent1", "role": "Effect", "text": "severe aplastic anemia ( AA )", "start": 5, "end": 11}, {"entity_id": "19018868_3_Ent2", "role": "Treatment", "text": "lenalidomide", "start": 16, "end": 17}, {"entity_id": "19018868_3_Ent3", "role": "Treatment_Drug", "text": "lenalidomide", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19018868_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19018868_3_Ent1", "text": "severe aplastic anemia ( AA )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "19018868_3_Ent2", "text": "lenalidomide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19018868_3_Ent3", "text": "lenalidomide", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "19034138_5", "wnd_id": "19034138_5_1", "text": "PURPOSE : To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term amantadine .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "corneal", "endothelial", "dysfunction", "in", "a", "patient", "with", "Parkinson", "disease", "who", "was", "treated", "with", "long", "-", "term", "amantadine", "."], "event_mentions": [{"id": "19034138_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "19034138_5_Ent1", "role": "Effect", "text": "bilateral corneal endothelial dysfunction", "start": 4, "end": 8}, {"entity_id": "19034138_5_Ent0", "role": "Subject", "text": "a patient with Parkinson disease", "start": 9, "end": 14}, {"entity_id": "19034138_5_Ent3", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 12, "end": 14}, {"entity_id": "19034138_5_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 18, "end": 21}, {"entity_id": "19034138_5_Ent2", "role": "Treatment", "text": "long - term amantadine", "start": 18, "end": 22}, {"entity_id": "19034138_5_Ent4", "role": "Treatment_Drug", "text": "amantadine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19034138_5_Ent1", "text": "bilateral corneal endothelial dysfunction", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19034138_5_Ent0", "text": "a patient with Parkinson disease", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19034138_5_Ent3", "text": "Parkinson disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19034138_5_Ent5", "text": "long - term", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19034138_5_Ent2", "text": "long - term amantadine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "19034138_5_Ent4", "text": "amantadine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19058340_2", "wnd_id": "19058340_2_1", "text": "Methotrexate induced sprue - like syndrome .", "tokens": ["Methotrexate", "induced", "sprue", "-", "like", "syndrome", "."], "event_mentions": [{"id": "19058340_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19058340_2_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "19058340_2_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "19058340_2_Ent0", "role": "Effect", "text": "sprue - like syndrome", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "19058340_2_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19058340_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19058340_2_Ent0", "text": "sprue - like syndrome", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "19097599_2", "wnd_id": "19097599_2_1", "text": "We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10 - day treatment with imatinib .", "tokens": ["We", "herein", "described", "an", "additional", "patient", "with", "BCR", "-", "ABL", "(", "ela2", ")", "positive", "acute", "lymphoblastic", "leukemia", "who", "developed", "tumor", "lysis", "syndrome", "after", "10", "-", "day", "treatment", "with", "imatinib", "."], "event_mentions": [{"id": "19097599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19097599_2_Ent0", "role": "Subject", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 5, "end": 17}, {"entity_id": "19097599_2_Ent5", "role": "Treatment_Disorder", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 7, "end": 17}, {"entity_id": "19097599_2_Ent1", "role": "Effect", "text": "tumor lysis syndrome", "start": 19, "end": 22}, {"entity_id": "19097599_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 - day", "start": 23, "end": 26}, {"entity_id": "19097599_2_Ent2", "role": "Treatment", "text": "10 - day treatment with imatinib", "start": 23, "end": 29}, {"entity_id": "19097599_2_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "19097599_2_Ent0", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19097599_2_Ent5", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "19097599_2_Ent1", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19097599_2_Ent4", "text": "10 - day", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19097599_2_Ent2", "text": "10 - day treatment with imatinib", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "19097599_2_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "19104709_2", "wnd_id": "19104709_2_1", "text": "In contrast to chronic or subacute thyroiditis , Graves ' disease rarely complicates IFN - alpha therapy for chronic viral C hepatitis .", "tokens": ["In", "contrast", "to", "chronic", "or", "subacute", "thyroiditis", ",", "Graves", "'", "disease", "rarely", "complicates", "IFN", "-", "alpha", "therapy", "for", "chronic", "viral", "C", "hepatitis", "."], "event_mentions": [{"id": "19104709_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 17, "end": 18}, "arguments": [{"entity_id": "19104709_2_Ent0", "role": "Subject", "text": "Graves ' disease", "start": 8, "end": 11}, {"entity_id": "19104709_2_Ent1", "role": "Subject_Disorder", "text": "Graves ' disease", "start": 8, "end": 11}, {"entity_id": "19104709_2_Ent2", "role": "Treatment", "text": "IFN - alpha", "start": 13, "end": 16}, {"entity_id": "19104709_2_Ent4", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 13, "end": 16}, {"entity_id": "19104709_2_Ent3", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "19104709_2_Ent0", "text": "Graves ' disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19104709_2_Ent1", "text": "Graves ' disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19104709_2_Ent2", "text": "IFN - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19104709_2_Ent4", "text": "IFN - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "19104709_2_Ent3", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "19116715_1", "wnd_id": "19116715_1_1", "text": "Gemcitabine is a known risk factor for hemolytic uremic syndrome ( HUS ) , which can often have a rapidly fatal clinical course despite intervention with steroids , plasmapheresis and hemodialysis .", "tokens": ["Gemcitabine", "is", "a", "known", "risk", "factor", "for", "hemolytic", "uremic", "syndrome", "(", "HUS", ")", ",", "which", "can", "often", "have", "a", "rapidly", "fatal", "clinical", "course", "despite", "intervention", "with", "steroids", ",", "plasmapheresis", "and", "hemodialysis", "."], "event_mentions": [{"id": "19116715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 4, "end": 5}, "arguments": [{"entity_id": "19116715_1_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19116715_1_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19116715_1_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 7, "end": 10}]}, {"id": "19116715_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "intervention", "start": 24, "end": 25}, "arguments": [{"entity_id": "19116715_1_Ent7", "role": "Treatment_Disorder", "text": "a rapidly fatal", "start": 18, "end": 21}, {"entity_id": "19116715_1_Ent3", "role": "Treatment", "text": "with steroids , plasmapheresis and hemodialysis", "start": 25, "end": 31}, {"entity_id": "19116715_1_Ent4", "role": "Treatment_Drug", "text": "steroids", "start": 26, "end": 27}, {"entity_id": "19116715_1_Ent5", "role": "Treatment_Drug", "text": "plasmapheresis", "start": 28, "end": 29}, {"entity_id": "19116715_1_Ent6", "role": "Treatment_Drug", "text": "hemodialysis", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19116715_1_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19116715_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19116715_1_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19116715_1_Ent7", "text": "a rapidly fatal", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19116715_1_Ent3", "text": "with steroids , plasmapheresis and hemodialysis", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "19116715_1_Ent4", "text": "steroids", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19116715_1_Ent5", "text": "plasmapheresis", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19116715_1_Ent6", "text": "hemodialysis", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19116715_2", "wnd_id": "19116715_2_1", "text": "METHODS : A retrospective report of the first case of gemcitabine - related HUS , in a patient with metastatic pancreatic adenocarcinoma , treated with a variety of standard therapies in addition to rituximab is presented .", "tokens": ["METHODS", ":", "A", "retrospective", "report", "of", "the", "first", "case", "of", "gemcitabine", "-", "related", "HUS", ",", "in", "a", "patient", "with", "metastatic", "pancreatic", "adenocarcinoma", ",", "treated", "with", "a", "variety", "of", "standard", "therapies", "in", "addition", "to", "rituximab", "is", "presented", "."], "event_mentions": [{"id": "19116715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "19116715_2_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "19116715_2_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "19116715_2_Ent1", "role": "Effect", "text": "HUS", "start": 13, "end": 14}, {"entity_id": "19116715_2_Ent0", "role": "Subject", "text": "a patient with metastatic pancreatic adenocarcinoma", "start": 16, "end": 22}, {"entity_id": "19116715_2_Ent4", "role": "Treatment_Disorder", "text": "metastatic pancreatic adenocarcinoma ,", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19116715_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19116715_2_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19116715_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19116715_2_Ent0", "text": "a patient with metastatic pancreatic adenocarcinoma", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "19116715_2_Ent4", "text": "metastatic pancreatic adenocarcinoma ,", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19122478_1", "wnd_id": "19122478_1_1", "text": "Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia .", "tokens": ["Drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "after", "chlorambucil", "treatment", "in", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "19122478_1_Ent0", "role": "Effect", "text": "Drug rash with eosinophilia and systemic symptoms", "start": 0, "end": 7}, {"entity_id": "19122478_1_Ent1", "role": "Treatment", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19122478_1_Ent0", "text": "Drug rash with eosinophilia and systemic symptoms", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19122478_1_Ent1", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent3", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19122478_6", "wnd_id": "19122478_6_1", "text": "He developed recurrent skin rash , fever , hypereosinophilia , and acute renal failure after rechallenge with chlorambucil .", "tokens": ["He", "developed", "recurrent", "skin", "rash", ",", "fever", ",", "hypereosinophilia", ",", "and", "acute", "renal", "failure", "after", "rechallenge", "with", "chlorambucil", "."], "event_mentions": [{"id": "19122478_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "19122478_6_Ent0", "role": "Effect", "text": "recurrent skin rash , fever , hypereosinophilia , and acute renal failure", "start": 2, "end": 14}, {"entity_id": "19122478_6_Ent1", "role": "Treatment", "text": "rechallenge with chlorambucil", "start": 15, "end": 18}, {"entity_id": "19122478_6_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "19122478_6_Ent0", "text": "recurrent skin rash , fever , hypereosinophilia , and acute renal failure", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "19122478_6_Ent1", "text": "rechallenge with chlorambucil", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19122478_6_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19131789_1", "wnd_id": "19131789_1_1", "text": "A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 ) , and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later .", "tokens": ["A", "10", "-", "year", "-", "old", "boy", "with", "osteosarcoma", "and", "normal", "renal", "function", "manifested", "laboratory", "evidence", "of", "impending", "renal", "toxicity", "and", "extreme", "elevation", "of", "aspartate", "aminotrasferase", "and", "alanine", "aminotransferase", "within", "2", "hours", "after", "the", "completion", "of", "a", "4", "-", "hour", "infusion", "of", "high", "-", "dose", "methotrexate", "(", "MTX", ")", "(", "12", "g", "/", "m2", ")", ",", "and", "went", "on", "to", "develop", "acute", "renal", "failure", "with", "life", "-", "threatening", "hyperkalemia", "29", "hours", "later", "."], "event_mentions": [{"id": "19131789_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 60, "end": 61}, "arguments": [{"entity_id": "19131789_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 1, "end": 6}, {"entity_id": "19131789_1_Ent0", "role": "Subject", "text": "10 - year - old boy with osteosarcoma and normal renal function", "start": 1, "end": 13}, {"entity_id": "19131789_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "19131789_1_Ent13", "role": "Treatment_Disorder", "text": "osteosarcoma", "start": 8, "end": 9}, {"entity_id": "19131789_1_Ent3", "role": "Effect", "text": "impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase", "start": 17, "end": 29}, {"entity_id": "19131789_1_Ent6", "role": "Treatment_Time_elapsed", "text": "within 2 hours", "start": 29, "end": 32}, {"entity_id": "19131789_1_Ent12", "role": "Treatment_Duration", "text": "4 - hour", "start": 37, "end": 40}, {"entity_id": "19131789_1_Ent5", "role": "Treatment", "text": "4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 )", "start": 37, "end": 55}, {"entity_id": "19131789_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 40, "end": 41}, {"entity_id": "19131789_1_Ent10", "role": "Treatment_Dosage", "text": "high - dose", "start": 42, "end": 45}, {"entity_id": "19131789_1_Ent9", "role": "Treatment_Drug", "text": "methotrexate", "start": 45, "end": 46}, {"entity_id": "19131789_1_Ent11", "role": "Treatment_Dosage", "text": "12 g / m2", "start": 50, "end": 54}, {"entity_id": "19131789_1_Ent4", "role": "Effect", "text": "acute renal failure with life - threatening hyperkalemia 29 hours later", "start": 61, "end": 72}, {"entity_id": "19131789_1_Ent7", "role": "Treatment_Time_elapsed", "text": "29 hours later", "start": 69, "end": 72}]}], "entity_mentions": [{"id": "19131789_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19131789_1_Ent0", "text": "10 - year - old boy with osteosarcoma and normal renal function", "entity_type": "Entity", "start": 1, "end": 13}, {"id": "19131789_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19131789_1_Ent13", "text": "osteosarcoma", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19131789_1_Ent3", "text": "impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase", "entity_type": "Entity", "start": 17, "end": 29}, {"id": "19131789_1_Ent6", "text": "within 2 hours", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "19131789_1_Ent12", "text": "4 - hour", "entity_type": "Entity", "start": 37, "end": 40}, {"id": "19131789_1_Ent5", "text": "4 - hour infusion of high - dose methotrexate ( MTX ) ( 12 g / m2 )", "entity_type": "Entity", "start": 37, "end": 55}, {"id": "19131789_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "19131789_1_Ent10", "text": "high - dose", "entity_type": "Entity", "start": 42, "end": 45}, {"id": "19131789_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 45, "end": 46}, {"id": "19131789_1_Ent11", "text": "12 g / m2", "entity_type": "Entity", "start": 50, "end": 54}, {"id": "19131789_1_Ent4", "text": "acute renal failure with life - threatening hyperkalemia 29 hours later", "entity_type": "Entity", "start": 61, "end": 72}, {"id": "19131789_1_Ent7", "text": "29 hours later", "entity_type": "Entity", "start": 69, "end": 72}], "lang": "en"}
{"doc_id": "19131789_2", "wnd_id": "19131789_2_1", "text": "Although his renal function recovered completely with high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2 , we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion , and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion .", "tokens": ["Although", "his", "renal", "function", "recovered", "completely", "with", "high", "-", "dose", "leucovorin", ",", "hemodialysis", ",", "charcoal", "hemoperfusion", ",", "and", "carboxypeptidase", "G2", ",", "we", "present", "this", "case", "to", "emphasize", "that", "signs", "of", "renal", "toxicity", "may", "be", "present", "as", "early", "as", "2", "hours", "after", "the", "completion", "of", "a", "4", "-", "hour", "MTX", "infusion", ",", "and", "to", "suggest", "that", "monitoring", "for", "MTX", "toxicity", "should", "perhaps", "begin", "within", "a", "few", "hours", "after", "the", "completion", "of", "4", "-", "hour", "MTX", "infusion", "."], "event_mentions": [{"id": "19131789_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovered", "start": 4, "end": 5}, "arguments": [{"entity_id": "19131789_2_Ent8", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "19131789_2_Ent6", "role": "Treatment", "text": "high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2", "start": 7, "end": 20}, {"entity_id": "19131789_2_Ent9", "role": "Treatment_Drug", "text": "leucovorin", "start": 10, "end": 11}, {"entity_id": "19131789_2_Ent14", "role": "Combination_Drug", "text": "leucovorin", "start": 10, "end": 11}, {"entity_id": "19131789_2_Ent10", "role": "Treatment_Drug", "text": "hemodialysis", "start": 12, "end": 13}, {"entity_id": "19131789_2_Ent15", "role": "Combination_Drug", "text": "hemodialysis", "start": 12, "end": 13}, {"entity_id": "19131789_2_Ent11", "role": "Treatment_Drug", "text": "charcoal", "start": 14, "end": 15}, {"entity_id": "19131789_2_Ent16", "role": "Combination_Drug", "text": "charcoal", "start": 14, "end": 15}, {"entity_id": "19131789_2_Ent13", "role": "Treatment_Route", "text": "hemoperfusion", "start": 15, "end": 16}, {"entity_id": "19131789_2_Ent12", "role": "Treatment_Drug", "text": "carboxypeptidase G2", "start": 18, "end": 20}, {"entity_id": "19131789_2_Ent17", "role": "Combination_Drug", "text": "carboxypeptidase G2", "start": 18, "end": 20}, {"entity_id": "19131789_2_Ent7", "role": "Treatment_Disorder", "text": "renal toxicity", "start": 30, "end": 32}]}, {"id": "19131789_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 40, "end": 41}, "arguments": [{"entity_id": "19131789_2_Ent0", "role": "Effect", "text": "renal toxicity", "start": 30, "end": 32}, {"entity_id": "19131789_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2 hours", "start": 38, "end": 40}, {"entity_id": "19131789_2_Ent1", "role": "Treatment", "text": "2 hours after the completion of a 4 - hour MTX infusion", "start": 38, "end": 50}, {"entity_id": "19131789_2_Ent2", "role": "Treatment_Duration", "text": "4 - hour", "start": 45, "end": 48}, {"entity_id": "19131789_2_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 48, "end": 49}, {"entity_id": "19131789_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 49, "end": 50}]}], "entity_mentions": [{"id": "19131789_2_Ent8", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19131789_2_Ent6", "text": "high - dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2", "entity_type": "Entity", "start": 7, "end": 20}, {"id": "19131789_2_Ent9", "text": "leucovorin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19131789_2_Ent14", "text": "leucovorin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19131789_2_Ent10", "text": "hemodialysis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19131789_2_Ent15", "text": "hemodialysis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19131789_2_Ent11", "text": "charcoal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19131789_2_Ent16", "text": "charcoal", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19131789_2_Ent13", "text": "hemoperfusion", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19131789_2_Ent12", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19131789_2_Ent17", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "19131789_2_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19131789_2_Ent7", "text": "renal toxicity", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "19131789_2_Ent5", "text": "2 hours", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "19131789_2_Ent1", "text": "2 hours after the completion of a 4 - hour MTX infusion", "entity_type": "Entity", "start": 38, "end": 50}, {"id": "19131789_2_Ent2", "text": "4 - hour", "entity_type": "Entity", "start": 45, "end": 48}, {"id": "19131789_2_Ent3", "text": "MTX", "entity_type": "Entity", "start": 48, "end": 49}, {"id": "19131789_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 49, "end": 50}], "lang": "en"}
{"doc_id": "19131789_3", "wnd_id": "19131789_3_1", "text": "Early recognition of renal toxicity of high - dose methotrexate therapy : a case report .", "tokens": ["Early", "recognition", "of", "renal", "toxicity", "of", "high", "-", "dose", "methotrexate", "therapy", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19131789_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recognition", "start": 1, "end": 2}, "arguments": [{"entity_id": "19131789_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 3, "end": 5}, {"entity_id": "19131789_3_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "19131789_3_Ent1", "role": "Treatment", "text": "high - dose methotrexate therapy", "start": 6, "end": 11}, {"entity_id": "19131789_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19131789_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19131789_3_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19131789_3_Ent1", "text": "high - dose methotrexate therapy", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19131789_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19151423_1", "wnd_id": "19151423_1_1", "text": "Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin .", "tokens": ["Rhabdomyolysis", "due", "to", "an", "uncommon", "interaction", "of", "ciprofloxacin", "with", "simvastatin", "."], "event_mentions": [{"id": "19151423_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19151423_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "19151423_1_Ent1", "role": "Treatment", "text": "interaction of ciprofloxacin with simvastatin", "start": 5, "end": 10}, {"entity_id": "19151423_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 9, "end": 10}, {"entity_id": "19151423_1_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19151423_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19151423_1_Ent1", "text": "interaction of ciprofloxacin with simvastatin", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19151423_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19151423_1_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19203515_3", "wnd_id": "19203515_3_1", "text": "The exact mechanism of IVIG - associated acute renal failure remains unclear .", "tokens": ["The", "exact", "mechanism", "of", "IVIG", "-", "associated", "acute", "renal", "failure", "remains", "unclear", "."], "event_mentions": [{"id": "19203515_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "19203515_3_Ent1", "role": "Treatment", "text": "IVIG", "start": 4, "end": 5}, {"entity_id": "19203515_3_Ent2", "role": "Treatment_Drug", "text": "IVIG", "start": 4, "end": 5}, {"entity_id": "19203515_3_Ent0", "role": "Effect", "text": "acute renal failure", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "19203515_3_Ent1", "text": "IVIG", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_3_Ent2", "text": "IVIG", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_3_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "19217693_2", "wnd_id": "19217693_2_1", "text": "Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis .", "tokens": ["Persistent", "hypoglycemia", "in", "a", "patient", "with", "diabetes", "taking", "etanercept", "for", "the", "treatment", "of", "psoriasis", "."], "event_mentions": [{"id": "19217693_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 7, "end": 8}, "arguments": [{"entity_id": "19217693_2_Ent2", "role": "Effect", "text": "Persistent hypoglycemia", "start": 0, "end": 2}, {"entity_id": "19217693_2_Ent0", "role": "Subject", "text": "a patient with diabetes", "start": 3, "end": 7}, {"entity_id": "19217693_2_Ent1", "role": "Subject_Disorder", "text": "diabetes", "start": 6, "end": 7}, {"entity_id": "19217693_2_Ent3", "role": "Treatment", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 8, "end": 9}, {"entity_id": "19217693_2_Ent5", "role": "Treatment_Disorder", "text": "psoriasis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19217693_2_Ent2", "text": "Persistent hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19217693_2_Ent0", "text": "a patient with diabetes", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "19217693_2_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19217693_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19217693_2_Ent5", "text": "psoriasis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19217693_3", "wnd_id": "19217693_3_1", "text": "We report a patient with type 2 diabetes mellitus who , while treated with the antitumor necrosis factor - alpha blocking agent etanercept for severe plaque psoriasis , experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen .", "tokens": ["We", "report", "a", "patient", "with", "type", "2", "diabetes", "mellitus", "who", ",", "while", "treated", "with", "the", "antitumor", "necrosis", "factor", "-", "alpha", "blocking", "agent", "etanercept", "for", "severe", "plaque", "psoriasis", ",", "experienced", "persistent", "hypoglycemia", "requiring", "the", "lowering", "and", "eventual", "elimination", "of", "his", "previous", "insulin", "regimen", "."], "event_mentions": [{"id": "19217693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "19217693_3_Ent0", "role": "Subject", "text": "a patient with type 2 diabetes mellitus", "start": 2, "end": 9}, {"entity_id": "19217693_3_Ent4", "role": "Treatment_Disorder", "text": "type 2 diabetes mellitus", "start": 5, "end": 9}, {"entity_id": "19217693_3_Ent2", "role": "Treatment", "text": "the antitumor necrosis factor - alpha blocking agent etanercept", "start": 14, "end": 23}, {"entity_id": "19217693_3_Ent6", "role": "Treatment_Drug", "text": "etanercept", "start": 22, "end": 23}, {"entity_id": "19217693_3_Ent9", "role": "Combination_Drug", "text": "etanercept", "start": 22, "end": 23}, {"entity_id": "19217693_3_Ent5", "role": "Treatment_Disorder", "text": "severe plaque psoriasis", "start": 24, "end": 27}, {"entity_id": "19217693_3_Ent1", "role": "Effect", "text": "persistent hypoglycemia", "start": 29, "end": 31}, {"entity_id": "19217693_3_Ent3", "role": "Treatment", "text": "previous insulin regimen", "start": 39, "end": 42}, {"entity_id": "19217693_3_Ent7", "role": "Treatment_Drug", "text": "insulin", "start": 40, "end": 41}, {"entity_id": "19217693_3_Ent8", "role": "Combination_Drug", "text": "insulin", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "19217693_3_Ent0", "text": "a patient with type 2 diabetes mellitus", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "19217693_3_Ent4", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19217693_3_Ent2", "text": "the antitumor necrosis factor - alpha blocking agent etanercept", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "19217693_3_Ent6", "text": "etanercept", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19217693_3_Ent9", "text": "etanercept", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19217693_3_Ent5", "text": "severe plaque psoriasis", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "19217693_3_Ent1", "text": "persistent hypoglycemia", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "19217693_3_Ent3", "text": "previous insulin regimen", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "19217693_3_Ent7", "text": "insulin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "19217693_3_Ent8", "text": "insulin", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "19235747_2", "wnd_id": "19235747_2_1", "text": "Bisphosphonate - related osteonecrosis of the skull base .", "tokens": ["Bisphosphonate", "-", "related", "osteonecrosis", "of", "the", "skull", "base", "."], "event_mentions": [{"id": "19235747_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "19235747_2_Ent1", "role": "Treatment", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_2_Ent2", "role": "Treatment_Drug", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_2_Ent0", "role": "Effect", "text": "osteonecrosis of the skull base", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "19235747_2_Ent1", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_2_Ent2", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_2_Ent0", "text": "osteonecrosis of the skull base", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "19249953_10", "wnd_id": "19249953_10_1", "text": "To our knowledge , however , this is the first case report of a possible sitagliptin - lovastatin interaction that may have caused rhabdomyolysis .", "tokens": ["To", "our", "knowledge", ",", "however", ",", "this", "is", "the", "first", "case", "report", "of", "a", "possible", "sitagliptin", "-", "lovastatin", "interaction", "that", "may", "have", "caused", "rhabdomyolysis", "."], "event_mentions": [{"id": "19249953_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 22, "end": 23}, "arguments": [{"entity_id": "19249953_10_Ent2", "role": "Treatment_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent5", "role": "Combination_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent1", "role": "Treatment", "text": "sitagliptin - lovastatin interaction", "start": 15, "end": 19}, {"entity_id": "19249953_10_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "19249953_10_Ent2", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent5", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent1", "text": "sitagliptin - lovastatin interaction", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19249953_10_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "19260037_5", "wnd_id": "19260037_5_1", "text": "We recommend that a TMA in association with quinine be consistently referred to as quinine - associated thrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP .", "tokens": ["We", "recommend", "that", "a", "TMA", "in", "association", "with", "quinine", "be", "consistently", "referred", "to", "as", "quinine", "-", "associated", "thrombotic", "microangiopathy", "(", "quinine", "-", "TMA", ")", "to", "better", "distinguish", "this", "entity", "from", "idiopathic", "TTP", "."], "event_mentions": [{"id": "19260037_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "19260037_5_Ent1", "role": "Treatment", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent2", "role": "Treatment_Drug", "text": "quinine", "start": 14, "end": 15}, {"entity_id": "19260037_5_Ent0", "role": "Effect", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "19260037_5_Ent1", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent2", "text": "quinine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19260037_5_Ent0", "text": "quinine - associated thrombotic microangiopathy ( quinine - TMA )", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "19266307_1", "wnd_id": "19266307_1_1", "text": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours .", "tokens": ["Complications", "associated", "with", "primary", "and", "secondary", "perforation", "of", "the", "bladder", "following", "immediate", "instillations", "of", "epirubicin", "after", "transurethral", "resection", "of", "superficial", "urothelial", "tumours", "."], "event_mentions": [{"id": "19266307_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "19266307_1_Ent0", "role": "Effect", "text": "Complications associated with primary and secondary perforation of the bladder", "start": 0, "end": 10}, {"entity_id": "19266307_1_Ent3", "role": "Treatment_Route", "text": "instillations", "start": 12, "end": 13}, {"entity_id": "19266307_1_Ent1", "role": "Treatment", "text": "instillations of epirubicin", "start": 12, "end": 15}, {"entity_id": "19266307_1_Ent2", "role": "Treatment_Drug", "text": "epirubicin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "19266307_1_Ent0", "text": "Complications associated with primary and secondary perforation of the bladder", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "19266307_1_Ent3", "text": "instillations", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19266307_1_Ent1", "text": "instillations of epirubicin", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "19266307_1_Ent2", "text": "epirubicin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "19275460_6", "wnd_id": "19275460_6_1", "text": "Despite aggressive medical management , including intravenous hydration and broad - spectrum antibiotics , the patient continued to become more confused , agitated , and despondent over the subsequent 24 hours .", "tokens": ["Despite", "aggressive", "medical", "management", ",", "including", "intravenous", "hydration", "and", "broad", "-", "spectrum", "antibiotics", ",", "the", "patient", "continued", "to", "become", "more", "confused", ",", "agitated", ",", "and", "despondent", "over", "the", "subsequent", "24", "hours", "."], "event_mentions": [{"id": "19275460_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "continued", "start": 16, "end": 17}, "arguments": [{"entity_id": "19275460_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "19275460_6_Ent2", "role": "Treatment", "text": "intravenous hydration and broad - spectrum antibiotics", "start": 6, "end": 13}, {"entity_id": "19275460_6_Ent3", "role": "Treatment_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent6", "role": "Combination_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent4", "role": "Treatment_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent7", "role": "Combination_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent0", "role": "Subject", "text": "patient", "start": 15, "end": 16}, {"entity_id": "19275460_6_Ent1", "role": "Effect", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "start": 18, "end": 31}]}], "entity_mentions": [{"id": "19275460_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19275460_6_Ent2", "text": "intravenous hydration and broad - spectrum antibiotics", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "19275460_6_Ent3", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent6", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent4", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent7", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19275460_6_Ent1", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "entity_type": "Entity", "start": 18, "end": 31}], "lang": "en"}
{"doc_id": "19296063_1", "wnd_id": "19296063_1_1", "text": "A case of acute cardiomyopathy and pericarditis associated with methylphenidate .", "tokens": ["A", "case", "of", "acute", "cardiomyopathy", "and", "pericarditis", "associated", "with", "methylphenidate", "."], "event_mentions": [{"id": "19296063_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "19296063_1_Ent0", "role": "Effect", "text": "acute cardiomyopathy and pericarditis", "start": 3, "end": 7}, {"entity_id": "19296063_1_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 9, "end": 10}, {"entity_id": "19296063_1_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19296063_1_Ent0", "text": "acute cardiomyopathy and pericarditis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "19296063_1_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19296063_1_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19299370_1", "wnd_id": "19299370_1_1", "text": "According to the Naranjo et al . adverse - reaction probability scale , enoxaparin was the probable cause of hepatotoxicity in this patient .", "tokens": ["According", "to", "the", "Naranjo", "et", "al", ".", "adverse", "-", "reaction", "probability", "scale", ",", "enoxaparin", "was", "the", "probable", "cause", "of", "hepatotoxicity", "in", "this", "patient", "."], "event_mentions": [{"id": "19299370_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 17, "end": 18}, "arguments": [{"entity_id": "19299370_1_Ent2", "role": "Treatment", "text": "enoxaparin", "start": 13, "end": 14}, {"entity_id": "19299370_1_Ent3", "role": "Treatment_Drug", "text": "enoxaparin", "start": 13, "end": 14}, {"entity_id": "19299370_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 19, "end": 20}, {"entity_id": "19299370_1_Ent0", "role": "Subject", "text": "this patient", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "19299370_1_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19299370_1_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19299370_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19299370_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "19299370_3", "wnd_id": "19299370_3_1", "text": "Probable enoxaparin - induced hepatotoxicity .", "tokens": ["Probable", "enoxaparin", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "19299370_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19299370_3_Ent1", "role": "Treatment", "text": "enoxaparin", "start": 1, "end": 2}, {"entity_id": "19299370_3_Ent2", "role": "Treatment_Drug", "text": "enoxaparin", "start": 1, "end": 2}, {"entity_id": "19299370_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19299370_3_Ent1", "text": "enoxaparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19299370_3_Ent2", "text": "enoxaparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19299370_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19331262_3", "wnd_id": "19331262_3_1", "text": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs , in which the clinical scenario encompass muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis .", "tokens": ["Neuroleptic", "malignant", "syndrome", "is", "an", "uncommon", "and", "potentially", "fatal", "idiosynchratic", "reaction", "of", "antipsychotic", "drugs", ",", "in", "which", "the", "clinical", "scenario", "encompass", "muscular", "rigidity", ",", "hyperthermia", ",", "autonomic", "dysfunction", ",", "altered", "consciousness", ",", "high", "creatinine", "phosphokinase", "levels", ",", "and", "leukocytosis", "."], "event_mentions": [{"id": "19331262_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 10, "end": 11}, "arguments": [{"entity_id": "19331262_3_Ent0", "role": "Effect", "text": "Neuroleptic malignant syndrome", "start": 0, "end": 3}, {"entity_id": "19331262_3_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 12, "end": 13}, {"entity_id": "19331262_3_Ent2", "role": "Treatment", "text": "antipsychotic drugs", "start": 12, "end": 14}, {"entity_id": "19331262_3_Ent1", "role": "Effect", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "start": 21, "end": 39}]}], "entity_mentions": [{"id": "19331262_3_Ent0", "text": "Neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19331262_3_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19331262_3_Ent2", "text": "antipsychotic drugs", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19331262_3_Ent1", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "entity_type": "Entity", "start": 21, "end": 39}], "lang": "en"}
{"doc_id": "19354059_1", "wnd_id": "19354059_1_1", "text": "The most common complication of warfarin use is adverse bleeding .", "tokens": ["The", "most", "common", "complication", "of", "warfarin", "use", "is", "adverse", "bleeding", "."], "event_mentions": [{"id": "19354059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 6, "end": 7}, "arguments": [{"entity_id": "19354059_1_Ent1", "role": "Treatment", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent0", "role": "Effect", "text": "adverse bleeding", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19354059_1_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent0", "text": "adverse bleeding", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19357764_1", "wnd_id": "19357764_1_1", "text": "CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute , Kampala , Uganda .", "tokens": ["CASE", "REPORT", ":", "We", "describe", "here", "a", "case", "of", "a", "60", "year", "old", "female", "that", "experienced", "a", "relapse", "of", "symptomatic", "hyperlactatemia", "after", "being", "switched", "from", "stavudine", "to", "zidovudine", "and", "how", "the", "case", "was", "managed", "at", "the", "Infectious", "Diseases", "Institute", ",", "Kampala", ",", "Uganda", "."], "event_mentions": [{"id": "19357764_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "19357764_1_Ent0", "role": "Subject", "text": "a case of a 60 year old female", "start": 6, "end": 14}, {"entity_id": "19357764_1_Ent1", "role": "Subject_Age", "text": "60 year old", "start": 10, "end": 13}, {"entity_id": "19357764_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 13, "end": 14}, {"entity_id": "19357764_1_Ent3", "role": "Effect", "text": "relapse of symptomatic hyperlactatemia", "start": 17, "end": 21}, {"entity_id": "19357764_1_Ent4", "role": "Treatment", "text": "switched from stavudine to zidovudine", "start": 23, "end": 28}, {"entity_id": "19357764_1_Ent5", "role": "Treatment_Drug", "text": "stavudine", "start": 25, "end": 26}, {"entity_id": "19357764_1_Ent6", "role": "Treatment_Drug", "text": "zidovudine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "19357764_1_Ent0", "text": "a case of a 60 year old female", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "19357764_1_Ent1", "text": "60 year old", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "19357764_1_Ent2", "text": "female", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19357764_1_Ent3", "text": "relapse of symptomatic hyperlactatemia", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "19357764_1_Ent4", "text": "switched from stavudine to zidovudine", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "19357764_1_Ent5", "text": "stavudine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19357764_1_Ent6", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "19357764_2", "wnd_id": "19357764_2_1", "text": "DISCUSSION : This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse .", "tokens": ["DISCUSSION", ":", "This", "case", "shows", "that", "switching", "to", "zidovudine", "potentially", "can", "lead", "to", "a", "hyperlactatemia", "relapse", "."], "event_mentions": [{"id": "19357764_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 11, "end": 12}, "arguments": [{"entity_id": "19357764_2_Ent0", "role": "Subject", "text": "This case", "start": 2, "end": 4}, {"entity_id": "19357764_2_Ent2", "role": "Treatment", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent3", "role": "Treatment_Drug", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent1", "role": "Effect", "text": "hyperlactatemia relapse", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19357764_2_Ent0", "text": "This case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19357764_2_Ent2", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent3", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent1", "text": "hyperlactatemia relapse", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19357764_3", "wnd_id": "19357764_3_1", "text": "INTRODUCTION : In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative .", "tokens": ["INTRODUCTION", ":", "In", "resource", "limited", "settings", "patients", "on", "antiretroviral", "treatment", "who", "develop", "stavudine", "induced", "hyperlactatemia", "are", "often", "switched", "to", "zidovudine", "on", "the", "basis", "of", "published", "studies", "that", "demonstrate", "that", "this", "agent", "can", "be", "a", "safe", "alternative", "."], "event_mentions": [{"id": "19357764_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "19357764_3_Ent0", "role": "Subject", "text": "patients on antiretroviral treatment", "start": 6, "end": 10}, {"entity_id": "19357764_3_Ent2", "role": "Treatment", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "19357764_3_Ent3", "role": "Treatment_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "19357764_3_Ent1", "role": "Effect", "text": "hyperlactatemia", "start": 14, "end": 15}]}, {"id": "19357764_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "switched", "start": 17, "end": 18}, "arguments": [{"entity_id": "19357764_3_Ent4", "role": "Subject", "text": "patients on antiretroviral treatment", "start": 6, "end": 10}, {"entity_id": "19357764_3_Ent7", "role": "Treatment_Disorder", "text": "stavudine induced hyperlactatemia", "start": 12, "end": 15}, {"entity_id": "19357764_3_Ent5", "role": "Treatment", "text": "zidovudine", "start": 19, "end": 20}, {"entity_id": "19357764_3_Ent6", "role": "Treatment_Drug", "text": "zidovudine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19357764_3_Ent0", "text": "patients on antiretroviral treatment", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19357764_3_Ent4", "text": "patients on antiretroviral treatment", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19357764_3_Ent2", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19357764_3_Ent3", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19357764_3_Ent7", "text": "stavudine induced hyperlactatemia", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "19357764_3_Ent1", "text": "hyperlactatemia", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19357764_3_Ent5", "text": "zidovudine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19357764_3_Ent6", "text": "zidovudine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19363904_2", "wnd_id": "19363904_2_1", "text": "We report a case of an 11 - year - old boy who experienced an anaphylactic reaction after administration of bacitracin ointment .", "tokens": ["We", "report", "a", "case", "of", "an", "11", "-", "year", "-", "old", "boy", "who", "experienced", "an", "anaphylactic", "reaction", "after", "administration", "of", "bacitracin", "ointment", "."], "event_mentions": [{"id": "19363904_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "19363904_2_Ent0", "role": "Subject", "text": "an 11 - year - old boy", "start": 5, "end": 12}, {"entity_id": "19363904_2_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 6, "end": 11}, {"entity_id": "19363904_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 11, "end": 12}, {"entity_id": "19363904_2_Ent3", "role": "Effect", "text": "an anaphylactic reaction", "start": 14, "end": 17}, {"entity_id": "19363904_2_Ent4", "role": "Treatment", "text": "after administration of bacitracin ointment", "start": 17, "end": 22}, {"entity_id": "19363904_2_Ent5", "role": "Treatment_Drug", "text": "bacitracin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19363904_2_Ent0", "text": "an 11 - year - old boy", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19363904_2_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19363904_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19363904_2_Ent3", "text": "an anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19363904_2_Ent4", "text": "after administration of bacitracin ointment", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "19363904_2_Ent5", "text": "bacitracin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19402273_2", "wnd_id": "19402273_2_1", "text": "Isoniazid induced gynaecomastia : a case report .", "tokens": ["Isoniazid", "induced", "gynaecomastia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19402273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19402273_2_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent0", "role": "Effect", "text": "gynaecomastia", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "19402273_2_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent0", "text": "gynaecomastia", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "19423476_4", "wnd_id": "19423476_4_1", "text": "We report a case of fatal C. neoformans fungemia in a neutropenic patient with a history of chronic lymphocytic leukemia treated with alemtuzumab .", "tokens": ["We", "report", "a", "case", "of", "fatal", "C.", "neoformans", "fungemia", "in", "a", "neutropenic", "patient", "with", "a", "history", "of", "chronic", "lymphocytic", "leukemia", "treated", "with", "alemtuzumab", "."], "event_mentions": [{"id": "19423476_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 20, "end": 22}, "arguments": [{"entity_id": "19423476_4_Ent1", "role": "Effect", "text": "fatal C. neoformans fungemia", "start": 5, "end": 9}, {"entity_id": "19423476_4_Ent0", "role": "Subject", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "start": 10, "end": 20}, {"entity_id": "19423476_4_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 17, "end": 20}, {"entity_id": "19423476_4_Ent2", "role": "Treatment", "text": "alemtuzumab", "start": 22, "end": 23}, {"entity_id": "19423476_4_Ent3", "role": "Treatment_Drug", "text": "alemtuzumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423476_4_Ent1", "text": "fatal C. neoformans fungemia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19423476_4_Ent0", "text": "a neutropenic patient with a history of chronic lymphocytic leukemia", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "19423476_4_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "19423476_4_Ent2", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19423476_4_Ent3", "text": "alemtuzumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19423610_4", "wnd_id": "19423610_4_1", "text": "We offered several tentative explanations for this event , including an adverse interaction between paroxetine and other agent(s ) used in the course of the anaesthesia .", "tokens": ["We", "offered", "several", "tentative", "explanations", "for", "this", "event", ",", "including", "an", "adverse", "interaction", "between", "paroxetine", "and", "other", "agent(s", ")", "used", "in", "the", "course", "of", "the", "anaesthesia", "."], "event_mentions": [{"id": "19423610_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 13, "end": 14}, "arguments": [{"entity_id": "19423610_4_Ent0", "role": "Effect", "text": "adverse interaction", "start": 11, "end": 13}, {"entity_id": "19423610_4_Ent2", "role": "Treatment_Drug", "text": "paroxetine", "start": 14, "end": 15}, {"entity_id": "19423610_4_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 14, "end": 15}, {"entity_id": "19423610_4_Ent1", "role": "Treatment", "text": "paroxetine and other agent(s )", "start": 14, "end": 19}, {"entity_id": "19423610_4_Ent3", "role": "Treatment_Drug", "text": "anaesthesia", "start": 25, "end": 26}, {"entity_id": "19423610_4_Ent4", "role": "Combination_Drug", "text": "anaesthesia", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19423610_4_Ent0", "text": "adverse interaction", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19423610_4_Ent2", "text": "paroxetine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19423610_4_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19423610_4_Ent1", "text": "paroxetine and other agent(s )", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "19423610_4_Ent3", "text": "anaesthesia", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19423610_4_Ent4", "text": "anaesthesia", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19434733_1", "wnd_id": "19434733_1_1", "text": "Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis .", "tokens": ["Secondary", "acute", "myeloid", "leukemia", "after", "etoposide", "therapy", "for", "haemophagocytic", "lymphohistiocytosis", "."], "event_mentions": [{"id": "19434733_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "19434733_1_Ent0", "role": "Effect", "text": "Secondary acute myeloid leukemia", "start": 0, "end": 4}, {"entity_id": "19434733_1_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_1_Ent1", "role": "Treatment", "text": "etoposide therapy", "start": 5, "end": 7}, {"entity_id": "19434733_1_Ent3", "role": "Treatment_Disorder", "text": "haemophagocytic lymphohistiocytosis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19434733_1_Ent0", "text": "Secondary acute myeloid leukemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19434733_1_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_1_Ent1", "text": "etoposide therapy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19434733_1_Ent3", "text": "haemophagocytic lymphohistiocytosis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19434733_3", "wnd_id": "19434733_3_1", "text": "Two patients with HLH developed etoposide - related secondary acute myeloid leukemia ( sAML ) following therapy for HLH .", "tokens": ["Two", "patients", "with", "HLH", "developed", "etoposide", "-", "related", "secondary", "acute", "myeloid", "leukemia", "(", "sAML", ")", "following", "therapy", "for", "HLH", "."], "event_mentions": [{"id": "19434733_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "19434733_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "19434733_3_Ent0", "role": "Subject", "text": "Two patients with HLH", "start": 0, "end": 4}, {"entity_id": "19434733_3_Ent4", "role": "Treatment_Disorder", "text": "HLH", "start": 3, "end": 4}, {"entity_id": "19434733_3_Ent3", "role": "Treatment", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_3_Ent5", "role": "Treatment_Drug", "text": "etoposide", "start": 5, "end": 6}, {"entity_id": "19434733_3_Ent2", "role": "Effect", "text": "secondary acute myeloid leukemia ( sAML )", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "19434733_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19434733_3_Ent0", "text": "Two patients with HLH", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19434733_3_Ent4", "text": "HLH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19434733_3_Ent3", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_3_Ent5", "text": "etoposide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19434733_3_Ent2", "text": "secondary acute myeloid leukemia ( sAML )", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "19499966_2", "wnd_id": "19499966_2_1", "text": "However , re - initiation of sunitinib treatment was followed by bilateral breast enlargement again .", "tokens": ["However", ",", "re", "-", "initiation", "of", "sunitinib", "treatment", "was", "followed", "by", "bilateral", "breast", "enlargement", "again", "."], "event_mentions": [{"id": "19499966_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19499966_2_Ent1", "role": "Treatment", "text": "sunitinib", "start": 6, "end": 7}, {"entity_id": "19499966_2_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 6, "end": 7}, {"entity_id": "19499966_2_Ent0", "role": "Effect", "text": "bilateral breast enlargement", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19499966_2_Ent1", "text": "sunitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19499966_2_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19499966_2_Ent0", "text": "bilateral breast enlargement", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19499966_3", "wnd_id": "19499966_3_1", "text": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma .", "tokens": ["Onset", "of", "male", "gynaecomastia", "in", "a", "patient", "treated", "with", "sunitinib", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19499966_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Onset", "start": 0, "end": 1}, "arguments": [{"entity_id": "19499966_3_Ent0", "role": "Subject", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent3", "role": "Effect", "text": "gynaecomastia", "start": 3, "end": 4}, {"entity_id": "19499966_3_Ent1", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "19499966_3_Ent6", "role": "Treatment_Drug", "text": "sunitinib", "start": 9, "end": 10}, {"entity_id": "19499966_3_Ent4", "role": "Treatment", "text": "sunitinib for metastatic renal cell carcinoma", "start": 9, "end": 15}, {"entity_id": "19499966_3_Ent5", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "19499966_3_Ent0", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent3", "text": "gynaecomastia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19499966_3_Ent1", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19499966_3_Ent6", "text": "sunitinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19499966_3_Ent4", "text": "sunitinib for metastatic renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19499966_3_Ent5", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "19531695_12", "wnd_id": "19531695_12_1", "text": "According to the Naranjo probability scale , flecainide was the probable cause of the patient 's delirium ; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "flecainide", "was", "the", "probable", "cause", "of", "the", "patient", "'s", "delirium", ";", "the", "Horn", "Drug", "Interaction", "Probability", "Scale", "indicates", "a", "possible", "pharmacokinetic", "drug", "interaction", "between", "flecainide", "and", "paroxetine", "."], "event_mentions": [{"id": "19531695_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531695_12_Ent2", "role": "Treatment", "text": "flecainide", "start": 7, "end": 8}, {"entity_id": "19531695_12_Ent3", "role": "Treatment_Drug", "text": "flecainide", "start": 7, "end": 8}, {"entity_id": "19531695_12_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "19531695_12_Ent1", "role": "Effect", "text": "delirium", "start": 16, "end": 17}, {"entity_id": "19531695_12_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 31, "end": 32}, {"entity_id": "19531695_12_Ent6", "role": "Combination_Drug", "text": "flecainide", "start": 31, "end": 32}, {"entity_id": "19531695_12_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 33, "end": 34}, {"entity_id": "19531695_12_Ent7", "role": "Combination_Drug", "text": "paroxetine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "19531695_12_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531695_12_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531695_12_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "19531695_12_Ent1", "text": "delirium", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19531695_12_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "19531695_12_Ent6", "text": "flecainide", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "19531695_12_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19531695_12_Ent7", "text": "paroxetine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "19531695_13", "wnd_id": "19531695_13_1", "text": "Supratherapeutic flecainide plasma concentrations may cause delirium .", "tokens": ["Supratherapeutic", "flecainide", "plasma", "concentrations", "may", "cause", "delirium", "."], "event_mentions": [{"id": "19531695_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "19531695_13_Ent1", "role": "Treatment", "text": "Supratherapeutic flecainide plasma concentrations", "start": 0, "end": 4}, {"entity_id": "19531695_13_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 1, "end": 2}, {"entity_id": "19531695_13_Ent0", "role": "Effect", "text": "delirium", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "19531695_13_Ent1", "text": "Supratherapeutic flecainide plasma concentrations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19531695_13_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_13_Ent0", "text": "delirium", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "19531695_5", "wnd_id": "19531695_5_1", "text": "Flecainide had been started 2 weeks prior for atrial fibrillation .", "tokens": ["Flecainide", "had", "been", "started", "2", "weeks", "prior", "for", "atrial", "fibrillation", "."], "event_mentions": [{"id": "19531695_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 7, "end": 8}, "arguments": [{"entity_id": "19531695_5_Ent0", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "19531695_5_Ent2", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "19531695_5_Ent1", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19531695_5_Ent0", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19531695_5_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19531695_5_Ent1", "text": "atrial fibrillation", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19531696_2", "wnd_id": "19531696_2_1", "text": "To report a probable interaction between warfarin and marijuana smoking , resulting in increased international normalized ratio ( INR ) values and bleeding complications .", "tokens": ["To", "report", "a", "probable", "interaction", "between", "warfarin", "and", "marijuana", "smoking", ",", "resulting", "in", "increased", "international", "normalized", "ratio", "(", "INR", ")", "values", "and", "bleeding", "complications", "."], "event_mentions": [{"id": "19531696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531696_2_Ent1", "role": "Treatment", "text": "interaction between warfarin and marijuana smoking", "start": 4, "end": 10}, {"entity_id": "19531696_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent3", "role": "Treatment_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent6", "role": "Combination_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent4", "role": "Treatment_Route", "text": "smoking", "start": 9, "end": 10}, {"entity_id": "19531696_2_Ent0", "role": "Effect", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "start": 13, "end": 24}]}], "entity_mentions": [{"id": "19531696_2_Ent1", "text": "interaction between warfarin and marijuana smoking", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "19531696_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent3", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent6", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent4", "text": "smoking", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531696_2_Ent0", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "entity_type": "Entity", "start": 13, "end": 24}], "lang": "en"}
{"doc_id": "19531696_3", "wnd_id": "19531696_3_1", "text": "A 56 - year - old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement .", "tokens": ["A", "56", "-", "year", "-", "old", "white", "male", "had", "been", "receiving", "chronic", "warfarin", "therapy", "for", "11", "years", "after", "mechanical", "heart", "valve", "replacement", "."], "event_mentions": [{"id": "19531696_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 10, "end": 11}, "arguments": [{"entity_id": "19531696_3_Ent0", "role": "Subject", "text": "A 56 - year - old white male", "start": 0, "end": 8}, {"entity_id": "19531696_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "19531696_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "19531696_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "19531696_3_Ent4", "role": "Treatment", "text": "chronic warfarin therapy for 11 years after mechanical heart valve replacement", "start": 11, "end": 22}, {"entity_id": "19531696_3_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19531696_3_Ent0", "text": "A 56 - year - old white male", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "19531696_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19531696_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_3_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531696_3_Ent4", "text": "chronic warfarin therapy for 11 years after mechanical heart valve replacement", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "19531696_3_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19537383_1", "wnd_id": "19537383_1_1", "text": "Localized dyskeratotic plaque with milia associated with sorafenib .", "tokens": ["Localized", "dyskeratotic", "plaque", "with", "milia", "associated", "with", "sorafenib", "."], "event_mentions": [{"id": "19537383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "19537383_1_Ent0", "role": "Effect", "text": "Localized dyskeratotic plaque with milia", "start": 0, "end": 5}, {"entity_id": "19537383_1_Ent1", "role": "Treatment", "text": "sorafenib", "start": 7, "end": 8}, {"entity_id": "19537383_1_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19537383_1_Ent0", "text": "Localized dyskeratotic plaque with milia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19537383_1_Ent1", "text": "sorafenib", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19537383_1_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19540093_1", "wnd_id": "19540093_1_1", "text": "According to the Naranjo adverse drug reaction probability scale , tigecycline was the probable cause of her acute pancreatitis .", "tokens": ["According", "to", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "tigecycline", "was", "the", "probable", "cause", "of", "her", "acute", "pancreatitis", "."], "event_mentions": [{"id": "19540093_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "19540093_1_Ent1", "role": "Treatment", "text": "tigecycline", "start": 10, "end": 11}, {"entity_id": "19540093_1_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 10, "end": 11}, {"entity_id": "19540093_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "19540093_1_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19540093_1_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19540093_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "19540093_3", "wnd_id": "19540093_3_1", "text": "Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline - induced acute pancreatitis have recently been raised .", "tokens": ["Pancreatitis", "has", "been", "associated", "with", "the", "tetracycline", "class", "of", "antibiotics", "and", "concerns", "about", "tigecycline", "-", "induced", "acute", "pancreatitis", "have", "recently", "been", "raised", "."], "event_mentions": [{"id": "19540093_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "19540093_3_Ent1", "role": "Treatment", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19540093_3_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "19669617_3", "wnd_id": "19669617_3_1", "text": "Acute bilateral phrenic neuropathy following treatment with adalimumab .", "tokens": ["Acute", "bilateral", "phrenic", "neuropathy", "following", "treatment", "with", "adalimumab", "."], "event_mentions": [{"id": "19669617_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "19669617_3_Ent0", "role": "Effect", "text": "Acute bilateral phrenic neuropathy", "start": 0, "end": 4}, {"entity_id": "19669617_3_Ent1", "role": "Treatment", "text": "adalimumab", "start": 7, "end": 8}, {"entity_id": "19669617_3_Ent2", "role": "Treatment_Drug", "text": "adalimumab", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19669617_3_Ent0", "text": "Acute bilateral phrenic neuropathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19669617_3_Ent1", "text": "adalimumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19669617_3_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19687711_3", "wnd_id": "19687711_3_1", "text": "Although the association between SJS / TEN and the sulfonamide class of antibiotics is well established , the increasing prevalence of CA - MRSA has left practitioners with limited regimens to effectively treat skin and soft tissue infections ( SSTIs ) in the outpatient setting .", "tokens": ["Although", "the", "association", "between", "SJS", "/", "TEN", "and", "the", "sulfonamide", "class", "of", "antibiotics", "is", "well", "established", ",", "the", "increasing", "prevalence", "of", "CA", "-", "MRSA", "has", "left", "practitioners", "with", "limited", "regimens", "to", "effectively", "treat", "skin", "and", "soft", "tissue", "infections", "(", "SSTIs", ")", "in", "the", "outpatient", "setting", "."], "event_mentions": [{"id": "19687711_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_3_Ent2", "role": "Effect", "text": "SJS / TEN", "start": 4, "end": 7}, {"entity_id": "19687711_3_Ent3", "role": "Treatment", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent4", "role": "Treatment_Drug", "text": "sulfonamide class of antibiotics", "start": 9, "end": 13}, {"entity_id": "19687711_3_Ent0", "role": "Subject", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent1", "role": "Subject_Disorder", "text": "CA - MRSA", "start": 21, "end": 24}, {"entity_id": "19687711_3_Ent5", "role": "Treatment_Disorder", "text": "skin and soft tissue infections ( SSTIs )", "start": 33, "end": 41}]}], "entity_mentions": [{"id": "19687711_3_Ent2", "text": "SJS / TEN", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19687711_3_Ent3", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent4", "text": "sulfonamide class of antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19687711_3_Ent0", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent1", "text": "CA - MRSA", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19687711_3_Ent5", "text": "skin and soft tissue infections ( SSTIs )", "entity_type": "Entity", "start": 33, "end": 41}], "lang": "en"}
{"doc_id": "19687711_6", "wnd_id": "19687711_6_1", "text": "The potential development of SJS / TEN , a severe life - threatening illness , emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs .", "tokens": ["The", "potential", "development", "of", "SJS", "/", "TEN", ",", "a", "severe", "life", "-", "threatening", "illness", ",", "emphasizes", "the", "need", "for", "judicious", "use", "of", "TMP", "-", "Sx", "and", "close", "monitoring", "and", "follow", "-", "up", "for", "patients", "who", "were", "given", "TMP", "-", "Sx", "for", "SSTIs", "."], "event_mentions": [{"id": "19687711_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 2, "end": 3}, "arguments": [{"entity_id": "19687711_6_Ent1", "role": "Effect", "text": "SJS / TEN , a severe life - threatening illness", "start": 4, "end": 14}, {"entity_id": "19687711_6_Ent0", "role": "Subject", "text": "patients", "start": 33, "end": 34}, {"entity_id": "19687711_6_Ent4", "role": "Treatment_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent6", "role": "Combination_Drug", "text": "TMP", "start": 37, "end": 38}, {"entity_id": "19687711_6_Ent2", "role": "Treatment", "text": "TMP - Sx", "start": 37, "end": 40}, {"entity_id": "19687711_6_Ent5", "role": "Treatment_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent7", "role": "Combination_Drug", "text": "Sx", "start": 39, "end": 40}, {"entity_id": "19687711_6_Ent3", "role": "Treatment_Disorder", "text": "SSTIs", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "19687711_6_Ent1", "text": "SJS / TEN , a severe life - threatening illness", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "19687711_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19687711_6_Ent4", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent6", "text": "TMP", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19687711_6_Ent2", "text": "TMP - Sx", "entity_type": "Entity", "start": 37, "end": 40}, {"id": "19687711_6_Ent5", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent7", "text": "Sx", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19687711_6_Ent3", "text": "SSTIs", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "19707032_1", "wnd_id": "19707032_1_1", "text": "Acute ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery .", "tokens": ["Acute", "ocular", "ischemic", "change", "may", "be", "associated", "with", "intravitreal", "injection", "of", "bevacizumab", "in", "patients", "with", "vascular", "compromised", "diabetic", "retinopathy", "and/or", "underlying", "stenosis", "of", "the", "carotid", "artery", "."], "event_mentions": [{"id": "19707032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "19707032_1_Ent3", "role": "Effect", "text": "Acute ocular ischemic change", "start": 0, "end": 4}, {"entity_id": "19707032_1_Ent6", "role": "Treatment_Dosage", "text": "intravitreal injection", "start": 8, "end": 10}, {"entity_id": "19707032_1_Ent4", "role": "Treatment", "text": "intravitreal injection of bevacizumab", "start": 8, "end": 12}, {"entity_id": "19707032_1_Ent5", "role": "Treatment_Drug", "text": "bevacizumab", "start": 11, "end": 12}, {"entity_id": "19707032_1_Ent0", "role": "Subject", "text": "patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery", "start": 13, "end": 26}, {"entity_id": "19707032_1_Ent1", "role": "Subject_Disorder", "text": "vascular compromised diabetic retinopathy", "start": 15, "end": 19}, {"entity_id": "19707032_1_Ent2", "role": "Subject_Disorder", "text": "underlying stenosis of the carotid artery", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "19707032_1_Ent3", "text": "Acute ocular ischemic change", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19707032_1_Ent6", "text": "intravitreal injection", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "19707032_1_Ent4", "text": "intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "19707032_1_Ent5", "text": "bevacizumab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19707032_1_Ent0", "text": "patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "19707032_1_Ent1", "text": "vascular compromised diabetic retinopathy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19707032_1_Ent2", "text": "underlying stenosis of the carotid artery", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "19707032_2", "wnd_id": "19707032_2_1", "text": "Acute vision loss after intravitreal injection of bevacizumab ( avastin ) associated with ocular ischemic syndrome .", "tokens": ["Acute", "vision", "loss", "after", "intravitreal", "injection", "of", "bevacizumab", "(", "avastin", ")", "associated", "with", "ocular", "ischemic", "syndrome", "."], "event_mentions": [{"id": "19707032_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "19707032_2_Ent0", "role": "Effect", "text": "Acute vision loss", "start": 0, "end": 3}, {"entity_id": "19707032_2_Ent3", "role": "Treatment_Route", "text": "intravitreal injection", "start": 4, "end": 6}, {"entity_id": "19707032_2_Ent2", "role": "Treatment", "text": "intravitreal injection of bevacizumab ( avastin )", "start": 4, "end": 11}, {"entity_id": "19707032_2_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "19707032_2_Ent1", "role": "Effect", "text": "ocular ischemic syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "19707032_2_Ent0", "text": "Acute vision loss", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19707032_2_Ent3", "text": "intravitreal injection", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19707032_2_Ent2", "text": "intravitreal injection of bevacizumab ( avastin )", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "19707032_2_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19707032_2_Ent1", "text": "ocular ischemic syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "19707032_3", "wnd_id": "19707032_3_1", "text": "AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab .", "tokens": ["AIM", ":", "To", "report", "a", "patient", "with", "diabetic", "rubeosis", "who", "suffered", "from", "acute", "retinal", "ischemic", "change", "and", "stroke", "after", "intravitreal", "injection", "of", "bevacizumab", "."], "event_mentions": [{"id": "19707032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 10, "end": 11}, "arguments": [{"entity_id": "19707032_3_Ent0", "role": "Subject", "text": "patient with diabetic rubeosis", "start": 5, "end": 9}, {"entity_id": "19707032_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic rubeosis", "start": 7, "end": 9}, {"entity_id": "19707032_3_Ent1", "role": "Effect", "text": "acute retinal ischemic change and stroke", "start": 12, "end": 18}, {"entity_id": "19707032_3_Ent5", "role": "Treatment_Route", "text": "intravitreal injection", "start": 19, "end": 21}, {"entity_id": "19707032_3_Ent2", "role": "Treatment", "text": "intravitreal injection of bevacizumab", "start": 19, "end": 23}, {"entity_id": "19707032_3_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19707032_3_Ent0", "text": "patient with diabetic rubeosis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19707032_3_Ent3", "text": "diabetic rubeosis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19707032_3_Ent1", "text": "acute retinal ischemic change and stroke", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19707032_3_Ent5", "text": "intravitreal injection", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19707032_3_Ent2", "text": "intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19707032_3_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19707032_6", "wnd_id": "19707032_6_1", "text": "Three days after receiving intravitreal injection of bevacizumab ( 1.25 mg in 0.1 ml ) , he developed acute vision loss and change of consciousness .", "tokens": ["Three", "days", "after", "receiving", "intravitreal", "injection", "of", "bevacizumab", "(", "1.25", "mg", "in", "0.1", "ml", ")", ",", "he", "developed", "acute", "vision", "loss", "and", "change", "of", "consciousness", "."], "event_mentions": [{"id": "19707032_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "19707032_6_Ent4", "role": "Treatment_Route", "text": "intravitreal injection", "start": 4, "end": 6}, {"entity_id": "19707032_6_Ent3", "role": "Treatment", "text": "intravitreal injection of bevacizumab ( 1.25 mg in 0.1 ml ) ,", "start": 4, "end": 16}, {"entity_id": "19707032_6_Ent5", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "19707032_6_Ent6", "role": "Treatment_Dosage", "text": "1.25 mg in 0.1 ml", "start": 9, "end": 14}, {"entity_id": "19707032_6_Ent0", "role": "Subject", "text": "he", "start": 16, "end": 17}, {"entity_id": "19707032_6_Ent1", "role": "Subject_Gender", "text": "he", "start": 16, "end": 17}, {"entity_id": "19707032_6_Ent2", "role": "Effect", "text": "acute vision loss and change of consciousness", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "19707032_6_Ent4", "text": "intravitreal injection", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19707032_6_Ent3", "text": "intravitreal injection of bevacizumab ( 1.25 mg in 0.1 ml ) ,", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "19707032_6_Ent5", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19707032_6_Ent6", "text": "1.25 mg in 0.1 ml", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19707032_6_Ent0", "text": "he", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19707032_6_Ent1", "text": "he", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19707032_6_Ent2", "text": "acute vision loss and change of consciousness", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "19733945_2", "wnd_id": "19733945_2_1", "text": "On day 7 of linezolid treatment , the patient developed severe pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level , and mild hepatitis .", "tokens": ["On", "day", "7", "of", "linezolid", "treatment", ",", "the", "patient", "developed", "severe", "pruritus", ",", "macular", "rash", ",", "facial", "edema", ",", "eosinophilia", ",", "marked", "increase", "in", "serum", "creatinine", "level", ",", "and", "mild", "hepatitis", "."], "event_mentions": [{"id": "19733945_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19733945_2_Ent3", "role": "Treatment", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19733945_2_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19733945_2_Ent0", "role": "Subject", "text": "the patient", "start": 7, "end": 9}, {"entity_id": "19733945_2_Ent1", "role": "Effect", "text": "pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level", "start": 11, "end": 27}, {"entity_id": "19733945_2_Ent2", "role": "Effect", "text": "hepatitis", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19733945_2_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19733945_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19733945_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19733945_2_Ent1", "text": "pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level", "entity_type": "Entity", "start": 11, "end": 27}, {"id": "19733945_2_Ent2", "text": "hepatitis", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19745701_2", "wnd_id": "19745701_2_1", "text": "Reversible methotrexate - associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis .", "tokens": ["Reversible", "methotrexate", "-", "associated", "lymphoproliferative", "disorder", "resembling", "advanced", "gastric", "cancer", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "19745701_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19745701_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent1", "role": "Effect", "text": "lymphoproliferative disorder", "start": 4, "end": 6}, {"entity_id": "19745701_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 11, "end": 16}, {"entity_id": "19745701_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19745701_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent1", "text": "lymphoproliferative disorder", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19745701_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19745701_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19754002_1", "wnd_id": "19754002_1_1", "text": "Mood stabilizer therapy and pravastatin : higher risk for adverse skin reactions ?", "tokens": ["Mood", "stabilizer", "therapy", "and", "pravastatin", ":", "higher", "risk", "for", "adverse", "skin", "reactions", "?"], "event_mentions": [{"id": "19754002_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 7, "end": 8}, "arguments": [{"entity_id": "19754002_1_Ent2", "role": "Treatment_Drug", "text": "Mood stabilizer", "start": 0, "end": 2}, {"entity_id": "19754002_1_Ent4", "role": "Combination_Drug", "text": "Mood stabilizer", "start": 0, "end": 2}, {"entity_id": "19754002_1_Ent1", "role": "Treatment", "text": "Mood stabilizer therapy and pravastatin", "start": 0, "end": 5}, {"entity_id": "19754002_1_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 4, "end": 5}, {"entity_id": "19754002_1_Ent5", "role": "Combination_Drug", "text": "pravastatin", "start": 4, "end": 5}, {"entity_id": "19754002_1_Ent0", "role": "Effect", "text": "adverse skin reactions", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "19754002_1_Ent2", "text": "Mood stabilizer", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19754002_1_Ent4", "text": "Mood stabilizer", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19754002_1_Ent1", "text": "Mood stabilizer therapy and pravastatin", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19754002_1_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19754002_1_Ent5", "text": "pravastatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19754002_1_Ent0", "text": "adverse skin reactions", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "1977935_6", "wnd_id": "1977935_6_1", "text": "We believe that a drug interaction between terfenadine and ketoconazole resulted in the elevated terfenadine levels in plasma and in the cardiotoxicity previously seen only in cases of terfenadine overdose .", "tokens": ["We", "believe", "that", "a", "drug", "interaction", "between", "terfenadine", "and", "ketoconazole", "resulted", "in", "the", "elevated", "terfenadine", "levels", "in", "plasma", "and", "in", "the", "cardiotoxicity", "previously", "seen", "only", "in", "cases", "of", "terfenadine", "overdose", "."], "event_mentions": [{"id": "1977935_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 10, "end": 11}, "arguments": [{"entity_id": "1977935_6_Ent1", "role": "Treatment", "text": "a drug interaction between terfenadine and ketoconazole", "start": 3, "end": 10}, {"entity_id": "1977935_6_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_6_Ent4", "role": "Combination_Drug", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_6_Ent3", "role": "Treatment_Drug", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "1977935_6_Ent5", "role": "Combination_Drug", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "1977935_6_Ent0", "role": "Effect", "text": "the elevated terfenadine levels in plasma and in the cardiotoxicity", "start": 12, "end": 22}]}], "entity_mentions": [{"id": "1977935_6_Ent1", "text": "a drug interaction between terfenadine and ketoconazole", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "1977935_6_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_6_Ent4", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_6_Ent3", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1977935_6_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1977935_6_Ent0", "text": "the elevated terfenadine levels in plasma and in the cardiotoxicity", "entity_type": "Entity", "start": 12, "end": 22}], "lang": "en"}
{"doc_id": "19782276_1", "wnd_id": "19782276_1_1", "text": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy .", "tokens": ["Fulminant", "fatal", "cardiotoxicity", "following", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "19782276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19782276_1_Ent0", "role": "Effect", "text": "Fulminant fatal cardiotoxicity", "start": 0, "end": 3}, {"entity_id": "19782276_1_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "19782276_1_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19782276_1_Ent0", "text": "Fulminant fatal cardiotoxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19782276_1_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19782276_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19789166_1", "wnd_id": "19789166_1_1", "text": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels , restoring most of them to normal , we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin .", "tokens": ["Given", "that", "discontinuation", "of", "nitrofurantoin", "and", "introduction", "of", "methylprednisolon", "therapy", "significantly", "lowered", "liver", "enzyme", "levels", ",", "restoring", "most", "of", "them", "to", "normal", ",", "we", "concluded", "that", "this", "was", "probably", "the", "case", "of", "toxic", "liver", "damage", "caused", "by", "nitrofurantoin", "."], "event_mentions": [{"id": "19789166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 35, "end": 36}, "arguments": [{"entity_id": "19789166_1_Ent0", "role": "Effect", "text": "toxic liver damage", "start": 32, "end": 35}, {"entity_id": "19789166_1_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 37, "end": 38}, {"entity_id": "19789166_1_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "19789166_1_Ent0", "text": "toxic liver damage", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "19789166_1_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19789166_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "19826099_2", "wnd_id": "19826099_2_1", "text": "Severe apnea in an infant exposed to lamotrigine in breast milk .", "tokens": ["Severe", "apnea", "in", "an", "infant", "exposed", "to", "lamotrigine", "in", "breast", "milk", "."], "event_mentions": [{"id": "19826099_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "19826099_2_Ent2", "role": "Effect", "text": "apnea", "start": 1, "end": 2}, {"entity_id": "19826099_2_Ent0", "role": "Subject", "text": "an infant", "start": 3, "end": 5}, {"entity_id": "19826099_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 4, "end": 5}, {"entity_id": "19826099_2_Ent3", "role": "Treatment", "text": "lamotrigine", "start": 7, "end": 8}, {"entity_id": "19826099_2_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 7, "end": 8}, {"entity_id": "19826099_2_Ent5", "role": "Treatment_Route", "text": "breast milk", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "19826099_2_Ent2", "text": "apnea", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19826099_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19826099_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19826099_2_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19826099_2_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19826099_2_Ent5", "text": "breast milk", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "19826099_3", "wnd_id": "19826099_3_1", "text": "The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast - feeding in this infant .", "tokens": ["The", "Naranjo", "probability", "scale", "indicated", "a", "probable", "relationship", "between", "apnea", "and", "exposure", "to", "lamotrigine", "through", "breast", "-", "feeding", "in", "this", "infant", "."], "event_mentions": [{"id": "19826099_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "a probable relationship", "start": 5, "end": 8}, "arguments": [{"entity_id": "19826099_3_Ent2", "role": "Effect", "text": "apnea", "start": 9, "end": 10}, {"entity_id": "19826099_3_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "19826099_3_Ent3", "role": "Treatment", "text": "lamotrigine through breast - feeding", "start": 13, "end": 18}, {"entity_id": "19826099_3_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 15, "end": 18}, {"entity_id": "19826099_3_Ent0", "role": "Subject", "text": "in this infant", "start": 18, "end": 21}, {"entity_id": "19826099_3_Ent1", "role": "Subject_Age", "text": "infant", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19826099_3_Ent2", "text": "apnea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19826099_3_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19826099_3_Ent3", "text": "lamotrigine through breast - feeding", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19826099_3_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19826099_3_Ent0", "text": "in this infant", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19826099_3_Ent1", "text": "infant", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19884751_2", "wnd_id": "19884751_2_1", "text": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug , Amikacin .", "tokens": ["Recovery", "of", "the", "tubular", "dysfunction", "took", "15", "days", "following", "cessation", "of", "the", "offending", "drug", ",", "Amikacin", "."], "event_mentions": [{"id": "19884751_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Recovery", "start": 0, "end": 1}, "arguments": [{"entity_id": "19884751_2_Ent1", "role": "Treatment_Disorder", "text": "tubular dysfunction", "start": 3, "end": 5}, {"entity_id": "19884751_2_Ent3", "role": "Treatment_Time_elapsed", "text": "15 days", "start": 6, "end": 8}, {"entity_id": "19884751_2_Ent0", "role": "Treatment", "text": "15 days following cessation of the offending drug , Amikacin", "start": 6, "end": 16}, {"entity_id": "19884751_2_Ent4", "role": "Treatment_Dosage", "text": "cessation", "start": 9, "end": 10}, {"entity_id": "19884751_2_Ent2", "role": "Treatment_Drug", "text": "Amikacin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "19884751_2_Ent1", "text": "tubular dysfunction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19884751_2_Ent3", "text": "15 days", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19884751_2_Ent0", "text": "15 days following cessation of the offending drug , Amikacin", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "19884751_2_Ent4", "text": "cessation", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19884751_2_Ent2", "text": "Amikacin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "19904536_1", "wnd_id": "19904536_1_1", "text": "Fatal gemcitabine - induced pulmonary toxicity in metastatic gallbladder adenocarcinoma .", "tokens": ["Fatal", "gemcitabine", "-", "induced", "pulmonary", "toxicity", "in", "metastatic", "gallbladder", "adenocarcinoma", "."], "event_mentions": [{"id": "19904536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19904536_1_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_1_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_1_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}, {"entity_id": "19904536_1_Ent3", "role": "Treatment_Disorder", "text": "metastatic gallbladder adenocarcinoma", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "19904536_1_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_1_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19904536_1_Ent3", "text": "metastatic gallbladder adenocarcinoma", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "19904536_14", "wnd_id": "19904536_14_1", "text": "Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy , mainly in elderly patients .", "tokens": ["Physicians", "should", "suspect", "pulmonary", "toxicity", "in", "patients", "with", "respiratory", "distress", "after", "gemcitabine", "chemotherapy", ",", "mainly", "in", "elderly", "patients", "."], "event_mentions": [{"id": "19904536_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "19904536_14_Ent2", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}, {"entity_id": "19904536_14_Ent0", "role": "Subject", "text": "patients with respiratory distress", "start": 6, "end": 10}, {"entity_id": "19904536_14_Ent5", "role": "Treatment_Disorder", "text": "respiratory distress", "start": 8, "end": 10}, {"entity_id": "19904536_14_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "19904536_14_Ent3", "role": "Treatment", "text": "gemcitabine chemotherapy", "start": 11, "end": 13}, {"entity_id": "19904536_14_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "19904536_14_Ent1", "role": "Subject", "text": "mainly in elderly patients", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "19904536_14_Ent2", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19904536_14_Ent0", "text": "patients with respiratory distress", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19904536_14_Ent5", "text": "respiratory distress", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "19904536_14_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19904536_14_Ent3", "text": "gemcitabine chemotherapy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19904536_14_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19904536_14_Ent1", "text": "mainly in elderly patients", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "19904536_3", "wnd_id": "19904536_3_1", "text": "In this report , we describe a fatal gemcitabine - induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma .", "tokens": ["In", "this", "report", ",", "we", "describe", "a", "fatal", "gemcitabine", "-", "induced", "pulmonary", "toxicity", "in", "a", "patient", "with", "gallbladder", "metastatic", "adenocarcinoma", "."], "event_mentions": [{"id": "19904536_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19904536_3_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "19904536_3_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "19904536_3_Ent1", "role": "Effect", "text": "pulmonary toxicity", "start": 11, "end": 13}, {"entity_id": "19904536_3_Ent0", "role": "Subject", "text": "a patient with gallbladder metastatic adenocarcinoma", "start": 14, "end": 20}, {"entity_id": "19904536_3_Ent3", "role": "Treatment_Disorder", "text": "gallbladder metastatic adenocarcinoma", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "19904536_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19904536_3_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19904536_3_Ent1", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19904536_3_Ent0", "text": "a patient with gallbladder metastatic adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "19904536_3_Ent3", "text": "gallbladder metastatic adenocarcinoma", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "19915794_3", "wnd_id": "19915794_3_1", "text": "Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice .", "tokens": ["Torsades", "de", "Pointes", "induced", "by", "a", "combination", "of", "garenoxacin", "and", "disopyramide", "and", "other", "cytochrome", "P450", ",", "family", "3", ",", "subfamily", "A", "polypeptide", "-", "4", "-", "influencing", "drugs", "during", "hypokalemia", "due", "to", "licorice", "."], "event_mentions": [{"id": "19915794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19915794_3_Ent0", "role": "Effect", "text": "Torsades de Pointes", "start": 0, "end": 3}, {"entity_id": "19915794_3_Ent1", "role": "Treatment", "text": "a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 5, "end": 27}, {"entity_id": "19915794_3_Ent2", "role": "Treatment_Drug", "text": "garenoxacin", "start": 8, "end": 9}, {"entity_id": "19915794_3_Ent5", "role": "Combination_Drug", "text": "garenoxacin", "start": 8, "end": 9}, {"entity_id": "19915794_3_Ent3", "role": "Treatment_Drug", "text": "disopyramide", "start": 10, "end": 11}, {"entity_id": "19915794_3_Ent6", "role": "Combination_Drug", "text": "disopyramide", "start": 10, "end": 11}, {"entity_id": "19915794_3_Ent4", "role": "Treatment_Drug", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 13, "end": 27}, {"entity_id": "19915794_3_Ent7", "role": "Combination_Drug", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 13, "end": 27}]}], "entity_mentions": [{"id": "19915794_3_Ent0", "text": "Torsades de Pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19915794_3_Ent1", "text": "a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 5, "end": 27}, {"id": "19915794_3_Ent2", "text": "garenoxacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_3_Ent5", "text": "garenoxacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_3_Ent3", "text": "disopyramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19915794_3_Ent6", "text": "disopyramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19915794_3_Ent4", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "19915794_3_Ent7", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 13, "end": 27}], "lang": "en"}
{"doc_id": "19934385_2", "wnd_id": "19934385_2_1", "text": "To report the results of therapeutic drug monitoring of lopinavir / ritonavir and itraconazole concentrations in an HIV - infected male who was treated for histoplasmosis .", "tokens": ["To", "report", "the", "results", "of", "therapeutic", "drug", "monitoring", "of", "lopinavir", "/", "ritonavir", "and", "itraconazole", "concentrations", "in", "an", "HIV", "-", "infected", "male", "who", "was", "treated", "for", "histoplasmosis", "."], "event_mentions": [{"id": "19934385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 23, "end": 24}, "arguments": [{"entity_id": "19934385_2_Ent7", "role": "Treatment_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent8", "role": "Combination_Drug", "text": "lopinavir", "start": 9, "end": 10}, {"entity_id": "19934385_2_Ent2", "role": "Treatment", "text": "lopinavir / ritonavir and itraconazole concentrations", "start": 9, "end": 15}, {"entity_id": "19934385_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 11, "end": 12}, {"entity_id": "19934385_2_Ent5", "role": "Treatment_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent10", "role": "Combination_Drug", "text": "itraconazole", "start": 13, "end": 14}, {"entity_id": "19934385_2_Ent0", "role": "Subject", "text": "an HIV - infected male", "start": 16, "end": 21}, {"entity_id": "19934385_2_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 17, "end": 18}, {"entity_id": "19934385_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 20, "end": 21}, {"entity_id": "19934385_2_Ent3", "role": "Treatment_Disorder", "text": "histoplasmosis", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19934385_2_Ent7", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent8", "text": "lopinavir", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_2_Ent2", "text": "lopinavir / ritonavir and itraconazole concentrations", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19934385_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19934385_2_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent10", "text": "itraconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19934385_2_Ent0", "text": "an HIV - infected male", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19934385_2_Ent4", "text": "HIV", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_2_Ent1", "text": "male", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19934385_2_Ent3", "text": "histoplasmosis", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19934385_3", "wnd_id": "19934385_3_1", "text": "A 34 - year - old HIV - infected man who had recently initiated efavirenz - based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection .", "tokens": ["A", "34", "-", "year", "-", "old", "HIV", "-", "infected", "man", "who", "had", "recently", "initiated", "efavirenz", "-", "based", "antiretroviral", "therapy", "was", "diagnosed", "with", "disseminated", "Histoplasma", "capsulatum", "infection", "."], "event_mentions": [{"id": "19934385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 13, "end": 14}, "arguments": [{"entity_id": "19934385_3_Ent0", "role": "Subject", "text": "A 34 - year - old HIV - infected man", "start": 0, "end": 10}, {"entity_id": "19934385_3_Ent2", "role": "Subject_Age", "text": "34 - year - old", "start": 1, "end": 6}, {"entity_id": "19934385_3_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "19934385_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "19934385_3_Ent4", "role": "Treatment", "text": "initiated efavirenz - based antiretroviral therapy", "start": 13, "end": 19}, {"entity_id": "19934385_3_Ent6", "role": "Treatment_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent8", "role": "Combination_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent7", "role": "Treatment_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent9", "role": "Combination_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent1", "role": "Subject_Disorder", "text": "disseminated Histoplasma capsulatum infection", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "19934385_3_Ent0", "text": "A 34 - year - old HIV - infected man", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "19934385_3_Ent2", "text": "34 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19934385_3_Ent5", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19934385_3_Ent3", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_3_Ent4", "text": "initiated efavirenz - based antiretroviral therapy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "19934385_3_Ent6", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent8", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent7", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent9", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent1", "text": "disseminated Histoplasma capsulatum infection", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "19949685_1", "wnd_id": "19949685_1_1", "text": "Colonic mucosal necrosis following administration of calcium polystryrene sulfonate ( Kalimate ) in a uremic patient .", "tokens": ["Colonic", "mucosal", "necrosis", "following", "administration", "of", "calcium", "polystryrene", "sulfonate", "(", "Kalimate", ")", "in", "a", "uremic", "patient", "."], "event_mentions": [{"id": "19949685_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 4, "end": 5}, "arguments": [{"entity_id": "19949685_1_Ent1", "role": "Effect", "text": "Colonic mucosal necrosis", "start": 0, "end": 3}, {"entity_id": "19949685_1_Ent3", "role": "Treatment_Drug", "text": "calcium polystryrene sulfonate", "start": 6, "end": 9}, {"entity_id": "19949685_1_Ent2", "role": "Treatment", "text": "calcium polystryrene sulfonate ( Kalimate )", "start": 6, "end": 12}, {"entity_id": "19949685_1_Ent4", "role": "Treatment_Disorder", "text": "uremic", "start": 14, "end": 15}, {"entity_id": "19949685_1_Ent0", "role": "Subject", "text": "uremic patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19949685_1_Ent1", "text": "Colonic mucosal necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19949685_1_Ent3", "text": "calcium polystryrene sulfonate", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_1_Ent2", "text": "calcium polystryrene sulfonate ( Kalimate )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "19949685_1_Ent4", "text": "uremic", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19949685_1_Ent0", "text": "uremic patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19949685_2", "wnd_id": "19949685_2_1", "text": "Colonic necrosis is known as a rare complication following the administration of Kayexalate ( sodium polystryrene sulfonate ) in sorbitol .", "tokens": ["Colonic", "necrosis", "is", "known", "as", "a", "rare", "complication", "following", "the", "administration", "of", "Kayexalate", "(", "sodium", "polystryrene", "sulfonate", ")", "in", "sorbitol", "."], "event_mentions": [{"id": "19949685_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "19949685_2_Ent0", "role": "Effect", "text": "Colonic necrosis", "start": 0, "end": 2}, {"entity_id": "19949685_2_Ent2", "role": "Treatment_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent5", "role": "Combination_Drug", "text": "Kayexalate", "start": 12, "end": 13}, {"entity_id": "19949685_2_Ent1", "role": "Treatment", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "start": 12, "end": 20}, {"entity_id": "19949685_2_Ent3", "role": "Treatment_Drug", "text": "sorbitol", "start": 19, "end": 20}, {"entity_id": "19949685_2_Ent4", "role": "Combination_Drug", "text": "sorbitol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19949685_2_Ent0", "text": "Colonic necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_2_Ent2", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19949685_2_Ent1", "text": "Kayexalate ( sodium polystryrene sulfonate ) in sorbitol", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "19949685_2_Ent3", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19949685_2_Ent4", "text": "sorbitol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19949685_4", "wnd_id": "19949685_4_1", "text": "We report a rare case of colonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol in a 34 - yr - old man .", "tokens": ["We", "report", "a", "rare", "case", "of", "colonic", "mucosal", "necrosis", "following", "Kalimate", "(", "calcium", "polystryrene", "sulfonate", ")", ",", "an", "analogue", "of", "Kayexalate", "without", "sorbitol", "in", "a", "34", "-", "yr", "-", "old", "man", "."], "event_mentions": [{"id": "19949685_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "19949685_4_Ent3", "role": "Effect", "text": "colonic mucosal necrosis", "start": 6, "end": 9}, {"entity_id": "19949685_4_Ent5", "role": "Treatment_Drug", "text": "Kalimate", "start": 10, "end": 11}, {"entity_id": "19949685_4_Ent4", "role": "Treatment", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "start": 10, "end": 23}, {"entity_id": "19949685_4_Ent6", "role": "Treatment_Drug", "text": "( calcium polystryrene sulfonate )", "start": 11, "end": 16}, {"entity_id": "19949685_4_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 20, "end": 21}, {"entity_id": "19949685_4_Ent0", "role": "Subject", "text": "a 34 - yr - old man", "start": 24, "end": 31}, {"entity_id": "19949685_4_Ent1", "role": "Subject_Age", "text": "34 - yr - old", "start": 25, "end": 30}, {"entity_id": "19949685_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19949685_4_Ent3", "text": "colonic mucosal necrosis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_4_Ent5", "text": "Kalimate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19949685_4_Ent4", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "19949685_4_Ent6", "text": "( calcium polystryrene sulfonate )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19949685_4_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19949685_4_Ent0", "text": "a 34 - yr - old man", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "19949685_4_Ent1", "text": "34 - yr - old", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "19949685_4_Ent2", "text": "man", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "20020238_1", "wnd_id": "20020238_1_1", "text": "BACKGROUND : To assess the nature , incidence , and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients .", "tokens": ["BACKGROUND", ":", "To", "assess", "the", "nature", ",", "incidence", ",", "and", "risk", "factors", "of", "retinopathy", "associated", "with", "pegylated", "interferon", "and", "ribavirin", "combination", "therapy", "in", "chronic", "hepatitis", "C", "patients", "."], "event_mentions": [{"id": "20020238_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "20020238_1_Ent1", "role": "Effect", "text": "retinopathy", "start": 13, "end": 14}, {"entity_id": "20020238_1_Ent4", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 16, "end": 18}, {"entity_id": "20020238_1_Ent7", "role": "Combination_Drug", "text": "pegylated interferon", "start": 16, "end": 18}, {"entity_id": "20020238_1_Ent2", "role": "Treatment", "text": "pegylated interferon and ribavirin combination therapy", "start": 16, "end": 22}, {"entity_id": "20020238_1_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 19, "end": 20}, {"entity_id": "20020238_1_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 19, "end": 20}, {"entity_id": "20020238_1_Ent5", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 23, "end": 26}, {"entity_id": "20020238_1_Ent0", "role": "Subject", "text": "chronic hepatitis C patients", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "20020238_1_Ent1", "text": "retinopathy", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20020238_1_Ent4", "text": "pegylated interferon", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "20020238_1_Ent7", "text": "pegylated interferon", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "20020238_1_Ent2", "text": "pegylated interferon and ribavirin combination therapy", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "20020238_1_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "20020238_1_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "20020238_1_Ent5", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "20020238_1_Ent0", "text": "chronic hepatitis C patients", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "2006943_1", "wnd_id": "2006943_1_1", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block ) during ritodrine therapy for preterm labor .", "tokens": ["Type", "I", "second", "-", "degree", "AV", "block", "(", "Mobitz", "type", "I", ",", "Wenckebach", "AV", "block", ")", "during", "ritodrine", "therapy", "for", "preterm", "labor", "."], "event_mentions": [{"id": "2006943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 16, "end": 17}, "arguments": [{"entity_id": "2006943_1_Ent0", "role": "Effect", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "start": 0, "end": 16}, {"entity_id": "2006943_1_Ent1", "role": "Treatment", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent3", "role": "Treatment_Drug", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent2", "role": "Treatment_Disorder", "text": "preterm labor", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2006943_1_Ent0", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "2006943_1_Ent1", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent3", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent2", "text": "preterm labor", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "20076952_11", "wnd_id": "20076952_11_1", "text": "The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid - associated adverse effects .", "tokens": ["The", "clinical", "use", "of", "itraconazole", "in", "patients", "receiving", "multiple", "doses", "of", "oxycodone", "for", "pain", "relief", "may", "increase", "the", "risk", "of", "opioid", "-", "associated", "adverse", "effects", "."], "event_mentions": [{"id": "20076952_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 16, "end": 17}, "arguments": [{"entity_id": "20076952_11_Ent2", "role": "Treatment", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent8", "role": "Combination_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "20076952_11_Ent3", "role": "Treatment", "text": "receiving multiple doses of oxycodone", "start": 7, "end": 12}, {"entity_id": "20076952_11_Ent7", "role": "Treatment_Dosage", "text": "multiple doses", "start": 8, "end": 10}, {"entity_id": "20076952_11_Ent5", "role": "Treatment_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent9", "role": "Combination_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent4", "role": "Treatment_Disorder", "text": "pain relief", "start": 13, "end": 15}, {"entity_id": "20076952_11_Ent1", "role": "Effect", "text": "opioid - associated adverse effects", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "20076952_11_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent8", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20076952_11_Ent3", "text": "receiving multiple doses of oxycodone", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20076952_11_Ent7", "text": "multiple doses", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20076952_11_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent9", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent4", "text": "pain relief", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "20076952_11_Ent1", "text": "opioid - associated adverse effects", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "20098333_1", "wnd_id": "20098333_1_1", "text": "Exacerbation of anthracycline - induced early chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of cardiac dysfunction .", "tokens": ["Exacerbation", "of", "anthracycline", "-", "induced", "early", "chronic", "cardiomyopathy", "with", "ATRA", ":", "role", "of", "B", "-", "type", "natriuretic", "peptide", "as", "an", "indicator", "of", "cardiac", "dysfunction", "."], "event_mentions": [{"id": "20098333_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "20098333_1_Ent1", "role": "Treatment", "text": "anthracycline", "start": 2, "end": 3}, {"entity_id": "20098333_1_Ent3", "role": "Treatment_Drug", "text": "anthracycline", "start": 2, "end": 3}, {"entity_id": "20098333_1_Ent5", "role": "Combination_Drug", "text": "anthracycline", "start": 2, "end": 3}, {"entity_id": "20098333_1_Ent0", "role": "Effect", "text": "early chronic cardiomyopathy", "start": 5, "end": 8}, {"entity_id": "20098333_1_Ent2", "role": "Treatment", "text": "with ATRA", "start": 8, "end": 10}, {"entity_id": "20098333_1_Ent4", "role": "Treatment_Drug", "text": "ATRA", "start": 9, "end": 10}, {"entity_id": "20098333_1_Ent6", "role": "Combination_Drug", "text": "ATRA", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "20098333_1_Ent1", "text": "anthracycline", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20098333_1_Ent3", "text": "anthracycline", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20098333_1_Ent5", "text": "anthracycline", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20098333_1_Ent0", "text": "early chronic cardiomyopathy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20098333_1_Ent2", "text": "with ATRA", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20098333_1_Ent4", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20098333_1_Ent6", "text": "ATRA", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20110001_4", "wnd_id": "20110001_4_1", "text": "OBJECTIVE : We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib .", "tokens": ["OBJECTIVE", ":", "We", "report", "a", "case", "of", "cutaneous", "KS", "lesions", "in", "a", "patient", "affected", "by", "CML", "treated", "with", "imatinib", "."], "event_mentions": [{"id": "20110001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "20110001_4_Ent1", "role": "Effect", "text": "cutaneous KS lesions", "start": 7, "end": 10}, {"entity_id": "20110001_4_Ent0", "role": "Subject", "text": "a patient affected by CML", "start": 11, "end": 16}, {"entity_id": "20110001_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 15, "end": 16}, {"entity_id": "20110001_4_Ent2", "role": "Treatment", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "20110001_4_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20110001_4_Ent1", "text": "cutaneous KS lesions", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20110001_4_Ent0", "text": "a patient affected by CML", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "20110001_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20110001_4_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20110001_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2011096_1", "wnd_id": "2011096_1_1", "text": "Bulbar and pseudobulbar palsy complicating therapy with high - dose cytosine arabinoside in children with leukemia .", "tokens": ["Bulbar", "and", "pseudobulbar", "palsy", "complicating", "therapy", "with", "high", "-", "dose", "cytosine", "arabinoside", "in", "children", "with", "leukemia", "."], "event_mentions": [{"id": "2011096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "2011096_1_Ent2", "role": "Effect", "text": "Bulbar and pseudobulbar palsy", "start": 0, "end": 4}, {"entity_id": "2011096_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2011096_1_Ent3", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 7, "end": 12}, {"entity_id": "2011096_1_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 10, "end": 12}, {"entity_id": "2011096_1_Ent1", "role": "Subject_Age", "text": "children", "start": 13, "end": 14}, {"entity_id": "2011096_1_Ent0", "role": "Subject", "text": "children with leukemia", "start": 13, "end": 16}, {"entity_id": "2011096_1_Ent6", "role": "Treatment_Disorder", "text": "leukemia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2011096_1_Ent2", "text": "Bulbar and pseudobulbar palsy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2011096_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2011096_1_Ent3", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2011096_1_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2011096_1_Ent1", "text": "children", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2011096_1_Ent0", "text": "children with leukemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "2011096_1_Ent6", "text": "leukemia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20118434_1", "wnd_id": "20118434_1_1", "text": "Interferon - based treatments have the potential to decrease the burden of disease , but are complicated by side effects , including neuropsychiatric symptoms .", "tokens": ["Interferon", "-", "based", "treatments", "have", "the", "potential", "to", "decrease", "the", "burden", "of", "disease", ",", "but", "are", "complicated", "by", "side", "effects", ",", "including", "neuropsychiatric", "symptoms", "."], "event_mentions": [{"id": "20118434_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 16, "end": 17}, "arguments": [{"entity_id": "20118434_1_Ent1", "role": "Treatment", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_1_Ent2", "role": "Treatment_Drug", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_1_Ent0", "role": "Effect", "text": "neuropsychiatric symptoms", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "20118434_1_Ent1", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_1_Ent2", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_1_Ent0", "text": "neuropsychiatric symptoms", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "20118434_2", "wnd_id": "20118434_2_1", "text": "Interferon - induced psychosis as a \" psychiatric contraindication \" to hepatitis C treatment : a review and case - based discussion .", "tokens": ["Interferon", "-", "induced", "psychosis", "as", "a", "\"", "psychiatric", "contraindication", "\"", "to", "hepatitis", "C", "treatment", ":", "a", "review", "and", "case", "-", "based", "discussion", "."], "event_mentions": [{"id": "20118434_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "20118434_2_Ent1", "role": "Treatment", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_2_Ent2", "role": "Treatment_Drug", "text": "Interferon", "start": 0, "end": 1}, {"entity_id": "20118434_2_Ent0", "role": "Effect", "text": "psychosis", "start": 3, "end": 4}, {"entity_id": "20118434_2_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20118434_2_Ent1", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_2_Ent2", "text": "Interferon", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20118434_2_Ent0", "text": "psychosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20118434_2_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "20120657_1", "wnd_id": "20120657_1_1", "text": "CONCLUSION : Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy .", "tokens": ["CONCLUSION", ":", "Zidovudine", "is", "well", "a", "known", "cause", "of", "anaemia", "and", "thus", "should", "be", "used", "with", "caution", "in", "the", "initiation", "of", "antiretroviral", "therapy", "."], "event_mentions": [{"id": "20120657_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "20120657_1_Ent1", "role": "Treatment", "text": "Zidovudine", "start": 2, "end": 3}, {"entity_id": "20120657_1_Ent2", "role": "Treatment_Drug", "text": "Zidovudine", "start": 2, "end": 3}, {"entity_id": "20120657_1_Ent0", "role": "Effect", "text": "anaemia", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "20120657_1_Ent1", "text": "Zidovudine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20120657_1_Ent2", "text": "Zidovudine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20120657_1_Ent0", "text": "anaemia", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2012922_2", "wnd_id": "2012922_2_1", "text": "Trazodone - induced transient hypomanic symptoms and their management .", "tokens": ["Trazodone", "-", "induced", "transient", "hypomanic", "symptoms", "and", "their", "management", "."], "event_mentions": [{"id": "2012922_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2012922_2_Ent1", "role": "Treatment", "text": "Trazodone", "start": 0, "end": 1}, {"entity_id": "2012922_2_Ent2", "role": "Treatment_Drug", "text": "Trazodone", "start": 0, "end": 1}, {"entity_id": "2012922_2_Ent0", "role": "Effect", "text": "transient hypomanic symptoms", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "2012922_2_Ent1", "text": "Trazodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2012922_2_Ent2", "text": "Trazodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2012922_2_Ent0", "text": "transient hypomanic symptoms", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "2016556_1", "wnd_id": "2016556_1_1", "text": "We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small , stable dose of oral morphine in the setting of mild renal insufficiency .", "tokens": ["We", "describe", "a", "patient", "who", "experienced", "chronic", "nausea", "and", "an", "episode", "of", "confusion", "while", "treated", "with", "a", "small", ",", "stable", "dose", "of", "oral", "morphine", "in", "the", "setting", "of", "mild", "renal", "insufficiency", "."], "event_mentions": [{"id": "2016556_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "2016556_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "2016556_1_Ent2", "role": "Effect", "text": "chronic nausea and an episode of confusion", "start": 6, "end": 13}, {"entity_id": "2016556_1_Ent3", "role": "Treatment", "text": "a small , stable dose of oral morphine", "start": 16, "end": 24}, {"entity_id": "2016556_1_Ent4", "role": "Treatment_Dosage", "text": "small , stable dose", "start": 17, "end": 21}, {"entity_id": "2016556_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 22, "end": 23}, {"entity_id": "2016556_1_Ent6", "role": "Treatment_Drug", "text": "morphine", "start": 23, "end": 24}, {"entity_id": "2016556_1_Ent1", "role": "Subject_Disorder", "text": "mild renal insufficiency", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "2016556_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2016556_1_Ent2", "text": "chronic nausea and an episode of confusion", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "2016556_1_Ent3", "text": "a small , stable dose of oral morphine", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "2016556_1_Ent4", "text": "small , stable dose", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "2016556_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2016556_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2016556_1_Ent1", "text": "mild renal insufficiency", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "20178709_3", "wnd_id": "20178709_3_1", "text": "We report here a rare case of pleuropericarditis due to methotrexate .", "tokens": ["We", "report", "here", "a", "rare", "case", "of", "pleuropericarditis", "due", "to", "methotrexate", "."], "event_mentions": [{"id": "20178709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "20178709_3_Ent0", "role": "Subject", "text": "a rare case", "start": 3, "end": 6}, {"entity_id": "20178709_3_Ent1", "role": "Effect", "text": "pleuropericarditis", "start": 7, "end": 8}, {"entity_id": "20178709_3_Ent2", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "20178709_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20178709_3_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20178709_3_Ent1", "text": "pleuropericarditis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20178709_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20178709_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20180933_5", "wnd_id": "20180933_5_1", "text": "In a randomised , investigator - blinded , multicentre phase III efficacy trial , 899 infants and children with acute uncomplicated Plasmodium falciparum malaria received six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets .", "tokens": ["In", "a", "randomised", ",", "investigator", "-", "blinded", ",", "multicentre", "phase", "III", "efficacy", "trial", ",", "899", "infants", "and", "children", "with", "acute", "uncomplicated", "Plasmodium", "falciparum", "malaria", "received", "six", "doses", "of", "AL", "according", "to", "body", "weight", "over", "3", "days", "either", "as", "crushed", "tablets", "(", "Coartem", ")", "or", "as", "dispersible", "tablets", "."], "event_mentions": [{"id": "20180933_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 24, "end": 25}, "arguments": [{"entity_id": "20180933_5_Ent1", "role": "Subject_Population", "text": "899", "start": 14, "end": 15}, {"entity_id": "20180933_5_Ent0", "role": "Subject", "text": "899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "start": 14, "end": 24}, {"entity_id": "20180933_5_Ent2", "role": "Subject_Age", "text": "infants and children", "start": 15, "end": 18}, {"entity_id": "20180933_5_Ent7", "role": "Treatment_Disorder", "text": "Plasmodium falciparum malaria", "start": 21, "end": 24}, {"entity_id": "20180933_5_Ent6", "role": "Treatment_Dosage", "text": "six doses", "start": 25, "end": 27}, {"entity_id": "20180933_5_Ent3", "role": "Treatment", "text": "six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets", "start": 25, "end": 47}, {"entity_id": "20180933_5_Ent4", "role": "Treatment_Drug", "text": "AL", "start": 28, "end": 29}, {"entity_id": "20180933_5_Ent5", "role": "Treatment_Duration", "text": "3 days", "start": 34, "end": 36}, {"entity_id": "20180933_5_Ent8", "role": "Treatment_Route", "text": "crushed tablets", "start": 38, "end": 40}, {"entity_id": "20180933_5_Ent9", "role": "Treatment_Route", "text": "dispersible tablets", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "20180933_5_Ent1", "text": "899", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20180933_5_Ent0", "text": "899 infants and children with acute uncomplicated Plasmodium falciparum malaria", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "20180933_5_Ent2", "text": "infants and children", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "20180933_5_Ent7", "text": "Plasmodium falciparum malaria", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "20180933_5_Ent6", "text": "six doses", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "20180933_5_Ent3", "text": "six doses of AL according to body weight over 3 days either as crushed tablets ( Coartem ) or as dispersible tablets", "entity_type": "Entity", "start": 25, "end": 47}, {"id": "20180933_5_Ent4", "text": "AL", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "20180933_5_Ent5", "text": "3 days", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "20180933_5_Ent8", "text": "crushed tablets", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "20180933_5_Ent9", "text": "dispersible tablets", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "20190474_2", "wnd_id": "20190474_2_1", "text": "Hypersensitivity to zonisamide was confirmed by the skin patch test .", "tokens": ["Hypersensitivity", "to", "zonisamide", "was", "confirmed", "by", "the", "skin", "patch", "test", "."], "event_mentions": [{"id": "20190474_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "20190474_2_Ent0", "role": "Effect", "text": "Hypersensitivity", "start": 0, "end": 1}, {"entity_id": "20190474_2_Ent1", "role": "Treatment", "text": "zonisamide", "start": 2, "end": 3}, {"entity_id": "20190474_2_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "20190474_2_Ent0", "text": "Hypersensitivity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20190474_2_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20190474_2_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "2022118_1", "wnd_id": "2022118_1_1", "text": "However , the use of lithium should be avoided with any patient who is purging , since it may exacerbate the loss of intracellular potassium , thereby increasing the risk of cardiac toxicity .", "tokens": ["However", ",", "the", "use", "of", "lithium", "should", "be", "avoided", "with", "any", "patient", "who", "is", "purging", ",", "since", "it", "may", "exacerbate", "the", "loss", "of", "intracellular", "potassium", ",", "thereby", "increasing", "the", "risk", "of", "cardiac", "toxicity", "."], "event_mentions": [{"id": "2022118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbate", "start": 19, "end": 20}, "arguments": [{"entity_id": "2022118_1_Ent3", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent0", "role": "Subject", "text": "patient who is purging", "start": 11, "end": 15}, {"entity_id": "2022118_1_Ent1", "role": "Effect", "text": "loss of intracellular potassium", "start": 21, "end": 25}, {"entity_id": "2022118_1_Ent2", "role": "Effect", "text": "increasing the risk of cardiac toxicity", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "2022118_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent0", "text": "patient who is purging", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "2022118_1_Ent1", "text": "loss of intracellular potassium", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "2022118_1_Ent2", "text": "increasing the risk of cardiac toxicity", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "20298401_10", "wnd_id": "20298401_10_1", "text": "CONCLUSION : Our case shows a fatal side effect of erlotinib .", "tokens": ["CONCLUSION", ":", "Our", "case", "shows", "a", "fatal", "side", "effect", "of", "erlotinib", "."], "event_mentions": [{"id": "20298401_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "20298401_10_Ent0", "role": "Effect", "text": "side effect", "start": 7, "end": 9}, {"entity_id": "20298401_10_Ent1", "role": "Treatment", "text": "erlotinib", "start": 10, "end": 11}, {"entity_id": "20298401_10_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20298401_10_Ent0", "text": "side effect", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20298401_10_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20298401_10_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20298401_2", "wnd_id": "20298401_2_1", "text": "INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ) , few case reports on erlotinib - induced ILD have been issued .", "tokens": ["INTRODUCTION", ":", "Although", "gefitinib", "used", "for", "the", "treatment", "of", "non", "-", "small", "-", "cell", "lung", "cancer", "is", "a", "well", "-", "known", "cause", "of", "interstitial", "lung", "disease", "(", "ILD", ")", ",", "few", "case", "reports", "on", "erlotinib", "-", "induced", "ILD", "have", "been", "issued", "."], "event_mentions": [{"id": "20298401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 21, "end": 22}, "arguments": [{"entity_id": "20298401_2_Ent1", "role": "Treatment", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent3", "role": "Treatment_Drug", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent2", "role": "Treatment_Disorder", "text": "non - small - cell lung cancer", "start": 9, "end": 16}, {"entity_id": "20298401_2_Ent0", "role": "Effect", "text": "interstitial lung disease ( ILD )", "start": 23, "end": 29}]}, {"id": "20298401_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 36, "end": 37}, "arguments": [{"entity_id": "20298401_2_Ent5", "role": "Treatment", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent4", "role": "Effect", "text": "ILD", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "20298401_2_Ent1", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent3", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent2", "text": "non - small - cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "20298401_2_Ent0", "text": "interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "20298401_2_Ent5", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent4", "text": "ILD", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "20349794_4", "wnd_id": "20349794_4_1", "text": "Carboplatin was substituted for cisplatin , and there were no further episodes of SIADH .", "tokens": ["Carboplatin", "was", "substituted", "for", "cisplatin", ",", "and", "there", "were", "no", "further", "episodes", "of", "SIADH", "."], "event_mentions": [{"id": "20349794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "substituted", "start": 2, "end": 3}, "arguments": [{"entity_id": "20349794_4_Ent0", "role": "Treatment", "text": "Carboplatin was substituted for cisplatin", "start": 0, "end": 5}, {"entity_id": "20349794_4_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}, {"entity_id": "20349794_4_Ent1", "role": "Treatment_Disorder", "text": "SIADH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20349794_4_Ent0", "text": "Carboplatin was substituted for cisplatin", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "20349794_4_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20349794_4_Ent1", "text": "SIADH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20412003_4", "wnd_id": "20412003_4_1", "text": "Trimethoprim - sulfamethoxazole - induced hepatotoxicity in a pediatric patient .", "tokens": ["Trimethoprim", "-", "sulfamethoxazole", "-", "induced", "hepatotoxicity", "in", "a", "pediatric", "patient", "."], "event_mentions": [{"id": "20412003_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "20412003_4_Ent4", "role": "Treatment_Drug", "text": "Trimethoprim", "start": 0, "end": 1}, {"entity_id": "20412003_4_Ent6", "role": "Combination_Drug", "text": "Trimethoprim", "start": 0, "end": 1}, {"entity_id": "20412003_4_Ent3", "role": "Treatment", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "20412003_4_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 2, "end": 3}, {"entity_id": "20412003_4_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 2, "end": 3}, {"entity_id": "20412003_4_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 5, "end": 6}, {"entity_id": "20412003_4_Ent0", "role": "Subject", "text": "a pediatric patient", "start": 7, "end": 10}, {"entity_id": "20412003_4_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "20412003_4_Ent4", "text": "Trimethoprim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20412003_4_Ent6", "text": "Trimethoprim", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20412003_4_Ent3", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20412003_4_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20412003_4_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20412003_4_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20412003_4_Ent0", "text": "a pediatric patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20412003_4_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2042691_1", "wnd_id": "2042691_1_1", "text": "Amiodarone was discontinued , and thyrotoxicosis gradually abated .", "tokens": ["Amiodarone", "was", "discontinued", ",", "and", "thyrotoxicosis", "gradually", "abated", "."], "event_mentions": [{"id": "2042691_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "was discontinued", "start": 1, "end": 3}, "arguments": [{"entity_id": "2042691_1_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2042691_1_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2042691_1_Ent0", "role": "Effect", "text": "thyrotoxicosis gradually abated", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "2042691_1_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2042691_1_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2042691_1_Ent0", "text": "thyrotoxicosis gradually abated", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "20456080_4", "wnd_id": "20456080_4_1", "text": "Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders .", "tokens": ["Corticosteroid", "injections", "are", "commonly", "used", "as", "effective", "treatments", "for", "a", "variety", "of", "pain", "disorders", "."], "event_mentions": [{"id": "20456080_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatments", "start": 7, "end": 8}, "arguments": [{"entity_id": "20456080_4_Ent1", "role": "Treatment_Drug", "text": "Corticosteroid", "start": 0, "end": 1}, {"entity_id": "20456080_4_Ent0", "role": "Treatment", "text": "Corticosteroid injections", "start": 0, "end": 2}, {"entity_id": "20456080_4_Ent2", "role": "Treatment_Route", "text": "injections", "start": 1, "end": 2}, {"entity_id": "20456080_4_Ent3", "role": "Treatment_Disorder", "text": "pain disorders", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "20456080_4_Ent1", "text": "Corticosteroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20456080_4_Ent0", "text": "Corticosteroid injections", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20456080_4_Ent2", "text": "injections", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20456080_4_Ent3", "text": "pain disorders", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "20628041_2", "wnd_id": "20628041_2_1", "text": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant - like syndrome ( NMLS ) in a polytrauma patient with Parkinson 's disease ( PD ) .", "tokens": ["To", "describe", "a", "probable", "interaction", "between", "enteral", "feeds", "and", "levodopa", "leading", "to", "neuroleptic", "malignant", "-", "like", "syndrome", "(", "NMLS", ")", "in", "a", "polytrauma", "patient", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "."], "event_mentions": [{"id": "20628041_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "20628041_2_Ent3", "role": "Treatment", "text": "interaction between enteral feeds and levodopa", "start": 4, "end": 10}, {"entity_id": "20628041_2_Ent5", "role": "Treatment_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent7", "role": "Combination_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent8", "role": "Combination_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent2", "role": "Effect", "text": "neuroleptic malignant - like syndrome ( NMLS )", "start": 12, "end": 20}, {"entity_id": "20628041_2_Ent0", "role": "Subject", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "start": 21, "end": 31}, {"entity_id": "20628041_2_Ent1", "role": "Subject_Disorder", "text": "polytrauma", "start": 22, "end": 23}, {"entity_id": "20628041_2_Ent6", "role": "Treatment_Disorder", "text": "Parkinson 's disease ( PD )", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "20628041_2_Ent3", "text": "interaction between enteral feeds and levodopa", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "20628041_2_Ent5", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent7", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent8", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent2", "text": "neuroleptic malignant - like syndrome ( NMLS )", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "20628041_2_Ent0", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "20628041_2_Ent1", "text": "polytrauma", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20628041_2_Ent6", "text": "Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "20666169_1", "wnd_id": "20666169_1_1", "text": "Atorvastatin induced multiple organ failure .", "tokens": ["Atorvastatin", "induced", "multiple", "organ", "failure", "."], "event_mentions": [{"id": "20666169_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "20666169_1_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent2", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "20666169_1_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent2", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "20666169_9", "wnd_id": "20666169_9_1", "text": "We presume the cause for multiple organ failure could be the result of drug - drug interaction , atorvastatin and verapamil , as verapamil is known to increase the serum concentration of atorvastatin significantly .", "tokens": ["We", "presume", "the", "cause", "for", "multiple", "organ", "failure", "could", "be", "the", "result", "of", "drug", "-", "drug", "interaction", ",", "atorvastatin", "and", "verapamil", ",", "as", "verapamil", "is", "known", "to", "increase", "the", "serum", "concentration", "of", "atorvastatin", "significantly", "."], "event_mentions": [{"id": "20666169_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "20666169_9_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 5, "end": 8}, {"entity_id": "20666169_9_Ent1", "role": "Treatment", "text": "interaction , atorvastatin and verapamil", "start": 16, "end": 21}, {"entity_id": "20666169_9_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 20, "end": 21}, {"entity_id": "20666169_9_Ent5", "role": "Combination_Drug", "text": "verapamil", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "20666169_9_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20666169_9_Ent1", "text": "interaction , atorvastatin and verapamil", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "20666169_9_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20666169_9_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "20925534_12", "wnd_id": "20925534_12_1", "text": "A total of 109 patients had a cardiovascular event , with event rates of 4.9 % with omeprazole and 5.7 % with placebo ( hazard ratio with omeprazole , 0.99 ; 95 % CI , 0.68 to 1.44 ; P = 0.96 ) ; high - risk subgroups did not show significant heterogeneity .", "tokens": ["A", "total", "of", "109", "patients", "had", "a", "cardiovascular", "event", ",", "with", "event", "rates", "of", "4.9", "%", "with", "omeprazole", "and", "5.7", "%", "with", "placebo", "(", "hazard", "ratio", "with", "omeprazole", ",", "0.99", ";", "95", "%", "CI", ",", "0.68", "to", "1.44", ";", "P", "=", "0.96", ")", ";", "high", "-", "risk", "subgroups", "did", "not", "show", "significant", "heterogeneity", "."], "event_mentions": [{"id": "20925534_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_12_Ent1", "role": "Subject_Population", "text": "109", "start": 3, "end": 4}, {"entity_id": "20925534_12_Ent0", "role": "Subject", "text": "109 patients", "start": 3, "end": 5}, {"entity_id": "20925534_12_Ent2", "role": "Effect", "text": "cardiovascular event", "start": 7, "end": 9}, {"entity_id": "20925534_12_Ent3", "role": "Treatment", "text": "4.9 % with omeprazole and 5.7 % with placebo", "start": 14, "end": 23}, {"entity_id": "20925534_12_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}, {"entity_id": "20925534_12_Ent5", "role": "Treatment_Drug", "text": "placebo", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "20925534_12_Ent1", "text": "109", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_12_Ent0", "text": "109 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20925534_12_Ent2", "text": "cardiovascular event", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20925534_12_Ent3", "text": "4.9 % with omeprazole and 5.7 % with placebo", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "20925534_12_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20925534_12_Ent5", "text": "placebo", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "20925534_14", "wnd_id": "20925534_14_1", "text": "Among patients receiving aspirin and clopidogrel , prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding .", "tokens": ["Among", "patients", "receiving", "aspirin", "and", "clopidogrel", ",", "prophylactic", "use", "of", "a", "PPI", "reduced", "the", "rate", "of", "upper", "gastrointestinal", "bleeding", "."], "event_mentions": [{"id": "20925534_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylactic use", "start": 7, "end": 9}, "arguments": [{"entity_id": "20925534_14_Ent0", "role": "Subject", "text": "patients receiving aspirin and clopidogrel", "start": 1, "end": 6}, {"entity_id": "20925534_14_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 3, "end": 4}, {"entity_id": "20925534_14_Ent6", "role": "Combination_Drug", "text": "aspirin", "start": 3, "end": 4}, {"entity_id": "20925534_14_Ent4", "role": "Treatment_Drug", "text": "clopidogrel", "start": 5, "end": 6}, {"entity_id": "20925534_14_Ent7", "role": "Combination_Drug", "text": "clopidogrel", "start": 5, "end": 6}, {"entity_id": "20925534_14_Ent2", "role": "Treatment", "text": "PPI", "start": 11, "end": 12}, {"entity_id": "20925534_14_Ent5", "role": "Treatment_Drug", "text": "PPI", "start": 11, "end": 12}, {"entity_id": "20925534_14_Ent8", "role": "Combination_Drug", "text": "PPI", "start": 11, "end": 12}, {"entity_id": "20925534_14_Ent1", "role": "Effect", "text": "reduced the rate of upper gastrointestinal bleeding", "start": 12, "end": 19}]}], "entity_mentions": [{"id": "20925534_14_Ent0", "text": "patients receiving aspirin and clopidogrel", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "20925534_14_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_14_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_14_Ent4", "text": "clopidogrel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20925534_14_Ent7", "text": "clopidogrel", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20925534_14_Ent2", "text": "PPI", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20925534_14_Ent5", "text": "PPI", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20925534_14_Ent8", "text": "PPI", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20925534_14_Ent1", "text": "reduced the rate of upper gastrointestinal bleeding", "entity_type": "Entity", "start": 12, "end": 19}], "lang": "en"}
{"doc_id": "2113320_1", "wnd_id": "2113320_1_1", "text": "A patient with Wegener 's granulomatosis rapidly developed a circumferential subglottic stenosis while on a cyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates .", "tokens": ["A", "patient", "with", "Wegener", "'s", "granulomatosis", "rapidly", "developed", "a", "circumferential", "subglottic", "stenosis", "while", "on", "a", "cyclophosphamide", "regimen", "that", "had", "caused", "resolution", "of", "systemic", "symptoms", "and", "pulmonary", "infiltrates", "."], "event_mentions": [{"id": "2113320_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2113320_1_Ent0", "role": "Subject", "text": "A patient with Wegener 's granulomatosis", "start": 0, "end": 6}, {"entity_id": "2113320_1_Ent5", "role": "Treatment_Disorder", "text": "Wegener 's granulomatosis", "start": 3, "end": 6}, {"entity_id": "2113320_1_Ent1", "role": "Effect", "text": "circumferential subglottic stenosis", "start": 9, "end": 12}, {"entity_id": "2113320_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 15, "end": 16}, {"entity_id": "2113320_1_Ent3", "role": "Treatment", "text": "cyclophosphamide regimen", "start": 15, "end": 17}, {"entity_id": "2113320_1_Ent2", "role": "Effect", "text": "resolution of systemic symptoms and pulmonary infiltrates", "start": 20, "end": 27}]}], "entity_mentions": [{"id": "2113320_1_Ent0", "text": "A patient with Wegener 's granulomatosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2113320_1_Ent5", "text": "Wegener 's granulomatosis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2113320_1_Ent1", "text": "circumferential subglottic stenosis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2113320_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2113320_1_Ent3", "text": "cyclophosphamide regimen", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2113320_1_Ent2", "text": "resolution of systemic symptoms and pulmonary infiltrates", "entity_type": "Entity", "start": 20, "end": 27}], "lang": "en"}
{"doc_id": "2116935_1", "wnd_id": "2116935_1_1", "text": "Splenic hemorrhage : a complication of tissue plasminogen activator treatment .", "tokens": ["Splenic", "hemorrhage", ":", "a", "complication", "of", "tissue", "plasminogen", "activator", "treatment", "."], "event_mentions": [{"id": "2116935_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication of", "start": 4, "end": 6}, "arguments": [{"entity_id": "2116935_1_Ent0", "role": "Effect", "text": "Splenic hemorrhage", "start": 0, "end": 2}, {"entity_id": "2116935_1_Ent2", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 6, "end": 9}, {"entity_id": "2116935_1_Ent1", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "2116935_1_Ent0", "text": "Splenic hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2116935_1_Ent2", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2116935_1_Ent1", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "2116935_2", "wnd_id": "2116935_2_1", "text": "Thrombolytic therapy with tissue plasminogen activator ( tPA ) for acute myocardial infarction may result in major bleeding complications such as gastrointestinal or intracranial bleeding .", "tokens": ["Thrombolytic", "therapy", "with", "tissue", "plasminogen", "activator", "(", "tPA", ")", "for", "acute", "myocardial", "infarction", "may", "result", "in", "major", "bleeding", "complications", "such", "as", "gastrointestinal", "or", "intracranial", "bleeding", "."], "event_mentions": [{"id": "2116935_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 14, "end": 15}, "arguments": [{"entity_id": "2116935_2_Ent1", "role": "Treatment", "text": "tissue plasminogen activator", "start": 3, "end": 6}, {"entity_id": "2116935_2_Ent3", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 3, "end": 6}, {"entity_id": "2116935_2_Ent2", "role": "Treatment_Disorder", "text": "acute myocardial infarction", "start": 10, "end": 13}, {"entity_id": "2116935_2_Ent0", "role": "Effect", "text": "gastrointestinal or intracranial bleeding", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "2116935_2_Ent1", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2116935_2_Ent3", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2116935_2_Ent2", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "2116935_2_Ent0", "text": "gastrointestinal or intracranial bleeding", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "21330680_1", "wnd_id": "21330680_1_1", "text": "Olanzapine - induced parkinsonism associated with smoking cessation .", "tokens": ["Olanzapine", "-", "induced", "parkinsonism", "associated", "with", "smoking", "cessation", "."], "event_mentions": [{"id": "21330680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "21330680_1_Ent2", "role": "Treatment", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "21330680_1_Ent3", "role": "Treatment_Drug", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "21330680_1_Ent0", "role": "Effect", "text": "parkinsonism", "start": 3, "end": 4}, {"entity_id": "21330680_1_Ent1", "role": "Treatment", "text": "associated with smoking cessation", "start": 4, "end": 8}, {"entity_id": "21330680_1_Ent4", "role": "Treatment_Dosage", "text": "cessation", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "21330680_1_Ent2", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21330680_1_Ent3", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21330680_1_Ent0", "text": "parkinsonism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21330680_1_Ent1", "text": "associated with smoking cessation", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "21330680_1_Ent4", "text": "cessation", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "21330680_13", "wnd_id": "21330680_13_1", "text": "A 73 - year - old woman receiving high - dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "receiving", "high", "-", "dosage", "olanzapine", "for", "bipolar", "disorder", "developed", "parkinsonism", "after", "smoking", "cessation", "."], "event_mentions": [{"id": "21330680_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "21330680_13_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "21330680_13_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "21330680_13_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "21330680_13_Ent9", "role": "Treatment_Dosage", "text": "high - dosage", "start": 8, "end": 11}, {"entity_id": "21330680_13_Ent4", "role": "Treatment", "text": "high - dosage olanzapine", "start": 8, "end": 12}, {"entity_id": "21330680_13_Ent7", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "21330680_13_Ent6", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 13, "end": 15}, {"entity_id": "21330680_13_Ent3", "role": "Effect", "text": "parkinsonism", "start": 16, "end": 17}, {"entity_id": "21330680_13_Ent8", "role": "Treatment_Drug", "text": "smoking", "start": 18, "end": 19}, {"entity_id": "21330680_13_Ent5", "role": "Treatment", "text": "smoking cessation", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "21330680_13_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "21330680_13_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21330680_13_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21330680_13_Ent9", "text": "high - dosage", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21330680_13_Ent4", "text": "high - dosage olanzapine", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21330680_13_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21330680_13_Ent6", "text": "bipolar disorder", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21330680_13_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21330680_13_Ent8", "text": "smoking", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21330680_13_Ent5", "text": "smoking cessation", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "2140997_1", "wnd_id": "2140997_1_1", "text": "A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug .", "tokens": ["A", "case", "of", "severe", "acute", "hepatitis", "caused", "by", "cyproterone", "acetate", "in", "a", "71", "year", "old", "man", "with", "prostatic", "carcinoma", "is", "reported", "with", "a", "review", "of", "the", "literature", "on", "hepatic", "reactions", "to", "this", "drug", "."], "event_mentions": [{"id": "2140997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "2140997_1_Ent3", "role": "Effect", "text": "acute hepatitis", "start": 4, "end": 6}, {"entity_id": "2140997_1_Ent4", "role": "Treatment", "text": "cyproterone acetate", "start": 8, "end": 10}, {"entity_id": "2140997_1_Ent5", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 8, "end": 10}, {"entity_id": "2140997_1_Ent0", "role": "Subject", "text": "a 71 year old man with prostatic carcinoma", "start": 11, "end": 19}, {"entity_id": "2140997_1_Ent1", "role": "Subject_Age", "text": "71 year old", "start": 12, "end": 15}, {"entity_id": "2140997_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}, {"entity_id": "2140997_1_Ent6", "role": "Treatment_Disorder", "text": "prostatic carcinoma", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2140997_1_Ent3", "text": "acute hepatitis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2140997_1_Ent4", "text": "cyproterone acetate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2140997_1_Ent5", "text": "cyproterone acetate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2140997_1_Ent0", "text": "a 71 year old man with prostatic carcinoma", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "2140997_1_Ent1", "text": "71 year old", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "2140997_1_Ent2", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2140997_1_Ent6", "text": "prostatic carcinoma", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "2144305_1", "wnd_id": "2144305_1_1", "text": "A unique case of a transient , nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported .", "tokens": ["A", "unique", "case", "of", "a", "transient", ",", "nonpigmenting", "fixed", "drug", "eruption", "caused", "by", "the", "radiopaque", "contrast", "medium", "iothalamate", "is", "reported", "."], "event_mentions": [{"id": "2144305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "2144305_1_Ent0", "role": "Effect", "text": "a transient , nonpigmenting fixed drug eruption", "start": 4, "end": 11}, {"entity_id": "2144305_1_Ent1", "role": "Treatment", "text": "iothalamate", "start": 17, "end": 18}, {"entity_id": "2144305_1_Ent2", "role": "Treatment_Drug", "text": "iothalamate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "2144305_1_Ent0", "text": "a transient , nonpigmenting fixed drug eruption", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "2144305_1_Ent1", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2144305_1_Ent2", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "21448111_5", "wnd_id": "21448111_5_1", "text": "During the second hospitalization it is possible that antipsychotic treatment combined with an antidepressant caused akathisia or there were symptoms of agitated depression and akathisia present at the same time , which is very difficult to determine in everyday clinical practice .", "tokens": ["During", "the", "second", "hospitalization", "it", "is", "possible", "that", "antipsychotic", "treatment", "combined", "with", "an", "antidepressant", "caused", "akathisia", "or", "there", "were", "symptoms", "of", "agitated", "depression", "and", "akathisia", "present", "at", "the", "same", "time", ",", "which", "is", "very", "difficult", "to", "determine", "in", "everyday", "clinical", "practice", "."], "event_mentions": [{"id": "21448111_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "21448111_5_Ent2", "role": "Treatment_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent5", "role": "Combination_Drug", "text": "antipsychotic", "start": 8, "end": 9}, {"entity_id": "21448111_5_Ent1", "role": "Treatment", "text": "antipsychotic treatment combined with an antidepressant", "start": 8, "end": 14}, {"entity_id": "21448111_5_Ent3", "role": "Treatment_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent4", "role": "Combination_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "21448111_5_Ent0", "role": "Effect", "text": "akathisia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "21448111_5_Ent2", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent5", "text": "antipsychotic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21448111_5_Ent1", "text": "antipsychotic treatment combined with an antidepressant", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "21448111_5_Ent3", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_5_Ent0", "text": "akathisia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "21448111_6", "wnd_id": "21448111_6_1", "text": "We can conclude that in this case , as in many others , akathisia as a possible adverse effect of psychopharmacs was very hard to identify .", "tokens": ["We", "can", "conclude", "that", "in", "this", "case", ",", "as", "in", "many", "others", ",", "akathisia", "as", "a", "possible", "adverse", "effect", "of", "psychopharmacs", "was", "very", "hard", "to", "identify", "."], "event_mentions": [{"id": "21448111_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 17, "end": 19}, "arguments": [{"entity_id": "21448111_6_Ent0", "role": "Subject", "text": "this case", "start": 5, "end": 7}, {"entity_id": "21448111_6_Ent1", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "21448111_6_Ent2", "role": "Treatment", "text": "psychopharmacs", "start": 20, "end": 21}, {"entity_id": "21448111_6_Ent3", "role": "Treatment_Drug", "text": "psychopharmacs", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21448111_6_Ent0", "text": "this case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "21448111_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_6_Ent2", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_6_Ent3", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "2154663_1", "wnd_id": "2154663_1_1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy , and the rash resolved .", "tokens": ["Aminoglutethimide", "was", "discontinued", "until", "completion", "of", "radiotherapy", ",", "and", "the", "rash", "resolved", "."], "event_mentions": [{"id": "2154663_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "and", "start": 8, "end": 9}, "arguments": [{"entity_id": "2154663_1_Ent2", "role": "Treatment_Drug", "text": "Aminoglutethimide", "start": 0, "end": 1}, {"entity_id": "2154663_1_Ent1", "role": "Treatment", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "start": 0, "end": 7}, {"entity_id": "2154663_1_Ent0", "role": "Effect", "text": "the rash resolved", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2154663_1_Ent2", "text": "Aminoglutethimide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2154663_1_Ent1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2154663_1_Ent0", "text": "the rash resolved", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "21712512_5", "wnd_id": "21712512_5_1", "text": "Seven weeks after the initiation of inhaled fluticasone , she developed vaginal candidiasis and was prescribed fluconazole 100 mg / day , a CYP3A4 inhibitor .", "tokens": ["Seven", "weeks", "after", "the", "initiation", "of", "inhaled", "fluticasone", ",", "she", "developed", "vaginal", "candidiasis", "and", "was", "prescribed", "fluconazole", "100", "mg", "/", "day", ",", "a", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "21712512_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Seven weeks", "start": 0, "end": 2}, {"entity_id": "21712512_5_Ent1", "role": "Treatment", "text": "Seven weeks after the initiation of inhaled fluticasone", "start": 0, "end": 8}, {"entity_id": "21712512_5_Ent2", "role": "Treatment_Route", "text": "inhaled", "start": 6, "end": 7}, {"entity_id": "21712512_5_Ent3", "role": "Treatment_Drug", "text": "fluticasone", "start": 7, "end": 8}, {"entity_id": "21712512_5_Ent0", "role": "Effect", "text": "vaginal candidiasis", "start": 11, "end": 13}]}, {"id": "21712512_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 15, "end": 16}, "arguments": [{"entity_id": "21712512_5_Ent6", "role": "Treatment_Disorder", "text": "vaginal candidiasis", "start": 11, "end": 13}, {"entity_id": "21712512_5_Ent7", "role": "Treatment_Drug", "text": "fluconazole", "start": 16, "end": 17}, {"entity_id": "21712512_5_Ent5", "role": "Treatment", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "start": 16, "end": 25}, {"entity_id": "21712512_5_Ent8", "role": "Treatment_Dosage", "text": "100 mg / day", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "21712512_5_Ent4", "text": "Seven weeks", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21712512_5_Ent1", "text": "Seven weeks after the initiation of inhaled fluticasone", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "21712512_5_Ent2", "text": "inhaled", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21712512_5_Ent3", "text": "fluticasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21712512_5_Ent0", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent6", "text": "vaginal candidiasis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21712512_5_Ent7", "text": "fluconazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21712512_5_Ent5", "text": "fluconazole 100 mg / day , a CYP3A4 inhibitor", "entity_type": "Entity", "start": 16, "end": 25}, {"id": "21712512_5_Ent8", "text": "100 mg / day", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "21728158_4", "wnd_id": "21728158_4_1", "text": "Drug resistant tuberculosis requires more complex and longer treatment with alternative substances .", "tokens": ["Drug", "resistant", "tuberculosis", "requires", "more", "complex", "and", "longer", "treatment", "with", "alternative", "substances", "."], "event_mentions": [{"id": "21728158_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "requires", "start": 3, "end": 4}, "arguments": [{"entity_id": "21728158_4_Ent1", "role": "Treatment_Disorder", "text": "Drug resistant tuberculosis", "start": 0, "end": 3}, {"entity_id": "21728158_4_Ent3", "role": "Treatment_Duration", "text": "complex and longer treatment", "start": 5, "end": 9}, {"entity_id": "21728158_4_Ent0", "role": "Treatment", "text": "complex and longer treatment with alternative substances", "start": 5, "end": 12}, {"entity_id": "21728158_4_Ent2", "role": "Treatment_Drug", "text": "substances", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "21728158_4_Ent1", "text": "Drug resistant tuberculosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21728158_4_Ent3", "text": "complex and longer treatment", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "21728158_4_Ent0", "text": "complex and longer treatment with alternative substances", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "21728158_4_Ent2", "text": "substances", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "21729965_1", "wnd_id": "21729965_1_1", "text": "Implanon    failure in an HIV - positive woman on antiretroviral therapy resulting in two ectopic pregnancies .", "tokens": ["Implanon", "  ", "failure", "in", "an", "HIV", "-", "positive", "woman", "on", "antiretroviral", "therapy", "resulting", "in", "two", "ectopic", "pregnancies", "."], "event_mentions": [{"id": "21729965_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 12, "end": 13}, "arguments": [{"entity_id": "21729965_1_Ent3", "role": "Treatment", "text": "Implanon    failure", "start": 0, "end": 3}, {"entity_id": "21729965_1_Ent0", "role": "Subject", "text": "an HIV - positive woman", "start": 4, "end": 9}, {"entity_id": "21729965_1_Ent5", "role": "Treatment_Disorder", "text": "HIV - positive", "start": 5, "end": 8}, {"entity_id": "21729965_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "21729965_1_Ent4", "role": "Treatment", "text": "on antiretroviral therapy", "start": 9, "end": 12}, {"entity_id": "21729965_1_Ent2", "role": "Effect", "text": "two ectopic pregnancies", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "21729965_1_Ent3", "text": "Implanon    failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21729965_1_Ent0", "text": "an HIV - positive woman", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "21729965_1_Ent5", "text": "HIV - positive", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21729965_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21729965_1_Ent4", "text": "on antiretroviral therapy", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21729965_1_Ent2", "text": "two ectopic pregnancies", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "21729965_4", "wnd_id": "21729965_4_1", "text": "We present an interesting case of an HIV - positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place .", "tokens": ["We", "present", "an", "interesting", "case", "of", "an", "HIV", "-", "positive", "woman", "on", "antiretroviral", "therapy", "having", "tubal", "pregnancies", "on", "two", "separate", "occasions", "with", "Implanon", "in", "place", "."], "event_mentions": [{"id": "21729965_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 14, "end": 15}, "arguments": [{"entity_id": "21729965_4_Ent0", "role": "Subject", "text": "an HIV - positive woman", "start": 6, "end": 11}, {"entity_id": "21729965_4_Ent4", "role": "Treatment_Disorder", "text": "HIV - positive", "start": 7, "end": 10}, {"entity_id": "21729965_4_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "21729965_4_Ent3", "role": "Treatment", "text": "antiretroviral", "start": 12, "end": 13}, {"entity_id": "21729965_4_Ent5", "role": "Treatment_Drug", "text": "antiretroviral", "start": 12, "end": 13}, {"entity_id": "21729965_4_Ent2", "role": "Effect", "text": "tubal pregnancies", "start": 15, "end": 17}, {"entity_id": "21729965_4_Ent6", "role": "Treatment_Drug", "text": "Implanon", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21729965_4_Ent0", "text": "an HIV - positive woman", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "21729965_4_Ent4", "text": "HIV - positive", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "21729965_4_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "21729965_4_Ent3", "text": "antiretroviral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21729965_4_Ent5", "text": "antiretroviral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21729965_4_Ent2", "text": "tubal pregnancies", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "21729965_4_Ent6", "text": "Implanon", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21751666_1", "wnd_id": "21751666_1_1", "text": "Post - exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient -- safe and effective without any immunosuppresive drug interaction .", "tokens": ["Post", "-", "exposure", "prophylaxis", "for", "H1N1", "with", "oseltamivir", "in", "renal", "allograft", "recipient", "--", "safe", "and", "effective", "without", "any", "immunosuppresive", "drug", "interaction", "."], "event_mentions": [{"id": "21751666_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Post - exposure prophylaxis", "start": 0, "end": 4}, "arguments": [{"entity_id": "21751666_1_Ent4", "role": "Treatment_Disorder", "text": "H1N1", "start": 5, "end": 6}, {"entity_id": "21751666_1_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent5", "role": "Treatment_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent1", "role": "Subject_Disorder", "text": "renal allograft", "start": 9, "end": 11}, {"entity_id": "21751666_1_Ent0", "role": "Subject", "text": "renal allograft recipient", "start": 9, "end": 12}, {"entity_id": "21751666_1_Ent2", "role": "Effect", "text": "safe and effective without any immunosuppresive drug interaction", "start": 13, "end": 21}]}], "entity_mentions": [{"id": "21751666_1_Ent4", "text": "H1N1", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21751666_1_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent5", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent1", "text": "renal allograft", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "21751666_1_Ent0", "text": "renal allograft recipient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21751666_1_Ent2", "text": "safe and effective without any immunosuppresive drug interaction", "entity_type": "Entity", "start": 13, "end": 21}], "lang": "en"}
{"doc_id": "21751666_5", "wnd_id": "21751666_5_1", "text": "Oseltamivir was effective for post - exposure prophylaxis of H1N1 in close contact .", "tokens": ["Oseltamivir", "was", "effective", "for", "post", "-", "exposure", "prophylaxis", "of", "H1N1", "in", "close", "contact", "."], "event_mentions": [{"id": "21751666_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "post - exposure prophylaxis", "start": 4, "end": 8}, "arguments": [{"entity_id": "21751666_5_Ent0", "role": "Treatment", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent2", "role": "Treatment_Drug", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent1", "role": "Treatment_Disorder", "text": "H1N1", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "21751666_5_Ent0", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent2", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent1", "text": "H1N1", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "21751692_5", "wnd_id": "21751692_5_1", "text": "Based on this experience , we suggest that low - dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA .", "tokens": ["Based", "on", "this", "experience", ",", "we", "suggest", "that", "low", "-", "dose", "ketamine", "added", "to", "propofol", "may", "be", "associated", "with", "prevention", "of", "EA", "in", "children", "with", "a", "history", "of", "EA", "with", "propofol", "TIVA", "."], "event_mentions": [{"id": "21751692_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevention", "start": 19, "end": 20}, "arguments": [{"entity_id": "21751692_5_Ent7", "role": "Treatment_Dosage", "text": "low - dose", "start": 8, "end": 11}, {"entity_id": "21751692_5_Ent3", "role": "Treatment", "text": "low - dose ketamine added to propofol", "start": 8, "end": 15}, {"entity_id": "21751692_5_Ent5", "role": "Treatment_Drug", "text": "ketamine", "start": 11, "end": 12}, {"entity_id": "21751692_5_Ent8", "role": "Combination_Drug", "text": "ketamine", "start": 11, "end": 12}, {"entity_id": "21751692_5_Ent6", "role": "Treatment_Drug", "text": "propofol", "start": 14, "end": 15}, {"entity_id": "21751692_5_Ent9", "role": "Combination_Drug", "text": "propofol", "start": 14, "end": 15}, {"entity_id": "21751692_5_Ent4", "role": "Treatment_Disorder", "text": "EA", "start": 21, "end": 22}, {"entity_id": "21751692_5_Ent2", "role": "Subject_Age", "text": "children", "start": 23, "end": 24}, {"entity_id": "21751692_5_Ent0", "role": "Subject", "text": "children with a history of EA with propofol TIVA", "start": 23, "end": 32}, {"entity_id": "21751692_5_Ent1", "role": "Subject_Disorder", "text": "EA with propofol TIVA", "start": 28, "end": 32}]}], "entity_mentions": [{"id": "21751692_5_Ent7", "text": "low - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21751692_5_Ent3", "text": "low - dose ketamine added to propofol", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "21751692_5_Ent5", "text": "ketamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_5_Ent8", "text": "ketamine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_5_Ent6", "text": "propofol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21751692_5_Ent9", "text": "propofol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21751692_5_Ent4", "text": "EA", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "21751692_5_Ent2", "text": "children", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21751692_5_Ent0", "text": "children with a history of EA with propofol TIVA", "entity_type": "Entity", "start": 23, "end": 32}, {"id": "21751692_5_Ent1", "text": "EA with propofol TIVA", "entity_type": "Entity", "start": 28, "end": 32}], "lang": "en"}
{"doc_id": "21762153_9", "wnd_id": "21762153_9_1", "text": "The zinc / o - cymen - 5 - ol system has direct antimicrobial effects and inhibits oral disease - related processes .", "tokens": ["The", "zinc", "/", "o", "-", "cymen", "-", "5", "-", "ol", "system", "has", "direct", "antimicrobial", "effects", "and", "inhibits", "oral", "disease", "-", "related", "processes", "."], "event_mentions": [{"id": "21762153_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibits", "start": 16, "end": 17}, "arguments": [{"entity_id": "21762153_9_Ent3", "role": "Treatment_Drug", "text": "zinc", "start": 1, "end": 2}, {"entity_id": "21762153_9_Ent5", "role": "Combination_Drug", "text": "zinc", "start": 1, "end": 2}, {"entity_id": "21762153_9_Ent2", "role": "Treatment", "text": "zinc / o - cymen - 5 - ol system", "start": 1, "end": 11}, {"entity_id": "21762153_9_Ent4", "role": "Treatment_Drug", "text": "o - cymen - 5 - ol", "start": 3, "end": 10}, {"entity_id": "21762153_9_Ent6", "role": "Combination_Drug", "text": "o - cymen - 5 - ol", "start": 3, "end": 10}, {"entity_id": "21762153_9_Ent0", "role": "Effect", "text": "antimicrobial effects", "start": 13, "end": 15}, {"entity_id": "21762153_9_Ent1", "role": "Effect", "text": "inhibits oral disease - related processes", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "21762153_9_Ent3", "text": "zinc", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21762153_9_Ent5", "text": "zinc", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21762153_9_Ent2", "text": "zinc / o - cymen - 5 - ol system", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "21762153_9_Ent4", "text": "o - cymen - 5 - ol", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21762153_9_Ent6", "text": "o - cymen - 5 - ol", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "21762153_9_Ent0", "text": "antimicrobial effects", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "21762153_9_Ent1", "text": "inhibits oral disease - related processes", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "21802143_1", "wnd_id": "21802143_1_1", "text": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations .", "tokens": ["Hepatic", "drug", "interaction", "between", "tacrolimus", "and", "lansoprazole", "in", "a", "bone", "marrow", "transplant", "patient", "receiving", "voriconazole", "and", "harboring", "CYP2C19", "and", "CYP3A5", "heterozygous", "mutations", "."], "event_mentions": [{"id": "21802143_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 3, "end": 4}, "arguments": [{"entity_id": "21802143_1_Ent2", "role": "Effect", "text": "Hepatic drug interaction", "start": 0, "end": 3}, {"entity_id": "21802143_1_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 4, "end": 5}, {"entity_id": "21802143_1_Ent9", "role": "Combination_Drug", "text": "tacrolimus", "start": 4, "end": 5}, {"entity_id": "21802143_1_Ent3", "role": "Treatment", "text": "tacrolimus and lansoprazole", "start": 4, "end": 7}, {"entity_id": "21802143_1_Ent7", "role": "Treatment_Drug", "text": "lansoprazole", "start": 6, "end": 7}, {"entity_id": "21802143_1_Ent10", "role": "Combination_Drug", "text": "lansoprazole", "start": 6, "end": 7}, {"entity_id": "21802143_1_Ent0", "role": "Subject", "text": "a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations", "start": 8, "end": 22}, {"entity_id": "21802143_1_Ent5", "role": "Treatment_Disorder", "text": "bone marrow transplant", "start": 9, "end": 12}, {"entity_id": "21802143_1_Ent4", "role": "Treatment", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent8", "role": "Treatment_Drug", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent11", "role": "Combination_Drug", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent1", "role": "Subject_Disorder", "text": "CYP2C19 and CYP3A5 heterozygous mutations", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "21802143_1_Ent2", "text": "Hepatic drug interaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21802143_1_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21802143_1_Ent9", "text": "tacrolimus", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21802143_1_Ent3", "text": "tacrolimus and lansoprazole", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "21802143_1_Ent7", "text": "lansoprazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21802143_1_Ent10", "text": "lansoprazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21802143_1_Ent0", "text": "a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations", "entity_type": "Entity", "start": 8, "end": 22}, {"id": "21802143_1_Ent5", "text": "bone marrow transplant", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21802143_1_Ent4", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent8", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent11", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent1", "text": "CYP2C19 and CYP3A5 heterozygous mutations", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "2196696_2", "wnd_id": "2196696_2_1", "text": "Our patient had headache , mild fever , nausea , vomiting , rash , and eosinophilia after 3 weeks of disulfiram therapy .", "tokens": ["Our", "patient", "had", "headache", ",", "mild", "fever", ",", "nausea", ",", "vomiting", ",", "rash", ",", "and", "eosinophilia", "after", "3", "weeks", "of", "disulfiram", "therapy", "."], "event_mentions": [{"id": "2196696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2196696_2_Ent0", "role": "Effect", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "start": 3, "end": 16}, {"entity_id": "2196696_2_Ent3", "role": "Treatment_Time_elapsed", "text": "after 3 weeks", "start": 16, "end": 19}, {"entity_id": "2196696_2_Ent1", "role": "Treatment", "text": "after 3 weeks of disulfiram", "start": 16, "end": 21}, {"entity_id": "2196696_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2196696_2_Ent0", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "2196696_2_Ent3", "text": "after 3 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2196696_2_Ent1", "text": "after 3 weeks of disulfiram", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "2196696_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "2196696_3", "wnd_id": "2196696_3_1", "text": "We reported a case of disulfiram - induced hepatitis with unique clinical features and compared our case with others in the literature .", "tokens": ["We", "reported", "a", "case", "of", "disulfiram", "-", "induced", "hepatitis", "with", "unique", "clinical", "features", "and", "compared", "our", "case", "with", "others", "in", "the", "literature", "."], "event_mentions": [{"id": "2196696_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2196696_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "2196696_3_Ent2", "role": "Treatment", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent1", "role": "Effect", "text": "hepatitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2196696_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2196696_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "22010004_12", "wnd_id": "22010004_12_1", "text": "An interaction between niacin and warfarin likely elevated the INR in this patient because of synergistic coagulopathy and pharmacokinetic effects of niacin .", "tokens": ["An", "interaction", "between", "niacin", "and", "warfarin", "likely", "elevated", "the", "INR", "in", "this", "patient", "because", "of", "synergistic", "coagulopathy", "and", "pharmacokinetic", "effects", "of", "niacin", "."], "event_mentions": [{"id": "22010004_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elevated", "start": 7, "end": 8}, "arguments": [{"entity_id": "22010004_12_Ent2", "role": "Treatment", "text": "interaction between niacin and warfarin", "start": 1, "end": 6}, {"entity_id": "22010004_12_Ent3", "role": "Treatment_Drug", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_12_Ent5", "role": "Combination_Drug", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_12_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "22010004_12_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "22010004_12_Ent1", "role": "Effect", "text": "elevated the INR", "start": 7, "end": 10}, {"entity_id": "22010004_12_Ent0", "role": "Subject", "text": "this patient", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "22010004_12_Ent2", "text": "interaction between niacin and warfarin", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "22010004_12_Ent3", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_12_Ent5", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_12_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22010004_12_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22010004_12_Ent1", "text": "elevated the INR", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "22010004_12_Ent0", "text": "this patient", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "22233409_4", "wnd_id": "22233409_4_1", "text": "We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa / ribavirin when oseltamivir was added to treat influenza .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "chronic", "hepatitis", "C", "infection", "who", "developed", "severe", "anaemia", "during", "antiviral", "treatment", "with", "peginterferon", "alfa", "/", "ribavirin", "when", "oseltamivir", "was", "added", "to", "treat", "influenza", "."], "event_mentions": [{"id": "22233409_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "22233409_4_Ent0", "role": "Subject", "text": "a patient with chronic hepatitis C infection", "start": 5, "end": 12}, {"entity_id": "22233409_4_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C infection", "start": 8, "end": 12}, {"entity_id": "22233409_4_Ent1", "role": "Effect", "text": "severe anaemia", "start": 14, "end": 16}, {"entity_id": "22233409_4_Ent6", "role": "Treatment_Drug", "text": "peginterferon alfa", "start": 20, "end": 22}, {"entity_id": "22233409_4_Ent9", "role": "Combination_Drug", "text": "peginterferon alfa", "start": 20, "end": 22}, {"entity_id": "22233409_4_Ent2", "role": "Treatment", "text": "peginterferon alfa / ribavirin", "start": 20, "end": 24}, {"entity_id": "22233409_4_Ent7", "role": "Treatment_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "22233409_4_Ent10", "role": "Combination_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "22233409_4_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent8", "role": "Treatment_Drug", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent11", "role": "Combination_Drug", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent5", "role": "Treatment_Disorder", "text": "influenza", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "22233409_4_Ent0", "text": "a patient with chronic hepatitis C infection", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "22233409_4_Ent4", "text": "chronic hepatitis C infection", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "22233409_4_Ent1", "text": "severe anaemia", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "22233409_4_Ent6", "text": "peginterferon alfa", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "22233409_4_Ent9", "text": "peginterferon alfa", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "22233409_4_Ent2", "text": "peginterferon alfa / ribavirin", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22233409_4_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "22233409_4_Ent10", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "22233409_4_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent8", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent11", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent5", "text": "influenza", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "22233409_5", "wnd_id": "22233409_5_1", "text": "The adverse events related to ribavirin and drug - drug interactions during therapy for hepatitis C are discussed .", "tokens": ["The", "adverse", "events", "related", "to", "ribavirin", "and", "drug", "-", "drug", "interactions", "during", "therapy", "for", "hepatitis", "C", "are", "discussed", "."], "event_mentions": [{"id": "22233409_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "22233409_5_Ent0", "role": "Effect", "text": "adverse events", "start": 1, "end": 3}, {"entity_id": "22233409_5_Ent1", "role": "Treatment", "text": "ribavirin", "start": 5, "end": 6}, {"entity_id": "22233409_5_Ent2", "role": "Treatment_Drug", "text": "ribavirin", "start": 5, "end": 6}, {"entity_id": "22233409_5_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "22233409_5_Ent0", "text": "adverse events", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22233409_5_Ent1", "text": "ribavirin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22233409_5_Ent2", "text": "ribavirin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22233409_5_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "2234880_1", "wnd_id": "2234880_1_1", "text": "Nitrendipine - induced gingival hyperplasia .", "tokens": ["Nitrendipine", "-", "induced", "gingival", "hyperplasia", "."], "event_mentions": [{"id": "2234880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2234880_1_Ent1", "role": "Treatment", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_1_Ent2", "role": "Treatment_Drug", "text": "Nitrendipine", "start": 0, "end": 1}, {"entity_id": "2234880_1_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2234880_1_Ent1", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_1_Ent2", "text": "Nitrendipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2234880_1_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2241449_1", "wnd_id": "2241449_1_1", "text": "Physicians using this \" new \" drug must be aware of the potential danger of sulfonamide - induced injury to the urinary tract .", "tokens": ["Physicians", "using", "this", "\"", "new", "\"", "drug", "must", "be", "aware", "of", "the", "potential", "danger", "of", "sulfonamide", "-", "induced", "injury", "to", "the", "urinary", "tract", "."], "event_mentions": [{"id": "2241449_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "2241449_1_Ent1", "role": "Treatment", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent2", "role": "Treatment_Drug", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent0", "role": "Effect", "text": "injury to the urinary tract", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "2241449_1_Ent1", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent2", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent0", "text": "injury to the urinary tract", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "2241449_3", "wnd_id": "2241449_3_1", "text": "We describe two cases of sulfadiazine - induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome , review the pertinent literature , and discuss the pathogenesis .", "tokens": ["We", "describe", "two", "cases", "of", "sulfadiazine", "-", "induced", "crystalluria", "and", "renal", "failure", "in", "patients", "with", "acquired", "immunodeficiency", "syndrome", ",", "review", "the", "pertinent", "literature", ",", "and", "discuss", "the", "pathogenesis", "."], "event_mentions": [{"id": "2241449_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2241449_3_Ent2", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "2241449_3_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "2241449_3_Ent4", "role": "Treatment", "text": "sulfadiazine", "start": 5, "end": 6}, {"entity_id": "2241449_3_Ent5", "role": "Treatment_Drug", "text": "sulfadiazine", "start": 5, "end": 6}, {"entity_id": "2241449_3_Ent3", "role": "Effect", "text": "crystalluria and renal failure", "start": 8, "end": 12}, {"entity_id": "2241449_3_Ent1", "role": "Subject", "text": "patients with acquired immunodeficiency syndrome", "start": 13, "end": 18}, {"entity_id": "2241449_3_Ent6", "role": "Treatment_Disorder", "text": "acquired immunodeficiency syndrome", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2241449_3_Ent2", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2241449_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2241449_3_Ent4", "text": "sulfadiazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2241449_3_Ent5", "text": "sulfadiazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2241449_3_Ent3", "text": "crystalluria and renal failure", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "2241449_3_Ent1", "text": "patients with acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "2241449_3_Ent6", "text": "acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "22550162_2", "wnd_id": "22550162_2_1", "text": "We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25 - year - old man with osteosarcoma .", "tokens": ["We", "report", "a", "case", "of", "methotrexate", "toxicity", "potentially", "induced", "by", "a", "drug", "interaction", "between", "methotrexate", "and", "omeprazole", "in", "a", "25", "-", "year", "-", "old", "man", "with", "osteosarcoma", "."], "event_mentions": [{"id": "22550162_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "22550162_2_Ent4", "role": "Effect", "text": "methotrexate toxicity", "start": 5, "end": 7}, {"entity_id": "22550162_2_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_2_Ent8", "role": "Combination_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_2_Ent5", "role": "Treatment", "text": "methotrexate and omeprazole", "start": 14, "end": 17}, {"entity_id": "22550162_2_Ent7", "role": "Treatment_Drug", "text": "omeprazole", "start": 16, "end": 17}, {"entity_id": "22550162_2_Ent9", "role": "Combination_Drug", "text": "omeprazole", "start": 16, "end": 17}, {"entity_id": "22550162_2_Ent0", "role": "Subject", "text": "a 25 - year - old man with osteosarcoma", "start": 18, "end": 27}, {"entity_id": "22550162_2_Ent1", "role": "Subject_Age", "text": "25 - year - old", "start": 19, "end": 24}, {"entity_id": "22550162_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 24, "end": 25}, {"entity_id": "22550162_2_Ent3", "role": "Subject_Disorder", "text": "osteosarcoma", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "22550162_2_Ent4", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "22550162_2_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_2_Ent8", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_2_Ent5", "text": "methotrexate and omeprazole", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "22550162_2_Ent7", "text": "omeprazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "22550162_2_Ent9", "text": "omeprazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "22550162_2_Ent0", "text": "a 25 - year - old man with osteosarcoma", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "22550162_2_Ent1", "text": "25 - year - old", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "22550162_2_Ent2", "text": "man", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_2_Ent3", "text": "osteosarcoma", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "22550162_6", "wnd_id": "22550162_6_1", "text": "Aggressive hydration , urinary alkalinization , and leucovorin were continued during the period of elevated methotrexate levels , with the patient receiving a course of hemodialysis and a dose of carboxypeptidase G2 .", "tokens": ["Aggressive", "hydration", ",", "urinary", "alkalinization", ",", "and", "leucovorin", "were", "continued", "during", "the", "period", "of", "elevated", "methotrexate", "levels", ",", "with", "the", "patient", "receiving", "a", "course", "of", "hemodialysis", "and", "a", "dose", "of", "carboxypeptidase", "G2", "."], "event_mentions": [{"id": "22550162_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "continued", "start": 9, "end": 10}, "arguments": [{"entity_id": "22550162_6_Ent1", "role": "Treatment", "text": "Aggressive hydration , urinary alkalinization , and leucovorin", "start": 0, "end": 8}, {"entity_id": "22550162_6_Ent4", "role": "Treatment_Drug", "text": "leucovorin", "start": 7, "end": 8}, {"entity_id": "22550162_6_Ent2", "role": "Treatment", "text": "elevated methotrexate", "start": 14, "end": 16}, {"entity_id": "22550162_6_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "22550162_6_Ent0", "role": "Subject", "text": "the patient", "start": 19, "end": 21}, {"entity_id": "22550162_6_Ent3", "role": "Treatment", "text": "course of hemodialysis and a dose of carboxypeptidase G2", "start": 23, "end": 32}, {"entity_id": "22550162_6_Ent7", "role": "Treatment_Dosage", "text": "a dose", "start": 27, "end": 29}, {"entity_id": "22550162_6_Ent6", "role": "Treatment_Drug", "text": "carboxypeptidase G2", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "22550162_6_Ent1", "text": "Aggressive hydration , urinary alkalinization , and leucovorin", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "22550162_6_Ent4", "text": "leucovorin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22550162_6_Ent2", "text": "elevated methotrexate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "22550162_6_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "22550162_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22550162_6_Ent3", "text": "course of hemodialysis and a dose of carboxypeptidase G2", "entity_type": "Entity", "start": 23, "end": 32}, {"id": "22550162_6_Ent7", "text": "a dose", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "22550162_6_Ent6", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "22550162_9", "wnd_id": "22550162_9_1", "text": "Although use of the Naranjo adverse reaction probability scale indicated a probable relationship ( score of 6 ) between the patient 's development of methotrexate toxicity and omeprazole use , we believe this was a drug - drug interaction case consistent with previous reports in the literature .", "tokens": ["Although", "use", "of", "the", "Naranjo", "adverse", "reaction", "probability", "scale", "indicated", "a", "probable", "relationship", "(", "score", "of", "6", ")", "between", "the", "patient", "'s", "development", "of", "methotrexate", "toxicity", "and", "omeprazole", "use", ",", "we", "believe", "this", "was", "a", "drug", "-", "drug", "interaction", "case", "consistent", "with", "previous", "reports", "in", "the", "literature", "."], "event_mentions": [{"id": "22550162_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 12, "end": 13}, "arguments": [{"entity_id": "22550162_9_Ent0", "role": "Subject", "text": "the patient", "start": 19, "end": 21}, {"entity_id": "22550162_9_Ent2", "role": "Treatment", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent6", "role": "Combination_Drug", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "22550162_9_Ent1", "role": "Effect", "text": "methotrexate toxicity", "start": 24, "end": 26}, {"entity_id": "22550162_9_Ent3", "role": "Treatment", "text": "and omeprazole use", "start": 26, "end": 29}, {"entity_id": "22550162_9_Ent5", "role": "Treatment_Drug", "text": "omeprazole", "start": 27, "end": 28}, {"entity_id": "22550162_9_Ent7", "role": "Combination_Drug", "text": "omeprazole", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "22550162_9_Ent0", "text": "the patient", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "22550162_9_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "22550162_9_Ent1", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "22550162_9_Ent3", "text": "and omeprazole use", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "22550162_9_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "22550162_9_Ent7", "text": "omeprazole", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "22791547_5", "wnd_id": "22791547_5_1", "text": "Although limb dyskinesia after methylphenidate is a commonly reported side effect , to the authors ' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate .", "tokens": ["Although", "limb", "dyskinesia", "after", "methylphenidate", "is", "a", "commonly", "reported", "side", "effect", ",", "to", "the", "authors", "'", "knowledge", "this", "is", "only", "the", "second", "reported", "case", "to", "develop", "both", "orofacial", "and", "limb", "dyskinesia", "in", "the", "acute", "period", "after", "the", "first", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "22791547_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "22791547_5_Ent3", "role": "Treatment_Drug", "text": "methylphenidate", "start": 4, "end": 5}, {"entity_id": "22791547_5_Ent0", "role": "Subject", "text": "the second reported case", "start": 20, "end": 24}, {"entity_id": "22791547_5_Ent1", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 27, "end": 31}, {"entity_id": "22791547_5_Ent2", "role": "Treatment", "text": "methylphenidate", "start": 40, "end": 41}, {"entity_id": "22791547_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "22791547_5_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22791547_5_Ent0", "text": "the second reported case", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22791547_5_Ent1", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "22791547_5_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "22791547_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "2292051_1", "wnd_id": "2292051_1_1", "text": "Acute coronary events following cisplatin - based chemotherapy .", "tokens": ["Acute", "coronary", "events", "following", "cisplatin", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "2292051_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "2292051_1_Ent0", "role": "Effect", "text": "Acute coronary events", "start": 0, "end": 3}, {"entity_id": "2292051_1_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 4, "end": 5}, {"entity_id": "2292051_1_Ent1", "role": "Treatment", "text": "cisplatin - based chemotherapy", "start": 4, "end": 8}, {"entity_id": "2292051_1_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "2292051_1_Ent0", "text": "Acute coronary events", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2292051_1_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2292051_1_Ent1", "text": "cisplatin - based chemotherapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2292051_1_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "2309833_1", "wnd_id": "2309833_1_1", "text": "After discontinuation of danazol the diabetes completely resolved .", "tokens": ["After", "discontinuation", "of", "danazol", "the", "diabetes", "completely", "resolved", "."], "event_mentions": [{"id": "2309833_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "2309833_1_Ent0", "role": "Treatment", "text": "discontinuation of danazol", "start": 1, "end": 4}, {"entity_id": "2309833_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 3, "end": 4}, {"entity_id": "2309833_1_Ent1", "role": "Treatment_Disorder", "text": "diabetes", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2309833_1_Ent0", "text": "discontinuation of danazol", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "2309833_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2309833_1_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2327115_2", "wnd_id": "2327115_2_1", "text": "Renal toxicities have been reported in less than one percent of the patients receiving ciprofloxacin therapy .", "tokens": ["Renal", "toxicities", "have", "been", "reported", "in", "less", "than", "one", "percent", "of", "the", "patients", "receiving", "ciprofloxacin", "therapy", "."], "event_mentions": [{"id": "2327115_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 4, "end": 5}, "arguments": [{"entity_id": "2327115_2_Ent2", "role": "Effect", "text": "Renal toxicities", "start": 0, "end": 2}, {"entity_id": "2327115_2_Ent1", "role": "Subject_Population", "text": "less than one percent", "start": 6, "end": 10}, {"entity_id": "2327115_2_Ent0", "role": "Subject", "text": "less than one percent of the patients", "start": 6, "end": 13}, {"entity_id": "2327115_2_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 14, "end": 15}, {"entity_id": "2327115_2_Ent3", "role": "Treatment", "text": "ciprofloxacin therapy .", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "2327115_2_Ent2", "text": "Renal toxicities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2327115_2_Ent1", "text": "less than one percent", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "2327115_2_Ent0", "text": "less than one percent of the patients", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "2327115_2_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2327115_2_Ent3", "text": "ciprofloxacin therapy .", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "2327115_4", "wnd_id": "2327115_4_1", "text": "This article describes a patient with suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["This", "article", "describes", "a", "patient", "with", "suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_4_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "2327115_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent1", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2327115_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent1", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2329972_1", "wnd_id": "2329972_1_1", "text": "In a female with acute lymphoblastic leukemia , inadvertent doxorubicin administration intrathecally caused severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus .", "tokens": ["In", "a", "female", "with", "acute", "lymphoblastic", "leukemia", ",", "inadvertent", "doxorubicin", "administration", "intrathecally", "caused", "severe", ",", "life", "-", "threatening", ",", "acute", "encephalopathy", "with", "high", "-", "pressure", "hydrocephalus", "."], "event_mentions": [{"id": "2329972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "2329972_1_Ent1", "role": "Subject_Gender", "text": "female", "start": 2, "end": 3}, {"entity_id": "2329972_1_Ent0", "role": "Subject", "text": "female with acute lymphoblastic leukemia", "start": 2, "end": 7}, {"entity_id": "2329972_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 4, "end": 7}, {"entity_id": "2329972_1_Ent3", "role": "Treatment", "text": "inadvertent doxorubicin administration intrathecally", "start": 8, "end": 12}, {"entity_id": "2329972_1_Ent4", "role": "Treatment_Drug", "text": "doxorubicin", "start": 9, "end": 10}, {"entity_id": "2329972_1_Ent6", "role": "Treatment_Route", "text": "intrathecally", "start": 11, "end": 12}, {"entity_id": "2329972_1_Ent2", "role": "Effect", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "2329972_1_Ent1", "text": "female", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2329972_1_Ent0", "text": "female with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2329972_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2329972_1_Ent3", "text": "inadvertent doxorubicin administration intrathecally", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "2329972_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2329972_1_Ent6", "text": "intrathecally", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2329972_1_Ent2", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "2332596_1", "wnd_id": "2332596_1_1", "text": "Phenobarbital hepatotoxicity in an 8 - month - old infant .", "tokens": ["Phenobarbital", "hepatotoxicity", "in", "an", "8", "-", "month", "-", "old", "infant", "."], "event_mentions": [{"id": "2332596_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "2332596_1_Ent3", "role": "Treatment", "text": "Phenobarbital", "start": 0, "end": 1}, {"entity_id": "2332596_1_Ent4", "role": "Treatment_Drug", "text": "Phenobarbital", "start": 0, "end": 1}, {"entity_id": "2332596_1_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 1, "end": 2}, {"entity_id": "2332596_1_Ent0", "role": "Subject", "text": "an 8 - month - old infant", "start": 3, "end": 10}, {"entity_id": "2332596_1_Ent1", "role": "Subject_Age", "text": "8 - month - old infant", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "2332596_1_Ent3", "text": "Phenobarbital", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2332596_1_Ent4", "text": "Phenobarbital", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2332596_1_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2332596_1_Ent0", "text": "an 8 - month - old infant", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "2332596_1_Ent1", "text": "8 - month - old infant", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "2347102_1", "wnd_id": "2347102_1_1", "text": "Atenolol - induced pseudolymphoma .", "tokens": ["Atenolol", "-", "induced", "pseudolymphoma", "."], "event_mentions": [{"id": "2347102_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2347102_1_Ent1", "role": "Treatment", "text": "Atenolol", "start": 0, "end": 1}, {"entity_id": "2347102_1_Ent2", "role": "Treatment_Drug", "text": "Atenolol", "start": 0, "end": 1}, {"entity_id": "2347102_1_Ent0", "role": "Effect", "text": "pseudolymphoma", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2347102_1_Ent1", "text": "Atenolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2347102_1_Ent2", "text": "Atenolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2347102_1_Ent0", "text": "pseudolymphoma", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "23471710_1", "wnd_id": "23471710_1_1", "text": "Severe hypoglycemia from Helicobacter pylori triple - drug therapy and insulin detemir drug interaction .", "tokens": ["Severe", "hypoglycemia", "from", "Helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "."], "event_mentions": [{"id": "23471710_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "23471710_1_Ent0", "role": "Effect", "text": "Severe hypoglycemia", "start": 0, "end": 2}, {"entity_id": "23471710_1_Ent2", "role": "Treatment_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent5", "role": "Combination_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent1", "role": "Treatment", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "start": 3, "end": 14}, {"entity_id": "23471710_1_Ent3", "role": "Treatment_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}, {"entity_id": "23471710_1_Ent4", "role": "Combination_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "23471710_1_Ent0", "text": "Severe hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "23471710_1_Ent2", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent5", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent1", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "23471710_1_Ent3", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "23471710_1_Ent4", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "2357706_1", "wnd_id": "2357706_1_1", "text": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents , it was only rarely reported in association with sulpiride , a selective D2 - receptor antagonist .", "tokens": ["Although", "tardive", "dyskinesia", "is", "a", "known", "adverse", "reaction", "of", "sustained", "treatment", "with", "traditional", "neuroleptic", "agents", ",", "it", "was", "only", "rarely", "reported", "in", "association", "with", "sulpiride", ",", "a", "selective", "D2", "-", "receptor", "antagonist", "."], "event_mentions": [{"id": "2357706_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 22, "end": 23}, "arguments": [{"entity_id": "2357706_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 1, "end": 3}, {"entity_id": "2357706_1_Ent1", "role": "Treatment", "text": "sulpiride", "start": 24, "end": 25}, {"entity_id": "2357706_1_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "2357706_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2357706_1_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "2357706_1_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "23624139_10", "wnd_id": "23624139_10_1", "text": "Risks and benefits of co - treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety .", "tokens": ["Risks", "and", "benefits", "of", "co", "-", "treatment", "should", "be", "carefully", "considered", "and", "therapeutic", "alternatives", "to", "NSAIDs", "should", "be", "recommended", "to", "patients", "with", "central", "DI", "in", "order", "to", "improve", "DDAVP", "safety", "."], "event_mentions": [{"id": "23624139_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recommended", "start": 18, "end": 19}, "arguments": [{"entity_id": "23624139_10_Ent2", "role": "Treatment", "text": "therapeutic alternatives to NSAIDs", "start": 12, "end": 16}, {"entity_id": "23624139_10_Ent4", "role": "Treatment_Drug", "text": "NSAIDs", "start": 15, "end": 16}, {"entity_id": "23624139_10_Ent0", "role": "Subject", "text": "patients with central DI", "start": 20, "end": 24}, {"entity_id": "23624139_10_Ent3", "role": "Treatment_Disorder", "text": "central DI", "start": 22, "end": 24}, {"entity_id": "23624139_10_Ent1", "role": "Effect", "text": "in order to improve DDAVP safety", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "23624139_10_Ent2", "text": "therapeutic alternatives to NSAIDs", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "23624139_10_Ent4", "text": "NSAIDs", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23624139_10_Ent0", "text": "patients with central DI", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "23624139_10_Ent3", "text": "central DI", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "23624139_10_Ent1", "text": "in order to improve DDAVP safety", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "2369419_1", "wnd_id": "2369419_1_1", "text": "A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate ( MTX ) .", "tokens": ["A", "patient", "with", "seropositive", "rheumatoid", "arthritis", "developed", "ascites", "while", "taking", "weekly", "doses", "of", "methotrexate", "(", "MTX", ")", "."], "event_mentions": [{"id": "2369419_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "2369419_1_Ent0", "role": "Subject", "text": "A patient with seropositive rheumatoid arthritis", "start": 0, "end": 6}, {"entity_id": "2369419_1_Ent3", "role": "Treatment_Disorder", "text": "seropositive rheumatoid arthritis", "start": 3, "end": 6}, {"entity_id": "2369419_1_Ent1", "role": "Effect", "text": "ascites", "start": 7, "end": 8}, {"entity_id": "2369419_1_Ent2", "role": "Treatment", "text": "taking weekly doses of methotrexate ( MTX )", "start": 9, "end": 17}, {"entity_id": "2369419_1_Ent4", "role": "Treatment_Freq", "text": "weekly", "start": 10, "end": 11}, {"entity_id": "2369419_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2369419_1_Ent0", "text": "A patient with seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2369419_1_Ent3", "text": "seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2369419_1_Ent1", "text": "ascites", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2369419_1_Ent2", "text": "taking weekly doses of methotrexate ( MTX )", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "2369419_1_Ent4", "text": "weekly", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2369419_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "23868369_2", "wnd_id": "23868369_2_1", "text": "A 27 year old female with a complex history of congenital heart disease , cardiac surgery , heart failure , and arrhythmias was admitted for a Pseudomonas aeruginosa sternal wound infection and treated with intravenous antibiotics .", "tokens": ["A", "27", "year", "old", "female", "with", "a", "complex", "history", "of", "congenital", "heart", "disease", ",", "cardiac", "surgery", ",", "heart", "failure", ",", "and", "arrhythmias", "was", "admitted", "for", "a", "Pseudomonas", "aeruginosa", "sternal", "wound", "infection", "and", "treated", "with", "intravenous", "antibiotics", "."], "event_mentions": [{"id": "23868369_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 32, "end": 33}, "arguments": [{"entity_id": "23868369_2_Ent0", "role": "Subject", "text": "A 27 year old female with a complex history of congenital heart disease , cardiac surgery , heart failure , and arrhythmias", "start": 0, "end": 22}, {"entity_id": "23868369_2_Ent1", "role": "Subject_Age", "text": "27 year old", "start": 1, "end": 4}, {"entity_id": "23868369_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 4, "end": 5}, {"entity_id": "23868369_2_Ent3", "role": "Subject_Disorder", "text": "congenital heart disease", "start": 10, "end": 13}, {"entity_id": "23868369_2_Ent4", "role": "Subject_Disorder", "text": "cardiac surgery", "start": 14, "end": 16}, {"entity_id": "23868369_2_Ent5", "role": "Subject_Disorder", "text": "heart failure", "start": 17, "end": 19}, {"entity_id": "23868369_2_Ent6", "role": "Subject_Disorder", "text": "arrhythmias", "start": 21, "end": 22}, {"entity_id": "23868369_2_Ent10", "role": "Treatment_Disorder", "text": "a Pseudomonas aeruginosa sternal wound infection", "start": 25, "end": 31}, {"entity_id": "23868369_2_Ent9", "role": "Treatment_Route", "text": "intravenous", "start": 34, "end": 35}, {"entity_id": "23868369_2_Ent7", "role": "Treatment", "text": "intravenous antibiotics", "start": 34, "end": 36}, {"entity_id": "23868369_2_Ent8", "role": "Treatment_Drug", "text": "antibiotics", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "23868369_2_Ent0", "text": "A 27 year old female with a complex history of congenital heart disease , cardiac surgery , heart failure , and arrhythmias", "entity_type": "Entity", "start": 0, "end": 22}, {"id": "23868369_2_Ent1", "text": "27 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "23868369_2_Ent2", "text": "female", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "23868369_2_Ent3", "text": "congenital heart disease", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "23868369_2_Ent4", "text": "cardiac surgery", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "23868369_2_Ent5", "text": "heart failure", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "23868369_2_Ent6", "text": "arrhythmias", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "23868369_2_Ent10", "text": "a Pseudomonas aeruginosa sternal wound infection", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "23868369_2_Ent9", "text": "intravenous", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "23868369_2_Ent7", "text": "intravenous antibiotics", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "23868369_2_Ent8", "text": "antibiotics", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "2394154_2", "wnd_id": "2394154_2_1", "text": "Following the institution of intravenous therapy with acyclovir , the patient developed fever , hemoptysis , and a pleural friction rub .", "tokens": ["Following", "the", "institution", "of", "intravenous", "therapy", "with", "acyclovir", ",", "the", "patient", "developed", "fever", ",", "hemoptysis", ",", "and", "a", "pleural", "friction", "rub", "."], "event_mentions": [{"id": "2394154_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2394154_2_Ent2", "role": "Treatment", "text": "acyclovir", "start": 7, "end": 8}, {"entity_id": "2394154_2_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 7, "end": 8}, {"entity_id": "2394154_2_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "2394154_2_Ent1", "role": "Effect", "text": "fever , hemoptysis , and a pleural friction rub", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "2394154_2_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2394154_2_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2394154_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2394154_2_Ent1", "text": "fever , hemoptysis , and a pleural friction rub", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "2406680_1", "wnd_id": "2406680_1_1", "text": "Quinine - induced hearing loss .", "tokens": ["Quinine", "-", "induced", "hearing", "loss", "."], "event_mentions": [{"id": "2406680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2406680_1_Ent1", "role": "Treatment", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "2406680_1_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "2406680_1_Ent0", "role": "Effect", "text": "hearing loss", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2406680_1_Ent1", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2406680_1_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2406680_1_Ent0", "text": "hearing loss", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2413037_1", "wnd_id": "2413037_1_1", "text": "Hemolytic uremic syndrome in a patient on cis - platinum , vinblastine and bleomycin .", "tokens": ["Hemolytic", "uremic", "syndrome", "in", "a", "patient", "on", "cis", "-", "platinum", ",", "vinblastine", "and", "bleomycin", "."], "event_mentions": [{"id": "2413037_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "2413037_1_Ent1", "role": "Effect", "text": "Hemolytic uremic syndrome", "start": 0, "end": 3}, {"entity_id": "2413037_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "2413037_1_Ent3", "role": "Treatment_Drug", "text": "cis - platinum", "start": 7, "end": 10}, {"entity_id": "2413037_1_Ent2", "role": "Treatment", "text": "cis - platinum , vinblastine and bleomycin", "start": 7, "end": 14}, {"entity_id": "2413037_1_Ent4", "role": "Treatment_Drug", "text": "vinblastine", "start": 11, "end": 12}, {"entity_id": "2413037_1_Ent5", "role": "Treatment_Drug", "text": "bleomycin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2413037_1_Ent1", "text": "Hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2413037_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2413037_1_Ent3", "text": "cis - platinum", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2413037_1_Ent2", "text": "cis - platinum , vinblastine and bleomycin", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "2413037_1_Ent4", "text": "vinblastine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2413037_1_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2417800_1", "wnd_id": "2417800_1_1", "text": "A case of a 53 - year - old man who developed acute pneumonitis after bleomycin and moderate oxygen administration is presented .", "tokens": ["A", "case", "of", "a", "53", "-", "year", "-", "old", "man", "who", "developed", "acute", "pneumonitis", "after", "bleomycin", "and", "moderate", "oxygen", "administration", "is", "presented", "."], "event_mentions": [{"id": "2417800_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "2417800_1_Ent0", "role": "Subject", "text": "A case of a 53 - year - old man", "start": 0, "end": 10}, {"entity_id": "2417800_1_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 4, "end": 9}, {"entity_id": "2417800_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "2417800_1_Ent3", "role": "Effect", "text": "acute pneumonitis", "start": 12, "end": 14}, {"entity_id": "2417800_1_Ent5", "role": "Treatment_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "2417800_1_Ent8", "role": "Combination_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "2417800_1_Ent4", "role": "Treatment", "text": "bleomycin and moderate oxygen", "start": 15, "end": 19}, {"entity_id": "2417800_1_Ent7", "role": "Treatment_Dosage", "text": "moderate", "start": 17, "end": 18}, {"entity_id": "2417800_1_Ent6", "role": "Treatment_Drug", "text": "oxygen", "start": 18, "end": 19}, {"entity_id": "2417800_1_Ent9", "role": "Combination_Drug", "text": "oxygen", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2417800_1_Ent0", "text": "A case of a 53 - year - old man", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "2417800_1_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2417800_1_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2417800_1_Ent3", "text": "acute pneumonitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2417800_1_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2417800_1_Ent8", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2417800_1_Ent4", "text": "bleomycin and moderate oxygen", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2417800_1_Ent7", "text": "moderate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2417800_1_Ent6", "text": "oxygen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2417800_1_Ent9", "text": "oxygen", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "24318743_3", "wnd_id": "24318743_3_1", "text": "Based on prior data suggesting that scheduling alterations of platinum would increase activity , the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin in PROC patients .", "tokens": ["Based", "on", "prior", "data", "suggesting", "that", "scheduling", "alterations", "of", "platinum", "would", "increase", "activity", ",", "the", "aim", "of", "the", "present", "study", "was", "to", "assess", "the", "potential", "therapeutic", "benefit", "of", "phenoxodiol", "(", "PXD", ")", ",", "a", "novel", "biomodulator", "shown", "to", "have", "chemoresistance", "reversing", "potential", ",", "when", "combined", "with", "weekly", "AUC2", "-", "carboplatin", "in", "PROC", "patients", "."], "event_mentions": [{"id": "24318743_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "assess", "start": 22, "end": 23}, "arguments": [{"entity_id": "24318743_3_Ent1", "role": "Effect", "text": "potential therapeutic benefit", "start": 24, "end": 27}, {"entity_id": "24318743_3_Ent3", "role": "Treatment_Drug", "text": "phenoxodiol", "start": 28, "end": 29}, {"entity_id": "24318743_3_Ent8", "role": "Combination_Drug", "text": "phenoxodiol", "start": 28, "end": 29}, {"entity_id": "24318743_3_Ent2", "role": "Treatment", "text": "phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin", "start": 28, "end": 50}, {"entity_id": "24318743_3_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 46, "end": 47}, {"entity_id": "24318743_3_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 49, "end": 50}, {"entity_id": "24318743_3_Ent7", "role": "Combination_Drug", "text": "carboplatin", "start": 49, "end": 50}, {"entity_id": "24318743_3_Ent5", "role": "Treatment_Disorder", "text": "PROC", "start": 51, "end": 52}, {"entity_id": "24318743_3_Ent0", "role": "Subject", "text": "PROC patients", "start": 51, "end": 53}]}], "entity_mentions": [{"id": "24318743_3_Ent1", "text": "potential therapeutic benefit", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "24318743_3_Ent3", "text": "phenoxodiol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24318743_3_Ent8", "text": "phenoxodiol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24318743_3_Ent2", "text": "phenoxodiol ( PXD ) , a novel biomodulator shown to have chemoresistance reversing potential , when combined with weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 28, "end": 50}, {"id": "24318743_3_Ent6", "text": "weekly", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "24318743_3_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "24318743_3_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "24318743_3_Ent5", "text": "PROC", "entity_type": "Entity", "start": 51, "end": 52}, {"id": "24318743_3_Ent0", "text": "PROC patients", "entity_type": "Entity", "start": 51, "end": 53}], "lang": "en"}
{"doc_id": "24429012_1", "wnd_id": "24429012_1_1", "text": "Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib .", "tokens": ["Elevated", "International", "Normalized", "Ratio", "in", "a", "patient", "concurrently", "using", "warfarin", "and", "vismodegib", "."], "event_mentions": [{"id": "24429012_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "using", "start": 8, "end": 9}, "arguments": [{"entity_id": "24429012_1_Ent1", "role": "Effect", "text": "Elevated International Normalized Ratio", "start": 0, "end": 4}, {"entity_id": "24429012_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "24429012_1_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "24429012_1_Ent2", "role": "Treatment", "text": "warfarin and vismodegib", "start": 9, "end": 12}, {"entity_id": "24429012_1_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 11, "end": 12}, {"entity_id": "24429012_1_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "24429012_1_Ent1", "text": "Elevated International Normalized Ratio", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "24429012_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24429012_1_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "24429012_1_Ent2", "text": "warfarin and vismodegib", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "24429012_1_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24429012_1_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "24429012_2", "wnd_id": "24429012_2_1", "text": "A case report of a sharp rise in International Normalized Ratio ( INR ) values during a patient 's concomitant use of warfarin and the antineoplastic agent vismodegib is presented .", "tokens": ["A", "case", "report", "of", "a", "sharp", "rise", "in", "International", "Normalized", "Ratio", "(", "INR", ")", "values", "during", "a", "patient", "'s", "concomitant", "use", "of", "warfarin", "and", "the", "antineoplastic", "agent", "vismodegib", "is", "presented", "."], "event_mentions": [{"id": "24429012_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "24429012_2_Ent1", "role": "Effect", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "start": 4, "end": 15}, {"entity_id": "24429012_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "24429012_2_Ent2", "role": "Treatment", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "start": 19, "end": 28}, {"entity_id": "24429012_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 27, "end": 28}, {"entity_id": "24429012_2_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24429012_2_Ent1", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "24429012_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "24429012_2_Ent2", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "24429012_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24429012_2_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "2442958_2", "wnd_id": "2442958_2_1", "text": "This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol ( DES ) therapy for prostatic cancer .", "tokens": ["This", "is", "a", "unique", "autopsy", "case", "of", "hepatocellular", "carcinoma", "closely", "related", "to", "diethylstilbestrol", "(", "DES", ")", "therapy", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "2442958_2_Ent0", "role": "Subject", "text": "a unique autopsy case", "start": 2, "end": 6}, {"entity_id": "2442958_2_Ent1", "role": "Effect", "text": "hepatocellular carcinoma", "start": 7, "end": 9}, {"entity_id": "2442958_2_Ent4", "role": "Treatment_Drug", "text": "diethylstilbestrol", "start": 12, "end": 13}, {"entity_id": "2442958_2_Ent2", "role": "Treatment", "text": "diethylstilbestrol ( DES )", "start": 12, "end": 16}, {"entity_id": "2442958_2_Ent3", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "2442958_2_Ent0", "text": "a unique autopsy case", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "2442958_2_Ent1", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2442958_2_Ent4", "text": "diethylstilbestrol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2442958_2_Ent2", "text": "diethylstilbestrol ( DES )", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2442958_2_Ent3", "text": "prostatic cancer", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "2442958_3", "wnd_id": "2442958_3_1", "text": "This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( PDES ) for prostatic cancer .", "tokens": ["This", "paper", "reports", "an", "autopsy", "case", "of", "a", "78", "-", "year", "-", "old", "male", "with", "multiple", "nodules", "in", "the", "liver", "developed", "after", "long", "-", "termed", "administration", "of", "phosphate", "diethylstilbestrol", "(", "PDES", ")", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2442958_3_Ent0", "role": "Subject", "text": "an autopsy case of a 78 - year - old male", "start": 3, "end": 14}, {"entity_id": "2442958_3_Ent2", "role": "Subject_Age", "text": "78 - year - old", "start": 8, "end": 13}, {"entity_id": "2442958_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "2442958_3_Ent4", "role": "Effect", "text": "multiple nodules in the liver", "start": 15, "end": 20}, {"entity_id": "2442958_3_Ent7", "role": "Treatment_Drug", "text": "phosphate diethylstilbestrol", "start": 27, "end": 29}, {"entity_id": "2442958_3_Ent5", "role": "Treatment", "text": "phosphate diethylstilbestrol ( PDES )", "start": 27, "end": 32}, {"entity_id": "2442958_3_Ent1", "role": "Subject", "text": "prostatic cancer", "start": 33, "end": 35}, {"entity_id": "2442958_3_Ent6", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2442958_3_Ent0", "text": "an autopsy case of a 78 - year - old male", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "2442958_3_Ent2", "text": "78 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2442958_3_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2442958_3_Ent4", "text": "multiple nodules in the liver", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "2442958_3_Ent7", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "2442958_3_Ent5", "text": "phosphate diethylstilbestrol ( PDES )", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "2442958_3_Ent1", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "2442958_3_Ent6", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2445709_1", "wnd_id": "2445709_1_1", "text": "A 52 - year - old woman developed symmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of amiodarone treatment .", "tokens": ["A", "52", "-", "year", "-", "old", "woman", "developed", "symmetric", "sensorimotor", "polyneuropathy", "and", "cerebellar", "syndrome", "after", "24", "months", "of", "amiodarone", "treatment", "."], "event_mentions": [{"id": "2445709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2445709_1_Ent0", "role": "Subject", "text": "A 52 - year - old woman", "start": 0, "end": 7}, {"entity_id": "2445709_1_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "2445709_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2445709_1_Ent3", "role": "Effect", "text": "symmetric sensorimotor polyneuropathy", "start": 8, "end": 11}, {"entity_id": "2445709_1_Ent4", "role": "Effect", "text": "cerebellar syndrome", "start": 12, "end": 14}, {"entity_id": "2445709_1_Ent6", "role": "Treatment_Time_elapsed", "text": "24 months", "start": 15, "end": 17}, {"entity_id": "2445709_1_Ent5", "role": "Treatment", "text": "amiodarone", "start": 18, "end": 19}, {"entity_id": "2445709_1_Ent7", "role": "Treatment_Drug", "text": "amiodarone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2445709_1_Ent0", "text": "A 52 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2445709_1_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2445709_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2445709_1_Ent3", "text": "symmetric sensorimotor polyneuropathy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2445709_1_Ent4", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2445709_1_Ent6", "text": "24 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "2445709_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2445709_1_Ent7", "text": "amiodarone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "24661191_5", "wnd_id": "24661191_5_1", "text": "Vitamin K1 caused skin rash possibly because of the distribution and metabolism characteristic of the drug in this patient .", "tokens": ["Vitamin", "K1", "caused", "skin", "rash", "possibly", "because", "of", "the", "distribution", "and", "metabolism", "characteristic", "of", "the", "drug", "in", "this", "patient", "."], "event_mentions": [{"id": "24661191_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "24661191_5_Ent1", "role": "Treatment", "text": "Vitamin K1", "start": 0, "end": 2}, {"entity_id": "24661191_5_Ent2", "role": "Treatment_Drug", "text": "Vitamin K1", "start": 0, "end": 2}, {"entity_id": "24661191_5_Ent0", "role": "Effect", "text": "skin rash", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "24661191_5_Ent1", "text": "Vitamin K1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24661191_5_Ent2", "text": "Vitamin K1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24661191_5_Ent0", "text": "skin rash", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "24791374_6", "wnd_id": "24791374_6_1", "text": "Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation .", "tokens": ["Propafenone", "is", "an", "established", "class", "IC", "antiarrhythmic", "drug", "commonly", "used", "in", "the", "treatment", "of", "atrial", "fibrillation", "."], "event_mentions": [{"id": "24791374_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "24791374_6_Ent0", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent2", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent1", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "24791374_6_Ent0", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent2", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent1", "text": "atrial fibrillation", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "2483959_1", "wnd_id": "2483959_1_1", "text": "A typical case of dextran - 40 associated acute renal failure is presented .", "tokens": ["A", "typical", "case", "of", "dextran", "-", "40", "associated", "acute", "renal", "failure", "is", "presented", "."], "event_mentions": [{"id": "2483959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2483959_1_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2483959_1_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "24846936_1", "wnd_id": "24846936_1_1", "text": "Fatal methylene blue associated serotonin toxicity .", "tokens": ["Fatal", "methylene", "blue", "associated", "serotonin", "toxicity", "."], "event_mentions": [{"id": "24846936_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "24846936_1_Ent1", "role": "Treatment", "text": "methylene blue", "start": 1, "end": 3}, {"entity_id": "24846936_1_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 1, "end": 3}, {"entity_id": "24846936_1_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "24846936_1_Ent1", "text": "methylene blue", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24846936_1_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24846936_1_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "24918555_1", "wnd_id": "24918555_1_1", "text": "Results of a Phase III , double - blind , randomized , parallel - group , non - inferiority study evaluating the safety and efficacy of isotretinoin - Lidose in patients with severe recalcitrant nodular acne .", "tokens": ["Results", "of", "a", "Phase", "III", ",", "double", "-", "blind", ",", "randomized", ",", "parallel", "-", "group", ",", "non", "-", "inferiority", "study", "evaluating", "the", "safety", "and", "efficacy", "of", "isotretinoin", "-", "Lidose", "in", "patients", "with", "severe", "recalcitrant", "nodular", "acne", "."], "event_mentions": [{"id": "24918555_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of", "start": 25, "end": 26}, "arguments": [{"entity_id": "24918555_1_Ent1", "role": "Effect", "text": "evaluating the safety and efficacy", "start": 20, "end": 25}, {"entity_id": "24918555_1_Ent2", "role": "Treatment", "text": "isotretinoin - Lidose", "start": 26, "end": 29}, {"entity_id": "24918555_1_Ent4", "role": "Treatment_Drug", "text": "isotretinoin - Lidose", "start": 26, "end": 29}, {"entity_id": "24918555_1_Ent0", "role": "Subject", "text": "patients with severe recalcitrant nodular acne", "start": 30, "end": 36}, {"entity_id": "24918555_1_Ent3", "role": "Treatment_Disorder", "text": "severe recalcitrant nodular acne", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "24918555_1_Ent1", "text": "evaluating the safety and efficacy", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "24918555_1_Ent2", "text": "isotretinoin - Lidose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "24918555_1_Ent4", "text": "isotretinoin - Lidose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "24918555_1_Ent0", "text": "patients with severe recalcitrant nodular acne", "entity_type": "Entity", "start": 30, "end": 36}, {"id": "24918555_1_Ent3", "text": "severe recalcitrant nodular acne", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "24927617_2", "wnd_id": "24927617_2_1", "text": "A 46 - year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin , pegylated interferon and telaprevir .", "tokens": ["A", "46", "-", "year", "old", "man", "with", "a", "chronic", "hepatitis", "C", "virus", "infection", "received", "triple", "therapy", "with", "ribavirin", ",", "pegylated", "interferon", "and", "telaprevir", "."], "event_mentions": [{"id": "24927617_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 13, "end": 14}, "arguments": [{"entity_id": "24927617_2_Ent0", "role": "Subject", "text": "A 46 - year old man with a chronic hepatitis C virus infection", "start": 0, "end": 13}, {"entity_id": "24927617_2_Ent1", "role": "Subject_Age", "text": "46 - year old", "start": 1, "end": 5}, {"entity_id": "24927617_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 5, "end": 6}, {"entity_id": "24927617_2_Ent4", "role": "Treatment_Disorder", "text": "a chronic hepatitis C virus infection", "start": 7, "end": 13}, {"entity_id": "24927617_2_Ent3", "role": "Treatment", "text": "triple therapy with ribavirin , pegylated interferon and telaprevir", "start": 14, "end": 23}, {"entity_id": "24927617_2_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 17, "end": 18}, {"entity_id": "24927617_2_Ent8", "role": "Combination_Drug", "text": "ribavirin", "start": 17, "end": 18}, {"entity_id": "24927617_2_Ent6", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 19, "end": 21}, {"entity_id": "24927617_2_Ent9", "role": "Combination_Drug", "text": "pegylated interferon", "start": 19, "end": 21}, {"entity_id": "24927617_2_Ent7", "role": "Treatment_Drug", "text": "telaprevir", "start": 22, "end": 23}, {"entity_id": "24927617_2_Ent10", "role": "Combination_Drug", "text": "telaprevir", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "24927617_2_Ent0", "text": "A 46 - year old man with a chronic hepatitis C virus infection", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "24927617_2_Ent1", "text": "46 - year old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "24927617_2_Ent2", "text": "man", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24927617_2_Ent4", "text": "a chronic hepatitis C virus infection", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "24927617_2_Ent3", "text": "triple therapy with ribavirin , pegylated interferon and telaprevir", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "24927617_2_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "24927617_2_Ent8", "text": "ribavirin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "24927617_2_Ent6", "text": "pegylated interferon", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "24927617_2_Ent9", "text": "pegylated interferon", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "24927617_2_Ent7", "text": "telaprevir", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24927617_2_Ent10", "text": "telaprevir", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "2523364_2", "wnd_id": "2523364_2_1", "text": "A 57 - year - old man developed morphea while taking bromocriptine .", "tokens": ["A", "57", "-", "year", "-", "old", "man", "developed", "morphea", "while", "taking", "bromocriptine", "."], "event_mentions": [{"id": "2523364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "2523364_2_Ent0", "role": "Subject", "text": "A 57 - year - old man", "start": 0, "end": 7}, {"entity_id": "2523364_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "2523364_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "2523364_2_Ent3", "role": "Effect", "text": "morphea", "start": 8, "end": 9}, {"entity_id": "2523364_2_Ent4", "role": "Treatment", "text": "bromocriptine", "start": 11, "end": 12}, {"entity_id": "2523364_2_Ent5", "role": "Treatment_Drug", "text": "bromocriptine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "2523364_2_Ent0", "text": "A 57 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2523364_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2523364_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2523364_2_Ent3", "text": "morphea", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2523364_2_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2523364_2_Ent5", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "25295553_3", "wnd_id": "25295553_3_1", "text": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off - label add - on treatment .", "tokens": ["Anxiety", "is", "common", "in", "patients", "with", "schizophrenia", "and", "pregabalin", "has", "been", "suggested", "as", "an", "off", "-", "label", "add", "-", "on", "treatment", "."], "event_mentions": [{"id": "25295553_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 20, "end": 21}, "arguments": [{"entity_id": "25295553_3_Ent4", "role": "Treatment_Disorder", "text": "Anxiety", "start": 0, "end": 1}, {"entity_id": "25295553_3_Ent0", "role": "Subject", "text": "patients with schizophrenia", "start": 4, "end": 7}, {"entity_id": "25295553_3_Ent1", "role": "Subject_Disorder", "text": "schizophrenia", "start": 6, "end": 7}, {"entity_id": "25295553_3_Ent3", "role": "Treatment_Drug", "text": "pregabalin", "start": 8, "end": 9}, {"entity_id": "25295553_3_Ent2", "role": "Treatment", "text": "pregabalin has been suggested as an off - label add - on treatment", "start": 8, "end": 21}]}], "entity_mentions": [{"id": "25295553_3_Ent4", "text": "Anxiety", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_3_Ent0", "text": "patients with schizophrenia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "25295553_3_Ent1", "text": "schizophrenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25295553_3_Ent3", "text": "pregabalin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25295553_3_Ent2", "text": "pregabalin has been suggested as an off - label add - on treatment", "entity_type": "Entity", "start": 8, "end": 21}], "lang": "en"}
{"doc_id": "25295553_4", "wnd_id": "25295553_4_1", "text": "Pregabalin was added to clozapine in 2 patients with schizophrenia , who both suffered from severe anxiety symptoms .", "tokens": ["Pregabalin", "was", "added", "to", "clozapine", "in", "2", "patients", "with", "schizophrenia", ",", "who", "both", "suffered", "from", "severe", "anxiety", "symptoms", "."], "event_mentions": [{"id": "25295553_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "25295553_4_Ent4", "role": "Treatment_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_4_Ent7", "role": "Combination_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_4_Ent2", "role": "Treatment", "text": "Pregabalin was added to clozapine", "start": 0, "end": 5}, {"entity_id": "25295553_4_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "25295553_4_Ent8", "role": "Combination_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "25295553_4_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "25295553_4_Ent0", "role": "Subject", "text": "2 patients with schizophrenia , who both suffered from severe anxiety symptoms", "start": 6, "end": 18}, {"entity_id": "25295553_4_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 9, "end": 10}, {"entity_id": "25295553_4_Ent5", "role": "Treatment_Disorder", "text": "anxiety symptoms", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "25295553_4_Ent4", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_4_Ent7", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_4_Ent2", "text": "Pregabalin was added to clozapine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "25295553_4_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "25295553_4_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "25295553_4_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25295553_4_Ent0", "text": "2 patients with schizophrenia , who both suffered from severe anxiety symptoms", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "25295553_4_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25295553_4_Ent5", "text": "anxiety symptoms", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "25417855_2", "wnd_id": "25417855_2_1", "text": "Azole antifungals , prescribed prophylactically to avoid severe infections in immunosuppressed organ transplant recipients , can interact with drug substrates of CYP3A4 .", "tokens": ["Azole", "antifungals", ",", "prescribed", "prophylactically", "to", "avoid", "severe", "infections", "in", "immunosuppressed", "organ", "transplant", "recipients", ",", "can", "interact", "with", "drug", "substrates", "of", "CYP3A4", "."], "event_mentions": [{"id": "25417855_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 16, "end": 17}, "arguments": [{"entity_id": "25417855_2_Ent2", "role": "Treatment", "text": "Azole antifungals", "start": 0, "end": 2}, {"entity_id": "25417855_2_Ent5", "role": "Treatment_Drug", "text": "Azole antifungals", "start": 0, "end": 2}, {"entity_id": "25417855_2_Ent8", "role": "Combination_Drug", "text": "Azole antifungals", "start": 0, "end": 2}, {"entity_id": "25417855_2_Ent4", "role": "Treatment_Disorder", "text": "severe infections", "start": 7, "end": 9}, {"entity_id": "25417855_2_Ent1", "role": "Subject_Disorder", "text": "immunosuppressed organ transplant", "start": 10, "end": 13}, {"entity_id": "25417855_2_Ent0", "role": "Subject", "text": "immunosuppressed organ transplant recipients", "start": 10, "end": 14}, {"entity_id": "25417855_2_Ent3", "role": "Treatment", "text": "drug substrates of CYP3A4", "start": 18, "end": 22}, {"entity_id": "25417855_2_Ent6", "role": "Treatment_Drug", "text": "drug substrates of CYP3A4", "start": 18, "end": 22}, {"entity_id": "25417855_2_Ent7", "role": "Combination_Drug", "text": "drug substrates of CYP3A4", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "25417855_2_Ent2", "text": "Azole antifungals", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "25417855_2_Ent5", "text": "Azole antifungals", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "25417855_2_Ent8", "text": "Azole antifungals", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "25417855_2_Ent4", "text": "severe infections", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "25417855_2_Ent1", "text": "immunosuppressed organ transplant", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "25417855_2_Ent0", "text": "immunosuppressed organ transplant recipients", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "25417855_2_Ent3", "text": "drug substrates of CYP3A4", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25417855_2_Ent6", "text": "drug substrates of CYP3A4", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25417855_2_Ent7", "text": "drug substrates of CYP3A4", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "2549018_1", "wnd_id": "2549018_1_1", "text": "Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .", "tokens": ["Akathisia", "appeared", "to", "be", "a", "common", "side", "effect", "of", "fluoxetine", "and", "generally", "responded", "well", "to", "treatment", "with", "the", "beta", "-", "adrenergic", "antagonist", "propranolol", ",", "dose", "reduction", ",", "or", "both", "."], "event_mentions": [{"id": "2549018_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 12, "end": 13}, "arguments": [{"entity_id": "2549018_1_Ent1", "role": "Treatment_Disorder", "text": "Akathisia", "start": 0, "end": 1}, {"entity_id": "2549018_1_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 9, "end": 10}, {"entity_id": "2549018_1_Ent0", "role": "Treatment", "text": "beta - adrenergic antagonist propranolol", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "2549018_1_Ent1", "text": "Akathisia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_1_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2549018_1_Ent0", "text": "beta - adrenergic antagonist propranolol", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "2549018_6", "wnd_id": "2549018_6_1", "text": "Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .", "tokens": ["Three", "patients", "who", "had", "experienced", "neuroleptic", "-", "induced", "akathisia", "in", "the", "past", "reported", "that", "the", "symptoms", "of", "fluoxetine", "-", "induced", "akathisia", "were", "identical", ",", "although", "somewhat", "milder", "."], "event_mentions": [{"id": "2549018_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2549018_6_Ent8", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent6", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent10", "role": "Treatment", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent11", "role": "Treatment_Drug", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent7", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent9", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}]}, {"id": "2549018_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "2549018_6_Ent2", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent1", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent4", "role": "Treatment", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent3", "role": "Effect", "text": "akathisia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2549018_6_Ent2", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent8", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent6", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent10", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent11", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent1", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent7", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent9", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2549018_6_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent3", "text": "akathisia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "25540831_1", "wnd_id": "25540831_1_1", "text": "Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor .", "tokens": ["Transient", "serotonin", "syndrome", "caused", "by", "concurrent", "use", "of", "tramadol", "and", "selective", "serotonin", "reuptake", "inhibitor", "."], "event_mentions": [{"id": "25540831_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "25540831_1_Ent0", "role": "Effect", "text": "Transient serotonin syndrome", "start": 0, "end": 3}, {"entity_id": "25540831_1_Ent1", "role": "Treatment", "text": "concurrent use of tramadol and selective serotonin reuptake inhibitor", "start": 5, "end": 14}, {"entity_id": "25540831_1_Ent2", "role": "Treatment_Drug", "text": "tramadol", "start": 8, "end": 9}, {"entity_id": "25540831_1_Ent4", "role": "Combination_Drug", "text": "tramadol", "start": 8, "end": 9}, {"entity_id": "25540831_1_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}, {"entity_id": "25540831_1_Ent5", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitor", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "25540831_1_Ent0", "text": "Transient serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "25540831_1_Ent1", "text": "concurrent use of tramadol and selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "25540831_1_Ent2", "text": "tramadol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25540831_1_Ent4", "text": "tramadol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25540831_1_Ent3", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "25540831_1_Ent5", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "25540831_8", "wnd_id": "25540831_8_1", "text": "Clinicians should also be aware of the possibility of serotonin syndrome when encountering a patient taking serotonergic drugs who presents with characteristic symptoms of serotonin syndrome .", "tokens": ["Clinicians", "should", "also", "be", "aware", "of", "the", "possibility", "of", "serotonin", "syndrome", "when", "encountering", "a", "patient", "taking", "serotonergic", "drugs", "who", "presents", "with", "characteristic", "symptoms", "of", "serotonin", "syndrome", "."], "event_mentions": [{"id": "25540831_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 15, "end": 16}, "arguments": [{"entity_id": "25540831_8_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 9, "end": 11}, {"entity_id": "25540831_8_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}, {"entity_id": "25540831_8_Ent2", "role": "Treatment", "text": "serotonergic drugs", "start": 16, "end": 18}, {"entity_id": "25540831_8_Ent3", "role": "Treatment_Drug", "text": "serotonergic drugs", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "25540831_8_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "25540831_8_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "25540831_8_Ent2", "text": "serotonergic drugs", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "25540831_8_Ent3", "text": "serotonergic drugs", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "2554727_1", "wnd_id": "2554727_1_1", "text": "Horner 's syndrome and demyelinating peripheral neuropathy caused by high - dose cytosine arabinoside .", "tokens": ["Horner", "'s", "syndrome", "and", "demyelinating", "peripheral", "neuropathy", "caused", "by", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "2554727_1_Ent0", "role": "Effect", "text": "Horner 's syndrome and demyelinating peripheral neuropathy", "start": 0, "end": 7}, {"entity_id": "2554727_1_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2554727_1_Ent1", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 9, "end": 14}, {"entity_id": "2554727_1_Ent3", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2554727_1_Ent0", "text": "Horner 's syndrome and demyelinating peripheral neuropathy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2554727_1_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2554727_1_Ent1", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "2554727_1_Ent3", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "25671244_3", "wnd_id": "25671244_3_1", "text": "The mechanism of action of this centrally acting muscle relaxant is unknown ; however , the observation of serotonin syndrome in patients with metaxalone overdose suggests a role in the serotonergic pathway .", "tokens": ["The", "mechanism", "of", "action", "of", "this", "centrally", "acting", "muscle", "relaxant", "is", "unknown", ";", "however", ",", "the", "observation", "of", "serotonin", "syndrome", "in", "patients", "with", "metaxalone", "overdose", "suggests", "a", "role", "in", "the", "serotonergic", "pathway", "."], "event_mentions": [{"id": "25671244_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 20, "end": 21}, "arguments": [{"entity_id": "25671244_3_Ent2", "role": "Treatment", "text": "centrally acting muscle relaxant", "start": 6, "end": 10}, {"entity_id": "25671244_3_Ent4", "role": "Treatment_Drug", "text": "centrally acting muscle relaxant", "start": 6, "end": 10}, {"entity_id": "25671244_3_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 18, "end": 20}, {"entity_id": "25671244_3_Ent0", "role": "Subject", "text": "patients", "start": 21, "end": 22}, {"entity_id": "25671244_3_Ent5", "role": "Treatment_Drug", "text": "metaxalone", "start": 23, "end": 24}, {"entity_id": "25671244_3_Ent3", "role": "Treatment", "text": "metaxalone overdose", "start": 23, "end": 25}, {"entity_id": "25671244_3_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "25671244_3_Ent2", "text": "centrally acting muscle relaxant", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "25671244_3_Ent4", "text": "centrally acting muscle relaxant", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "25671244_3_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "25671244_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "25671244_3_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25671244_3_Ent3", "text": "metaxalone overdose", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "25671244_3_Ent6", "text": "overdose", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "25671244_4", "wnd_id": "25671244_4_1", "text": "( Case 1 ) A 29 - year - old woman with overdose of metaxalone presented to the emergency department with altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia .", "tokens": ["(", "Case", "1", ")", "A", "29", "-", "year", "-", "old", "woman", "with", "overdose", "of", "metaxalone", "presented", "to", "the", "emergency", "department", "with", "altered", "mental", "status", ",", "seizure", "-", "like", "activity", ",", "hyperthermia", ",", "rigidity", "in", "the", "lower", "extremities", ",", "myoclonus", ",", "and", "hyperreflexia", "."], "event_mentions": [{"id": "25671244_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "25671244_4_Ent0", "role": "Subject", "text": "A 29 - year - old woman", "start": 4, "end": 11}, {"entity_id": "25671244_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 5, "end": 10}, {"entity_id": "25671244_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "25671244_4_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "25671244_4_Ent4", "role": "Treatment", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent5", "role": "Treatment_Drug", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent3", "role": "Effect", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "start": 21, "end": 42}]}], "entity_mentions": [{"id": "25671244_4_Ent0", "text": "A 29 - year - old woman", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "25671244_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "25671244_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "25671244_4_Ent6", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25671244_4_Ent4", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent3", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "entity_type": "Entity", "start": 21, "end": 42}], "lang": "en"}
{"doc_id": "2568058_1", "wnd_id": "2568058_1_1", "text": "Nail - changes induced by penicillamine .", "tokens": ["Nail", "-", "changes", "induced", "by", "penicillamine", "."], "event_mentions": [{"id": "2568058_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2568058_1_Ent0", "role": "Effect", "text": "Nail - changes", "start": 0, "end": 3}, {"entity_id": "2568058_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 5, "end": 6}, {"entity_id": "2568058_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2568058_1_Ent0", "text": "Nail - changes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2568058_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2568058_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2586773_1", "wnd_id": "2586773_1_1", "text": "Ibuprofen - induced meningitis : detection of intrathecal IgG synthesis and immune complexes .", "tokens": ["Ibuprofen", "-", "induced", "meningitis", ":", "detection", "of", "intrathecal", "IgG", "synthesis", "and", "immune", "complexes", "."], "event_mentions": [{"id": "2586773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2586773_1_Ent1", "role": "Treatment", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2586773_1_Ent2", "role": "Treatment_Drug", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "2586773_1_Ent0", "role": "Effect", "text": "meningitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2586773_1_Ent1", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2586773_1_Ent2", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2586773_1_Ent0", "text": "meningitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2690546_3", "wnd_id": "2690546_3_1", "text": "We report three cases of amiodarone - induced torsades de pointe .", "tokens": ["We", "report", "three", "cases", "of", "amiodarone", "-", "induced", "torsades", "de", "pointe", "."], "event_mentions": [{"id": "2690546_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2690546_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "2690546_3_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "2690546_3_Ent3", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "2690546_3_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "2690546_3_Ent2", "role": "Effect", "text": "torsades de pointe", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2690546_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2690546_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2690546_3_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2690546_3_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2690546_3_Ent2", "text": "torsades de pointe", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "2717661_1", "wnd_id": "2717661_1_1", "text": "The syndrome of irreversible lithium - effectuated neurotoxicity ( SILENT ) .", "tokens": ["The", "syndrome", "of", "irreversible", "lithium", "-", "effectuated", "neurotoxicity", "(", "SILENT", ")", "."], "event_mentions": [{"id": "2717661_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effectuated", "start": 6, "end": 7}, "arguments": [{"entity_id": "2717661_1_Ent0", "role": "Effect", "text": "syndrome of irreversible lithium - effectuated neurotoxicity ( SILENT )", "start": 1, "end": 11}, {"entity_id": "2717661_1_Ent1", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "2717661_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "2717661_1_Ent0", "text": "syndrome of irreversible lithium - effectuated neurotoxicity ( SILENT )", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "2717661_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2717661_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "2728526_4", "wnd_id": "2728526_4_1", "text": "This article reports the occurrence of rifampin - associated thrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis .", "tokens": ["This", "article", "reports", "the", "occurrence", "of", "rifampin", "-", "associated", "thrombocytopenia", "in", "an", "indigent", "patient", "after", "a", "four", "-", "month", "lapse", "in", "therapy", "for", "pulmonary", "tuberculosis", "."], "event_mentions": [{"id": "2728526_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "2728526_4_Ent2", "role": "Treatment", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent4", "role": "Treatment_Drug", "text": "rifampin", "start": 6, "end": 7}, {"entity_id": "2728526_4_Ent1", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "2728526_4_Ent0", "role": "Subject", "text": "an indigent patient", "start": 11, "end": 14}, {"entity_id": "2728526_4_Ent3", "role": "Treatment", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "start": 14, "end": 25}, {"entity_id": "2728526_4_Ent5", "role": "Treatment_Time_elapsed", "text": "four - month", "start": 16, "end": 19}, {"entity_id": "2728526_4_Ent6", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "2728526_4_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2728526_4_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2728526_4_Ent0", "text": "an indigent patient", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "2728526_4_Ent3", "text": "after a four - month lapse in therapy for pulmonary tuberculosis", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "2728526_4_Ent5", "text": "four - month", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2728526_4_Ent6", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "282937_3", "wnd_id": "282937_3_1", "text": "Paraplegia following prophylactic intrathecal cytosine arabinoside ( Ara - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2/d for 5 consecutive days .", "tokens": ["Paraplegia", "following", "prophylactic", "intrathecal", "cytosine", "arabinoside", "(", "Ara", "-", "C", ")", "is", "described", "in", "a", "patient", "with", "acute", "myelogenous", "leukemia", "in", "remission", "who", "received", "doses", "of", "100", "mg", "/", "m2/d", "for", "5", "consecutive", "days", "."], "event_mentions": [{"id": "282937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "282937_3_Ent1", "role": "Effect", "text": "Paraplegia", "start": 0, "end": 1}, {"entity_id": "282937_3_Ent2", "role": "Treatment", "text": "prophylactic intrathecal cytosine arabinoside ( Ara - C )", "start": 2, "end": 11}, {"entity_id": "282937_3_Ent5", "role": "Treatment_Route", "text": "intrathecal", "start": 3, "end": 4}, {"entity_id": "282937_3_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 4, "end": 6}, {"entity_id": "282937_3_Ent0", "role": "Subject", "text": "a patient with acute myelogenous leukemia in remission", "start": 14, "end": 22}, {"entity_id": "282937_3_Ent6", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia in remission", "start": 17, "end": 22}, {"entity_id": "282937_3_Ent3", "role": "Treatment", "text": "doses of 100 mg / m2/d for 5 consecutive days", "start": 24, "end": 34}, {"entity_id": "282937_3_Ent7", "role": "Treatment_Dosage", "text": "100 mg / m2/d", "start": 26, "end": 30}, {"entity_id": "282937_3_Ent8", "role": "Treatment_Duration", "text": "5 consecutive days", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "282937_3_Ent1", "text": "Paraplegia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "282937_3_Ent2", "text": "prophylactic intrathecal cytosine arabinoside ( Ara - C )", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "282937_3_Ent5", "text": "intrathecal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "282937_3_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "282937_3_Ent0", "text": "a patient with acute myelogenous leukemia in remission", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "282937_3_Ent6", "text": "acute myelogenous leukemia in remission", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "282937_3_Ent3", "text": "doses of 100 mg / m2/d for 5 consecutive days", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "282937_3_Ent7", "text": "100 mg / m2/d", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "282937_3_Ent8", "text": "5 consecutive days", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "2830062_2", "wnd_id": "2830062_2_1", "text": "Two patients with adrenal carcinoma treated with 2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy were studied .", "tokens": ["Two", "patients", "with", "adrenal", "carcinoma", "treated", "with", "2,2", "-", "bis", "(", "2", "-", "chlorophenyl", "-", "4", "-", "chlorophenyl)", "-", "1,1", "-", "dichloroethane", "(", "o", ",", "p'", "-", "DDD", ")", "as", "adjuvant", "therapy", "were", "studied", "."], "event_mentions": [{"id": "2830062_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2830062_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2830062_2_Ent0", "role": "Subject", "text": "Two patients with adrenal carcinoma", "start": 0, "end": 5}, {"entity_id": "2830062_2_Ent4", "role": "Treatment_Disorder", "text": "adrenal carcinoma", "start": 3, "end": 5}, {"entity_id": "2830062_2_Ent3", "role": "Treatment_Drug", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane", "start": 7, "end": 22}, {"entity_id": "2830062_2_Ent2", "role": "Treatment", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy", "start": 7, "end": 32}]}], "entity_mentions": [{"id": "2830062_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2830062_2_Ent0", "text": "Two patients with adrenal carcinoma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2830062_2_Ent4", "text": "adrenal carcinoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2830062_2_Ent3", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane", "entity_type": "Entity", "start": 7, "end": 22}, {"id": "2830062_2_Ent2", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy", "entity_type": "Entity", "start": 7, "end": 32}], "lang": "en"}
{"doc_id": "2830062_4", "wnd_id": "2830062_4_1", "text": "The hypoadrenalism was overcome by increasing steroid replacement therapy .", "tokens": ["The", "hypoadrenalism", "was", "overcome", "by", "increasing", "steroid", "replacement", "therapy", "."], "event_mentions": [{"id": "2830062_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "overcome", "start": 3, "end": 4}, "arguments": [{"entity_id": "2830062_4_Ent1", "role": "Treatment_Disorder", "text": "The hypoadrenalism", "start": 0, "end": 2}, {"entity_id": "2830062_4_Ent3", "role": "Treatment_Dosage", "text": "increasing", "start": 5, "end": 6}, {"entity_id": "2830062_4_Ent0", "role": "Treatment", "text": "increasing steroid replacement therapy", "start": 5, "end": 9}, {"entity_id": "2830062_4_Ent2", "role": "Treatment_Drug", "text": "steroid", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2830062_4_Ent1", "text": "The hypoadrenalism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2830062_4_Ent3", "text": "increasing", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2830062_4_Ent0", "text": "increasing steroid replacement therapy", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2830062_4_Ent2", "text": "steroid", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "2863342_1", "wnd_id": "2863342_1_1", "text": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease ( IBD ) in adults .", "tokens": ["Sulfasalazine", "has", "been", "associated", "with", "bronchopulmonary", "complications", "of", "inflammatory", "bowel", "disease", "(", "IBD", ")", "in", "adults", "."], "event_mentions": [{"id": "2863342_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2863342_1_Ent3", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2863342_1_Ent4", "role": "Treatment_Drug", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2863342_1_Ent2", "role": "Effect", "text": "bronchopulmonary complications of inflammatory bowel disease ( IBD )", "start": 5, "end": 14}, {"entity_id": "2863342_1_Ent0", "role": "Subject", "text": "adults", "start": 15, "end": 16}, {"entity_id": "2863342_1_Ent1", "role": "Subject_Age", "text": "adults", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2863342_1_Ent3", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2863342_1_Ent4", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2863342_1_Ent2", "text": "bronchopulmonary complications of inflammatory bowel disease ( IBD )", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "2863342_1_Ent0", "text": "adults", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2863342_1_Ent1", "text": "adults", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2875665_1", "wnd_id": "2875665_1_1", "text": "Exacerbation of schizophrenia associated with amantadine .", "tokens": ["Exacerbation", "of", "schizophrenia", "associated", "with", "amantadine", "."], "event_mentions": [{"id": "2875665_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2875665_1_Ent0", "role": "Effect", "text": "Exacerbation of schizophrenia", "start": 0, "end": 3}, {"entity_id": "2875665_1_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "2875665_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2875665_1_Ent0", "text": "Exacerbation of schizophrenia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2875665_1_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2875665_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2931445_2", "wnd_id": "2931445_2_1", "text": "A study of in vitro reactivity to L - T4 , as assessed by peripheral blood lymphocyte transformation , was carried out in a patient with Hashimoto 's disease who developed leukopenia during treatment with L - T4 .", "tokens": ["A", "study", "of", "in", "vitro", "reactivity", "to", "L", "-", "T4", ",", "as", "assessed", "by", "peripheral", "blood", "lymphocyte", "transformation", ",", "was", "carried", "out", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", "who", "developed", "leukopenia", "during", "treatment", "with", "L", "-", "T4", "."], "event_mentions": [{"id": "2931445_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 30, "end": 31}, "arguments": [{"entity_id": "2931445_2_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 23, "end": 29}, {"entity_id": "2931445_2_Ent3", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 26, "end": 29}, {"entity_id": "2931445_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 31, "end": 32}, {"entity_id": "2931445_2_Ent2", "role": "Treatment", "text": "L - T4", "start": 35, "end": 38}, {"entity_id": "2931445_2_Ent4", "role": "Treatment_Drug", "text": "L - T4", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "2931445_2_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2931445_2_Ent3", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "2931445_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2931445_2_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2931445_2_Ent4", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "2937155_3", "wnd_id": "2937155_3_1", "text": "Vancomycin - induced vasculitis .", "tokens": ["Vancomycin", "-", "induced", "vasculitis", "."], "event_mentions": [{"id": "2937155_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2937155_3_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent2", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent0", "role": "Effect", "text": "vasculitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2937155_3_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent2", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2979256_2", "wnd_id": "2979256_2_1", "text": "Gastro - oesophageal reflux associated with nifedipine .", "tokens": ["Gastro", "-", "oesophageal", "reflux", "associated", "with", "nifedipine", "."], "event_mentions": [{"id": "2979256_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "2979256_2_Ent0", "role": "Effect", "text": "Gastro - oesophageal reflux", "start": 0, "end": 4}, {"entity_id": "2979256_2_Ent1", "role": "Treatment", "text": "nifedipine", "start": 6, "end": 7}, {"entity_id": "2979256_2_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2979256_2_Ent0", "text": "Gastro - oesophageal reflux", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2979256_2_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2979256_2_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3115809_1", "wnd_id": "3115809_1_1", "text": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol .", "tokens": ["A", "patient", "developed", "optic", "neuropathy", "while", "being", "treated", "with", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "3115809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "3115809_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3115809_1_Ent1", "role": "Effect", "text": "optic neuropathy", "start": 3, "end": 5}, {"entity_id": "3115809_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent5", "role": "Combination_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent2", "role": "Treatment", "text": "isoniazid and ethambutol", "start": 9, "end": 12}, {"entity_id": "3115809_1_Ent4", "role": "Treatment_Drug", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "3115809_1_Ent6", "role": "Combination_Drug", "text": "ethambutol", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3115809_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3115809_1_Ent1", "text": "optic neuropathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3115809_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent5", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent2", "text": "isoniazid and ethambutol", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3115809_1_Ent4", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3115809_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3115809_2", "wnd_id": "3115809_2_1", "text": "A well - recognized complication of ethambutol use is optic neuropathy , but the potential ocular toxicity of isoniazid is often overlooked .", "tokens": ["A", "well", "-", "recognized", "complication", "of", "ethambutol", "use", "is", "optic", "neuropathy", ",", "but", "the", "potential", "ocular", "toxicity", "of", "isoniazid", "is", "often", "overlooked", "."], "event_mentions": [{"id": "3115809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "3115809_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 6, "end": 7}, {"entity_id": "3115809_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 6, "end": 7}, {"entity_id": "3115809_2_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 9, "end": 11}]}, {"id": "3115809_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 16, "end": 17}, "arguments": [{"entity_id": "3115809_2_Ent3", "role": "Effect", "text": "ocular toxicity", "start": 15, "end": 17}, {"entity_id": "3115809_2_Ent4", "role": "Treatment", "text": "isoniazid", "start": 18, "end": 19}, {"entity_id": "3115809_2_Ent5", "role": "Treatment_Drug", "text": "isoniazid", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "3115809_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3115809_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3115809_2_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3115809_2_Ent3", "text": "ocular toxicity", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3115809_2_Ent4", "text": "isoniazid", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3115809_2_Ent5", "text": "isoniazid", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "3143551_3", "wnd_id": "3143551_3_1", "text": "Camptocormia , a new side effect of sodium valproate .", "tokens": ["Camptocormia", ",", "a", "new", "side", "effect", "of", "sodium", "valproate", "."], "event_mentions": [{"id": "3143551_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "3143551_3_Ent0", "role": "Effect", "text": "Camptocormia", "start": 0, "end": 1}, {"entity_id": "3143551_3_Ent1", "role": "Treatment", "text": "sodium valproate", "start": 7, "end": 9}, {"entity_id": "3143551_3_Ent2", "role": "Treatment_Drug", "text": "sodium valproate", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "3143551_3_Ent0", "text": "Camptocormia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3143551_3_Ent1", "text": "sodium valproate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3143551_3_Ent2", "text": "sodium valproate", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "3143551_5", "wnd_id": "3143551_5_1", "text": "Hepatopathy subsided after the cessation of carbamazepine and lynestrenol .", "tokens": ["Hepatopathy", "subsided", "after", "the", "cessation", "of", "carbamazepine", "and", "lynestrenol", "."], "event_mentions": [{"id": "3143551_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3143551_5_Ent0", "role": "Effect", "text": "Hepatopathy subsided", "start": 0, "end": 2}, {"entity_id": "3143551_5_Ent3", "role": "Treatment_Dosage", "text": "cessation", "start": 4, "end": 5}, {"entity_id": "3143551_5_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent2", "role": "Treatment", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent5", "role": "Treatment_Drug", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent6", "role": "Combination_Drug", "text": "lynestrenol", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3143551_5_Ent0", "text": "Hepatopathy subsided", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3143551_5_Ent3", "text": "cessation", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3143551_5_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent2", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent5", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent6", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3156465_2", "wnd_id": "3156465_2_1", "text": "Isotretinoin teratogenicity .", "tokens": ["Isotretinoin", "teratogenicity", "."], "event_mentions": [{"id": "3156465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Isotretinoin teratogenicity", "start": 0, "end": 2}, "arguments": [{"entity_id": "3156465_2_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent0", "role": "Effect", "text": "teratogenicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "3156465_2_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent0", "text": "teratogenicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "3159106_1", "wnd_id": "3159106_1_1", "text": "A case of allopurinol hypersensitivity , possibly the first in a black African , is reported .", "tokens": ["A", "case", "of", "allopurinol", "hypersensitivity", ",", "possibly", "the", "first", "in", "a", "black", "African", ",", "is", "reported", "."], "event_mentions": [{"id": "3159106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "3159106_1_Ent3", "role": "Treatment", "text": "allopurinol", "start": 3, "end": 4}, {"entity_id": "3159106_1_Ent4", "role": "Treatment_Drug", "text": "allopurinol", "start": 3, "end": 4}, {"entity_id": "3159106_1_Ent2", "role": "Effect", "text": "hypersensitivity", "start": 4, "end": 5}, {"entity_id": "3159106_1_Ent0", "role": "Subject", "text": "a black African", "start": 10, "end": 13}, {"entity_id": "3159106_1_Ent1", "role": "Subject_Race", "text": "black African", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "3159106_1_Ent3", "text": "allopurinol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3159106_1_Ent4", "text": "allopurinol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3159106_1_Ent2", "text": "hypersensitivity", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3159106_1_Ent0", "text": "a black African", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3159106_1_Ent1", "text": "black African", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "3159106_3", "wnd_id": "3159106_3_1", "text": "The allopurinol hypersensitivity syndrome is a rare adverse drug reaction .", "tokens": ["The", "allopurinol", "hypersensitivity", "syndrome", "is", "a", "rare", "adverse", "drug", "reaction", "."], "event_mentions": [{"id": "3159106_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 7, "end": 8}, "arguments": [{"entity_id": "3159106_3_Ent1", "role": "Treatment", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent2", "role": "Treatment_Drug", "text": "allopurinol", "start": 1, "end": 2}, {"entity_id": "3159106_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "3159106_3_Ent1", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent2", "text": "allopurinol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3159106_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "3195622_1", "wnd_id": "3195622_1_1", "text": "A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented .", "tokens": ["A", "case", "report", "of", "the", "hypersensitivity", "syndrome", "occurring", "in", "a", "patient", "being", "treated", "with", "dapsone", "for", "a", "brown", "recluse", "spider", "bite", "is", "presented", "."], "event_mentions": [{"id": "3195622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "3195622_1_Ent1", "role": "Effect", "text": "hypersensitivity syndrome", "start": 5, "end": 7}, {"entity_id": "3195622_1_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "3195622_1_Ent2", "role": "Treatment", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "3195622_1_Ent3", "role": "Treatment_Drug", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "3195622_1_Ent4", "role": "Treatment_Disorder", "text": "brown recluse spider bite", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "3195622_1_Ent1", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3195622_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3195622_1_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3195622_1_Ent3", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3195622_1_Ent4", "text": "brown recluse spider bite", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "3195622_2", "wnd_id": "3195622_2_1", "text": "A dapsone hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy .", "tokens": ["A", "dapsone", "hypersensitivity", "syndrome", ",", "consisting", "of", "fever", ",", "headache", ",", "nausea", ",", "vomiting", ",", "lymphadenopathy", ",", "hepatitis", ",", "hemolysis", ",", "leukopenia", ",", "and", "mononucleosis", ",", "has", "been", "described", "in", "patients", "treated", "with", "the", "drug", "for", "leprosy", "."], "event_mentions": [{"id": "3195622_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 31, "end": 32}, "arguments": [{"entity_id": "3195622_2_Ent2", "role": "Treatment", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "3195622_2_Ent3", "role": "Treatment_Drug", "text": "dapsone", "start": 1, "end": 2}, {"entity_id": "3195622_2_Ent1", "role": "Effect", "text": "hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis", "start": 2, "end": 25}, {"entity_id": "3195622_2_Ent0", "role": "Subject", "text": "patients", "start": 30, "end": 31}, {"entity_id": "3195622_2_Ent4", "role": "Treatment_Disorder", "text": "leprosy", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "3195622_2_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3195622_2_Ent3", "text": "dapsone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3195622_2_Ent1", "text": "hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis", "entity_type": "Entity", "start": 2, "end": 25}, {"id": "3195622_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "3195622_2_Ent4", "text": "leprosy", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "3200786_3", "wnd_id": "3200786_3_1", "text": "We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a ' normal ' screening test for adrenal insufficiency , yet had clinical evidence of adrenal failure .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "the", "acquired", "immunodeficiency", "syndrome", "treated", "with", "rifampicin", "who", "had", "a", "'", "normal", "'", "screening", "test", "for", "adrenal", "insufficiency", ",", "yet", "had", "clinical", "evidence", "of", "adrenal", "failure", "."], "event_mentions": [{"id": "3200786_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 28, "end": 29}, "arguments": [{"entity_id": "3200786_3_Ent0", "role": "Subject", "text": "a patient with the acquired immunodeficiency syndrome", "start": 5, "end": 12}, {"entity_id": "3200786_3_Ent4", "role": "Treatment_Disorder", "text": "acquired immunodeficiency syndrome", "start": 9, "end": 12}, {"entity_id": "3200786_3_Ent2", "role": "Treatment", "text": "rifampicin", "start": 14, "end": 15}, {"entity_id": "3200786_3_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 14, "end": 15}, {"entity_id": "3200786_3_Ent1", "role": "Effect", "text": "adrenal failure", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "3200786_3_Ent0", "text": "a patient with the acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "3200786_3_Ent4", "text": "acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3200786_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3200786_3_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3200786_3_Ent1", "text": "adrenal failure", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "3211830_1", "wnd_id": "3211830_1_1", "text": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem , a recently introduced calcium antagonist .", "tokens": ["Two", "cases", "of", "widespread", "cutaneous", "vasculitis", "are", "described", "in", "association", "with", "diltiazem", ",", "a", "recently", "introduced", "calcium", "antagonist", "."], "event_mentions": [{"id": "3211830_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 9, "end": 10}, "arguments": [{"entity_id": "3211830_1_Ent0", "role": "Effect", "text": "widespread cutaneous vasculitis", "start": 3, "end": 6}, {"entity_id": "3211830_1_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 11, "end": 12}, {"entity_id": "3211830_1_Ent1", "role": "Treatment", "text": "diltiazem , a recently introduced calcium antagonist", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "3211830_1_Ent0", "text": "widespread cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3211830_1_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3211830_1_Ent1", "text": "diltiazem , a recently introduced calcium antagonist", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "3211830_2", "wnd_id": "3211830_2_1", "text": "Widespread cutaneous vasculitis associated with diltiazem .", "tokens": ["Widespread", "cutaneous", "vasculitis", "associated", "with", "diltiazem", "."], "event_mentions": [{"id": "3211830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "3211830_2_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 1, "end": 3}, {"entity_id": "3211830_2_Ent1", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "3211830_2_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3211830_2_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3211830_2_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3211830_2_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3242521_2", "wnd_id": "3242521_2_1", "text": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics .", "tokens": ["We", "report", "a", "premature", "infant", "who", "developed", "seizures", "associated", "with", "intraventricular", "administration", "of", "nafcillin", "and", "discuss", "the", "need", "for", "electroencephalographic", "monitoring", "of", "patients", "receiving", "intraventricular", "antibiotics", "."], "event_mentions": [{"id": "3242521_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 8, "end": 10}, "arguments": [{"entity_id": "3242521_2_Ent0", "role": "Subject", "text": "a premature infant", "start": 2, "end": 5}, {"entity_id": "3242521_2_Ent2", "role": "Subject_Disorder", "text": "premature", "start": 3, "end": 4}, {"entity_id": "3242521_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 4, "end": 5}, {"entity_id": "3242521_2_Ent3", "role": "Effect", "text": "seizures", "start": 7, "end": 8}, {"entity_id": "3242521_2_Ent6", "role": "Treatment_Route", "text": "intraventricular", "start": 10, "end": 11}, {"entity_id": "3242521_2_Ent4", "role": "Treatment", "text": "intraventricular administration of nafcillin", "start": 10, "end": 14}, {"entity_id": "3242521_2_Ent5", "role": "Treatment_Drug", "text": "nafcillin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3242521_2_Ent0", "text": "a premature infant", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "3242521_2_Ent2", "text": "premature", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3242521_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3242521_2_Ent3", "text": "seizures", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3242521_2_Ent6", "text": "intraventricular", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3242521_2_Ent4", "text": "intraventricular administration of nafcillin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "3242521_2_Ent5", "text": "nafcillin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3301251_1", "wnd_id": "3301251_1_1", "text": "A case of a 21 - year - old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described .", "tokens": ["A", "case", "of", "a", "21", "-", "year", "-", "old", "woman", "who", "had", "developed", "mild", "hepatotoxicity", "while", "receiving", "choline", "magnesium", "trisalicylate", "therapy", "is", "described", "."], "event_mentions": [{"id": "3301251_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "3301251_1_Ent0", "role": "Subject", "text": "a 21 - year - old woman", "start": 3, "end": 10}, {"entity_id": "3301251_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 4, "end": 9}, {"entity_id": "3301251_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "3301251_1_Ent3", "role": "Effect", "text": "mild hepatotoxicity", "start": 13, "end": 15}, {"entity_id": "3301251_1_Ent4", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}, {"entity_id": "3301251_1_Ent5", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "3301251_1_Ent0", "text": "a 21 - year - old woman", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "3301251_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "3301251_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_1_Ent3", "text": "mild hepatotoxicity", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3301251_1_Ent4", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3301251_1_Ent5", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "3301251_3", "wnd_id": "3301251_3_1", "text": "Salicylate - induced hepatotoxicity is reviewed .", "tokens": ["Salicylate", "-", "induced", "hepatotoxicity", "is", "reviewed", "."], "event_mentions": [{"id": "3301251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3301251_3_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent2", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3301251_3_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent2", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3310776_1", "wnd_id": "3310776_1_1", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure .", "tokens": ["A", "51", "-", "yr", "-", "old", "nonsmoking", "male", "patient", "without", "any", "history", "of", "previous", "allergies", ",", "asthma", ",", "hay", "fever", ",", "or", "urticaria", "developed", "attacks", "of", "asthma", "when", "captopril", "was", "added", "to", "the", "nadolol", "and", "dyazide", "treatment", "for", "his", "high", "blood", "pressure", "."], "event_mentions": [{"id": "3310776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "3310776_1_Ent0", "role": "Subject", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "start": 0, "end": 23}, {"entity_id": "3310776_1_Ent1", "role": "Subject_Age", "text": "51 - yr - old", "start": 1, "end": 6}, {"entity_id": "3310776_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "3310776_1_Ent3", "role": "Effect", "text": "attacks of asthma", "start": 24, "end": 27}, {"entity_id": "3310776_1_Ent6", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent9", "role": "Combination_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent4", "role": "Treatment", "text": "captopril was added to the nadolol and dyazide", "start": 28, "end": 36}, {"entity_id": "3310776_1_Ent7", "role": "Treatment_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent10", "role": "Combination_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent8", "role": "Treatment_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent11", "role": "Combination_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent5", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "3310776_1_Ent0", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "entity_type": "Entity", "start": 0, "end": 23}, {"id": "3310776_1_Ent1", "text": "51 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3310776_1_Ent2", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3310776_1_Ent3", "text": "attacks of asthma", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "3310776_1_Ent6", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent9", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent4", "text": "captopril was added to the nadolol and dyazide", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "3310776_1_Ent7", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent10", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent8", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent11", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent5", "text": "high blood pressure", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "3310776_2", "wnd_id": "3310776_2_1", "text": "Captopril - related ( and -induced ? ) asthma .", "tokens": ["Captopril", "-", "related", "(", "and", "-induced", "?", ")", "asthma", "."], "event_mentions": [{"id": "3310776_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "3310776_2_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3310776_2_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3310776_2_Ent0", "role": "Effect", "text": "asthma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3310776_2_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3310776_2_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3310776_2_Ent0", "text": "asthma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3346128_1", "wnd_id": "3346128_1_1", "text": "A 43 - year - old white man developed a shallow erosion of a psoriatic plaque after chronic administration of methotrexate .", "tokens": ["A", "43", "-", "year", "-", "old", "white", "man", "developed", "a", "shallow", "erosion", "of", "a", "psoriatic", "plaque", "after", "chronic", "administration", "of", "methotrexate", "."], "event_mentions": [{"id": "3346128_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "3346128_1_Ent0", "role": "Subject", "text": "A 43 - year - old white man", "start": 0, "end": 8}, {"entity_id": "3346128_1_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 1, "end": 6}, {"entity_id": "3346128_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "3346128_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "3346128_1_Ent4", "role": "Effect", "text": "shallow erosion of a psoriatic plaque", "start": 10, "end": 16}, {"entity_id": "3346128_1_Ent7", "role": "Treatment_Disorder", "text": "psoriatic plaque", "start": 14, "end": 16}, {"entity_id": "3346128_1_Ent8", "role": "Treatment_Duration", "text": "chronic", "start": 17, "end": 18}, {"entity_id": "3346128_1_Ent5", "role": "Treatment", "text": "chronic administration of methotrexate", "start": 17, "end": 21}, {"entity_id": "3346128_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3346128_1_Ent0", "text": "A 43 - year - old white man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3346128_1_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3346128_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3346128_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3346128_1_Ent4", "text": "shallow erosion of a psoriatic plaque", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3346128_1_Ent7", "text": "psoriatic plaque", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3346128_1_Ent8", "text": "chronic", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "3346128_1_Ent5", "text": "chronic administration of methotrexate", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "3346128_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3359700_1", "wnd_id": "3359700_1_1", "text": "After a six - week course of low - dose cyclosporine A , she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels .", "tokens": ["After", "a", "six", "-", "week", "course", "of", "low", "-", "dose", "cyclosporine", "A", ",", "she", "developed", "a", "severe", "but", "reversible", "loss", "of", "glomerular", "filtration", "rate", "and", "effective", "renal", "plasma", "flow", "despite", "of", "low", "cyclosporine", "A", "plasma", "levels", "."], "event_mentions": [{"id": "3359700_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "3359700_1_Ent1", "role": "Treatment", "text": "After a six - week course of low - dose cyclosporine A", "start": 0, "end": 12}, {"entity_id": "3359700_1_Ent4", "role": "Treatment_Time_elapsed", "text": "six - week course", "start": 2, "end": 6}, {"entity_id": "3359700_1_Ent2", "role": "Treatment_Dosage", "text": "low - dose", "start": 7, "end": 10}, {"entity_id": "3359700_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine A", "start": 10, "end": 12}, {"entity_id": "3359700_1_Ent0", "role": "Effect", "text": "loss of glomerular filtration rate and effective renal plasma flow", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "3359700_1_Ent1", "text": "After a six - week course of low - dose cyclosporine A", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "3359700_1_Ent4", "text": "six - week course", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "3359700_1_Ent2", "text": "low - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3359700_1_Ent3", "text": "cyclosporine A", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3359700_1_Ent0", "text": "loss of glomerular filtration rate and effective renal plasma flow", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "3359700_2", "wnd_id": "3359700_2_1", "text": "Based upon the observed fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria , we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity .", "tokens": ["Based", "upon", "the", "observed", "fall", "of", "the", "filtration", "fraction", ",", "the", "rise", "in", "the", "relative", "clearance", "of", "99Tc", "-", "dimercaptosuccinic", "acid", "and", "the", "increase", "in", "proteinuria", ",", "we", "suggest", "that", "in", "this", "case", "the", "tubules", "and/or", "interstitium", "are", "the", "main", "targets", "for", "cyclosporine", "A", "nephrotoxicity", "."], "event_mentions": [{"id": "3359700_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3359700_2_Ent0", "role": "Effect", "text": "fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria", "start": 4, "end": 26}, {"entity_id": "3359700_2_Ent1", "role": "Treatment", "text": "cyclosporine A", "start": 42, "end": 44}, {"entity_id": "3359700_2_Ent2", "role": "Treatment_Drug", "text": "cyclosporine A", "start": 42, "end": 44}]}], "entity_mentions": [{"id": "3359700_2_Ent0", "text": "fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria", "entity_type": "Entity", "start": 4, "end": 26}, {"id": "3359700_2_Ent1", "text": "cyclosporine A", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "3359700_2_Ent2", "text": "cyclosporine A", "entity_type": "Entity", "start": 42, "end": 44}], "lang": "en"}
{"doc_id": "3370103_1", "wnd_id": "3370103_1_1", "text": "Cardiopulmonary arrest following intravenous phenytoin loading .", "tokens": ["Cardiopulmonary", "arrest", "following", "intravenous", "phenytoin", "loading", "."], "event_mentions": [{"id": "3370103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3370103_1_Ent0", "role": "Effect", "text": "Cardiopulmonary arrest", "start": 0, "end": 2}, {"entity_id": "3370103_1_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "3370103_1_Ent1", "role": "Treatment", "text": "intravenous phenytoin loading", "start": 3, "end": 6}, {"entity_id": "3370103_1_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3370103_1_Ent0", "text": "Cardiopulmonary arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3370103_1_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3370103_1_Ent1", "text": "intravenous phenytoin loading", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3370103_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3397227_2", "wnd_id": "3397227_2_1", "text": "We report two patients with anhedonic ejaculation ( ejaculation without orgasm ) associated with initiation of treatment with desipramine .", "tokens": ["We", "report", "two", "patients", "with", "anhedonic", "ejaculation", "(", "ejaculation", "without", "orgasm", ")", "associated", "with", "initiation", "of", "treatment", "with", "desipramine", "."], "event_mentions": [{"id": "3397227_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "3397227_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "3397227_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "3397227_2_Ent2", "role": "Effect", "text": "anhedonic ejaculation ( ejaculation without orgasm )", "start": 5, "end": 12}, {"entity_id": "3397227_2_Ent3", "role": "Treatment", "text": "desipramine", "start": 18, "end": 19}, {"entity_id": "3397227_2_Ent4", "role": "Treatment_Drug", "text": "desipramine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "3397227_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3397227_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3397227_2_Ent2", "text": "anhedonic ejaculation ( ejaculation without orgasm )", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "3397227_2_Ent3", "text": "desipramine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3397227_2_Ent4", "text": "desipramine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "3400849_1", "wnd_id": "3400849_1_1", "text": "Myoclonic spasms following intrathecal morphine .", "tokens": ["Myoclonic", "spasms", "following", "intrathecal", "morphine", "."], "event_mentions": [{"id": "3400849_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3400849_1_Ent0", "role": "Effect", "text": "Myoclonic spasms", "start": 0, "end": 2}, {"entity_id": "3400849_1_Ent1", "role": "Treatment", "text": "intrathecal morphine", "start": 3, "end": 5}, {"entity_id": "3400849_1_Ent2", "role": "Treatment_Drug", "text": "morphine .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3400849_1_Ent0", "text": "Myoclonic spasms", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3400849_1_Ent1", "text": "intrathecal morphine", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3400849_1_Ent2", "text": "morphine .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3405528_2", "wnd_id": "3405528_2_1", "text": "Halothane hepatitis and prompt resolution with methionine therapy : case report .", "tokens": ["Halothane", "hepatitis", "and", "prompt", "resolution", "with", "methionine", "therapy", ":", "case", "report", "."], "event_mentions": [{"id": "3405528_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 4, "end": 5}, "arguments": [{"entity_id": "3405528_2_Ent2", "role": "Treatment_Disorder", "text": "Halothane hepatitis", "start": 0, "end": 2}, {"entity_id": "3405528_2_Ent1", "role": "Treatment", "text": "methionine", "start": 6, "end": 7}, {"entity_id": "3405528_2_Ent3", "role": "Treatment_Drug", "text": "methionine", "start": 6, "end": 7}, {"entity_id": "3405528_2_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "3405528_2_Ent2", "text": "Halothane hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3405528_2_Ent1", "text": "methionine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3405528_2_Ent3", "text": "methionine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3405528_2_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "3430507_6", "wnd_id": "3430507_6_1", "text": "A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "tokens": ["A", "56", "-", "year", "-", "old", "woman", "with", "scleroderma", "developed", "rapidly", "progressive", "glomerulonephritis", "with", "epithelial", "crescents", "associated", "with", "hemoptysis", "after", "27", "months", "of", "D", "-", "penicillamine", "therapy", "and", "a", "cumulative", "dose", "of", "1,200", "g."], "event_mentions": [{"id": "3430507_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "3430507_6_Ent0", "role": "Subject", "text": "A 56 - year - old woman with scleroderma", "start": 0, "end": 9}, {"entity_id": "3430507_6_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "3430507_6_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "3430507_6_Ent5", "role": "Treatment_Disorder", "text": "scleroderma", "start": 8, "end": 9}, {"entity_id": "3430507_6_Ent3", "role": "Effect", "text": "rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis", "start": 10, "end": 19}, {"entity_id": "3430507_6_Ent6", "role": "Treatment_Time_elapsed", "text": "27 months", "start": 20, "end": 22}, {"entity_id": "3430507_6_Ent4", "role": "Treatment", "text": "27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "start": 20, "end": 34}, {"entity_id": "3430507_6_Ent7", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 23, "end": 26}, {"entity_id": "3430507_6_Ent8", "role": "Treatment_Dosage", "text": "1,200 g.", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "3430507_6_Ent0", "text": "A 56 - year - old woman with scleroderma", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "3430507_6_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3430507_6_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3430507_6_Ent5", "text": "scleroderma", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3430507_6_Ent3", "text": "rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "3430507_6_Ent6", "text": "27 months", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "3430507_6_Ent4", "text": "27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "entity_type": "Entity", "start": 20, "end": 34}, {"id": "3430507_6_Ent7", "text": "D - penicillamine", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "3430507_6_Ent8", "text": "1,200 g.", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "3449312_1", "wnd_id": "3449312_1_1", "text": "Gold - induced aplastic anemia .", "tokens": ["Gold", "-", "induced", "aplastic", "anemia", "."], "event_mentions": [{"id": "3449312_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3449312_1_Ent1", "role": "Treatment", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3449312_1_Ent2", "role": "Treatment_Drug", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3449312_1_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "3449312_1_Ent1", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3449312_1_Ent2", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3449312_1_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3470173_1", "wnd_id": "3470173_1_1", "text": "Because the cerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms , prompt termination of HDARAC is recommended .", "tokens": ["Because", "the", "cerebellar", "toxicity", "may", "be", "worsened", "by", "continuation", "of", "therapy", "after", "initial", "onset", "of", "symptoms", ",", "prompt", "termination", "of", "HDARAC", "is", "recommended", "."], "event_mentions": [{"id": "3470173_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 19, "end": 20}, "arguments": [{"entity_id": "3470173_1_Ent0", "role": "Effect", "text": "cerebellar toxicity", "start": 2, "end": 4}, {"entity_id": "3470173_1_Ent1", "role": "Treatment", "text": "HDARAC", "start": 20, "end": 21}, {"entity_id": "3470173_1_Ent2", "role": "Treatment_Drug", "text": "HDARAC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3470173_1_Ent0", "text": "cerebellar toxicity", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3470173_1_Ent1", "text": "HDARAC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3470173_1_Ent2", "text": "HDARAC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3513544_1", "wnd_id": "3513544_1_1", "text": "Herpes simplex esophagitis in a renal transplant patient treated with cyclosporine A : a case report .", "tokens": ["Herpes", "simplex", "esophagitis", "in", "a", "renal", "transplant", "patient", "treated", "with", "cyclosporine", "A", ":", "a", "case", "report", "."], "event_mentions": [{"id": "3513544_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "3513544_1_Ent1", "role": "Effect", "text": "Herpes simplex esophagitis", "start": 0, "end": 3}, {"entity_id": "3513544_1_Ent4", "role": "Treatment_Disorder", "text": "renal transplant", "start": 5, "end": 7}, {"entity_id": "3513544_1_Ent0", "role": "Subject", "text": "renal transplant patient", "start": 5, "end": 8}, {"entity_id": "3513544_1_Ent2", "role": "Treatment", "text": "cyclosporine", "start": 10, "end": 11}, {"entity_id": "3513544_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3513544_1_Ent1", "text": "Herpes simplex esophagitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3513544_1_Ent4", "text": "renal transplant", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_1_Ent0", "text": "renal transplant patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3513544_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3513544_1_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3542612_1", "wnd_id": "3542612_1_1", "text": "Captopril - induced lichen planus pemphigoides with pemphigus - like features .", "tokens": ["Captopril", "-", "induced", "lichen", "planus", "pemphigoides", "with", "pemphigus", "-", "like", "features", "."], "event_mentions": [{"id": "3542612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3542612_1_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3542612_1_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "3542612_1_Ent0", "role": "Effect", "text": "lichen planus pemphigoides", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3542612_1_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3542612_1_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3542612_1_Ent0", "text": "lichen planus pemphigoides", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "354311_1", "wnd_id": "354311_1_1", "text": "An 8 - year - old girl , who had been vaccinated with BCG without subsequent regional reactions , developed osteomyelitis in the left calcaneus 7 months later .", "tokens": ["An", "8", "-", "year", "-", "old", "girl", ",", "who", "had", "been", "vaccinated", "with", "BCG", "without", "subsequent", "regional", "reactions", ",", "developed", "osteomyelitis", "in", "the", "left", "calcaneus", "7", "months", "later", "."], "event_mentions": [{"id": "354311_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "354311_1_Ent1", "role": "Subject_Age", "text": "8 - year - old", "start": 1, "end": 6}, {"entity_id": "354311_1_Ent0", "role": "Subject", "text": "8 - year - old girl", "start": 1, "end": 7}, {"entity_id": "354311_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "354311_1_Ent4", "role": "Treatment", "text": "BCG", "start": 13, "end": 14}, {"entity_id": "354311_1_Ent5", "role": "Treatment_Drug", "text": "BCG", "start": 13, "end": 14}, {"entity_id": "354311_1_Ent3", "role": "Effect", "text": "osteomyelitis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "354311_1_Ent1", "text": "8 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "354311_1_Ent0", "text": "8 - year - old girl", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "354311_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "354311_1_Ent4", "text": "BCG", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "354311_1_Ent5", "text": "BCG", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "354311_1_Ent3", "text": "osteomyelitis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "354311_2", "wnd_id": "354311_2_1", "text": "Metastatic osteomyelitis following BCG vaccination .", "tokens": ["Metastatic", "osteomyelitis", "following", "BCG", "vaccination", "."], "event_mentions": [{"id": "354311_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "354311_2_Ent0", "role": "Effect", "text": "Metastatic osteomyelitis", "start": 0, "end": 2}, {"entity_id": "354311_2_Ent1", "role": "Treatment", "text": "BCG vaccination", "start": 3, "end": 5}, {"entity_id": "354311_2_Ent2", "role": "Treatment_Drug", "text": "BCG vaccination", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "354311_2_Ent0", "text": "Metastatic osteomyelitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "354311_2_Ent1", "text": "BCG vaccination", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "354311_2_Ent2", "text": "BCG vaccination", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3579660_3", "wnd_id": "3579660_3_1", "text": "We describe a patient with Wilson 's disease who presented with neurologic disease , was treated with D - penicillamine , and suffered sudden neurologic deterioration coincident with therapy .", "tokens": ["We", "describe", "a", "patient", "with", "Wilson", "'s", "disease", "who", "presented", "with", "neurologic", "disease", ",", "was", "treated", "with", "D", "-", "penicillamine", ",", "and", "suffered", "sudden", "neurologic", "deterioration", "coincident", "with", "therapy", "."], "event_mentions": [{"id": "3579660_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 22, "end": 23}, "arguments": [{"entity_id": "3579660_3_Ent0", "role": "Subject", "text": "a patient with Wilson 's disease who presented with neurologic disease", "start": 2, "end": 13}, {"entity_id": "3579660_3_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 5, "end": 8}, {"entity_id": "3579660_3_Ent1", "role": "Subject_Disorder", "text": "neurologic disease", "start": 11, "end": 13}, {"entity_id": "3579660_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 17, "end": 20}, {"entity_id": "3579660_3_Ent2", "role": "Effect", "text": "sudden neurologic deterioration", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "3579660_3_Ent0", "text": "a patient with Wilson 's disease who presented with neurologic disease", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "3579660_3_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3579660_3_Ent1", "text": "neurologic disease", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3579660_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3579660_3_Ent2", "text": "sudden neurologic deterioration", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "3620420_6", "wnd_id": "3620420_6_1", "text": "Cyclosporin side effects included hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "tokens": ["Cyclosporin", "side", "effects", "included", "hirsutism", ",", "hypertension", ",", "increased", "blood", "levels", "of", "urea", "and", "creatinine", ",", "and", "abnormalities", "in", "liver", "function", "tests", "."], "event_mentions": [{"id": "3620420_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 1, "end": 3}, "arguments": [{"entity_id": "3620420_6_Ent1", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent0", "role": "Effect", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "start": 4, "end": 23}]}], "entity_mentions": [{"id": "3620420_6_Ent1", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent0", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "entity_type": "Entity", "start": 4, "end": 23}], "lang": "en"}
{"doc_id": "3677571_4", "wnd_id": "3677571_4_1", "text": "She was receiving phenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia .", "tokens": ["She", "was", "receiving", "phenytoin", "sodium", "300", "mg", "/", "day", ";", "carbamazepine", "200", "mg", "four", "times", "daily", "had", "been", "discontinued", "four", "days", "before", "admission", "because", "of", "leukopenia", "."], "event_mentions": [{"id": "3677571_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 23, "end": 24}, "arguments": [{"entity_id": "3677571_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "3677571_4_Ent1", "role": "Treatment", "text": "carbamazepine 200 mg four times daily", "start": 10, "end": 16}, {"entity_id": "3677571_4_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 11, "end": 13}, {"entity_id": "3677571_4_Ent4", "role": "Treatment_Freq", "text": "four times daily", "start": 13, "end": 16}, {"entity_id": "3677571_4_Ent0", "role": "Effect", "text": "leukopenia", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "3677571_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3677571_4_Ent1", "text": "carbamazepine 200 mg four times daily", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3677571_4_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3677571_4_Ent4", "text": "four times daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3677571_4_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "3688031_1", "wnd_id": "3688031_1_1", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol .", "tokens": ["An", "infant", "girl", "with", "choanal", "atresia", ",", "athelia", ",", "minor", "anomalies", ",", "and", "mild", "to", "moderate", "mental", "retardation", "was", "born", "to", "a", "woman", "treated", "for", "hyperthyroidism", "throughout", "pregnancy", "with", "methimazole", "and", "propranolol", "."], "event_mentions": [{"id": "3688031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 28, "end": 29}, "arguments": [{"entity_id": "3688031_1_Ent2", "role": "Effect", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation", "start": 0, "end": 18}, {"entity_id": "3688031_1_Ent0", "role": "Subject", "text": "a woman", "start": 21, "end": 23}, {"entity_id": "3688031_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 22, "end": 23}, {"entity_id": "3688031_1_Ent6", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 25, "end": 26}, {"entity_id": "3688031_1_Ent4", "role": "Treatment_Drug", "text": "methimazole", "start": 29, "end": 30}, {"entity_id": "3688031_1_Ent7", "role": "Combination_Drug", "text": "methimazole", "start": 29, "end": 30}, {"entity_id": "3688031_1_Ent3", "role": "Treatment", "text": "methimazole and propranolol", "start": 29, "end": 32}, {"entity_id": "3688031_1_Ent5", "role": "Treatment_Drug", "text": "propranolol", "start": 31, "end": 32}, {"entity_id": "3688031_1_Ent8", "role": "Combination_Drug", "text": "propranolol", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "3688031_1_Ent2", "text": "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate mental retardation", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "3688031_1_Ent0", "text": "a woman", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "3688031_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "3688031_1_Ent6", "text": "hyperthyroidism", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3688031_1_Ent4", "text": "methimazole", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3688031_1_Ent7", "text": "methimazole", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3688031_1_Ent3", "text": "methimazole and propranolol", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "3688031_1_Ent5", "text": "propranolol", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "3688031_1_Ent8", "text": "propranolol", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "3725284_2", "wnd_id": "3725284_2_1", "text": "We report a case of a 60 - year - old woman affected by squamous lung carcinoma , who developed paroxysmal supraventricular tachycardia during cisplatin and etoposide combination chemotherapy .", "tokens": ["We", "report", "a", "case", "of", "a", "60", "-", "year", "-", "old", "woman", "affected", "by", "squamous", "lung", "carcinoma", ",", "who", "developed", "paroxysmal", "supraventricular", "tachycardia", "during", "cisplatin", "and", "etoposide", "combination", "chemotherapy", "."], "event_mentions": [{"id": "3725284_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "3725284_2_Ent1", "role": "Subject_Age", "text": "60 - year - old", "start": 6, "end": 11}, {"entity_id": "3725284_2_Ent0", "role": "Subject", "text": "60 - year - old woman affected by squamous lung carcinoma", "start": 6, "end": 17}, {"entity_id": "3725284_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "3725284_2_Ent7", "role": "Treatment_Disorder", "text": "squamous lung carcinoma ,", "start": 14, "end": 18}, {"entity_id": "3725284_2_Ent3", "role": "Effect", "text": "paroxysmal supraventricular tachycardia", "start": 20, "end": 23}, {"entity_id": "3725284_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "3725284_2_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "3725284_2_Ent4", "role": "Treatment", "text": "cisplatin and etoposide combination", "start": 24, "end": 28}, {"entity_id": "3725284_2_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 26, "end": 27}, {"entity_id": "3725284_2_Ent8", "role": "Combination_Drug", "text": "etoposide", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3725284_2_Ent1", "text": "60 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3725284_2_Ent0", "text": "60 - year - old woman affected by squamous lung carcinoma", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "3725284_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3725284_2_Ent7", "text": "squamous lung carcinoma ,", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "3725284_2_Ent3", "text": "paroxysmal supraventricular tachycardia", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "3725284_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "3725284_2_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "3725284_2_Ent4", "text": "cisplatin and etoposide combination", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "3725284_2_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3725284_2_Ent8", "text": "etoposide", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3732375_1", "wnd_id": "3732375_1_1", "text": "Theophylline intoxication following viloxazine induced decrease in clearance .", "tokens": ["Theophylline", "intoxication", "following", "viloxazine", "induced", "decrease", "in", "clearance", "."], "event_mentions": [{"id": "3732375_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3732375_1_Ent3", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent5", "role": "Combination_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "3732375_1_Ent0", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "3732375_1_Ent1", "role": "Treatment", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent2", "role": "Treatment_Drug", "text": "viloxazine", "start": 3, "end": 4}, {"entity_id": "3732375_1_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3732375_1_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent5", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3732375_1_Ent0", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3732375_1_Ent1", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent2", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3732375_1_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3744305_1", "wnd_id": "3744305_1_1", "text": "Idiosyncratic pulmonary reactions to nitrofurantoin are not unusual , often presenting as eosinophilic pneumonia .", "tokens": ["Idiosyncratic", "pulmonary", "reactions", "to", "nitrofurantoin", "are", "not", "unusual", ",", "often", "presenting", "as", "eosinophilic", "pneumonia", "."], "event_mentions": [{"id": "3744305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "3744305_1_Ent0", "role": "Effect", "text": "Idiosyncratic pulmonary reactions", "start": 0, "end": 3}, {"entity_id": "3744305_1_Ent2", "role": "Treatment", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "3744305_1_Ent3", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 4, "end": 5}, {"entity_id": "3744305_1_Ent1", "role": "Effect", "text": "eosinophilic pneumonia", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3744305_1_Ent0", "text": "Idiosyncratic pulmonary reactions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3744305_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3744305_1_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3744305_1_Ent1", "text": "eosinophilic pneumonia", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3790438_1", "wnd_id": "3790438_1_1", "text": "Generalized pustular psoriasis precipitated by trazodone in the treatment of depression .", "tokens": ["Generalized", "pustular", "psoriasis", "precipitated", "by", "trazodone", "in", "the", "treatment", "of", "depression", "."], "event_mentions": [{"id": "3790438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 3, "end": 4}, "arguments": [{"entity_id": "3790438_1_Ent0", "role": "Effect", "text": "Generalized pustular psoriasis", "start": 0, "end": 3}, {"entity_id": "3790438_1_Ent1", "role": "Treatment", "text": "trazodone", "start": 5, "end": 6}, {"entity_id": "3790438_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 5, "end": 6}, {"entity_id": "3790438_1_Ent2", "role": "Treatment_Disorder", "text": "depression", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3790438_1_Ent0", "text": "Generalized pustular psoriasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3790438_1_Ent1", "text": "trazodone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3790438_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3790438_1_Ent2", "text": "depression", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3804181_2", "wnd_id": "3804181_2_1", "text": "The authors report a further case of methimazole - associated liver damage and present a brief review of eleven previous cases found in the literature .", "tokens": ["The", "authors", "report", "a", "further", "case", "of", "methimazole", "-", "associated", "liver", "damage", "and", "present", "a", "brief", "review", "of", "eleven", "previous", "cases", "found", "in", "the", "literature", "."], "event_mentions": [{"id": "3804181_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "3804181_2_Ent0", "role": "Subject", "text": "a further case", "start": 3, "end": 6}, {"entity_id": "3804181_2_Ent4", "role": "Treatment", "text": "methimazole", "start": 7, "end": 8}, {"entity_id": "3804181_2_Ent5", "role": "Treatment_Drug", "text": "methimazole", "start": 7, "end": 8}, {"entity_id": "3804181_2_Ent3", "role": "Effect", "text": "liver damage", "start": 10, "end": 12}, {"entity_id": "3804181_2_Ent2", "role": "Subject_Population", "text": "eleven", "start": 18, "end": 19}, {"entity_id": "3804181_2_Ent1", "role": "Subject", "text": "eleven previous cases", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "3804181_2_Ent0", "text": "a further case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3804181_2_Ent4", "text": "methimazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3804181_2_Ent5", "text": "methimazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3804181_2_Ent3", "text": "liver damage", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3804181_2_Ent2", "text": "eleven", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3804181_2_Ent1", "text": "eleven previous cases", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "3868420_1", "wnd_id": "3868420_1_1", "text": "We present a case report of a patient with alveolar hydatid disease , whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia ; and review the features of this disease which , with increasing international migration , may be encountered more frequently in Australia .", "tokens": ["We", "present", "a", "case", "report", "of", "a", "patient", "with", "alveolar", "hydatid", "disease", ",", "whose", "treatment", "with", "mebendazole", "was", "brief", "due", "to", "side", "effects", "of", "alopecia", "and", "granulocytopenia", ";", "and", "review", "the", "features", "of", "this", "disease", "which", ",", "with", "increasing", "international", "migration", ",", "may", "be", "encountered", "more", "frequently", "in", "Australia", "."], "event_mentions": [{"id": "3868420_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 19, "end": 20}, "arguments": [{"entity_id": "3868420_1_Ent0", "role": "Subject", "text": "a patient with alveolar hydatid disease", "start": 6, "end": 12}, {"entity_id": "3868420_1_Ent4", "role": "Treatment_Disorder", "text": "alveolar hydatid disease", "start": 9, "end": 12}, {"entity_id": "3868420_1_Ent2", "role": "Treatment", "text": "mebendazole", "start": 16, "end": 17}, {"entity_id": "3868420_1_Ent3", "role": "Treatment_Drug", "text": "mebendazole", "start": 16, "end": 17}, {"entity_id": "3868420_1_Ent1", "role": "Effect", "text": "alopecia and granulocytopenia", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "3868420_1_Ent0", "text": "a patient with alveolar hydatid disease", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "3868420_1_Ent4", "text": "alveolar hydatid disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3868420_1_Ent2", "text": "mebendazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3868420_1_Ent3", "text": "mebendazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3868420_1_Ent1", "text": "alopecia and granulocytopenia", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "3926849_2", "wnd_id": "3926849_2_1", "text": "Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension .", "tokens": ["Paradoxical", "pulmonary", "vasoconstriction", "induced", "by", "nitroglycerin", "in", "idiopathic", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "3926849_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3926849_2_Ent0", "role": "Effect", "text": "Paradoxical pulmonary vasoconstriction", "start": 0, "end": 3}, {"entity_id": "3926849_2_Ent1", "role": "Treatment", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent2", "role": "Treatment_Drug", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent3", "role": "Treatment_Disorder", "text": "idiopathic pulmonary hypertension", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "3926849_2_Ent0", "text": "Paradoxical pulmonary vasoconstriction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3926849_2_Ent1", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent2", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent3", "text": "idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "3947272_2", "wnd_id": "3947272_2_1", "text": "Ampicillin may aggravate clinical and experimental myasthenia gravis .", "tokens": ["Ampicillin", "may", "aggravate", "clinical", "and", "experimental", "myasthenia", "gravis", "."], "event_mentions": [{"id": "3947272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aggravate", "start": 2, "end": 3}, "arguments": [{"entity_id": "3947272_2_Ent1", "role": "Treatment", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent2", "role": "Treatment_Drug", "text": "Ampicillin", "start": 0, "end": 1}, {"entity_id": "3947272_2_Ent0", "role": "Effect", "text": "myasthenia gravis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "3947272_2_Ent1", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent2", "text": "Ampicillin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_2_Ent0", "text": "myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3982906_1", "wnd_id": "3982906_1_1", "text": "Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia .", "tokens": ["Cardiac", "decompensation", "following", "verapamil", "therapy", "in", "infants", "with", "supraventricular", "tachycardia", "."], "event_mentions": [{"id": "3982906_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3982906_1_Ent2", "role": "Effect", "text": "Cardiac decompensation", "start": 0, "end": 2}, {"entity_id": "3982906_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "3982906_1_Ent3", "role": "Treatment", "text": "verapamil therapy", "start": 3, "end": 5}, {"entity_id": "3982906_1_Ent1", "role": "Subject_Age", "text": "infants", "start": 6, "end": 7}, {"entity_id": "3982906_1_Ent0", "role": "Subject", "text": "infants with supraventricular tachycardia", "start": 6, "end": 10}, {"entity_id": "3982906_1_Ent4", "role": "Treatment_Disorder", "text": "supraventricular tachycardia", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3982906_1_Ent2", "text": "Cardiac decompensation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3982906_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3982906_1_Ent3", "text": "verapamil therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3982906_1_Ent1", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3982906_1_Ent0", "text": "infants with supraventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3982906_1_Ent4", "text": "supraventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3997294_1", "wnd_id": "3997294_1_1", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .", "tokens": ["Pneumonitis", "with", "pleural", "and", "pericardial", "effusion", "and", "neuropathy", "during", "amiodarone", "therapy", "."], "event_mentions": [{"id": "3997294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "3997294_1_Ent0", "role": "Effect", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "start": 0, "end": 8}, {"entity_id": "3997294_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 9, "end": 10}, {"entity_id": "3997294_1_Ent1", "role": "Treatment", "text": "amiodarone therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3997294_1_Ent0", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3997294_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3997294_1_Ent1", "text": "amiodarone therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3997294_2", "wnd_id": "3997294_2_1", "text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .", "tokens": ["Review", "of", "this", "and", "previously", "reported", "cases", "indicates", "the", "need", "for", "early", "diagnosis", "of", "amiodarone", "pneumonitis", ",", "immediate", "withdrawal", "of", "amiodarone", ",", "and", "prompt", "but", "continued", "steroid", "therapy", "to", "ensure", "full", "recovery", "."], "event_mentions": [{"id": "3997294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 13, "end": 14}, "arguments": [{"entity_id": "3997294_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent0", "role": "Effect", "text": "pneumonitis", "start": 15, "end": 16}]}, {"id": "3997294_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovery", "start": 31, "end": 32}, "arguments": [{"entity_id": "3997294_2_Ent4", "role": "Treatment_Disorder", "text": "pneumonitis", "start": 15, "end": 16}, {"entity_id": "3997294_2_Ent3", "role": "Treatment", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "start": 17, "end": 28}, {"entity_id": "3997294_2_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "3997294_2_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3997294_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent4", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent3", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "3997294_2_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3997294_2_Ent5", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "4004433_1", "wnd_id": "4004433_1_1", "text": "Heparin - induced hyperkalemia .", "tokens": ["Heparin", "-", "induced", "hyperkalemia", "."], "event_mentions": [{"id": "4004433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4004433_1_Ent1", "role": "Treatment", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "4004433_1_Ent2", "role": "Treatment_Drug", "text": "Heparin", "start": 0, "end": 1}, {"entity_id": "4004433_1_Ent0", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4004433_1_Ent1", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4004433_1_Ent2", "text": "Heparin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4004433_1_Ent0", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4004433_3", "wnd_id": "4004433_3_1", "text": "We present four cases in which the use of heparin was associated with hyperkalemia and discuss the pathophysiology .", "tokens": ["We", "present", "four", "cases", "in", "which", "the", "use", "of", "heparin", "was", "associated", "with", "hyperkalemia", "and", "discuss", "the", "pathophysiology", "."], "event_mentions": [{"id": "4004433_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "4004433_3_Ent1", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "4004433_3_Ent0", "role": "Subject", "text": "four cases", "start": 2, "end": 4}, {"entity_id": "4004433_3_Ent3", "role": "Treatment", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "4004433_3_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "4004433_3_Ent2", "role": "Effect", "text": "hyperkalemia", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "4004433_3_Ent1", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4004433_3_Ent0", "text": "four cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "4004433_3_Ent3", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4004433_3_Ent4", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4004433_3_Ent2", "text": "hyperkalemia", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "4025011_1", "wnd_id": "4025011_1_1", "text": "Prolonged severe cholestasis induced by oxacillin derivatives .", "tokens": ["Prolonged", "severe", "cholestasis", "induced", "by", "oxacillin", "derivatives", "."], "event_mentions": [{"id": "4025011_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "4025011_1_Ent0", "role": "Effect", "text": "Prolonged severe cholestasis", "start": 0, "end": 3}, {"entity_id": "4025011_1_Ent2", "role": "Treatment_Drug", "text": "oxacillin", "start": 5, "end": 6}, {"entity_id": "4025011_1_Ent1", "role": "Treatment", "text": "oxacillin derivatives", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "4025011_1_Ent0", "text": "Prolonged severe cholestasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "4025011_1_Ent2", "text": "oxacillin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4025011_1_Ent1", "text": "oxacillin derivatives", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "4054170_2", "wnd_id": "4054170_2_1", "text": "Chlorambucil central nervous toxicity : a significant side effect of chlorambucil therapy in childhood nephrotic syndrome .", "tokens": ["Chlorambucil", "central", "nervous", "toxicity", ":", "a", "significant", "side", "effect", "of", "chlorambucil", "therapy", "in", "childhood", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "4054170_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "4054170_2_Ent1", "role": "Treatment", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "4054170_2_Ent2", "role": "Treatment_Drug", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "4054170_2_Ent0", "role": "Effect", "text": "central nervous toxicity", "start": 1, "end": 4}, {"entity_id": "4054170_2_Ent3", "role": "Treatment_Disorder", "text": "childhood nephrotic syndrome", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "4054170_2_Ent1", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4054170_2_Ent2", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4054170_2_Ent0", "text": "central nervous toxicity", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4054170_2_Ent3", "text": "childhood nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "4063627_1", "wnd_id": "4063627_1_1", "text": "A 35 - year - old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac .", "tokens": ["A", "35", "-", "year", "-", "old", "man", "with", "seropositive", "rheumatoid", "arthritis", "developed", "selective", "IgA", "deficiency", "during", "treatment", "with", "fenclofenac", "."], "event_mentions": [{"id": "4063627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "4063627_1_Ent0", "role": "Subject", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "start": 0, "end": 11}, {"entity_id": "4063627_1_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 1, "end": 6}, {"entity_id": "4063627_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "4063627_1_Ent6", "role": "Treatment_Disorder", "text": "seropositive rheumatoid arthritis", "start": 8, "end": 11}, {"entity_id": "4063627_1_Ent3", "role": "Effect", "text": "selective IgA deficiency", "start": 12, "end": 15}, {"entity_id": "4063627_1_Ent4", "role": "Treatment", "text": "fenclofenac", "start": 18, "end": 19}, {"entity_id": "4063627_1_Ent5", "role": "Treatment_Drug", "text": "fenclofenac", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "4063627_1_Ent0", "text": "A 35 - year - old man with seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "4063627_1_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4063627_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4063627_1_Ent6", "text": "seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "4063627_1_Ent3", "text": "selective IgA deficiency", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "4063627_1_Ent4", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "4063627_1_Ent5", "text": "fenclofenac", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "4082283_6", "wnd_id": "4082283_6_1", "text": "A literature review revealed 83 other reported cases of rifampicin - induced renal insufficiency .", "tokens": ["A", "literature", "review", "revealed", "83", "other", "reported", "cases", "of", "rifampicin", "-", "induced", "renal", "insufficiency", "."], "event_mentions": [{"id": "4082283_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4082283_6_Ent1", "role": "Subject_Population", "text": "83", "start": 4, "end": 5}, {"entity_id": "4082283_6_Ent0", "role": "Subject", "text": "83 other reported cases", "start": 4, "end": 8}, {"entity_id": "4082283_6_Ent3", "role": "Treatment", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_6_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_6_Ent2", "role": "Effect", "text": "renal insufficiency", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "4082283_6_Ent1", "text": "83", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "4082283_6_Ent0", "text": "83 other reported cases", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "4082283_6_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_6_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_6_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "424824_1", "wnd_id": "424824_1_1", "text": "Conversely , diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving methotrexate who develop bilateral pulmonary infiltrates seen on chest roentgenograms .", "tokens": ["Conversely", ",", "diffuse", "interstitial", "pulmonary", "fibrosis", "should", "be", "considered", "in", "the", "differential", "diagnosis", "of", "patients", "receiving", "methotrexate", "who", "develop", "bilateral", "pulmonary", "infiltrates", "seen", "on", "chest", "roentgenograms", "."], "event_mentions": [{"id": "424824_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 18, "end": 19}, "arguments": [{"entity_id": "424824_1_Ent1", "role": "Effect", "text": "diffuse interstitial pulmonary fibrosis", "start": 2, "end": 6}, {"entity_id": "424824_1_Ent0", "role": "Subject", "text": "patients", "start": 14, "end": 15}, {"entity_id": "424824_1_Ent3", "role": "Treatment", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "424824_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "424824_1_Ent2", "role": "Effect", "text": "bilateral pulmonary infiltrates", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "424824_1_Ent1", "text": "diffuse interstitial pulmonary fibrosis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "424824_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "424824_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "424824_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "424824_1_Ent2", "text": "bilateral pulmonary infiltrates", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "426502_1", "wnd_id": "426502_1_1", "text": "A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of adenine arabinoside .", "tokens": ["A", "patient", "with", "disseminated", "herpes", "zoster", "developed", "a", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "and", "profound", "hyponatremia", "secondary", "to", "the", "administration", "of", "adenine", "arabinoside", "."], "event_mentions": [{"id": "426502_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "426502_1_Ent0", "role": "Subject", "text": "A patient with disseminated herpes zoster", "start": 0, "end": 6}, {"entity_id": "426502_1_Ent4", "role": "Treatment_Disorder", "text": "disseminated herpes zoster", "start": 3, "end": 6}, {"entity_id": "426502_1_Ent1", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone and profound hyponatremia", "start": 8, "end": 16}, {"entity_id": "426502_1_Ent2", "role": "Treatment", "text": "adenine arabinoside", "start": 21, "end": 23}, {"entity_id": "426502_1_Ent3", "role": "Treatment_Drug", "text": "adenine arabinoside", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "426502_1_Ent0", "text": "A patient with disseminated herpes zoster", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "426502_1_Ent4", "text": "disseminated herpes zoster", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "426502_1_Ent1", "text": "syndrome of inappropriate antidiuretic hormone and profound hyponatremia", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "426502_1_Ent2", "text": "adenine arabinoside", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "426502_1_Ent3", "text": "adenine arabinoside", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "433855_1", "wnd_id": "433855_1_1", "text": "The toxic effects of methotrexate included elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 ) .", "tokens": ["The", "toxic", "effects", "of", "methotrexate", "included", "elevated", "liver", "transaminases", "(", "3/4", ")", ",", "nausea", "(", "2/4", ")", ",", "abdominal", "pain", "(", "2/4", ")", ",", "bone", "pain", "(", "2/4", ")", ",", "mild", "neutropenia", "(", "1/4", ")", ",", "and", "mild", "pruritus", "(", "1/4", ")", "."], "event_mentions": [{"id": "433855_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 3, "end": 4}, "arguments": [{"entity_id": "433855_1_Ent0", "role": "Effect", "text": "toxic effects", "start": 1, "end": 3}, {"entity_id": "433855_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 4, "end": 5}, {"entity_id": "433855_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 4, "end": 5}, {"entity_id": "433855_1_Ent1", "role": "Effect", "text": "elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 )", "start": 6, "end": 42}]}], "entity_mentions": [{"id": "433855_1_Ent0", "text": "toxic effects", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "433855_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "433855_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "433855_1_Ent1", "text": "elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 )", "entity_type": "Entity", "start": 6, "end": 42}], "lang": "en"}
{"doc_id": "440873_3", "wnd_id": "440873_3_1", "text": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia .", "tokens": ["The", "currently", "available", "clinical", "and", "neuropharmacologic", "data", "suggest", "that", "carbamazepine", "may", "be", "an", "antagonist", "of", "dopamine", "and", "that", "this", "property", "is", "responsible", "for", "the", "production", "of", "dystonia", "."], "event_mentions": [{"id": "440873_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 21, "end": 22}, "arguments": [{"entity_id": "440873_3_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "440873_3_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "440873_3_Ent0", "role": "Effect", "text": "dystonia", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "440873_3_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "440873_3_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "440873_3_Ent0", "text": "dystonia", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "448845_3", "wnd_id": "448845_3_1", "text": "Several case reports of aplastic anemia with use of acetazolamide , and two cases with use of methazolamide , have appeared in the literature .", "tokens": ["Several", "case", "reports", "of", "aplastic", "anemia", "with", "use", "of", "acetazolamide", ",", "and", "two", "cases", "with", "use", "of", "methazolamide", ",", "have", "appeared", "in", "the", "literature", "."], "event_mentions": [{"id": "448845_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 2, "end": 3}, "arguments": [{"entity_id": "448845_3_Ent1", "role": "Subject_Population", "text": "Several", "start": 0, "end": 1}, {"entity_id": "448845_3_Ent0", "role": "Subject", "text": "Several case", "start": 0, "end": 2}, {"entity_id": "448845_3_Ent2", "role": "Effect", "text": "aplastic anemia", "start": 4, "end": 6}, {"entity_id": "448845_3_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 9, "end": 10}, {"entity_id": "448845_3_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "448845_3_Ent1", "text": "Several", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "448845_3_Ent0", "text": "Several case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "448845_3_Ent2", "text": "aplastic anemia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "448845_3_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "448845_3_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "458006_2", "wnd_id": "458006_2_1", "text": "We report the development of squamous - cell carcinoma within a basal - cell epithelioma that was treated with intralesional injections of 5 - FU .", "tokens": ["We", "report", "the", "development", "of", "squamous", "-", "cell", "carcinoma", "within", "a", "basal", "-", "cell", "epithelioma", "that", "was", "treated", "with", "intralesional", "injections", "of", "5", "-", "FU", "."], "event_mentions": [{"id": "458006_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "458006_2_Ent0", "role": "Effect", "text": "squamous - cell carcinoma within a basal - cell epithelioma", "start": 5, "end": 15}, {"entity_id": "458006_2_Ent2", "role": "Treatment_Route", "text": "intralesional injections", "start": 19, "end": 21}, {"entity_id": "458006_2_Ent1", "role": "Treatment", "text": "intralesional injections of 5 - FU", "start": 19, "end": 25}, {"entity_id": "458006_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "458006_2_Ent0", "text": "squamous - cell carcinoma within a basal - cell epithelioma", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "458006_2_Ent2", "text": "intralesional injections", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "458006_2_Ent1", "text": "intralesional injections of 5 - FU", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "458006_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "507889_1", "wnd_id": "507889_1_1", "text": "In two patients with mycosis fungoides , a squamous cell carcinoma developed during therapy with psoralens plus long - wave ultraviolet radiation ( PUVA ) .", "tokens": ["In", "two", "patients", "with", "mycosis", "fungoides", ",", "a", "squamous", "cell", "carcinoma", "developed", "during", "therapy", "with", "psoralens", "plus", "long", "-", "wave", "ultraviolet", "radiation", "(", "PUVA", ")", "."], "event_mentions": [{"id": "507889_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "507889_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "507889_1_Ent0", "role": "Subject", "text": "two patients with mycosis fungoides", "start": 1, "end": 6}, {"entity_id": "507889_1_Ent4", "role": "Treatment_Disorder", "text": "mycosis fungoides", "start": 4, "end": 6}, {"entity_id": "507889_1_Ent2", "role": "Effect", "text": "squamous cell carcinoma", "start": 8, "end": 11}, {"entity_id": "507889_1_Ent5", "role": "Treatment_Drug", "text": "psoralens", "start": 15, "end": 16}, {"entity_id": "507889_1_Ent3", "role": "Treatment", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "start": 15, "end": 25}]}], "entity_mentions": [{"id": "507889_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "507889_1_Ent0", "text": "two patients with mycosis fungoides", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "507889_1_Ent4", "text": "mycosis fungoides", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "507889_1_Ent2", "text": "squamous cell carcinoma", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "507889_1_Ent5", "text": "psoralens", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "507889_1_Ent3", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "entity_type": "Entity", "start": 15, "end": 25}], "lang": "en"}
{"doc_id": "527355_2", "wnd_id": "527355_2_1", "text": "Severe acidosis from acetazolamide in a diabetic patient .", "tokens": ["Severe", "acidosis", "from", "acetazolamide", "in", "a", "diabetic", "patient", "."], "event_mentions": [{"id": "527355_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "527355_2_Ent2", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "527355_2_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent0", "role": "Subject", "text": "a diabetic patient", "start": 5, "end": 8}, {"entity_id": "527355_2_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "527355_2_Ent2", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "527355_2_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent0", "text": "a diabetic patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "527355_2_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "536461_1", "wnd_id": "536461_1_1", "text": "Five cases of clindamycin - associated pseudomembranous colitis in leukaemic patients are reported .", "tokens": ["Five", "cases", "of", "clindamycin", "-", "associated", "pseudomembranous", "colitis", "in", "leukaemic", "patients", "are", "reported", "."], "event_mentions": [{"id": "536461_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "536461_1_Ent3", "role": "Treatment", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent4", "role": "Treatment_Drug", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent2", "role": "Effect", "text": "pseudomembranous colitis", "start": 6, "end": 8}, {"entity_id": "536461_1_Ent1", "role": "Subject_Disorder", "text": "leukaemic", "start": 9, "end": 10}, {"entity_id": "536461_1_Ent0", "role": "Subject", "text": "leukaemic patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "536461_1_Ent3", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent4", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent2", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "536461_1_Ent1", "text": "leukaemic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "536461_1_Ent0", "text": "leukaemic patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "556126_1", "wnd_id": "556126_1_1", "text": "An infertile patient with amenorrhea - galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment .", "tokens": ["An", "infertile", "patient", "with", "amenorrhea", "-", "galactorrhea", "syndrome", "lost", "vision", "during", "a", "pregnancy", "occurring", "after", "Bromocryptine", "treatment", "."], "event_mentions": [{"id": "556126_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "556126_1_Ent0", "role": "Subject", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "start": 0, "end": 8}, {"entity_id": "556126_1_Ent1", "role": "Subject_Disorder", "text": "infertile", "start": 1, "end": 2}, {"entity_id": "556126_1_Ent5", "role": "Treatment_Disorder", "text": "amenorrhea - galactorrhea syndrome", "start": 4, "end": 8}, {"entity_id": "556126_1_Ent2", "role": "Effect", "text": "lost vision", "start": 8, "end": 10}, {"entity_id": "556126_1_Ent3", "role": "Treatment", "text": "Bromocryptine", "start": 15, "end": 16}, {"entity_id": "556126_1_Ent4", "role": "Treatment_Drug", "text": "Bromocryptine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "556126_1_Ent0", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "556126_1_Ent1", "text": "infertile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "556126_1_Ent5", "text": "amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "556126_1_Ent2", "text": "lost vision", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "556126_1_Ent3", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "556126_1_Ent4", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "576675_1", "wnd_id": "576675_1_1", "text": "A 15 - kg weight gain developed in a patient during the third week of ibuprofen therapy .", "tokens": ["A", "15", "-", "kg", "weight", "gain", "developed", "in", "a", "patient", "during", "the", "third", "week", "of", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "576675_1_Ent1", "role": "Effect", "text": "A 15 - kg weight gain", "start": 0, "end": 6}, {"entity_id": "576675_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "576675_1_Ent4", "role": "Treatment_Time_elapsed", "text": "the third week", "start": 11, "end": 14}, {"entity_id": "576675_1_Ent2", "role": "Treatment", "text": "ibuprofen", "start": 15, "end": 16}, {"entity_id": "576675_1_Ent3", "role": "Treatment_Drug", "text": "ibuprofen", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "576675_1_Ent1", "text": "A 15 - kg weight gain", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "576675_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "576675_1_Ent4", "text": "the third week", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "576675_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "576675_1_Ent3", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "576675_2", "wnd_id": "576675_2_1", "text": "Edema associated with ibuprofen therapy .", "tokens": ["Edema", "associated", "with", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "576675_2_Ent0", "role": "Effect", "text": "Edema", "start": 0, "end": 1}, {"entity_id": "576675_2_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 3, "end": 4}, {"entity_id": "576675_2_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "576675_2_Ent0", "text": "Edema", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "576675_2_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "576675_2_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "58443_1", "wnd_id": "58443_1_1", "text": "In keeping with findings in the literature , the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment .", "tokens": ["In", "keeping", "with", "findings", "in", "the", "literature", ",", "the", "aortic", "wall", "in", "this", "case", "was", "damaged", "by", "secondary", "changes", "following", "irradiation", "and", "Bleomycin", "treatment", "."], "event_mentions": [{"id": "58443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "58443_1_Ent0", "role": "Effect", "text": "aortic wall in this case was damaged", "start": 9, "end": 16}, {"entity_id": "58443_1_Ent1", "role": "Treatment", "text": "irradiation and Bleomycin treatment .", "start": 20, "end": 25}, {"entity_id": "58443_1_Ent2", "role": "Treatment_Drug", "text": "Bleomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "58443_1_Ent0", "text": "aortic wall in this case was damaged", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "58443_1_Ent1", "text": "irradiation and Bleomycin treatment .", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "58443_1_Ent2", "text": "Bleomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "589261_3", "wnd_id": "589261_3_1", "text": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain , and none of the 16 who were receiving digoxin .", "tokens": ["Minor", "electrocardiographical", "changes", "were", "noted", "in", "five", "out", "of", "six", "patients", "who", "were", "not", "receiving", "a", "cardiac", "glycoside", "and", "four", "out", "of", "six", "who", "were", "receiving", "ouabain", ",", "and", "none", "of", "the", "16", "who", "were", "receiving", "digoxin", "."], "event_mentions": [{"id": "589261_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "589261_3_Ent6", "role": "Effect", "text": "electrocardiographical changes", "start": 1, "end": 3}, {"entity_id": "589261_3_Ent5", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "589261_3_Ent4", "role": "Subject", "text": "five out of six patients", "start": 6, "end": 11}, {"entity_id": "589261_3_Ent7", "role": "Treatment", "text": "cardiac glycoside", "start": 16, "end": 18}, {"entity_id": "589261_3_Ent8", "role": "Treatment_Drug", "text": "cardiac glycoside", "start": 16, "end": 18}]}, {"id": "589261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 25, "end": 26}, "arguments": [{"entity_id": "589261_3_Ent1", "role": "Effect", "text": "electrocardiographical changes", "start": 1, "end": 3}, {"entity_id": "589261_3_Ent0", "role": "Subject", "text": "four out of six", "start": 19, "end": 23}, {"entity_id": "589261_3_Ent2", "role": "Treatment", "text": "ouabain", "start": 26, "end": 27}, {"entity_id": "589261_3_Ent3", "role": "Treatment_Drug", "text": "ouabain", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "589261_3_Ent1", "text": "electrocardiographical changes", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "589261_3_Ent6", "text": "electrocardiographical changes", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "589261_3_Ent5", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "589261_3_Ent4", "text": "five out of six patients", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "589261_3_Ent7", "text": "cardiac glycoside", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "589261_3_Ent8", "text": "cardiac glycoside", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "589261_3_Ent0", "text": "four out of six", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "589261_3_Ent2", "text": "ouabain", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "589261_3_Ent3", "text": "ouabain", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "6093724_3", "wnd_id": "6093724_3_1", "text": "To our knowledge , we describe the first reported case of isolated paresthesia and peripheral neuropathy , without systemic involvement , secondary to sulindac administration .", "tokens": ["To", "our", "knowledge", ",", "we", "describe", "the", "first", "reported", "case", "of", "isolated", "paresthesia", "and", "peripheral", "neuropathy", ",", "without", "systemic", "involvement", ",", "secondary", "to", "sulindac", "administration", "."], "event_mentions": [{"id": "6093724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 21, "end": 22}, "arguments": [{"entity_id": "6093724_3_Ent0", "role": "Effect", "text": "isolated paresthesia and peripheral neuropathy", "start": 11, "end": 16}, {"entity_id": "6093724_3_Ent2", "role": "Treatment_Drug", "text": "sulindac", "start": 23, "end": 24}, {"entity_id": "6093724_3_Ent1", "role": "Treatment", "text": "sulindac administration", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "6093724_3_Ent0", "text": "isolated paresthesia and peripheral neuropathy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "6093724_3_Ent2", "text": "sulindac", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6093724_3_Ent1", "text": "sulindac administration", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "6108450_1", "wnd_id": "6108450_1_1", "text": "Reversal of ergotamine - induced arteriospasm by mechanical intra - arterial dilatation .", "tokens": ["Reversal", "of", "ergotamine", "-", "induced", "arteriospasm", "by", "mechanical", "intra", "-", "arterial", "dilatation", "."], "event_mentions": [{"id": "6108450_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6108450_1_Ent1", "role": "Treatment", "text": "ergotamine", "start": 2, "end": 3}, {"entity_id": "6108450_1_Ent2", "role": "Treatment_Drug", "text": "ergotamine", "start": 2, "end": 3}, {"entity_id": "6108450_1_Ent0", "role": "Effect", "text": "arteriospasm", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6108450_1_Ent1", "text": "ergotamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6108450_1_Ent2", "text": "ergotamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6108450_1_Ent0", "text": "arteriospasm", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6108450_2", "wnd_id": "6108450_2_1", "text": "Two patients with imminent gangrene of the extremities caused by ergot - induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation , vasodilation , and sympathetic blockade produced no improvement .", "tokens": ["Two", "patients", "with", "imminent", "gangrene", "of", "the", "extremities", "caused", "by", "ergot", "-", "induced", "arteriospasm", "underwent", "mechanical", "dilatation", "of", "the", "arteries", "when", "conventional", "measures", "such", "as", "anticoagulation", ",", "vasodilation", ",", "and", "sympathetic", "blockade", "produced", "no", "improvement", "."], "event_mentions": [{"id": "6108450_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "6108450_2_Ent5", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6108450_2_Ent3", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "6108450_2_Ent6", "role": "Effect", "text": "imminent gangrene of the extremities", "start": 3, "end": 8}, {"entity_id": "6108450_2_Ent7", "role": "Treatment", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent8", "role": "Treatment_Drug", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent4", "role": "Subject_Disorder", "text": "ergot - induced arteriospasm", "start": 10, "end": 14}]}, {"id": "6108450_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "6108450_2_Ent1", "role": "Treatment", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent2", "role": "Treatment_Drug", "text": "ergot", "start": 10, "end": 11}, {"entity_id": "6108450_2_Ent0", "role": "Effect", "text": "arteriospasm", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6108450_2_Ent5", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6108450_2_Ent3", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6108450_2_Ent6", "text": "imminent gangrene of the extremities", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6108450_2_Ent1", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent2", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent7", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent8", "text": "ergot", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6108450_2_Ent4", "text": "ergot - induced arteriospasm", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "6108450_2_Ent0", "text": "arteriospasm", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6142995_2", "wnd_id": "6142995_2_1", "text": "Sister chromatid exchanges ( SCEs ) , a sensitive measure of chromosome damage , were counted in peripheral - blood lymphocytes from 10 patients with Behcet 's syndrome receiving chlorambucil .", "tokens": ["Sister", "chromatid", "exchanges", "(", "SCEs", ")", ",", "a", "sensitive", "measure", "of", "chromosome", "damage", ",", "were", "counted", "in", "peripheral", "-", "blood", "lymphocytes", "from", "10", "patients", "with", "Behcet", "'s", "syndrome", "receiving", "chlorambucil", "."], "event_mentions": [{"id": "6142995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 28, "end": 29}, "arguments": [{"entity_id": "6142995_2_Ent2", "role": "Effect", "text": "chromosome damage", "start": 11, "end": 13}, {"entity_id": "6142995_2_Ent1", "role": "Subject_Population", "text": "10", "start": 22, "end": 23}, {"entity_id": "6142995_2_Ent0", "role": "Subject", "text": "10 patients with Behcet 's syndrome", "start": 22, "end": 28}, {"entity_id": "6142995_2_Ent4", "role": "Treatment_Disorder", "text": "Behcet 's syndrome", "start": 25, "end": 28}, {"entity_id": "6142995_2_Ent3", "role": "Treatment", "text": "chlorambucil", "start": 29, "end": 30}, {"entity_id": "6142995_2_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6142995_2_Ent2", "text": "chromosome damage", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6142995_2_Ent1", "text": "10", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6142995_2_Ent0", "text": "10 patients with Behcet 's syndrome", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "6142995_2_Ent4", "text": "Behcet 's syndrome", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6142995_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6142995_2_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6149250_3", "wnd_id": "6149250_3_1", "text": "One of the patients had a dexamethasone dependent brain metastatic condition .", "tokens": ["One", "of", "the", "patients", "had", "a", "dexamethasone", "dependent", "brain", "metastatic", "condition", "."], "event_mentions": [{"id": "6149250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 4, "end": 5}, "arguments": [{"entity_id": "6149250_3_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "6149250_3_Ent0", "role": "Subject", "text": "One of the patients", "start": 0, "end": 4}, {"entity_id": "6149250_3_Ent3", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent2", "role": "Effect", "text": "brain metastatic condition", "start": 8, "end": 11}, {"entity_id": "6149250_3_Ent5", "role": "Treatment_Disorder", "text": "brain metastatic condition", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "6149250_3_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6149250_3_Ent0", "text": "One of the patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6149250_3_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent2", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6149250_3_Ent5", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "6197014_1", "wnd_id": "6197014_1_1", "text": "Salicylate hepato toxicity in rheumatic fever .", "tokens": ["Salicylate", "hepato", "toxicity", "in", "rheumatic", "fever", "."], "event_mentions": [{"id": "6197014_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 2, "end": 3}, "arguments": [{"entity_id": "6197014_1_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "6197014_1_Ent3", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "6197014_1_Ent0", "role": "Effect", "text": "hepato toxicity", "start": 1, "end": 3}, {"entity_id": "6197014_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatic fever", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "6197014_1_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6197014_1_Ent3", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6197014_1_Ent0", "text": "hepato toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6197014_1_Ent2", "text": "rheumatic fever", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "6199475_2", "wnd_id": "6199475_2_1", "text": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum , vinblastine , and bleomycin .", "tokens": ["Transient", "left", "homonymous", "hemianopsia", "and", "encephalopathy", "following", "treatment", "of", "testicular", "carcinoma", "with", "cisplatinum", ",", "vinblastine", ",", "and", "bleomycin", "."], "event_mentions": [{"id": "6199475_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "6199475_2_Ent0", "role": "Effect", "text": "Transient left homonymous hemianopsia and encephalopathy", "start": 0, "end": 6}, {"entity_id": "6199475_2_Ent2", "role": "Treatment_Disorder", "text": "testicular carcinoma", "start": 9, "end": 11}, {"entity_id": "6199475_2_Ent3", "role": "Treatment_Drug", "text": "cisplatinum", "start": 12, "end": 13}, {"entity_id": "6199475_2_Ent6", "role": "Combination_Drug", "text": "cisplatinum", "start": 12, "end": 13}, {"entity_id": "6199475_2_Ent1", "role": "Treatment", "text": "cisplatinum , vinblastine , and bleomycin", "start": 12, "end": 18}, {"entity_id": "6199475_2_Ent4", "role": "Treatment_Drug", "text": "vinblastine", "start": 14, "end": 15}, {"entity_id": "6199475_2_Ent7", "role": "Combination_Drug", "text": "vinblastine", "start": 14, "end": 15}, {"entity_id": "6199475_2_Ent5", "role": "Treatment_Drug", "text": "bleomycin", "start": 17, "end": 18}, {"entity_id": "6199475_2_Ent8", "role": "Combination_Drug", "text": "bleomycin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6199475_2_Ent0", "text": "Transient left homonymous hemianopsia and encephalopathy", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6199475_2_Ent2", "text": "testicular carcinoma", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6199475_2_Ent3", "text": "cisplatinum", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_2_Ent6", "text": "cisplatinum", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_2_Ent1", "text": "cisplatinum , vinblastine , and bleomycin", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "6199475_2_Ent4", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6199475_2_Ent7", "text": "vinblastine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6199475_2_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "6199475_2_Ent8", "text": "bleomycin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6292681_1", "wnd_id": "6292681_1_1", "text": "Severe neurotoxicity with methyl G : CALGB experience .", "tokens": ["Severe", "neurotoxicity", "with", "methyl", "G", ":", "CALGB", "experience", "."], "event_mentions": [{"id": "6292681_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "6292681_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "6292681_1_Ent1", "role": "Treatment", "text": "methyl G", "start": 3, "end": 5}, {"entity_id": "6292681_1_Ent2", "role": "Treatment_Drug", "text": "methyl G", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "6292681_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6292681_1_Ent1", "text": "methyl G", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6292681_1_Ent2", "text": "methyl G", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6311654_6", "wnd_id": "6311654_6_1", "text": "It is concluded that ' cerebral atrophy ' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion , and in as low a dose as possible .", "tokens": ["It", "is", "concluded", "that", "'", "cerebral", "atrophy", "'", "on", "CT", "scans", "may", "represent", "an", "accumulative", "effect", "of", "ACTH", "and", "that", "ACTH", "should", "be", "given", "with", "the", "utmost", "discretion", ",", "and", "in", "as", "low", "a", "dose", "as", "possible", "."], "event_mentions": [{"id": "6311654_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "represent", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_6_Ent0", "role": "Effect", "text": "cerebral atrophy", "start": 5, "end": 7}, {"entity_id": "6311654_6_Ent1", "role": "Treatment", "text": "ACTH", "start": 17, "end": 18}, {"entity_id": "6311654_6_Ent2", "role": "Treatment_Drug", "text": "ACTH", "start": 17, "end": 18}, {"entity_id": "6311654_6_Ent3", "role": "Treatment_Drug", "text": "ACTH", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "6311654_6_Ent0", "text": "cerebral atrophy", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6311654_6_Ent1", "text": "ACTH", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "6311654_6_Ent2", "text": "ACTH", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "6311654_6_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "6340463_4", "wnd_id": "6340463_4_1", "text": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long - term prednisone for graft - versus - host disease .", "tokens": ["Patients", "from", "endemic", "areas", "referred", "to", "transplant", "centers", "may", "be", "at", "high", "risk", "for", "disseminated", "histoplasmosis", "when", "treated", "with", "long", "-", "term", "prednisone", "for", "graft", "-", "versus", "-", "host", "disease", "."], "event_mentions": [{"id": "6340463_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 18, "end": 19}, "arguments": [{"entity_id": "6340463_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "6340463_4_Ent1", "role": "Effect", "text": "disseminated histoplasmosis", "start": 14, "end": 16}, {"entity_id": "6340463_4_Ent2", "role": "Treatment", "text": "long - term prednisone", "start": 19, "end": 23}, {"entity_id": "6340463_4_Ent3", "role": "Treatment_Drug", "text": "prednisone", "start": 22, "end": 23}, {"entity_id": "6340463_4_Ent4", "role": "Treatment_Disorder", "text": "graft - versus - host disease .", "start": 24, "end": 31}]}], "entity_mentions": [{"id": "6340463_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6340463_4_Ent1", "text": "disseminated histoplasmosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6340463_4_Ent2", "text": "long - term prednisone", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "6340463_4_Ent3", "text": "prednisone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6340463_4_Ent4", "text": "graft - versus - host disease .", "entity_type": "Entity", "start": 24, "end": 31}], "lang": "en"}
{"doc_id": "6344831_1", "wnd_id": "6344831_1_1", "text": "Acute renal failure most likely was secondary to the nephrotoxic effect of captopril on chronically hypoperfused kidneys .", "tokens": ["Acute", "renal", "failure", "most", "likely", "was", "secondary", "to", "the", "nephrotoxic", "effect", "of", "captopril", "on", "chronically", "hypoperfused", "kidneys", "."], "event_mentions": [{"id": "6344831_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "nephrotoxic effect", "start": 9, "end": 11}, "arguments": [{"entity_id": "6344831_1_Ent2", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "6344831_1_Ent3", "role": "Treatment", "text": "captopril", "start": 12, "end": 13}, {"entity_id": "6344831_1_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 12, "end": 13}, {"entity_id": "6344831_1_Ent0", "role": "Subject", "text": "chronically hypoperfused kidneys", "start": 14, "end": 17}, {"entity_id": "6344831_1_Ent1", "role": "Subject_Disorder", "text": "chronically hypoperfused kidneys", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "6344831_1_Ent2", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6344831_1_Ent3", "text": "captopril", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6344831_1_Ent4", "text": "captopril", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6344831_1_Ent0", "text": "chronically hypoperfused kidneys", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "6344831_1_Ent1", "text": "chronically hypoperfused kidneys", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "6362443_1", "wnd_id": "6362443_1_1", "text": "A case of mania associated with fluoxetine .", "tokens": ["A", "case", "of", "mania", "associated", "with", "fluoxetine", "."], "event_mentions": [{"id": "6362443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6362443_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6362443_1_Ent1", "role": "Effect", "text": "mania", "start": 3, "end": 4}, {"entity_id": "6362443_1_Ent2", "role": "Treatment", "text": "fluoxetine", "start": 6, "end": 7}, {"entity_id": "6362443_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6362443_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6362443_1_Ent1", "text": "mania", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6362443_1_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6362443_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6401771_2", "wnd_id": "6401771_2_1", "text": "Three cases of acute renal toxicity in patients receiving long - term therapy with mitomycin C and 5 - fluorouracil are reported .", "tokens": ["Three", "cases", "of", "acute", "renal", "toxicity", "in", "patients", "receiving", "long", "-", "term", "therapy", "with", "mitomycin", "C", "and", "5", "-", "fluorouracil", "are", "reported", "."], "event_mentions": [{"id": "6401771_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 21, "end": 22}, "arguments": [{"entity_id": "6401771_2_Ent1", "role": "Effect", "text": "acute renal toxicity", "start": 3, "end": 6}, {"entity_id": "6401771_2_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "6401771_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 14, "end": 16}, {"entity_id": "6401771_2_Ent2", "role": "Treatment", "text": "mitomycin C and 5 - fluorouracil", "start": 14, "end": 20}, {"entity_id": "6401771_2_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "6401771_2_Ent1", "text": "acute renal toxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6401771_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6401771_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6401771_2_Ent2", "text": "mitomycin C and 5 - fluorouracil", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "6401771_2_Ent4", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "6414095_3", "wnd_id": "6414095_3_1", "text": "A 52 - year - old Black woman on phenytoin therapy for post - traumatic epilepsy developed transient hemiparesis contralateral to the injury .", "tokens": ["A", "52", "-", "year", "-", "old", "Black", "woman", "on", "phenytoin", "therapy", "for", "post", "-", "traumatic", "epilepsy", "developed", "transient", "hemiparesis", "contralateral", "to", "the", "injury", "."], "event_mentions": [{"id": "6414095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "6414095_3_Ent0", "role": "Subject", "text": "A 52 - year - old Black woman", "start": 0, "end": 8}, {"entity_id": "6414095_3_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6414095_3_Ent2", "role": "Subject_Race", "text": "Black", "start": 6, "end": 7}, {"entity_id": "6414095_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "6414095_3_Ent5", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent6", "role": "Treatment_Disorder", "text": "post - traumatic epilepsy", "start": 12, "end": 16}, {"entity_id": "6414095_3_Ent4", "role": "Effect", "text": "transient hemiparesis contralateral to the injury", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "6414095_3_Ent0", "text": "A 52 - year - old Black woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6414095_3_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6414095_3_Ent2", "text": "Black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6414095_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6414095_3_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent6", "text": "post - traumatic epilepsy", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6414095_3_Ent4", "text": "transient hemiparesis contralateral to the injury", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "6416845_1", "wnd_id": "6416845_1_1", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "tokens": ["A", "7", "-", "year", "-", "old", "boy", "developed", "a", "severe", "unilateral", "grand", "mal", "seizure", "at", "the", "age", "of", "5", "years", "(", "phenobarbitone", "therapy", ")", ";", "1.5", "years", "later", "valproate", "(", "2", "-", "propylpentanoic", "acid", ",", "VPA", ")", "was", "added", "to", "the", "therapy", "."], "event_mentions": [{"id": "6416845_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 41, "end": 42}, "arguments": [{"entity_id": "6416845_1_Ent0", "role": "Subject", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure", "start": 0, "end": 14}, {"entity_id": "6416845_1_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 1, "end": 6}, {"entity_id": "6416845_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "6416845_1_Ent3", "role": "Subject_Disorder", "text": "a severe unilateral grand mal seizure", "start": 8, "end": 14}, {"entity_id": "6416845_1_Ent4", "role": "Treatment", "text": "at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "start": 14, "end": 43}, {"entity_id": "6416845_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbitone", "start": 21, "end": 22}, {"entity_id": "6416845_1_Ent9", "role": "Combination_Drug", "text": "phenobarbitone", "start": 21, "end": 22}, {"entity_id": "6416845_1_Ent7", "role": "Treatment_Time_elapsed", "text": "1.5 years later", "start": 25, "end": 28}, {"entity_id": "6416845_1_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 28, "end": 29}, {"entity_id": "6416845_1_Ent8", "role": "Combination_Drug", "text": "valproate", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "6416845_1_Ent0", "text": "A 7 - year - old boy developed a severe unilateral grand mal seizure", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "6416845_1_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6416845_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6416845_1_Ent3", "text": "a severe unilateral grand mal seizure", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "6416845_1_Ent4", "text": "at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2 - propylpentanoic acid , VPA ) was added to the therapy .", "entity_type": "Entity", "start": 14, "end": 43}, {"id": "6416845_1_Ent5", "text": "phenobarbitone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6416845_1_Ent9", "text": "phenobarbitone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6416845_1_Ent7", "text": "1.5 years later", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6416845_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6416845_1_Ent8", "text": "valproate", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "6460590_1", "wnd_id": "6460590_1_1", "text": "One type of SMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of clioquinol .", "tokens": ["One", "type", "of", "SMON", "is", "associated", "with", "acrodermatitis", "enteropathica", "which", "has", "a", "very", "high", "frequency", "of", "occurrence", "in", "association", "with", "administration", "of", "clioquinol", "."], "event_mentions": [{"id": "6460590_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 18, "end": 19}, "arguments": [{"entity_id": "6460590_1_Ent0", "role": "Effect", "text": "SMON", "start": 3, "end": 4}, {"entity_id": "6460590_1_Ent1", "role": "Effect", "text": "acrodermatitis enteropathica", "start": 7, "end": 9}, {"entity_id": "6460590_1_Ent2", "role": "Treatment", "text": "clioquinol", "start": 22, "end": 23}, {"entity_id": "6460590_1_Ent3", "role": "Treatment_Drug", "text": "clioquinol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6460590_1_Ent0", "text": "SMON", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6460590_1_Ent1", "text": "acrodermatitis enteropathica", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6460590_1_Ent2", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6460590_1_Ent3", "text": "clioquinol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "647693_1", "wnd_id": "647693_1_1", "text": "Four patients receiving high - dose tamoxifen for greater than 1 year have demonstrated similar retinal changes .", "tokens": ["Four", "patients", "receiving", "high", "-", "dose", "tamoxifen", "for", "greater", "than", "1", "year", "have", "demonstrated", "similar", "retinal", "changes", "."], "event_mentions": [{"id": "647693_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "647693_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "647693_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "647693_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "647693_1_Ent3", "role": "Treatment", "text": "high - dose tamoxifen for greater than 1 year", "start": 3, "end": 12}, {"entity_id": "647693_1_Ent6", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "647693_1_Ent4", "role": "Treatment_Duration", "text": "1 year", "start": 10, "end": 12}, {"entity_id": "647693_1_Ent2", "role": "Effect", "text": "retinal changes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "647693_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "647693_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "647693_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "647693_1_Ent3", "text": "high - dose tamoxifen for greater than 1 year", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "647693_1_Ent6", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "647693_1_Ent4", "text": "1 year", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "647693_1_Ent2", "text": "retinal changes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "6484655_3", "wnd_id": "6484655_3_1", "text": "Two patients had ampicillin - associated seizures .", "tokens": ["Two", "patients", "had", "ampicillin", "-", "associated", "seizures", "."], "event_mentions": [{"id": "6484655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6484655_3_Ent1", "role": "Treatment", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent0", "role": "Effect", "text": "seizures", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6484655_3_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent0", "text": "seizures", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6507240_1", "wnd_id": "6507240_1_1", "text": "Hyponatremia in patients treated with lorcainide , a new antiarrhythmic drug .", "tokens": ["Hyponatremia", "in", "patients", "treated", "with", "lorcainide", ",", "a", "new", "antiarrhythmic", "drug", "."], "event_mentions": [{"id": "6507240_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 3, "end": 4}, "arguments": [{"entity_id": "6507240_1_Ent1", "role": "Effect", "text": "Hyponatremia", "start": 0, "end": 1}, {"entity_id": "6507240_1_Ent0", "role": "Subject", "text": "patients", "start": 2, "end": 3}, {"entity_id": "6507240_1_Ent2", "role": "Treatment", "text": "lorcainide", "start": 5, "end": 6}, {"entity_id": "6507240_1_Ent3", "role": "Treatment_Drug", "text": "lorcainide", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6507240_1_Ent1", "text": "Hyponatremia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6507240_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6507240_1_Ent2", "text": "lorcainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6507240_1_Ent3", "text": "lorcainide", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6507240_3", "wnd_id": "6507240_3_1", "text": "It is concluded that SIADH is an important side effect of lorcainide therapy .", "tokens": ["It", "is", "concluded", "that", "SIADH", "is", "an", "important", "side", "effect", "of", "lorcainide", "therapy", "."], "event_mentions": [{"id": "6507240_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 8, "end": 10}, "arguments": [{"entity_id": "6507240_3_Ent0", "role": "Effect", "text": "SIADH", "start": 4, "end": 5}, {"entity_id": "6507240_3_Ent2", "role": "Treatment_Drug", "text": "lorcainide", "start": 11, "end": 12}, {"entity_id": "6507240_3_Ent1", "role": "Treatment", "text": "lorcainide therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "6507240_3_Ent0", "text": "SIADH", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6507240_3_Ent2", "text": "lorcainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6507240_3_Ent1", "text": "lorcainide therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "6510223_1", "wnd_id": "6510223_1_1", "text": "Chlorpropamide - induced hemolytic anemia .", "tokens": ["Chlorpropamide", "-", "induced", "hemolytic", "anemia", "."], "event_mentions": [{"id": "6510223_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6510223_1_Ent1", "role": "Treatment", "text": "Chlorpropamide", "start": 0, "end": 1}, {"entity_id": "6510223_1_Ent2", "role": "Treatment_Drug", "text": "Chlorpropamide", "start": 0, "end": 1}, {"entity_id": "6510223_1_Ent0", "role": "Effect", "text": "hemolytic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "6510223_1_Ent1", "text": "Chlorpropamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6510223_1_Ent2", "text": "Chlorpropamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6510223_1_Ent0", "text": "hemolytic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6529939_2", "wnd_id": "6529939_2_1", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman , under treatment for angina with 80 mg propranolol daily .", "tokens": ["Alternating", "sinus", "rhythm", "and", "intermittent", "sinoatrial", "(", "S", "-", "A", ")", "block", "was", "observed", "in", "a", "57", "-", "year", "-", "old", "woman", ",", "under", "treatment", "for", "angina", "with", "80", "mg", "propranolol", "daily", "."], "event_mentions": [{"id": "6529939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 24, "end": 25}, "arguments": [{"entity_id": "6529939_2_Ent3", "role": "Effect", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block", "start": 0, "end": 12}, {"entity_id": "6529939_2_Ent0", "role": "Subject", "text": "a 57 - year - old woman", "start": 15, "end": 22}, {"entity_id": "6529939_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 16, "end": 21}, {"entity_id": "6529939_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 21, "end": 22}, {"entity_id": "6529939_2_Ent8", "role": "Treatment_Disorder", "text": "angina", "start": 26, "end": 27}, {"entity_id": "6529939_2_Ent5", "role": "Treatment_Dosage", "text": "80 mg", "start": 28, "end": 30}, {"entity_id": "6529939_2_Ent4", "role": "Treatment", "text": "80 mg propranolol daily .", "start": 28, "end": 33}, {"entity_id": "6529939_2_Ent6", "role": "Treatment_Drug", "text": "propranolol", "start": 30, "end": 31}, {"entity_id": "6529939_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "6529939_2_Ent3", "text": "Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6529939_2_Ent0", "text": "a 57 - year - old woman", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "6529939_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "6529939_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6529939_2_Ent8", "text": "angina", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6529939_2_Ent5", "text": "80 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "6529939_2_Ent4", "text": "80 mg propranolol daily .", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "6529939_2_Ent6", "text": "propranolol", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "6529939_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "6597713_1", "wnd_id": "6597713_1_1", "text": "After taking cholestyramine II sachets twice daily for two months she presented with lethargy , confusion and drowsiness .", "tokens": ["After", "taking", "cholestyramine", "II", "sachets", "twice", "daily", "for", "two", "months", "she", "presented", "with", "lethargy", ",", "confusion", "and", "drowsiness", "."], "event_mentions": [{"id": "6597713_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "6597713_1_Ent3", "role": "Treatment_Drug", "text": "cholestyramine II", "start": 2, "end": 4}, {"entity_id": "6597713_1_Ent2", "role": "Treatment", "text": "cholestyramine II sachets twice daily for two months", "start": 2, "end": 10}, {"entity_id": "6597713_1_Ent4", "role": "Treatment_Route", "text": "sachets", "start": 4, "end": 5}, {"entity_id": "6597713_1_Ent5", "role": "Treatment_Freq", "text": "twice daily", "start": 5, "end": 7}, {"entity_id": "6597713_1_Ent6", "role": "Treatment_Duration", "text": "two months", "start": 8, "end": 10}, {"entity_id": "6597713_1_Ent0", "role": "Subject", "text": "she", "start": 10, "end": 11}, {"entity_id": "6597713_1_Ent1", "role": "Effect", "text": "lethargy , confusion and drowsiness", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "6597713_1_Ent3", "text": "cholestyramine II", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "6597713_1_Ent2", "text": "cholestyramine II sachets twice daily for two months", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "6597713_1_Ent4", "text": "sachets", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6597713_1_Ent5", "text": "twice daily", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6597713_1_Ent6", "text": "two months", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "6597713_1_Ent0", "text": "she", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6597713_1_Ent1", "text": "lethargy , confusion and drowsiness", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "6597713_3", "wnd_id": "6597713_3_1", "text": "It is presumed that her hyperchloremic metabolic acidosis was secondary to cholestyramine because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium , chloride and bicarbonate despite continued spironolactone therapy after recovery .", "tokens": ["It", "is", "presumed", "that", "her", "hyperchloremic", "metabolic", "acidosis", "was", "secondary", "to", "cholestyramine", "because", "of", "the", "similarity", "to", "pediatric", "reports", ";", "the", "rapid", "and", "lasting", "response", "to", "intravenous", "sodium", "bicarbonate", ";", "the", "absence", "of", "another", "etiology", ";", "normal", "serum", "potassium", ",", "chloride", "and", "bicarbonate", "despite", "continued", "spironolactone", "therapy", "after", "recovery", "."], "event_mentions": [{"id": "6597713_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "6597713_3_Ent0", "role": "Effect", "text": "hyperchloremic metabolic acidosis", "start": 5, "end": 8}, {"entity_id": "6597713_3_Ent1", "role": "Treatment", "text": "cholestyramine", "start": 11, "end": 12}, {"entity_id": "6597713_3_Ent2", "role": "Treatment_Drug", "text": "cholestyramine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6597713_3_Ent0", "text": "hyperchloremic metabolic acidosis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6597713_3_Ent1", "text": "cholestyramine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6597713_3_Ent2", "text": "cholestyramine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6608139_1", "wnd_id": "6608139_1_1", "text": "Although myelosuppression is mild , immunosuppression and superinfection are potential hazards of treatment with DCF .", "tokens": ["Although", "myelosuppression", "is", "mild", ",", "immunosuppression", "and", "superinfection", "are", "potential", "hazards", "of", "treatment", "with", "DCF", "."], "event_mentions": [{"id": "6608139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hazards", "start": 10, "end": 11}, "arguments": [{"entity_id": "6608139_1_Ent0", "role": "Effect", "text": "myelosuppression", "start": 1, "end": 2}, {"entity_id": "6608139_1_Ent1", "role": "Effect", "text": "immunosuppression and superinfection", "start": 5, "end": 8}, {"entity_id": "6608139_1_Ent2", "role": "Treatment", "text": "DCF", "start": 14, "end": 15}, {"entity_id": "6608139_1_Ent3", "role": "Treatment_Drug", "text": "DCF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6608139_1_Ent0", "text": "myelosuppression", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6608139_1_Ent1", "text": "immunosuppression and superinfection", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6608139_1_Ent2", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6608139_1_Ent3", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6610943_4", "wnd_id": "6610943_4_1", "text": "This association should be considered in the period after vasopressin - treated gastrointestinal hemorrhage .", "tokens": ["This", "association", "should", "be", "considered", "in", "the", "period", "after", "vasopressin", "-", "treated", "gastrointestinal", "hemorrhage", "."], "event_mentions": [{"id": "6610943_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "6610943_4_Ent1", "role": "Treatment", "text": "vasopressin", "start": 9, "end": 10}, {"entity_id": "6610943_4_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 9, "end": 10}, {"entity_id": "6610943_4_Ent0", "role": "Effect", "text": "gastrointestinal hemorrhage", "start": 12, "end": 14}, {"entity_id": "6610943_4_Ent3", "role": "Treatment_Disorder", "text": "gastrointestinal hemorrhage", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6610943_4_Ent1", "text": "vasopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6610943_4_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6610943_4_Ent0", "text": "gastrointestinal hemorrhage", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6610943_4_Ent3", "text": "gastrointestinal hemorrhage", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6628806_2", "wnd_id": "6628806_2_1", "text": "Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis .", "tokens": ["Toxic", "hepatitis", "due", "to", "combination", "therapy", "with", "methotrexate", "and", "etretinate", "in", "psoriasis", "."], "event_mentions": [{"id": "6628806_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "6628806_2_Ent0", "role": "Effect", "text": "Toxic hepatitis", "start": 0, "end": 2}, {"entity_id": "6628806_2_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "6628806_2_Ent5", "role": "Combination_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "6628806_2_Ent1", "role": "Treatment", "text": "methotrexate and etretinate", "start": 7, "end": 10}, {"entity_id": "6628806_2_Ent3", "role": "Treatment_Drug", "text": "etretinate", "start": 9, "end": 10}, {"entity_id": "6628806_2_Ent6", "role": "Combination_Drug", "text": "etretinate", "start": 9, "end": 10}, {"entity_id": "6628806_2_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6628806_2_Ent0", "text": "Toxic hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6628806_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6628806_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6628806_2_Ent1", "text": "methotrexate and etretinate", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6628806_2_Ent3", "text": "etretinate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6628806_2_Ent6", "text": "etretinate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6628806_2_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6671350_1", "wnd_id": "6671350_1_1", "text": "Cephalosporins are most likely associated with Vitamin K deficiency .", "tokens": ["Cephalosporins", "are", "most", "likely", "associated", "with", "Vitamin", "K", "deficiency", "."], "event_mentions": [{"id": "6671350_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6671350_1_Ent1", "role": "Treatment", "text": "Cephalosporins", "start": 0, "end": 1}, {"entity_id": "6671350_1_Ent2", "role": "Treatment_Drug", "text": "Cephalosporins", "start": 0, "end": 1}, {"entity_id": "6671350_1_Ent0", "role": "Effect", "text": "Vitamin K deficiency .", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "6671350_1_Ent1", "text": "Cephalosporins", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_1_Ent2", "text": "Cephalosporins", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_1_Ent0", "text": "Vitamin K deficiency .", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "6671350_3", "wnd_id": "6671350_3_1", "text": "Moxalactam is more likely to be associated with platelet dysfunction .", "tokens": ["Moxalactam", "is", "more", "likely", "to", "be", "associated", "with", "platelet", "dysfunction", "."], "event_mentions": [{"id": "6671350_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "6671350_3_Ent1", "role": "Treatment", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent2", "role": "Treatment_Drug", "text": "Moxalactam", "start": 0, "end": 1}, {"entity_id": "6671350_3_Ent0", "role": "Effect", "text": "platelet dysfunction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "6671350_3_Ent1", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent2", "text": "Moxalactam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6671350_3_Ent0", "text": "platelet dysfunction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "6692713_2", "wnd_id": "6692713_2_1", "text": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy .", "tokens": ["Possible", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "following", "corticosteroid", "therapy", "."], "event_mentions": [{"id": "6692713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "6692713_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "6692713_2_Ent0", "role": "Effect", "text": "amiodarone pulmonary toxicity", "start": 3, "end": 6}, {"entity_id": "6692713_2_Ent1", "role": "Treatment", "text": "corticosteroid", "start": 7, "end": 8}, {"entity_id": "6692713_2_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6692713_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6692713_2_Ent0", "text": "amiodarone pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6692713_2_Ent1", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_2_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6693840_4", "wnd_id": "6693840_4_1", "text": "The gynecomastia regressed when the theophylline was discontinued .", "tokens": ["The", "gynecomastia", "regressed", "when", "the", "theophylline", "was", "discontinued", "."], "event_mentions": [{"id": "6693840_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_4_Ent0", "role": "Effect", "text": "gynecomastia", "start": 1, "end": 2}, {"entity_id": "6693840_4_Ent1", "role": "Treatment", "text": "theophylline", "start": 5, "end": 6}, {"entity_id": "6693840_4_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6693840_4_Ent0", "text": "gynecomastia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6693840_4_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_4_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6697887_1", "wnd_id": "6697887_1_1", "text": "Parenteral - verapamil - induced sustained hypotension .", "tokens": ["Parenteral", "-", "verapamil", "-", "induced", "sustained", "hypotension", "."], "event_mentions": [{"id": "6697887_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6697887_1_Ent2", "role": "Treatment_Route", "text": "Parenteral", "start": 0, "end": 1}, {"entity_id": "6697887_1_Ent1", "role": "Treatment", "text": "Parenteral - verapamil", "start": 0, "end": 3}, {"entity_id": "6697887_1_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 2, "end": 3}, {"entity_id": "6697887_1_Ent0", "role": "Effect", "text": "sustained hypotension", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "6697887_1_Ent2", "text": "Parenteral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6697887_1_Ent1", "text": "Parenteral - verapamil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6697887_1_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6697887_1_Ent0", "text": "sustained hypotension", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "6702890_3", "wnd_id": "6702890_3_1", "text": "This case represents the third example of erythroid aplasia associated with an anti - inflammatory agent and the first instance due to fenoprofen .", "tokens": ["This", "case", "represents", "the", "third", "example", "of", "erythroid", "aplasia", "associated", "with", "an", "anti", "-", "inflammatory", "agent", "and", "the", "first", "instance", "due", "to", "fenoprofen", "."], "event_mentions": [{"id": "6702890_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "6702890_3_Ent0", "role": "Effect", "text": "erythroid aplasia", "start": 7, "end": 9}, {"entity_id": "6702890_3_Ent1", "role": "Treatment", "text": "fenoprofen", "start": 22, "end": 23}, {"entity_id": "6702890_3_Ent2", "role": "Treatment_Drug", "text": "fenoprofen", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6702890_3_Ent0", "text": "erythroid aplasia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6702890_3_Ent1", "text": "fenoprofen", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6702890_3_Ent2", "text": "fenoprofen", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "6731466_1", "wnd_id": "6731466_1_1", "text": "Focal renal cortical necrosis associated with zomepirac .", "tokens": ["Focal", "renal", "cortical", "necrosis", "associated", "with", "zomepirac", "."], "event_mentions": [{"id": "6731466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6731466_1_Ent0", "role": "Effect", "text": "Focal renal cortical necrosis", "start": 0, "end": 4}, {"entity_id": "6731466_1_Ent1", "role": "Treatment", "text": "zomepirac", "start": 6, "end": 7}, {"entity_id": "6731466_1_Ent2", "role": "Treatment_Drug", "text": "zomepirac", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6731466_1_Ent0", "text": "Focal renal cortical necrosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6731466_1_Ent1", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6731466_1_Ent2", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6731466_10", "wnd_id": "6731466_10_1", "text": "The mechanism of anaphylactoid reaction to zomepirac in this case , therefore , remains unclear .", "tokens": ["The", "mechanism", "of", "anaphylactoid", "reaction", "to", "zomepirac", "in", "this", "case", ",", "therefore", ",", "remains", "unclear", "."], "event_mentions": [{"id": "6731466_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 4, "end": 5}, "arguments": [{"entity_id": "6731466_10_Ent0", "role": "Effect", "text": "anaphylactoid", "start": 3, "end": 4}, {"entity_id": "6731466_10_Ent1", "role": "Treatment", "text": "zomepirac", "start": 6, "end": 7}, {"entity_id": "6731466_10_Ent2", "role": "Treatment_Drug", "text": "zomepirac", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6731466_10_Ent0", "text": "anaphylactoid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6731466_10_Ent1", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6731466_10_Ent2", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6766717_1", "wnd_id": "6766717_1_1", "text": "A patient with alcoholic cerebellar degeneration had periodic alternating nystagmus during a period of phenytoin intoxication .", "tokens": ["A", "patient", "with", "alcoholic", "cerebellar", "degeneration", "had", "periodic", "alternating", "nystagmus", "during", "a", "period", "of", "phenytoin", "intoxication", "."], "event_mentions": [{"id": "6766717_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "6766717_1_Ent0", "role": "Subject", "text": "A patient with alcoholic cerebellar degeneration", "start": 0, "end": 6}, {"entity_id": "6766717_1_Ent1", "role": "Subject_Disorder", "text": "alcoholic cerebellar degeneration", "start": 3, "end": 6}, {"entity_id": "6766717_1_Ent2", "role": "Effect", "text": "periodic alternating nystagmus", "start": 7, "end": 10}, {"entity_id": "6766717_1_Ent3", "role": "Treatment", "text": "phenytoin", "start": 14, "end": 15}, {"entity_id": "6766717_1_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6766717_1_Ent0", "text": "A patient with alcoholic cerebellar degeneration", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6766717_1_Ent1", "text": "alcoholic cerebellar degeneration", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6766717_1_Ent2", "text": "periodic alternating nystagmus", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6766717_1_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6766717_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6810714_1", "wnd_id": "6810714_1_1", "text": "The authors describe a woman with chronic schizophrenia who experienced delirium , grand mal seizure , and photosensitivity after the addition of propranolol to her neuroleptic regimen .", "tokens": ["The", "authors", "describe", "a", "woman", "with", "chronic", "schizophrenia", "who", "experienced", "delirium", ",", "grand", "mal", "seizure", ",", "and", "photosensitivity", "after", "the", "addition", "of", "propranolol", "to", "her", "neuroleptic", "regimen", "."], "event_mentions": [{"id": "6810714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "6810714_1_Ent0", "role": "Subject", "text": "a woman with chronic schizophrenia", "start": 3, "end": 8}, {"entity_id": "6810714_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "6810714_1_Ent5", "role": "Treatment_Disorder", "text": "chronic schizophrenia", "start": 6, "end": 8}, {"entity_id": "6810714_1_Ent2", "role": "Effect", "text": "delirium , grand mal seizure , and photosensitivity", "start": 10, "end": 18}, {"entity_id": "6810714_1_Ent3", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "6810714_1_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "6810714_1_Ent0", "text": "a woman with chronic schizophrenia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6810714_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6810714_1_Ent5", "text": "chronic schizophrenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6810714_1_Ent2", "text": "delirium , grand mal seizure , and photosensitivity", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "6810714_1_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6810714_1_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "681921_2", "wnd_id": "681921_2_1", "text": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed .", "tokens": ["Neurophysiological", "mechanisms", "which", "aid", "in", "elucidating", "the", "role", "of", "disulfiram", "in", "the", "etiology", "of", "catatonia", "are", "discussed", "."], "event_mentions": [{"id": "681921_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "etiology", "start": 12, "end": 13}, "arguments": [{"entity_id": "681921_2_Ent1", "role": "Treatment", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "681921_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "681921_2_Ent0", "role": "Effect", "text": "catatonia", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "681921_2_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "681921_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "681921_2_Ent0", "text": "catatonia", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6837655_2", "wnd_id": "6837655_2_1", "text": "The spectrum of renal lesions occurring during antituberculous therapy , particularly in association with rifampin , may be wider than previously suspected .", "tokens": ["The", "spectrum", "of", "renal", "lesions", "occurring", "during", "antituberculous", "therapy", ",", "particularly", "in", "association", "with", "rifampin", ",", "may", "be", "wider", "than", "previously", "suspected", "."], "event_mentions": [{"id": "6837655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "6837655_2_Ent0", "role": "Effect", "text": "The spectrum of renal lesions occurring", "start": 0, "end": 6}, {"entity_id": "6837655_2_Ent3", "role": "Treatment_Drug", "text": "antituberculous therapy", "start": 7, "end": 9}, {"entity_id": "6837655_2_Ent5", "role": "Combination_Drug", "text": "antituberculous therapy", "start": 7, "end": 9}, {"entity_id": "6837655_2_Ent1", "role": "Treatment", "text": "antituberculous therapy , particularly in association with rifampin", "start": 7, "end": 15}, {"entity_id": "6837655_2_Ent2", "role": "Treatment_Drug", "text": "rifampin", "start": 14, "end": 15}, {"entity_id": "6837655_2_Ent4", "role": "Combination_Drug", "text": "rifampin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6837655_2_Ent0", "text": "The spectrum of renal lesions occurring", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6837655_2_Ent3", "text": "antituberculous therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6837655_2_Ent5", "text": "antituberculous therapy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6837655_2_Ent1", "text": "antituberculous therapy , particularly in association with rifampin", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "6837655_2_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6837655_2_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6860059_1", "wnd_id": "6860059_1_1", "text": "Fulminant hepatitis associated with disulfiram .", "tokens": ["Fulminant", "hepatitis", "associated", "with", "disulfiram", "."], "event_mentions": [{"id": "6860059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6860059_1_Ent0", "role": "Effect", "text": "Fulminant hepatitis", "start": 0, "end": 2}, {"entity_id": "6860059_1_Ent1", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6860059_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6860059_1_Ent0", "text": "Fulminant hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6860059_1_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6860059_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6865827_3", "wnd_id": "6865827_3_1", "text": "This is , to the best of our knowledge , the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient .", "tokens": ["This", "is", ",", "to", "the", "best", "of", "our", "knowledge", ",", "the", "first", "report", "of", "a", "case", "in", "which", "agranulocytosis", "followed", "treatment", "with", "both", "propylthiouracil", "and", "methimazole", "in", "the", "same", "patient", "."], "event_mentions": [{"id": "6865827_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 19, "end": 20}, "arguments": [{"entity_id": "6865827_3_Ent1", "role": "Effect", "text": "agranulocytosis", "start": 18, "end": 19}, {"entity_id": "6865827_3_Ent2", "role": "Treatment", "text": "both propylthiouracil and methimazole", "start": 22, "end": 26}, {"entity_id": "6865827_3_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 23, "end": 24}, {"entity_id": "6865827_3_Ent5", "role": "Combination_Drug", "text": "propylthiouracil", "start": 23, "end": 24}, {"entity_id": "6865827_3_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 25, "end": 26}, {"entity_id": "6865827_3_Ent6", "role": "Combination_Drug", "text": "methimazole", "start": 25, "end": 26}, {"entity_id": "6865827_3_Ent0", "role": "Subject", "text": "the same patient", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "6865827_3_Ent1", "text": "agranulocytosis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6865827_3_Ent2", "text": "both propylthiouracil and methimazole", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "6865827_3_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6865827_3_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6865827_3_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6865827_3_Ent6", "text": "methimazole", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6865827_3_Ent0", "text": "the same patient", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "6933231_1", "wnd_id": "6933231_1_1", "text": "Intracranial hemorrhage and focal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia .", "tokens": ["Intracranial", "hemorrhage", "and", "focal", "seizures", "secondary", "to", "use", "of", "L", "-", "asparaginase", "during", "induction", "therapy", "of", "acute", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "6933231_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 5, "end": 7}, "arguments": [{"entity_id": "6933231_1_Ent0", "role": "Effect", "text": "Intracranial hemorrhage and focal seizures", "start": 0, "end": 5}, {"entity_id": "6933231_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 9, "end": 12}, {"entity_id": "6933231_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "6933231_1_Ent0", "text": "Intracranial hemorrhage and focal seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6933231_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6933231_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "6998294_1", "wnd_id": "6998294_1_1", "text": "Clinicians should be aware of fasting hypoglycemia as an unusual but potentially serious complication of disopyramide therapy .", "tokens": ["Clinicians", "should", "be", "aware", "of", "fasting", "hypoglycemia", "as", "an", "unusual", "but", "potentially", "serious", "complication", "of", "disopyramide", "therapy", "."], "event_mentions": [{"id": "6998294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "6998294_1_Ent0", "role": "Effect", "text": "fasting hypoglycemia", "start": 5, "end": 7}, {"entity_id": "6998294_1_Ent1", "role": "Treatment", "text": "disopyramide", "start": 15, "end": 16}, {"entity_id": "6998294_1_Ent2", "role": "Treatment_Drug", "text": "disopyramide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6998294_1_Ent0", "text": "fasting hypoglycemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6998294_1_Ent1", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6998294_1_Ent2", "text": "disopyramide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7019786_1", "wnd_id": "7019786_1_1", "text": "Cefoxitin - associated renal failure .", "tokens": ["Cefoxitin", "-", "associated", "renal", "failure", "."], "event_mentions": [{"id": "7019786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7019786_1_Ent1", "role": "Treatment", "text": "Cefoxitin", "start": 0, "end": 1}, {"entity_id": "7019786_1_Ent2", "role": "Treatment_Drug", "text": "Cefoxitin", "start": 0, "end": 1}, {"entity_id": "7019786_1_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "7019786_1_Ent1", "text": "Cefoxitin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_1_Ent2", "text": "Cefoxitin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7019786_1_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "7071645_3", "wnd_id": "7071645_3_1", "text": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy .", "tokens": ["Complete", "remission", "of", "the", "nephrosis", "occurred", "after", "discontinuation", "of", "hydroxychloroquine", "therapy", "."], "event_mentions": [{"id": "7071645_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "7071645_3_Ent0", "role": "Effect", "text": "nephrosis", "start": 4, "end": 5}, {"entity_id": "7071645_3_Ent2", "role": "Treatment_Route", "text": "discontinuation", "start": 7, "end": 8}, {"entity_id": "7071645_3_Ent1", "role": "Treatment", "text": "discontinuation of hydroxychloroquine", "start": 7, "end": 10}, {"entity_id": "7071645_3_Ent3", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7071645_3_Ent0", "text": "nephrosis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7071645_3_Ent2", "text": "discontinuation", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7071645_3_Ent1", "text": "discontinuation of hydroxychloroquine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7071645_3_Ent3", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7139589_2", "wnd_id": "7139589_2_1", "text": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L - asparaginase .", "tokens": ["Delayed", "pseudocyst", "of", "the", "pancreas", "can", "be", "a", "complication", "of", "intramuscular", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "can", "start": 5, "end": 6}, "arguments": [{"entity_id": "7139589_2_Ent0", "role": "Effect", "text": "Delayed pseudocyst of the pancreas", "start": 0, "end": 5}, {"entity_id": "7139589_2_Ent3", "role": "Treatment_Route", "text": "intramuscular", "start": 10, "end": 11}, {"entity_id": "7139589_2_Ent1", "role": "Treatment", "text": "intramuscular L - asparaginase", "start": 10, "end": 14}, {"entity_id": "7139589_2_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7139589_2_Ent0", "text": "Delayed pseudocyst of the pancreas", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7139589_2_Ent3", "text": "intramuscular", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7139589_2_Ent1", "text": "intramuscular L - asparaginase", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7139589_2_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7139589_4", "wnd_id": "7139589_4_1", "text": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L - asparaginase .", "tokens": ["Three", "cases", "of", "pseudocyst", "of", "the", "pancreas", "in", "two", "women", "and", "one", "man", "have", "previously", "been", "reported", "with", "the", "use", "of", "intravenous", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "7139589_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 16, "end": 17}, "arguments": [{"entity_id": "7139589_4_Ent5", "role": "Effect", "text": "pseudocyst of the pancreas", "start": 3, "end": 7}, {"entity_id": "7139589_4_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "7139589_4_Ent0", "role": "Subject", "text": "two women and one man", "start": 8, "end": 13}, {"entity_id": "7139589_4_Ent3", "role": "Subject_Gender", "text": "women", "start": 9, "end": 10}, {"entity_id": "7139589_4_Ent2", "role": "Subject_Population", "text": "one", "start": 11, "end": 12}, {"entity_id": "7139589_4_Ent4", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "7139589_4_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "7139589_4_Ent6", "role": "Treatment", "text": "intravenous L - asparaginase", "start": 21, "end": 25}, {"entity_id": "7139589_4_Ent7", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "7139589_4_Ent5", "text": "pseudocyst of the pancreas", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7139589_4_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7139589_4_Ent0", "text": "two women and one man", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "7139589_4_Ent3", "text": "women", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7139589_4_Ent2", "text": "one", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7139589_4_Ent4", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7139589_4_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7139589_4_Ent6", "text": "intravenous L - asparaginase", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "7139589_4_Ent7", "text": "L - asparaginase", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "7235792_1", "wnd_id": "7235792_1_1", "text": "Although transient increases in ectopy after bretylium therapy have been described , presumably due to catecholamine release , the occurrence of life - threatening ventricular arrhythmia leading to cardiac arrest has not previously been emphasized .", "tokens": ["Although", "transient", "increases", "in", "ectopy", "after", "bretylium", "therapy", "have", "been", "described", ",", "presumably", "due", "to", "catecholamine", "release", ",", "the", "occurrence", "of", "life", "-", "threatening", "ventricular", "arrhythmia", "leading", "to", "cardiac", "arrest", "has", "not", "previously", "been", "emphasized", "."], "event_mentions": [{"id": "7235792_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "7235792_1_Ent0", "role": "Effect", "text": "transient increases in ectopy", "start": 1, "end": 5}, {"entity_id": "7235792_1_Ent2", "role": "Treatment", "text": "bretylium", "start": 6, "end": 7}, {"entity_id": "7235792_1_Ent3", "role": "Treatment_Drug", "text": "bretylium", "start": 6, "end": 7}, {"entity_id": "7235792_1_Ent1", "role": "Effect", "text": "life - threatening ventricular arrhythmia leading to cardiac arrest", "start": 21, "end": 30}]}], "entity_mentions": [{"id": "7235792_1_Ent0", "text": "transient increases in ectopy", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "7235792_1_Ent2", "text": "bretylium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_1_Ent3", "text": "bretylium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_1_Ent1", "text": "life - threatening ventricular arrhythmia leading to cardiac arrest", "entity_type": "Entity", "start": 21, "end": 30}], "lang": "en"}
{"doc_id": "7249424_1", "wnd_id": "7249424_1_1", "text": "Lithium is known to cause acute renal failure and tubulo - interstitial disease , but the recently described association with proteinuria or nephrotic syndrome is little recognized .", "tokens": ["Lithium", "is", "known", "to", "cause", "acute", "renal", "failure", "and", "tubulo", "-", "interstitial", "disease", ",", "but", "the", "recently", "described", "association", "with", "proteinuria", "or", "nephrotic", "syndrome", "is", "little", "recognized", "."], "event_mentions": [{"id": "7249424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 18, "end": 19}, "arguments": [{"entity_id": "7249424_1_Ent2", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "7249424_1_Ent3", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "7249424_1_Ent0", "role": "Effect", "text": "acute renal failure and tubulo - interstitial disease", "start": 5, "end": 13}, {"entity_id": "7249424_1_Ent1", "role": "Effect", "text": "proteinuria or nephrotic syndrome", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "7249424_1_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_1_Ent3", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_1_Ent0", "text": "acute renal failure and tubulo - interstitial disease", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "7249424_1_Ent1", "text": "proteinuria or nephrotic syndrome", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "7272895_3", "wnd_id": "7272895_3_1", "text": "Bilateral acoustic ( VIII ) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity .", "tokens": ["Bilateral", "acoustic", "(", "VIII", ")", "nerve", "palsy", "in", "this", "patient", "was", "most", "likely", "a", "manifestation", "of", "vincristine", "neurotoxicity", "."], "event_mentions": [{"id": "7272895_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "most likely", "start": 11, "end": 13}, "arguments": [{"entity_id": "7272895_3_Ent1", "role": "Effect", "text": "Bilateral acoustic ( VIII ) nerve palsy", "start": 0, "end": 7}, {"entity_id": "7272895_3_Ent0", "role": "Subject", "text": "this patient", "start": 8, "end": 10}, {"entity_id": "7272895_3_Ent3", "role": "Treatment", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "7272895_3_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 16, "end": 17}, {"entity_id": "7272895_3_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "7272895_3_Ent1", "text": "Bilateral acoustic ( VIII ) nerve palsy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7272895_3_Ent0", "text": "this patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7272895_3_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7272895_3_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7272895_3_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7304798_2", "wnd_id": "7304798_2_1", "text": "The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L - dopa shortened the manic - depressive cycle length when administered in a double - blind trial .", "tokens": ["The", "authors", "report", "a", "longitudinal", "case", "study", "of", "a", "woman", "with", "a", "history", "of", "bipolar", "affective", "disorder", "in", "which", "L", "-", "dopa", "shortened", "the", "manic", "-", "depressive", "cycle", "length", "when", "administered", "in", "a", "double", "-", "blind", "trial", "."], "event_mentions": [{"id": "7304798_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "shortened", "start": 22, "end": 23}, "arguments": [{"entity_id": "7304798_2_Ent0", "role": "Subject", "text": "a woman with a history of bipolar affective disorder", "start": 8, "end": 17}, {"entity_id": "7304798_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "7304798_2_Ent2", "role": "Subject_Disorder", "text": "bipolar affective disorder", "start": 14, "end": 17}, {"entity_id": "7304798_2_Ent4", "role": "Treatment", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent5", "role": "Treatment_Drug", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent3", "role": "Effect", "text": "shortened the manic - depressive cycle length", "start": 22, "end": 29}]}], "entity_mentions": [{"id": "7304798_2_Ent0", "text": "a woman with a history of bipolar affective disorder", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "7304798_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7304798_2_Ent2", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7304798_2_Ent4", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent5", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent3", "text": "shortened the manic - depressive cycle length", "entity_type": "Entity", "start": 22, "end": 29}], "lang": "en"}
{"doc_id": "7351000_3", "wnd_id": "7351000_3_1", "text": "Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient - years up to February 1978 .", "tokens": ["Seven", "of", "the", "eight", "cases", "of", "acute", "leukemia", "occurred", "in", "a", "series", "of", "553", "patients", "treated", "with", "Treosulfan", "for", "ovarian", "cancer", "in", "the", "period", "from", "1970", "to", "1977", "and", "followed", "closely", "for", "a", "total", "of", "1159", "patient", "-", "years", "up", "to", "February", "1978", "."], "event_mentions": [{"id": "7351000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "7351000_3_Ent0", "role": "Subject", "text": "Seven of the eight cases", "start": 0, "end": 5}, {"entity_id": "7351000_3_Ent1", "role": "Subject_Population", "text": "eight", "start": 3, "end": 4}, {"entity_id": "7351000_3_Ent2", "role": "Effect", "text": "acute leukemia", "start": 6, "end": 8}, {"entity_id": "7351000_3_Ent3", "role": "Treatment", "text": "Treosulfan", "start": 17, "end": 18}, {"entity_id": "7351000_3_Ent4", "role": "Treatment_Drug", "text": "Treosulfan", "start": 17, "end": 18}, {"entity_id": "7351000_3_Ent5", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "7351000_3_Ent0", "text": "Seven of the eight cases", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_3_Ent1", "text": "eight", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7351000_3_Ent2", "text": "acute leukemia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7351000_3_Ent3", "text": "Treosulfan", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7351000_3_Ent4", "text": "Treosulfan", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7351000_3_Ent5", "text": "ovarian cancer", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "7355327_4", "wnd_id": "7355327_4_1", "text": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension .", "tokens": ["Three", "patients", "with", "no", "history", "of", "asthma", "or", "allergy", "developed", "bronchospasm", "while", "taking", "propranolol", "for", "hypertension", "."], "event_mentions": [{"id": "7355327_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "7355327_4_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "7355327_4_Ent0", "role": "Subject", "text": "Three patients with no history of asthma or allergy", "start": 0, "end": 9}, {"entity_id": "7355327_4_Ent2", "role": "Effect", "text": "bronchospasm", "start": 10, "end": 11}, {"entity_id": "7355327_4_Ent3", "role": "Treatment", "text": "propranolol", "start": 13, "end": 14}, {"entity_id": "7355327_4_Ent5", "role": "Treatment_Drug", "text": "propranolol", "start": 13, "end": 14}, {"entity_id": "7355327_4_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7355327_4_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7355327_4_Ent0", "text": "Three patients with no history of asthma or allergy", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "7355327_4_Ent2", "text": "bronchospasm", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7355327_4_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7355327_4_Ent5", "text": "propranolol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7355327_4_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "736591_1", "wnd_id": "736591_1_1", "text": "Interstitial fibrosis of the lung is a potential complication of methotrexate therapy for psoriasis .", "tokens": ["Interstitial", "fibrosis", "of", "the", "lung", "is", "a", "potential", "complication", "of", "methotrexate", "therapy", "for", "psoriasis", "."], "event_mentions": [{"id": "736591_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 8, "end": 9}, "arguments": [{"entity_id": "736591_1_Ent0", "role": "Effect", "text": "Interstitial fibrosis of the lung", "start": 0, "end": 5}, {"entity_id": "736591_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "736591_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "736591_1_Ent3", "role": "Treatment_Disorder", "text": "psoriasis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "736591_1_Ent0", "text": "Interstitial fibrosis of the lung", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "736591_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "736591_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "736591_1_Ent3", "text": "psoriasis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7369302_1", "wnd_id": "7369302_1_1", "text": "Abnormalities of the pupil and visual - evoked potential in quinine amblyopia .", "tokens": ["Abnormalities", "of", "the", "pupil", "and", "visual", "-", "evoked", "potential", "in", "quinine", "amblyopia", "."], "event_mentions": [{"id": "7369302_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "7369302_1_Ent1", "role": "Effect", "text": "Abnormalities of the pupil and visual - evoked potential", "start": 0, "end": 9}, {"entity_id": "7369302_1_Ent2", "role": "Treatment", "text": "quinine", "start": 10, "end": 11}, {"entity_id": "7369302_1_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 10, "end": 11}, {"entity_id": "7369302_1_Ent0", "role": "Effect", "text": "amblyopia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7369302_1_Ent1", "text": "Abnormalities of the pupil and visual - evoked potential", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "7369302_1_Ent2", "text": "quinine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7369302_1_Ent3", "text": "quinine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7369302_1_Ent0", "text": "amblyopia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7375145_1", "wnd_id": "7375145_1_1", "text": "Diagnosis : practolol induced sclerosing peritonitis .", "tokens": ["Diagnosis", ":", "practolol", "induced", "sclerosing", "peritonitis", "."], "event_mentions": [{"id": "7375145_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7375145_1_Ent1", "role": "Treatment", "text": "practolol", "start": 2, "end": 3}, {"entity_id": "7375145_1_Ent2", "role": "Treatment_Drug", "text": "practolol", "start": 2, "end": 3}, {"entity_id": "7375145_1_Ent0", "role": "Effect", "text": "sclerosing peritonitis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7375145_1_Ent1", "text": "practolol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7375145_1_Ent2", "text": "practolol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7375145_1_Ent0", "text": "sclerosing peritonitis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7379406_1", "wnd_id": "7379406_1_1", "text": "Niflumic acid - induced skeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis ?", "tokens": ["Niflumic", "acid", "-", "induced", "skeletal", "fluorosis", ":", "iatrogenic", "disease", "or", "therapeutic", "perspective", "for", "osteoporosis", "?"], "event_mentions": [{"id": "7379406_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7379406_1_Ent1", "role": "Treatment", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent2", "role": "Treatment_Drug", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent0", "role": "Effect", "text": "skeletal fluorosis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7379406_1_Ent1", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent2", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent0", "text": "skeletal fluorosis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7379406_2", "wnd_id": "7379406_2_1", "text": "A case of skeletal fluorosis induced by prolonged treatment with niflumic acid , a fast - acting non - steroid antiinflammatory agent , is reported in a 35 - year - old woman suffering from rheumatoid arthritis and treated , in addition , with corticosteroids .", "tokens": ["A", "case", "of", "skeletal", "fluorosis", "induced", "by", "prolonged", "treatment", "with", "niflumic", "acid", ",", "a", "fast", "-", "acting", "non", "-", "steroid", "antiinflammatory", "agent", ",", "is", "reported", "in", "a", "35", "-", "year", "-", "old", "woman", "suffering", "from", "rheumatoid", "arthritis", "and", "treated", ",", "in", "addition", ",", "with", "corticosteroids", "."], "event_mentions": [{"id": "7379406_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7379406_2_Ent3", "role": "Effect", "text": "skeletal fluorosis", "start": 3, "end": 5}, {"entity_id": "7379406_2_Ent4", "role": "Treatment", "text": "niflumic acid", "start": 10, "end": 12}, {"entity_id": "7379406_2_Ent6", "role": "Treatment_Drug", "text": "niflumic acid", "start": 10, "end": 12}, {"entity_id": "7379406_2_Ent10", "role": "Combination_Drug", "text": "niflumic acid", "start": 10, "end": 12}, {"entity_id": "7379406_2_Ent0", "role": "Subject", "text": "a 35 - year - old woman suffering from rheumatoid arthritis", "start": 26, "end": 37}, {"entity_id": "7379406_2_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 27, "end": 32}, {"entity_id": "7379406_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 32, "end": 33}, {"entity_id": "7379406_2_Ent8", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 35, "end": 37}, {"entity_id": "7379406_2_Ent5", "role": "Treatment", "text": "in addition , with corticosteroids", "start": 40, "end": 45}, {"entity_id": "7379406_2_Ent7", "role": "Treatment_Drug", "text": "corticosteroids", "start": 44, "end": 45}, {"entity_id": "7379406_2_Ent9", "role": "Combination_Drug", "text": "corticosteroids", "start": 44, "end": 45}]}], "entity_mentions": [{"id": "7379406_2_Ent3", "text": "skeletal fluorosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7379406_2_Ent4", "text": "niflumic acid", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7379406_2_Ent6", "text": "niflumic acid", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7379406_2_Ent10", "text": "niflumic acid", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7379406_2_Ent0", "text": "a 35 - year - old woman suffering from rheumatoid arthritis", "entity_type": "Entity", "start": 26, "end": 37}, {"id": "7379406_2_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "7379406_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "7379406_2_Ent8", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "7379406_2_Ent5", "text": "in addition , with corticosteroids", "entity_type": "Entity", "start": 40, "end": 45}, {"id": "7379406_2_Ent7", "text": "corticosteroids", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "7379406_2_Ent9", "text": "corticosteroids", "entity_type": "Entity", "start": 44, "end": 45}], "lang": "en"}
{"doc_id": "7379406_7", "wnd_id": "7379406_7_1", "text": "After ruling out a hydrotelluric source of fluorine , the patient 's fluorosis was linked to chronic use of niflumic acid , following the publication in 1978 of the 2 previously reported cases affected by this drug .", "tokens": ["After", "ruling", "out", "a", "hydrotelluric", "source", "of", "fluorine", ",", "the", "patient", "'s", "fluorosis", "was", "linked", "to", "chronic", "use", "of", "niflumic", "acid", ",", "following", "the", "publication", "in", "1978", "of", "the", "2", "previously", "reported", "cases", "affected", "by", "this", "drug", "."], "event_mentions": [{"id": "7379406_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "linked to", "start": 14, "end": 16}, "arguments": [{"entity_id": "7379406_7_Ent0", "role": "Subject", "text": "the patient 's", "start": 9, "end": 12}, {"entity_id": "7379406_7_Ent1", "role": "Effect", "text": "fluorosis", "start": 12, "end": 13}, {"entity_id": "7379406_7_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 16, "end": 17}, {"entity_id": "7379406_7_Ent2", "role": "Treatment", "text": "chronic use of niflumic acid", "start": 16, "end": 21}, {"entity_id": "7379406_7_Ent3", "role": "Treatment_Drug", "text": "niflumic acid", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "7379406_7_Ent0", "text": "the patient 's", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "7379406_7_Ent1", "text": "fluorosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7379406_7_Ent4", "text": "chronic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7379406_7_Ent2", "text": "chronic use of niflumic acid", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "7379406_7_Ent3", "text": "niflumic acid", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "7416268_3", "wnd_id": "7416268_3_1", "text": "Although useful in the management of chronic alcoholism , disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae , which now include catatonia .", "tokens": ["Although", "useful", "in", "the", "management", "of", "chronic", "alcoholism", ",", "disulfiram", "is", "being", "increasingly", "associated", "with", "a", "wide", "spectrum", "of", "side", "effects", "and", "untoward", "medical", "sequelae", ",", "which", "now", "include", "catatonia", "."], "event_mentions": [{"id": "7416268_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "7416268_3_Ent3", "role": "Treatment_Disorder", "text": "chronic alcoholism", "start": 6, "end": 8}, {"entity_id": "7416268_3_Ent1", "role": "Treatment", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent0", "role": "Effect", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "start": 15, "end": 30}]}], "entity_mentions": [{"id": "7416268_3_Ent3", "text": "chronic alcoholism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7416268_3_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent0", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "entity_type": "Entity", "start": 15, "end": 30}], "lang": "en"}
{"doc_id": "7420580_2", "wnd_id": "7420580_2_1", "text": "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of vinblastine .", "tokens": ["We", "report", "on", "a", "patient", "with", "an", "embryonal", "teratocarcinoma", "of", "the", "testicle", "who", "had", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "after", "receiving", "a", "high", "dose", "of", "vinblastine", "."], "event_mentions": [{"id": "7420580_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 13, "end": 14}, "arguments": [{"entity_id": "7420580_2_Ent0", "role": "Subject", "text": "a patient with an embryonal teratocarcinoma of the testicle", "start": 3, "end": 12}, {"entity_id": "7420580_2_Ent5", "role": "Treatment_Disorder", "text": "embryonal teratocarcinoma of the testicle", "start": 7, "end": 12}, {"entity_id": "7420580_2_Ent1", "role": "Effect", "text": "syndrome of inappropriate secretion of antidiuretic hormone", "start": 15, "end": 22}, {"entity_id": "7420580_2_Ent2", "role": "Treatment", "text": "a high dose of vinblastine", "start": 24, "end": 29}, {"entity_id": "7420580_2_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 25, "end": 27}, {"entity_id": "7420580_2_Ent4", "role": "Treatment_Drug", "text": "vinblastine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7420580_2_Ent0", "text": "a patient with an embryonal teratocarcinoma of the testicle", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "7420580_2_Ent5", "text": "embryonal teratocarcinoma of the testicle", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7420580_2_Ent1", "text": "syndrome of inappropriate secretion of antidiuretic hormone", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "7420580_2_Ent2", "text": "a high dose of vinblastine", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "7420580_2_Ent3", "text": "high dose", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "7420580_2_Ent4", "text": "vinblastine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7439122_1", "wnd_id": "7439122_1_1", "text": "Clofibrate - induced myopathy in patients with diabetes insipidus .", "tokens": ["Clofibrate", "-", "induced", "myopathy", "in", "patients", "with", "diabetes", "insipidus", "."], "event_mentions": [{"id": "7439122_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7439122_1_Ent2", "role": "Treatment", "text": "Clofibrate", "start": 0, "end": 1}, {"entity_id": "7439122_1_Ent4", "role": "Treatment_Drug", "text": "Clofibrate", "start": 0, "end": 1}, {"entity_id": "7439122_1_Ent1", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "7439122_1_Ent0", "role": "Subject", "text": "patients with diabetes insipidus", "start": 5, "end": 9}, {"entity_id": "7439122_1_Ent3", "role": "Treatment_Disorder", "text": "diabetes insipidus", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7439122_1_Ent2", "text": "Clofibrate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7439122_1_Ent4", "text": "Clofibrate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7439122_1_Ent1", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7439122_1_Ent0", "text": "patients with diabetes insipidus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "7439122_1_Ent3", "text": "diabetes insipidus", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7485371_2", "wnd_id": "7485371_2_1", "text": "PURPOSE : We studied a case of vortex keratopathy that was associated with the use of atovaquone .", "tokens": ["PURPOSE", ":", "We", "studied", "a", "case", "of", "vortex", "keratopathy", "that", "was", "associated", "with", "the", "use", "of", "atovaquone", "."], "event_mentions": [{"id": "7485371_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "7485371_2_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "7485371_2_Ent1", "role": "Effect", "text": "vortex keratopathy", "start": 7, "end": 9}, {"entity_id": "7485371_2_Ent2", "role": "Treatment", "text": "atovaquone", "start": 16, "end": 17}, {"entity_id": "7485371_2_Ent3", "role": "Treatment_Drug", "text": "atovaquone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7485371_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7485371_2_Ent1", "text": "vortex keratopathy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7485371_2_Ent2", "text": "atovaquone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7485371_2_Ent3", "text": "atovaquone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7538828_2", "wnd_id": "7538828_2_1", "text": "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days , respectively , following a single dose of 40 mg / m2 methotrexate ( MTX ) .", "tokens": ["A", "64", "year", "old", "man", "with", "recurrent", "metastatic", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "developed", "severe", "skin", "rash", "and", "bone", "marrow", "aplasia", "4", "and", "7", "days", ",", "respectively", ",", "following", "a", "single", "dose", "of", "40", "mg", "/", "m2", "methotrexate", "(", "MTX", ")", "."], "event_mentions": [{"id": "7538828_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "7538828_2_Ent0", "role": "Subject", "text": "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck", "start": 0, "end": 16}, {"entity_id": "7538828_2_Ent1", "role": "Subject_Age", "text": "64 year old", "start": 1, "end": 4}, {"entity_id": "7538828_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "7538828_2_Ent5", "role": "Treatment_Disorder", "text": "recurrent metastatic squamous cell carcinoma of the head and neck", "start": 6, "end": 16}, {"entity_id": "7538828_2_Ent3", "role": "Effect", "text": "skin rash and bone marrow aplasia", "start": 18, "end": 24}, {"entity_id": "7538828_2_Ent9", "role": "Treatment_Time_elapsed", "text": "4 and 7 days", "start": 24, "end": 28}, {"entity_id": "7538828_2_Ent8", "role": "Treatment_Freq", "text": "a single dose", "start": 32, "end": 35}, {"entity_id": "7538828_2_Ent4", "role": "Treatment", "text": "a single dose of 40 mg / m2 methotrexate ( MTX )", "start": 32, "end": 44}, {"entity_id": "7538828_2_Ent6", "role": "Treatment_Dosage", "text": "40 mg / m2", "start": 36, "end": 40}, {"entity_id": "7538828_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "7538828_2_Ent0", "text": "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "7538828_2_Ent1", "text": "64 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7538828_2_Ent2", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7538828_2_Ent5", "text": "recurrent metastatic squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "7538828_2_Ent3", "text": "skin rash and bone marrow aplasia", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "7538828_2_Ent9", "text": "4 and 7 days", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "7538828_2_Ent8", "text": "a single dose", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "7538828_2_Ent4", "text": "a single dose of 40 mg / m2 methotrexate ( MTX )", "entity_type": "Entity", "start": 32, "end": 44}, {"id": "7538828_2_Ent6", "text": "40 mg / m2", "entity_type": "Entity", "start": 36, "end": 40}, {"id": "7538828_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "7538828_8", "wnd_id": "7538828_8_1", "text": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life - threatening bone marrow aplasia .", "tokens": ["Development", "of", "an", "extensive", "skin", "rash", "following", "a", "single", "dose", "of", "MTX", "may", "be", "an", "early", "warning", "sign", "for", "life", "-", "threatening", "bone", "marrow", "aplasia", "."], "event_mentions": [{"id": "7538828_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "7538828_8_Ent0", "role": "Effect", "text": "extensive skin rash", "start": 3, "end": 6}, {"entity_id": "7538828_8_Ent1", "role": "Treatment", "text": "MTX", "start": 11, "end": 12}, {"entity_id": "7538828_8_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7538828_8_Ent0", "text": "extensive skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7538828_8_Ent1", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7538828_8_Ent2", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7577414_2", "wnd_id": "7577414_2_1", "text": "To our knowledge , this is the first case of griseofulvin - exacerbated lupus in which nephrotic syndrome has been observed .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "griseofulvin", "-", "exacerbated", "lupus", "in", "which", "nephrotic", "syndrome", "has", "been", "observed", "."], "event_mentions": [{"id": "7577414_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 12, "end": 13}, "arguments": [{"entity_id": "7577414_2_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "7577414_2_Ent3", "role": "Treatment", "text": "griseofulvin", "start": 10, "end": 11}, {"entity_id": "7577414_2_Ent4", "role": "Treatment_Drug", "text": "griseofulvin", "start": 10, "end": 11}, {"entity_id": "7577414_2_Ent1", "role": "Effect", "text": "lupus", "start": 13, "end": 14}, {"entity_id": "7577414_2_Ent2", "role": "Effect", "text": "nephrotic syndrome", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "7577414_2_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7577414_2_Ent3", "text": "griseofulvin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7577414_2_Ent4", "text": "griseofulvin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7577414_2_Ent1", "text": "lupus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7577414_2_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "7594371_1", "wnd_id": "7594371_1_1", "text": "Acute sensorineural hearing loss following intravenous ketoralac administration .", "tokens": ["Acute", "sensorineural", "hearing", "loss", "following", "intravenous", "ketoralac", "administration", "."], "event_mentions": [{"id": "7594371_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "7594371_1_Ent0", "role": "Effect", "text": "Acute sensorineural hearing loss", "start": 0, "end": 4}, {"entity_id": "7594371_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "7594371_1_Ent1", "role": "Treatment", "text": "intravenous ketoralac", "start": 5, "end": 7}, {"entity_id": "7594371_1_Ent2", "role": "Treatment_Drug", "text": "ketoralac", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7594371_1_Ent0", "text": "Acute sensorineural hearing loss", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7594371_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7594371_1_Ent1", "text": "intravenous ketoralac", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7594371_1_Ent2", "text": "ketoralac", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7594371_2", "wnd_id": "7594371_2_1", "text": "Both PAN and methotrexate have been independently demonstrated to cause sensorineural hearing loss .", "tokens": ["Both", "PAN", "and", "methotrexate", "have", "been", "independently", "demonstrated", "to", "cause", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "7594371_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "7594371_2_Ent2", "role": "Treatment_Drug", "text": "PAN", "start": 1, "end": 2}, {"entity_id": "7594371_2_Ent4", "role": "Combination_Drug", "text": "PAN", "start": 1, "end": 2}, {"entity_id": "7594371_2_Ent1", "role": "Treatment", "text": "PAN and methotrexate", "start": 1, "end": 4}, {"entity_id": "7594371_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "7594371_2_Ent5", "role": "Combination_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "7594371_2_Ent0", "role": "Effect", "text": "sensorineural hearing loss", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "7594371_2_Ent2", "text": "PAN", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7594371_2_Ent4", "text": "PAN", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7594371_2_Ent1", "text": "PAN and methotrexate", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7594371_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7594371_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7594371_2_Ent0", "text": "sensorineural hearing loss", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "7594371_4", "wnd_id": "7594371_4_1", "text": "We report the case of a 20 - year - old female with polyarteritis nodosa ( PAN ) who developed bilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous ketoralac .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "female", "with", "polyarteritis", "nodosa", "(", "PAN", ")", "who", "developed", "bilateral", "sensorineural", "hearing", "loss", "25", "minutes", "after", "receiving", "30", "mg", "of", "intravenous", "ketoralac", "."], "event_mentions": [{"id": "7594371_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "7594371_4_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "7594371_4_Ent0", "role": "Subject", "text": "20 - year - old female with polyarteritis nodosa ( PAN )", "start": 6, "end": 18}, {"entity_id": "7594371_4_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "7594371_4_Ent5", "role": "Treatment_Disorder", "text": "polyarteritis nodosa", "start": 13, "end": 15}, {"entity_id": "7594371_4_Ent3", "role": "Effect", "text": "bilateral sensorineural hearing loss", "start": 20, "end": 24}, {"entity_id": "7594371_4_Ent6", "role": "Treatment_Time_elapsed", "text": "25 minutes after", "start": 24, "end": 27}, {"entity_id": "7594371_4_Ent7", "role": "Treatment_Dosage", "text": "30 mg", "start": 28, "end": 30}, {"entity_id": "7594371_4_Ent4", "role": "Treatment", "text": "30 mg of intravenous ketoralac", "start": 28, "end": 33}, {"entity_id": "7594371_4_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 31, "end": 32}, {"entity_id": "7594371_4_Ent9", "role": "Treatment_Drug", "text": "ketoralac", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "7594371_4_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "7594371_4_Ent0", "text": "20 - year - old female with polyarteritis nodosa ( PAN )", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "7594371_4_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7594371_4_Ent5", "text": "polyarteritis nodosa", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "7594371_4_Ent3", "text": "bilateral sensorineural hearing loss", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "7594371_4_Ent6", "text": "25 minutes after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "7594371_4_Ent7", "text": "30 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "7594371_4_Ent4", "text": "30 mg of intravenous ketoralac", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "7594371_4_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "7594371_4_Ent9", "text": "ketoralac", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "7619765_2", "wnd_id": "7619765_2_1", "text": "The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .", "tokens": ["The", "occurrence", "of", "a", "myocardial", "infarction", "is", "reported", "after", "chemotherapy", "containing", "etoposide", ",", "in", "a", "man", "with", "no", "risk", "factors", "for", "coronary", "heart", "disease", "."], "event_mentions": [{"id": "7619765_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "7619765_2_Ent2", "role": "Effect", "text": "myocardial infarction", "start": 4, "end": 6}, {"entity_id": "7619765_2_Ent3", "role": "Treatment", "text": "chemotherapy containing etoposide", "start": 9, "end": 12}, {"entity_id": "7619765_2_Ent4", "role": "Treatment_Drug", "text": "etoposide", "start": 11, "end": 12}, {"entity_id": "7619765_2_Ent0", "role": "Subject", "text": "a man with no risk factors for coronary heart disease", "start": 14, "end": 24}, {"entity_id": "7619765_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7619765_2_Ent2", "text": "myocardial infarction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7619765_2_Ent3", "text": "chemotherapy containing etoposide", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "7619765_2_Ent4", "text": "etoposide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7619765_2_Ent0", "text": "a man with no risk factors for coronary heart disease", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "7619765_2_Ent1", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7632529_1", "wnd_id": "7632529_1_1", "text": "A 9 - year - old boy developed acute renal failure following intravenous acyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis .", "tokens": ["A", "9", "-", "year", "-", "old", "boy", "developed", "acute", "renal", "failure", "following", "intravenous", "acyclovir", "(", "30", "mg", "/", "kg", "per", "day", ")", "administered", "for", "6", "days", "to", "treat", "herpetic", "encephalitis", "."], "event_mentions": [{"id": "7632529_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7632529_1_Ent0", "role": "Subject", "text": "A 9 - year - old boy", "start": 0, "end": 7}, {"entity_id": "7632529_1_Ent1", "role": "Subject_Age", "text": "9 - year - old", "start": 1, "end": 6}, {"entity_id": "7632529_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "7632529_1_Ent3", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}, {"entity_id": "7632529_1_Ent4", "role": "Treatment", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent6", "role": "Treatment_Drug", "text": "intravenous acyclovir", "start": 12, "end": 14}, {"entity_id": "7632529_1_Ent7", "role": "Treatment_Dosage", "text": "30 mg / kg", "start": 15, "end": 19}, {"entity_id": "7632529_1_Ent8", "role": "Treatment_Freq", "text": "per day", "start": 19, "end": 21}, {"entity_id": "7632529_1_Ent9", "role": "Treatment_Duration", "text": "6 days", "start": 24, "end": 26}, {"entity_id": "7632529_1_Ent5", "role": "Treatment_Disorder", "text": "herpetic encephalitis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "7632529_1_Ent0", "text": "A 9 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7632529_1_Ent1", "text": "9 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7632529_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7632529_1_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7632529_1_Ent4", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent6", "text": "intravenous acyclovir", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7632529_1_Ent7", "text": "30 mg / kg", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "7632529_1_Ent8", "text": "per day", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "7632529_1_Ent9", "text": "6 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7632529_1_Ent5", "text": "herpetic encephalitis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "7663030_1", "wnd_id": "7663030_1_1", "text": "Probable propafenone - induced transient global amnesia .", "tokens": ["Probable", "propafenone", "-", "induced", "transient", "global", "amnesia", "."], "event_mentions": [{"id": "7663030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7663030_1_Ent1", "role": "Treatment", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent0", "role": "Effect", "text": "transient global amnesia", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7663030_1_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent0", "text": "transient global amnesia", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7663030_14", "wnd_id": "7663030_14_1", "text": "Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .", "tokens": ["Comparable", "adverse", "effects", ",", "such", "as", "disorientation", "and", "temporary", "amnesia", ",", "have", "been", "reported", "in", "patients", "in", "the", "analogous", "agent", ",", "propranolol", "."], "event_mentions": [{"id": "7663030_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "been reported", "start": 12, "end": 14}, "arguments": [{"entity_id": "7663030_14_Ent1", "role": "Effect", "text": "disorientation and temporary amnesia", "start": 6, "end": 10}, {"entity_id": "7663030_14_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "7663030_14_Ent2", "role": "Treatment", "text": "propranolol", "start": 21, "end": 22}, {"entity_id": "7663030_14_Ent3", "role": "Treatment_Drug", "text": "propranolol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "7663030_14_Ent1", "text": "disorientation and temporary amnesia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7663030_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7663030_14_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7663030_14_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "7663030_5", "wnd_id": "7663030_5_1", "text": "He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue .", "tokens": ["He", "began", "taking", "propafenone", "only", "6", "days", "prior", "to", "admission", "because", "of", "uncontrolled", "atrial", "fibrillation", "and", "symptoms", "of", "fatigue", "."], "event_mentions": [{"id": "7663030_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "taking", "start": 2, "end": 3}, "arguments": [{"entity_id": "7663030_5_Ent0", "role": "Treatment", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "7663030_5_Ent1", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "7663030_5_Ent2", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 13, "end": 15}, {"entity_id": "7663030_5_Ent3", "role": "Treatment_Disorder", "text": "fatigue", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7663030_5_Ent0", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7663030_5_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7663030_5_Ent2", "text": "atrial fibrillation", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "7663030_5_Ent3", "text": "fatigue", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7668127_1", "wnd_id": "7668127_1_1", "text": "Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .", "tokens": ["Intracranial", "haemorrhage", "from", "a", "meningioma", "in", "a", "patient", "receiving", "aspirin", "prophylaxis", ":", "a", "case", "report", "."], "event_mentions": [{"id": "7668127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "7668127_1_Ent1", "role": "Effect", "text": "Intracranial haemorrhage from a meningioma", "start": 0, "end": 5}, {"entity_id": "7668127_1_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "7668127_1_Ent2", "role": "Treatment", "text": "aspirin", "start": 9, "end": 10}, {"entity_id": "7668127_1_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7668127_1_Ent1", "text": "Intracranial haemorrhage from a meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7668127_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7668127_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7668127_1_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7668127_2", "wnd_id": "7668127_2_1", "text": "A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .", "tokens": ["A", "case", "of", "acute", "subdural", "haematoma", "originating", "spontaneously", "from", "an", "angiomatous", "meningioma", "in", "a", "patient", "receiving", "prophylactic", "aspirin", "therapy", "is", "presented", "."], "event_mentions": [{"id": "7668127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 20, "end": 21}, "arguments": [{"entity_id": "7668127_2_Ent1", "role": "Effect", "text": "acute subdural haematoma", "start": 3, "end": 6}, {"entity_id": "7668127_2_Ent0", "role": "Subject", "text": "an angiomatous meningioma in a patient", "start": 9, "end": 15}, {"entity_id": "7668127_2_Ent2", "role": "Treatment", "text": "aspirin", "start": 17, "end": 18}, {"entity_id": "7668127_2_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "7668127_2_Ent1", "text": "acute subdural haematoma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7668127_2_Ent0", "text": "an angiomatous meningioma in a patient", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "7668127_2_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7668127_2_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7696938_1", "wnd_id": "7696938_1_1", "text": "Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .", "tokens": ["Arrhythmias", "and", "cardiac", "arrest", "have", "been", "reported", "during", "amphotericin", "B", "administration", "but", "no", "effective", "technique", "has", "been", "described", "to", "prevent", "them", "."], "event_mentions": [{"id": "7696938_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "7696938_1_Ent0", "role": "Effect", "text": "Arrhythmias and cardiac arrest", "start": 0, "end": 4}, {"entity_id": "7696938_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 8, "end": 10}, {"entity_id": "7696938_1_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "7696938_1_Ent0", "text": "Arrhythmias and cardiac arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7696938_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7696938_1_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "7718983_1", "wnd_id": "7718983_1_1", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "tokens": ["Graves", "'", "hyperthyroidism", "following", "transient", "thyrotoxicosis", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "type", "C."], "event_mentions": [{"id": "7718983_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "7718983_1_Ent0", "role": "Effect", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "start": 0, "end": 6}, {"entity_id": "7718983_1_Ent1", "role": "Treatment", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis type C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "7718983_1_Ent0", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7718983_1_Ent1", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent2", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent3", "text": "chronic hepatitis type C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "7724306_2", "wnd_id": "7724306_2_1", "text": "Acute isoniazid neurotoxicity in an urban hospital .", "tokens": ["Acute", "isoniazid", "neurotoxicity", "in", "an", "urban", "hospital", "."], "event_mentions": [{"id": "7724306_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "7724306_2_Ent0", "role": "Effect", "text": "Acute", "start": 0, "end": 1}, {"entity_id": "7724306_2_Ent2", "role": "Treatment", "text": "isoniazid", "start": 1, "end": 2}, {"entity_id": "7724306_2_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 1, "end": 2}, {"entity_id": "7724306_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "7724306_2_Ent0", "text": "Acute", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7724306_2_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7724306_2_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7724306_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "7748076_1", "wnd_id": "7748076_1_1", "text": "CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .", "tokens": ["CONCLUSION", ":", "Squamous", "metaplasia", "in", "these", "cases", "appears", "to", "be", "a", "consequence", "of", "progestin", "therapy", "."], "event_mentions": [{"id": "7748076_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 11, "end": 12}, "arguments": [{"entity_id": "7748076_1_Ent1", "role": "Effect", "text": "Squamous metaplasia", "start": 2, "end": 4}, {"entity_id": "7748076_1_Ent0", "role": "Subject", "text": "these cases", "start": 5, "end": 7}, {"entity_id": "7748076_1_Ent3", "role": "Treatment_Drug", "text": "progestin", "start": 13, "end": 14}, {"entity_id": "7748076_1_Ent2", "role": "Treatment", "text": "progestin therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7748076_1_Ent1", "text": "Squamous metaplasia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7748076_1_Ent0", "text": "these cases", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7748076_1_Ent3", "text": "progestin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7748076_1_Ent2", "text": "progestin therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7748076_2", "wnd_id": "7748076_2_1", "text": "OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "finding", "of", "squamous", "metaplasia", "within", "endometrial", "glands", "occurring", "as", "a", "result", "of", "progestin", "therapy", "of", "hyperplasia", "."], "event_mentions": [{"id": "7748076_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "as a result of", "start": 13, "end": 17}, "arguments": [{"entity_id": "7748076_2_Ent0", "role": "Effect", "text": "squamous metaplasia within endometrial glands", "start": 7, "end": 12}, {"entity_id": "7748076_2_Ent3", "role": "Treatment_Drug", "text": "progestin", "start": 17, "end": 18}, {"entity_id": "7748076_2_Ent1", "role": "Treatment", "text": "progestin therapy", "start": 17, "end": 19}, {"entity_id": "7748076_2_Ent2", "role": "Treatment_Disorder", "text": "hyperplasia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "7748076_2_Ent0", "text": "squamous metaplasia within endometrial glands", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7748076_2_Ent3", "text": "progestin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7748076_2_Ent1", "text": "progestin therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7748076_2_Ent2", "text": "hyperplasia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "7752014_1", "wnd_id": "7752014_1_1", "text": "Furosemide - associated fever .", "tokens": ["Furosemide", "-", "associated", "fever", "."], "event_mentions": [{"id": "7752014_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7752014_1_Ent1", "role": "Treatment", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent2", "role": "Treatment_Drug", "text": "Furosemide", "start": 0, "end": 1}, {"entity_id": "7752014_1_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "7752014_1_Ent1", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent2", "text": "Furosemide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "7756684_1", "wnd_id": "7756684_1_1", "text": "The dose - limiting toxicity of KW - 2149 is pulmonary toxicity .", "tokens": ["The", "dose", "-", "limiting", "toxicity", "of", "KW", "-", "2149", "is", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "7756684_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 11, "end": 12}, "arguments": [{"entity_id": "7756684_1_Ent1", "role": "Treatment", "text": "KW - 2149", "start": 6, "end": 9}, {"entity_id": "7756684_1_Ent2", "role": "Treatment_Drug", "text": "KW - 2149", "start": 6, "end": 9}, {"entity_id": "7756684_1_Ent0", "role": "Effect", "text": "pulmonary", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7756684_1_Ent1", "text": "KW - 2149", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7756684_1_Ent2", "text": "KW - 2149", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7756684_1_Ent0", "text": "pulmonary", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7776854_4", "wnd_id": "7776854_4_1", "text": "We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .", "tokens": ["We", "stress", "the", "potential", "of", "benzarone", "to", "cause", "hepatotoxicity", ",", "which", "usually", "resembles", "severe", "chronic", "active", "hepatitis", "."], "event_mentions": [{"id": "7776854_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_4_Ent2", "role": "Treatment", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent3", "role": "Treatment_Drug", "text": "benzarone", "start": 5, "end": 6}, {"entity_id": "7776854_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "7776854_4_Ent1", "role": "Effect", "text": "severe chronic active hepatitis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "7776854_4_Ent2", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7776854_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7776854_4_Ent1", "text": "severe chronic active hepatitis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "7781845_10", "wnd_id": "7781845_10_1", "text": "Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .", "tokens": ["Mechanisms", "and", "triggering", "factors", "of", "hypoglycaemia", "induced", "by", "mefloquine", "and", "some", "other", "anti", "-", "malarial", "quinine", "analogues", "are", "discussed", "."], "event_mentions": [{"id": "7781845_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "7781845_10_Ent0", "role": "Effect", "text": "hypoglycaemia", "start": 5, "end": 6}, {"entity_id": "7781845_10_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 8, "end": 9}, {"entity_id": "7781845_10_Ent4", "role": "Combination_Drug", "text": "mefloquine", "start": 8, "end": 9}, {"entity_id": "7781845_10_Ent1", "role": "Treatment", "text": "mefloquine and some other anti - malarial quinine analogues", "start": 8, "end": 17}, {"entity_id": "7781845_10_Ent3", "role": "Treatment_Drug", "text": "quinine analogues", "start": 15, "end": 17}, {"entity_id": "7781845_10_Ent5", "role": "Combination_Drug", "text": "quinine analogues", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "7781845_10_Ent0", "text": "hypoglycaemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7781845_10_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7781845_10_Ent4", "text": "mefloquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7781845_10_Ent1", "text": "mefloquine and some other anti - malarial quinine analogues", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "7781845_10_Ent3", "text": "quinine analogues", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7781845_10_Ent5", "text": "quinine analogues", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "7835785_2", "wnd_id": "7835785_2_1", "text": "The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .", "tokens": ["The", "association", "with", "prolonged", "unopposed", "estrogen", "-", "like", "stimulation", "with", "tamoxifen", "as", "a", "possible", "factor", "in", "the", "development", "of", "ovarian", "endometrioid", "carcinoma", "is", "discussed", "."], "event_mentions": [{"id": "7835785_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "7835785_2_Ent2", "role": "Treatment_Duration", "text": "prolonged", "start": 3, "end": 4}, {"entity_id": "7835785_2_Ent1", "role": "Treatment", "text": "prolonged unopposed estrogen - like stimulation with tamoxifen", "start": 3, "end": 11}, {"entity_id": "7835785_2_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 10, "end": 11}, {"entity_id": "7835785_2_Ent0", "role": "Effect", "text": "development of ovarian endometrioid carcinoma", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "7835785_2_Ent2", "text": "prolonged", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7835785_2_Ent1", "text": "prolonged unopposed estrogen - like stimulation with tamoxifen", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "7835785_2_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7835785_2_Ent0", "text": "development of ovarian endometrioid carcinoma", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "788666_2", "wnd_id": "788666_2_1", "text": "Gentamicin - associated acute renal failure .", "tokens": ["Gentamicin", "-", "associated", "acute", "renal", "failure", "."], "event_mentions": [{"id": "788666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "788666_2_Ent1", "role": "Treatment", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent2", "role": "Treatment_Drug", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "788666_2_Ent1", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent2", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7893301_1", "wnd_id": "7893301_1_1", "text": "Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .", "tokens": ["Albuterol", "-", "induced", "hypokalemia", "and", "its", "potential", "cardiac", "toxicity", "are", "discussed", "briefly", "."], "event_mentions": [{"id": "7893301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7893301_1_Ent1", "role": "Treatment", "text": "Albuterol", "start": 0, "end": 1}, {"entity_id": "7893301_1_Ent2", "role": "Treatment_Drug", "text": "Albuterol", "start": 0, "end": 1}, {"entity_id": "7893301_1_Ent0", "role": "Effect", "text": "hypokalemia and its potential cardiac toxicity", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "7893301_1_Ent1", "text": "Albuterol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7893301_1_Ent2", "text": "Albuterol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7893301_1_Ent0", "text": "hypokalemia and its potential cardiac toxicity", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "7893301_3", "wnd_id": "7893301_3_1", "text": "The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .", "tokens": ["The", "cases", "of", "two", "asthmatic", "patients", "who", "became", "hypokalemic", "after", "inhalation", "of", "normal", "doses", "of", "albuterol", "are", "presented", "."], "event_mentions": [{"id": "7893301_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "7893301_3_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "7893301_3_Ent0", "role": "Subject", "text": "two asthmatic patients", "start": 3, "end": 6}, {"entity_id": "7893301_3_Ent4", "role": "Treatment_Disorder", "text": "asthmatic", "start": 4, "end": 5}, {"entity_id": "7893301_3_Ent2", "role": "Effect", "text": "hypokalemic", "start": 8, "end": 9}, {"entity_id": "7893301_3_Ent5", "role": "Treatment_Route", "text": "inhalation", "start": 10, "end": 11}, {"entity_id": "7893301_3_Ent3", "role": "Treatment", "text": "inhalation of normal doses of albuterol", "start": 10, "end": 16}, {"entity_id": "7893301_3_Ent6", "role": "Treatment_Dosage", "text": "normal doses", "start": 12, "end": 14}, {"entity_id": "7893301_3_Ent7", "role": "Treatment_Drug", "text": "albuterol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "7893301_3_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7893301_3_Ent0", "text": "two asthmatic patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7893301_3_Ent4", "text": "asthmatic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7893301_3_Ent2", "text": "hypokalemic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7893301_3_Ent5", "text": "inhalation", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7893301_3_Ent3", "text": "inhalation of normal doses of albuterol", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "7893301_3_Ent6", "text": "normal doses", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7893301_3_Ent7", "text": "albuterol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "7919557_1", "wnd_id": "7919557_1_1", "text": "CASE SUMMARY : A 68 - year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .", "tokens": ["CASE", "SUMMARY", ":", "A", "68", "-", "year", "-", "old", "woman", "developed", "a", "dry", ",", "irritating", "cough", "within", "one", "month", "of", "starting", "quinapril", "therapy", "for", "the", "treatment", "of", "essential", "hypertension", "."], "event_mentions": [{"id": "7919557_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "starting", "start": 20, "end": 21}, "arguments": [{"entity_id": "7919557_1_Ent0", "role": "Subject", "text": "A 68 - year - old woman", "start": 3, "end": 10}, {"entity_id": "7919557_1_Ent1", "role": "Subject_Age", "text": "68 - year - old", "start": 4, "end": 9}, {"entity_id": "7919557_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "7919557_1_Ent3", "role": "Effect", "text": "a dry , irritating cough", "start": 11, "end": 16}, {"entity_id": "7919557_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within one month", "start": 16, "end": 19}, {"entity_id": "7919557_1_Ent6", "role": "Treatment_Drug", "text": "quinapril", "start": 21, "end": 22}, {"entity_id": "7919557_1_Ent4", "role": "Treatment", "text": "quinapril therapy", "start": 21, "end": 23}, {"entity_id": "7919557_1_Ent7", "role": "Treatment_Disorder", "text": "essential hypertension", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "7919557_1_Ent0", "text": "A 68 - year - old woman", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "7919557_1_Ent1", "text": "68 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "7919557_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7919557_1_Ent3", "text": "a dry , irritating cough", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7919557_1_Ent5", "text": "within one month", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7919557_1_Ent6", "text": "quinapril", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7919557_1_Ent4", "text": "quinapril therapy", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "7919557_1_Ent7", "text": "essential hypertension", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "7933665_1", "wnd_id": "7933665_1_1", "text": "Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .", "tokens": ["Fracture", "of", "the", "femoral", "neck", "occurred", "in", "one", "patient", "during", "PSL", "therapy", ",", "although", "the", "relationship", "between", "the", "fracture", "and", "PSL", "therapy", "was", "uncertain", "."], "event_mentions": [{"id": "7933665_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "7933665_1_Ent2", "role": "Effect", "text": "Fracture of the femoral neck", "start": 0, "end": 5}, {"entity_id": "7933665_1_Ent1", "role": "Subject_Population", "text": "one", "start": 7, "end": 8}, {"entity_id": "7933665_1_Ent0", "role": "Subject", "text": "one patient", "start": 7, "end": 9}, {"entity_id": "7933665_1_Ent4", "role": "Treatment_Drug", "text": "PSL", "start": 10, "end": 11}, {"entity_id": "7933665_1_Ent3", "role": "Treatment", "text": "PSL therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7933665_1_Ent2", "text": "Fracture of the femoral neck", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7933665_1_Ent1", "text": "one", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7933665_1_Ent0", "text": "one patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7933665_1_Ent4", "text": "PSL", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7933665_1_Ent3", "text": "PSL therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7949255_1", "wnd_id": "7949255_1_1", "text": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .", "tokens": ["Temporary", "neurologic", "abnormalities", "were", "observed", "in", "one", "out", "of", "23", "patients", "undergoing", "chemotherapy", "with", "high", "-", "dose", "methotrexate", "(", "HD", "-", "MTX", ")", "for", "osteogenic", "sarcoma", "."], "event_mentions": [{"id": "7949255_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 4, "end": 5}, "arguments": [{"entity_id": "7949255_1_Ent2", "role": "Effect", "text": "Temporary neurologic abnormalities", "start": 0, "end": 3}, {"entity_id": "7949255_1_Ent1", "role": "Subject_Population", "text": "one out of 23", "start": 6, "end": 10}, {"entity_id": "7949255_1_Ent0", "role": "Subject", "text": "one out of 23 patients", "start": 6, "end": 11}, {"entity_id": "7949255_1_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "7949255_1_Ent3", "role": "Treatment", "text": "chemotherapy with high - dose methotrexate ( HD - MTX )", "start": 12, "end": 23}, {"entity_id": "7949255_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 14, "end": 17}, {"entity_id": "7949255_1_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "7949255_1_Ent4", "role": "Treatment_Disorder", "text": "osteogenic sarcoma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "7949255_1_Ent2", "text": "Temporary neurologic abnormalities", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7949255_1_Ent1", "text": "one out of 23", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7949255_1_Ent0", "text": "one out of 23 patients", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "7949255_1_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7949255_1_Ent3", "text": "chemotherapy with high - dose methotrexate ( HD - MTX )", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "7949255_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7949255_1_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7949255_1_Ent4", "text": "osteogenic sarcoma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "7973922_1", "wnd_id": "7973922_1_1", "text": "Acyclovir neurotoxicity : clinical experience and review of the literature .", "tokens": ["Acyclovir", "neurotoxicity", ":", "clinical", "experience", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7973922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experience", "start": 4, "end": 5}, "arguments": [{"entity_id": "7973922_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "7973922_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "7986915_2", "wnd_id": "7986915_2_1", "text": "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .", "tokens": ["We", "describe", "a", "patient", "with", "a", "liver", "abscess", "due", "to", "Entamoeba", "histolytica", ",", "in", "whom", "metronidazole", "therapy", "(", "total", "dose", ",", "21", "g", "over", "14", "days", ")", "was", "complicated", "by", "reversible", "deafness", ",", "tinnitus", ",", "and", "ataxia", "and", "who", "relapsed", "5", "months", "later", "with", "a", "splenic", "abscess", "."], "event_mentions": [{"id": "7986915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 28, "end": 29}, "arguments": [{"entity_id": "7986915_2_Ent0", "role": "Subject", "text": "a patient with a liver abscess due to Entamoeba histolytica", "start": 2, "end": 12}, {"entity_id": "7986915_2_Ent6", "role": "Treatment_Disorder", "text": "liver abscess", "start": 6, "end": 8}, {"entity_id": "7986915_2_Ent7", "role": "Treatment_Disorder", "text": "Entamoeba histolytica", "start": 10, "end": 12}, {"entity_id": "7986915_2_Ent3", "role": "Treatment_Drug", "text": "metronidazole", "start": 15, "end": 16}, {"entity_id": "7986915_2_Ent2", "role": "Treatment", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "start": 15, "end": 27}, {"entity_id": "7986915_2_Ent4", "role": "Treatment_Dosage", "text": "21 g", "start": 21, "end": 23}, {"entity_id": "7986915_2_Ent5", "role": "Treatment_Duration", "text": "14 days", "start": 24, "end": 26}, {"entity_id": "7986915_2_Ent1", "role": "Effect", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "start": 30, "end": 47}]}], "entity_mentions": [{"id": "7986915_2_Ent0", "text": "a patient with a liver abscess due to Entamoeba histolytica", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "7986915_2_Ent6", "text": "liver abscess", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7986915_2_Ent7", "text": "Entamoeba histolytica", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7986915_2_Ent3", "text": "metronidazole", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7986915_2_Ent2", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "7986915_2_Ent4", "text": "21 g", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "7986915_2_Ent5", "text": "14 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7986915_2_Ent1", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "entity_type": "Entity", "start": 30, "end": 47}], "lang": "en"}
{"doc_id": "7991279_2", "wnd_id": "7991279_2_1", "text": "There are now reports of liver failure following treatment of childhood cancers with AMD .", "tokens": ["There", "are", "now", "reports", "of", "liver", "failure", "following", "treatment", "of", "childhood", "cancers", "with", "AMD", "."], "event_mentions": [{"id": "7991279_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "7991279_2_Ent2", "role": "Effect", "text": "liver failure", "start": 5, "end": 7}, {"entity_id": "7991279_2_Ent1", "role": "Subject_Age", "text": "childhood", "start": 10, "end": 11}, {"entity_id": "7991279_2_Ent0", "role": "Subject", "text": "childhood cancers", "start": 10, "end": 12}, {"entity_id": "7991279_2_Ent4", "role": "Treatment_Disorder", "text": "cancers", "start": 11, "end": 12}, {"entity_id": "7991279_2_Ent3", "role": "Treatment", "text": "AMD", "start": 13, "end": 14}, {"entity_id": "7991279_2_Ent5", "role": "Treatment_Drug", "text": "AMD", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7991279_2_Ent2", "text": "liver failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7991279_2_Ent1", "text": "childhood", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7991279_2_Ent0", "text": "childhood cancers", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7991279_2_Ent4", "text": "cancers", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7991279_2_Ent3", "text": "AMD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7991279_2_Ent5", "text": "AMD", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7995508_2", "wnd_id": "7995508_2_1", "text": "We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .", "tokens": ["We", "report", "a", "cae", "of", "paranoid", "psychosis", "following", "use", "of", "a", "decongestant", "containing", "PPA", "and", "summarize", "the", "case", "report", "literature", "of", "psychiatric", "adverse", "effects", "to", "PPA", "in", "which", "doses", "were", "known", "and", "stated", "to", "be", "within", "recommended", "guidelines", "."], "event_mentions": [{"id": "7995508_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "7995508_2_Ent0", "role": "Subject", "text": "a cae", "start": 2, "end": 4}, {"entity_id": "7995508_2_Ent1", "role": "Effect", "text": "paranoid psychosis", "start": 5, "end": 7}, {"entity_id": "7995508_2_Ent2", "role": "Treatment", "text": "decongestant containing PPA", "start": 11, "end": 14}, {"entity_id": "7995508_2_Ent3", "role": "Treatment_Drug", "text": "PPA", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7995508_2_Ent0", "text": "a cae", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7995508_2_Ent1", "text": "paranoid psychosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7995508_2_Ent2", "text": "decongestant containing PPA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7995508_2_Ent3", "text": "PPA", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8007037_2", "wnd_id": "8007037_2_1", "text": "Methemoglobinemia : an occupational hazard of phenylpropanolamine production .", "tokens": ["Methemoglobinemia", ":", "an", "occupational", "hazard", "of", "phenylpropanolamine", "production", "."], "event_mentions": [{"id": "8007037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "production", "start": 7, "end": 8}, "arguments": [{"entity_id": "8007037_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8007037_2_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 6, "end": 7}, {"entity_id": "8007037_2_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8007037_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8007037_2_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8007037_2_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8013261_2", "wnd_id": "8013261_2_1", "text": "Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .", "tokens": ["Four", "years", "after", "the", "beginning", "of", "IFN", "therapy", ",", "he", "acutely", "developed", "moderate", "hyperglycemia", "and", "severe", "ketonuria", "with", "positive", "islet", "cell", "antibody", ",", "and", "then", "28", "units", "/", "day", "of", "insulin", "injection", "was", "started", "."], "event_mentions": [{"id": "8013261_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "8013261_2_Ent4", "role": "Treatment_Time_elapsed", "text": "Four years after", "start": 0, "end": 3}, {"entity_id": "8013261_2_Ent3", "role": "Treatment", "text": "Four years after the beginning of IFN therapy", "start": 0, "end": 8}, {"entity_id": "8013261_2_Ent5", "role": "Treatment_Drug", "text": "IFN", "start": 6, "end": 7}, {"entity_id": "8013261_2_Ent0", "role": "Subject", "text": "he", "start": 9, "end": 10}, {"entity_id": "8013261_2_Ent1", "role": "Subject_Gender", "text": "he", "start": 9, "end": 10}, {"entity_id": "8013261_2_Ent2", "role": "Effect", "text": "acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody", "start": 10, "end": 22}]}], "entity_mentions": [{"id": "8013261_2_Ent4", "text": "Four years after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8013261_2_Ent3", "text": "Four years after the beginning of IFN therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8013261_2_Ent5", "text": "IFN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8013261_2_Ent0", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_2_Ent1", "text": "he", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8013261_2_Ent2", "text": "acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody", "entity_type": "Entity", "start": 10, "end": 22}], "lang": "en"}
{"doc_id": "8013261_3", "wnd_id": "8013261_3_1", "text": "Occurrence of IDDM during interferon therapy for chronic viral hepatitis .", "tokens": ["Occurrence", "of", "IDDM", "during", "interferon", "therapy", "for", "chronic", "viral", "hepatitis", "."], "event_mentions": [{"id": "8013261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "8013261_3_Ent0", "role": "Effect", "text": "IDDM", "start": 2, "end": 3}, {"entity_id": "8013261_3_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 4, "end": 5}, {"entity_id": "8013261_3_Ent1", "role": "Treatment", "text": "interferon therapy", "start": 4, "end": 6}, {"entity_id": "8013261_3_Ent3", "role": "Treatment_Disorder", "text": "chronic viral hepatitis", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "8013261_3_Ent0", "text": "IDDM", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8013261_3_Ent2", "text": "interferon", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8013261_3_Ent1", "text": "interferon therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8013261_3_Ent3", "text": "chronic viral hepatitis", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "8038468_1", "wnd_id": "8038468_1_1", "text": "CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of warfarin alone .", "tokens": ["CONCLUSIONS", ":", "This", "case", "describes", "the", "clinically", "significant", "increase", "of", "INR", "in", "an", "elderly", "patient", "after", "adding", "a", "chemotherapy", "regimen", "of", "levamisole", "and", "5", "-", "FU", "to", "a", "previous", "regimen", "of", "warfarin", "alone", "."], "event_mentions": [{"id": "8038468_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "8038468_1_Ent2", "role": "Effect", "text": "increase of INR", "start": 8, "end": 11}, {"entity_id": "8038468_1_Ent0", "role": "Subject", "text": "an elderly patient", "start": 12, "end": 15}, {"entity_id": "8038468_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "8038468_1_Ent5", "role": "Treatment_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent8", "role": "Combination_Drug", "text": "levamisole", "start": 21, "end": 22}, {"entity_id": "8038468_1_Ent3", "role": "Treatment", "text": "levamisole and 5 - FU", "start": 21, "end": 26}, {"entity_id": "8038468_1_Ent6", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent9", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_1_Ent4", "role": "Treatment", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent7", "role": "Treatment_Drug", "text": "warfarin", "start": 31, "end": 32}, {"entity_id": "8038468_1_Ent10", "role": "Combination_Drug", "text": "warfarin", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "8038468_1_Ent2", "text": "increase of INR", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8038468_1_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8038468_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8038468_1_Ent5", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent8", "text": "levamisole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8038468_1_Ent3", "text": "levamisole and 5 - FU", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "8038468_1_Ent6", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent9", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "8038468_1_Ent10", "text": "warfarin", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "8038468_2", "wnd_id": "8038468_2_1", "text": "However , prolongation of 5 - FU half - life and an increase in INR have been reported with the concurrent use of 5 - FU and warfarin .", "tokens": ["However", ",", "prolongation", "of", "5", "-", "FU", "half", "-", "life", "and", "an", "increase", "in", "INR", "have", "been", "reported", "with", "the", "concurrent", "use", "of", "5", "-", "FU", "and", "warfarin", "."], "event_mentions": [{"id": "8038468_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 17, "end": 18}, "arguments": [{"entity_id": "8038468_2_Ent0", "role": "Effect", "text": "prolongation of 5 - FU half - life and an increase in INR", "start": 2, "end": 15}, {"entity_id": "8038468_2_Ent1", "role": "Treatment", "text": "the concurrent use of 5 - FU and warfarin", "start": 19, "end": 28}, {"entity_id": "8038468_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent4", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 27, "end": 28}, {"entity_id": "8038468_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "8038468_2_Ent0", "text": "prolongation of 5 - FU half - life and an increase in INR", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "8038468_2_Ent1", "text": "the concurrent use of 5 - FU and warfarin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "8038468_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8038468_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "8071504_1", "wnd_id": "8071504_1_1", "text": "Toxic optic neuropathy associated with ethambutol : implications for current therapy .", "tokens": ["Toxic", "optic", "neuropathy", "associated", "with", "ethambutol", ":", "implications", "for", "current", "therapy", "."], "event_mentions": [{"id": "8071504_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "8071504_1_Ent0", "role": "Effect", "text": "Toxic optic neuropathy", "start": 0, "end": 3}, {"entity_id": "8071504_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 5, "end": 6}, {"entity_id": "8071504_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8071504_1_Ent0", "text": "Toxic optic neuropathy", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8071504_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8071504_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8071504_5", "wnd_id": "8071504_5_1", "text": "METHODS : A patient who developed dramatic , permanent vision loss after a 9 - month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .", "tokens": ["METHODS", ":", "A", "patient", "who", "developed", "dramatic", ",", "permanent", "vision", "loss", "after", "a", "9", "-", "month", "course", "of", "treatment", "with", "ethambutol", "and", "isoniazid", "for", "pulmonary", "tuberculosis", "is", "presented", "."], "event_mentions": [{"id": "8071504_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8071504_5_Ent0", "role": "Subject", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "8071504_5_Ent1", "role": "Effect", "text": "permanent vision loss", "start": 8, "end": 11}, {"entity_id": "8071504_5_Ent4", "role": "Treatment_Time_elapsed", "text": "9 - month", "start": 13, "end": 16}, {"entity_id": "8071504_5_Ent2", "role": "Treatment", "text": "9 - month course of treatment with ethambutol and isoniazid", "start": 13, "end": 23}, {"entity_id": "8071504_5_Ent5", "role": "Treatment_Drug", "text": "ethambutol", "start": 20, "end": 21}, {"entity_id": "8071504_5_Ent7", "role": "Combination_Drug", "text": "ethambutol", "start": 20, "end": 21}, {"entity_id": "8071504_5_Ent6", "role": "Treatment_Drug", "text": "isoniazid", "start": 22, "end": 23}, {"entity_id": "8071504_5_Ent8", "role": "Combination_Drug", "text": "isoniazid", "start": 22, "end": 23}, {"entity_id": "8071504_5_Ent3", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "8071504_5_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8071504_5_Ent1", "text": "permanent vision loss", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8071504_5_Ent4", "text": "9 - month", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8071504_5_Ent2", "text": "9 - month course of treatment with ethambutol and isoniazid", "entity_type": "Entity", "start": 13, "end": 23}, {"id": "8071504_5_Ent5", "text": "ethambutol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8071504_5_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8071504_5_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8071504_5_Ent8", "text": "isoniazid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8071504_5_Ent3", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "8104147_1", "wnd_id": "8104147_1_1", "text": "Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .", "tokens": ["Ibopamine", "-", "induced", "reversible", "leukopenia", "during", "treatment", "for", "congestive", "heart", "failure", "."], "event_mentions": [{"id": "8104147_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8104147_1_Ent1", "role": "Treatment", "text": "Ibopamine", "start": 0, "end": 1}, {"entity_id": "8104147_1_Ent3", "role": "Treatment_Drug", "text": "Ibopamine", "start": 0, "end": 1}, {"entity_id": "8104147_1_Ent0", "role": "Effect", "text": "leukopenia", "start": 4, "end": 5}, {"entity_id": "8104147_1_Ent2", "role": "Treatment_Disorder", "text": "congestive heart failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8104147_1_Ent1", "text": "Ibopamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8104147_1_Ent3", "text": "Ibopamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8104147_1_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8104147_1_Ent2", "text": "congestive heart failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8120934_2", "wnd_id": "8120934_2_1", "text": "Bromocriptine - induced schizophrenia .", "tokens": ["Bromocriptine", "-", "induced", "schizophrenia", "."], "event_mentions": [{"id": "8120934_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8120934_2_Ent1", "role": "Treatment", "text": "Bromocriptine", "start": 0, "end": 1}, {"entity_id": "8120934_2_Ent2", "role": "Treatment_Drug", "text": "Bromocriptine", "start": 0, "end": 1}, {"entity_id": "8120934_2_Ent0", "role": "Effect", "text": "schizophrenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8120934_2_Ent1", "text": "Bromocriptine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8120934_2_Ent2", "text": "Bromocriptine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8120934_2_Ent0", "text": "schizophrenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8140860_2", "wnd_id": "8140860_2_1", "text": "We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis , who maintained an international normalized ratio ( INR ) of between 2.5 and 4 for 2 months .", "tokens": ["We", "present", "the", "case", "of", "a", "woman", "undergoing", "treatment", "with", "acenocoumarol", "for", "deep", "vein", "thrombosis", ",", "who", "maintained", "an", "international", "normalized", "ratio", "(", "INR", ")", "of", "between", "2.5", "and", "4", "for", "2", "months", "."], "event_mentions": [{"id": "8140860_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "8140860_2_Ent0", "role": "Subject", "text": "a woman", "start": 5, "end": 7}, {"entity_id": "8140860_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "8140860_2_Ent2", "role": "Treatment", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent4", "role": "Treatment_Disorder", "text": "deep vein thrombosis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8140860_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8140860_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8140860_2_Ent2", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent4", "text": "deep vein thrombosis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8145359_2", "wnd_id": "8145359_2_1", "text": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration .", "tokens": ["The", "association", "of", "phenothiazine", "overdose", "and", "respiratory", "distress", "syndrome", "merits", "consideration", "."], "event_mentions": [{"id": "8145359_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "8145359_2_Ent2", "role": "Treatment_Drug", "text": "phenothiazine", "start": 3, "end": 4}, {"entity_id": "8145359_2_Ent1", "role": "Treatment", "text": "phenothiazine overdose", "start": 3, "end": 5}, {"entity_id": "8145359_2_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8145359_2_Ent0", "role": "Effect", "text": "respiratory distress syndrome", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8145359_2_Ent2", "text": "phenothiazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8145359_2_Ent1", "text": "phenothiazine overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8145359_2_Ent3", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8145359_2_Ent0", "text": "respiratory distress syndrome", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8157823_1", "wnd_id": "8157823_1_1", "text": "Generalized argyria after habitual use of AgNO3 .", "tokens": ["Generalized", "argyria", "after", "habitual", "use", "of", "AgNO3", "."], "event_mentions": [{"id": "8157823_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "8157823_1_Ent0", "role": "Effect", "text": "Generalized argyria", "start": 0, "end": 2}, {"entity_id": "8157823_1_Ent1", "role": "Treatment", "text": "habitual use of AgNO3", "start": 3, "end": 7}, {"entity_id": "8157823_1_Ent2", "role": "Treatment_Drug", "text": "AgNO3", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8157823_1_Ent0", "text": "Generalized argyria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8157823_1_Ent1", "text": "habitual use of AgNO3", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8157823_1_Ent2", "text": "AgNO3", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8162401_3", "wnd_id": "8162401_3_1", "text": "Seizures associated with fluoxetine therapy .", "tokens": ["Seizures", "associated", "with", "fluoxetine", "therapy", "."], "event_mentions": [{"id": "8162401_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 1, "end": 3}, "arguments": [{"entity_id": "8162401_3_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8162401_3_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_3_Ent1", "role": "Treatment", "text": "fluoxetine therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8162401_3_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8162401_3_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_3_Ent1", "text": "fluoxetine therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8175330_2", "wnd_id": "8175330_2_1", "text": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .", "tokens": ["We", "present", "findings", "from", "three", "patients", "who", "experienced", "a", "psoriasiform", "eruption", "apparently", "due", "to", "the", "antiepileptic", "agents", "sodium", "valproate", "and", "carbamazepine", "."], "event_mentions": [{"id": "8175330_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "8175330_2_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8175330_2_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8175330_2_Ent2", "role": "Effect", "text": "psoriasiform eruption", "start": 9, "end": 11}, {"entity_id": "8175330_2_Ent3", "role": "Treatment", "text": "antiepileptic agents sodium valproate and carbamazepine", "start": 15, "end": 21}, {"entity_id": "8175330_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent6", "role": "Combination_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "8175330_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8175330_2_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8175330_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8175330_2_Ent2", "text": "psoriasiform eruption", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8175330_2_Ent3", "text": "antiepileptic agents sodium valproate and carbamazepine", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8175330_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8175330_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8186884_1", "wnd_id": "8186884_1_1", "text": "A 78 - year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "transvenous", "cardioverter", "defibrillator", "system", "developed", "frequent", "shocks", "during", "oral", "procainamide", "therapy", "."], "event_mentions": [{"id": "8186884_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "8186884_1_Ent0", "role": "Subject", "text": "A 78 - year - old man with a transvenous cardioverter defibrillator system", "start": 0, "end": 13}, {"entity_id": "8186884_1_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8186884_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8186884_1_Ent5", "role": "Treatment_Disorder", "text": "a transvenous cardioverter defibrillator system", "start": 8, "end": 13}, {"entity_id": "8186884_1_Ent3", "role": "Effect", "text": "frequent shocks", "start": 14, "end": 16}, {"entity_id": "8186884_1_Ent4", "role": "Treatment", "text": "during oral procainamide therapy", "start": 16, "end": 20}, {"entity_id": "8186884_1_Ent6", "role": "Treatment_Route", "text": "oral", "start": 17, "end": 18}, {"entity_id": "8186884_1_Ent7", "role": "Treatment_Drug", "text": "procainamide", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8186884_1_Ent0", "text": "A 78 - year - old man with a transvenous cardioverter defibrillator system", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "8186884_1_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8186884_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8186884_1_Ent5", "text": "a transvenous cardioverter defibrillator system", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8186884_1_Ent3", "text": "frequent shocks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8186884_1_Ent4", "text": "during oral procainamide therapy", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "8186884_1_Ent6", "text": "oral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8186884_1_Ent7", "text": "procainamide", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8207519_1", "wnd_id": "8207519_1_1", "text": "She received an accidental 450 - mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .", "tokens": ["She", "received", "an", "accidental", "450", "-", "mg", "bolus", "injection", "of", "morphine", "intrathecally", "and", "developed", "hypertension", ",", "status", "epilepticus", ",", "intracerebral", "hemorrhage", ",", "and", "respiratory", "failure", "."], "event_mentions": [{"id": "8207519_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "8207519_1_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "8207519_1_Ent1", "role": "Subject_Age", "text": "She", "start": 0, "end": 1}, {"entity_id": "8207519_1_Ent5", "role": "Treatment_Dosage", "text": "450 - mg", "start": 4, "end": 7}, {"entity_id": "8207519_1_Ent3", "role": "Treatment", "text": "450 - mg bolus injection of morphine", "start": 4, "end": 11}, {"entity_id": "8207519_1_Ent6", "role": "Treatment_Route", "text": "bolus injection", "start": 7, "end": 9}, {"entity_id": "8207519_1_Ent4", "role": "Treatment_Drug", "text": "morphine", "start": 10, "end": 11}, {"entity_id": "8207519_1_Ent2", "role": "Effect", "text": "hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure", "start": 14, "end": 25}]}], "entity_mentions": [{"id": "8207519_1_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8207519_1_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8207519_1_Ent5", "text": "450 - mg", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8207519_1_Ent3", "text": "450 - mg bolus injection of morphine", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "8207519_1_Ent6", "text": "bolus injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8207519_1_Ent4", "text": "morphine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8207519_1_Ent2", "text": "hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure", "entity_type": "Entity", "start": 14, "end": 25}], "lang": "en"}
{"doc_id": "8222875_1", "wnd_id": "8222875_1_1", "text": "Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .", "tokens": ["Mitomycin", "C", "(", "MMC", ")", "is", "an", "alkylating", "agent", "that", "has", "been", "recently", "associated", "with", "the", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", "."], "event_mentions": [{"id": "8222875_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "8222875_1_Ent1", "role": "Treatment", "text": "Mitomycin C ( MMC )", "start": 0, "end": 5}, {"entity_id": "8222875_1_Ent0", "role": "Effect", "text": "the hemolytic - uremic syndrome ( HUS )", "start": 15, "end": 23}]}], "entity_mentions": [{"id": "8222875_1_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_1_Ent1", "text": "Mitomycin C ( MMC )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8222875_1_Ent0", "text": "the hemolytic - uremic syndrome ( HUS )", "entity_type": "Entity", "start": 15, "end": 23}], "lang": "en"}
{"doc_id": "8222875_2", "wnd_id": "8222875_2_1", "text": "Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .", "tokens": ["Pulmonary", "hemorrhage", "as", "a", "clinical", "manifestation", "of", "hemolytic", "-", "uremic", "syndrome", "associated", "with", "mitomycin", "C", "therapy", "."], "event_mentions": [{"id": "8222875_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "8222875_2_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_2_Ent1", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 7, "end": 11}, {"entity_id": "8222875_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 13, "end": 15}, {"entity_id": "8222875_2_Ent2", "role": "Treatment", "text": "mitomycin C therapy", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "8222875_2_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_2_Ent1", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8222875_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8222875_2_Ent2", "text": "mitomycin C therapy", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "8222875_4", "wnd_id": "8222875_4_1", "text": "We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .", "tokens": ["We", "describe", "two", "women", "who", "developed", "HUS", "after", "MMC", "therapy", "and", "presented", "massive", "pulmonary", "bleeding", "."], "event_mentions": [{"id": "8222875_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8222875_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8222875_4_Ent0", "role": "Subject", "text": "two women", "start": 2, "end": 4}, {"entity_id": "8222875_4_Ent2", "role": "Subject_Gender", "text": "women", "start": 3, "end": 4}, {"entity_id": "8222875_4_Ent3", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "8222875_4_Ent5", "role": "Treatment", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent6", "role": "Treatment_Drug", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent4", "role": "Effect", "text": "massive pulmonary bleeding", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8222875_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8222875_4_Ent0", "text": "two women", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8222875_4_Ent2", "text": "women", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8222875_4_Ent3", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8222875_4_Ent5", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent6", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent4", "text": "massive pulmonary bleeding", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8276031_1", "wnd_id": "8276031_1_1", "text": "Imidazoline intoxication in children .", "tokens": ["Imidazoline", "intoxication", "in", "children", "."], "event_mentions": [{"id": "8276031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 1, "end": 2}, "arguments": [{"entity_id": "8276031_1_Ent3", "role": "Treatment", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_1_Ent4", "role": "Treatment_Drug", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_1_Ent2", "role": "Effect", "text": "Imidazoline intoxication", "start": 0, "end": 2}, {"entity_id": "8276031_1_Ent0", "role": "Subject", "text": "children", "start": 3, "end": 4}, {"entity_id": "8276031_1_Ent1", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8276031_1_Ent3", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_1_Ent4", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_1_Ent2", "text": "Imidazoline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8276031_1_Ent0", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8276031_1_Ent1", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8305778_3", "wnd_id": "8305778_3_1", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "history", "of", "congestive", "heart", "failure", "and", "coronary", "artery", "disease", "began", "taking", "amiodarone", "to", "suppress", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "8305778_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "suppress", "start": 22, "end": 23}, "arguments": [{"entity_id": "8305778_3_Ent0", "role": "Subject", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "start": 0, "end": 18}, {"entity_id": "8305778_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8305778_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8305778_3_Ent3", "role": "Subject_Disorder", "text": "congestive heart failure", "start": 11, "end": 14}, {"entity_id": "8305778_3_Ent4", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 15, "end": 18}, {"entity_id": "8305778_3_Ent5", "role": "Treatment", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent7", "role": "Treatment_Disorder", "text": "sustained ventricular tachycardia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "8305778_3_Ent0", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "8305778_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8305778_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8305778_3_Ent3", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8305778_3_Ent4", "text": "coronary artery disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8305778_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent7", "text": "sustained ventricular tachycardia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "8308951_4", "wnd_id": "8308951_4_1", "text": "Percutaneous absorption of warfarin causing coagulopathy , reported three times in the past , is a significant risk if protective measures , such as gloves , are not used .", "tokens": ["Percutaneous", "absorption", "of", "warfarin", "causing", "coagulopathy", ",", "reported", "three", "times", "in", "the", "past", ",", "is", "a", "significant", "risk", "if", "protective", "measures", ",", "such", "as", "gloves", ",", "are", "not", "used", "."], "event_mentions": [{"id": "8308951_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 4, "end": 5}, "arguments": [{"entity_id": "8308951_4_Ent3", "role": "Treatment_Route", "text": "Percutaneous absorption", "start": 0, "end": 2}, {"entity_id": "8308951_4_Ent1", "role": "Treatment", "text": "Percutaneous absorption of warfarin", "start": 0, "end": 4}, {"entity_id": "8308951_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "8308951_4_Ent0", "role": "Effect", "text": "coagulopathy", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8308951_4_Ent3", "text": "Percutaneous absorption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8308951_4_Ent1", "text": "Percutaneous absorption of warfarin", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8308951_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8308951_4_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8360712_2", "wnd_id": "8360712_2_1", "text": "Delayed neurotoxicity of intraventricular interleukin - 2 : a case report .", "tokens": ["Delayed", "neurotoxicity", "of", "intraventricular", "interleukin", "-", "2", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8360712_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "8360712_2_Ent1", "role": "Effect", "text": "Delayed neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8360712_2_Ent4", "role": "Treatment_Route", "text": "intraventricular", "start": 3, "end": 4}, {"entity_id": "8360712_2_Ent2", "role": "Treatment", "text": "intraventricular interleukin - 2", "start": 3, "end": 7}, {"entity_id": "8360712_2_Ent3", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 4, "end": 7}, {"entity_id": "8360712_2_Ent0", "role": "Subject", "text": "a case report", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8360712_2_Ent1", "text": "Delayed neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8360712_2_Ent4", "text": "intraventricular", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8360712_2_Ent2", "text": "intraventricular interleukin - 2", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8360712_2_Ent3", "text": "interleukin - 2", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8360712_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8363533_3", "wnd_id": "8363533_3_1", "text": "Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .", "tokens": ["Lithium", "-", "associated", "transient", "thyrotoxicosis", "in", "4", "Chinese", "women", "with", "autoimmune", "thyroiditis", "."], "event_mentions": [{"id": "8363533_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8363533_3_Ent6", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8363533_3_Ent7", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8363533_3_Ent5", "role": "Effect", "text": "transient thyrotoxicosis", "start": 3, "end": 5}, {"entity_id": "8363533_3_Ent1", "role": "Subject_Population", "text": "4", "start": 6, "end": 7}, {"entity_id": "8363533_3_Ent0", "role": "Subject", "text": "4 Chinese women with autoimmune thyroiditis", "start": 6, "end": 12}, {"entity_id": "8363533_3_Ent2", "role": "Subject_Race", "text": "Chinese", "start": 7, "end": 8}, {"entity_id": "8363533_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 8, "end": 9}, {"entity_id": "8363533_3_Ent4", "role": "Subject_Disorder", "text": "autoimmune thyroiditis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "8363533_3_Ent6", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8363533_3_Ent7", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8363533_3_Ent5", "text": "transient thyrotoxicosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8363533_3_Ent1", "text": "4", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8363533_3_Ent0", "text": "4 Chinese women with autoimmune thyroiditis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "8363533_3_Ent2", "text": "Chinese", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8363533_3_Ent3", "text": "women", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8363533_3_Ent4", "text": "autoimmune thyroiditis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "8391300_3", "wnd_id": "8391300_3_1", "text": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36 - year - old woman .", "tokens": ["In", "this", "case", "report", "we", "present", "a", "rare", "drug", "interaction", "between", "erythromycin", "and", "ergotamine", "at", "normal", "doses", "causing", "lower", "extremity", "ischemia", "in", "a", "36", "-", "year", "-", "old", "woman", "."], "event_mentions": [{"id": "8391300_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 17, "end": 18}, "arguments": [{"entity_id": "8391300_3_Ent4", "role": "Treatment", "text": "a rare drug interaction between erythromycin and ergotamine at normal doses", "start": 6, "end": 17}, {"entity_id": "8391300_3_Ent5", "role": "Treatment_Drug", "text": "erythromycin", "start": 11, "end": 12}, {"entity_id": "8391300_3_Ent8", "role": "Combination_Drug", "text": "erythromycin", "start": 11, "end": 12}, {"entity_id": "8391300_3_Ent6", "role": "Treatment_Drug", "text": "ergotamine", "start": 13, "end": 14}, {"entity_id": "8391300_3_Ent9", "role": "Combination_Drug", "text": "ergotamine", "start": 13, "end": 14}, {"entity_id": "8391300_3_Ent7", "role": "Treatment_Dosage", "text": "normal doses", "start": 15, "end": 17}, {"entity_id": "8391300_3_Ent3", "role": "Effect", "text": "lower extremity ischemia", "start": 18, "end": 21}, {"entity_id": "8391300_3_Ent0", "role": "Subject", "text": "a 36 - year - old woman", "start": 22, "end": 29}, {"entity_id": "8391300_3_Ent1", "role": "Subject_Age", "text": "36 - year - old", "start": 23, "end": 28}, {"entity_id": "8391300_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "8391300_3_Ent4", "text": "a rare drug interaction between erythromycin and ergotamine at normal doses", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "8391300_3_Ent5", "text": "erythromycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8391300_3_Ent8", "text": "erythromycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8391300_3_Ent6", "text": "ergotamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8391300_3_Ent9", "text": "ergotamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8391300_3_Ent7", "text": "normal doses", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8391300_3_Ent3", "text": "lower extremity ischemia", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8391300_3_Ent0", "text": "a 36 - year - old woman", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8391300_3_Ent1", "text": "36 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8391300_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "8396491_1", "wnd_id": "8396491_1_1", "text": "Interference with the cortisol axis by the microtubule antagonist , CPH82 .", "tokens": ["Interference", "with", "the", "cortisol", "axis", "by", "the", "microtubule", "antagonist", ",", "CPH82", "."], "event_mentions": [{"id": "8396491_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8396491_1_Ent0", "role": "Effect", "text": "Interference with the cortisol axis", "start": 0, "end": 5}, {"entity_id": "8396491_1_Ent1", "role": "Treatment", "text": "CPH82", "start": 10, "end": 11}, {"entity_id": "8396491_1_Ent2", "role": "Treatment_Drug", "text": "CPH82", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8396491_1_Ent0", "text": "Interference with the cortisol axis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8396491_1_Ent1", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8396491_1_Ent2", "text": "CPH82", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8404753_2", "wnd_id": "8404753_2_1", "text": "A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .", "tokens": ["A", "variety", "of", "movement", "disorders", "are", "known", "to", "occur", "in", "association", "with", "carbamazepine", "(", "CBZ", ")", "therapy", "in", "adults", "and", "children", ",", "but", "development", "of", "tics", "has", "been", "described", "infrequently", "and", "only", "in", "patients", "with", "underlying", "Tourette", "'s", "syndrome", "or", "other", "movement", "disorders", "."], "event_mentions": [{"id": "8404753_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 8, "end": 9}, "arguments": [{"entity_id": "8404753_2_Ent3", "role": "Effect", "text": "movement disorders", "start": 3, "end": 5}, {"entity_id": "8404753_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 12, "end": 13}, {"entity_id": "8404753_2_Ent4", "role": "Treatment", "text": "carbamazepine ( CBZ ) therapy", "start": 12, "end": 17}, {"entity_id": "8404753_2_Ent1", "role": "Subject_Age", "text": "adults", "start": 18, "end": 19}, {"entity_id": "8404753_2_Ent0", "role": "Subject", "text": "adults and children", "start": 18, "end": 21}, {"entity_id": "8404753_2_Ent2", "role": "Subject_Age", "text": "children", "start": 20, "end": 21}, {"entity_id": "8404753_2_Ent6", "role": "Treatment_Disorder", "text": "Tourette 's syndrome", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "8404753_2_Ent3", "text": "movement disorders", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8404753_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8404753_2_Ent4", "text": "carbamazepine ( CBZ ) therapy", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8404753_2_Ent1", "text": "adults", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8404753_2_Ent0", "text": "adults and children", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8404753_2_Ent2", "text": "children", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8404753_2_Ent6", "text": "Tourette 's syndrome", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "8430717_4", "wnd_id": "8430717_4_1", "text": "PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .", "tokens": ["PURPOSE", ":", "To", "investigate", "the", "concentration", "-", "side", "effect", "relationship", "in", "a", "patient", "with", "severe", "acyclovir", "-", "induced", "neurotoxicity", "and", "to", "summarize", "the", "information", "available", "in", "the", "literature", "about", "central", "nervous", "system", "side", "effects", "due", "to", "acyclovir", "."], "event_mentions": [{"id": "8430717_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "8430717_4_Ent2", "role": "Treatment", "text": "acyclovir", "start": 15, "end": 16}, {"entity_id": "8430717_4_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 15, "end": 16}, {"entity_id": "8430717_4_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 18, "end": 19}, {"entity_id": "8430717_4_Ent1", "role": "Effect", "text": "central nervous system side effects", "start": 29, "end": 34}]}], "entity_mentions": [{"id": "8430717_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8430717_4_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8430717_4_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8430717_4_Ent1", "text": "central nervous system side effects", "entity_type": "Entity", "start": 29, "end": 34}], "lang": "en"}
{"doc_id": "8452107_3", "wnd_id": "8452107_3_1", "text": "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .", "tokens": ["We", "describe", "a", "patient", "with", "transitional", "cell", "carcinoma", "of", "the", "renal", "pelvis", "who", "developed", "respiratory", "dysfunction", "and", "an", "abnormal", "chest", "x", "-", "ray", "with", "diffuse", "interstitial", "opacities", "while", "on", "chemotherapy", "with", "piritrexim", ",", "a", "methotrexate", "analog", "."], "event_mentions": [{"id": "8452107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "8452107_3_Ent0", "role": "Subject", "text": "a patient with transitional cell carcinoma of the renal pelvis", "start": 2, "end": 12}, {"entity_id": "8452107_3_Ent3", "role": "Treatment_Disorder", "text": "transitional cell carcinoma of the renal pelvis", "start": 5, "end": 12}, {"entity_id": "8452107_3_Ent1", "role": "Effect", "text": "respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities", "start": 14, "end": 27}, {"entity_id": "8452107_3_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 29, "end": 30}, {"entity_id": "8452107_3_Ent2", "role": "Treatment", "text": "chemotherapy with piritrexim , a methotrexate analog", "start": 29, "end": 36}, {"entity_id": "8452107_3_Ent4", "role": "Treatment_Drug", "text": "piritrexim", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "8452107_3_Ent0", "text": "a patient with transitional cell carcinoma of the renal pelvis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "8452107_3_Ent3", "text": "transitional cell carcinoma of the renal pelvis", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8452107_3_Ent1", "text": "respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities", "entity_type": "Entity", "start": 14, "end": 27}, {"id": "8452107_3_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "8452107_3_Ent2", "text": "chemotherapy with piritrexim , a methotrexate analog", "entity_type": "Entity", "start": 29, "end": 36}, {"id": "8452107_3_Ent4", "text": "piritrexim", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "8503421_2", "wnd_id": "8503421_2_1", "text": "Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .", "tokens": ["Cholesterol", "crystal", "embolization", "-", "associated", "renal", "failure", "after", "therapy", "with", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "."], "event_mentions": [{"id": "8503421_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8503421_2_Ent0", "role": "Effect", "text": "Cholesterol crystal embolization - associated renal failure", "start": 0, "end": 7}, {"entity_id": "8503421_2_Ent1", "role": "Treatment", "text": "therapy with recombinant tissue - type plasminogen activator", "start": 8, "end": 16}, {"entity_id": "8503421_2_Ent2", "role": "Treatment_Drug", "text": "plasminogen activator", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8503421_2_Ent0", "text": "Cholesterol crystal embolization - associated renal failure", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8503421_2_Ent1", "text": "therapy with recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "8503421_2_Ent2", "text": "plasminogen activator", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8520081_1", "wnd_id": "8520081_1_1", "text": "Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .", "tokens": ["Intravenous", "haloperidol", "is", "generally", "well", "tolerated", ",", "but", "multiform", "ventricular", "tachycardia", "has", "been", "reported", "."], "event_mentions": [{"id": "8520081_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 13, "end": 14}, "arguments": [{"entity_id": "8520081_1_Ent1", "role": "Treatment", "text": "Intravenous haloperidol", "start": 0, "end": 2}, {"entity_id": "8520081_1_Ent0", "role": "Effect", "text": "multiform ventricular tachycardia", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8520081_1_Ent1", "text": "Intravenous haloperidol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8520081_1_Ent0", "text": "multiform ventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8586895_1", "wnd_id": "8586895_1_1", "text": "However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .", "tokens": ["However", ",", "in", "1993", ",", "a", "clinical", "study", "involving", "400", "patients", "on", "the", "Thai", "-", "Burmese", "border", "revealed", "cardiac", "effects", "of", "antimalarial", "treatment", "with", "halofantrine", ",", "including", "one", "sudden", "death", "after", "the", "treatment", "."], "event_mentions": [{"id": "8586895_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effects", "start": 19, "end": 20}, "arguments": [{"entity_id": "8586895_1_Ent1", "role": "Subject_Population", "text": "400", "start": 9, "end": 10}, {"entity_id": "8586895_1_Ent0", "role": "Subject", "text": "400 patients on the Thai - Burmese border", "start": 9, "end": 17}, {"entity_id": "8586895_1_Ent2", "role": "Effect", "text": "cardiac effects", "start": 18, "end": 20}, {"entity_id": "8586895_1_Ent6", "role": "Treatment_Drug", "text": "antimalarial treatment", "start": 21, "end": 23}, {"entity_id": "8586895_1_Ent8", "role": "Combination_Drug", "text": "antimalarial treatment", "start": 21, "end": 23}, {"entity_id": "8586895_1_Ent4", "role": "Treatment", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent5", "role": "Treatment_Drug", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent7", "role": "Combination_Drug", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent3", "role": "Effect", "text": "sudden death", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8586895_1_Ent1", "text": "400", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8586895_1_Ent0", "text": "400 patients on the Thai - Burmese border", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "8586895_1_Ent2", "text": "cardiac effects", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8586895_1_Ent6", "text": "antimalarial treatment", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8586895_1_Ent8", "text": "antimalarial treatment", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8586895_1_Ent4", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent5", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent7", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8589490_2", "wnd_id": "8589490_2_1", "text": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents .", "tokens": ["Pigmentary", "aberrations", "are", "well", "known", "side", "effects", "of", "cytostatic", "chemotherapeutic", "agents", "."], "event_mentions": [{"id": "8589490_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "8589490_2_Ent0", "role": "Effect", "text": "Pigmentary aberrations", "start": 0, "end": 2}, {"entity_id": "8589490_2_Ent1", "role": "Treatment", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}, {"entity_id": "8589490_2_Ent2", "role": "Treatment_Drug", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8589490_2_Ent0", "text": "Pigmentary aberrations", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8589490_2_Ent1", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8589490_2_Ent2", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8597009_2", "wnd_id": "8597009_2_1", "text": "Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .", "tokens": ["Seventy", "-", "four", "per", "cent", "of", "patients", "with", "epileptogenic", "disorders", "seen", "at", "the", "Emergency", "Unit", "at", "Groote", "Schuur", "Hospital", "were", "on", "phenytoin", "and", "11.6", "%", "of", "these", "had", "blood", "levels", "in", "the", "toxic", "range", "."], "event_mentions": [{"id": "8597009_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 27, "end": 28}, "arguments": [{"entity_id": "8597009_2_Ent2", "role": "Subject_Population", "text": "Seventy - four per cent", "start": 0, "end": 5}, {"entity_id": "8597009_2_Ent0", "role": "Subject", "text": "Seventy - four per cent of patients with epileptogenic disorders", "start": 0, "end": 10}, {"entity_id": "8597009_2_Ent7", "role": "Treatment_Disorder", "text": "epileptogenic", "start": 8, "end": 9}, {"entity_id": "8597009_2_Ent5", "role": "Treatment", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent6", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "8597009_2_Ent3", "role": "Subject_Population", "text": "11.6 %", "start": 23, "end": 25}, {"entity_id": "8597009_2_Ent1", "role": "Subject", "text": "11.6 % of these", "start": 23, "end": 27}, {"entity_id": "8597009_2_Ent4", "role": "Effect", "text": "blood levels in the toxic range", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "8597009_2_Ent2", "text": "Seventy - four per cent", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8597009_2_Ent0", "text": "Seventy - four per cent of patients with epileptogenic disorders", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "8597009_2_Ent7", "text": "epileptogenic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent6", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8597009_2_Ent3", "text": "11.6 %", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "8597009_2_Ent1", "text": "11.6 % of these", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "8597009_2_Ent4", "text": "blood levels in the toxic range", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "8610807_1", "wnd_id": "8610807_1_1", "text": "Choroidal hemorrhage associated with systemic tissue plasminogen activator .", "tokens": ["Choroidal", "hemorrhage", "associated", "with", "systemic", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8610807_1_Ent0", "role": "Effect", "text": "Choroidal hemorrhage", "start": 0, "end": 2}, {"entity_id": "8610807_1_Ent1", "role": "Treatment", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}, {"entity_id": "8610807_1_Ent2", "role": "Treatment_Drug", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "8610807_1_Ent0", "text": "Choroidal hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8610807_1_Ent1", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8610807_1_Ent2", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "8627446_1", "wnd_id": "8627446_1_1", "text": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .", "tokens": ["Accelerated", "nodulosis", "during", "methotrexate", "therapy", "for", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8627446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "8627446_1_Ent0", "role": "Effect", "text": "Accelerated nodulosis", "start": 0, "end": 2}, {"entity_id": "8627446_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent3", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8627446_1_Ent0", "text": "Accelerated nodulosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8627446_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent3", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8627446_2", "wnd_id": "8627446_2_1", "text": "We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .", "tokens": ["We", "describe", "two", "patients", "with", "rheumatoid", "factor", "-", "positive", ",", "polyarticular", "-", "onset", "juvenile", "rheumatoid", "arthritis", "in", "whom", "accelerated", "nodulosis", "developed", "during", "methotrexate", "therapy", "."], "event_mentions": [{"id": "8627446_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8627446_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8627446_2_Ent0", "role": "Subject", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 2, "end": 16}, {"entity_id": "8627446_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 5, "end": 16}, {"entity_id": "8627446_2_Ent2", "role": "Effect", "text": "accelerated nodulosis", "start": 18, "end": 20}, {"entity_id": "8627446_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8627446_2_Ent3", "role": "Treatment", "text": "methotrexate therapy", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "8627446_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8627446_2_Ent0", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 16}, {"id": "8627446_2_Ent5", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "8627446_2_Ent2", "text": "accelerated nodulosis", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8627446_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8627446_2_Ent3", "text": "methotrexate therapy", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "8641617_2", "wnd_id": "8641617_2_1", "text": "Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .", "tokens": ["Based", "on", "our", "findings", ",", "it", "is", "thus", "concluded", "that", "cisplatin", "may", "cause", "C.", "difficile", "colitis", "."], "event_mentions": [{"id": "8641617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "8641617_2_Ent1", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "8641617_2_Ent0", "role": "Effect", "text": "C. difficile colitis", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "8641617_2_Ent1", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8641617_2_Ent0", "text": "C. difficile colitis", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "8645078_3", "wnd_id": "8645078_3_1", "text": "Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .", "tokens": ["Captopril", "is", "known", "to", "be", "associated", "with", "dermatologic", ",", "hematologic", ",", "and", "pulmonary", "adverse", "effects", "."], "event_mentions": [{"id": "8645078_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "8645078_3_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_3_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_3_Ent0", "role": "Effect", "text": "dermatologic , hematologic , and pulmonary adverse effects", "start": 7, "end": 15}]}], "entity_mentions": [{"id": "8645078_3_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_3_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_3_Ent0", "text": "dermatologic , hematologic , and pulmonary adverse effects", "entity_type": "Entity", "start": 7, "end": 15}], "lang": "en"}
{"doc_id": "8651254_2", "wnd_id": "8651254_2_1", "text": "It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .", "tokens": ["It", "should", "be", "emphasized", "that", "the", "recurrence", "of", "nephrotic", "syndrome", "was", "observed", "after", "the", "following", "chemotherapy", ",", "including", "M", "-", "CSF", ",", "whereas", "the", "bone", "marrow", "still", "remained", "completely", "remitted", "."], "event_mentions": [{"id": "8651254_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "8651254_2_Ent0", "role": "Effect", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "8651254_2_Ent2", "role": "Treatment", "text": "chemotherapy , including M - CSF", "start": 15, "end": 21}, {"entity_id": "8651254_2_Ent3", "role": "Treatment_Drug", "text": "M - CSF", "start": 18, "end": 21}, {"entity_id": "8651254_2_Ent1", "role": "Effect", "text": "the bone marrow still remained completely remitted", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "8651254_2_Ent0", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8651254_2_Ent2", "text": "chemotherapy , including M - CSF", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8651254_2_Ent3", "text": "M - CSF", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8651254_2_Ent1", "text": "the bone marrow still remained completely remitted", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "8651254_5", "wnd_id": "8651254_5_1", "text": "We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .", "tokens": ["We", "describe", "a", "patient", "with", "acute", "myeloblastic", "leukemia", "(", "AML", ")", "who", "developed", "nephrotic", "syndrome", "after", "receiving", "several", "courses", "of", "chemotherapy", ",", "including", "macrophage", "-", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "."], "event_mentions": [{"id": "8651254_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "8651254_5_Ent0", "role": "Subject", "text": "a patient with acute myeloblastic leukemia ( AML )", "start": 2, "end": 11}, {"entity_id": "8651254_5_Ent3", "role": "Treatment_Disorder", "text": "acute myeloblastic leukemia", "start": 5, "end": 8}, {"entity_id": "8651254_5_Ent1", "role": "Effect", "text": "nephrotic syndrome", "start": 13, "end": 15}, {"entity_id": "8651254_5_Ent2", "role": "Treatment", "text": "several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF )", "start": 17, "end": 34}, {"entity_id": "8651254_5_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 20, "end": 21}, {"entity_id": "8651254_5_Ent4", "role": "Treatment_Drug", "text": "macrophage - colony - stimulating factor", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "8651254_5_Ent0", "text": "a patient with acute myeloblastic leukemia ( AML )", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "8651254_5_Ent3", "text": "acute myeloblastic leukemia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8651254_5_Ent1", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8651254_5_Ent2", "text": "several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF )", "entity_type": "Entity", "start": 17, "end": 34}, {"id": "8651254_5_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8651254_5_Ent4", "text": "macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "8667442_1", "wnd_id": "8667442_1_1", "text": "Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .", "tokens": ["Milk", "-", "alkali", "syndrome", "induced", "by", "1,25(OH)2D", "in", "a", "patient", "with", "hypoparathyroidism", "."], "event_mentions": [{"id": "8667442_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "8667442_1_Ent1", "role": "Effect", "text": "Milk - alkali syndrome", "start": 0, "end": 4}, {"entity_id": "8667442_1_Ent2", "role": "Treatment", "text": "1,25(OH)2D", "start": 6, "end": 7}, {"entity_id": "8667442_1_Ent3", "role": "Treatment_Drug", "text": "1,25(OH)2D", "start": 6, "end": 7}, {"entity_id": "8667442_1_Ent0", "role": "Subject", "text": "a patient with hypoparathyroidism .", "start": 8, "end": 13}, {"entity_id": "8667442_1_Ent4", "role": "Treatment_Disorder", "text": "hypoparathyroidism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8667442_1_Ent1", "text": "Milk - alkali syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8667442_1_Ent2", "text": "1,25(OH)2D", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8667442_1_Ent3", "text": "1,25(OH)2D", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8667442_1_Ent0", "text": "a patient with hypoparathyroidism .", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8667442_1_Ent4", "text": "hypoparathyroidism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8672829_5", "wnd_id": "8672829_5_1", "text": "OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "patient", "with", "ifosfamide", "-", "induced", "nonconvulsive", "status", "epilepticus", "."], "event_mentions": [{"id": "8672829_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_5_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "8672829_5_Ent2", "role": "Treatment", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "8672829_5_Ent3", "role": "Treatment_Drug", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "8672829_5_Ent1", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "8672829_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8672829_5_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_5_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8672829_5_Ent1", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "8672829_6", "wnd_id": "8672829_6_1", "text": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .", "tokens": ["This", "represents", "the", "first", "report", "of", "nonconvulsive", "status", "epilepticus", "induced", "by", "ifosfamide", "."], "event_mentions": [{"id": "8672829_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_6_Ent0", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 6, "end": 9}, {"entity_id": "8672829_6_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "8672829_6_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8672829_6_Ent0", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8672829_6_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8672829_6_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8691927_2", "wnd_id": "8691927_2_1", "text": "FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .", "tokens": ["FINDINGS", ":", "Six", "children", "with", "growth", "retardation", "noted", "after", "treatment", "with", "high", "-", "dose", "fluticasone", "propionate", "were", "found", "to", "have", "adrenal", "suppression", "."], "event_mentions": [{"id": "8691927_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 19, "end": 20}, "arguments": [{"entity_id": "8691927_2_Ent1", "role": "Subject_Population", "text": "Six", "start": 2, "end": 3}, {"entity_id": "8691927_2_Ent0", "role": "Subject", "text": "Six children with growth retardation", "start": 2, "end": 7}, {"entity_id": "8691927_2_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "8691927_2_Ent7", "role": "Treatment_Disorder", "text": "growth retardation", "start": 5, "end": 7}, {"entity_id": "8691927_2_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "8691927_2_Ent4", "role": "Treatment", "text": "high - dose fluticasone propionate", "start": 11, "end": 16}, {"entity_id": "8691927_2_Ent6", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 14, "end": 16}, {"entity_id": "8691927_2_Ent3", "role": "Effect", "text": "adrenal suppression", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "8691927_2_Ent1", "text": "Six", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8691927_2_Ent0", "text": "Six children with growth retardation", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8691927_2_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8691927_2_Ent7", "text": "growth retardation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8691927_2_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8691927_2_Ent4", "text": "high - dose fluticasone propionate", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "8691927_2_Ent6", "text": "fluticasone propionate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8691927_2_Ent3", "text": "adrenal suppression", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "8726608_1", "wnd_id": "8726608_1_1", "text": "Does acyclovir increase serum lithium levels ?", "tokens": ["Does", "acyclovir", "increase", "serum", "lithium", "levels", "?"], "event_mentions": [{"id": "8726608_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 2, "end": 3}, "arguments": [{"entity_id": "8726608_1_Ent1", "role": "Treatment", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent5", "role": "Combination_Drug", "text": "acyclovir", "start": 1, "end": 2}, {"entity_id": "8726608_1_Ent0", "role": "Effect", "text": "serum lithium levels", "start": 3, "end": 6}, {"entity_id": "8726608_1_Ent2", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "8726608_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "8726608_1_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8726608_1_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8726608_1_Ent0", "text": "serum lithium levels", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8726608_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8742573_1", "wnd_id": "8742573_1_1", "text": "CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .", "tokens": ["CASE", ":", "We", "report", "a", "case", "of", "a", "woman", "with", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "who", "has", "been", "treated", "exclusively", "with", "recombinant", "DNA", "human", "insulin", "since", "the", "onset", "of", "IDDM", "."], "event_mentions": [{"id": "8742573_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "8742573_1_Ent0", "role": "Subject", "text": "woman", "start": 8, "end": 9}, {"entity_id": "8742573_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "8742573_1_Ent2", "role": "Effect", "text": "severe human insulin - induced lipoatrophy", "start": 10, "end": 16}, {"entity_id": "8742573_1_Ent3", "role": "Treatment", "text": "recombinant DNA human insulin", "start": 22, "end": 26}, {"entity_id": "8742573_1_Ent4", "role": "Treatment_Drug", "text": "recombinant DNA human insulin", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "8742573_1_Ent0", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8742573_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8742573_1_Ent2", "text": "severe human insulin - induced lipoatrophy", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "8742573_1_Ent3", "text": "recombinant DNA human insulin", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "8742573_1_Ent4", "text": "recombinant DNA human insulin", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "8749646_1", "wnd_id": "8749646_1_1", "text": "Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .", "tokens": ["Improved", "awareness", "of", "and", "further", "investigation", "into", "the", "neurotoxic", "effects", "of", "ofloxacin", "may", "enhance", "its", "safe", "use", "."], "event_mentions": [{"id": "8749646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 10, "end": 11}, "arguments": [{"entity_id": "8749646_1_Ent0", "role": "Effect", "text": "neurotoxic effects", "start": 8, "end": 10}, {"entity_id": "8749646_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 11, "end": 12}, {"entity_id": "8749646_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8749646_1_Ent0", "text": "neurotoxic effects", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8749646_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8749646_3", "wnd_id": "8749646_3_1", "text": "The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .", "tokens": ["The", "renal", "insufficiency", "of", "three", "patients", "and", "the", "timing", "of", "the", "seizures", "implicate", "accumulation", "of", "ofloxacin", "as", "a", "contributing", "factor", "."], "event_mentions": [{"id": "8749646_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicate", "start": 12, "end": 13}, "arguments": [{"entity_id": "8749646_3_Ent2", "role": "Effect", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "8749646_3_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8749646_3_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8749646_3_Ent3", "role": "Effect", "text": "seizures", "start": 11, "end": 12}, {"entity_id": "8749646_3_Ent4", "role": "Treatment", "text": "accumulation of ofloxacin", "start": 13, "end": 16}, {"entity_id": "8749646_3_Ent5", "role": "Treatment_Drug", "text": "ofloxacin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8749646_3_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8749646_3_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8749646_3_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8749646_3_Ent3", "text": "seizures", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_3_Ent4", "text": "accumulation of ofloxacin", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8749646_3_Ent5", "text": "ofloxacin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "876914_1", "wnd_id": "876914_1_1", "text": "A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .", "tokens": ["A", "patient", "is", "described", "who", "developed", "a", "poorly", "differentiated", "sarcoma", "after", "cyclophosphamide", "was", "used", "to", "treat", "his", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "876914_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "876914_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "876914_1_Ent3", "role": "Effect", "text": "poorly differentiated sarcoma", "start": 7, "end": 10}, {"entity_id": "876914_1_Ent4", "role": "Treatment", "text": "cyclophosphamide", "start": 11, "end": 12}, {"entity_id": "876914_1_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 11, "end": 12}, {"entity_id": "876914_1_Ent2", "role": "Subject_Gender", "text": "his", "start": 16, "end": 17}, {"entity_id": "876914_1_Ent1", "role": "Subject", "text": "his rheumatoid arthritis", "start": 16, "end": 19}, {"entity_id": "876914_1_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "876914_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "876914_1_Ent3", "text": "poorly differentiated sarcoma", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "876914_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "876914_1_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "876914_1_Ent2", "text": "his", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "876914_1_Ent1", "text": "his rheumatoid arthritis", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "876914_1_Ent6", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "879939_2", "wnd_id": "879939_2_1", "text": "Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .", "tokens": ["Severe", "osteomalacia", "was", "present", "in", "two", "epileptic", "patients", "who", "were", "under", "long", "-", "term", "treatment", "with", "congeners", "of", "phenytoin", ",", "phenobarbital", ",", "and", "acetazolamide", "."], "event_mentions": [{"id": "879939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_2_Ent2", "role": "Effect", "text": "osteomalacia", "start": 1, "end": 2}, {"entity_id": "879939_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "879939_2_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 5, "end": 8}, {"entity_id": "879939_2_Ent4", "role": "Treatment_Disorder", "text": "epileptic", "start": 6, "end": 7}, {"entity_id": "879939_2_Ent3", "role": "Treatment", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "start": 11, "end": 24}, {"entity_id": "879939_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent9", "role": "Combination_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent7", "role": "Treatment_Drug", "text": "acetazolamide", "start": 23, "end": 24}, {"entity_id": "879939_2_Ent10", "role": "Combination_Drug", "text": "acetazolamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "879939_2_Ent2", "text": "osteomalacia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "879939_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "879939_2_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "879939_2_Ent4", "text": "epileptic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "879939_2_Ent3", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "879939_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent9", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent7", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "879939_2_Ent10", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "8832451_2", "wnd_id": "8832451_2_1", "text": "The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate ( MgSO4 ) administration is well known .", "tokens": ["The", "occurrence", "of", "neuromuscular", "blockade", "and", "the", "resulting", "potentiation", "of", "muscle", "relaxants", "during", "magnesium", "sulfate", "(", "MgSO4", ")", "administration", "is", "well", "known", "."], "event_mentions": [{"id": "8832451_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "8832451_2_Ent0", "role": "Effect", "text": "neuromuscular blockade", "start": 3, "end": 5}, {"entity_id": "8832451_2_Ent1", "role": "Effect", "text": "potentiation of muscle relaxants", "start": 8, "end": 12}, {"entity_id": "8832451_2_Ent2", "role": "Treatment", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8832451_2_Ent3", "role": "Treatment_Drug", "text": "magnesium sulfate ( MgSO4 )", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "8832451_2_Ent0", "text": "neuromuscular blockade", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8832451_2_Ent1", "text": "potentiation of muscle relaxants", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "8832451_2_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8832451_2_Ent3", "text": "magnesium sulfate ( MgSO4 )", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "8903300_2", "wnd_id": "8903300_2_1", "text": "Tetany in a child with AIDS receiving intravenous tobramycin .", "tokens": ["Tetany", "in", "a", "child", "with", "AIDS", "receiving", "intravenous", "tobramycin", "."], "event_mentions": [{"id": "8903300_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8903300_2_Ent3", "role": "Effect", "text": "Tetany", "start": 0, "end": 1}, {"entity_id": "8903300_2_Ent0", "role": "Subject", "text": "a child with AIDS", "start": 2, "end": 6}, {"entity_id": "8903300_2_Ent1", "role": "Subject_Age", "text": "child", "start": 3, "end": 4}, {"entity_id": "8903300_2_Ent2", "role": "Subject_Disorder", "text": "AIDS", "start": 5, "end": 6}, {"entity_id": "8903300_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8903300_2_Ent4", "role": "Treatment", "text": "intravenous tobramycin", "start": 7, "end": 9}, {"entity_id": "8903300_2_Ent5", "role": "Treatment_Drug", "text": "tobramycin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8903300_2_Ent3", "text": "Tetany", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8903300_2_Ent0", "text": "a child with AIDS", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8903300_2_Ent1", "text": "child", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8903300_2_Ent2", "text": "AIDS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8903300_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8903300_2_Ent4", "text": "intravenous tobramycin", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8903300_2_Ent5", "text": "tobramycin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8903300_3", "wnd_id": "8903300_3_1", "text": "This pattern is suggestive of renal toxicity due to tobramycin .", "tokens": ["This", "pattern", "is", "suggestive", "of", "renal", "toxicity", "due", "to", "tobramycin", "."], "event_mentions": [{"id": "8903300_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 7, "end": 9}, "arguments": [{"entity_id": "8903300_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 5, "end": 7}, {"entity_id": "8903300_3_Ent1", "role": "Treatment", "text": "tobramycin", "start": 9, "end": 10}, {"entity_id": "8903300_3_Ent2", "role": "Treatment_Drug", "text": "tobramycin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8903300_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8903300_3_Ent1", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8903300_3_Ent2", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8949576_1", "wnd_id": "8949576_1_1", "text": "A potential role for renal and hepatic impairment in the observed protracted course of amiodarone - induced thyrotoxicosis is suggested .", "tokens": ["A", "potential", "role", "for", "renal", "and", "hepatic", "impairment", "in", "the", "observed", "protracted", "course", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "is", "suggested", "."], "event_mentions": [{"id": "8949576_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "8949576_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8949576_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "897744_1", "wnd_id": "897744_1_1", "text": "Focal glomerulonephritis and interstitial nephritis in methicillin - treated , heroin - related infective endocarditis .", "tokens": ["Focal", "glomerulonephritis", "and", "interstitial", "nephritis", "in", "methicillin", "-", "treated", ",", "heroin", "-", "related", "infective", "endocarditis", "."], "event_mentions": [{"id": "897744_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "897744_1_Ent3", "role": "Effect", "text": "Focal glomerulonephritis and interstitial nephritis", "start": 0, "end": 5}, {"entity_id": "897744_1_Ent4", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent6", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent5", "role": "Treatment_Disorder", "text": "heroin - related infective endocarditis", "start": 10, "end": 15}]}, {"id": "897744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "897744_1_Ent1", "role": "Treatment", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent0", "role": "Effect", "text": "infective endocarditis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "897744_1_Ent3", "text": "Focal glomerulonephritis and interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "897744_1_Ent4", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent6", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent1", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent2", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent5", "text": "heroin - related infective endocarditis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "897744_1_Ent0", "text": "infective endocarditis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "8996514_2", "wnd_id": "8996514_2_1", "text": "Large cerebral infarction during praziquantel therapy in neurocysticercosis .", "tokens": ["Large", "cerebral", "infarction", "during", "praziquantel", "therapy", "in", "neurocysticercosis", "."], "event_mentions": [{"id": "8996514_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "8996514_2_Ent0", "role": "Effect", "text": "Large cerebral infarction", "start": 0, "end": 3}, {"entity_id": "8996514_2_Ent1", "role": "Treatment", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent2", "role": "Treatment_Drug", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent3", "role": "Treatment_Disorder", "text": "neurocysticercosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "8996514_2_Ent0", "text": "Large cerebral infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8996514_2_Ent1", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent2", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent3", "text": "neurocysticercosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9007910_8", "wnd_id": "9007910_8_1", "text": "IMPLICATIONS FOR NURSING PRACTICE : Nurses must understand the pharmacology , mechanism of action , clinical presentation , potentially lethal risks , and traumatic psychosocial stresses experienced by DPD - deficient patients with cancer receiving 5 - FU therapy in order to develop timely interventions and alternative plans of care .", "tokens": ["IMPLICATIONS", "FOR", "NURSING", "PRACTICE", ":", "Nurses", "must", "understand", "the", "pharmacology", ",", "mechanism", "of", "action", ",", "clinical", "presentation", ",", "potentially", "lethal", "risks", ",", "and", "traumatic", "psychosocial", "stresses", "experienced", "by", "DPD", "-", "deficient", "patients", "with", "cancer", "receiving", "5", "-", "FU", "therapy", "in", "order", "to", "develop", "timely", "interventions", "and", "alternative", "plans", "of", "care", "."], "event_mentions": [{"id": "9007910_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 34, "end": 35}, "arguments": [{"entity_id": "9007910_8_Ent1", "role": "Subject_Disorder", "text": "DPD - deficient", "start": 28, "end": 31}, {"entity_id": "9007910_8_Ent0", "role": "Subject", "text": "DPD - deficient patients with cancer", "start": 28, "end": 34}, {"entity_id": "9007910_8_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 33, "end": 34}, {"entity_id": "9007910_8_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 35, "end": 38}, {"entity_id": "9007910_8_Ent2", "role": "Treatment", "text": "5 - FU therapy", "start": 35, "end": 39}]}], "entity_mentions": [{"id": "9007910_8_Ent1", "text": "DPD - deficient", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "9007910_8_Ent0", "text": "DPD - deficient patients with cancer", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "9007910_8_Ent4", "text": "cancer", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "9007910_8_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "9007910_8_Ent2", "text": "5 - FU therapy", "entity_type": "Entity", "start": 35, "end": 39}], "lang": "en"}
{"doc_id": "9013348_1", "wnd_id": "9013348_1_1", "text": "A 49 - year - old man with Crohn 's disease treated with prednisone and mesalamine ( 5 - ASA ) developed worsening respiratory distress and fever .", "tokens": ["A", "49", "-", "year", "-", "old", "man", "with", "Crohn", "'s", "disease", "treated", "with", "prednisone", "and", "mesalamine", "(", "5", "-", "ASA", ")", "developed", "worsening", "respiratory", "distress", "and", "fever", "."], "event_mentions": [{"id": "9013348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "9013348_1_Ent1", "role": "Subject_Age", "text": "49 - year - old", "start": 1, "end": 6}, {"entity_id": "9013348_1_Ent0", "role": "Subject", "text": "49 - year - old man with Crohn 's disease", "start": 1, "end": 11}, {"entity_id": "9013348_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "9013348_1_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}, {"entity_id": "9013348_1_Ent7", "role": "Treatment_Drug", "text": "prednisone", "start": 13, "end": 14}, {"entity_id": "9013348_1_Ent8", "role": "Combination_Drug", "text": "prednisone", "start": 13, "end": 14}, {"entity_id": "9013348_1_Ent4", "role": "Treatment", "text": "prednisone and mesalamine ( 5 - ASA )", "start": 13, "end": 21}, {"entity_id": "9013348_1_Ent6", "role": "Treatment_Drug", "text": "mesalamine", "start": 15, "end": 16}, {"entity_id": "9013348_1_Ent9", "role": "Combination_Drug", "text": "mesalamine", "start": 15, "end": 16}, {"entity_id": "9013348_1_Ent3", "role": "Effect", "text": "worsening respiratory distress and fever .", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "9013348_1_Ent1", "text": "49 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9013348_1_Ent0", "text": "49 - year - old man with Crohn 's disease", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "9013348_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9013348_1_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9013348_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9013348_1_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9013348_1_Ent4", "text": "prednisone and mesalamine ( 5 - ASA )", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "9013348_1_Ent6", "text": "mesalamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9013348_1_Ent9", "text": "mesalamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9013348_1_Ent3", "text": "worsening respiratory distress and fever .", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "9013348_2", "wnd_id": "9013348_2_1", "text": "Mesalamine - induced hypersensitivity pneumonitis .", "tokens": ["Mesalamine", "-", "induced", "hypersensitivity", "pneumonitis", "."], "event_mentions": [{"id": "9013348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9013348_2_Ent1", "role": "Treatment", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_2_Ent2", "role": "Treatment_Drug", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_2_Ent0", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9013348_2_Ent1", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_2_Ent2", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_2_Ent0", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9022114_1", "wnd_id": "9022114_1_1", "text": "BACKGROUND : Colchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation .", "tokens": ["BACKGROUND", ":", "Colchicine", "has", "a", "known", "adverse", "effect", "on", "wound", "healing", "through", "its", "inhibitory", "effect", "on", "tubulin", "-", "dependent", "cell", "functions", "and", "through", "collagenase", "activation", "."], "event_mentions": [{"id": "9022114_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 6, "end": 8}, "arguments": [{"entity_id": "9022114_1_Ent1", "role": "Treatment", "text": "Colchicine", "start": 2, "end": 3}, {"entity_id": "9022114_1_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 2, "end": 3}, {"entity_id": "9022114_1_Ent0", "role": "Effect", "text": "wound healing", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9022114_1_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9022114_1_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9022114_1_Ent0", "text": "wound healing", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9052919_3", "wnd_id": "9052919_3_1", "text": "We postulate that cyclosporin , possibly together with ganciclovir , can produce transient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients .", "tokens": ["We", "postulate", "that", "cyclosporin", ",", "possibly", "together", "with", "ganciclovir", ",", "can", "produce", "transient", "brain", "stem", "or", "neuromuscular", "dysfunction", "with", "eye", "movement", "abnormality", "in", "occasional", "patients", "."], "event_mentions": [{"id": "9052919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9052919_3_Ent2", "role": "Treatment", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent6", "role": "Combination_Drug", "text": "cyclosporin", "start": 3, "end": 4}, {"entity_id": "9052919_3_Ent3", "role": "Treatment", "text": "together with ganciclovir", "start": 6, "end": 9}, {"entity_id": "9052919_3_Ent4", "role": "Treatment_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent7", "role": "Combination_Drug", "text": "ganciclovir", "start": 8, "end": 9}, {"entity_id": "9052919_3_Ent1", "role": "Effect", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "start": 12, "end": 22}, {"entity_id": "9052919_3_Ent0", "role": "Subject", "text": "occasional patients", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9052919_3_Ent2", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent5", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent6", "text": "cyclosporin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9052919_3_Ent3", "text": "together with ganciclovir", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "9052919_3_Ent4", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent7", "text": "ganciclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_3_Ent1", "text": "transient brain stem or neuromuscular dysfunction with eye movement abnormality", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9052919_3_Ent0", "text": "occasional patients", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9103523_2", "wnd_id": "9103523_2_1", "text": "The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity .", "tokens": ["The", "volatile", "anesthetic", "halothane", "undergoes", "substantial", "biotransformation", "generating", "metabolites", "that", "mediate", "hepatotoxicity", "."], "event_mentions": [{"id": "9103523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mediate", "start": 10, "end": 11}, "arguments": [{"entity_id": "9103523_2_Ent3", "role": "Treatment_Route", "text": "volatile", "start": 1, "end": 2}, {"entity_id": "9103523_2_Ent1", "role": "Treatment", "text": "volatile anesthetic halothane", "start": 1, "end": 4}, {"entity_id": "9103523_2_Ent2", "role": "Treatment_Drug", "text": "halothane", "start": 3, "end": 4}, {"entity_id": "9103523_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9103523_2_Ent3", "text": "volatile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9103523_2_Ent1", "text": "volatile anesthetic halothane", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9103523_2_Ent2", "text": "halothane", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9103523_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9149614_1", "wnd_id": "9149614_1_1", "text": "Eleven days after initiation of therapy with amiodarone , the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia .", "tokens": ["Eleven", "days", "after", "initiation", "of", "therapy", "with", "amiodarone", ",", "the", "patient", "experienced", "syncope", "and", "was", "noted", "to", "have", "recurrent", "episodes", "of", "polymorphous", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "9149614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 11, "end": 12}, "arguments": [{"entity_id": "9149614_1_Ent3", "role": "Treatment_Time_elapsed", "text": "Eleven days after", "start": 0, "end": 3}, {"entity_id": "9149614_1_Ent2", "role": "Treatment", "text": "Eleven days after initiation of therapy with amiodarone", "start": 0, "end": 8}, {"entity_id": "9149614_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "9149614_1_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "9149614_1_Ent1", "role": "Effect", "text": "syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia", "start": 12, "end": 24}]}], "entity_mentions": [{"id": "9149614_1_Ent3", "text": "Eleven days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9149614_1_Ent2", "text": "Eleven days after initiation of therapy with amiodarone", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "9149614_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9149614_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9149614_1_Ent1", "text": "syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia", "entity_type": "Entity", "start": 12, "end": 24}], "lang": "en"}
{"doc_id": "9169264_3", "wnd_id": "9169264_3_1", "text": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed .", "tokens": ["The", "case", "of", "a", "patient", "with", "infectious", "mononucleosis", "treated", "with", "cephalexin", "who", "later", "showed", "a", "rash", "is", "presented", "and", "the", "previous", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "9169264_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 13, "end": 14}, "arguments": [{"entity_id": "9169264_3_Ent0", "role": "Subject", "text": "a patient with infectious mononucleosis", "start": 3, "end": 8}, {"entity_id": "9169264_3_Ent4", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 6, "end": 8}, {"entity_id": "9169264_3_Ent2", "role": "Treatment", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent3", "role": "Treatment_Drug", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent1", "role": "Effect", "text": "rash", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9169264_3_Ent0", "text": "a patient with infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9169264_3_Ent4", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9169264_3_Ent2", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent3", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent1", "text": "rash", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9184269_2", "wnd_id": "9184269_2_1", "text": "Methotrexate - induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis : report of five cases and review of the literature .", "tokens": ["Methotrexate", "-", "induced", "pneumonitis", "in", "patients", "with", "rheumatoid", "arthritis", "and", "psoriatic", "arthritis", ":", "report", "of", "five", "cases", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "9184269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9184269_2_Ent2", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9184269_2_Ent5", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9184269_2_Ent1", "role": "Effect", "text": "pneumonitis", "start": 3, "end": 4}, {"entity_id": "9184269_2_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis and psoriatic arthritis", "start": 5, "end": 12}, {"entity_id": "9184269_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "9184269_2_Ent4", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "9184269_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9184269_2_Ent5", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9184269_2_Ent1", "text": "pneumonitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9184269_2_Ent0", "text": "patients with rheumatoid arthritis and psoriatic arthritis", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9184269_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9184269_2_Ent4", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "9205466_1", "wnd_id": "9205466_1_1", "text": "Although its side effects are few , tamoxifen increases the incidence of proliferative lesions of the endometrium , which theoretically should be preventable with progestational agents .", "tokens": ["Although", "its", "side", "effects", "are", "few", ",", "tamoxifen", "increases", "the", "incidence", "of", "proliferative", "lesions", "of", "the", "endometrium", ",", "which", "theoretically", "should", "be", "preventable", "with", "progestational", "agents", "."], "event_mentions": [{"id": "9205466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increases", "start": 8, "end": 9}, "arguments": [{"entity_id": "9205466_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "9205466_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "9205466_1_Ent0", "role": "Effect", "text": "incidence of proliferative lesions of the endometrium", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "9205466_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9205466_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9205466_1_Ent0", "text": "incidence of proliferative lesions of the endometrium", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "9211543_1", "wnd_id": "9211543_1_1", "text": "Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer .", "tokens": ["Bleomycin", "and", "cyclophosphamide", "toxicity", "simulating", "metastatic", "nodules", "to", "the", "lungs", "in", "childhood", "cancer", "."], "event_mentions": [{"id": "9211543_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "simulating", "start": 4, "end": 5}, "arguments": [{"entity_id": "9211543_1_Ent5", "role": "Treatment_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent8", "role": "Combination_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent3", "role": "Treatment", "text": "Bleomycin and cyclophosphamide toxicity", "start": 0, "end": 4}, {"entity_id": "9211543_1_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent7", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent2", "role": "Effect", "text": "metastatic nodules to the lungs", "start": 5, "end": 10}, {"entity_id": "9211543_1_Ent1", "role": "Subject_Age", "text": "childhood", "start": 11, "end": 12}, {"entity_id": "9211543_1_Ent0", "role": "Subject", "text": "childhood cancer", "start": 11, "end": 13}, {"entity_id": "9211543_1_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9211543_1_Ent5", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent8", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent3", "text": "Bleomycin and cyclophosphamide toxicity", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9211543_1_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent2", "text": "metastatic nodules to the lungs", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9211543_1_Ent1", "text": "childhood", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9211543_1_Ent0", "text": "childhood cancer", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9211543_1_Ent4", "text": "cancer", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "921427_2", "wnd_id": "921427_2_1", "text": "Circulating anticoagulant in the procainamide - induced lupus syndrome .", "tokens": ["Circulating", "anticoagulant", "in", "the", "procainamide", "-", "induced", "lupus", "syndrome", "."], "event_mentions": [{"id": "921427_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "921427_2_Ent1", "role": "Treatment", "text": "procainamide", "start": 4, "end": 5}, {"entity_id": "921427_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 4, "end": 5}, {"entity_id": "921427_2_Ent0", "role": "Effect", "text": "lupus syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "921427_2_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "921427_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "921427_2_Ent0", "text": "lupus syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9220046_3", "wnd_id": "9220046_3_1", "text": "DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis , including lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor .", "tokens": ["DISCUSSION", ":", "Rhabdomyolysis", "is", "a", "clinical", "syndrome", "resulting", "from", "the", "destruction", "of", "skeletal", "muscle", "that", "may", "progress", "to", "renal", "failure", "Several", "drugs", "have", "been", "associated", "with", "rhabdomyolysis", ",", "including", "lovastatin", ",", "a", "hydroxymethylglutaryl", "-", "coenzyme", "A", "reductase", "inhibitor", "."], "event_mentions": [{"id": "9220046_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 24, "end": 25}, "arguments": [{"entity_id": "9220046_3_Ent0", "role": "Effect", "text": "Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure", "start": 2, "end": 20}, {"entity_id": "9220046_3_Ent2", "role": "Treatment_Drug", "text": "lovastatin", "start": 29, "end": 30}, {"entity_id": "9220046_3_Ent1", "role": "Treatment", "text": "lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor", "start": 29, "end": 38}]}], "entity_mentions": [{"id": "9220046_3_Ent0", "text": "Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure", "entity_type": "Entity", "start": 2, "end": 20}, {"id": "9220046_3_Ent2", "text": "lovastatin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "9220046_3_Ent1", "text": "lovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor", "entity_type": "Entity", "start": 29, "end": 38}], "lang": "en"}
{"doc_id": "9220046_6", "wnd_id": "9220046_6_1", "text": "OBJECTIVE : To describe two cases of rhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin .", "tokens": ["OBJECTIVE", ":", "To", "describe", "two", "cases", "of", "rhabdomyolysis", "in", "patients", "taking", "lovastatin", "that", "were", "precipitated", "by", "the", "use", "of", "the", "newer", "macrolide", "antibiotics", "clarithromycin", "and", "azithromycin", "."], "event_mentions": [{"id": "9220046_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "9220046_6_Ent2", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9220046_6_Ent0", "role": "Subject", "text": "two cases", "start": 4, "end": 6}, {"entity_id": "9220046_6_Ent3", "role": "Effect", "text": "rhabdomyolysis", "start": 7, "end": 8}, {"entity_id": "9220046_6_Ent1", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "9220046_6_Ent5", "role": "Treatment_Drug", "text": "lovastatin", "start": 11, "end": 12}, {"entity_id": "9220046_6_Ent4", "role": "Treatment", "text": "lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin", "start": 11, "end": 26}, {"entity_id": "9220046_6_Ent6", "role": "Treatment_Drug", "text": "clarithromycin", "start": 23, "end": 24}, {"entity_id": "9220046_6_Ent8", "role": "Combination_Drug", "text": "clarithromycin", "start": 23, "end": 24}, {"entity_id": "9220046_6_Ent7", "role": "Treatment_Drug", "text": "azithromycin", "start": 25, "end": 26}, {"entity_id": "9220046_6_Ent9", "role": "Combination_Drug", "text": "azithromycin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9220046_6_Ent2", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9220046_6_Ent0", "text": "two cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9220046_6_Ent3", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9220046_6_Ent1", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9220046_6_Ent5", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9220046_6_Ent4", "text": "lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "9220046_6_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9220046_6_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9220046_6_Ent7", "text": "azithromycin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9220046_6_Ent9", "text": "azithromycin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9224230_1", "wnd_id": "9224230_1_1", "text": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients died of PCP occurring during the first month of treatment with prednisone .", "tokens": ["These", "cases", "were", "considered", "unusual", "in", "light", "of", "the", "short", "delay", "of", "their", "onset", "after", "initiation", "of", "immunosuppressive", "therapy", "and", "their", "fulminant", "course", ":", "3", "of", "these", "patients", "died", "of", "PCP", "occurring", "during", "the", "first", "month", "of", "treatment", "with", "prednisone", "."], "event_mentions": [{"id": "9224230_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 28, "end": 29}, "arguments": [{"entity_id": "9224230_1_Ent1", "role": "Subject_Population", "text": "3", "start": 24, "end": 25}, {"entity_id": "9224230_1_Ent0", "role": "Subject", "text": "3 of these patients", "start": 24, "end": 28}, {"entity_id": "9224230_1_Ent2", "role": "Effect", "text": "PCP", "start": 30, "end": 31}, {"entity_id": "9224230_1_Ent4", "role": "Treatment_Duration", "text": "first month", "start": 34, "end": 36}, {"entity_id": "9224230_1_Ent3", "role": "Treatment", "text": "first month of treatment with prednisone", "start": 34, "end": 40}, {"entity_id": "9224230_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "9224230_1_Ent1", "text": "3", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9224230_1_Ent0", "text": "3 of these patients", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "9224230_1_Ent2", "text": "PCP", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "9224230_1_Ent4", "text": "first month", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "9224230_1_Ent3", "text": "first month of treatment with prednisone", "entity_type": "Entity", "start": 34, "end": 40}, {"id": "9224230_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "9253492_4", "wnd_id": "9253492_4_1", "text": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration .", "tokens": ["The", "oligohidrosis", "caused", "by", "zonisamide", "was", "reversible", "in", "that", "the", "patient", "regained", "the", "ability", "to", "sweat", "within", "2", "weeks", "of", "the", "cessation", "of", "drug", "administration", "."], "event_mentions": [{"id": "9253492_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "of the", "start": 19, "end": 21}, "arguments": [{"entity_id": "9253492_4_Ent2", "role": "Treatment", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent4", "role": "Treatment_Drug", "text": "zonisamide", "start": 4, "end": 5}, {"entity_id": "9253492_4_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "9253492_4_Ent1", "role": "Effect", "text": "regained the ability to sweat within 2 weeks", "start": 11, "end": 19}, {"entity_id": "9253492_4_Ent6", "role": "Treatment_Time_elapsed", "text": "within 2 weeks", "start": 16, "end": 19}, {"entity_id": "9253492_4_Ent5", "role": "Treatment_Dosage", "text": "cessation", "start": 21, "end": 22}, {"entity_id": "9253492_4_Ent3", "role": "Treatment", "text": "cessation of drug administration", "start": 21, "end": 25}]}], "entity_mentions": [{"id": "9253492_4_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9253492_4_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9253492_4_Ent1", "text": "regained the ability to sweat within 2 weeks", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "9253492_4_Ent6", "text": "within 2 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9253492_4_Ent5", "text": "cessation", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9253492_4_Ent3", "text": "cessation of drug administration", "entity_type": "Entity", "start": 21, "end": 25}], "lang": "en"}
{"doc_id": "9256906_4", "wnd_id": "9256906_4_1", "text": "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin .", "tokens": ["We", "describe", "a", "patient", "with", "metastatic", "prostate", "cancer", "who", "developed", "nonoliguric", "renal", "failure", "during", "treatment", "with", "suramin", "."], "event_mentions": [{"id": "9256906_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "9256906_4_Ent0", "role": "Subject", "text": "a patient with metastatic prostate cancer", "start": 2, "end": 8}, {"entity_id": "9256906_4_Ent4", "role": "Treatment_Disorder", "text": "metastatic prostate cancer", "start": 5, "end": 8}, {"entity_id": "9256906_4_Ent1", "role": "Effect", "text": "nonoliguric renal failure", "start": 10, "end": 13}, {"entity_id": "9256906_4_Ent2", "role": "Treatment", "text": "suramin", "start": 16, "end": 17}, {"entity_id": "9256906_4_Ent3", "role": "Treatment_Drug", "text": "suramin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9256906_4_Ent0", "text": "a patient with metastatic prostate cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "9256906_4_Ent4", "text": "metastatic prostate cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9256906_4_Ent1", "text": "nonoliguric renal failure", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9256906_4_Ent2", "text": "suramin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9256906_4_Ent3", "text": "suramin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9315405_1", "wnd_id": "9315405_1_1", "text": "We report an unusually short lived and asymptomatic episode of severe cisplatin - induced renal tubular salt wasting in a fit 41 - year - old patient with malignant teratoma .", "tokens": ["We", "report", "an", "unusually", "short", "lived", "and", "asymptomatic", "episode", "of", "severe", "cisplatin", "-", "induced", "renal", "tubular", "salt", "wasting", "in", "a", "fit", "41", "-", "year", "-", "old", "patient", "with", "malignant", "teratoma", "."], "event_mentions": [{"id": "9315405_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9315405_1_Ent3", "role": "Treatment", "text": "cisplatin", "start": 11, "end": 12}, {"entity_id": "9315405_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 11, "end": 12}, {"entity_id": "9315405_1_Ent2", "role": "Effect", "text": "renal tubular salt wasting", "start": 14, "end": 18}, {"entity_id": "9315405_1_Ent0", "role": "Subject", "text": "a fit 41 - year - old patient with malignant teratoma", "start": 19, "end": 30}, {"entity_id": "9315405_1_Ent1", "role": "Subject_Age", "text": "41 - year - old", "start": 21, "end": 26}, {"entity_id": "9315405_1_Ent4", "role": "Treatment_Disorder", "text": "malignant teratoma", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "9315405_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9315405_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9315405_1_Ent2", "text": "renal tubular salt wasting", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "9315405_1_Ent0", "text": "a fit 41 - year - old patient with malignant teratoma", "entity_type": "Entity", "start": 19, "end": 30}, {"id": "9315405_1_Ent1", "text": "41 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "9315405_1_Ent4", "text": "malignant teratoma", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "9337441_1", "wnd_id": "9337441_1_1", "text": "Phenolphthalein - induced toxic epidermal necrolysis .", "tokens": ["Phenolphthalein", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "9337441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9337441_1_Ent1", "role": "Treatment", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent2", "role": "Treatment_Drug", "text": "Phenolphthalein", "start": 0, "end": 1}, {"entity_id": "9337441_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "9337441_1_Ent1", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent2", "text": "Phenolphthalein", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9337441_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "9352164_3", "wnd_id": "9352164_3_1", "text": "She was thus diagnosed as having AZ intoxication .", "tokens": ["She", "was", "thus", "diagnosed", "as", "having", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 5, "end": 6}, "arguments": [{"entity_id": "9352164_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent3", "role": "Treatment", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent2", "role": "Effect", "text": "AZ intoxication", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "9352164_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent3", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent4", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent2", "text": "AZ intoxication", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "9352164_4", "wnd_id": "9352164_4_1", "text": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["We", "experienced", "a", "case", "of", "chronic", "renal", "failure", "in", "a", "patient", "suffering", "from", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "9352164_4_Ent0", "role": "Subject", "text": "a case of chronic renal failure in a patient", "start": 2, "end": 11}, {"entity_id": "9352164_4_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 5, "end": 8}, {"entity_id": "9352164_4_Ent2", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_4_Ent3", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_4_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9352164_4_Ent0", "text": "a case of chronic renal failure in a patient", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "9352164_4_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9352164_4_Ent2", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_4_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_4_Ent4", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9362107_1", "wnd_id": "9362107_1_1", "text": "Danazol induced thrombocytopenia .", "tokens": ["Danazol", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "9362107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "9362107_1_Ent1", "role": "Treatment", "text": "Danazol", "start": 0, "end": 1}, {"entity_id": "9362107_1_Ent2", "role": "Treatment_Drug", "text": "Danazol", "start": 0, "end": 1}, {"entity_id": "9362107_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "9362107_1_Ent1", "text": "Danazol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9362107_1_Ent2", "text": "Danazol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9362107_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "9399776_1", "wnd_id": "9399776_1_1", "text": "Acute pancreatitis after long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "after", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "9399776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "9399776_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "9399776_1_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 3, "end": 6}, {"entity_id": "9399776_1_Ent1", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 3, "end": 11}, {"entity_id": "9399776_1_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "9399776_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9399776_1_Ent3", "text": "long - term", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9399776_1_Ent1", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "9399776_1_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "941054_1", "wnd_id": "941054_1_1", "text": "Nephropathy caused by methicillin therapy for staphylococcal septicemia .", "tokens": ["Nephropathy", "caused", "by", "methicillin", "therapy", "for", "staphylococcal", "septicemia", "."], "event_mentions": [{"id": "941054_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "941054_1_Ent0", "role": "Effect", "text": "Nephropathy", "start": 0, "end": 1}, {"entity_id": "941054_1_Ent3", "role": "Treatment_Drug", "text": "methicillin", "start": 3, "end": 4}, {"entity_id": "941054_1_Ent1", "role": "Treatment", "text": "methicillin therapy for staphylococcal septicemia", "start": 3, "end": 8}, {"entity_id": "941054_1_Ent2", "role": "Treatment_Disorder", "text": "staphylococcal septicemia", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "941054_1_Ent0", "text": "Nephropathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "941054_1_Ent3", "text": "methicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "941054_1_Ent1", "text": "methicillin therapy for staphylococcal septicemia", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "941054_1_Ent2", "text": "staphylococcal septicemia", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "941054_2", "wnd_id": "941054_2_1", "text": "Review of the literature relating to methicillin - induced nephropathy suggests a hypersensitivity origin for this disorder , but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis .", "tokens": ["Review", "of", "the", "literature", "relating", "to", "methicillin", "-", "induced", "nephropathy", "suggests", "a", "hypersensitivity", "origin", "for", "this", "disorder", ",", "but", "immunologic", "and", "ultrastructural", "investigation", "to", "date", "has", "failed", "to", "elucidate", "pathogenesis", "."], "event_mentions": [{"id": "941054_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "941054_2_Ent2", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "941054_2_Ent3", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "941054_2_Ent0", "role": "Effect", "text": "nephropathy", "start": 9, "end": 10}, {"entity_id": "941054_2_Ent1", "role": "Effect", "text": "hypersensitivity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "941054_2_Ent2", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "941054_2_Ent3", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "941054_2_Ent0", "text": "nephropathy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "941054_2_Ent1", "text": "hypersensitivity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9413296_1", "wnd_id": "9413296_1_1", "text": "A 25 - year - old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide .", "tokens": ["A", "25", "-", "year", "-", "old", "woman", "sought", "medical", "attention", "because", "of", "iliocaval", "manifestations", "of", "retroperitoneal", "fibrosis", "while", "she", "was", "taking", "methysergide", "."], "event_mentions": [{"id": "9413296_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 17, "end": 18}, "arguments": [{"entity_id": "9413296_1_Ent0", "role": "Subject", "text": "A 25 - year - old woman", "start": 0, "end": 7}, {"entity_id": "9413296_1_Ent2", "role": "Subject_Age", "text": "25 - year - old", "start": 1, "end": 6}, {"entity_id": "9413296_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "9413296_1_Ent4", "role": "Effect", "text": "iliocaval manifestations of retroperitoneal fibrosis", "start": 12, "end": 17}, {"entity_id": "9413296_1_Ent1", "role": "Subject", "text": "she", "start": 18, "end": 19}, {"entity_id": "9413296_1_Ent5", "role": "Treatment", "text": "methysergide", "start": 21, "end": 22}, {"entity_id": "9413296_1_Ent6", "role": "Treatment_Drug", "text": "methysergide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9413296_1_Ent0", "text": "A 25 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9413296_1_Ent2", "text": "25 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9413296_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9413296_1_Ent4", "text": "iliocaval manifestations of retroperitoneal fibrosis", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9413296_1_Ent1", "text": "she", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9413296_1_Ent5", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9413296_1_Ent6", "text": "methysergide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9443627_1", "wnd_id": "9443627_1_1", "text": "Hemodialysis was also shown to reverse ifosfamide - related neurotoxicity .", "tokens": ["Hemodialysis", "was", "also", "shown", "to", "reverse", "ifosfamide", "-", "related", "neurotoxicity", "."], "event_mentions": [{"id": "9443627_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reverse", "start": 5, "end": 6}, "arguments": [{"entity_id": "9443627_1_Ent3", "role": "Treatment", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "9443627_1_Ent4", "role": "Treatment_Drug", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "9443627_1_Ent5", "role": "Treatment_Disorder", "text": "ifosfamide - related neurotoxicity .", "start": 6, "end": 11}]}, {"id": "9443627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 8, "end": 9}, "arguments": [{"entity_id": "9443627_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 6, "end": 7}, {"entity_id": "9443627_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 6, "end": 7}, {"entity_id": "9443627_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9443627_1_Ent3", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9443627_1_Ent4", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9443627_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9443627_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9443627_1_Ent5", "text": "ifosfamide - related neurotoxicity .", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9443627_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "946400_2", "wnd_id": "946400_2_1", "text": "Methyldopa - induced liver injury .", "tokens": ["Methyldopa", "-", "induced", "liver", "injury", "."], "event_mentions": [{"id": "946400_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "946400_2_Ent1", "role": "Treatment", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent2", "role": "Treatment_Drug", "text": "Methyldopa", "start": 0, "end": 1}, {"entity_id": "946400_2_Ent0", "role": "Effect", "text": "liver injury", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "946400_2_Ent1", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent2", "text": "Methyldopa", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "946400_2_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9466030_3", "wnd_id": "9466030_3_1", "text": "PURPOSE : To present a case of respiratory depression following the administration of nebulised morphine .", "tokens": ["PURPOSE", ":", "To", "present", "a", "case", "of", "respiratory", "depression", "following", "the", "administration", "of", "nebulised", "morphine", "."], "event_mentions": [{"id": "9466030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "9466030_3_Ent0", "role": "Effect", "text": "respiratory depression", "start": 7, "end": 9}, {"entity_id": "9466030_3_Ent3", "role": "Treatment_Route", "text": "nebulised", "start": 13, "end": 14}, {"entity_id": "9466030_3_Ent1", "role": "Treatment", "text": "nebulised morphine", "start": 13, "end": 15}, {"entity_id": "9466030_3_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9466030_3_Ent0", "text": "respiratory depression", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9466030_3_Ent3", "text": "nebulised", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9466030_3_Ent1", "text": "nebulised morphine", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9466030_3_Ent2", "text": "morphine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9476721_1", "wnd_id": "9476721_1_1", "text": "Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson 's disease .", "tokens": ["Acute", "dystonia", "with", "thalamic", "and", "brainstem", "lesions", "after", "initial", "penicillamine", "treatment", "in", "Wilson", "'s", "disease", "."], "event_mentions": [{"id": "9476721_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "9476721_1_Ent0", "role": "Effect", "text": "Acute dystonia with thalamic and brainstem lesions", "start": 0, "end": 7}, {"entity_id": "9476721_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 9, "end": 10}, {"entity_id": "9476721_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 9, "end": 10}, {"entity_id": "9476721_1_Ent3", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "9476721_1_Ent0", "text": "Acute dystonia with thalamic and brainstem lesions", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9476721_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9476721_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9476721_1_Ent3", "text": "Wilson 's disease", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "9494448_2", "wnd_id": "9494448_2_1", "text": "Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine : case report and review .", "tokens": ["Anaphylaxis", "to", "intravenous", "cyclosporine", "and", "tolerance", "to", "oral", "cyclosporine", ":", "case", "report", "and", "review", "."], "event_mentions": [{"id": "9494448_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "9494448_2_Ent1", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "9494448_2_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 2, "end": 3}, {"entity_id": "9494448_2_Ent2", "role": "Treatment", "text": "intravenous cyclosporine", "start": 2, "end": 4}, {"entity_id": "9494448_2_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 3, "end": 4}, {"entity_id": "9494448_2_Ent0", "role": "Subject", "text": "case", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9494448_2_Ent1", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9494448_2_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9494448_2_Ent2", "text": "intravenous cyclosporine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9494448_2_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9494448_2_Ent0", "text": "case", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9494448_3", "wnd_id": "9494448_3_1", "text": "BACKGROUND : Hypersensitivity reactions to cyclosporine are rare .", "tokens": ["BACKGROUND", ":", "Hypersensitivity", "reactions", "to", "cyclosporine", "are", "rare", "."], "event_mentions": [{"id": "9494448_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 4, "end": 5}, "arguments": [{"entity_id": "9494448_3_Ent0", "role": "Effect", "text": "Hypersensitivity reactions", "start": 2, "end": 4}, {"entity_id": "9494448_3_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 5, "end": 6}, {"entity_id": "9494448_3_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "9494448_3_Ent0", "text": "Hypersensitivity reactions", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9494448_3_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9494448_3_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "9494448_4", "wnd_id": "9494448_4_1", "text": "CONCLUSIONS : Hypersensitivity reactions to cyclosporine are due to Cremophor EL .", "tokens": ["CONCLUSIONS", ":", "Hypersensitivity", "reactions", "to", "cyclosporine", "are", "due", "to", "Cremophor", "EL", "."], "event_mentions": [{"id": "9494448_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "9494448_4_Ent0", "role": "Effect", "text": "Hypersensitivity reactions to cyclosporine", "start": 2, "end": 6}, {"entity_id": "9494448_4_Ent1", "role": "Treatment", "text": "Cremophor EL", "start": 9, "end": 11}, {"entity_id": "9494448_4_Ent2", "role": "Treatment_Drug", "text": "Cremophor EL", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9494448_4_Ent0", "text": "Hypersensitivity reactions to cyclosporine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9494448_4_Ent1", "text": "Cremophor EL", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_4_Ent2", "text": "Cremophor EL", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9494448_6", "wnd_id": "9494448_6_1", "text": "METHODS : We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine .", "tokens": ["METHODS", ":", "We", "report", "a", "patient", "who", "had", "an", "anaphylactic", "reaction", "during", "the", "intravenous", "infusion", "of", "cyclosporine", "."], "event_mentions": [{"id": "9494448_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "9494448_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "9494448_6_Ent1", "role": "Effect", "text": "anaphylactic reaction", "start": 9, "end": 11}, {"entity_id": "9494448_6_Ent4", "role": "Treatment_Route", "text": "intravenous infusion", "start": 13, "end": 15}, {"entity_id": "9494448_6_Ent2", "role": "Treatment", "text": "intravenous infusion of cyclosporine", "start": 13, "end": 17}, {"entity_id": "9494448_6_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9494448_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_6_Ent1", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_6_Ent4", "text": "intravenous infusion", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9494448_6_Ent2", "text": "intravenous infusion of cyclosporine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "9494448_6_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9497597_2", "wnd_id": "9497597_2_1", "text": "We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride .", "tokens": ["We", "present", "the", "first", "case", "of", "a", "patient", "with", "priapism", "after", "oral", "intake", "of", "the", "phenothiazine", "prothipendylhydrochloride", "."], "event_mentions": [{"id": "9497597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "9497597_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "9497597_2_Ent1", "role": "Effect", "text": "priapism", "start": 9, "end": 10}, {"entity_id": "9497597_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 11, "end": 12}, {"entity_id": "9497597_2_Ent2", "role": "Treatment", "text": "oral intake of the phenothiazine prothipendylhydrochloride", "start": 11, "end": 17}, {"entity_id": "9497597_2_Ent3", "role": "Treatment_Drug", "text": "prothipendylhydrochloride", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9497597_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9497597_2_Ent1", "text": "priapism", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9497597_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9497597_2_Ent2", "text": "oral intake of the phenothiazine prothipendylhydrochloride", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "9497597_2_Ent3", "text": "prothipendylhydrochloride", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9545161_4", "wnd_id": "9545161_4_1", "text": "It was hypothesized that valproic acid may interfere with glucuronidation of lamotrigine , leading to increased serum lamotrigine levels , or perhaps alter the drug 's metabolism , resulting in accumulation of a toxic intermediate metabolite .", "tokens": ["It", "was", "hypothesized", "that", "valproic", "acid", "may", "interfere", "with", "glucuronidation", "of", "lamotrigine", ",", "leading", "to", "increased", "serum", "lamotrigine", "levels", ",", "or", "perhaps", "alter", "the", "drug", "'s", "metabolism", ",", "resulting", "in", "accumulation", "of", "a", "toxic", "intermediate", "metabolite", "."], "event_mentions": [{"id": "9545161_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 13, "end": 14}, "arguments": [{"entity_id": "9545161_4_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 4, "end": 6}, {"entity_id": "9545161_4_Ent4", "role": "Combination_Drug", "text": "valproic acid", "start": 4, "end": 6}, {"entity_id": "9545161_4_Ent1", "role": "Treatment", "text": "valproic acid may interfere with glucuronidation of lamotrigine", "start": 4, "end": 12}, {"entity_id": "9545161_4_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 11, "end": 12}, {"entity_id": "9545161_4_Ent5", "role": "Combination_Drug", "text": "lamotrigine", "start": 11, "end": 12}, {"entity_id": "9545161_4_Ent0", "role": "Effect", "text": "increased serum lamotrigine levels , or perhaps alter the drug 's metabolism , resulting in accumulation of a toxic intermediate metabolite", "start": 15, "end": 36}]}], "entity_mentions": [{"id": "9545161_4_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9545161_4_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9545161_4_Ent1", "text": "valproic acid may interfere with glucuronidation of lamotrigine", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "9545161_4_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9545161_4_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9545161_4_Ent0", "text": "increased serum lamotrigine levels , or perhaps alter the drug 's metabolism , resulting in accumulation of a toxic intermediate metabolite", "entity_type": "Entity", "start": 15, "end": 36}], "lang": "en"}
{"doc_id": "9554064_1", "wnd_id": "9554064_1_1", "text": "Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies .", "tokens": ["Methanol", "toxicity", "can", "cause", "severe", "central", "nervous", "system", "insult", "in", "which", "a", "characteristic", "pattern", "of", "bilateral", "putaminal", "injury", "is", "noted", "on", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "9554064_1_Ent2", "role": "Treatment_Drug", "text": "Methanol", "start": 0, "end": 1}, {"entity_id": "9554064_1_Ent1", "role": "Treatment", "text": "Methanol toxicity", "start": 0, "end": 2}, {"entity_id": "9554064_1_Ent0", "role": "Effect", "text": "central nervous system insult", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "9554064_1_Ent2", "text": "Methanol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9554064_1_Ent1", "text": "Methanol toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9554064_1_Ent0", "text": "central nervous system insult", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "9554064_2", "wnd_id": "9554064_2_1", "text": "Putaminal infarct in methanol intoxication : case report and role of brain imaging studies .", "tokens": ["Putaminal", "infarct", "in", "methanol", "intoxication", ":", "case", "report", "and", "role", "of", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_2_Ent0", "role": "Effect", "text": "Putaminal infarct in methanol intoxication", "start": 0, "end": 5}, {"entity_id": "9554064_2_Ent1", "role": "Treatment", "text": "methanol", "start": 3, "end": 4}, {"entity_id": "9554064_2_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9554064_2_Ent0", "text": "Putaminal infarct in methanol intoxication", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9554064_2_Ent1", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9554064_2_Ent2", "text": "methanol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9554064_3", "wnd_id": "9554064_3_1", "text": "Theoretical basal ganglia toxicologic mechanisms of methanol poisoning are reviewed , and the role of brain imaging studies will regard to diagnosis , prognosis and impact on management is discussed .", "tokens": ["Theoretical", "basal", "ganglia", "toxicologic", "mechanisms", "of", "methanol", "poisoning", "are", "reviewed", ",", "and", "the", "role", "of", "brain", "imaging", "studies", "will", "regard", "to", "diagnosis", ",", "prognosis", "and", "impact", "on", "management", "is", "discussed", "."], "event_mentions": [{"id": "9554064_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanisms", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_3_Ent1", "role": "Treatment", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent0", "role": "Effect", "text": "poisoning", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9554064_3_Ent1", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent2", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent0", "text": "poisoning", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9562211_1", "wnd_id": "9562211_1_1", "text": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements .", "tokens": ["A", "28", "year", "old", "white", "schizophrenic", "male", "has", "been", "under", "risperidone", "monotherapy", "for", "about", "one", "year", "when", "he", "developed", "dyskinetic", "movements", "."], "event_mentions": [{"id": "9562211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "9562211_1_Ent0", "role": "Subject", "text": "A 28 year old white schizophrenic male", "start": 0, "end": 7}, {"entity_id": "9562211_1_Ent1", "role": "Subject_Age", "text": "28 year old", "start": 1, "end": 4}, {"entity_id": "9562211_1_Ent2", "role": "Subject_Race", "text": "white", "start": 4, "end": 5}, {"entity_id": "9562211_1_Ent8", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 5, "end": 6}, {"entity_id": "9562211_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "9562211_1_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 10, "end": 11}, {"entity_id": "9562211_1_Ent5", "role": "Treatment", "text": "risperidone monotherapy", "start": 10, "end": 12}, {"entity_id": "9562211_1_Ent7", "role": "Treatment_Duration", "text": "about one year", "start": 13, "end": 16}, {"entity_id": "9562211_1_Ent4", "role": "Effect", "text": "dyskinetic movements", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "9562211_1_Ent0", "text": "A 28 year old white schizophrenic male", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9562211_1_Ent1", "text": "28 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9562211_1_Ent2", "text": "white", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9562211_1_Ent8", "text": "schizophrenic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9562211_1_Ent3", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9562211_1_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9562211_1_Ent5", "text": "risperidone monotherapy", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9562211_1_Ent7", "text": "about one year", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9562211_1_Ent4", "text": "dyskinetic movements", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "9627209_1", "wnd_id": "9627209_1_1", "text": "In case 1 , a total daily dose of 25 mg sertraline , with nondetectable sertraline and desmethylsertraline blood levels , resulted in a doubling of the lamotrigine blood level with symptoms of toxicity .", "tokens": ["In", "case", "1", ",", "a", "total", "daily", "dose", "of", "25", "mg", "sertraline", ",", "with", "nondetectable", "sertraline", "and", "desmethylsertraline", "blood", "levels", ",", "resulted", "in", "a", "doubling", "of", "the", "lamotrigine", "blood", "level", "with", "symptoms", "of", "toxicity", "."], "event_mentions": [{"id": "9627209_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 21, "end": 22}, "arguments": [{"entity_id": "9627209_1_Ent0", "role": "Subject", "text": "In case 1", "start": 0, "end": 3}, {"entity_id": "9627209_1_Ent2", "role": "Treatment", "text": "a total daily dose of 25 mg sertraline", "start": 4, "end": 12}, {"entity_id": "9627209_1_Ent3", "role": "Treatment_Dosage", "text": "daily dose of 25 mg", "start": 6, "end": 11}, {"entity_id": "9627209_1_Ent4", "role": "Treatment_Drug", "text": "sertraline", "start": 11, "end": 12}, {"entity_id": "9627209_1_Ent1", "role": "Effect", "text": "doubling of the lamotrigine blood level with symptoms of toxicity", "start": 24, "end": 34}]}], "entity_mentions": [{"id": "9627209_1_Ent0", "text": "In case 1", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9627209_1_Ent2", "text": "a total daily dose of 25 mg sertraline", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "9627209_1_Ent3", "text": "daily dose of 25 mg", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9627209_1_Ent4", "text": "sertraline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9627209_1_Ent1", "text": "doubling of the lamotrigine blood level with symptoms of toxicity", "entity_type": "Entity", "start": 24, "end": 34}], "lang": "en"}
{"doc_id": "9634122_3", "wnd_id": "9634122_3_1", "text": "This case illustrates the potential decoupling of PSA response from disease status in flutamide withdrawal .", "tokens": ["This", "case", "illustrates", "the", "potential", "decoupling", "of", "PSA", "response", "from", "disease", "status", "in", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "illustrates", "start": 2, "end": 3}, "arguments": [{"entity_id": "9634122_3_Ent0", "role": "Effect", "text": "potential decoupling of PSA response", "start": 4, "end": 9}, {"entity_id": "9634122_3_Ent2", "role": "Treatment_Drug", "text": "flutamide", "start": 13, "end": 14}, {"entity_id": "9634122_3_Ent1", "role": "Treatment", "text": "flutamide withdrawal", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9634122_3_Ent0", "text": "potential decoupling of PSA response", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9634122_3_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9634122_3_Ent1", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9634122_4", "wnd_id": "9634122_4_1", "text": "We describe a patient with androgen - independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal .", "tokens": ["We", "describe", "a", "patient", "with", "androgen", "-", "independent", "prostate", "cancer", "in", "whom", "PSA", "continued", "to", "decrease", "for", "a", "period", "of", "15", "months", "after", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "9634122_4_Ent0", "role": "Subject", "text": "a patient with androgen - independent prostate cancer", "start": 2, "end": 10}, {"entity_id": "9634122_4_Ent4", "role": "Treatment_Disorder", "text": "androgen - independent prostate cancer", "start": 5, "end": 10}, {"entity_id": "9634122_4_Ent1", "role": "Effect", "text": "PSA continued to decrease for a period of 15 months", "start": 12, "end": 22}, {"entity_id": "9634122_4_Ent3", "role": "Treatment_Drug", "text": "flutamide", "start": 23, "end": 24}, {"entity_id": "9634122_4_Ent2", "role": "Treatment", "text": "flutamide withdrawal", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9634122_4_Ent0", "text": "a patient with androgen - independent prostate cancer", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "9634122_4_Ent4", "text": "androgen - independent prostate cancer", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9634122_4_Ent1", "text": "PSA continued to decrease for a period of 15 months", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9634122_4_Ent3", "text": "flutamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9634122_4_Ent2", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9642842_2", "wnd_id": "9642842_2_1", "text": "We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone .", "tokens": ["We", "describe", "the", "case", "of", "a", "nonatopic", "17", "-", "year", "-", "old", "girl", "with", "bronchial", "asthma", "and", "aspirin", "intolerance", "who", "developed", "a", "dramatic", "anaphylactic", "reaction", "to", "oral", "prednisone", "."], "event_mentions": [{"id": "9642842_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "9642842_2_Ent0", "role": "Subject", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "start": 5, "end": 19}, {"entity_id": "9642842_2_Ent1", "role": "Subject_Disorder", "text": "nonatopic", "start": 6, "end": 7}, {"entity_id": "9642842_2_Ent3", "role": "Subject_Age", "text": "17 - year - old", "start": 7, "end": 12}, {"entity_id": "9642842_2_Ent4", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "9642842_2_Ent9", "role": "Treatment_Disorder", "text": "bronchial asthma", "start": 14, "end": 16}, {"entity_id": "9642842_2_Ent2", "role": "Subject_Disorder", "text": "aspirin intolerance", "start": 17, "end": 19}, {"entity_id": "9642842_2_Ent5", "role": "Effect", "text": "a dramatic anaphylactic reaction", "start": 21, "end": 25}, {"entity_id": "9642842_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "9642842_2_Ent6", "role": "Treatment", "text": "oral prednisone", "start": 26, "end": 28}, {"entity_id": "9642842_2_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "9642842_2_Ent0", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "9642842_2_Ent1", "text": "nonatopic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9642842_2_Ent3", "text": "17 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9642842_2_Ent4", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9642842_2_Ent9", "text": "bronchial asthma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9642842_2_Ent2", "text": "aspirin intolerance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9642842_2_Ent5", "text": "a dramatic anaphylactic reaction", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9642842_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9642842_2_Ent6", "text": "oral prednisone", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "9642842_2_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "9651465_2", "wnd_id": "9651465_2_1", "text": "She was treated with Pancrease MT 16 , but had consistent vomiting 1 to 2 hours after administration of enzymes .", "tokens": ["She", "was", "treated", "with", "Pancrease", "MT", "16", ",", "but", "had", "consistent", "vomiting", "1", "to", "2", "hours", "after", "administration", "of", "enzymes", "."], "event_mentions": [{"id": "9651465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "9651465_2_Ent2", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 4, "end": 7}, {"entity_id": "9651465_2_Ent0", "role": "Effect", "text": "vomiting", "start": 11, "end": 12}, {"entity_id": "9651465_2_Ent4", "role": "Treatment_Time_elapsed", "text": "1 to 2 hours", "start": 12, "end": 16}, {"entity_id": "9651465_2_Ent1", "role": "Treatment", "text": "enzymes", "start": 19, "end": 20}, {"entity_id": "9651465_2_Ent3", "role": "Treatment_Drug", "text": "enzymes", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9651465_2_Ent2", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9651465_2_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9651465_2_Ent4", "text": "1 to 2 hours", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "9651465_2_Ent1", "text": "enzymes", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9651465_2_Ent3", "text": "enzymes", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9660541_1", "wnd_id": "9660541_1_1", "text": "In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , thrombocytopenia and progressive renal failure .", "tokens": ["In", "rare", "cases", "mitomycin", "C", "(", "MMC", ")", "may", "induce", "cancer", "-", "associated", "hemolytic", "uremic", "syndrome", ",", "which", "is", "characterized", "by", "hemolytic", "anemia", ",", "thrombocytopenia", "and", "progressive", "renal", "failure", "."], "event_mentions": [{"id": "9660541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 9, "end": 10}, "arguments": [{"entity_id": "9660541_1_Ent0", "role": "Subject", "text": "In rare cases", "start": 0, "end": 3}, {"entity_id": "9660541_1_Ent4", "role": "Treatment_Drug", "text": "mitomycin C", "start": 3, "end": 5}, {"entity_id": "9660541_1_Ent3", "role": "Treatment", "text": "mitomycin C ( MMC )", "start": 3, "end": 8}, {"entity_id": "9660541_1_Ent1", "role": "Effect", "text": "cancer - associated hemolytic uremic syndrome", "start": 10, "end": 16}, {"entity_id": "9660541_1_Ent2", "role": "Effect", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "start": 21, "end": 29}]}], "entity_mentions": [{"id": "9660541_1_Ent0", "text": "In rare cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9660541_1_Ent4", "text": "mitomycin C", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9660541_1_Ent3", "text": "mitomycin C ( MMC )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9660541_1_Ent1", "text": "cancer - associated hemolytic uremic syndrome", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9660541_1_Ent2", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "entity_type": "Entity", "start": 21, "end": 29}], "lang": "en"}
{"doc_id": "9681092_13", "wnd_id": "9681092_13_1", "text": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine , monitor for other cytochrome P450 inhibitors , and avoid concomitant drugs known to prolong the QT interval .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "dysrhythmic", "potential", "of", "cyclobenzaprine", "and", "fluoxetine", ",", "monitor", "for", "other", "cytochrome", "P450", "inhibitors", ",", "and", "avoid", "concomitant", "drugs", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 7, "end": 8}, "arguments": [{"entity_id": "9681092_13_Ent0", "role": "Effect", "text": "dysrhythmic", "start": 6, "end": 7}, {"entity_id": "9681092_13_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent4", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent1", "role": "Treatment", "text": "cyclobenzaprine and fluoxetine", "start": 9, "end": 12}, {"entity_id": "9681092_13_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "9681092_13_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9681092_13_Ent0", "text": "dysrhythmic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9681092_13_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent4", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent1", "text": "cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9681092_13_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9681092_13_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "968449_1", "wnd_id": "968449_1_1", "text": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera .", "tokens": ["Chromosome", "abnormalities", "after", "chlorambucil", "therapy", "of", "polycythaemia", "vera", "."], "event_mentions": [{"id": "968449_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "968449_1_Ent0", "role": "Effect", "text": "Chromosome abnormalities", "start": 0, "end": 2}, {"entity_id": "968449_1_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 3, "end": 4}, {"entity_id": "968449_1_Ent1", "role": "Treatment", "text": "chlorambucil therapy", "start": 3, "end": 5}, {"entity_id": "968449_1_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "968449_1_Ent0", "text": "Chromosome abnormalities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "968449_1_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "968449_1_Ent1", "text": "chlorambucil therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "968449_1_Ent3", "text": "polycythaemia vera", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "968449_4", "wnd_id": "968449_4_1", "text": "Case 1 presented after 25 months of myelosuppressive therapy a deletion of chromosome no . 12 , del ( 12 ) ( p11 ) , in 60 % of the diploid cells .", "tokens": ["Case", "1", "presented", "after", "25", "months", "of", "myelosuppressive", "therapy", "a", "deletion", "of", "chromosome", "no", ".", "12", ",", "del", "(", "12", ")", "(", "p11", ")", ",", "in", "60", "%", "of", "the", "diploid", "cells", "."], "event_mentions": [{"id": "968449_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "968449_4_Ent0", "role": "Subject", "text": "Case 1", "start": 0, "end": 2}, {"entity_id": "968449_4_Ent1", "role": "Subject_Population", "text": "1", "start": 1, "end": 2}, {"entity_id": "968449_4_Ent4", "role": "Treatment_Time_elapsed", "text": "25 months", "start": 4, "end": 6}, {"entity_id": "968449_4_Ent3", "role": "Treatment", "text": "25 months of myelosuppressive therapy", "start": 4, "end": 9}, {"entity_id": "968449_4_Ent5", "role": "Treatment_Drug", "text": "myelosuppressive", "start": 7, "end": 8}, {"entity_id": "968449_4_Ent2", "role": "Effect", "text": "a deletion of chromosome no . 12 , del ( 12 ) ( p11 ) , in 60 % of the diploid cells", "start": 9, "end": 32}]}], "entity_mentions": [{"id": "968449_4_Ent0", "text": "Case 1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "968449_4_Ent1", "text": "1", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "968449_4_Ent4", "text": "25 months", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "968449_4_Ent3", "text": "25 months of myelosuppressive therapy", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "968449_4_Ent5", "text": "myelosuppressive", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "968449_4_Ent2", "text": "a deletion of chromosome no . 12 , del ( 12 ) ( p11 ) , in 60 % of the diploid cells", "entity_type": "Entity", "start": 9, "end": 32}], "lang": "en"}
{"doc_id": "9695308_1", "wnd_id": "9695308_1_1", "text": "Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared .", "tokens": ["Administration", "of", "steroid", "and", "decreasing", "the", "dose", "of", "PTU", "produced", "a", "good", "clinical", "response", "and", "the", "ANCA", "disappeared", "."], "event_mentions": [{"id": "9695308_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "produced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9695308_1_Ent1", "role": "Treatment", "text": "steroid", "start": 2, "end": 3}, {"entity_id": "9695308_1_Ent3", "role": "Treatment_Drug", "text": "steroid", "start": 2, "end": 3}, {"entity_id": "9695308_1_Ent2", "role": "Treatment", "text": "PTU", "start": 8, "end": 9}, {"entity_id": "9695308_1_Ent4", "role": "Treatment_Drug", "text": "PTU", "start": 8, "end": 9}, {"entity_id": "9695308_1_Ent0", "role": "Effect", "text": "a good clinical response and the ANCA disappeared", "start": 10, "end": 18}]}], "entity_mentions": [{"id": "9695308_1_Ent1", "text": "steroid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9695308_1_Ent3", "text": "steroid", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9695308_1_Ent2", "text": "PTU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9695308_1_Ent4", "text": "PTU", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9695308_1_Ent0", "text": "a good clinical response and the ANCA disappeared", "entity_type": "Entity", "start": 10, "end": 18}], "lang": "en"}
{"doc_id": "9695308_3", "wnd_id": "9695308_3_1", "text": "A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody ( ANCA ) detected after she had received propylthiouracil ( PTU ) for hyperthyroidism without cutaneous vasculitis .", "tokens": ["A", "teenage", "girl", "with", "crescentic", "glomerulonephritis", "had", "antineutrophil", "cytoplasmic", "antibody", "(", "ANCA", ")", "detected", "after", "she", "had", "received", "propylthiouracil", "(", "PTU", ")", "for", "hyperthyroidism", "without", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "9695308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 6, "end": 7}, "arguments": [{"entity_id": "9695308_3_Ent0", "role": "Subject", "text": "A teenage girl with crescentic glomerulonephritis", "start": 0, "end": 6}, {"entity_id": "9695308_3_Ent2", "role": "Subject_Age", "text": "teenage", "start": 1, "end": 2}, {"entity_id": "9695308_3_Ent3", "role": "Subject_Gender", "text": "girl", "start": 2, "end": 3}, {"entity_id": "9695308_3_Ent1", "role": "Subject_Disorder", "text": "crescentic glomerulonephritis", "start": 4, "end": 6}, {"entity_id": "9695308_3_Ent4", "role": "Effect", "text": "antineutrophil cytoplasmic antibody ( ANCA )", "start": 7, "end": 13}, {"entity_id": "9695308_3_Ent6", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 18, "end": 19}, {"entity_id": "9695308_3_Ent5", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 18, "end": 22}, {"entity_id": "9695308_3_Ent7", "role": "Treatment_Disorder", "text": "hyperthyroidism without cutaneous vasculitis", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "9695308_3_Ent0", "text": "A teenage girl with crescentic glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9695308_3_Ent2", "text": "teenage", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9695308_3_Ent3", "text": "girl", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9695308_3_Ent1", "text": "crescentic glomerulonephritis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9695308_3_Ent4", "text": "antineutrophil cytoplasmic antibody ( ANCA )", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "9695308_3_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_3_Ent5", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "9695308_3_Ent7", "text": "hyperthyroidism without cutaneous vasculitis", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "9695308_4", "wnd_id": "9695308_4_1", "text": "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA .", "tokens": ["It", "was", "concluded", "that", "ANCA", "is", "closely", "related", "to", "the", "pathogenesis", "of", "crescentic", "glomerulonephritis", "and", "that", "treatment", "with", "PTU", "appeared", "to", "induce", "ANCA", "."], "event_mentions": [{"id": "9695308_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 21, "end": 22}, "arguments": [{"entity_id": "9695308_4_Ent1", "role": "Treatment", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent2", "role": "Treatment_Drug", "text": "PTU", "start": 18, "end": 19}, {"entity_id": "9695308_4_Ent0", "role": "Effect", "text": "ANCA", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9695308_4_Ent1", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent2", "text": "PTU", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9695308_4_Ent0", "text": "ANCA", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9704170_2", "wnd_id": "9704170_2_1", "text": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium - activated K+ channels .", "tokens": ["Clozapine", "is", "speculated", "to", "cause", "rhabdomyolysis", "in", "patients", "with", "defective", "calcium", "-", "activated", "K+", "channels", "."], "event_mentions": [{"id": "9704170_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9704170_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "9704170_2_Ent0", "role": "Subject", "text": "patients with defective calcium - activated K+ channels", "start": 7, "end": 15}, {"entity_id": "9704170_2_Ent1", "role": "Subject_Disorder", "text": "defective calcium - activated K+ channels", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "9704170_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9704170_2_Ent0", "text": "patients with defective calcium - activated K+ channels", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9704170_2_Ent1", "text": "defective calcium - activated K+ channels", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "9719245_4", "wnd_id": "9719245_4_1", "text": "We report a case of pancytopenia in a 23 - year - old man with Crohn 's disease who was treated with 5 - aminosalicylic acid ( Pentasa ; Nisshin , Tokyo , Japan ) 3.0 g / day .", "tokens": ["We", "report", "a", "case", "of", "pancytopenia", "in", "a", "23", "-", "year", "-", "old", "man", "with", "Crohn", "'s", "disease", "who", "was", "treated", "with", "5", "-", "aminosalicylic", "acid", "(", "Pentasa", ";", "Nisshin", ",", "Tokyo", ",", "Japan", ")", "3.0", "g", "/", "day", "."], "event_mentions": [{"id": "9719245_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 20, "end": 22}, "arguments": [{"entity_id": "9719245_4_Ent3", "role": "Effect", "text": "pancytopenia", "start": 5, "end": 6}, {"entity_id": "9719245_4_Ent0", "role": "Subject", "text": "a 23 - year - old man with Crohn 's disease", "start": 7, "end": 18}, {"entity_id": "9719245_4_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 8, "end": 13}, {"entity_id": "9719245_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "9719245_4_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 15, "end": 18}, {"entity_id": "9719245_4_Ent6", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 22, "end": 26}, {"entity_id": "9719245_4_Ent4", "role": "Treatment", "text": "5 - aminosalicylic acid ( Pentasa ; Nisshin , Tokyo , Japan ) 3.0 g / day", "start": 22, "end": 39}, {"entity_id": "9719245_4_Ent7", "role": "Treatment_Drug", "text": "Pentasa", "start": 27, "end": 28}, {"entity_id": "9719245_4_Ent8", "role": "Treatment_Dosage", "text": "3.0 g / day", "start": 35, "end": 39}]}], "entity_mentions": [{"id": "9719245_4_Ent3", "text": "pancytopenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9719245_4_Ent0", "text": "a 23 - year - old man with Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "9719245_4_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "9719245_4_Ent2", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9719245_4_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9719245_4_Ent6", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "9719245_4_Ent4", "text": "5 - aminosalicylic acid ( Pentasa ; Nisshin , Tokyo , Japan ) 3.0 g / day", "entity_type": "Entity", "start": 22, "end": 39}, {"id": "9719245_4_Ent7", "text": "Pentasa", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9719245_4_Ent8", "text": "3.0 g / day", "entity_type": "Entity", "start": 35, "end": 39}], "lang": "en"}
{"doc_id": "9760614_1", "wnd_id": "9760614_1_1", "text": "However , 1 eye had vitreous hemorrhage after repeated injections of tPA .", "tokens": ["However", ",", "1", "eye", "had", "vitreous", "hemorrhage", "after", "repeated", "injections", "of", "tPA", "."], "event_mentions": [{"id": "9760614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "9760614_1_Ent0", "role": "Effect", "text": "1 eye had vitreous hemorrhage", "start": 2, "end": 7}, {"entity_id": "9760614_1_Ent1", "role": "Treatment", "text": "repeated injections of tPA", "start": 8, "end": 12}, {"entity_id": "9760614_1_Ent2", "role": "Treatment_Route", "text": "injections", "start": 9, "end": 10}, {"entity_id": "9760614_1_Ent3", "role": "Treatment_Drug", "text": "tPA", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9760614_1_Ent0", "text": "1 eye had vitreous hemorrhage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "9760614_1_Ent1", "text": "repeated injections of tPA", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9760614_1_Ent2", "text": "injections", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9760614_1_Ent3", "text": "tPA", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9760614_2", "wnd_id": "9760614_2_1", "text": "However , repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage .", "tokens": ["However", ",", "repeated", "intracameral", "tPA", "injections", "may", "cause", "unwanted", "complications", "such", "as", "vitreous", "hemorrhage", "."], "event_mentions": [{"id": "9760614_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "9760614_2_Ent1", "role": "Treatment", "text": "repeated intracameral tPA injections", "start": 2, "end": 6}, {"entity_id": "9760614_2_Ent3", "role": "Treatment_Route", "text": "intracameral", "start": 3, "end": 4}, {"entity_id": "9760614_2_Ent2", "role": "Treatment_Drug", "text": "tPA", "start": 4, "end": 5}, {"entity_id": "9760614_2_Ent4", "role": "Treatment_Route", "text": "injections", "start": 5, "end": 6}, {"entity_id": "9760614_2_Ent0", "role": "Effect", "text": "unwanted complications such as vitreous hemorrhage", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "9760614_2_Ent1", "text": "repeated intracameral tPA injections", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9760614_2_Ent3", "text": "intracameral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9760614_2_Ent2", "text": "tPA", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9760614_2_Ent4", "text": "injections", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9760614_2_Ent0", "text": "unwanted complications such as vitreous hemorrhage", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "9776099_1", "wnd_id": "9776099_1_1", "text": "NMS is a drug - related response to various medications , such as Haloperidol , which the patient was receiving .", "tokens": ["NMS", "is", "a", "drug", "-", "related", "response", "to", "various", "medications", ",", "such", "as", "Haloperidol", ",", "which", "the", "patient", "was", "receiving", "."], "event_mentions": [{"id": "9776099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 6, "end": 7}, "arguments": [{"entity_id": "9776099_1_Ent1", "role": "Effect", "text": "NMS", "start": 0, "end": 1}, {"entity_id": "9776099_1_Ent2", "role": "Treatment", "text": "Haloperidol", "start": 13, "end": 14}, {"entity_id": "9776099_1_Ent3", "role": "Treatment_Drug", "text": "Haloperidol", "start": 13, "end": 14}, {"entity_id": "9776099_1_Ent0", "role": "Subject", "text": "patient", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9776099_1_Ent1", "text": "NMS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9776099_1_Ent2", "text": "Haloperidol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9776099_1_Ent3", "text": "Haloperidol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9776099_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9792602_1", "wnd_id": "9792602_1_1", "text": "The case demonstrates that hypersensitivity reaction to pranlukast and resultant ATIN is possible , and that periodic urine testing in patients receiving pranlukast should be considered .", "tokens": ["The", "case", "demonstrates", "that", "hypersensitivity", "reaction", "to", "pranlukast", "and", "resultant", "ATIN", "is", "possible", ",", "and", "that", "periodic", "urine", "testing", "in", "patients", "receiving", "pranlukast", "should", "be", "considered", "."], "event_mentions": [{"id": "9792602_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 6, "end": 7}, "arguments": [{"entity_id": "9792602_1_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 4, "end": 6}, {"entity_id": "9792602_1_Ent1", "role": "Treatment", "text": "pranlukast", "start": 7, "end": 8}, {"entity_id": "9792602_1_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 7, "end": 8}, {"entity_id": "9792602_1_Ent3", "role": "Treatment_Drug", "text": "pranlukast", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9792602_1_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9792602_1_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_1_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_1_Ent3", "text": "pranlukast", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9804082_1", "wnd_id": "9804082_1_1", "text": "Three diabetic cases of acute dizziness due to initial administration of voglibose .", "tokens": ["Three", "diabetic", "cases", "of", "acute", "dizziness", "due", "to", "initial", "administration", "of", "voglibose", "."], "event_mentions": [{"id": "9804082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "9804082_1_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "9804082_1_Ent0", "role": "Subject", "text": "Three diabetic cases", "start": 0, "end": 3}, {"entity_id": "9804082_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic", "start": 1, "end": 2}, {"entity_id": "9804082_1_Ent2", "role": "Effect", "text": "acute dizziness", "start": 4, "end": 6}, {"entity_id": "9804082_1_Ent3", "role": "Treatment", "text": "initial administration of voglibose", "start": 8, "end": 12}, {"entity_id": "9804082_1_Ent4", "role": "Treatment_Drug", "text": "voglibose", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9804082_1_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9804082_1_Ent0", "text": "Three diabetic cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9804082_1_Ent5", "text": "diabetic", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9804082_1_Ent2", "text": "acute dizziness", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9804082_1_Ent3", "text": "initial administration of voglibose", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9804082_1_Ent4", "text": "voglibose", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9819544_2", "wnd_id": "9819544_2_1", "text": "Naproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include tinnitus and transient hearing loss .", "tokens": ["Naproxen", "is", "a", "commonly", "used", "nonsteroidal", "anti", "-", "inflammatory", "drug", "(", "NSAID", ")", "whose", "side", "effects", "include", "tinnitus", "and", "transient", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "include", "start": 16, "end": 17}, "arguments": [{"entity_id": "9819544_2_Ent1", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_2_Ent2", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_2_Ent0", "role": "Effect", "text": "tinnitus and transient hearing loss", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "9819544_2_Ent1", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_2_Ent2", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_2_Ent0", "text": "tinnitus and transient hearing loss", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "9824032_1", "wnd_id": "9824032_1_1", "text": "Dental and gingival pain as side effects of niacin therapy .", "tokens": ["Dental", "and", "gingival", "pain", "as", "side", "effects", "of", "niacin", "therapy", "."], "event_mentions": [{"id": "9824032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "9824032_1_Ent0", "role": "Effect", "text": "Dental and gingival pain", "start": 0, "end": 4}, {"entity_id": "9824032_1_Ent1", "role": "Treatment", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "9824032_1_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9824032_1_Ent0", "text": "Dental and gingival pain", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9824032_1_Ent1", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9824032_1_Ent2", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9831311_2", "wnd_id": "9831311_2_1", "text": "High - dose phosphate treatment leads to hypokalemia in hypophosphatemic osteomalacia .", "tokens": ["High", "-", "dose", "phosphate", "treatment", "leads", "to", "hypokalemia", "in", "hypophosphatemic", "osteomalacia", "."], "event_mentions": [{"id": "9831311_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leads", "start": 5, "end": 6}, "arguments": [{"entity_id": "9831311_2_Ent4", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "9831311_2_Ent1", "role": "Treatment", "text": "High - dose phosphate", "start": 0, "end": 4}, {"entity_id": "9831311_2_Ent3", "role": "Treatment_Drug", "text": "phosphate", "start": 3, "end": 4}, {"entity_id": "9831311_2_Ent0", "role": "Effect", "text": "hypokalemia", "start": 7, "end": 8}, {"entity_id": "9831311_2_Ent2", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9831311_2_Ent4", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9831311_2_Ent1", "text": "High - dose phosphate", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9831311_2_Ent3", "text": "phosphate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9831311_2_Ent0", "text": "hypokalemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9831311_2_Ent2", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9840249_1", "wnd_id": "9840249_1_1", "text": "Alveolar - interstitial pneumopathy after gold - salts compounds administration , requiring mechanical ventilation .", "tokens": ["Alveolar", "-", "interstitial", "pneumopathy", "after", "gold", "-", "salts", "compounds", "administration", ",", "requiring", "mechanical", "ventilation", "."], "event_mentions": [{"id": "9840249_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "9840249_1_Ent0", "role": "Effect", "text": "Alveolar - interstitial pneumopathy", "start": 0, "end": 4}, {"entity_id": "9840249_1_Ent2", "role": "Treatment_Drug", "text": "gold - salts compounds", "start": 5, "end": 9}, {"entity_id": "9840249_1_Ent1", "role": "Treatment", "text": "gold - salts compounds administration", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "9840249_1_Ent0", "text": "Alveolar - interstitial pneumopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9840249_1_Ent2", "text": "gold - salts compounds", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9840249_1_Ent1", "text": "gold - salts compounds administration", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "9840249_2", "wnd_id": "9840249_2_1", "text": "The pulmonary toxicity of gold salts is an uncommon cause of life - threatening respiratory failure .", "tokens": ["The", "pulmonary", "toxicity", "of", "gold", "salts", "is", "an", "uncommon", "cause", "of", "life", "-", "threatening", "respiratory", "failure", "."], "event_mentions": [{"id": "9840249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "9840249_2_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 1, "end": 3}, {"entity_id": "9840249_2_Ent3", "role": "Treatment_Drug", "text": "gold", "start": 4, "end": 5}, {"entity_id": "9840249_2_Ent2", "role": "Treatment", "text": "gold salts", "start": 4, "end": 6}, {"entity_id": "9840249_2_Ent1", "role": "Effect", "text": "life - threatening respiratory failure", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "9840249_2_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9840249_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9840249_2_Ent2", "text": "gold salts", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9840249_2_Ent1", "text": "life - threatening respiratory failure", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "9846036_6", "wnd_id": "9846036_6_1", "text": "To date , only 1 death attributable to risperidone overdose has been reported .", "tokens": ["To", "date", ",", "only", "1", "death", "attributable", "to", "risperidone", "overdose", "has", "been", "reported", "."], "event_mentions": [{"id": "9846036_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributable", "start": 6, "end": 7}, "arguments": [{"entity_id": "9846036_6_Ent0", "role": "Subject", "text": "1", "start": 4, "end": 5}, {"entity_id": "9846036_6_Ent1", "role": "Subject_Population", "text": "1", "start": 4, "end": 5}, {"entity_id": "9846036_6_Ent2", "role": "Effect", "text": "death", "start": 5, "end": 6}, {"entity_id": "9846036_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 8, "end": 9}, {"entity_id": "9846036_6_Ent3", "role": "Treatment", "text": "risperidone overdose", "start": 8, "end": 10}, {"entity_id": "9846036_6_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9846036_6_Ent0", "text": "1", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9846036_6_Ent1", "text": "1", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9846036_6_Ent2", "text": "death", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9846036_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9846036_6_Ent3", "text": "risperidone overdose", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9846036_6_Ent5", "text": "overdose", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9846036_7", "wnd_id": "9846036_7_1", "text": "The case presented here documents adverse cardiac effects in a 28 - year - old man who intentionally ingested 24 mg of risperidone - - 4 times the recommended dose .", "tokens": ["The", "case", "presented", "here", "documents", "adverse", "cardiac", "effects", "in", "a", "28", "-", "year", "-", "old", "man", "who", "intentionally", "ingested", "24", "mg", "of", "risperidone", "-", "-", "4", "times", "the", "recommended", "dose", "."], "event_mentions": [{"id": "9846036_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "ingested", "start": 18, "end": 19}, "arguments": [{"entity_id": "9846036_7_Ent3", "role": "Effect", "text": "adverse cardiac effects", "start": 5, "end": 8}, {"entity_id": "9846036_7_Ent1", "role": "Subject_Age", "text": "28 - year - old", "start": 10, "end": 15}, {"entity_id": "9846036_7_Ent0", "role": "Subject", "text": "28 - year - old man", "start": 10, "end": 16}, {"entity_id": "9846036_7_Ent2", "role": "Subject_Gender", "text": "man", "start": 15, "end": 16}, {"entity_id": "9846036_7_Ent5", "role": "Treatment_Dosage", "text": "24 mg", "start": 19, "end": 21}, {"entity_id": "9846036_7_Ent4", "role": "Treatment", "text": "24 mg of risperidone", "start": 19, "end": 23}, {"entity_id": "9846036_7_Ent6", "role": "Treatment_Drug", "text": "risperidone", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9846036_7_Ent3", "text": "adverse cardiac effects", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9846036_7_Ent1", "text": "28 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "9846036_7_Ent0", "text": "28 - year - old man", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9846036_7_Ent2", "text": "man", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9846036_7_Ent5", "text": "24 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9846036_7_Ent4", "text": "24 mg of risperidone", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "9846036_7_Ent6", "text": "risperidone", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9847899_1", "wnd_id": "9847899_1_1", "text": "As this relapse coincided with development of a strong delayed - type hypersensitivity response to tuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline , it was probably caused by restoration of pathogen - specific cellular immunity .", "tokens": ["As", "this", "relapse", "coincided", "with", "development", "of", "a", "strong", "delayed", "-", "type", "hypersensitivity", "response", "to", "tuberculin", "and", "improved", "after", "treatment", "with", "the", "anti", "-", "inflammatory", "agent", "oxpentifylline", ",", "it", "was", "probably", "caused", "by", "restoration", "of", "pathogen", "-", "specific", "cellular", "immunity", "."], "event_mentions": [{"id": "9847899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "9847899_1_Ent0", "role": "Effect", "text": "a strong delayed - type hypersensitivity response", "start": 7, "end": 14}, {"entity_id": "9847899_1_Ent1", "role": "Treatment", "text": "tuberculin", "start": 15, "end": 16}, {"entity_id": "9847899_1_Ent2", "role": "Treatment_Drug", "text": "tuberculin", "start": 15, "end": 16}]}, {"id": "9847899_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 17, "end": 18}, "arguments": [{"entity_id": "9847899_1_Ent4", "role": "Treatment_Disorder", "text": "this relapse", "start": 1, "end": 3}, {"entity_id": "9847899_1_Ent3", "role": "Treatment", "text": "anti - inflammatory agent oxpentifylline", "start": 22, "end": 27}, {"entity_id": "9847899_1_Ent5", "role": "Treatment_Drug", "text": "oxpentifylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9847899_1_Ent4", "text": "this relapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9847899_1_Ent0", "text": "a strong delayed - type hypersensitivity response", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "9847899_1_Ent1", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent2", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent3", "text": "anti - inflammatory agent oxpentifylline", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "9847899_1_Ent5", "text": "oxpentifylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9865241_2", "wnd_id": "9865241_2_1", "text": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning .", "tokens": ["Pamidronate", "therapy", "should", "be", "considered", "in", "patients", "with", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 1, "end": 2}, "arguments": [{"entity_id": "9865241_2_Ent3", "role": "Treatment", "text": "Pamidronate", "start": 0, "end": 1}, {"entity_id": "9865241_2_Ent5", "role": "Treatment_Drug", "text": "Pamidronate", "start": 0, "end": 1}, {"entity_id": "9865241_2_Ent4", "role": "Treatment_Disorder", "text": "hypercalcemia", "start": 8, "end": 9}]}, {"id": "9865241_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "9865241_2_Ent0", "role": "Effect", "text": "hypercalcemia", "start": 8, "end": 9}, {"entity_id": "9865241_2_Ent1", "role": "Treatment", "text": "vitamin D", "start": 12, "end": 14}, {"entity_id": "9865241_2_Ent2", "role": "Treatment_Drug", "text": "vitamin D", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9865241_2_Ent3", "text": "Pamidronate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9865241_2_Ent5", "text": "Pamidronate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9865241_2_Ent0", "text": "hypercalcemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_2_Ent4", "text": "hypercalcemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_2_Ent1", "text": "vitamin D", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9865241_2_Ent2", "text": "vitamin D", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9870779_2", "wnd_id": "9870779_2_1", "text": "Methotrexate - induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis .", "tokens": ["Methotrexate", "-", "induced", "hepatic", "necrosis", "requiring", "liver", "transplantation", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "9870779_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9870779_2_Ent2", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9870779_2_Ent3", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "9870779_2_Ent1", "role": "Effect", "text": "hepatic necrosis", "start": 3, "end": 5}, {"entity_id": "9870779_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 9, "end": 14}, {"entity_id": "9870779_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9870779_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_2_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9870779_2_Ent1", "text": "hepatic necrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9870779_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9870779_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9876812_3", "wnd_id": "9876812_3_1", "text": "OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( SIADH ) associated with vinorelbine therapy for advanced breast cancer .", "tokens": ["OBJECTIVE", ":", "To", "describe", "onset", "of", "syndrome", "of", "inappropriate", "antidiuretic", "hormone", "(", "SIADH", ")", "associated", "with", "vinorelbine", "therapy", "for", "advanced", "breast", "cancer", "."], "event_mentions": [{"id": "9876812_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 14, "end": 16}, "arguments": [{"entity_id": "9876812_3_Ent0", "role": "Effect", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "start": 6, "end": 14}, {"entity_id": "9876812_3_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 16, "end": 17}, {"entity_id": "9876812_3_Ent3", "role": "Treatment_Disorder", "text": "advanced breast cancer", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9876812_3_Ent0", "text": "syndrome of inappropriate antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "9876812_3_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9876812_3_Ent3", "text": "advanced breast cancer", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9883483_2", "wnd_id": "9883483_2_1", "text": "Thus , an immunological mechanism might be involved in the mechanism of pirmenol - induced QT prolongation and T wave inversion on the electrocardiogram .", "tokens": ["Thus", ",", "an", "immunological", "mechanism", "might", "be", "involved", "in", "the", "mechanism", "of", "pirmenol", "-", "induced", "QT", "prolongation", "and", "T", "wave", "inversion", "on", "the", "electrocardiogram", "."], "event_mentions": [{"id": "9883483_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9883483_2_Ent1", "role": "Treatment", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent2", "role": "Treatment_Drug", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent0", "role": "Effect", "text": "QT prolongation and T wave inversion", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "9883483_2_Ent1", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent2", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent0", "text": "QT prolongation and T wave inversion", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "9883483_3", "wnd_id": "9883483_3_1", "text": "We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy .", "tokens": ["We", "report", "on", "a", "56", "-", "year", "-", "old", "female", "who", "exhibited", "drug", "refractory", "paroxysmal", "atrial", "fibrillation", ",", "in", "which", "marked", "prolongation", "of", "the", "QT", "interval", "and", "T", "wave", "inversion", "on", "electrocardiogram", "was", "demonstrated", "reproducibly", "shortly", "after", "the", "administration", "of", "oral", "pirmenol", "therapy", "."], "event_mentions": [{"id": "9883483_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 36, "end": 37}, "arguments": [{"entity_id": "9883483_3_Ent0", "role": "Subject", "text": "a 56 - year - old female", "start": 3, "end": 10}, {"entity_id": "9883483_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 4, "end": 9}, {"entity_id": "9883483_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "9883483_3_Ent3", "role": "Effect", "text": "drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion", "start": 12, "end": 30}, {"entity_id": "9883483_3_Ent6", "role": "Treatment_Route", "text": "oral", "start": 40, "end": 41}, {"entity_id": "9883483_3_Ent4", "role": "Treatment", "text": "pirmenol", "start": 41, "end": 42}, {"entity_id": "9883483_3_Ent5", "role": "Treatment_Drug", "text": "pirmenol", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "9883483_3_Ent0", "text": "a 56 - year - old female", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "9883483_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9883483_3_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9883483_3_Ent3", "text": "drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion", "entity_type": "Entity", "start": 12, "end": 30}, {"id": "9883483_3_Ent6", "text": "oral", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "9883483_3_Ent4", "text": "pirmenol", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "9883483_3_Ent5", "text": "pirmenol", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "9892272_4", "wnd_id": "9892272_4_1", "text": "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma .", "tokens": ["The", "development", "of", "cutaneous", "ecchymosis", "associated", "with", "a", "sudden", "fall", "in", "hemoglobin", "after", "the", "administration", "of", "alteplase", "should", "strongly", "suggest", "the", "possibility", "of", "diffuse", "subfascial", "hematoma", "."], "event_mentions": [{"id": "9892272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "9892272_4_Ent0", "role": "Effect", "text": "cutaneous ecchymosis", "start": 3, "end": 5}, {"entity_id": "9892272_4_Ent1", "role": "Effect", "text": "a sudden fall in hemoglobin", "start": 7, "end": 12}, {"entity_id": "9892272_4_Ent3", "role": "Treatment", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent4", "role": "Treatment_Drug", "text": "alteplase", "start": 16, "end": 17}, {"entity_id": "9892272_4_Ent2", "role": "Effect", "text": "diffuse subfascial hematoma", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "9892272_4_Ent0", "text": "cutaneous ecchymosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9892272_4_Ent1", "text": "a sudden fall in hemoglobin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9892272_4_Ent3", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent4", "text": "alteplase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9892272_4_Ent2", "text": "diffuse subfascial hematoma", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "9920368_2", "wnd_id": "9920368_2_1", "text": "Among 12 thyrotoxic patients , a patient with arrhythmogenic right ventricular dysplasia , who had been taking amiodarone for 4 years , developed thyrotoxicosis with subacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ) , or thyrotropin - binding inhibiting immunoglobulin ( TBII ) .", "tokens": ["Among", "12", "thyrotoxic", "patients", ",", "a", "patient", "with", "arrhythmogenic", "right", "ventricular", "dysplasia", ",", "who", "had", "been", "taking", "amiodarone", "for", "4", "years", ",", "developed", "thyrotoxicosis", "with", "subacute", "onset", ",", "accompanied", "by", "transiently", "positive", "thyrotropin", "(", "TSH", ")", "receptor", "antibody", "(", "TRAb", ")", ",", "or", "thyrotropin", "-", "binding", "inhibiting", "immunoglobulin", "(", "TBII", ")", "."], "event_mentions": [{"id": "9920368_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "9920368_2_Ent0", "role": "Subject", "text": "a patient with arrhythmogenic right ventricular dysplasia", "start": 5, "end": 12}, {"entity_id": "9920368_2_Ent5", "role": "Treatment_Disorder", "text": "arrhythmogenic right ventricular dysplasia", "start": 8, "end": 12}, {"entity_id": "9920368_2_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 17, "end": 18}, {"entity_id": "9920368_2_Ent2", "role": "Treatment", "text": "amiodarone for 4 years", "start": 17, "end": 21}, {"entity_id": "9920368_2_Ent3", "role": "Treatment_Duration", "text": "4 years", "start": 19, "end": 21}, {"entity_id": "9920368_2_Ent1", "role": "Effect", "text": "thyrotoxicosis with subacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ) , or thyrotropin - binding inhibiting immunoglobulin ( TBII )", "start": 23, "end": 51}]}], "entity_mentions": [{"id": "9920368_2_Ent0", "text": "a patient with arrhythmogenic right ventricular dysplasia", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9920368_2_Ent5", "text": "arrhythmogenic right ventricular dysplasia", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9920368_2_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9920368_2_Ent2", "text": "amiodarone for 4 years", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "9920368_2_Ent3", "text": "4 years", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9920368_2_Ent1", "text": "thyrotoxicosis with subacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ) , or thyrotropin - binding inhibiting immunoglobulin ( TBII )", "entity_type": "Entity", "start": 23, "end": 51}], "lang": "en"}
{"doc_id": "9934637_1", "wnd_id": "9934637_1_1", "text": "An unusual cause of burn injury : unsupervised use of drugs that contain psoralens .", "tokens": ["An", "unusual", "cause", "of", "burn", "injury", ":", "unsupervised", "use", "of", "drugs", "that", "contain", "psoralens", "."], "event_mentions": [{"id": "9934637_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "9934637_1_Ent0", "role": "Effect", "text": "burn injury", "start": 4, "end": 6}, {"entity_id": "9934637_1_Ent1", "role": "Treatment", "text": "use of drugs that contain psoralens .", "start": 8, "end": 15}, {"entity_id": "9934637_1_Ent2", "role": "Treatment_Drug", "text": "psoralens", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9934637_1_Ent0", "text": "burn injury", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9934637_1_Ent1", "text": "use of drugs that contain psoralens .", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9934637_1_Ent2", "text": "psoralens", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
